CP Scorecard
Derived from Current Agreements, the partnering scorecard gives an instant overview of the top partnering deals in the life sciences by year.
The following article contains a snapshot of the largest deals by value for the year.
Our Current Agreements database stores and categorizes deal data dating as far back as 2000 saving you valuable time on your deal making research activities.
Searching for more deal information? Current Partnering offers the following options:
|
Top partnering deals of 2025 valued at over US$500m.
Partners | Date | Value, US$m | Subject | Termsheet |
---|---|---|---|---|
Roche, Zealand Pharma | Mar 2025 | 5250 | Collaboration, development and licensing agreement for petrelintide as therapy for obesity | Key Deal Terms Summary1. Agreement Overview
2. Financial Terms
3. Development & Commercialization Plans
4. Strategic Impact
Overall SummaryRoche and Zealand Pharma have entered into a strategic collaboration worth up to USD 5.3 billion to co-develop and co-commercialize petrelintide for obesity treatment, both as a standalone therapy and in combination with Roche’s GLP-1/GIP receptor agonist CT-388. The transaction includes an upfront payment of USD 1.65 billion, milestone-based payments of up to USD 3.6 billion, and profit-sharing in key markets. Roche will lead global manufacturing and commercialization outside the U.S. and Europe, with Zealand Pharma contributing to commercialization in North America and Europe. This agreement strengthens Roche’s CVRM portfolio and positions Zealand Pharma as a key player in next-generation obesity treatments. [collapse expanded text] |
Novo Nordisk, Valo Health | Jan 2025 | 4790 | Research, development and licensing agreement for drug programmes in obesity, type 2 diabetes and cardiovascular disease | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryValo Health and Novo Nordisk have expanded their AI-driven drug discovery collaboration to develop up to 20 novel therapies for obesity, type 2 diabetes, and cardiovascular disease. Novo Nordisk will provide up to $4.6 billion in milestone payments, $190 million upfront and near-term payments, as well as R&D funding and royalties. Valo will apply its Opal Computational Platform™ to identify new therapeutic targets and develop AI-driven small molecule drugs, while Novo Nordisk will lead clinical development and commercialization. This expansion significantly strengthens Novo Nordisk’s cardiometabolic drug pipeline and deepens its commitment to AI-powered precision medicine. [collapse expanded text] |
AstraZeneca, Harbour Biomed | Mar 2025 | 4575 | Research, development and licensing agreement for next-generation therapeutic antibodies | Key Deal Terms SummaryAgreement Overview
Financial Terms
Development & Collaboration Scope
Strategic Impact
Overall SummaryHarbour BioMed and AstraZeneca have entered a broad, multi-program global collaboration combining Harbour's proprietary multi-specific antibody discovery capabilities with AstraZeneca's clinical and commercial scale. With $280 million in upfront and equity payments and potential future milestones up to $4.4 billion, this partnership supports the co-discovery and potential licensing of multiple therapeutic antibody candidates. A co-located Innovation Center in Beijing will further advance joint development, marking a major step in Harbour BioMed's global expansion and AstraZeneca's deepening commitment to biologics innovation. [collapse expanded text] |
AstraZeneca, Syneron Bio | Mar 2025 | 3475 | Licensing agreement for Synova platform | Key Deal Terms Summary1. Agreement Overview
2. Financial Terms
3. Development & Commercialization Scope
4. Strategic Impact
Overall SummaryAstraZeneca and Syneron Bio have entered a high-value strategic collaboration combining Syneron's Synova™ macrocyclic peptide discovery platform with AstraZeneca’s global development and commercialization capabilities. The deal includes $75 million in upfront and near-term milestones, up to $3.4 billion in success-based payments, tiered royalties, and a strategic equity investment by AstraZeneca. The partnership will support novel chronic disease programs and enable Syneron Bio to expand R&D infrastructure, advancing its global presence in macrocyclic drug innovation. [collapse expanded text] |
Sciwind Biosciences, Verdiva Bio | Jan 2025 | 2470 | Licensing and collaboration agreement for metabolic disease portfolio | Parties Involved
Collaboration Scope
Licensing Agreement & Financial Terms
Overall SummarySciwind Biosciences and Verdiva Bio have entered into a global licensing and collaboration agreement for the development and commercialization of a portfolio of metabolic disease therapies, including oral and injectable GLP-1 and Amylin receptor agonists. Verdiva Bio gains exclusive global rights outside of Greater China and South Korea, while Sciwind retains rights in these regions. Sciwind receives a $70 million upfront payment, with potential milestone payments exceeding $2.4 billion, plus tiered royalties on global sales. The partnership is designed to accelerate the global commercialization of these innovative metabolic therapies. [collapse expanded text] |
Abbvie, Gubra | Mar 2025 | 2225 | Development and licensing agreement for an Amylin Analog for treatment of obesity | Key Deal Terms Summary1. Agreement Overview
2. Financial Terms
3. Development & Commercialization Plans
4. Strategic Impact
Overall SummaryAbbVie and Gubra have entered into a license agreement for GUB014295, an amylin analog in Phase 1 clinical trials for obesity. The deal grants AbbVie exclusive worldwide rights to develop and commercialize the drug. Gubra will receive $350M upfront, up to $1.875B in milestone payments, and tiered royalties on global net sales. AbbVie’s entry into the obesity market strengthens its metabolic disease pipeline, while Gubra benefits from AbbVie’s commercialization expertise. The amylin analog's mechanism could enhance appetite suppression and weight loss outcomes, positioning it as a potential best-in-class therapy in the growing global obesity market. [collapse expanded text] |
Abbvie, Xilio Therapeutics | Feb 2025 | 2162 | Collaboration and option agreement to develop novel tumor-activated immunotherapies | Key Deal Terms Summary1. Agreement Overview
2. Financial Terms
3. Development & Commercialization Plans
4. Strategic Impact
Overall SummaryAbbVie and Xilio Therapeutics have entered into a collaboration and option-to-license agreement to develop novel tumor-activated immunotherapies, including masked T-cell engagers. Under the agreement, Xilio will receive $52 million upfront, with potential milestone payments of up to $2.1 billion, plus tiered royalties. The partnership leverages Xilio’s proprietary tumor-activation platform to improve immune-oncology therapies, while AbbVie brings its oncology expertise and commercialization capabilities. This collaboration strengthens both companies' positions in immuno-oncology and could lead to more effective, safer cancer treatments. [collapse expanded text] |
Dren Bio, Sanofi | Mar 2025 | 1900 | Asset purchase agreement for bispecific myeloid cell engager for deep B-cell depletion | Key Deal Terms SummaryAgreement Overview
Financial Terms
Development & Commercialization Plans
Strategic Impact
Overall SummarySanofi will acquire Dren Bio’s affiliate housing DR-0201, a next-generation bispecific CD20-targeting antibody designed for deep B-cell depletion, for $600 million upfront and up to $1.3 billion in milestones. The deal strengthens Sanofi’s ambition to reset the immune system in autoimmune diseases and underscores its commitment to leading in immunology. DR-0201’s unique myeloid engagement mechanism could offer transformative potential for refractory B-cell mediated autoimmune conditions such as lupus, supporting long-term remission. The acquisition is expected to close in Q2 2025. [collapse expanded text] |
Gilead Sciences, LEO Pharma | Jan 2025 | 1700 | Development, licensing and option agreement for oral STAT6 program | Parties Involved
Collaboration Scope
Financial Terms
Regulatory Approval
Overall SummaryGilead Sciences and LEO Pharma have entered a strategic partnership to develop oral STAT6 inhibitors for multiple inflammatory diseases, including atopic dermatitis, asthma, and COPD. Gilead gains exclusive global rights to the oral STAT6 program, while LEO Pharma retains global rights to topical formulations and has the option to co-commercialize oral STAT6 therapies for dermatology indications outside the U.S. LEO Pharma will receive $250 million upfront, with the potential for $1.7 billion in total payments and royalties on future sales. [collapse expanded text] |
Abbvie, Neomorph | Jan 2025 | 1640 | Development and option agreement for molecular glue degraders for oncology and immunology | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryAbbVie and Neomorph have entered into a collaboration and option-to-license agreement to develop molecular glue degraders targeting oncology and immunology indications. Neomorph will lead drug discovery, while AbbVie will have the option to license and advance selected programs into clinical development and commercialization. Neomorph stands to receive up to $1.64 billion in milestone payments and royalties, reinforcing the growing potential of molecular glue degraders in targeting previously "undruggable" proteins. [collapse expanded text] |
Samsung Biologics | Jan 2025 | 1400 | Manufacturing agreement with pharmaceutical company based in European Union | Samsung Biologics Secures $1.4B European Manufacturing ContractContract Overview Samsung Biologics has entered into a manufacturing agreement with an unnamed pharmaceutical company based in the European Union. Deal Value Strategic Significance |
Boehringer Ingelheim, Synaffix | Jan 2025 | 1300 | Licensing agreement for ADC technology | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryBoehringer Ingelheim and Synaffix have entered into a licensing agreement for the development of multiple ADC programs using Synaffix’s GlycoConnect™, HydraSpace®, and toxSYN® technologies. Under the agreement, Boehringer will nominate multiple tumor targets, starting with an initial target selected at signing, and NBE Therapeutics will oversee development and commercialization. Synaffix will receive an upfront payment, up to $1.3 billion in milestone payments, and royalties on net sales. This collaboration expands Boehringer’s ADC pipeline and reinforces Synaffix’s position as a leader in ADC technology licensing. [collapse expanded text] |
Eli Lilly, Magnet Biomedicine | Feb 2025 | 1290 | Collaboration and license agreement to discover and develop novel molecular glue medicines | Key Deal Terms Summary1. Agreement Overview
2. Financial Terms
3. Development & Commercialization Plans
4. Strategic Impact
Overall SummaryMagnet Biomedicine has entered into a strategic collaboration with Eli Lilly to develop novel molecular glue therapeutics for oncology. Under the deal, Magnet will receive up to $40 million in upfront, near-term payments, and an equity investment, with over $1.25 billion in potential milestone payments, plus tiered royalties on global net sales. The agreement combines Magnet’s TrueGlue™ platform with Lilly’s expertise in small molecule drug development, aiming to address difficult-to-drug cancer targets with innovative molecular glue medicines. [collapse expanded text] |
ArriVent Biopharma, Lepu Biopharma | Jan 2025 | 1207 | Licensing agreement for MRG007 | ArriVent BioPharma & Lepu Biopharma Exclusive License Agreement for MRG007… read moreParties Involved
Collaboration ScopeArriVent BioPharma has obtained exclusive global rights outside of Greater China to develop, manufacture, and commercialize MRG007, a novel antibody-drug conjugate (ADC) in development for gastrointestinal (GI) cancers. The first Investigational New Drug (IND) submission is planned for the first half of 2025. Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryArriVent BioPharma has entered into an exclusive global licensing agreement (excluding Greater China) with Lepu Biopharma for MRG007, a next-generation ADC targeting GI cancers. This collaboration strengthens ArriVent’s ADC pipeline and accelerates clinical development. Lepu Biopharma will receive $47 million upfront and near-term milestones, with potential total payments reaching $1.16 billion plus tiered royalties. The first IND submission is expected in 1H 2025, with initial clinical focus on CRC, pancreatic, and other GI cancers. [collapse expanded text] |
Avenzo Therapeutics, DualityBio | Jan 2025 | 1200 | Licensing agreement for EGFR/HER3 antibody-drug conjugate | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryAvenzo Therapeutics has entered into an exclusive global license agreement (excluding Greater China) with DualityBio for AVZO-1418/DB-1418, an EGFR/HER3 bispecific ADC targeting various solid tumors. Avenzo will oversee global development, manufacturing, and commercialization, while DualityBio will receive upfront, milestone, and royalty payments. The first-in-human trial is expected to begin this year, aiming to establish AVZO-1418/DB-1418 as a best-in-class ADC therapy. [collapse expanded text] |
CSPC Megalith Biopharmaceutical, Radiance Biopharma | Feb 2025 | 1165 | Licensing agreement for ROR-1 targeted antibody drug conjugate RB-164 (SYS6005) | Key Deal Terms Summary1. Agreement Overview
2. Financial Terms
3. Development & Commercialization Plans
4. Strategic Impact
Overall SummaryRadiance Biopharma has entered into an exclusive licensing agreement with CSPC Megalith Biopharmaceutical to develop and commercialize RB-164 (SYS6005), a ROR-1 targeted ADC. The deal grants Radiance commercialization rights across the U.S., Canada, Europe, and Australia, while CSPC retains rights for China and other global markets. Radiance will pay $15 million upfront, up to $150 million in regulatory milestones, and over $1 billion in commercial milestones, with tiered royalties based on net sales. RB-164 is currently in Phase 1 clinical trials in China, and Radiance will lead clinical development in its licensed territories, aiming to advance a best-in-class ADC therapy for hematological and solid tumor malignancies. [collapse expanded text] |
Innovent Biologics, Roche | Jan 2025 | 1080 | Licensing agreement for DLL3 antibody drug conjugate | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryInnovent has granted Roche exclusive global rights to develop, manufacture, and commercialize IBI3009, a DLL3-targeted ADC for small cell lung cancer and neuroendocrine tumors. The agreement provides Innovent with an upfront payment of $80 million, potential milestone payments of up to $1 billion, and tiered royalties on future net sales. Roche will assume full late-stage development and commercialization responsibilities, leveraging its expertise in ADCs and oncology drug development. [collapse expanded text] |
Orna Therapeutics, ReNAgade Therapeutics, Vertex Pharmaceuticals | Jan 2025 | 1065 | Research, development, licensing and option agreement for next generation approaches for sickle cell disease and transfusion-dependent beta thalassemia | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryOrna Therapeutics and Vertex Pharmaceuticals have entered a three-year strategic research collaboration to develop next-generation gene editing therapies for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT). Vertex will leverage Orna’s LNP delivery technology to enhance in vivo gene editing approaches targeting hematopoietic stem cells. Orna will receive $65 million upfront, with up to $635 million in milestone payments, plus tiered royalties on future sales. The agreement also includes the potential for up to ten additional products, with milestone payments of up to $365 million per product if Vertex expands its rights. [collapse expanded text] |
Abbvie, Simcere Pharmaceuticals | Jan 2025 | 1055 | Development and option agreement for trispecific antibody candidate in multiple myeloma | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummarySimcere Zaiming and AbbVie have entered into an option-to-license agreement for SIM0500, a trispecific antibody for multiple myeloma targeting GPRC5D, BCMA, and CD3. AbbVie will have the option to license the drug for global commercialization outside Greater China, while Simcere Zaiming retains Greater China rights. Simcere Zaiming will receive an undisclosed upfront payment, with total potential milestone payments of up to $1.055 billion, plus tiered royalties on net sales. The collaboration leverages Simcere Zaiming’s T-cell engager platform and AbbVie’s expertise in hematologic oncology. [collapse expanded text] |
Oxford BioTherapeutics, Roche | Mar 2025 | 1036 | Research agreement to discover novel targets for antibody-based therapeutics for treatment of cancer | Key Deal Terms SummaryAgreement Overview
Financial Terms
Development & Commercialization Plans
Strategic Impact
Overall SummaryOxford BioTherapeutics has entered a strategic collaboration with Roche to identify and develop first-in-class antibody-based oncology therapeutics using its OGAP®-Verify discovery platform. The agreement includes up to $36 million upfront, over $1 billion in potential milestone payments, and tiered royalties on net sales. Roche will take the lead on post-validation development and commercialization. The collaboration combines OBT’s innovative target discovery capabilities with Roche’s deep clinical and global commercial expertise to accelerate the development of transformative cancer therapies. [collapse expanded text] |
Light Horse Therapeutics, Novartis | Jan 2025 | 1025 | Licensing agreement for multi-target collaboration to identify and develop small molecule therapeutics | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Overall SummaryLight Horse Therapeutics and Novartis have entered into a multi-target discovery collaboration to develop first-in-class small molecule therapeutics, primarily in oncology. Light Horse will receive a $25 million upfront payment and is eligible for up to $1 billion in milestone payments, along with royalties on licensed products. The partnership aims to leverage Light Horse’s precision genome editing and discovery platform to identify and develop novel, high-value drug targets. [collapse expanded text] |
Dropshot Therapeutics, eTheRNA immunotherapies | Jan 2025 | 950 | Development and licensing agreement for RNA-based therapeutics for the multiple new drug candidates | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryBoehringer Ingelheim and Synaffix have entered into a licensing agreement for the development of multiple ADC programs using Synaffix’s GlycoConnect™, HydraSpace®, and toxSYN® technologies. Under the agreement, Boehringer will nominate multiple tumor targets, starting with an initial target selected at signing, and NBE Therapeutics will oversee development and commercialization. Synaffix will receive an upfront payment, up to $1.3 billion in milestone payments, and royalties on net sales. This collaboration expands Boehringer’s ADC pipeline and reinforces Synaffix’s position as a leader in ADC technology licensing. [collapse expanded text] |
Ionis Pharmaceuticals, Ono Pharmaceutical | Mar 2025 | 940 | Licensing agreement for sapablursen for treatment of polycythemia vera | Key Deal Terms Summary1. Agreement Overview
2. Financial Terms
3. Development & Commercialization Plans
4. Strategic Impact
Overall SummaryOno Pharmaceutical has secured exclusive global development and commercialization rights for sapablursen from Ionis Pharmaceuticals in a deal valued at up to $940 million, including a $280 million upfront payment and milestone-based payouts. Ionis will complete the ongoing Phase 2 IMPRSSION study, after which Ono will lead further development and commercialization. Sapablursen, which has Fast Track and orphan drug designation from the U.S. FDA, represents a promising new approach for polycythemia vera (PV) by modulating iron homeostasis through RNA-targeted therapy. This agreement strengthens Ono’s hematology pipeline while allowing Ionis to focus on core areas such as neurology and cardiology. [collapse expanded text] |
Kyorin Pharmaceutical, Novartis | Mar 2025 | 832.5 | Licensing and option agreement for KRP-M223 | Key Deal Terms Summary1. Agreement Overview
2. Financial Terms
3. Development & Commercialization Plans
4. Strategic Impact
Overall SummaryKYORIN and Novartis have entered into a global license agreement for KRP-M223, a preclinical MRGPRX2 antagonist targeting chronic spontaneous urticaria (CSU) and other allergic/inflammatory diseases. Novartis gains exclusive global rights, while KYORIN retains an option to commercialize and manufacture for Japan, with Novartis having the right to co-promote in Japan. KYORIN will receive $55M upfront, up to $777.5M in milestone payments, and tiered royalties on net sales. The deal strengthens Novartis’ immunology portfolio and supports KYORIN’s global expansion strategy, positioning KRP-M223 as a potential first-in-class therapy for millions of CSU patients worldwide. [collapse expanded text] |
Biotronik, Teleflex | Feb 2025 | 823 | Asset purchase agreement for vascular intervention business | Key Deal Terms Summary1. Agreement Overview
2. Financial Terms
3. Development & Commercialization Plans
4. Strategic Impact
Overall SummaryTeleflex is acquiring BIOTRONIK’s Vascular Intervention business for €760 million to expand its global interventional cardiology and peripheral vascular portfolio. The deal broadens Teleflex’s footprint in the cath lab, adding a differentiated suite of coronary and peripheral vascular intervention devices, including drug-coated balloons, drug-eluting stents, covered stents, and self-expanding stents. The transaction is expected to be EPS accretive by $0.10 in year one, with 6%+ annual revenue growth beginning in 2026. The acquisition strengthens Teleflex’s geographic reach (50% of revenue from EMEA) and positions the company to advance resorbable scaffold technologies for future regulatory approvals. [collapse expanded text] |
BridGene Biosciences, Takeda Pharmaceutical | Feb 2025 | 816 | Collaboration and licensing agreement to discover small molecule drugs for immunology and neurology targets | **Key Deal Terms1. Agreement Overview
2. Financial Terms
3. Development & Commercialization Plans
4. Strategic Impact
Overall SummaryBridGene Biosciences and Takeda have formed a strategic collaboration to discover novel small molecule drugs targeting undruggable immunology and neurology proteins. The partnership leverages BridGene’s IMTAC™ chemoproteomics platform to identify drug candidates, with Takeda gaining exclusive development and commercialization rights. BridGene will receive $46 million upfront, with potential milestone payments totaling $770 million and tiered royalties on future sales. This collaboration aligns with Takeda’s strategy to expand its small molecule portfolio and BridGene’s mission to pioneer first-in-class therapies. [collapse expanded text] |
Nippon Shinyaku, Regenxbio | Jan 2025 | 810 | Development and licensing agreement for RGX-121 and RGX-111 for MPS Diseases | Key Deal Terms Summary: REGENXBIO and Nippon Shinyaku Partnership for RGX-121 and RGX-111… read more1. Scope of Collaboration
2. Financial Terms
3. Strategic Impact
4. Closing Conditions
Overall SummaryREGENXBIO and Nippon Shinyaku entered a $810 million+ partnership to develop and commercialize gene therapies RGX-121 and RGX-111 for MPS diseases in the U.S. and Asia. REGENXBIO receives $110 million upfront, up to $700 million in milestones, and double-digit royalties. Nippon Shinyaku will lead commercialization, while REGENXBIO retains manufacturing control and rights outside the Licensed Territory. The deal is expected to close in early 2025. [collapse expanded text] |
Eli Lilly, Mediar Therapeutics | Jan 2025 | 786 | Licensing agreement for WISP1 antibody MTX-463 | Parties Involved
Collaboration Scope
Licensing Agreement
Regulatory & Clinical Development
Overall SummaryMediar Therapeutics and Eli Lilly have entered into a global licensing agreement for MTX-463, a first-in-class anti-WISP1 antibody targeting fibrosis progression. Mediar will lead Phase 2 development in IPF, after which Lilly will assume clinical development and global commercialization. Mediar receives a $99 million upfront and near-term payment, with up to $687 million in milestone payments and tiered royalties. The collaboration leverages Lilly’s expertise in immunology and fibrosis drug development, aiming to deliver a novel, best-in-class fibrosis treatment to patients. [collapse expanded text] |
Araris Biotech, Chugai Pharmaceutical | Jan 2025 | 780 | Research and option agreement for next-generation adcs using AraLinQ technology | Araris Biotech announced they entered Research Collaboration and Option to License Agreement under … read morewhich Araris will use its proprietary linker-conjugation platform AraLinQ to generate novel ADCs using antibodies against undisclosed targets provided by Chugai Pharmaceutical Chugai will pay an upfront fee Fund all research activities After exercising option be solely responsible for development, manufacturing and global commercialization activities Araris will be eligible for development, regulatory and commercial milestones of approximately USD 780 million Royalties on net sales of products [collapse expanded text] |
Black Diamond Therapeutics, Les Laboratoires Servier | Mar 2025 | 780 | Licensing agreement for BDTX-4933 | Key Deal Terms SummaryAgreement Overview
Financial Terms
Development & Commercialization Plans
Strategic Impact
Overall SummaryServier has entered into a global exclusive license agreement with Black Diamond Therapeutics for BDTX-4933, a Phase 1 oral targeted therapy for RAS/RAF-mutant solid tumors, including NSCLC. The deal includes $70 million upfront, up to $710 million in milestones, and tiered royalties. Servier will lead global development and commercialization, aiming to accelerate this potential best-in-class therapy across multiple indications. The agreement strengthens both companies' positions in the targeted oncology space and marks a significant step in delivering innovative precision therapies to cancer patients worldwide. [collapse expanded text] |
AB2 Bio, Nippon Shinyaku | Jan 2025 | 686 | Option and licensing agreement for Tadekinig alfa for an ultra-rare autoimmune disease | Key Deal Terms Summary1. Agreement Overview
2. Financial Terms
3. Development & Commercialization Plans
4. Strategic Impact
Overall SummaryAB2 Bio and Nippon Shinyaku have signed an option and licensing agreement for Tadekinig alfa, granting Nippon Shinyaku the exclusive U.S. commercialization rights for a severe IL-18 driven hyperinflammatory syndrome in pediatric patients. AB2 Bio will receive up to $36 million in early payments, with the potential for $150 million in development milestones and $500 million in commercial milestones and royalties. AB2 Bio will continue to advance regulatory filings while retaining broader commercialization rights beyond the licensed indication. The agreement leverages Nippon Shinyaku’s rare disease expertise, ensuring a strategic pathway for bringing Tadekinig alfa to market. [collapse expanded text] |
Pfizer, PostEra | Jan 2025 | 610 | Licensing agreement for antibody-drug-conjugate discovery | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryPostEra and Pfizer have expanded their AI-driven drug discovery collaboration from $260M to $610M, adding ADC payload optimization to their existing small molecule programs. PostEra will use its Proton AI platform to accelerate drug discovery and development, receiving an upfront payment of $12M, with potential milestone and royalty payments. This marks PostEra’s third major partnership with Pfizer, further solidifying its position in AI-driven medicinal chemistry. [collapse expanded text] |
Insilico Medicine, Menarini, Stemline Therapeutics | Jan 2025 | 550 | Licensing agreement for AI discovered preclinical asset | Menarini and Stemline Therapeutics and Insilico Medicine announced companies have entered exclusive … read morelicensing agreement granting Stemline global rights to develop and commercialize preclinical small molecule targeting high unmet needs in oncology Asset is highly selective and potentially best-in-class small molecule inhibitor targeting broad range of solid tumor cancers developed with Chemistry42 Insilico’s generative chemistry engine and Insilico’s drug discovery team Asset has successfully completed preclinical development and has demonstrated broad anti-tumor activity in selected cancers Stemline will provide a $20 million upfront payment to Insilico Combined value of deal including all development, regulatory, and commercial milestones is over $550 million Tiered royalties Prior to this collaboration, the Menarini Group and Insilico entered an exclusive licensing agreement in January 2024 for MEN2312, an innovative small molecule for breast cancer treatment and other oncology indications. [collapse expanded text] |
Biogen, Stoke Therapeutics | Feb 2025 | 550 | Collaboration and licensing agreement for zorevunersen for treatment of Dravet syndrome | Key Deal Terms Summary1. Agreement Overview
2. Financial Terms
3. Development & Commercialization Plans
4. Strategic Impact
Overall SummaryBiogen and Stoke Therapeutics have entered a global collaboration for zorevunersen, an investigational antisense oligonucleotide targeting SCN1A, the genetic driver of Dravet syndrome. Stoke retains North American rights, while Biogen will commercialize the therapy globally. The deal provides $165 million upfront, with up to $385 million in milestones and tiered royalties on sales. The Phase 3 EMPEROR study is set to begin in Q2 2025, with results expected in 2H 2027, supporting potential global regulatory filings. This partnership broadens Biogen’s rare disease portfolio while giving Stoke financial runway into 2028 to advance its ASO pipeline. [collapse expanded text] |
Merck and Co, WuXi Biologics | Jan 2025 | 521 | Asset purchase agreement for vaccines manufacturing facility | MSD has agreed to acquire the WuXi Vaccines manufacturing facility located in Dundalk, Co Louth … read moreAcquisition signifies an investment of over €500 million [collapse expanded text] |
Beijing InnoCare Pharma, Keymed Biosciences, Prolium Bioscience | Jan 2025 | 520 | Licensing and development agreement for CD20xCD3 bispecific antibody | Key Deal Terms of the InnoCare, KeyMed, and Prolium License Agreement for ICP-B02 … read moreAgreement Scope Financial Terms About ICP-B02 (CM355) About Prolium |
Top partnering deals of 2024 valued at over US$500m.
Partners | Date | Value, US$m | Subject | Termsheet |
---|---|---|---|---|
Flagship Pioneering, GSK | Jul 2024 | 7350 | Development and option agreement for drug discovery in respiratory and immunology | Key Deal Terms Summary1. Collaboration Scope
2. Financial Commitments
3. Development & Commercialization Rights
4. Strategic Intent & Innovation Model
5. Overall SummaryGSK and Flagship Pioneering have formed a strategic partnership to develop innovative medicines and vaccines, starting with respiratory and immunology. They will jointly fund up to $150 million upfront for an exploration phase, with Flagship eligible for up to $720 million per acquired program in upfront, milestone, and commercial payments, along with preclinical funding and royalties. The deal allows GSK to leverage Flagship’s ecosystem of bioplatform companies while securing exclusive options for up to 10 novel medicines and vaccines. [collapse expanded text] |
Novartis, Shanghai Argo Biopharmaceutical | Jan 2024 | 4350 | Collaboration and licensing agreement for multi-program RNAi | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryArgo has entered into two exclusive license and collaboration agreements with Novartis, granting the global rights to develop and commercialize two cardiovascular RNAi programs and the option to license additional targets. The agreements, valued at up to $4.165 billion, include upfront payments of $185 million, milestone payments, and tiered royalties. This partnership expands Novartis' RNAi portfolio in Cardiovascular and Metabolic Diseases (CVM), leveraging Argo's advanced RNAi platform technology. [collapse expanded text] |
Bristol-Myers Squibb, Prime Medicine | Sep 2024 | 3610 | Research, development and licensing agreement for multiple prime edited ex vivo T-cell therapies | Parties Involved
… read more Collaboration ScopePrime Medicine and Bristol Myers Squibb have entered a strategic research collaboration to develop next-generation ex vivo T-cell therapies using Prime Medicine’s Prime Editing technology and its PASSIGE™ platform. Prime Medicine will design optimized Prime Editor reagents for a select number of targets, which will be used in Bristol Myers Squibb’s development, manufacturing, and commercialization of novel cell therapies targeting immunological diseases and cancer. Rights & Responsibilities
Financial Terms
Regulatory ApprovalThe collaboration focuses on advancing Prime Medicine’s technologies into clinical applications, with Bristol Myers Squibb responsible for the regulatory pathway in developing, manufacturing, and commercializing the cell therapies. Overall SummaryPrime Medicine and Bristol Myers Squibb have formed a strategic collaboration to develop next-generation ex vivo T-cell therapies leveraging Prime Medicine’s Prime Editing and PASSIGE™ technology. Prime Medicine will receive $55 million upfront and $55 million equity investment, with the potential to earn over $3.5 billion in milestone payments, plus royalties. Bristol Myers Squibb will handle the development, manufacturing, and commercialization of the therapies, using Prime Medicine’s reagents for gene editing strategies. This collaboration aims to target immunological diseases and cancer, offering significant potential in the cell therapy field. [collapse expanded text] |
LaNova Medicines, Merck and Co | Nov 2024 | 3288 | Licensing agreement for LM-299 PD-1/VEGF bispecific antibody | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall Summary
|
Dren Bio, Novartis | Jul 2024 | 3000 | Research, development and licensing agreement for targeted myeloid engagers for cancer | Parties Involved
… read more Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryDren Bio has entered into a strategic collaboration with Novartis Pharma AG to discover and develop bispecific antibodies for oncology using Dren Bio’s Targeted Myeloid Engager and Phagocytosis Platform. Dren Bio will receive an upfront payment of $150 million, with additional milestone payments of up to $2.85 billion and royalties on future net sales. Novartis will take on full responsibility for development, manufacturing, and commercialization following clinical candidate selection. [collapse expanded text] |
Novartis, PTC Therapeutics | Dec 2024 | 2900 | Licensing and collaboration agreement for PTC518 Huntington's disease program | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Overall SummaryPTC Therapeutics has entered into a global license and collaboration agreement with Novartis for PTC518, an oral disease-modifying therapy for Huntington's Disease (HD). Under the terms, Novartis will assume responsibility for global development, manufacturing, and commercialization of the therapy after the completion of the ongoing PIVOT-HD trial in H1 2025. PTC will receive an upfront payment of $1.0 billion and is eligible for up to $1.9 billion in milestones, as well as profit sharing (40% of U.S. profits) and royalties on ex-U.S. sales. [collapse expanded text] |
Novartis, PeptiDream | Apr 2024 | 2890 | Licensing agreement for peptide drug conjugate multi-program | Parties Involved
… read more Collaboration ScopePeptiDream Inc. and Novartis Pharma AG have expanded their peptide discovery collaboration. PeptiDream will utilize its Peptide Discovery Platform System (PDPS®) technology to identify and optimize novel macrocyclic peptides targeting specific indications chosen by Novartis. These peptides may be conjugated to radionuclides for use in radioligand therapies (RLTs) or other therapeutic and diagnostic applications. This expansion builds on the 2019 peptide-drug conjugate (PDC) collaboration and enhances their long-standing partnership, which began in 2010 and was extended in 2015 when Novartis licensed PeptiDream’s PDPS technology. Rights & Responsibilities
Financial Terms
Regulatory ApprovalThe closing of the transaction is subject to necessary consents or approvals, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Overall SummaryPeptiDream Inc. and Novartis Pharma AG have expanded their collaboration to include additional macrocyclic peptide programs, focused on radioligand therapies and other diagnostic and therapeutic applications. PeptiDream will receive an upfront payment of $180 million USD and is eligible for up to $2.71 billion USD in milestone payments, alongside royalties. This expansion builds on their long-standing relationship and aims to enhance the development of targeted, novel therapies for patients. [collapse expanded text] |
Novartis, Schrodinger | Nov 2024 | 2422 | Research and licensing agreement for multi-target development candidates and software | Parties Involved
Collaboration ScopeSchrödinger and Novartis have entered into a multi-year, multi-target research collaboration and licensing agreement. The collaboration focuses on advancing therapeutics for undisclosed targets within Novartis’s core therapeutic areas. Schrödinger and Novartis will jointly discover development candidates, while Novartis will lead clinical development, manufacturing, and global commercialization. In addition, the companies have expanded their existing software agreement, granting Novartis enhanced access to Schrödinger’s computational predictive modeling technology and enterprise informatics platform at scale, to accelerate drug discovery across Novartis's global research network. Rights & Responsibilities
Financial Terms
Regulatory ApprovalThe agreement is subject to customary closing conditions, including regulatory clearance. Overall SummarySchrödinger and Novartis have entered a multi-target research collaboration, with Schrödinger receiving $150 million upfront and the potential to earn up to $2.3 billion in milestone payments, plus royalties on future sales. Schrödinger will provide its computational platform to advance Novartis’s drug discovery efforts, while Novartis will handle clinical development and commercialization. This collaboration further strengthens the relationship between the two companies, expanding the use of Schrödinger's technology at scale across Novartis’s global research network. [collapse expanded text] |
Monte Rosa Therapeutics, Novartis | Oct 2024 | 2250 | Development and licensing agreement for T and B cell-modulating VAV1-directed molecular glue degraders | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryMonte Rosa Therapeutics has entered a global license agreement with Novartis to develop and commercialize VAV1-directed molecular glue degraders (MGDs), including MRT-6160, for immune-mediated conditions. Under the terms, Monte Rosa will receive an upfront payment of $150 million, with the potential for up to $2.1 billion in milestone payments, along with tiered royalties on ex-U.S. net sales. Novartis will take the lead in clinical development and commercialization, while Monte Rosa remains responsible for completing the ongoing Phase 1 study. The agreement also includes a U.S. profit and loss share for Phase 3 development. [collapse expanded text] |
Astellas Pharma, AviadoBio | Oct 2024 | 2230 | Option and licensing agreement for gene therapy AVB-101 targeting frontotemporal dementia | Parties Involved
… read more Collaboration ScopeThe collaboration focuses on AVB-101, an AAV-based gene therapy in Phase 1/2 development for frontotemporal dementia with progranulin mutations (FTD-GRN). Astellas will have the option to license AVB-101 for FTD-GRN and other potential indications. Rights & Responsibilities
Financial Terms
Regulatory ApprovalAVB-101 is currently in Phase 1/2 of development for FTD-GRN. Overall SummaryAstellas Pharma and AviadoBio have entered an exclusive option and license agreement for AVB-101, a gene therapy in development for frontotemporal dementia. Astellas will make an equity investment and upfront payments, with milestone and royalty potential. This partnership aims to accelerate the development of AVB-101 and expand Astellas’ gene therapy pipeline for neurodegenerative diseases. [collapse expanded text] |
Inhibrx, Inhibrx Biosciences, Sanofi | Jan 2024 | 2200 | Spin out agreement for Inhibrx Biosciences | Key Deal Terms Summary1. Agreement Overview
2. Financial Terms
3. Structure & Spin-Off of New Inhibrx
4. Development & Commercialization Plans
5. Strategic Impact
Overall SummarySanofi has acquired INBRX-101 from Inhibrx, Inc. for up to $2.2 billion, including $30 per share in cash, a $5 per share contingent value right, and the assumption of all outstanding debt. |
AC Immune, Takeda Pharmaceuticals U.S.A | May 2024 | 2200 | Option and licensing agreement for active immunotherapy targeting amyloid beta for alzheimer’s | Parties Involved
Collaboration Scope… read more
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall Summary
|
MOMA Therapeutics, Roche | Jan 2024 | 2066 | Collaboration and licensing agreement for KnowledgeBase platform for the identification and prosecution of a certain number of novel drug targets involved in promoting cancer cell growth and survival | Parties Involved
Collaboration… read moreScope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryMOMA Therapeutics and Roche have entered into a five-year discovery collaboration where MOMA will use its KnowledgeBase platform to identify and target novel cancer dependencies. MOMA will receive an upfront payment of $66 million and is eligible for up to $2 billion in milestone payments, along with tiered royalties. Roche will manage clinical development and commercialization, with an option for MOMA to co-fund late-stage development in exchange for increased royalties. [collapse expanded text] |
ImmuneOnco Biopharmaceuticals, Instil Bio | Aug 2024 | 2050 | Licensing and development agreement for PD-L1xVEGF bispecific antibody IMM2510 and next-generation anti-CTLA-4 antibody IMM27M | Key Deal Terms Summary1. Parties Involved
2. Agreement Scope
3. Financial Terms
4. Strategic Rationale
5. Next Steps
Overall SummaryInstil Bio and ImmuneOnco have entered into a global license and collaboration agreement, granting Instil ex-China rights to IMM2510 (PD-L1xVEGF bispecific antibody) and IMM27M (anti-CTLA-4 antibody). ImmuneOnco receives up to $50 million upfront and near-term payments, plus over $2 billion in potential milestone payments, along with royalties on global ex-China sales. This partnership expands Instil Bio’s oncology pipeline while enabling ImmuneOnco to retain China market leadership and access global development resources. [collapse expanded text] |
AstraZeneca, CSPC Pharmaceutical Group | Oct 2024 | 2020 | Licensing agreement for lipid-lowering therapy | Parties Involved
Collaboration ScopeAstraZeneca has entered into an exclusive license agreement with CSPC to advance the development of YS2302018, a pre-clinical small molecule Lp(a) disruptor aimed at addressing dyslipidaemia and related cardiovascular conditions. The therapy will be developed either alone or in combination with other treatments, such as the oral PCSK9 inhibitor AZD0780. Rights & Responsibilities
Financial Terms
Regulatory ApprovalThe asset is currently in pre-clinical development, with AstraZeneca taking the lead in advancing it through clinical development and regulatory approval. Overall SummaryAstraZeneca has secured an exclusive license agreement with CSPC for YS2302018, a novel small molecule Lp(a) disruptor with potential for treating dyslipidaemia and other cardiovascular diseases. AstraZeneca will manage the clinical development and commercialization of the therapy, while CSPC will receive an upfront payment and is eligible for milestones and royalties. This agreement strengthens AstraZeneca’s cardiovascular pipeline, addressing significant unmet needs in cardiometabolic diseases. [collapse expanded text] |
Abbvie, Gilgamesh Pharmaceuticals | May 2024 | 2015 | Collaboration and option agreement to develop next-generation therapies for psychiatric disorders | AbbVie and Gilgamesh Pharmaceuticals announced a collaboration and option-to-license agreement to … read moredevelop next-generation therapies for psychiatric disorders AbbVie and Gilgamesh have agreed to research and develop a portfolio of next-generation therapeutics for psychiatric disorders Upon exercise of the option, AbbVie will lead development and commercialization activities Gilgamesh will receive an upfront payment of $65 million from AbbVie and is eligible to receive up to $1.95 billion in aggregate option fees and milestones Tiered royalties from mid-single to low-double digits on net sales [collapse expanded text] |
Jiangsu Hansoh Pharmaceutical, Merck and Co | Dec 2024 | 2012 | Licensing agreement for investigational oral GLP-1 receptor agonist | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryMerck and Hansoh Pharma have entered into an exclusive global license agreement for HS-10535, an investigational oral GLP-1 receptor agonist. The collaboration will leverage Merck's expertise in cardiometabolic diseases to develop and commercialize the asset globally, with potential additional benefits beyond weight reduction. Hansoh Pharma will receive $112 million upfront and is eligible for up to $1.9 billion in milestone payments, alongside royalties on product sales. Additionally, Hansoh Pharma may have the opportunity to co-promote or solely commercialize the drug in China. [collapse expanded text] |
Boehringer Ingelheim, Suzhou Ribo Life Sciences | Jan 2024 | 2000 | Collaboration and licensing agreement for treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval[No specific regulatory approval details were provided.] Overall SummaryBoehringer Ingelheim and Ribo have formed a collaboration to develop RNAi-based therapies for NASH/MASH, a liver disease with no approved treatments. Ribo’s RIBO-GalSTAR™ platform will be central to the partnership, enabling targeted gene silencing in hepatocytes. Ribo will receive an upfront payment, milestone payments, and tiered royalties, with the collaboration valued at over USD 2 billion. [collapse expanded text] |
Genentech, Sangamo Therapeutics | Aug 2024 | 1950 | Licensing agreement for genomic medicines for neurodegenerative diseases | Key Deal Terms Summary1. Parties Involved
2. Agreement Scope
3. Financial Terms
4. Strategic Rationale
5. Next Steps
Overall SummarySangamo Therapeutics has signed a global license agreement with Genentech, granting exclusive rights to its zinc finger repressors targeting tau and an undisclosed neurology target, along with its STAC-BBB AAV capsid technology. Sangamo will receive $50 million upfront, with potential milestone payments of up to $1.9 billion, plus tiered royalties on sales. Genentech will lead clinical development and commercialization, further strengthening its neuroscience and gene therapy pipeline. This partnership enhances Sangamo’s position in genomic medicine, while providing Genentech with a novel gene regulation approach for neurodegenerative diseases. [collapse expanded text] |
Abbvie, MedinCell | Apr 2024 | 1935 | Licensing and development agreement for next generation long-acting injectable technology platform | Parties Involved
Collaboration Scope… read moreMedincell and AbbVie have entered into a co-development and licensing agreement to develop up to six long-acting injectable therapies across multiple therapeutic areas. Medincell will provide its commercial-stage long-acting injectable technology, while AbbVie will handle clinical development, regulatory approval, manufacturing, and commercialization of the therapies. Rights & Responsibilities
Financial Terms
Regulatory ApprovalMedincell’s technology was used in the development of its first FDA-approved product, UZEDY®, for the treatment of schizophrenia, approved in April 2023. Overall SummaryMedincell has entered into a strategic partnership with AbbVie to co-develop up to six long-acting injectable therapies using Medincell’s innovative BEPO® technology. Medincell will receive a $35 million upfront payment and is eligible for up to $1.9 billion in potential milestones, plus royalties on sales. AbbVie will handle the clinical development, regulatory approval, manufacturing, and commercialization of the programs. [collapse expanded text] |
Merck and Co, Mestag Therapeutics | Oct 2024 | 1900 | Research and option agreement to identify targets for inflammatory diseases | Mestag Therapeutics announced it entered into license and collaboration agreement with MSD to … read moreidentify novel targets for development of therapies against inflammatory diseases Mestag will employ its Reversing Activated Fibroblast Technology (RAFT) platform, a proprietary platform purposely built to model the pathogenic role of fibroblasts in human disease to identify drug targets MSD has option to license one or more targets up to prespecified number and will be responsible for discovery, development and commercialization of resulting therapeutics Mestag will provide MSD options to obtain exclusive licenses to develop and commercialize therapeutics directed against a prespecified number of potential targets identified under collaboration Mestag will receive upfront payment and access fees Eligible to receive option fees as well as downstream payments with potential to total $1.9 billion [collapse expanded text] |
Flare Therapeutics, Roche | Nov 2024 | 1870 | Licensing agreement for small molecule discovery using proteomic and mass spectrometry platform | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall Summary
|
Bristol-Myers Squibb, Repertoire Immune Medicines | Apr 2024 | 1865 | Development and licensing agreement for tolerizing vaccines for autoimmune diseases | Parties Involved
Collaboration ScopeThe collaboration between Repertoire Immune Medicines and Bristol Myers Squibb aims to develop tolerizing vaccines for up to three autoimmune diseases. The focus is to create selective and durable treatments that reset the immune system in patients with autoimmune conditions. Repertoire will utilize its DECODE™ platform to identify disease-associated epitopes and develop the vaccine candidates, while Bristol Myers Squibb will lead clinical development, regulatory affairs, and commercialization. Rights & Responsibilities
Financial Terms
Overall SummaryRepertoire Immune Medicines has entered into a multi-year strategic collaboration with Bristol Myers Squibb to develop tolerizing vaccines for autoimmune diseases. Repertoire will provide its innovative DECODE™ platform for T cell epitope discovery and vaccine development, while Bristol Myers Squibb will lead the clinical and commercial development. Repertoire is set to receive $65 million upfront, with the potential for $1.8 billion in milestone payments and royalties based on the vaccines' success. [collapse expanded text] |
Ascidian Therapeutics, Roche | Jun 2024 | 1842 | Research and licensing agreement for RNA Exon editing therapeutics targeting neurological diseases | Parties Involved
… read more Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryAscidian Therapeutics and Roche have entered into a collaboration to develop RNA exon editing therapeutics for neurological diseases. The deal, valued at up to $1.8 billion, will see Roche responsible for clinical development, manufacturing, and commercialization, while Ascidian focuses on discovery and preclinical activities. Ascidian will receive $42 million upfront, with additional milestones and royalties. [collapse expanded text] |
BioNTech, MediLink Therapeutics | May 2024 | 1825 | Licensing and option agreement for TMALIN antibody-drug conjugate platform | Parties Involved
… read more Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall Summary
|
Ipsen, Skyhawk Therapeutics | Apr 2024 | 1800 | Option and licensing agreement for small molecules that modulate RNA for rare neurological diseases | Parties Involved
… read more Collaboration ScopeIpsen and Skyhawk Therapeutics have entered into an exclusive worldwide collaboration to discover and develop novel small molecules targeting RNA for rare neurological diseases. The collaboration will leverage Skyhawk’s RNA-targeting platform to explore previously undruggable RNA targets and expand the landscape of potential treatments for rare neurological conditions, including those related to movement disorders. Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryIpsen and Skyhawk Therapeutics have formed a strategic partnership to develop RNA-targeting small molecules aimed at treating rare neurological diseases. Under the agreement, Ipsen will gain exclusive rights to two development candidates and assume responsibility for their future development and commercialization. Skyhawk is eligible for significant milestone payments, up to $1.8 billion, plus royalties. This collaboration aims to address unmet medical needs in movement disorders and other rare neurological conditions. [collapse expanded text] |
Eli Lilly, Isomorphic Labs | Jan 2024 | 1745 | Collaboration agreement to discover small molecule therapeutics against multiple targets | Parties Involved
… read more Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval[No specific regulatory approval details mentioned in the release.] Overall SummaryIsomorphic Labs has entered into a strategic research collaboration with Lilly to discover small molecule therapeutics using its AI-driven platform, based on the next generation of AlphaFold. The deal includes an upfront payment of $45 million, with the potential for up to $1.7 billion in milestone payments and royalties on net sales. This marks Isomorphic Labs' first pharmaceutical partnership and aims to accelerate the development of novel drug candidates for multiple therapeutic targets. [collapse expanded text] |
Eli Lilly, Isomorphic Labs | Jan 2024 | 1745 | Collaboration agreement for small molecule therapeutics against multiple targets | Parties Involved
… read more Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval[No specific regulatory approval details mentioned in the release.] Overall SummaryIsomorphic Labs has entered into a strategic collaboration with Eli Lilly to apply its AI-driven drug discovery platform for the development of small molecule therapeutics. The deal includes an upfront payment of $45 million, with the potential for up to $1.7 billion in milestone payments and tiered royalties. This partnership marks Isomorphic Labs' first pharmaceutical collaboration and is aimed at advancing groundbreaking drug design approaches. [collapse expanded text] |
Abbvie, FutureGen Biopharm | Jun 2024 | 1710 | Development and licensing agreement for next-generation therapy for inflammatory bowel disease | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Overall SummaryAbbVie has secured an exclusive global license from FutureGen to develop, manufacture, and commercialize FG-M701, a next-generation TL1A antibody for inflammatory bowel disease (IBD). In return, FutureGen will receive an upfront payment of $150 million, with the potential for additional milestone payments of up to $1.56 billion and royalties on sales. This partnership combines AbbVie’s global expertise in autoimmune diseases with FutureGen’s innovative drug development platform. [collapse expanded text] |
Merck and Co, Orion | Jul 2024 | 1630 | Licensing agreement for opevesostat investigational CYP11A1 inhibitor for metastatic castration-resistant prostate cancer | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryMerck and Orion have exercised their option to convert their co-development agreement into an exclusive global license for opevesostat, an investigational treatment for metastatic castration-resistant prostate cancer (mCRPC). Merck now assumes full responsibility for the development and commercialization of the compound, while Orion retains manufacturing responsibilities. Orion will receive milestone payments and royalties based on future sales. The agreement is expected to become effective in Q3 2024, contingent on regulatory approval. [collapse expanded text] |
Gilead Sciences, Merus | Mar 2024 | 1581 | Research, option and license agreement for discovery of antibody-based trispecific T-Cell engagers | Key Deal Terms Summary1. Agreement Overview
2. Financial Terms
3. Development & Commercialization Responsibilities
4. Strategic Impact
Overall SummaryGilead and Merus have entered into a trispecific antibody research and licensing agreement, under which Gilead will invest $25 million in Merus and pay $56 million upfront. Merus is eligible for up to $1.5 billion in milestone payments, along with tiered royalties on future sales. Gilead has the exclusive option to license the programs, while Merus may opt into profit-sharing for a third program. This collaboration enhances Gilead’s oncology pipeline while validating Merus’ Triclonics® platform as a next-generation immunotherapy approach. [collapse expanded text] |
CureVac, GSK | Jul 2024 | 1568 | Licensing agreement for mRNA candidate vaccines | Key Deal Terms Summary1. Parties Involved
2. Agreement Scope
3. Financial Terms
4. Strategic Rationale
5. Next Steps & Closing Conditions
Overall SummaryGSK and CureVac have restructured their collaboration into a new licensing agreement, granting GSK full global rights to develop, manufacture, and commercialize CureVac’s mRNA vaccine candidates for influenza, COVID-19, and combinations. CureVac will receive €400 million upfront, up to €1.05 billion in milestone payments, and royalties in the high single to low teens range. The deal strengthens GSK’s mRNA vaccine pipeline, while CureVac retains select infectious disease programs and secures significant non-dilutive funding for its R&D pipeline. Regulatory approvals are pending. [collapse expanded text] |
Pfizer, TRIANA Biomedicines | Oct 2024 | 1549 | Research, licensing and option agreement for molecular glue degraders for multiple disease areas | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryTRIANA Biomedicines has entered a strategic collaboration with Pfizer to discover novel molecular glue degraders for a range of disease targets, including oncology. TRIANA will receive $49 million upfront, with potential milestone payments exceeding $1.5 billion and tiered royalties. Pfizer will have the exclusive option to license the discovered molecules for further development. This partnership leverages TRIANA's cutting-edge discovery platform to create innovative therapies for diseases with unmet needs. [collapse expanded text] |
Eisai, Seed Therapeutics | Aug 2024 | 1500 | Research, development and licensing agreement for molecular glue degraders for neurodegeneration and oncology indications | Parties Involved
… read more Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummarySEED Therapeutics has formed a strategic research collaboration with Eisai to advance molecular glue degraders for neurodegeneration and oncology. The deal includes upfront and milestone payments totaling up to $1.5 billion plus tiered royalties for SEED. Alongside the collaboration, SEED has raised $24 million in a Series A-3 financing, which will support its clinical programs in cancer and neurodegenerative diseases. [collapse expanded text] |
Kura Oncology, Kyowa Hakko Kirin | Nov 2024 | 1491 | Development and licensing agreement for ziftomenib | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval & Product Development
Overall SummaryKura Oncology and Kyowa Kirin have entered a global strategic collaboration to develop and commercialize ziftomenib, a selective oral menin inhibitor for AML. Kura will lead U.S. development and commercialization, while Kyowa Kirin will handle commercialization outside the U.S. Both companies will share profits and losses in the U.S. and have committed to a joint global development program. Kura is poised to receive up to $1.2 billion in milestone payments, along with royalties on global sales. This collaboration will also explore solid tumor indications, should Kyowa Kirin exercise its opt-in rights. [collapse expanded text] |
Abbvie, EvolveImmune Therapeutics | Oct 2024 | 1465 | Development and option agreement for next-generation cancer biotherapeutics | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryAbbVie and EvolveImmune Therapeutics have entered a collaboration and option-to-license agreement to develop next-generation cancer biotherapeutics. This partnership will combine AbbVie’s oncology expertise with EvolveImmune’s EVOLVE T-Cell Engager Platform to create innovative multispecific antibody therapies for both solid and hematologic cancers. EvolveImmune will receive $65 million in upfront payments and equity investment, with potential for up to $1.4 billion in milestones and tiered royalties on future sales. The collaboration marks a significant step towards developing therapeutics that could address cancer-driven immunodeficiency. [collapse expanded text] |
Neomorph, Novo Nordisk | Feb 2024 | 1460 | Collaboration and licensing agreement for molecular glue degraders for cardiometabolic and rare diseases | Parties Involved
… read more Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryNeomorph and Novo Nordisk have entered into a partnership to discover and develop molecular glue degraders aimed at addressing cardiometabolic and rare diseases. The collaboration leverages Neomorph’s innovative discovery platform and Novo Nordisk’s expertise in these therapeutic areas. Neomorph will lead early-stage discovery and preclinical work, while Novo Nordisk will handle clinical development and commercialization. The deal has a potential value of $1.46 billion, plus tiered royalties. [collapse expanded text] |
Biogen, Neomorph | Oct 2024 | 1450 | Research, development and licensing agreement for multi-target molecular glue degraders | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryBiogen and Neomorph have entered a multi-target research collaboration to develop molecular glue degraders for key targets in Alzheimer's, rare neurological, and immunological diseases. The deal involves an upfront payment, milestone payments up to $1.45 billion, and royalties on successful sales. Neomorph will leverage its molecular glue discovery platform while Biogen provides its clinical expertise to move the candidates toward commercialization. [collapse expanded text] |
Abbvie, Umoja Biopharma | Jan 2024 | 1440 | Collaboration, option and licensing agreement for in-situ CAR-T cell therapies | Parties Involved
Collaboration… read moreScope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryAbbVie and Umoja Biopharma have entered into two exclusive option and license agreements to develop in-situ generated CAR-T cell therapies using Umoja's VivoVec™ gene delivery platform. AbbVie will have the option to license Umoja's CD19-directed CAR-T candidates and will collaborate on additional CAR-T therapies. The deal includes upfront payments, an equity investment, and the potential for up to $1.44 billion in milestone payments, along with tiered royalties on worldwide sales. [collapse expanded text] |
Caris Life Sciences, Merck KGaA | Apr 2024 | 1400 | Licensing agreement for discovery of cancer targets and acceleration of antibody drug conjugate development | Parties Involved
Collaboration ScopeCaris Life Sciences and Merck KGaA, Darmstadt, Germany will collaborate to accelerate the discovery and development of first-in-class antibody-drug conjugates (ADCs) for cancer. The collaboration will leverage Caris Discovery’s AI-driven platform to identify novel cancer targets that could be used for ADC therapeutics. Rights & Responsibilities
Financial Terms
Regulatory ApprovalNo specific regulatory approval details were provided for this collaboration. Overall SummaryCaris Life Sciences has entered a multi-year strategic partnership with Merck KGaA, Darmstadt, Germany, to discover novel cancer targets for antibody-drug conjugates (ADCs). Caris will utilize its AI-driven discovery platform to identify targets, while Merck will be responsible for the development and commercialization of the resulting therapeutics. Caris is eligible for upfront payment, milestone payments (up to $1.4 billion), and tiered royalties. [collapse expanded text] |
Eli Lilly, KeyBioScience | Oct 2024 | 1400 | Licensing agreement for Dual Amylin Calcitonin Receptor Agonists | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryKeyBioscience and Eli Lilly have extended their collaboration to develop DACRA molecules as a potential therapy for obesity and osteoarthritis. The extension includes a Phase 2 study for a new DACRA molecule and the investigation of the platform for multiple indications. Lilly will have global rights to develop and commercialize the molecules, while KeyBioscience will receive upfront payments, milestone payments up to $1.4 billion, and royalties based on net sales. [collapse expanded text] |
BioArctic AB, Bristol-Myers Squibb | Dec 2024 | 1350 | Licensing and option agreement for PyroGlutamate-amyloid-beta antibody program | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryBioArctic has entered into an exclusive global licensing agreement with Bristol Myers Squibb for its PyroGlu-Aβ antibody program, which includes BAN1503 and BAN2803, the latter incorporating BrainTransporter™ technology. Under the terms, BioArctic will receive a USD 100 million upfront payment, up to USD 1.25 billion in milestones, and royalties on sales. BMS will take full responsibility for the clinical development and commercialization of these assets, with BioArctic retaining an option to co-commercialize in the Nordic region. This collaboration has the potential to leverage innovative technology to improve the treatment of Alzheimer's disease and other neurodegenerative conditions by overcoming the blood-brain barrier. [collapse expanded text] |
Kumquat Biosciences, Takeda Pharmaceutical | Apr 2024 | 1330 | Licensing and development agreement for immuno-oncology small molecule inhibitor | Parties Involved
… read more Collaboration ScopeKumquat Biosciences and Takeda have entered into a strategic and exclusive collaboration to develop and commercialize a novel immuno-oncology small molecule inhibitor. The inhibitor is being explored as a mono- and/or combination-therapy for cancer treatment. Kumquat will lead the research and Phase 1 clinical development, with an option to co-develop and share profits/losses in the U.S. market. Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryKumquat Biosciences has entered a strategic collaboration with Takeda to develop a novel immuno-oncology small molecule inhibitor. Kumquat will lead the research and Phase 1 clinical development, while Takeda will handle global development and commercialization beyond Phase 1. The agreement includes up to $130 million in near-term payments and up to $1.2 billion in milestone payments, with tiered royalties on any commercial sales. Kumquat also has the option to co-develop and share profits or losses for the U.S. market. [collapse expanded text] |
Astellas Pharma, Sangamo Therapeutics | Dec 2024 | 1320 | Licensing agreement for neurotropic adeno-associated virus STAC-BBB capsid | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummarySangamo Therapeutics and Astellas Pharma have entered into a capsid licensing agreement to develop gene therapies for neurological diseases. The deal grants Astellas worldwide exclusive rights to use Sangamo’s STAC-BBB capsid, initially for one neurological disease target, with an option to expand to four additional targets. Sangamo receives $20 million upfront and is eligible for up to $1.3 billion in milestone payments and tiered royalties on future net sales. Astellas will handle all research, development, regulatory, and commercialization efforts, further expanding its gene therapy capabilities. [collapse expanded text] |
Novartis, Voyager Therapeutics | Jan 2024 | 1300 | Collaboration and licensing agreement for novel gene therapies | Parties Involved
… read more Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval[No specific regulatory approval details were provided.] Overall SummaryVoyager Therapeutics has entered a strategic collaboration with Novartis to develop gene therapies for Huntington's disease (HD) and spinal muscular atrophy (SMA). Voyager will provide Novartis exclusive rights to its TRACER capsids for these diseases, with Voyager handling preclinical development for HD and Novartis overseeing clinical development and commercialization. The agreement includes an upfront payment of $100 million, with the potential for $1.2 billion in milestone payments and royalties on global sales. [collapse expanded text] |
Elanco, Merck Animal Health | Feb 2024 | 1300 | Asset purchase agreement for aqua business | Merck Animal Health has signed a definitive agreement to acquire the aqua business of Elanco Animal … read moreHealth for $1.3 billion in cash, consisting of an innovative portfolio of medicines and vaccines, nutritionals and supplements for aquatic species; two related aqua manufacturing facilities in Canada and Vietnam; as well as a research facility in Chile. The acquisition is expected to be completed by mid-year 2024, subject to approvals from regulatory authorities and other customary closing conditions. [collapse expanded text] |
Ascentage Pharma, Takeda Pharmaceutical | Jun 2024 | 1300 | Licensing agreement for third-generation BCR-ABL tyrosine kinase inhibitor olverembatinib | Parties Involved
… read more Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryAscentage Pharma has signed an option agreement with Takeda for the potential global license of olverembatinib outside of China and select other regions. Ascentage will receive an option payment of $100 million and could earn up to $1.2 billion in milestones and royalties. If Takeda exercises the option, they will assume global commercialization and further development responsibilities for olverembatinib, which is already approved in China for CML treatment. Additionally, Takeda will make a minority equity investment in Ascentage. [collapse expanded text] |
Curon Biopharmaceutical, Merck and Co | Aug 2024 | 1300 | Asset purchase agreement for B-Cell depletion therapy CN201 | Merck and Curon Biopharmaceutical announced that they entered into definitive agreement under which … read moreMerck through a subsidiary has agreed to acquire CN201 investigational clinical-stage bispecific antibody for treatment of B-cell associated diseases Merck will acquire full global rights to CN201 for an upfront payment of $700 million in cash Curon is eligible to receive up to $600 million in milestone payments associated with the development and regulatory approval of CN201 [collapse expanded text] |
Keros Therapeutics, Takeda Pharmaceutical | Dec 2024 | 1300 | Development and licensing agreement for Elritercept | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryKeros Therapeutics has entered into an exclusive global license agreement with Takeda to advance elritercept, an engineered ligand trap for treating cytopenias in MDS and MF patients. Keros will receive an upfront payment of $200 million and is eligible for up to $1.1 billion in milestone payments, along with tiered royalties on net sales. Takeda will take over the responsibility for development, manufacturing, and commercialization of elritercept globally, excluding specific regions in Asia. The agreement is subject to regulatory clearance. [collapse expanded text] |
Isomorphic Labs, Novartis | Jan 2024 | 1237.5 | Collaboration agreement for small molecule therapeutics against three undisclosed targets | Parties Involved
Collaboration… read moreScope
Rights & Responsibilities
Financial Terms
Regulatory Approval[No specific regulatory approval details mentioned in the release.] Overall SummaryIsomorphic Labs has entered into a strategic collaboration with Novartis to discover small molecule therapeutics against three undisclosed targets. The deal includes an upfront payment of $37.5 million, with the potential for up to $1.2 billion in milestone payments and tiered royalties. The collaboration will leverage Isomorphic Labs' AI-driven platform, including the next-generation AlphaFold model, to enhance Novartis' drug discovery capabilities. [collapse expanded text] |
Day One Biopharmaceuticals, MabCare Therapeutics | Jun 2024 | 1207 | Licensing agreement for antibody drug conjugate targeting PTK7 in solid tumors | Key Deal Terms Summary1. Agreement Overview
2. Financial Terms
3. Development Plan
4. Target Indications
Overall SummaryDay One Biopharmaceuticals has secured exclusive global rights (excluding Greater China) to DAY301, a first-in-class ADC targeting PTK7, under a $55 million upfront payment deal with MabCare Therapeutics. The agreement includes potential milestone payments of up to $1.152 billion and low-to-mid single-digit royalties on sales. DAY301 has received FDA IND clearance, with Phase 1 trials expected to begin in late 2024 or early 2025. This acquisition aligns with Day One’s strategy to expand its pipeline with targeted therapies for pediatric and adult cancers. [collapse expanded text] |
Genentech, Lonza, Roche | Mar 2024 | 1200 | Asset agreement for Genentech manufacturing facility in Vacaville (US) from Roche | Lonza has signed an agreement to acquire the Genentech manufacturing facility in Vacaville (US) … read morefrom Roche for USD 1.2 billion in cash Vacaville (US) site is one of the largest biologics manufacturing facilities in the world by volume Acquisition is set to increase Lonza’s large-scale biologics manufacturing capacity for mammalian therapies and significantly extend the presence of its facility network in the US Lonza plans to invest approximately CHF 500 million to upgrade the facility and enhance capabilities at the site to accommodate the next generation of mammalian biologics therapies Roche products currently manufactured at the site will be supplied by Lonza, with committed volumes over the medium term, phasing out as the site transitions to serve alternative customers [collapse expanded text] |
Novavax, Sanofi | May 2024 | 1200 | Licensing and development agreement for COVID-19 vaccine and flu-COVID-19 combination vaccines | Key Deal Terms Summary1. Agreement Overview
2. Financial Terms
3. Commercialization and Development
4. Strategic Impact
Overall SummarySanofi and Novavax have signed a co-exclusive licensing agreement for the co-commercialization of Novavax’s adjuvanted COVID-19 vaccine and the development of flu-COVID-19 combination vaccines. Sanofi will pay Novavax up to $1.2 billion, including $500 million upfront and $700 million in milestones, along with tiered double-digit royalties on vaccine sales. Sanofi will book sales of Novavax’s COVID-19 vaccine starting in 2025 and lead the development of combination vaccines. The deal expands patient access to protein-based vaccines and strengthens Novavax’s financial position while bolstering Sanofi’s vaccine portfolio. [collapse expanded text] |
Degron Therapeutics, Takeda Pharmaceutical | May 2024 | 1200 | Licensing and option agreement for molecular glue degraders | Degron Therapeutics announced it has entered into a collaboration and exclusive license agreement … read morewith Takeda to discover and develop novel molecular glue degraders for multiple targets in oncology, neuroscience, and inflammation Degron Therapeutics will receive an upfront payment Eligible to receive potential future preclinical, clinical development and commercial milestone payments that could total $1.2 billion if all related milestones are achieved Degron is also eligible to receive tiered royalty payments on sales of any potential commercialized products Parties have option to expand the collaboration to include more targets Takeda will make an equity investment in Degron Degron Therapeutics will retain full ownership of its pipeline programs [collapse expanded text] |
Ipsen, Marengo Therapeutics | Jun 2024 | 1200 | Research and licensing agreement for precision T cell engagers from Tri-STAR platform | Parties Involved
… read more Collaboration Scope
Rights & Responsibilities
Financial Terms
Overall SummaryIpsen and Marengo Therapeutics are enhancing their partnership by focusing on Marengo's TriSTAR platform, which aims to improve T cell engager therapies for ‘cold’ tumors. The collaboration is expected to boost the immune response in these traditionally hard-to-treat cancers. The deal includes potential milestone payments of up to $1.2 billion and tiered sales royalties. [collapse expanded text] |
Evaxion Biotech, Merck and Co | Sep 2024 | 1197 | Option and licensing agreement for AI-designed vaccine candidates EVX-B2 and EVX-B3 | Key Deal Terms Summary1. Parties Involved
2. Agreement Scope
3. Financial Terms
4. Strategic Rationale
5. Previous Collaboration & Investment
Overall SummaryEvaxion has expanded its vaccine development collaboration with MSD, granting MSD an option to license two AI-designed preclinical vaccine candidates (EVX-B2 for Gonorrhea and EVX-B3 for an undisclosed infectious agent). Evaxion receives $3.2 million upfront, with up to $10 million in 2025 if MSD exercises its option. The deal includes milestones of up to $592 million per product and royalties on future sales. This agreement reinforces MSD’s commitment to infectious disease vaccines and validates Evaxion’s AI-Immunology™ platform. [collapse expanded text] |
Chengdu Baiyu Pharmaceutical, Novartis | Oct 2024 | 1170 | Licensing agreement for small molecule anti-tumor asset | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryChengdu Baiyu Pharmaceutical has entered into an exclusive license agreement with Novartis for the development and commercialization of its anti-tumor small molecule asset. Baiyu will receive $70 million upfront, with the potential for up to $1.1 billion in milestone payments, as well as royalties. [collapse expanded text] |
Arvinas, Novartis | Apr 2024 | 1160 | Licensing agreement for PROTAC androgen receptor protein degrader ARV-766 | Key Deal Terms Summary1. Agreement Overview
2. Financial Terms
3. Development & Commercialization Responsibilities
4. Strategic Rationale
5. Closing Conditions
Overall SummaryArvinas has entered into an exclusive global licensing agreement with Novartis for ARV-766, a potential first-in-class PROTAC® androgen receptor degrader for prostate cancer. Novartis will take full responsibility for development, manufacturing, and commercialization, while Arvinas receives $150 million upfront and is eligible for up to $1.01 billion in additional milestone payments, plus tiered royalties. The deal accelerates the clinical development of ARV-766, expands Novartis' oncology pipeline, and validates Arvinas' PROTAC® protein degradation platform. [collapse expanded text] |
Aktis Oncology, Eli Lilly | May 2024 | 1160 | Development and licensing agreement for anticancer radiopharmaceuticals | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall Summary
|
Recordati, Sanofi | Oct 2024 | 1075 | Asset purchase agreement for Enjaymo | Recordati announces agreement with Sanofi to acquire global rights to Enjaymo (sutimlimab) biologic … read morewhich is only approved targeted product for treatment of cold agglutinin disease rare B-cell lymphoproliferative disorder Enjaymo (sutimlimab) is a humanized monoclonal antibody indicated for treatment of hemolysis in adults with CAD Recordati will make upfront payment of US$ 825 million Commercial milestone payments of up to US$ 250 million Deal will be funded by existing cash and new committed bank debt facilities Net debt is expected to be approximately 2.4 - 2.5x EBITDA (pro-forma) at the end of 2024, de-leveraging to less than 2.0x EBITDA at the end of 2025, assuming no additional business development transactions Group’s dividend and capital allocation policy remains unchanged [collapse expanded text] |
Arrowhead Pharmaceuticals, Sarepta Therapeutics | Nov 2024 | 1075 | Licensing and development agreement for multiple clinical and preclinical siRNA programs | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory & Transition Plan
Overall SummarySarepta Therapeutics has entered into a global licensing and collaboration agreement with Arrowhead Pharmaceuticals, acquiring exclusive global rights to multiple clinical, preclinical, and discovery-stage siRNA-based programs targeting muscle, CNS, and pulmonary disorders. These include potential treatments for FSHD, DM1, SCA2, and more. The agreement involves significant financial commitments, including $500 million upfront, an equity investment of $325 million, and future milestone payments. Sarepta aims to enhance its mid- and early-stage pipeline, complementing its existing leadership in genetic therapies. The deal provides access to Arrowhead’s leading RNAi platform, with Sarepta expected to take over clinical programs after ongoing trials. [collapse expanded text] |
Generate Biomedicines, Novartis | Sep 2024 | 1065 | Licensing agreement for protein therapeutics with generative AI | Parties Involved
… read more Collaboration ScopeGenerate:Biomedicines and Novartis will collaborate to discover and develop protein therapeutics across multiple disease areas, leveraging Generate’s proprietary generative AI platform. This platform will integrate machine learning with high-throughput experimental validation to create potentially first- and best-in-class molecules. The collaboration aims to combine novel therapeutic creation with Novartis’ expertise in target biology, biologics development, and clinical development. Rights & Responsibilities
Financial Terms
Regulatory ApprovalDetails on regulatory approval status are not disclosed at this time. Overall SummaryGenerate:Biomedicines and Novartis have entered a multi-target collaboration to discover and develop protein therapeutics leveraging Generate’s AI-driven platform for novel molecule creation. The collaboration will combine machine learning with Novartis’ expertise in target biology and biologics development. Generate will receive $65 million upfront, including $15 million for equity purchase, and is eligible for up to $1 billion in milestones and tiered royalties. [collapse expanded text] |
Fulcrum Therapeutics, Sanofi | May 2024 | 1055 | Collaboration and licensing agreement for losmapimod in facioscapulohumeral muscular dystrophy | Key Deal Terms Summary1. Agreement Overview
2. Financial Terms
3. Development and Commercialization
4. Strategic Impact
Overall SummaryFulcrum Therapeutics and Sanofi have entered into a global collaboration and licensing deal for losmapimod, with Sanofi securing ex-U.S. commercialization rights while Fulcrum retains U.S. rights. Fulcrum will receive $80 million upfront, with up to $975 million in milestone payments, and tiered royalties on ex-U.S. sales. The global development costs will be shared equally (50:50). The partnership leverages Sanofi’s global commercial capabilities, positioning losmapimod to potentially become the first approved treatment for FSHD. [collapse expanded text] |
MediLink Therapeutics, Roche | Jan 2024 | 1050 | Collaboration and licensing agreement for next-generation antibody drug conjugate in oncology | Parties Involved
… read more Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval[No specific regulatory approval details were provided.] Overall SummaryMediLink Therapeutics has entered a worldwide collaboration with Roche to develop YL211, a next-generation ADC targeting c-Met for solid tumors. MediLink will work with Roche's R&D unit to start the Phase I clinical trial, with Roche assuming responsibility for the continued development and global commercialization. The agreement includes an upfront payment of $50 million, with the potential for up to $1 billion in milestone payments and royalties on global sales. [collapse expanded text] |
Samsung Biologics | Jun 2024 | 1050 | Manufacturing agreement with large unnamed U.S. drugmaker | Key Deal Terms Summary1. Parties Involved
2. Agreement Details
3. Financial Impact
4. Strategic Rationale
5. Additional Considerations
Overall SummarySamsung Biologics has signed a $1.05 billion manufacturing agreement with a large U.S. pharmaceutical company, marking one of its largest deals to date. This long-term contract, running through 2030, reinforces Samsung’s position as a leading global biologics CDMO and represents more than 39% of its 2023 revenue. The deal highlights the increasing demand for biologics manufacturing and strengthens Samsung’s revenue pipeline for the next several years. [collapse expanded text] |
Dyno Therapeutics, Roche | Oct 2024 | 1050 | Research, development and licensing agreement to advance AAV gene therapy vectors for neurological diseases | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryDyno Therapeutics has entered a new strategic partnership with Roche to advance AAV gene therapies targeting neurological diseases. Dyno will provide AI-driven gene delivery platform capabilities, including AAV capsid design, while Roche will manage validation, preclinical, clinical, and commercialization efforts. Dyno will receive $50 million upfront and is eligible for over $1 billion in milestone payments, along with royalties on commercial sales. [collapse expanded text] |
IDEAYA Biosciences, Jiangsu Hengrui Pharmaceuticals | Dec 2024 | 1045 | Licensing agreement for SHR-4849 | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryIDEAYA secures exclusive global rights (excluding Greater China) to develop and commercialize SHR-4849, a DLL3-targeting Topo-I ADC for SCLC and NETs, from Hengrui Pharma. The deal includes a $75 million upfront payment, up to $1.045 billion in total milestone payments, and mid-single to low-double-digit royalties for Hengrui. IDEAYA plans to file a U.S. IND in H1 2025, integrating SHR-4849 into its precision oncology pipeline with potential combination strategies to enhance treatment efficacy. [collapse expanded text] |
Remix Therapeutics, Roche | Jan 2024 | 1042 | Collaboration agreement for small molecule therapeutics modulating RNA processing | Parties Involved
Collaboration… read moreScope
Rights & Responsibilities
Financial Terms
Regulatory Approval[No specific regulatory approval details were provided.] Overall SummaryRemix Therapeutics has entered into a collaboration and license agreement with Roche to discover and develop small molecule therapeutics modulating RNA processing. Remix will receive a $30 million upfront and is eligible for significant milestone payments, with Roche assuming responsibility for development and commercialization. The collaboration leverages Remix’s REMaster™ platform to address disease drivers at the RNA level. [collapse expanded text] |
Foreseen Biotechnology, Ipsen | Jul 2024 | 1030 | Licensing agreement for FS001 antibody-drug conjugate | Parties Involved
… read more Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryIpsen and Foreseen Biotechnology have entered an exclusive global licensing agreement for FS001, a first-in-class antibody-drug conjugate (ADC) targeting a novel tumor-associated antigen in solid tumors. Ipsen will handle all clinical development, manufacturing, and global commercialization. Foreseen will receive milestones and royalties based on the drug's success. The agreement is valued at up to $1.03 billion, contingent on successful development and approvals. [collapse expanded text] |
DualityBio, GSK | Dec 2024 | 1005 | Option agreement for antibody-drug conjugate (DB-1324) | Duality Biologics announced it entered exclusive option agreement with GSK for potentially best-in- … read moreclass ADC candidate DB-1324 DualityBio will grant GSK an exclusive option to obtain license to develop and commercialize DB-1324 worldwide excluding mainland China, Hong Kong and Macau GSK will pay $30 million upfront Pre-option milestone payments to obtain exclusive option for exclusive worldwide rights for DualityBio's ADC DualityBio will receive option exercise fee Development, regulatory and commercial milestone payments totalling up to $975 million GSK will pay tiered royalties on DB-1324's global net sales outside mainland China, Hong Kong, and Macau GSK will receive royalties on net sales in mainland China, Hong Kong and Macau [collapse expanded text] |
Allorion Therapeutics, Avenzo Therapeutics | Jan 2024 | 1000 | Licensing and option agreement for AVZO-021 | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryAvenzo Therapeutics and Allorion Therapeutics have entered into an exclusive licensing agreement for the global development and commercialization (excluding Greater China) of AVZO-021, a CDK2 selective inhibitor currently in a Phase 1 clinical trial for HR+/HER2- metastatic breast cancer. The deal includes a $40 million upfront payment, milestone payments potentially exceeding $1 billion, and tiered royalties on future sales. [collapse expanded text] |
Merck and Co, Pearl Bio | Mar 2024 | 1000 | Licensing and option agreement for discovery and development of biologic therapies for the treatment of cancer | Parties Involved
Collaboration ScopePearl Bio and Merck have entered into a license, collaboration, and option agreement to discover novel biologic therapies incorporating non-standard amino acids. The collaboration will focus on utilizing Pearl Bio’s GRO technology (Genomically Recoded Organisms) to create multi-functionalized biologics with tunable properties. Initially, the partnership will prioritize cancer treatments, leveraging Pearl’s ability to work in both cell-based and cell-free systems, along with proprietary tethered ribosomes for encoding synthetic monomers and targeting difficult-to-reach epitopes. Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryPearl Bio has entered a collaboration with Merck to discover novel biologic therapies using non-standard amino acids and GRO technology. The focus will initially be on cancer treatments, with Pearl Bio providing its expertise in synthetic biology to create multi-functionalized biologics. The partnership is valued at up to $1 billion, including upfront, option, and milestone payments, in addition to potential royalties. [collapse expanded text] |
Boehringer Ingelheim, Ochre Bio | Apr 2024 | 1000 | Development and licensing agreement for treatments for chronic liver diseases | Parties Involved
… read more Collaboration ScopeOchre Bio and Boehringer Ingelheim have entered a multi-year collaboration to discover and develop novel regenerative treatments for chronic liver diseases (CLDs), including late-stage metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis. The collaboration focuses on identifying and validating multiple regenerative targets using Ochre Bio’s proprietary human-centric discovery platform which combines machine learning, advanced genomic phenotyping, RNA chemistry, and ex-vivo human-organ perfusion models. Rights & Responsibilities
Financial Terms
Regulatory ApprovalThe collaboration aims to develop treatments for chronic liver diseases, including those caused by MASH cirrhosis, an area with significant unmet medical need and no currently approved therapies for cirrhosis. The goal is to accelerate the discovery of novel regenerative pathways that can improve liver regeneration and function. Overall SummaryOchre Bio and Boehringer Ingelheim have partnered to develop first-in-class regenerative therapies for chronic liver diseases (CLDs), with a particular focus on MASH cirrhosis. Ochre Bio will contribute its advanced discovery platform to identify and validate new regenerative targets, while Boehringer Ingelheim will lead the development efforts. Ochre Bio will receive up to USD 35 million in upfront payments, with the potential for a deal value exceeding USD 1 billion based on research, clinical, and commercial milestones. [collapse expanded text] |
Adcendo, Multitude Therapeutics | Aug 2024 | 1000 | Development and licensing agreement for ADC drug candidate targeting tissue factor | Parties Involved
… read more Collaboration Scope
Rights & Responsibilities
Financial Terms
Overall SummaryAdcendo ApS and Multitude Therapeutics have entered a global licensing agreement to develop ADCE-T02, a first-in-class ADC targeting Tissue Factor for several cancer indications. Adcendo will take the lead on development and commercialization worldwide, excluding Greater China, where Multitude retains rights. The deal includes up to $1 billion in milestone payments and royalties on sales, and ADCE-T02 promises to offer a superior safety profile and efficacy due to its unique linker/payload technology. The Phase I trial in Australia is expected to start in Q4 2024. [collapse expanded text] |
Eli Lilly, HAYA Therapeutics | Sep 2024 | 1000 | Development and licensing agreement for regulatory genome derived RNA-based drug targets | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryHAYA Therapeutics has entered into a multi-year collaboration with Eli Lilly to develop novel RNA-based drug targets for obesity and related metabolic conditions. The deal includes up to $1 billion USD in milestone payments and royalties on sales. HAYA will utilize its RNA-guided regulatory genome platform to identify potential therapies, while Lilly will support the development process. [collapse expanded text] |
Candid Therapeutics, EpimAb Biotherapeutics | Dec 2024 | 1000 | Research, development and licensing agreement for novel T-Cell engagers | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryCandid Therapeutics and EpimAb Biotherapeutics have entered into a research collaboration to discover and develop novel T-cell engager (TCE) candidates targeting autoimmune diseases. EpimAb will contribute its expertise in bispecific antibody technologies (FIT-Ig® and MAT-Fab), while Candid will have exclusive global rights to develop and commercialize any successful programs. The agreement includes an upfront payment, milestone payments potentially totaling over $1 billion, and royalties on net sales. [collapse expanded text] |
Lindy Biosciences, Novartis | Aug 2024 | 954 | Licensing and development agreement for multi-target drug delivery innovation | Parties Involved
… read more Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryLindy Biosciences and Novartis have entered a collaboration to utilize Lindy Biosciences’ microglassification technology for developing self-administered subcutaneous injections of biologic drugs. Lindy Biosciences will receive an upfront payment of $20 million, with potential additional payments of up to $934 million upon achieving milestones. The collaboration also includes tiered royalties on net sales, aiming to revolutionize biologic drug delivery for improved patient convenience and treatment compliance. [collapse expanded text] |
COUR Pharmaceuticals, Genentech | Dec 2024 | 940 | Development and licensing agreement for tolerogenic nanoparticle treatments | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryCOUR Pharmaceuticals has entered into a strategic collaboration and licensing agreement with Genentech, a member of the Roche Group, for the development and commercialization of tolerogenic nanoparticle treatments targeting autoimmune diseases. COUR will provide its proprietary platform and handle preclinical development and manufacturing, while Genentech will lead clinical trials, regulatory filings, and commercialization. The agreement includes $40 million in upfront and near-term milestone payments, with potential milestone payments exceeding $900 million and tiered royalties on net sales. [collapse expanded text] |
Apollo Therapeutics, Sunshine Lake Pharma | Nov 2024 | 938 | Licensing agreement for FGF21 / GLP-1 dual receptor agonist | Parties Involved
Collaboration ScopeApollo Therapeutics and Sunshine Lake Pharma have entered into an exclusive licensing agreement for the development of APL-18881 (HEC88473), a FGF21 / GLP-1 dual receptor agonist. Sunshine Lake will retain the rights for development, manufacturing, and commercialization of the drug in China, while Apollo will hold rights for the rest of the world for all current and future therapeutic indications. Rights & Responsibilities
Financial Terms
Regulatory ApprovalAPL-18881 (HEC88473) is currently in a Phase 2 trial in patients with type 2 diabetes in China, with results expected in H1 2025. The drug has also completed Phase 1 trials in Australia and China, showing a promising safety and pharmacodynamic profile. There is an open IND with the U.S. FDA, and further clinical studies are planned for 2025. Overall SummaryApollo Therapeutics has entered into an exclusive license agreement with Sunshine Lake Pharma for the FGF21 / GLP-1 dual receptor agonist, APL-18881 (HEC88473), which is currently in Phase 2 development for type 2 diabetes. Sunshine Lake will receive $12 million upfront, with the potential for up to $926 million in milestone payments, as well as tiered royalties. Apollo will focus on global development outside of China, while Sunshine Lake will manage development in China. The collaboration aims to explore the drug's potential across multiple cardiometabolic, liver, and related diseases. [collapse expanded text] |
Orlando Health, Tenet Healthcare | Aug 2024 | 910 | Asset purchase agreement for 5 Alabama hospitals | Tenet Healthcare entered into definitive agreement with Orlando Health for the sale of Tenet’s 70% … read moremajority ownership interest in Brookwood Baptist Health in Birmingham for approximately $910 million in cash (after-tax proceeds of approximately $790 million) Transaction will include five hospitals – Brookwood Baptist Medical Center, Princeton Baptist Medical Center, Walker Baptist Medical Center, Shelby Baptist Medical Center, Citizens Baptist Medical Center – as well as affiliated physician practices and other related operations Brookwood Baptist Health will remain joint venture with Baptist Health System Tenet’s Conifer Health Solutions subsidiary will enter into new and expanded ten-year contract to provide revenue cycle management services for Birmingham hospitals and related operations [collapse expanded text] |
Agios Pharmaceuticals, Royalty Pharma | May 2024 | 905 | Royalty financing agreement for vorasidenib | Agios Pharmaceuticals announced that the company has agreed to sell its rights to its 15% royalty … read moreon potential U.S. net sales of Servier’s vorasidenib to Royalty Pharma Agios will receive an upfront payment of $905 million upon approval of vorasidenib by the U.S. Food and Drug Administration Royalty Pharma will receive the entirety of the 15% royalty on annual U.S. net sales of vorasidenib up to $1 billion 12% royalty on annual U.S. net sales greater than $1 billion Agios will retain a 3% royalty on annual U.S. net sales greater than $1 billion Agios is owed from Servier a milestone payment of $200 million upon vorasidenib’s approval by the FDA [collapse expanded text] |
Ipsen, Sutro Biopharma | Apr 2024 | 900 | Licensing agreement for antibody-drug conjugate STRO-003 | Key Deal Terms Summary1. Agreement Overview
2. Financial Terms
3. Development & Commercialization Responsibilities
4. Strategic Impact
Overall SummaryIpsen and Sutro Biopharma have entered a global licensing agreement for STRO-003, a next-generation ADC targeting ROR1, a clinically validated tumor antigen. Ipsen will develop and commercialize STRO-003, assuming responsibility for clinical trials and global marketing. Sutro will receive up to $900 million, including $90 million in near-term payments, plus tiered royalties on global sales. The partnership reinforces Ipsen’s commitment to ADCs and expands Sutro’s oncology pipeline, advancing a promising cancer therapy with strong preclinical potential. [collapse expanded text] |
Jazz Pharmaceuticals, Redx Pharma | Feb 2024 | 880 | Collaboration and licensing agreement for KRAS (Kirsten rat sarcoma virus) inhibitor program | Parties Involved
… read more Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryJazz Pharmaceuticals has acquired Redx Pharma’s KRAS inhibitor program, which includes promising preclinical candidates targeting KRAS mutations in various cancers. The deal includes an upfront payment of USD 10 million, with potential for up to USD 870 million in milestone payments and mid-single digit royalties. Jazz will manage the clinical development and commercialization of the program, expanding its oncology pipeline. [collapse expanded text] |
Kelonia Therapeutics, Xyphos Biosciences | Feb 2024 | 875 | Research and licensing agreement for immuno-oncology therapeutics | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryAstellas Pharma and Kelonia Therapeutics have entered into a research and licensing agreement to jointly develop innovative in vivo CAR-T cell therapies for cancer using Kelonia’s iGPS® technology and Xyphos' ACCEL™ platform. Kelonia will receive significant upfront payments totaling up to US $75 million and may earn up to US $800 million in milestone payments, along with royalties. Xyphos will lead the development and commercialization of the resulting therapies. [collapse expanded text] |
Genentech, Regor Therapeutics | Sep 2024 | 850 | Asset purchase agreement for portfolio of next-generation CDK inhibitors for treatment of breast cancer | Regor Pharmaceuticals entered definitive purchase agreement whereby Genentech will acquire a … read moreportfolio of next-generation CDK inhibitors from Regor for treatment of breast cancer Regor will receive an upfront cash payment of $850 million Additional cash payments based on achievement of certain predetermined development, regulatory and commercial milestones Genentech will be responsible for clinical development, manufacturing and commercialization worldwide Regor will continue to manage the two ongoing Phase 1 trials to their completion Regor will also advance its other distinct assets, unrelated to this deal, in oncology, metabolic diseases and auto-immunity [collapse expanded text] |
Chimagen Biosciences, GSK | Oct 2024 | 850 | Asset purchase agreement for CMG1A46 T cell-engager | GSK and Chimagen Biosciences announced agreement for GSK to acquire CMG1A46 clinical-stage dual … read moreCD19 and CD20-targeted T cell-engager from Chimagen for $300 million upfront GSK plans to develop and commercialise CMG1A46 with focus on B cell-driven autoimmune diseases such as systemic lupus erythematosus and lupus nephritis with potential to expand into related autoimmune diseases GSK will pay $300 million upfront to acquire full global rights to CMG1A46 Chimagen will be eligible to receive success-based development and commercial milestone payments for CMG1A46 totalling $550 million [collapse expanded text] |
Aadi Bioscience, WuXi Biologics | Dec 2024 | 849 | Licensing agreement for three-asset ADC Portfolio | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryAadi Bioscience is transforming its business by acquiring a next-generation ADC portfolio and divesting FYARRO® to KAKEN Pharmaceutical for $100 million. Aadi secures $100 million in PIPE financing to fund ADC development into late 2028, including anticipated clinical data readouts. The ADC portfolio, developed through a collaboration between WuXi Biologics and HANGZHOU DAC, includes three preclinical ADCs targeting PTK7, MUC16, and SEZ6, utilizing HANGZHOU DAC’s CPT113 linker-payload platform. This move positions Aadi as a key player in next-generation ADC development, leveraging broad tumor targets with first-generation proof of concept. [collapse expanded text] |
Boehringer Ingelheim, Sosei Heptares | Mar 2024 | 825.4 | Licensing agreement for G protein-coupled receptor target portfolio of GPR52 agonists. | Parties Involved
… read more Collaboration ScopeBoehringer Ingelheim has entered into a partnership with Sosei Heptares to develop first-in-class treatments targeting all symptoms of schizophrenia. The agreement focuses on GPR52 agonists, a novel G protein-coupled receptor target for treating positive, negative, and cognitive symptoms of schizophrenia. Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryBoehringer Ingelheim has secured an agreement with Sosei Heptares to develop first-in-class schizophrenia treatments targeting GPR52. The deal includes a €25 million upfront payment, up to €670 million in milestones, and potential royalties. The collaboration focuses on a portfolio that could treat positive, negative, and cognitive symptoms of schizophrenia, with the option for Boehringer Ingelheim to license the portfolio after Phase I and Phase Ib trials. [collapse expanded text] |
Peak Rock Capital, Steris Corporation | Apr 2024 | 800 | Asset and equity purchase agreement for STERIS dental segment | STERIS to sell dental segment to an affiliate of Peak Rock Capital Transaction expected to close … read morein STERIS’s first quarter of fiscal 2025 Divestiture allows STERIS to focus on Customers within core markets Proceeds primarily to be used to repay debt Transaction is structured as an equity sale STERIS has entered a definitive agreement to divest its Dental segment to Peak Rock Capital for $787.5 million Transaction terms also include the opportunity for STERIS to receive an additional earnout of up to $12.5 million, subject to the achievement of certain revenue targets of the Dental segment in fiscal 2025 [collapse expanded text] |
Avenzo Therapeutics, VelaVigo | Nov 2024 | 800 | Option agreement for Nectin4/TROP2 bispecific antibody-drug conjugate | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall Summary
|
Elektrofi, Janssen Biotech | Jan 2024 | 793 | Collaboration and licensing agreement for subcutaneous version of a lead oncology asset | Parties Involved
… read more Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval[No specific regulatory approval details were provided.] Overall SummaryElektrofi and Janssen Biotech have formed a worldwide collaboration to develop subcutaneous biologic therapies for oncology, with a focus on making treatment more convenient through self-administration at home. Elektrofi will provide its formulation technology, while Janssen will take the lead on clinical development and commercialization. The agreement includes an $18 million upfront payment, with milestones potentially exceeding $155 million per target, and royalties on sales. [collapse expanded text] |
TreeFrog Therapeutics, Vertex Pharmaceuticals | Apr 2024 | 780 | Collaboration and licensing agreement for C-Stem manufacturing technology in type 1 diabetes | Parties Involved
Collaboration ScopeVertex has obtained an exclusive license to TreeFrog's C-Stem™ manufacturing technology to optimize the production of its cell therapies for type 1 diabetes (T1D). The companies will collaborate to scale-up the process to produce and amplify fully differentiated, insulin-producing pancreatic islet cells for Vertex's T1D therapies. Rights & Responsibilities
Financial Terms
Regulatory ApprovalVertex will be responsible for obtaining regulatory approvals for its T1D cell therapies as they progress through clinical development and commercialization. Overall SummaryVertex and TreeFrog Therapeutics have entered into a collaboration where Vertex will use TreeFrog's C-Stem™ technology to optimize production of its cell therapies for type 1 diabetes. TreeFrog will receive an upfront payment, equity investment, and up to $755 million in milestones, plus royalties. Vertex will lead all research, development, and commercialization efforts for the cell therapies. [collapse expanded text] |
C4 Therapeutics, Merck KGaA | Mar 2024 | 756 | Research collaboration and licensing agreement for targeted protein degraders against critical oncogenic proteins | Key Deal Terms Summary1. Agreement Overview
2. Financial Terms
3. Development & Commercialization Responsibilities
4. Strategic Impact
Overall SummaryC4 Therapeutics and Merck KGaA, Darmstadt, Germany, have entered into a collaboration to develop two targeted protein degraders for oncology. C4T will receive $16 million upfront, with up to $740 million in milestone payments and mid-single to low-double digit royalties on future sales. C4T will lead discovery efforts, while Merck KGaA, Darmstadt, Germany, will handle clinical development and commercialization. This agreement strengthens both companies' positions in targeted protein degradation and oncology drug development. [collapse expanded text] |
Novartis, Ratio Therapeutics | Nov 2024 | 745 | Licensing and research agreement for SSTR2-targeting radiotherapeutic candidate | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall Summary
|
Belharra Therapeutics, Sanofi | Jun 2024 | 740 | Licensing agreement to advance discovery of novel small molecule therapeutics for immunological diseases | Parties Involved
… read more Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryBelharra Therapeutics and Sanofi have entered into a strategic collaboration to discover small molecule therapeutics for immunological diseases. The deal, valued at up to $740 million, will leverage Belharra’s proprietary chemoproteomics platform to identify novel targets, with Sanofi leading clinical and commercial efforts. Belharra will receive upfront payments, milestones, and royalties. [collapse expanded text] |
Capricor Therapeutics, Nippon Shinyaku | Sep 2024 | 735 | Licensing and distribution agreement for deramiocel in Europe | Parties Involved
… read more Collaboration ScopeCapricor Therapeutics and Nippon Shinyaku have entered into a binding term sheet for the European commercialization and distribution of deramiocel (CAP-1002), a treatment for Duchenne muscular dystrophy (DMD). The partnership expands their existing collaboration in the United States and Japan, with a focus on DMD treatment in Europe. Capricor will manage development and manufacturing, while Nippon Shinyaku will handle sales and distribution in the region. Rights & Responsibilities
Financial Terms
Regulatory ApprovalCapricor is preparing to meet with the EMA (European Medicines Agency) to discuss the European approval pathway for deramiocel. Overall SummaryCapricor Therapeutics has signed a binding term sheet with Nippon Shinyaku to expand the commercialization and distribution of deramiocel for Duchenne muscular dystrophy in Europe. The deal includes an upfront payment of $20 million, a $15 million equity investment, and up to $715 million in potential milestones, as well as a double-digit royalty on future sales. The partnership is expected to extend Capricor’s cash runway into 2026 and supports their regulatory and commercialization efforts in Europe. [collapse expanded text] |
BridGene Biosciences, Galapagos | Jan 2024 | 727 | Collaboration and licensing agreement for small molecule drug discovery in oncology | Parties Involved
… read more Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryGalapagos NV and BridGene Biosciences have entered into a strategic collaboration to discover and develop small molecule drugs for oncology, leveraging Galapagos’ expertise in drug discovery and BridGene’s IMTAC™ platform. The collaboration could lead to up to $27 million in upfront and preclinical milestone payments for BridGene, with the potential for over $700 million in clinical and commercial milestones. Galapagos holds exclusive rights for the further development and commercialization of any resulting product candidates. [collapse expanded text] |
Abbvie, OSE Immunotherapeutics | Feb 2024 | 713 | Development and licensing agreement for OSE-230 | Parties Involved
… read more Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryAbbVie has entered into a strategic partnership with OSE Immunotherapeutics to develop OSE-230, a monoclonal antibody aimed at resolving chronic inflammation. AbbVie will hold exclusive rights for global development and commercialization, with OSE Immunotherapeutics receiving an upfront payment of $48 million, milestone payments up to $665 million, and royalties on future sales. The partnership targets novel treatments for chronic inflammatory diseases through a new mechanism of action. [collapse expanded text] |
Jemincare, RAPT Therapeutics | Dec 2024 | 707.5 | Licensing agreement for long-acting anti-IgE antibody | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryRAPT Therapeutics acquires global rights (excluding Greater China) to JYB1904 (RPT904), a long-acting anti-IgE monoclonal antibody, from Jemincare for $35M upfront, with up to $672.5M in milestone payments and royalties on net sales. RAPT plans to initiate a Phase 2b trial in food allergy, while Jemincare continues Phase 2 trials in asthma and CSU in China. The drug demonstrates extended half-life compared to omalizumab, positioning it as a potential best-in-class treatment. [collapse expanded text] |
3D Medicines, Alphamab Oncology, Glenmark Pharmaceuticals S.A. | Jan 2024 | 700.8 | Licensing agreement for KN035 | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryAlphamab Oncology and 3DMedicines have entered into a licensing agreement with Glenmark for the development and commercialization of Envafolimab (KN035) in multiple regions, including India, Asia Pacific (excluding certain countries), the Middle East and Africa, Russia, CIS, and Latin America. The deal provides up to $700.8 million in upfront and milestone payments and royalties on net sales. Glenmark will lead KN035's development and commercialization in these territories, while Alphamab and 3DMedicines retain certain rights to the product. Glenmark will develop and commercialize KN035 in the Field in the Territory at its own cost and expense. Licensors will receive from GSSA (a) a total of up to US$700.8 million of a non-refundable upfront payment and milestones payments subject to the achievement of certain development, regulatory and commercialization milestones, and (b) a single to double digits percentage royalty fee according to the level of net sales of KN035. The Licensors' respective entitlement to the payments (including the upfront payment, milestone payment and the royalty fees) under the License Agreement are subject to the agreements between Jiangsu Alphamab and 3D Medicines. Jiangsu Alphamab retains its sole right to manufacture KN035 for any purpose within or outside the Territory. 3D Medicines retains the right to develop and commercialize KN035 for any purpose in the field of tumor outside the Territory. [collapse expanded text] |
Johnson Matthey, Montagu Private Equity | Mar 2024 | 700 | Asset purchase agreement for medical device components business | Johnson Matthey Plc signed a definitive agreement to sell 100% of its Medical Device Components … read morebusiness (MDC) to Montagu Private Equity for cash consideration of US$700 million (£550 million) on a cash free debt free basis
The gross assets that are the subject of this transaction amounted to £60 million as at 30th September 2023 For the financial year ended 31st March 2023, these assets generated reported profit before tax of £17 million Proceeds after tax and divestment costs for the disposal of MDC are expected to be c.£450 million [collapse expanded text] |
LigaChem Biosciences, Ono Pharmaceutical | Oct 2024 | 700 | Research and licensing agreement for LCB97 | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryOno Pharmaceutical has entered into a license agreement with LigaChem Biosciences for the exclusive worldwide rights to develop, manufacture, and commercialize LCB97, an antibody-drug conjugate (ADC) for solid tumors. In addition, Ono and LCB will collaborate to generate novel ADC candidates using LCB’s ConjuAll™ ADC platform. The deal includes potential milestone payments up to $700 million and tiered royalties based on net sales. This partnership aims to enhance oncology treatments with novel ADC technologies. [collapse expanded text] |
Bristol-Myers Squibb, Prothena | May 2024 | 697.5 | Licensing agreement for PRX019 | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Overall SummaryProthena has granted Bristol Myers Squibb an exclusive global license for PRX019, a potential treatment for neurodegenerative diseases. Prothena will receive $80 million upfront and is eligible for up to $617.5 million in milestones and royalties on net sales. The Phase 1 clinical trial for PRX019 is set to begin by the end of 2024. [collapse expanded text] |
CBC Group, Mubadala Investment Company, UCB | Nov 2024 | 680 | Asset purchase agreement for mature neurology and allergy business | CBC Group completed strategic acquisition of global biopharmaceutical company UCB's mature … read moreneurology and allergy business in China in partnership with Mubadala Investment Company Transaction valued at US$680 million includes UCB's well-known brands Keppra, Vimpat, Neupro, Zyrtec, Xyzal, and the Zhuhai manufacturing site [collapse expanded text] |
Bristol-Myers Squibb, VantAI | Feb 2024 | 674 | Collaboration, option and licensing agreement for molecular glue drug discovery through artificial intelligence | Parties Involved
… read more Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryVantAI and Bristol Myers Squibb have entered into a strategic collaboration to leverage VantAI's AI platform for discovering molecular glues for targeted protein degradation. VantAI is eligible for up to $674 million in milestone payments plus tiered royalties from BMS. This partnership will focus on generative AI to design small molecule therapeutics aimed at induced proximity and protein-protein interactions, with an option to expand into additional programs. [collapse expanded text] |
Samsung Biologics | Nov 2024 | 668 | Manufacturing agreement with European pharmaceutical company | Samsung Biologics announced series of manufacturing deals with a Europe-based pharmaceutical … read morecompany Disclosed deals worth over USD 668 million combined will run through December 2031 Latest agreements bring up the company's cumulative contract value for this year to more than USD 4 billion [collapse expanded text] |
Adaptimmune, Galapagos | May 2024 | 665 | Collaboration and licensing option agreement for uza-cel | Galapagos and Adaptimmune Therapeutics announced they have entered into clinical collaboration … read moreagreement with an option to exclusively license Adaptimmune’s next-generation TCR T-cell therapy, uza-cel, targeting MAGE-A4 for head & neck cancer and potential future solid tumor indications, using Galapagos’ decentralized cell manufacturing platform Adaptimmune will receive an upfront exclusivity payment of $70 million $15 million in R&D funding at signing $15 million in R&D funding will follow subject to the start of dosing in the proof-of-concept trial Adaptimmune will be responsible for clinical proof-of-concept trial in head & neck cancer and supply of vector for manufacturing of uza-cel Galapagos will be responsible for the delivery of fresh uza-cel product for the head & neck cancer proof-of-concept trial using its decentralized cell therapy manufacturing platform Adaptimmune will retain the right to develop, manufacture, commercialize, and otherwise exploit uza-cel for platinum-resistant ovarian cancer Galapagos has an exclusive option to license global rights to uza-cel for a maximum of $100 million, depending on the number of indications in relation to which the option is exercised Adaptimmune is eligible to receive development, regulatory and sales milestone payments of up $465 million, unless the agreement is terminated Tiered royalties on net sales in the mid-single to low-double digit range [collapse expanded text] |
Bayer, Cytokinetics | Nov 2024 | 656 | Licensing and development agreement for aficamten | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval & Product Development
Overall SummaryCytokinetics and Bayer have entered into an exclusive collaboration for the development and commercialization of Aficamten in Japan for treating obstructive and non-obstructive hypertrophic cardiomyopathy (HCM). Cytokinetics will receive €50 million upfront, with the potential for €90 million in near-term milestones, and up to €490 million in commercial milestone payments. Bayer will lead clinical trials in Japan, and the agreement also includes tiered royalties on future sales. This partnership combines Cytokinetics’ expertise in cardiovascular drugs with Bayer’s regional capabilities, aiming to provide innovative treatments to patients with HCM in Japan. [collapse expanded text] |
GSK, Vesalius Therapeutics | Nov 2024 | 650 | Research, development, licensing and option agreement for treatments for Parkinson’s disease | Parties Involved
Collaboration ScopeVesalius Therapeutics and GSK have entered a multi-target strategic alliance to discover and develop novel treatments for Parkinson’s disease and another undisclosed neurodegenerative indication. Vesalius will leverage its proprietary platform to identify novel intervention points, which GSK may then advance into development. Additionally, GSK will gain worldwide development and commercialization rights for a preclinical small molecule program, initially focused on Parkinson’s disease. Rights & Responsibilities
Financial Terms
Regulatory ApprovalThe preclinical small molecule program, focused on Parkinson’s disease, is at the preclinical stage, and regulatory progress will be made as GSK advances the program. Details on regulatory milestones for the novel intervention points remain to be defined. Overall SummaryVesalius Therapeutics has formed a strategic alliance with GSK to leverage its platform in identifying novel intervention points for Parkinson’s disease and another undisclosed neurodegenerative condition. As part of the collaboration, GSK will advance a preclinical small molecule program targeting Parkinson's disease and control further development and commercialization. Vesalius will receive $80 million upfront, with additional potential milestone payments totaling up to $570 million, as well as royalties. Further payments are possible for each novel intervention point discovered during the collaboration. [collapse expanded text] |
Gilead Sciences, Xilio Therapeutics | Mar 2024 | 647.5 | License agreement for Phase 1 tumor-activated IL-12 program, XTX301 | Key Deal Terms Summary1. Agreement Overview
2. Financial Terms
3. Development & Commercialization Responsibilities
4. Strategic Impact
Overall SummaryGilead Sciences and Xilio Therapeutics have entered into a global licensing agreement for XTX301, a tumor-activated IL-12 therapy currently in Phase 1 clinical trials. Gilead secures worldwide rights to develop and commercialize XTX301, with Xilio leading early-stage development. The deal includes a $43.5 million upfront payment, up to $604.0 million in milestone payments, a $75 million transition fee, and tiered royalties on future sales. The partnership enhances Gilead’s immuno-oncology strategy, while enabling Xilio to expand the development of its tumor-activated technology platform. [collapse expanded text] |
GenEdit, Genentech | Jan 2024 | 644 | Collaboration and licensing agreement for nanoparticles to deliver genetic medicines for autoimmune disease | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryGenEdit has entered into a multiyear collaboration and license agreement with Genentech to use GenEdit’s NanoGalaxy platform for the development of hydrophilic nanoparticles (HNPs) aimed at delivering nucleic acid-based medicines for autoimmune diseases. The deal includes an upfront payment of $15 million, with the potential for up to $629 million in milestone payments and tiered royalties on global sales. Genentech will handle the preclinical, clinical, and regulatory development as well as the commercialization of resulting products. [collapse expanded text] |
EpimAb Biotherapeutics, Vignette Bio | Sep 2024 | 635 | Licensing agreement for BCMA-targeting T-cell engager EMB-06 | Parties Involved
… read more Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryEpimAb Biotherapeutics and Vignette Bio have entered a licensing agreement for EMB-06, a BCMA×CD3 bispecific antibody. EpimAb grants Vignette exclusive rights to develop and commercialize EMB-06 outside of Greater China, with EpimAb retaining rights in this region. EpimAb will receive $60 million upfront, plus up to $575 million in milestone payments and royalties on net sales. The collaboration aims to expand the use of EMB-06 in treating autoimmune diseases and multiple myeloma. [collapse expanded text] |
Genmab, Scancell | Dec 2024 | 630 | Licensing agreement for anti-glycan monoclonal antibody | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryScancell has entered into its second commercial license agreement with Genmab, following an exclusive evaluation period. Under the terms of this agreement, Genmab gains exclusive worldwide rights to develop and commercialize an anti-glycan monoclonal antibody from Scancell's GlyMab® platform for multiple therapeutic applications, particularly in cancer treatment. Scancell is set to receive an upfront payment, milestone payments of up to $630 million, and royalties from net sales of the resulting products. This agreement builds upon their previous collaboration, further validating the potential of Scancell’s GlyMab® platform in generating differentiated, tumor-specific antibodies for therapeutic development. [collapse expanded text] |
Eli Lilly, QurAlis | Jun 2024 | 622 | Research, development and licensing agreement for QRL-204 | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Overall SummaryQurAlis Corporation and Eli Lilly and Company have entered into an exclusive global license agreement for QRL-204, a potential first-in-class precision therapy targeting UNC13A to treat ALS, FTD, and other neurodegenerative diseases. The agreement includes an upfront payment, significant milestone potential, and royalty payments. The collaboration also involves the development of additional UNC13A-targeting compounds using QurAlis' FlexASO™ Platform. [collapse expanded text] |
Aditum Bio, Nanjing Leads Biolabs | Nov 2024 | 614 | Option and licensing agreement for LBL-051 tri-specific T-cell engager | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Overall Summary
|
ACADIA Pharmaceuticals, Saniona | Nov 2024 | 610 | Licensing agreement for SAN711 | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval & Product Development
Overall SummaryAcadia Pharmaceuticals has entered into an exclusive worldwide license agreement with Saniona for the development and commercialization of SAN711, a novel GABAA-α3 positive allosteric modulator. The collaboration will initially focus on essential tremor, a neurological condition with significant unmet need. Acadia will take the lead on clinical development, regulatory approvals, and global commercialization, while Saniona will receive an upfront payment, milestone payments, and royalties on future sales. The deal underscores Acadia’s commitment to advancing innovative therapies for CNS disorders. [collapse expanded text] |
Biomunex Pharmaceuticals, Ipsen | Dec 2024 | 610 | Licensing agreement for BMX-502 | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryIpsen and Biomunex Pharmaceuticals have entered into an exclusive global licensing agreement for BMX-502, a first-in-class MAIT cell engager targeting GPC3 in solid tumors. Biomunex will complete the IND-enabling work, and Ipsen will assume responsibility for Phase I development and global commercialization. Biomunex is eligible for up to $610 million in milestone payments plus tiered royalties on net sales. The collaboration leverages Biomunex's BiXAb platform to develop innovative bispecific antibodies with a focus on engaging MAIT cells for enhanced anti-tumor activity. [collapse expanded text] |
Genmab, Revitope Oncology | Oct 2024 | 609 | Licensing and research agreement for next-generation T cell engagement technology | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryRevitope Oncology and Genmab have entered a license agreement for Revitope’s TwoGATE™ T Cell Engagement technology, granting Genmab the rights to research, develop, and commercialize up to three cancer immunotherapies targeting solid tumors. The deal includes an upfront payment of USD $9 million, with additional milestone payments up to USD $600 million, plus royalties on product sales. The collaboration leverages TwoGATE™'s ability to selectively target cancer cells with high precision, aiming to improve efficacy and reduce systemic toxicities. [collapse expanded text] |
KdT Ventures, NGM Biopharmaceuticals | Dec 2024 | 608 | Licensing agreement for NGM313 | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryNGM Bio and KdT Ventures have signed a worldwide exclusive license agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho agonist drug candidate. KdT has formed NewCo to develop NGM313 in a rare disease indication, expanding its potential beyond metabolic disorders. NGM Bio will receive up to $608 million in milestone payments, royalties on net sales, and equity in NewCo. A Phase 2 study is expected in 2025, with KdT leading clinical development and commercialization. [collapse expanded text] |
Boehringer Ingelheim, Circle Pharma | Oct 2024 | 607 | Research and license agreement for precision cancer treatment | Parties Involved
Collaboration ScopeThe companies are collaborating to develop a first-in-class cyclin inhibitor targeting cancer cells using Circle Pharma's proprietary macrocycle platform. Rights & Responsibilities
Financial Terms
Regulatory ApprovalDetails on regulatory approval were not specified in the announcement. Overall SummaryBoehringer Ingelheim and Circle Pharma have entered a collaboration to develop novel cyclin inhibitors for cancer treatment, with Circle’s macrocycle platform at the core. The collaboration includes potential milestone payments of up to $607 million based on progress. [collapse expanded text] |
AstraZeneca, Nona Biosciences | May 2024 | 604 | Licensing and option agreement for monoclonal antibody to be developed into tumor targeted therapies | Parties Involved
… read more Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall Summary
|
Astellas Pharma, Poseida Therapeutics, Xyphos Biosciences | May 2024 | 600 | Research and licensing agreement for allogeneic cell therapies in oncology | Key Deal Terms Summary1. Agreement Overview
2. Financial Terms
3. Research and Development Collaboration
4. Strategic Impact
Overall SummaryAstellas and Poseida Therapeutics have entered a strategic research collaboration and license agreement to develop novel allogeneic cell therapies for solid tumors, leveraging Poseida’s allogeneic CAR-T platform and Astellas’ ACCEL™ technology. Poseida will receive up to $600 million, including a $50 million upfront payment and up to $550 million in milestone payments, plus low double-digit tiered royalties on net sales. Astellas/Xyphos will lead commercialization, while Poseida contributes its gene editing technologies to develop two convertibleCAR® product candidates. The agreement strengthens Astellas’ immuno-oncology pipeline and validates Poseida’s non-viral gene engineering approach. [collapse expanded text] |
Flagship Pioneering, Metaphore Biotechnologies, Novo Nordisk | May 2024 | 600 | Research, development and licensing agreement for Next-Generation therapeutics for obesity management | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall Summary
|
NanoVation Therapeutics, Novo Nordisk | Sep 2024 | 600 | Research, development and licensing agreement for genetic medicines targeting cardiometabolic and rare diseases | Parties Involved
… read more Collaboration ScopeNanoVation Therapeutics and Novo Nordisk have entered into a multi-year partnership to develop genetic medicines targeting cardiometabolic and rare diseases. The collaboration focuses on the use of NanoVation’s proprietary long-circulating lipid nanoparticle (lcLNP™) technology for RNA delivery to cells outside the liver, which is essential for the development of base-editing therapies for certain rare genetic diseases. Rights & Responsibilities
Financial Terms
Regulatory ApprovalDetails regarding regulatory approval are not disclosed at this time. Overall SummaryNanoVation Therapeutics has partnered with Novo Nordisk to utilize NanoVation’s lcLNP technology for the development of genetic medicines targeting cardiometabolic and rare diseases. The collaboration aims to overcome existing nucleic acid delivery barriers, enabling the delivery of genetic therapies to extrahepatic cells. NanoVation will receive research funding, upfront cash, milestone payments, and royalties as part of the deal. [collapse expanded text] |
Cytokinetics, Royalty Pharma | May 2024 | 575 | Royalty financing agreement for commercial launch of aficamten | Key Deal Terms Summary1. Agreement Overview
2. Commercial Launch Funding
3. Royalty Restructuring
4. Development Funding
5. Equity Investment
6. Financial and Strategic Impact
Overall SummaryCytokinetics and Royalty Pharma have expanded their strategic funding collaboration, providing up to $575 million to support the launch of aficamten and advance Cytokinetics’ cardiovascular pipeline. Cytokinetics will receive $250 million upfront, with additional funding tied to FDA approvals and sales milestones. The deal includes restructured royalties, commercial launch financing, development funding for omecamtiv mecarbil and CK-586, and a $50 million equity purchase. This lowers Cytokinetics' cost of capital, extends its cash runway, and accelerates the company’s cardiovascular drug development and commercialization strategy. [collapse expanded text] |
Full-Life Technologies, SK Biopharmaceuticals | Jul 2024 | 571.5 | Licensing agreement for therapeutic targeting multiple solid tumors | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryFull-Life Technologies has entered into a licensing agreement with SK Biopharmaceuticals worth $571.5 million for the development and commercialization of FL-091, a radiopharmaceutical targeting NTSR1-positive cancers. SK Biopharmaceuticals will be responsible for the clinical research, development, and manufacturing of FL-091, and also has the right of first negotiation for other radiopharmaceutical drug conjugates (RDC) from Full-Life. Full-Life will receive upfront and milestone payments, along with royalties on future sales. [collapse expanded text] |
Coherus Biosciences, Intas Pharmaceuticals | Dec 2024 | 558.4 | Asset purchase agreement for UDENYCA (pegfilgrastim-cbqv) | Accord BioPharma to Acquire UDENYCA® Business from Coherus BioSciences… read more Transaction Overview Financial Terms Strategic Rationale Closing & Integration |
BioAge Labs, Novartis | Dec 2024 | 550 | Research and licensing agreement to discover novel targets for therapies that address age-related diseases and conditions | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryBioAge Labs has entered into a multi-year research collaboration with Novartis to explore novel therapeutic drug targets for age-related diseases. This collaboration leverages BioAge's human longevity data and Novartis' expertise in exercise biology to accelerate the development of treatments based on biological mechanisms driving aging and the benefits of physical exercise. BioAge will receive up to $20 million in upfront payments and research funding, with the potential for up to $530 million in future milestone payments. Both companies share rights to the discovered targets, and success is rewarded with tiered royalties and milestones. [collapse expanded text] |
BioAge Labs, Novartis | Dec 2024 | 550 | Research, development and licensing agreement for therapies to address age-related diseases and conditions | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Overall SummaryBioAge Labs and Novartis have entered into a multi-year research collaboration to identify and validate novel drug targets related to aging and the beneficial effects of physical exercise. BioAge will contribute its human longevity data and advanced discovery platform, while Novartis will bring expertise in exercise biology. The collaboration is designed to uncover new therapeutic targets for age-related diseases, with BioAge eligible to receive up to $530 million in future milestones and royalties. [collapse expanded text] |
Bayer, NextRNA Therapeutics | Aug 2024 | 547 | Development and licensing agreement for small molecules targeting long non-coding RNAs in oncology | Parties Involved
… read more Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryBayer and NextRNA Therapeutics have entered a strategic collaboration to develop small molecule therapeutics targeting lncRNAs in oncology. NextRNA will develop an initial lncRNA-targeting program, and Bayer will have the option to select additional targets. The partnership includes a potential total of $547 million in milestone payments, research funding, and royalties on sales. This collaboration enhances Bayer’s oncology portfolio and leverages NextRNA’s expertise in lncRNA biology to pursue innovative cancer therapies. [collapse expanded text] |
GSK, Rgenta Therapeutics | Dec 2024 | 546 | Research, development and option agreement for RNA-targeted small molecule splice modulators | Rgenta Therapeutics announced it entered multi-year, multi-target strategic research alliance with … read moreGSK Alliance aims to advance discovery and development of novel RNA-targeted small molecule splice modulators for multiple disease areas including oncology Rgenta will receive up to $46 million in a cash upfront and pre-option milestone payments Rgenta has potential to receive up to nearly $500 million per target in option exercise, research, development, regulatory, and commercial milestone payments plus tiered royalties and future equity investment GSK also has option to expand alliance to include additional targets Rgenta will use its proprietary discovery platform to develop novel oral RNA-targeting small molecule splice modulators against multiple targets nominated by GSK for development Following GSK's exercise of its options, GSK will be responsible for further development and commercialization of any drug candidates that arise from alliance [collapse expanded text] |
Allorion Therapeutics, AstraZeneca | Jan 2024 | 540 | Option and licensing agreement for L858R allosteric inhibitor program | Parties Involved
… read more Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryAllorion Therapeutics has entered into an exclusive option and global license agreement with AstraZeneca for a novel EGFR L858R allosteric inhibitor aimed at treating advanced EGFR-mutant NSCLC. AstraZeneca has the option to license the program for global development and commercialization, with Allorion receiving an upfront payment of $40 million and potential milestone payments totaling over $500 million. The agreement also includes tiered royalties on global net sales. [collapse expanded text] |
3T Biosciences, Boehringer Ingelheim | Jan 2024 | 538.5 | Collaboration and licensing agreement for next-generation life-changing cancer immunotherapies | Parties Involved
… read more Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryBoehringer Ingelheim and 3T Biosciences have entered into a strategic collaboration to develop next-generation cancer immunotherapies. 3T Biosciences will leverage its 3T-TRACE platform to discover new cancer immunogenic targets using TCR data provided by Boehringer Ingelheim. The agreement includes an upfront payment to 3T Biosciences, milestone payments totaling $538.5 million, and royalties on future product sales. It brings together 3T's best-in-class 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform with Boehringer Ingelheim's commitment to develop first-in-class immuno-oncology treatments that boost the immune system's ability to recognize, attack and kill tumors. Boehringer Ingelheim will provide patient-derived T-cell receptor data to fuel 3T's target discovery efforts to identify cognate antigens using its 3T TRACE discovery platform. 3T will receive an upfront payment and research and development support, and is eligible for discovery, preclinical, clinical, regulatory, and commercial milestones for both agreements totaling $538.5 million in addition to royalties on future Boehringer Ingelheim product sales. Boehringer Ingelheim is eligible to receive royalties on future product sales by 3T Biosciences arising from the agreement. [collapse expanded text] |
Korro Bio, Novo Nordisk | Sep 2024 | 530 | Licensing agreement for oligonucleotide-directed RNA edits into two undisclosed targets | Key Deal Terms Summary1. Parties Involved
2. Agreement Scope
3. Financial Terms
4. Strategic Rationale
5. Next Steps
Overall SummaryKorro Bio and Novo Nordisk have entered a collaboration to develop two RNA editing therapeutic candidates using Korro’s OPERA™ platform, initially targeting cardiometabolic diseases. Korro will receive up to $530 million in upfront, milestone payments, and royalties, along with R&D funding from Novo Nordisk. Korro will lead preclinical development, after which Novo Nordisk may advance the programs into clinical trials. This deal strengthens Novo Nordisk’s genetic medicine pipeline while supporting Korro’s innovative RNA editing technology. [collapse expanded text] |
ImmuNext, Royalty Pharma, Sanofi | May 2024 | 525 | Royalty financing agreement for Frexalimab | Royalty Pharma announced that it will acquire royalties and milestones on frexalimab owned by … read moreImmuNext for approximately $525 million in cash including estimated transaction costs ImmuNext is entitled to receive an upward tiering net royalty ranging from a high-single digit to low-double digit percentage of worldwide net sales of frexalimab Royalty Pharma will receive 100% of net royalties on annual worldwide net sales of frexalimab of up to $2.0 billion and share a minority of the royalties above this threshold with ImmuNext shareholders Acquisition will include substantial potential milestone payments from Sanofi [collapse expanded text] |
Nestle Health Science, Seres Therapeutics | Jun 2024 | 505 | Asset purchase and cross licensing agreement for global rights to VOWST | Key Deal Terms Summary1. Agreement Overview
2. Financial Terms
3. Use of Proceeds and Cash Runway
4. Strategic Focus Post-Transaction
Overall SummarySeres Therapeutics is selling its VOWST™ business to Nestlé Health Science in a $175 million upfront transaction, with $75 million in additional payments in 2025 and up to $275 million in future sales-based milestones. Nestlé will take full control of VOWST commercialization and manufacturing, while Seres will exit the microbiome therapy market and focus on its next-generation cultivated live biotherapeutic programs. Proceeds will allow Seres to retire its debt, extend its cash runway into Q4 2025, and advance its SER-155 program targeting high-risk infections in transplant patients. [collapse expanded text] |
Menarini, Stemline Therapeutics | Jan 2024 | 500 | Licensing agreement for small molecule KAT6A inhibitor | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryMenarini Group, Stemline Therapeutics, and Insilico Medicine have entered into an exclusive licensing agreement for a novel KAT6A inhibitor aimed at treating hormone-sensitive breast cancer and other cancers. The deal includes an upfront payment of $12 million, potential milestone payments exceeding $500 million, and royalties for Insilico Medicine. Stemline will lead the development and commercialization of the inhibitor, with Menarini Group and Stemline guiding the project through regulatory approval. [collapse expanded text] |
AstraZeneca, PineTree Therapeutics | Jul 2024 | 500 | Option and licensing agreement for preclinical EGFR degrader candidate | Parties Involved
… read more Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryPinetree Therapeutics has entered into an exclusive option and global license agreement with AstraZeneca for a preclinical EGFR degrader. AstraZeneca will have the option to license the program for global development and commercialization. Pinetree will receive up to $45 million in upfront and near-term payments, with additional milestones that could bring the total value to over $500 million, along with tiered royalties on worldwide sales. [collapse expanded text] |
Elevar Therapeutics, Relay Therapeutics | Dec 2024 | 500 | Licensing and partnership agreement for lirafugratinib (RLY-4008) | Parties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Overall SummaryRelay Therapeutics has entered into an exclusive global licensing agreement with Elevar Therapeutics for lirafugratinib (RLY-4008), a selective FGFR2 inhibitor for FGFR2-driven cholangiocarcinoma and other FGFR2-altered solid tumors. Under the terms, Elevar will assume full responsibility for the global development and commercialization of the therapy, while Relay will receive up to $75 million in upfront and regulatory milestones and tiered royalties on global sales. Relay will continue to focus on advancing its other pipeline programs, including RLY-2608 for breast cancer. [collapse expanded text] |
Top partnering deals of 2023 valued at over US$500m.
Partners | Date | Value, US$m | Subject | Termsheet |
---|---|---|---|---|
Daiichi Sankyo, Merck and Co | Oct 2023 | 22000 | Development and licensing agreement for patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd) and raludotatug deruxtecan | Parties Involved
Collaboration ScopeThe collaboration covers the global co-development and co-commercialization of three Daiichi Sankyo DXd antibody-drug conjugates (ADCs): The partnership spans all territories except Japan, where Daiichi Sankyo retains exclusive rights. The ADCs are in various stages of development for treating multiple solid tumors as monotherapy or in combination. Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryDaiichi Sankyo and Merck have entered into a global collaboration to jointly develop and commercialize three DXd-based ADCs outside of Japan. The deal leverages Daiichi Sankyo’s ADC platform and Merck’s oncology development expertise, with shared costs and profits and a total potential value of up to $22B. The ADCs are being developed for a broad range of solid tumors, with one nearing regulatory submission. [collapse expanded text] |
Bristol-Myers Squibb, Systimmune | Dec 2023 | 8400 | Collaboration and licensing agreement for BL-B01D1 | Key Deal Terms Summary 1. Agreement Overview
2. Financial Terms
3. Development & Commercialization Plans
4. Strategic Impact
Overall SummarySystImmune and Bristol Myers Squibb have entered a global strategic collaboration for the development and commercialization of BL-B01D1, a first-in-class bispecific EGFRxHER3 ADC. This agreement leverages SystImmune’s ADC expertise and BMS’s oncology leadership to accelerate the clinical and commercial potential of BL-B01D1. With a potential total deal value of $8.4 billion, the collaboration represents a significant investment in next-generation cancer therapies, aiming to expand treatment options for lung and breast cancer patients while exploring additional tumor indications. [collapse expanded text] |
Nurix Therapeutics, Seagen | Sep 2023 | 3460 | Collaboration, licensing, option and co-promotion agreement for Degrader-Antibody Conjugates for use in cancer | Key Deal Terms Summary1. Collaboration Scope
2. Financial Terms
3. Development and Commercialization Responsibilities
4. Financial Impact on Nurix
5. Overall SummaryNurix and Seagen have entered into a multi-year strategic collaboration to develop Degrader-Antibody Conjugates (DACs). The deal provides Nurix with $60 million upfront, potential milestone payments of up to $3.4 billion, tiered royalties, and an option for U.S. profit sharing on two products. Seagen will take the lead in development and commercialization, while Nurix will leverage its DELigase platform to design targeted protein degraders for antibody conjugation. [collapse expanded text] |
Alnylam Pharmaceuticals, Roche | Jul 2023 | 3110 | Co-development, licensing and co-promotion agreement for zilebesiran | Alnylam Pharmaceuticals has entered into a strategic agreement with Roche to develop and … read morecommercialize zilebesiran, Alnylam’s investigational RNAi therapeutic for the treatment of hypertension, which is currently in Phase 2 of development. The partnership allows for a bold development plan with the goal of disrupting the hypertension treatment paradigm globally while advancing Alnylam’s P5x25 strategy. Alnylam will receive an upfront cash payment of $310 million and is eligible to receive additional substantial near-term payments, including development milestone payments over the next few years, as well as regulatory and sales milestones, for a potential deal value of up to $2.8 billion. Alnylam is entitled to an equal profit share in the US, where Alnylam and Roche will co-commercialize zilebesiran. Roche obtained the exclusive right to commercialize zilebesiran outside the US in exchange for low double digit royalties on net sales of zilebesiran outside of the US. Alnylam believes that this partnership will allow the companies to pursue a joint development plan and commercialization approach that has the potential to unlock the full value of zilebesiran. Alnylam will lead a joint clinical development plan for the first indication with Roche’s participation, which includes a cardiovascular outcomes trial prior to submission of zilebesiran for regulatory approval, with all development costs shared 40% by Alnylam and 60% by Roche. Roche may lead development for additional indications in the future. [collapse expanded text] |
Novo Nordisk, Valo Health | Sep 2023 | 2760 | Collaboration and licensing agreement for treatments for cardiometabolic diseases using human data and artificial intelligence | Key Deal Terms Summary: Valo Health and Novo Nordisk CollaborationParties… read moreInvolved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Considerations
Overall SummaryNovo Nordisk and Valo Health have established a strategic collaboration to leverage AI-driven drug discovery and human-centric data for cardiometabolic drug development. Novo Nordisk licenses three preclinical programs and gains access to Valo’s Opal Computational Platform™. Valo receives a $60 million upfront payment and could earn up to $2.7 billion in milestone payments, plus R&D funding and royalties. This partnership strengthens Novo Nordisk’s cardiometabolic pipeline while validating Valo’s AI-powered drug discovery platform. [collapse expanded text] |
Janssen Pharmaceutica NV, Nanobiotix | Jul 2023 | 2700 | Licensing and co-development agreement for radioenhancer NBTXR3 | January 2024 NANOBIOTIX announced achievement of operational requirements in NANORAY-312, an … read moreongoing pivotal Phase 3 study evaluating potential first-in-class radioenhancer NBTXR3 for elderly patients with head and neck cancer, resulting in a $20M milestone payment from strategic partner Janssen Pharmaceutica. July 2023 NANOBIOTIX announced a global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica for the investigational, potential first-in-class radioenhancer NBTXR3. Under the terms of the license agreement, in collaboration with the Interventional Oncology R&D Unit at Johnson & Johnson, Nanobiotix will grant Janssen a worldwide license for the development and commercialization of NBTXR3. The license is exclusive, excepting territories previously licensed to Nanobiotix partner LianBio. Nanobiotix will receive near term cash and operational support valued up to $60 million. This includes an upfront cash licensing fee of $30 million, and in-kind regulatory and development support for study NANORAY-312 valued at up to $30 million that Janssen may provide at its sole discretion. Nanobiotix will maintain operational control of NANORAY-312 and all other currently ongoing studies, along with NBTXR3 manufacture, clinical supply, and initial commercial supply. Janssen will be fully responsible for an initial Phase 2 study evaluating NBTXR3 for patients with stage three lung cancer and will have the right to assume control of studies currently led by Nanobiotix. Nanobiotix is eligible for success-based payments of up to $1.8 billion, in the aggregate, relating to potential development, regulatory, and sales milestones. Moreover, the agreement includes a framework for additional success-based potential development and regulatory milestone payments of up to $650 million, in the aggregate, for five new indications that may be developed by Janssen at its sole discretion; and of up to $220 million, in the aggregate, per indication that may be developed by Nanobiotix in alignment with Janssen. Following commercialization, Nanobiotix will also receive tiered double-digit royalties on net sales of NBTXR3. [collapse expanded text] |
Merck and Co, Proxygen | Apr 2023 | 2550 | Collaboration and licensing agreement for molecular glue degraders | Proxygen announced a multi-year research collaboration and license agreement with Merck & Co to … read morejointly identify and develop molecular glue degraders against multiple therapeutic targets. Proxygen will receive an upfront payment from MSD and be eligible for future payments of up to $2.55 billion based on the achievement of specified research, development, and commercial milestones across all programs. Proxygen is eligible to receive royalties on net sales of any such products. [collapse expanded text] |
Bausch & Lomb, Novartis | Jun 2023 | 2500 | Licensing agreement for XIIDRA, libvatrep and AcuStream | Bausch + Lomb has entered into a definitive agreement with Novartis to acquire XIIDRA (lifitegrast … read moreophthalmic solution) 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease focusing on inflammation associated with dry eye. Bausch + Lomb, through an affiliate, has agreed to acquire XIIDRA, libvatrep and AcuStream from Novartis for up to $2.5 billion, including an upfront payment of $1.75 billion in cash with potential milestone obligations up to $750 million based on sales thresholds and pipeline commercialization. Bausch + Lomb will also bring on the sales force supporting XIIDRA. [collapse expanded text] |
C4 Therapeutics, Merck and Co | Dec 2023 | 2500 | Collaboration, option and licensing agreement for degrader-antibody conjugates | C4 Therapeutics has entered into an exclusive license and collaboration agreement with Merck & … read moreCo to develop degrader-antibody conjugates, an emerging modality designed to selectively target and neutralize disease-causing proteins in cancer cells. C4T will receive a $10 million upfront payment. C4T and Merck will collaborate to develop DACs directed to an initial undisclosed oncology target that is exclusive to the collaboration. For DACs directed to this initial target, C4T is eligible to receive milestone payments totaling approximately $600 million, as well as tiered royalties on future sales. The agreement also provides Merck with the option to extend the collaboration to include three additional targets that would be exclusive to the collaboration, which could yield option exercise payments as well as potential milestones and royalties. If Merck exercises all of its options to extend the collaboration, C4T would be eligible to receive up to approximately $2.5 billion in potential payments across the entire collaboration. [collapse expanded text] |
Avidity Biosciences, Bristol-Myers Squibb | Nov 2023 | 2275 | Collaboration and licensing agreement for multiple cardiovascular targets | Avidity Biosciences announced a global licensing and research collaboration with Bristol Myers … read moreSquibb focused on the discovery, development and commercialization of multiple cardiovascular targets with potential cumulative payments of up to $2.3 billion. AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. This strategic collaboration broadens the reach of AOCs through the expansion of the existing relationship with Bristol Myers Squibb. Avidity continues to advance its internal research and development programs in rare cardiac indications. Avidity will receive $100 million upfront, which includes a $60 million cash payment as well as the purchase of approximately $40 million of Avidity common stock at a purchase price of $7.88 per share. Avidity is also eligible to receive up to approximately $1.35 billion in research and development milestone payments, up to approximately $825 million in commercial milestone payments, and tiered royalties up to low double-digits on net sales. Bristol Myers Squibb will fund all future clinical development, regulatory and commercialization activities coming from this collaboration. [collapse expanded text] |
AstraZeneca, Cellectis | Nov 2023 | 2225 | Collaboration, option and licensing agreement for next generation therapeutics in areas of high unmet need, including oncology, immunology and rare diseases | Cellectis has entered into a Joint Research Collaboration Agreement with AstraZeneca. The … read moreCollaboration Agreement aims to accelerate the development of next generation therapeutics in areas of high unmet need, including oncology, immunology and rare diseases. AstraZeneca will leverage Cellectis’ proprietary gene editing technologies and manufacturing capabilities to design novel cell and gene therapy candidate products. 25 genetic targets have been exclusively reserved for AstraZeneca, from which up to 10 candidate products could be explored for development. AstraZeneca will have an option for a worldwide exclusive license on the candidate products, to be exercised before IND filing. Pursuant to the Collaboration Agreement, Cellectis’ research costs under the collaboration will be funded by AstraZeneca and Cellectis will receive an upfront payment of $25M. Cellectis is also eligible to receive an investigational new drug option fee and development, regulatory and sales-related milestone payments, ranging from $70M up to $220M, per each of the 10 candidate products, plus tiered royalties. [collapse expanded text] |
AstraZeneca, Quell Therapeutics | Jun 2023 | 2085 | Collaboration, option and licensing agreement for engineered T-regulatory cell therapies for autoimmune diseases | AstraZeneca has entered into a collaboration, exclusive option and license agreement with Quell … read moreTherapeutics to develop multiple engineered T-regulator cell therapies that have the potential to be curative in Type 1 Diabetes and Inflammatory Bowel Disease indications. Quell’s proprietary toolbox of Treg cell engineering modules, including its innovative Foxp3 Phenotype Lock will be leveraged to develop autologous multi-modular Treg cell therapy candidates for major autoimmune disease indications. AstraZeneca will have the option to further development and commercialisation of successful clinical candidates in T1D and IBD. Quell will receive $85 million upfront from AstraZeneca, which comprises a predominant cash payment and an equity investment. Quell is also eligible to receive over $2 billion for further development and commercialisation milestones, if successful, plus tiered royalties. In addition, Quell retains an option, which can be exercised either after approval of an Investigational New Drug application or at the end of the Phase I/II clinical study, to co-develop Treg cell therapies from the T1D programme with AstraZeneca in the United States in exchange for additional milestone payments and increased royalties on US net sales. [collapse expanded text] |
Belharra Therapeutics, Genentech | Jan 2023 | 2080 | Collaboration, option, co-development and co-promotion agreement for small molecule medicines | Belharra Therapeutics announced a multi-year collaboration with Genentech. The companies will … read morecollaborate employing Belharra’s proprietary platform to discover and develop small molecule medicines in multiple therapeutic areas including oncology, immuno-oncology, autoimmune, and neurodegenerative diseases. Belharra will be responsible for discovery and early preclinical development of small molecules against Genentech’s designated targets, while Genentech will be responsible for late preclinical, clinical, and regulatory development, and commercialization of such small molecules. Belharra will receive an upfront cash payment of $80 million. Belharra is eligible to receive development, commercial, and net sales milestones that could exceed $2 billion and a tiered royalty on Genentech’s sale of collaboration products. For certain oncology or immunology programs to be designated by Genentech, Belharra will have an option to co-develop such programs’ compounds through Phase 1 and to co-fund the remaining development of those programs’ compounds in exchange for a US cost/profit split and ex-US milestone payments and royalties. [collapse expanded text] |
Monte Rosa Therapeutics, Roche | Oct 2023 | 2050 | Collaboration, licensing and option agreement for molecular glue degraders targeting cancer and neurological diseases | Deal Summary: Monte Rosa Therapeutics & Roche CollaborationParties… read moreInvolved
Collaboration ScopeMonte Rosa Therapeutics and Roche have entered a strategic collaboration and licensing agreement to discover and develop molecular glue degraders (MGDs) targeting cancer and neurological diseases. The collaboration leverages Monte Rosa’s QuEEN™ discovery engine and Roche’s expertise in oncology and neuroscience to develop therapies for previously undruggable targets. Rights & Responsibilities
Financial Terms
Regulatory ApprovalNo specific regulatory approval conditions disclosed. Overall SummaryMonte Rosa Therapeutics and Roche have formed a strategic collaboration to develop molecular glue degraders (MGDs) for cancer and neurological diseases, utilizing Monte Rosa’s QuEEN™ discovery engine. Monte Rosa will lead early discovery efforts, while Roche will handle further preclinical and clinical development. The deal includes an upfront payment of $50 million, with potential milestone payments exceeding $2 billion and tiered royalties. The agreement also allows for expansion to additional targets within the first two years. [collapse expanded text] |
Genentech, Orionis Biosciences | Sep 2023 | 2047 | Collaboration agreement for molecular glue class medicines | Orionis Biosciences announced a multi-year collaboration with Genentech to discover novel small … read moremolecule medicines for challenging targets in major disease areas, including oncology and neurodegeneration. Orionis will be responsible for the discovery and optimization of molecular glues for Genentech’s designated targets, while Genentech will be responsible for subsequent later-stage preclinical, clinical development, regulatory filing, and commercialization of such small molecules. Orionis will receive an upfront payment of $47 million and is eligible for development milestone payments, as well as commercial and net sales milestone payments that could exceed $2 billion and a tiered royalty upon sale of collaboration products. [collapse expanded text] |
Astellas Pharma, Cullgen | Jun 2023 | 2020 | Collaboration, option, licensing and co-promotion agreement for innovative targeted protein degraders | Astellas Pharma and Cullgen announced a research collaboration and exclusive option agreement to … read morediscover multiple innovative protein degraders. the two companies aim to develop multiple targeted protein degraders by combining Cullgen's proprietary uSMITE targeted protein degradation platform featuring novel E3 ligands with Astellas' drug discovery capabilities. Cullgen and Astellas will collaboratively conduct joint research to identify clinical development candidates. Astellas will then have an exclusive option of exclusively license the rights for clinical development and commercialization of the protein degrader compounds identified during the research activities. Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses, and to co-promote partnered products in the US for the lead program, previously identified by Cullgen as a cell cycle protein degrader for the treatment of breast cancer and other solid tumors. Astellas will provide Cullgen an upfront payment of $35M USD. Cullgen is also entitled to receive an additional $85M USD upon Astellas' exercise of the license option with respect to the lead program. Total compensation to Cullgen could exceed $1.9 billion if Astellas exercises all of its license options and all milestones for all programs are achieved. Cullgen is also eligible to receive royalty payments from Astellas on any potential commercial sales. [collapse expanded text] |
AstraZeneca, Eccogene | Nov 2023 | 2010 | Licensing agreement for ECC5004 | Eccogene entered into an exclusive license agreement with AstraZeneca under which AstraZeneca will … read moredevelop and commercialize Eccogene's small molecule GLP-1 receptor agonist ECC5004 for the potential treatment of obesity, type-2 diabetes and other comorbidities. Eccogene will receive an initial upfront payment of $185 million. Eccogene will be eligible to receive up to an additional $1.825 billion in future clinical, regulatory, and commercial milestones. Eccogene is further eligible to receive tiered royalties on net product sales. AstraZeneca will receive exclusive rights to develop and commercialize Eccogene's ECC5004 small molecule GLP-1RA for any indication in all territories except China. Eccogene and AstraZeneca will partner for co-development and co-commercialization of ECC5004 in China. [collapse expanded text] |
Amgen, Synaffix | Jan 2023 | 2000 | Licensing and option agreement for next generation antibody drug conjugates | Synaffix announced the signing of a licensing agreement with Amgen to develop next generation ADCs. … read moreAmgen will gain access to Synaffix's antibody conjugation technology platforms comprising GlycoConnect, HydraSpace and select toxSYN linker-payloads for one ADC program with the option to exercise exclusive research and commercial licenses for an additional four programs at a later date. Synaffix will be eligible to receive up to $2 billion in payments spanning signature, program nomination and milestone payments, plus tiered royalties on commercial sales which are consistent with the financials of the recently signed licenses of Synaffix ADC technology platform. Amgen will be responsible for the research, development, manufacturing and commercialization of the ADCs and Synaffix will continue to be responsible for the manufacturing of components that are specifically related to its proprietary technologies. [collapse expanded text] |
Bliss Biopharmaceutical, Eisai | May 2023 | 2000 | Collaboration, option and licensing agreement for BB-1701 | Bliss Biopharmaceutical announced a clinical trial collaboration agreement with option for … read morestrategic collaboration with Eisai, for BB-1701, eribulin-payload based ADC directed against Human Epidermal Growth Factor Receptor 2 for the treatment of cancers. This collaboration with Eisai is an important advancement in BlissBio's corporate development plan to further develop BB-1701 globally and help advance BB-1701 toward late stage of development. BB-1701 is currently in Phase I/II studies in the US and China with over one hundred patients dosed in various types of cancers. BlissBio will receive upfront and milestone payments, and BlissBio and Eisai will conduct co-development activities related to BB-1701 through an option period. Upon Eisai's exercise of its option to enter into a strategic collaboration license of BB-1701, BlissBio will receive an option exercise payment and be eligible for development and commercial milestone payments up to an aggregate of $2 billion, as well as royalties on sales. Upon the exercise of the option, Eisai will receive worldwide (excluding Greater China) rights to develop and commercialize BB-1701. [collapse expanded text] |
Immatics Biotechnologies, Moderna | Sep 2023 | 1820 | Collaboration, licensing and option agreement for oncology therapeutics | Moderna and Immatics announced a strategic research and development collaboration to pioneer novel … read moreand transformative therapies for cancer patients with high unmet medical need. This broad multi-platform collaboration will leverage the deep scientific expertise and core operational capabilities of both companies, combining Immatics' TCR platform with Moderna's cutting-edge mRNA technology, and span various therapeutic modalities including bispecifics, cell therapy and cancer vaccines. The strategic R&D collaboration between Moderna and Immatics focuses on three pillars: Applying Moderna's mRNA technology for in vivo expression of Immatics' next-generation, half-life extended TCR bispecifics (TCER) targeting cancer-specific HLA-presented peptides. Enabling the discovery and development of novel mRNA-based cancer vaccines by leveraging Moderna's deep knowledge of mRNA science and customized information from Immatics' wealth of tumor and normal tissue data included in the target discovery platform XPRESIDENT and its bioinformatics and AI platform XCUBE. Evaluating Immatics' IMA203 TCR-T therapy targeting PRAME in combination with Moderna's PRAME mRNA-based cancer vaccine. The collaboration contemplates conducting preclinical studies and a Phase 1 clinical trial evaluating the safety and efficacy of the combination with the objective of further enhancing IMA203 T cell responses. Immatics will receive an upfront payment of $120 million. Immatics will also receive research funding and is eligible to receive development, regulatory, and commercial milestone payments that could exceed $1.7 billion. Immatics is also eligible to receive tiered royalties on global net sales of TCER products and certain vaccine products that are commercialized under the agreement. Immatics has an option to enter into a global profit and loss share arrangement for the most advanced TCER. Moderna will lead the clinical development and commercialization of cancer vaccines and TCER therapeutics resulting from the collaboration. Immatics will be responsible for conducting the preclinical studies and a potential Phase 1 clinical trial investigating IMA203 TCR-T in combination with the PRAME mRNA vaccine to further enhance IMA203 T cell responses. Each party will retain full ownership of its investigational PRAME compound, and the parties will fund the clinical study on a cost sharing basis. Within the collaboration, preclinical activities conducted by Immatics will be managed by the Immatics Discovery Unit, a recently created internal division at Immatics integrating its technology platforms into one interdisciplinary team focused on all early-stage preclinical pipeline and collaboration programs. [collapse expanded text] |
Bicycle Therapeutics, Novartis | Mar 2023 | 1750 | Collaboration and licensing agreement for Bicycle radio-conjugates | Bicycle Therapeutics has entered into a strategic collaboration agreement with Novartis to develop, … read moremanufacture and commercialize Bicycle radio-conjugates for multiple agreed upon oncology targets. Bicycle will utilize its proprietary phage platform to discover Bicycles to be developed into BRCs. Novartis will be responsible for further development, manufacture and commercialization of the BRCs. Novartis will fund all pre-clinical and clinical development and commercialization activities. Bicycle will receive a $50 million upfront payment and is eligible for development and commercial-based milestone payments totaling up to $1.7 billion. Bicycle will also be eligible to receive tiered royalties on Bicycle-based medicines commercialized by Novartis. [collapse expanded text] |
Astellas Pharma, Elpiscience | Dec 2023 | 1737 | Collaboration and licensing agreement for ES019 and another program | Elpiscience Biopharma and Astellas Pharma announced a research collaboration and license agreement … read morefor novel bi-specific macrophage engagers, ES019 and another program. The two companies will collaboratively conduct early-stage research for these two programs. Elpiscience will also grant Astellas the right to add up to two additional programs to be included in the collaboration. If Astellas exercises its option, Elpiscience will grant Astellas the exclusive right to further research, develop, manufacture and commercialize the products for each program. Elpiscience will receive up to US $37 million, including the upfront payment and license option fees. Elpiscience will receive research funding from Astellas to advance the programs. After Astellas exercises its option, Elpiscience is eligible to potentially receive more than US $1.7 billion in payments for the achievement of future development, regulatory, and commercial milestones. Elpiscience is also eligible to receive single-digit to lower double-digit percent royalty payments on net sales for licensed products per each program. [collapse expanded text] |
GSK, Jiangsu Hansoh Pharmaceutical | Dec 2023 | 1710 | Licensing agreement for HS-20093 | GSK and Hansoh Pharma have entered into an exclusive license agreement for HS-20093, a B7-H3 … read moretargeted antibody-drug conjugate utilising a clinically validated topoisomerase inhibitor payload. GSK will obtain exclusive worldwide rights (excluding China’s mainland, Hong Kong, Macau, and Taiwan) to progress clinical development and commercialisation of HS-20093. GSK will pay $185 million upfront. Hansoh will be eligible to receive up to $1.525 billion in success-based milestones for HS-20093. Upon commercialisation of HS-20093, GSK will pay tiered royalties on global net sales outside of China’s mainland, Hong Kong, Macau, and Taiwan. [collapse expanded text] |
Bayer, Bicycle Therapeutics | May 2023 | 1700 | Collaboration and licensing agreement for targeted radionuclide therapies in oncology | Bayer and Bicycle Therapeutics have entered into a strategic collaboration agreement to discover, … read moredevelop, manufacture, and commercialize Bicycle radioconjugates for multiple agreed upon oncology targets. Bayer and Bicycle will collaborate on the development of bicyclic peptides for multiple oncology targets. Bicycle will utilize its proprietary phage platform to discover and develop bicyclic peptides and Bayer will be responsible for, and fully fund, all further preclinical and clinical development, manufacturing, and commercialization activities. Bicycle will receive a $45 million upfront payment and with potential development and commercial-based milestone fees, payments to Bicycle could total up to $1.7 billion. Bicycle will also be eligible to receive mid-single to double-digit tiered royalties on Bicycle-based medicines commercialized by Bayer. [collapse expanded text] |
Janssen Biotech, LegoChem Biosciences | Dec 2023 | 1700 | Licensing agreement for LCB84 Trop2-targeted ADC | LegoChem Biosciences has entered into a license agreement with Janssen Biotech to develop and … read morecommercialize LCB84, a Trop2 directed antibody drug conjugate. LCB will grant Janssen an exclusive, worldwide license for the development and commercialization of LCB84. LCB is eligible for up to potentially USD 1.7 billion in total consideration including an upfront payment of USD 100 million, an option exercise payment of USD 200 million as well as potential development, regulatory, and commercial milestone payments, plus tiered royalties on net sales. The companies will collaborate during the ongoing Phase 1/2 clinical trial, with Janssen solely responsible for clinical development and commercialization after option exercise. [collapse expanded text] |
BioNTech, DualityBio | Apr 2023 | 1670 | Collaboration and licensing agreement for antibody-drug conjugate therapeutics for solid tumors | August 2023 Duality Biologics has expanded its collaboration with BioNTech to develop, … read moremanufacture and commercialize a third ADC candidate DB-1305 globally, excluding Mainland China, Hong Kong Special Administrative Region and Macau Special Administrative Region. DB-1305 is currently in a Phase 1/2 clinical trial for solid tumors. The agreement further builds upon the strategic collaboration the companies announced in April 2023. DualityBio will receive upfront payments, additional development, regulatory and commercial milestone payments, and single-digit to low-double digit tiered royalties on net sales of DB-1305. BioNTech will hold commercial rights globally (excluding Mainland China, Hong Kong Special Administrative Region and Macau Special Administrative Region), while DualityBio will retain commercial rights for Mainland China, Hong Kong Special Administrative Region and Macau Special Administrative Region. April 2023 BioNTech and Duality Biologics have entered into exclusive license and collaboration agreements for two ADC assets to develop, manufacture and commercialize the two assets globally, excluding Mainland China, Hong Kong Special Administrative Region and Macau Special Administrative Region. With this collaboration, ADCs will become an additional drug class in BioNTech’s oncology portfolio with the aim to further support BioNTech’s mission of developing highly efficacious therapies for cancer patients at every stage of disease. BioNTech will gain access to DualityBio’s lead candidate, DB-1303, which is a topoisomerase-1 inhibitor-based ADC directed against Human Epidermal Growth Factor Receptor 2, a target that is overexpressed in a variety of cancers, which contributes to the aggressive growth and spread of cancer cells. Antibody therapy targeting HER2 has been shown to be an effective treatment strategy for HER2-expressing cancers. The DB-1303 program received the Fast Track designation from the US Food and Drug Administration and is currently in a Phase 2 clinical trial (NCT05150691) for HER2-expressing advanced solid tumors. BioNTech will also gain access to a second topoisomerase-1 inhibitor-based ADC candidate, DB-1311. DualityBio will receive upfront payments for both asset licenses totaling $170 million, and additional development, regulatory and commercial milestone payments for both assets, potentially totaling over $1.5 billion. DualityBio will be eligible to receive single-digit to double-digit tiered royalties on net sales for both ADC assets. BioNTech will hold commercial rights globally (excluding Mainland China, Hong Kong Special Administrative Region and Macau Special Administrative Region), while DualityBio will retain commercial rights for Mainland China, Hong Kong Special Administrative Region and Macau Special Administrative Region. As part of the agreement for DB-1311, DualityBio has the right to exercise a co-development cost and profit/loss sharing option for DB-1311 for the US market, as well as a co-promotion option for the US market. [collapse expanded text] |
Prevail Therapeutics, Scribe Therapeutics | May 2023 | 1575 | Collaboration agreement for in vivo CRISPR-based genetic medicines for neurological and neuromuscular diseases | Scribe Therapeutics announced a strategic collaboration with Prevail Therapeutics granting Prevail … read moreexclusive rights to Scribe’s CRISPR X-Editing technologies for the development of in vivo therapies directed to specified targets known to cause serious neurological and neuromuscular diseases. Scribe will receive $75 million consisting of an upfront payment and equity investment in the form of a convertible note, and is eligible to receive more than $1.5 billion in development and commercial milestone payments. Prevail will pay research funding and tiered royalties ranging into the low double-digits on net future sales. Scribe also has the right to opt-in to co-fund and share profits in the US on one collaboration program. [collapse expanded text] |
GSK, WuXi Biologics | Jan 2023 | 1500 | Licensing and option agreement for multiple bi- and multi-specific T cell engagers | WuXi Biologics announced a license agreement with GSK under which GSK will have exclusive licenses … read morefor up to four bi- & multi-specific TCE antibodies developed using WuXi Biologics' proprietary technology platforms. GSK will be granted an exclusive global license for the research, development, manufacturing, and commercialization of a pre-clinical bispecific antibody that crosslinks tumor cells and T cells by targeting a tumor-associated antigen on tumor cells and CD3 expression on T cells and up to three additional pre-clinical TCE antibodies currently at an earlier discovery stage. WuXi Biologics will receive a $40 million upfront payment and up to $1.46 billion in additional payments for research, development, regulatory and commercial milestones across the four TCE antibodies. WuXi Biologics is also eligible to receive tiered royalties on net sales. [collapse expanded text] |
Otsuka, Shape Therapeutics | Sep 2023 | 1500 | Collaboration agreement for AAV gene therapies for ocular diseases | Otsuka Pharmaceutical and ShapeTX announced a multi-target collaboration to develop intravitreally- … read moredelivered adeno-associated viruses for ocular diseases, with options to add additional targets and tissue types. The companies will collaborate to apply ShapeTX’s AAVid capsid discovery platform and transgene engineering technology along with Otsuka’s expertise in genetic payload design and ophthalmology to develop novel treatment options for people living with serious eye diseases. ShapeTX will also apply the company’s transgene engineering technology to optimize payloads provided by Otsuka for therapeutic levels of gene expression in targeted cell types. ShapeTX will receive an initial payment from Otsuka and is eligible to receive development, regulatory, and sales milestone payments potentially exceeding $1.5 billion in aggregate value. ShapeTX is also eligible to receive tiered royalties on future sales of products resulting from the collaboration. [collapse expanded text] |
Sanofi, Teva Pharmaceutical Industries | Oct 2023 | 1500 | Collaboration, co-development and co-promotion agreement for inflammatory bowel disease treatment | Sanofi and Teva Pharmaceuticals announced a collaboration to co-develop and co-commercialize asset … read moreTEV’574, currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn's Disease, two types of inflammatory bowel disease. Teva will receive an upfront payment of €469 million ($500 million) and up to €940 million ($1 billion) in development and launch milestones. Each company will equally share the development costs globally and net profits and losses in major markets, with other markets subject to a royalty arrangement and Sanofi will lead the development of the Phase 3 program. Teva will lead commercialization of the product in Europe, Israel and specified other countries, and Sanofi will lead commercialization in North America, Japan, other parts of Asia and the rest of the world. [collapse expanded text] |
PTC Therapeutics, Royalty Pharma | Oct 2023 | 1500 | Royalty financing agreement for Evrysdi | PTC Therapeutics announced an agreement with Royalty Pharma to monetize up to $1.5 billion of the … read moreEvrysdi royalty stream. Royalty Pharma acquires additional royalties on Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date. PTC maintains all economics associated with up to $250 million in remaining commercial sales milestones associated with Evrysdi global net sales. [collapse expanded text] |
Jiangsu Hengrui Pharmaceuticals, Merck KGaA | Oct 2023 | 1400 | Collaboration, licensing, option and co-promotion agreement for HRS-1167 | Merck KGaA announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals. The … read morepartnership includes an exclusive license worldwide (ex-China) to develop, manufacture and commercialize Hengrui’s next-generation potent and selective PARP1 (poly (ADP-ribose) polymerase 1) trapping inhibitor HRS-1167. The agreement also includes an option to an exclusive license worldwide (ex-China) to develop, manufacture and commercialize Hengrui’s Claudin-18.2 antibody-drug conjugate SHR-A1904. Merck KGaA has the option to co-promote both assets in China. Additionally, should the company exercise its option, SHR-A1904 would complement Merck KGaA's internal preclinical and clinical ADC portfolio applying different linker payload technologies. The first ADC developed using Merck KGaA's own technology, M9140, a CEACAM5-targeting ADC, is being evaluated in an ongoing Phase Ia/b study in patients with metastatic colorectal cancer. Merck KGaA will provide Hengrui with an upfront payment of €160 million. Hengrui will receive payments for the achievement of certain development, regulatory and commercial milestones and tiered royalties on net sales by Merck KGaA. Potential payments may total up to €1.4 billion. [collapse expanded text] |
BeiGene, Ensem Therapeutics | Nov 2023 | 1330 | Licensing agreement for oral cyclin-dependent kinase 2 inhibitor | BeiGene and Ensem Therapeutics announced an agreement for BeiGene to acquire an exclusive global … read morelicense to an Investigational New Drug application-ready oral cyclin-dependent kinase 2 inhibitor. ENSEM will receive an upfront payment, and will be eligible for additional payments upon the achievement of certain development, regulatory, and commercial milestones, totaling up to $1.33 billion, in addition to tiered royalties. [collapse expanded text] |
Chong Kun Dang, Novartis | Nov 2023 | 1305 | Licensing agreement for CKD-510 | Chong Kun Dang Pharmaceutical has signed a $1.3 billion deal with Novartis to license out a new … read moredrug candidate, CKD-510. Novartis will have global exclusive rights to develop and commercialize CKD-510, a small molecule histone deacetylase 6 inhibitor developed by CKD Pharm worldwide, excluding Korea. The termination date will be the royalty expiration date from the date of signing the contract and be based on the later of 10 years after the first release, the patent expiration date, or the expiration of the licensee's exclusive rights. CKD Pharm will receive a non-refundable upfront payment of $80 million, milestone payments of up to $1.225 billion for future development and approval milestones, and sales royalties based on sales. It will also receive an ongoing technology fee based on net sales. CKD-510 is a drug candidate with a platform technology that selectively inhibits HDAC6. CKD Pharm has completed a European phase 1 clinical trial of CKD-510 for treating Charcot-Marie-Tooth, a rare disease caused by a genetic abnormality. [collapse expanded text] |
Abbvie, Immunome | Jan 2023 | 1300 | Collaboration and option agreement to discover multiple novel oncology targets | AbbVie and Immunome announced a worldwide collaboration and option agreement directed to the … read morediscovery of up to 10 novel antibody-target pairs arising from three specified tumor types using Immunome's Discovery Engine. Immunome will grant AbbVie the option to purchase worldwide rights for up to 10 novel target-antibody pairs arising from the selected tumors. Immunome will receive an upfront payment of $30M and will be eligible to receive additional platform access payments in the aggregate amount of up to $70M based on AbbVie's election for Immunome to continue research using its Discovery Engine. Immunome is also eligible to receive development and first commercial sale milestones of up to $120M per target with respect to certain products derived from target-antibody pairs that AbbVie elects to purchase, with potential for further sales-based milestones as well as tiered royalties on global sales. [collapse expanded text] |
BeiGene, DualityBio | Jul 2023 | 1300 | Option and licensing agreement for investigational, preclinical ADC therapy for select solid tumors | December 2024 Duality Biologics announced BeiGene has exercised its exclusive option for the … read moreB7H4 antibody-drug conjugate DB1312/BG-C9074 from DualityBio securing global development, manufacturing and commercialization rights for the investigational product In 2024 DualityBio received an option exercise fee and a milestone payment based on the Phase I dose-escalation advancement July 2023 BeiGene and DualityBio announced an agreement for BeiGene to acquire an exclusive option for a global clinical and commercial license to an investigational, preclinical ADC therapy for patients with select solid tumors. DualityBio will receive an upfront payment, and will be eligible for a payment contingent upon BeiGene exercising its option and additional payments based upon the achievement of certain development, regulatory, and commercial milestones, totaling up to $1.3 billion, in addition to tiered royalties. Upon exercising its option, BeiGene will hold global clinical, manufacturing, and commercial rights while DualityBio will perform all research activities through IND-enabling studies and support future IND filings by BeiGene. [collapse expanded text] |
KBP BioSciences, Novo Nordisk | Oct 2023 | 1300 | Asset purchase agreement for ocedurenone for uncontrolled hypertension | Novo Nordisk has agreed to acquire ocedurenone for uncontrolled hypertension with potential … read moreapplication in cardiovascular and kidney disease from KBP Biosciences for up to 1.3 billion US dollars. [collapse expanded text] |
CytomX Therapeutics, Moderna | Jan 2023 | 1240 | Collaboration agreement for mRNA-based conditionally activated therapeutics | CytomX Therapeutics and Moderna announced a collaboration and licensing agreement to create … read moreinvestigational mRNA-based conditionally activated therapies utilizing Moderna’s mRNA technologies and CytomX’s Probody therapeutic platform. The research collaboration will leverage core scientific advances at Moderna and CytomX. Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. CytomX’s Probody technology enables proteins to be activated locally in diseased tissue, while remaining masked in systemic circulation. These advances open up the strategy of encoding potent, masked biologics with mRNA, for the potential treatment of a wide range of diseases. CytomX will receive an upfront payment of $35 million, including $5 million of pre-paid research funding. CytomX will continue to receive research funding and is eligible to receive up to approximately $1.2 billion in future development, regulatory, and commercial milestone payments. CytomX is also eligible to receive tiered royalties on global net sales of any products that are commercialized under the agreement. Moderna and CytomX will collaborate on discovery and pre-clinical development and Moderna will lead clinical development and commercialization of therapeutics resulting from the agreement. The agreement additionally provides Moderna with an option to participate in a future equity financing by CytomX subject to certain terms, conditions and regulatory requirements. [collapse expanded text] |
Recludix Pharma, Sanofi | Jul 2023 | 1225 | Collaboration, option and co-promotion agreement for oral small molecule STAT6 inhibitors | Recludix Pharma has entered into a strategic collaboration with Sanofi US to develop and … read morecommercialize first-in-class oral small molecule STAT6 (signal transducer and activator of transcription 6) inhibitors for patients with immunological and inflammatory diseases. STAT6 is believed to play a key role in multiple dermatological and respiratory diseases. Sanofi will have global rights to small molecule STAT6 inhibitors. Recludix will advance STAT6 inhibitors from preclinical research and development until the start of Phase 2 clinical trials. Sanofi will assume worldwide clinical development and commercialization responsibilities thereafter. Recludix has the option to participate in US profit/loss share, which includes the ability to share equally in the costs, profits and losses, and to certain co-promotion activities for the partnered product in the US. Recludix will receive $125 million in near-term payments, and additionally, Recludix may receive more than $1.2 billion in potential development, regulatory and sales milestones, as well as up to double-digit royalties on possible future product sales. [collapse expanded text] |
Prevail Therapeutics, Sangamo Therapeutics | Jul 2023 | 1190 | Research, evaluation and option agreement for novel engineered capsids | Sangamo Therapeutics has signed an evaluation and option agreement with Prevail Therapeutics … read morethrough which Prevail has been granted rights to evaluate certain proprietary adeno-associated virus capsids developed by Sangamo and may exercise certain options to license these capsids for multiple undisclosed neurological targets. Generated through Sangamo’s AAV capsid engineering platform, SIFTER (Selecting In vivo For Transduction and Expression of RNA), these capsids have demonstrated a potential for high efficiency delivery of investigatory gene therapy constructs to the central nervous system in pre-clinical animal models following administration into the cerebrospinal fluid and seek to optimize delivery of therapeutics to a range of previously inaccessible areas. Prevail will evaluate Sangamo’s proprietary capsids by performing in vitro and in vivo studies, with an option to obtain an exclusive license to use the capsids for certain neurological targets. Sangamo will provide the capsids to Prevail for evaluation in exchange for an upfront payment. If Prevail exercises its option for all targets, and a Prevail product is approved in the US and Europe for each target, Sangamo would be eligible to receive exercise fees and developmental milestones of up to approximately $415 million and commercial milestones of up to approximately $775 million, in addition to tiered royalties based on net sales of Prevail products incorporating the licensed capsids. Prevail would lead all further development, manufacturing and commercialization of products incorporating the licensed capsids. [collapse expanded text] |
AstraZeneca, Keymed Biosciences, Lepu Biopharma | Feb 2023 | 1163 | Licensing agreement for CMG901 | Keymed Biosciences and Lepu Biopharma announced a global exclusive licence agreement with … read moreAstraZeneca for CMG901, a potential first-in-class Claudin 18.2 antibody drug conjugate. AstraZeneca will be responsible for the research, development, manufacture and commercialisation of CMG901 globally. KYM Biosciences, the joint venture established by Keymed and Lepu Biopharma, will receive an upfront payment of $63m on transaction closing and additional development and sales-related milestone payments of up to $1.1bn as well as tiered royalties up to low double-digits. [collapse expanded text] |
Neurocrine Biosciences, Voyager Therapeutics | Jan 2023 | 1160 | Collaboration, option, co-development and licensing agreement for GBA1 program and other next-generation gene therapies for neurological diseases | Key Deal Terms Summary1. Agreement Overview
2. Financial Terms
3. Development & Commercialization Responsibilities
4. Strategic Impact
Overall SummaryNeurocrine Biosciences and Voyager Therapeutics have entered a strategic gene therapy collaboration focused on Parkinson’s disease and other CNS disorders. Voyager receives $175 million upfront, with up to $1.5 billion in potential milestone payments and tiered royalties. Neurocrine gains worldwide rights to Voyager’s GBA1 gene therapy program and three additional CNS-focused gene therapy programs, leveraging Voyager’s TRACER™ capsid platform. The partnership accelerates gene therapy advancements in neuroscience, providing financial, commercial, and R&D benefits to both companies. [collapse expanded text] |
Eli Lilly, TRexBio | Jan 2023 | 1155 | Collaboration and licensing agreement for therapies for immune-mediated diseases | TRex Bio announced a multi-year research collaboration and exclusive worldwide license agreement … read morewith Eli Lilly to develop novel therapies for the treatment of immune-mediated diseases. This agreement builds on a previous collaboration with Lilly. TRexBio receives an upfront payment of $55 million and is eligible to receive more than $1.1 billion on achievement of certain development, regulatory, and commercial milestones. TRexBio is also entitled to receive tiered royalties on product sales. Eli Lilly will be granted an exclusive worldwide license to develop and commercialize drug candidates from three programs and will be fully responsible for all related clinical development and commercialization costs. [collapse expanded text] |
Hutchmed, Takeda Pharmaceutical | Jan 2023 | 1130 | Licensing agreement for fruquintinib | HUTCHMED has entered into an exclusive license agreement with a subsidiary of Takeda Pharmaceutical … read moreCompany to further the global development, commercialization and manufacture of fruquintinib outside of mainland China, Hong Kong and Macau, where it is marketed by HUTCHMED. HUTCHMED will receive up to US$1.13 billion including US$400 million upfront on closing as well as potential regulatory, development and commercial sales milestone payments, plus royalties on net sales. [collapse expanded text] |
Ionis Pharmaceuticals, Royalty Pharma | Jan 2023 | 1125 | Royalty financing agreement for SPINRAZA | Ionis Pharmaceuticals and Royalty Pharma announced that Royalty Pharma has acquired an interest in … read moreIonis' royalty in Biogen's SPINRAZA (nusinersen) and Novartis' pelacarsen for up to $1.125 billion, including an upfront payment of $500 million and up to $625 million in additional pelacarsen milestone payments. Royalty Pharma will receive: 25% of Ionis' SPINRAZA royalty payments through 2027, increasing to 45% of royalty payments in 2028, on up to $1.5 billion in annual sales. Royalty Pharma's royalty interest in SPINRAZA will revert to Ionis after total SPINRAZA royalty payments reach either $475 million or $550 million, depending on the timing and occurrence of certain events; and 25% of Ionis' pelacarsen royalty payments. Under the terms of Ionis' exclusive licensing agreement with Biogen, Ionis is entitled to tiered royalties up to the mid-teens on annual worldwide net sales of SPINRAZA. Ionis' exclusive license agreement with Novartis entitles Ionis to receive tiered royalties in the mid-teens to low 20% range on net sales of pelacarsen. Ionis also retains all rights to $650 million in pelacarsen development, regulatory and commercial milestones from Novartis. [collapse expanded text] |
Legend Biotech, Novartis | Nov 2023 | 1110 | Licensing agreement for CAR-T therapies targeting DLL3 | Legend Biotech announced that Legend Biotech Ireland has entered into an exclusive, global license … read moreagreement with Novartis Pharma for certain Legend Biotech chimeric antigen receptor T-cell cell therapies targeting DLL3, including its autologous CAR-T cell therapy candidate, LB2102. The License Agreement grants Novartis the exclusive worldwide rights to develop, manufacture and commercialize these cell therapies, and Novartis may apply its T-Charge™ platform to their manufacture. Legend Biotech will conduct a Phase 1 clinical trial for LB2102 in the US Novartis will conduct all other development for the licensed products. Legend Biotech will receive a $100 million upfront payment and will be eligible to receive up to $1.01 billion in clinical, regulatory and commercial milestone payments and tiered royalties. [collapse expanded text] |
Nona Biosciences, Pfizer | Dec 2023 | 1103 | Licensing agreement for HBM9033 | Nona Biosciences has entered into an exclusive license agreement with Pfizer for the global … read moreclinical development and commercialization of Nona Biosciences' MSLN-targeted antibody-drug conjugate, HBM9033. Nona Biosciences will receive a total of up to $53 million in upfront and near-term payments, with the potential for additional payments of up to $1.05 billion upon achieving certain development and commercial milestones. Nona Biosciences is also eligible to receive tiered royalties on net sales ranging from high single digits to high teens. [collapse expanded text] |
Contineum Therapeutics, Janssen Pharmaceutica NV | Apr 2023 | 1075 | Licensing, option and co-development agreement for PIPE-307 | Pipeline Therapeutics has entered into a global license and development agreement with Janssen … read morePharmaceutica for the investigational compound, PIPE-307 to treat nervous system disorders. PIPE-307 is an oral, highly selective antagonist of the muscarinic M1 receptor, which has completed two Phase 1 clinical trials in healthy patients and has received Investigational New Drug clearance from the Food and Drug Administration to initiate clinical development in relapsing-remitting multiple sclerosis patients. Pipeline will grant Janssen a worldwide, exclusive license to research, develop and commercialize PIPE-307 in all indications. Pipeline will have the right to continue to advance PIPE-307 for the treatment of RRMS through conduct of a Phase 2 clinical trial. Upon closing of the transaction, Pipeline will receive $50M in an upfront payment from Janssen and separately up to $25M in an equity investment from Johnson & Johnson Innovation and up to $25M in equity investments from Pipeline’s existing investors. Pipeline is also eligible to receive approximately $1 billion in success-based payments including clinical, regulatory and commercial milestones, as well as tiered double-digit royalty payments, which increase if the co-development option for PIPE-307 is exercised by Pipeline. [collapse expanded text] |
Amphastar Pharmaceuticals, Eli Lilly | Apr 2023 | 1075 | Asset purchase agreement for BAQSIMI | Eli Lilly and Amphastar Pharmaceuticals have entered into a definitive agreement for Lilly to … read moredivest BAQSIMI worldwide to Amphastar. BAQSIMI is the first and only nasally administered glucagon for the treatment of severe hypoglycemia in people with diabetes. Amphastar will pay Lilly $500 million in cash at closing and an additional $125 million in cash upon the one-year anniversary of closing. Lilly is also eligible to receive sales-based milestone payments of up to $450 million in aggregate. [collapse expanded text] |
Assembly Biosciences, Gilead Sciences | Oct 2023 | 1075 | Collaboration, option and licensing agreement for next-generation therapeutics for serious viral diseases | Gilead Sciences and Assembly Biosciences have entered into a 12-year partnership to advance the … read moreresearch and development of novel antiviral therapies, with an initial focus in Assembly Bio’s established areas of herpesviruses, hepatitis B virus and hepatitis D virus. Assembly Bio will receive $100 million, consisting of an $84.8 million upfront payment and a $15.2 million equity investment from Gilead. Gilead’s initial equity investment at a premium represents 19.9 percent of the outstanding voting stock of Assembly Bio as of the date of closing. In addition, subject to certain conditions, Gilead has agreed to purchase up to 29.9 percent of Assembly Bio’s outstanding voting stock at a premium. Gilead may opt-in to obtain exclusive rights for each of Assembly Bio’s current and future programs, including two preclinical programs targeting HSV and transplant-associated herpesviruses that Gilead is licensing to Assembly Bio, upon payment of an opt-in fee of at least $45 million per program after clinical proof-of-concept is achieved. If Gilead opts-in to any current or future program under the collaboration, Assembly Bio is eligible to receive up to $330 million per program in potential regulatory and commercial milestones, in addition to royalties ranging from the high single digits to high teens. During the term of the collaboration, Assembly Bio will also be eligible to receive three separate $75 million collaboration extension payments at prespecified timepoints during the collaboration term to help fund future research and development. Following Gilead’s exercise of its option for an Assembly Bio program, Assembly Bio will have the right to opt-in to share profits and costs in the United States. For future new programs, Assembly Bio will also have an option to co-promote those products in the United States. Assembly Bio will be primarily responsible for the research and development efforts on the collaboration programs, including the two contributed Gilead programs, prior to Gilead’s potential opt-in. Following Gilead’s opt-in, Gilead will control discovery, research, development and commercialization on the optioned program(s). Gilead has the right to appoint two individuals to Assembly Bio’s Board of Directors. [collapse expanded text] |
BioNTech, MediLink Therapeutics | Oct 2023 | 1070 | Collaboration and licensing agreement for next-generation anti-cancer antibody-drug conjugate | MediLink Therapeutics has entered into a strategic research collaboration and worldwide license … read moreagreement with BioNTech on the development of a next-generation antibody-drug conjugate candidate, against Human Epidermal Growth Factor Receptor. MediLink will grant BioNTech exclusive global rights for the development, manufacturing, and commercialization of one of MediLink's ADC assets excluding Mainland China, Hong Kong Special Administrative Region, and Macau Special Administrative Region. BioNTech will provide MediLink with an upfront payment totaling of $70 million and additional development, regulatory and commercial milestone payments potentially totaling over $1 billion. [collapse expanded text] |
BioNTech, Biotheus | Nov 2023 | 1055 | Development and licensing agreement for PM8002 | Biotheus has entered into an exclusive global license and collaboration agreement under which … read moreBioNTech will be developing, manufacturing and commercializing PM8002 globally ex-Greater China, whereas Biotheus retains the rights to exploit PM8002 in Greater China. PM8002 is currently being tested in Phase 2 studies in China to evaluate the efficacy and safety of the candidate as a monotherapy or in combination with chemotherapy in patients with advanced solid tumors. Biotheus will receive an upfront payment of $55 million, and is eligible to receive additional development, regulatory and sales milestone payments potentially totalling over $1 billion as well as tiered royalties on potential future product sales. [collapse expanded text] |
Genentech, PeptiDream | Sep 2023 | 1040 | Collaboration and licensing agreement for peptide-radioisotope drug conjugates | PeptiDream announced a new multi-target collaboration and license agreement with Genentech focused … read moreon the discovery and development of novel macrocyclic peptide-radioisotope drug conjugates. PeptiDream will use its proprietary Peptide Discovery Platform System technology to discover, optimize, and develop macrocyclic peptide candidates for use as peptide-RI drug conjugates against targets of interest to Genentech. PeptiDream will lead early preclinical development before transitioning peptide-RI drug conjugate products arising from the collaboration to Genentech for further development and commercialization. PeptiDream will retain the right to develop and commercialize such peptide-RI drug conjugate products in Japan. The new collaboration and license agreement builds upon the long collaborative relationship between the companies, which started with a multi-target collaboration and license agreement in December 2015, followed by Genentech licensing PeptiDream’s PDPS technology in 2016, and expansion of the companies’ collaboration in 2018. PeptiDream will receive an upfront payment of $40 million USD (¥5.9 billion JPY)(1 USD = 147.7 JPY) from Genentech and be eligible for payments based on the achievement of specified development, regulatory, and commercial milestones potentially up to $1 billion USD (¥147.7 billion JPY). PeptiDream is eligible to receive tiered royalties on net sales (ex-Japan) of any such products arising from the collaboration. [collapse expanded text] |
Department of Veterans Affairs, Valor Healthcare | Jun 2023 | 1032 | Contract service agreement for remote patient monitoring services | Valor Healthcare announced its selection as one of four companies awarded a position on Veterans … read moreAffairs' eight-year, $1.032 billion contract to provide Remote Patient Monitoring and Home Telehealth services for veterans. VA's Office of Connected Care will deploy the systems and tools needed to monitor veterans' chronic health conditions while they are at home. The contract award represents the largest Remote Patient Monitoring effort in the federal government. The VA's award notice, posted Monday, May 1st, states that the work supports at least 72,000 veterans whose needs can include chronic care, acute care, health promotion, disease prevention, and non-institutional care. Awardees will also be responsible for providing prosthetic appliances in support of care coordination and chronic disease management efforts. [collapse expanded text] |
Aqilion, Merck and Co | Feb 2023 | 1025.7 | Collaboration and licensing agreement for small molecule inhibitors of transforming growth factor-β-activated kinase 1 (TAK1) protein | AQILION announced an exclusive license and strategic research collaboration with Merck to discover, … read moredevelop and commercialize small molecule inhibitors of the transforming growth factor-β-activated kinase 1 protein. Merck will make an upfront cash payment of EUR 10 million to Aqilion. Aqilion is eligible to receive potential development and commercialization milestones up to over EUR 950 million and tiered royalties on worldwide net sales. The research collaboration will aim to develop first-in-class and differentiated TAK1 therapeutics in a broad range of autoimmune and inflammatory disease indications, including neurological diseases. During the collaboration, Aqilion will be responsible for the design and synthesis of novel small molecule TAK1 inhibitors while Merck will lead preclinical pharmacology and biology studies. [collapse expanded text] |
Bristol-Myers Squibb, Tubulis | Apr 2023 | 1022.75 | Licensing agreement for differentiated antibody-drug conjugates | Tubulis and Bristol Myers Squibb have entered into a strategic license agreement to develop … read moredifferentiated antibody-drug conjugates. Bristol Myers Squibb will gain exclusive rights to access Tubulis’ Tubutecan payloads in combination with Tubulis’ proprietary P5 conjugation platform for the development of a selected number of highly differentiated ADCs to treat solid tumors. P5 and Tubutecans facilitate the generation of ultra-stable ADCs that have the potential to actively reduce unwanted target-independent toxicities and are optimized for on-target delivery of potent topoisomerase-1 inhibitors. The terms of the agreement include an upfront payment of $22.75 million to Tubulis in addition to the potential for over $1 billion in development, regulatory, and commercial milestone payments plus royalty payments on resulting marketed products. Following antibody target selection by Bristol Myers Squibb, Tubulis will provide the company with its linker-payload to generate a uniquely matched ADC for each antibody. Bristol Myers Squibb will assume sole responsibility for development, manufacturing, and commercialization of the resulting ADC candidates. [collapse expanded text] |
GeneQuantum Healthcare, Pyramid Biosciences | Apr 2023 | 1020 | Licensing agreement for GQ1010 | Pyramid Biosciences has entered into an exclusive license agreement with GeneQuantum Healthcare to … read moredevelop and commercialize GQ1010, a potential best-in-class antibody drug conjugate targeting TROP2, worldwide except for Greater China (mainland China, Hong Kong, Macau, and Taiwan). GQ1010 has shown a highly differentiated preclinical profile, and is anticipated to enter a first-in-human trial within the next 12 months. Pyramid Biosciences will develop and commercialize GQ1010 in exchange for an upfront payment of $20 million and up to an additional $1 billion of milestone payments. GeneQuantum would also be eligible to receive tiered royalties ranging from mid-single digit to low double digits on net sales. [collapse expanded text] |
F-Star Therapeutics, Takeda Pharmaceutical | Jul 2023 | 1000 | Collaboration and licensing agreement for fully-human Fcab and tetravalent mAb² platforms to research and develop next-generation multi-specific immunotherapies for cancer | F-star Therapeutics has entered into a strategic discovery collaboration and licence agreement with … read moreTakeda. The collaboration will leverage F-star’s proprietary fully-human Fcab and tetravalent mAb² platforms to research and develop next-generation multi-specific immunotherapies for patients with cancer. F-star and Takeda will jointly research and develop novel Fcab domains against undisclosed immuno-oncology targets. Takeda will receive a worldwide, exclusive royalty-bearing licence to research, develop, and commercialise antibodies incorporating Fcab domains arising from the collaboration, and F-star will retain the right to research, develop, and commercialise antibodies incorporating certain other Fcab domains. F-star will receive an undisclosed upfront payment as well as research funding for the period of the collaboration. F-star is also eligible to receive potential future development and commercialisation milestone payments of up to approximately $1 billion if all milestones across multiple programs are reached during the term of the agreement, plus royalties on potential annual net sales of any commercial product resulting from the licence. [collapse expanded text] |
Alexion Pharmaceuticals, Pfizer | Jul 2023 | 1000 | Asset purchase and licensing agreement for portfolio of preclinical rare disease gene therapies | Alexion has entered a definitive purchase and licence agreement for a portfolio of preclinical gene … read moretherapy programmes and enabling technologies from Pfizer. The agreement furthers Alexion and AstraZeneca’s commitment to advancing next-generation genomic medicines with the addition of complementary pipeline assets and innovative technologies. As part of the agreement, the transaction will bring to Alexion a number of novel adeno-associated virus capsids. AAV capsids have been shown to be an effective mechanism for delivering therapeutic gene cargos for gene therapy and gene editing. These new resources build on Alexion and AstraZeneca’s combined capabilities in genomic medicine, recently strengthened with the acquisition of LogicBio, with the objective to develop new genetic therapies with improved safety and efficacy profiles. Additionally, Alexion will seek to welcome talent from Pfizer associated with the portfolio. Alexion will purchase and licence the assets of Pfizer’s early-stage rare disease gene therapy portfolio for a total consideration of up to $1bn, plus tiered royalties on sales. [collapse expanded text] |
BioMap, Sanofi | Oct 2023 | 1000 | Collaboration and co-development agreement for drug discovery for biotherapeutics | BioMap announced a strategic collaboration with Sanofi to co-develop cutting-edge AI modules for … read morebiotherapeutic drug discovery leveraging BioMap’s AI platform. Leveraging BioMap’s custom-built foundational models and world-leading AI expertise, as well as Sanofi’s proprietary data, computational innovations in protein engineering, and deep biologics development experience, both parties aim to create advanced AI models and protein Large Language Models that will enable biologics design and multiparametric optimization. BioMap will receive an upfront cash payment and near-term payments for reaching module development milestones from Sanofi. BioMap will be eligible to receive payments of over $1 billion based on achievement of pre-clinical development, clinical development, regulatory, and commercial milestones. [collapse expanded text] |
Arrowhead Pharmaceuticals, GSK, Janssen Pharmaceuticals | Oct 2023 | 1000 | Licensing agreement for JNJ-3989 | GSK and Arrowhead Pharmaceuticals have reached an agreement with Janssen Pharmaceuticals to … read moretransfer exclusive worldwide rights to further develop and commercialise JNJ-3989 to GSK. JNJ-3989 (formerly ARO-HBV) was initially in-licensed by Janssen from Arrowhead in 2018. GSK will assume rights and obligations of the existing license agreement between Janssen and Arrowhead, including all remaining financial obligations owed to Arrowhead for JNJ-3989 under the original agreement. GSK will be responsible for upfront and potential milestone-based payments to both Janssen and Arrowhead totalling approximately $1 billion. Janssen will continue to be responsible for the ongoing clinical trials of JNJ-3989 at its expense and GSK will be solely responsible for all future development and commercialisation activities. Additionally, Arrowhead will receive tiered royalties on net sales pursuant to the original agreement. [collapse expanded text] |
Biohaven Pharmaceuticals, Hangzhou Highlightll Pharmaceutical | Mar 2023 | 970 | Licensing agreement for brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders | Biohaven acquired global rights, excluding China regions, for the development of an oral, brain- … read morepenetrant, dual inhibitor of Tyrosine Kinase 2 and Janus Kinase 1 for the treatment of brain disorders. BHV-8000 (previously TLL-041) was licensed from Hangzhou Highlightll Pharmaceutical and Biohaven anticipates advancing the agent into a Phase 1 study in 2023. Highlightll will receive $10 million in upfront cash and $10 million in BHVN equity, development and commercial milestone payments of up to $950 million, and tiered royalty payments ranging from mid-single digit to lower teens percentages. Biohaven and Highlightll will coordinate clinical development across global regions. [collapse expanded text] |
4D Molecular Therapeutics, Astellas Pharma | Jul 2023 | 962.5 | Licensing and option agreement for intravitreal R100 vector for rare ophthalmic targets | Key Deal Terms Summary: Astellas and 4D Molecular Therapeutics License Agreement… read moreParties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Considerations
Overall SummaryAstellas has entered a license agreement with 4DMT to leverage its R100 vector for gene therapy targeting rare ophthalmic diseases. The deal includes an upfront payment of $20 million, potential future payments up to $942.5 million, and royalties on sales. Astellas assumes responsibility for development, manufacturing, and commercialization, while 4DMT retains rights to non-hereditary ophthalmic diseases. This agreement strengthens Astellas’ ophthalmology and gene therapy portfolio, while further validating 4DMT’s vector technology. [collapse expanded text] |
Merck and Co, ModeX Therapeutics | Mar 2023 | 922.5 | Collaboration and licensing agreement for MDX-2201 | ModeX Therapeutics entered into an exclusive worldwide license and collaboration agreement with … read moreMerck for the development of MDX-2201, ModeX’s preclinical nanoparticle vaccine candidate targeting EBV. OPKO will receive an upfront payment of $50 million and is eligible for milestone payments associated with progress in the development and commercialization of MDX-2201 of up to $872.5 million, as well as royalties on global sales. ModeX and Merck will jointly advance MDX-2201 to an Investigational New Drug application filing, after which Merck will be responsible for clinical and regulatory activities, as well as product commercialization. Pre-IND filing activity will be guided by a joint steering committee comprised of representatives from both companies. [collapse expanded text] |
Compugen, Gilead Sciences | Dec 2023 | 848 | Licensing agreement for pre-clinical antibody program against IL-18 binding protein, including COM503 drug candidate | Gilead Sciences announced an agreement with Compugen to exclusively license its potential first-in- … read moreclass, pre-clinical antibody program against IL-18 binding protein, including the COM503 drug candidate. Compugen will be responsible for the ongoing pre-clinical development and the future Phase 1 study of COM503. Thereafter, Gilead will have the sole right to develop and commercialize COM503. Gilead will make Compugen an upfront payment of $60 million and $30 million in a near term milestone payment subject to IND clearance of COM503 expected in 2024. Compugen will also be eligible to receive up to an additional $758 million in future development, regulatory and commercial milestone payments, with a total deal value of $848 million. Compugen will also be eligible to receive single-digit to low double-digit tiered royalties on worldwide net sales. [collapse expanded text] |
Alexion Pharmaceuticals, AstraZeneca, Verge Genomics | Sep 2023 | 840 | Collaboration, option and licensing agreement for drug discovery for rare neurodegenerative and neuromuscular diseases | Verge Genomics announced a multi-target collaboration with Alexion to identify novel drug targets … read morefor rare neurodegenerative and neuromuscular diseases. Verge will receive up to $42 million, consisting of upfront fee, equity, and near-term payments, with a potential deal value of $840 million plus potential downstream royalties. The collaboration will leverage CONVERGE, a full-stack platform that combines highly predictive human tissue datasets with machine learning to find new targets with a higher probability of clinical success. Instead of starting with cell or animal models, Verge’s drug discovery platform is based on a proprietary library of genomic datasets derived directly from human tissue that is coupled with an advanced human-centered biology platform to rapidly advance new data insights into clinical candidates. This approach, validated through the successful advancement of Verge’s lead program in amyotrophic lateral sclerosis, will be used to identify novel therapeutic targets. Alexion will select high-potential targets for each indication, with the option to license and advance successful targets through clinical development and commercialization. AstraZeneca will take an equity position in Verge Genomics, building upon Verge’s strong roster of industry-leading strategic investors that include Eli Lilly and Merck Global Health Innovation Fund. [collapse expanded text] |
Flagship Pioneering, Pfizer | Jul 2023 | 800 | Collaboration and option agreement for innovative medicines | Flagship Pioneering and Pfizer announced the companies have partnered to create a new pipeline of … read moreinnovative medicines. Flagship and Pfizer will each invest $50M upfront to explore opportunities to develop 10 single-asset programs by leveraging Flagship’s ecosystem of more than 40 human health companies and multiple biotechnology platforms. Pfizer will fund and have an option to acquire each selected development program. Flagship and its bioplatform companies will be eligible to receive up to $700M in milestones and royalties for each successfully commercialized program. Pioneering Medicines, an initiative of Flagship Pioneering, working in collaboration with Pfizer’s research and development leadership, will lead the exploration process to drive rapid potential portfolio creation. The focus will be addressing unmet needs within Pfizer’s core strategic areas of interest, including in broad patient populations and diseases with high potential to benefit from a diverse range of technology platforms and modalities. [collapse expanded text] |
Cognizant, Gilead Sciences | Jul 2023 | 800 | Contract service agreement for global IT infrastructure | Cognizant announced an expansion of its relationship with Gilead Sciences. Cognizant will … read moremanage Gilead's global IT infrastructure, platforms, applications and advanced analytics, and lead initiatives designed to accelerate its digital transformation. The agreement includes renewal and expansion of Cognizant services for a total expected value of $800 million over the next five years. This collaboration is aimed at enabling Gilead to streamline various parts of its business with the goal of faster time to market of various medicines for life-threatening diseases, including HIV, viral hepatitis, and cancer. [collapse expanded text] |
Autifony Therapeutics, Jazz Pharmaceuticals | Nov 2023 | 770.5 | Collaboration and licensing agreement for ion channel targets associated with neurological disorders | Autifony Therapeutics has entered into an exclusive global licensing agreement with Jazz … read morePharmaceuticals for up to $770.5 million to discover and develop drug candidates targeting two different ion channel targets associated with neurological disorders. Autifony will lead drug discovery and preclinical development activities on the two targets. Subsequent to successful completion of such preclinical development, Jazz will lead all clinical development, manufacturing and regulatory activities and commercialization. Autifony will receive an upfront payment from Jazz and is eligible to receive development, regulatory and commercial milestone payments across the two programmes. The upfront and milestone payments have a combined total value of up to $770.5 million. Autifony is also eligible to receive royalties on future net sales. [collapse expanded text] |
Maze Therapeutics, Sanofi | May 2023 | 750 | Licensing agreement for MZE001 | December 2023 Terminated Maze Therapeutics announced the signing of an exclusive worldwide … read morelicense agreement with Sanofi for Maze’s glycogen synthase 1 program, including clinical candidate MZE001, which is currently in development for the treatment of Pompe disease and other potential indications. MZE001, designed and developed by Maze, is an oral GYS1 inhibitor that aims to address Pompe disease by limiting disease-causing glycogen accumulation. Maze will receive a $150 million payment consisting of both upfront cash and future equity investment for the rights to further develop and commercialize MZE001, as well as an exclusive license to related GYS1-targeting back-up programs and intellectual property. Maze will be eligible to receive up to an additional approximately $600 million in potential development, regulatory and sales milestones, as well as meaningful royalties on sales if MZE001 is successfully commercialized. [collapse expanded text] |
Capsida Biotherapeutics, Prevail Therapeutics | Jan 2023 | 745 | Collaboration, licensing, option and co-promotion agreement for non-invasive gene therapies for CNS diseases | Capsida Biotherapeutics announced a multi-year strategic collaboration with Prevail Therapeutics to … read moredevelop transformative genetic medicines for serious diseases. Prevail will leverage Capsida's novel adeno-associated virus engineering platform to identify and advance clinically translatable capsids paired with Prevail's cargo to develop best-in-class, IV-administered gene therapies directed to specified targets known to cause serious diseases that affect the central nervous system. Capsida will receive $55 million consisting of an upfront payment and a commitment to participate in the company's next financing round, plus the potential to receive up to $685 million in research and development and commercial milestones as well as tiered royalties. In addition, for one of the programs under the collaboration, Capsida will have an option to participate in development and commercialization in the US in exchange for a gross margin share in that program. For all programs, Capsida will lead capsid discovery efforts using its high throughput AAV engineering and screening platform and Prevail will be responsible for preclinical and Investigational New Drug-enabling studies with therapeutic payloads. [collapse expanded text] |
Dewpoint Therapeutics, Novo Nordisk | Mar 2023 | 745 | Research, development and licensing agreement for drug candidates using discovery platform related to biomolecular condensates to treat insulin resistance and diabetic complications | Dewpoint Therapeutics announced a research and development partnership with Novo Nordisk to … read moreidentify drug candidates using Dewpoint's discovery platform related to biomolecular condensates to treat insulin resistance and diabetic complications. The partnership brings together Novo Nordisk's global leadership in treating diabetes and metabolic diseases with Dewpoint's groundbreaking discovery and AI technology platform to identify modulators of biomolecular condensates. The scope of the agreement includes discovering potential small molecule drugs against multiple new condensate targets that may be involved in mechanisms of insulin resistance and insulin sensitivity. Novo Nordisk can also choose to discover non-small molecule drugs against the identified condensates using internal Novo Nordisk capabilities and gains rights to further develop and commercialize such potential drugs. Dewpoint is eligible to receive up to $55 million in the near term which includes an upfront payment, research funding and potential research milestones across two programs. Dewpoint is also eligible to receive up to $690 million of clinical, commercial and sales milestones plus royalties across two commercial products. If Novo Nordisk decides to pursue other modalities for the condensates, Dewpoint will be eligible to receive up to $107.5 million in total milestones per product. [collapse expanded text] |
Astellas Pharma, PeptiDream | Jul 2023 | 741 | Collaboration, option and licensing agreement for targeted protein degraders | Astellas Pharma US and PeptiDream announced a research collaboration and license agreement to … read morediscover novel protein degraders for two targets selected by Astellas. Astellas will have the option to select up to three additional targets to be included in the collaboration. Under the terms of the agreement, the companies plan to combine PeptiDream's PDPS (Peptide Discovery Platform System) technology with Astellas' drug discovery capabilities to discover multiple next-generation protein degraders targeting diverse targets that go beyond existing technologies. Astellas will be responsible for the development and commercialization of products created from this collaborative research. Astellas will provide PeptiDream with an upfront payment of ¥3.0 billion. PeptiDream is eligible to receive discovery, development and commercial sales milestones of up to ¥20.6 billion per target. PeptiDream is also eligible to receive single-digit percent royalty payments on net sales of any products arising from the collaboration. [collapse expanded text] |
SOTIO, Synaffix | Oct 2023 | 740 | Licensing aoption agreement for ADC technology platform | SOTIO announced a license and option agreement with Synaffix to develop next-generation antibody- … read moredrug conjugates for the treatment of solid tumors. SOTIO will leverage Synaffix’s ADC technology platform to develop up to three novel ADCs targeting distinct tumor-associated antigens. The deal enables SOTIO to combine its proprietary antibodies with Synaffix’s ADC technology platform in order to deliver innovative new ADCs that can overcome the challenges of treating solid tumors. In addition to GlycoConnect and HydraSpace, the deal also includes Synaffix’s potent linker-payload platform including multiple different payloads. Synaffix is eligible to receive upfront and potential milestone payments worth up to $740 million, plus single-digit royalties on net sales. SOTIO will be responsible for research, development, manufacturing and commercialization of the ADC products, while Synaffix will closely support SOTIO’s research activities and be responsible for the manufacturing of components that are specifically related to its proprietary GlycoConnect, HydraSpace, and linker-payload technologies. [collapse expanded text] |
Coya Therapeutics, Dr. Reddy's Laboratories | Dec 2023 | 733.15 | Development and licensing agreement for COYA 302 | Dr. Reddy's Laboratories and Coya Therapeutics have entered into a development and license … read moreagreement for the development and commercialization of COYA 302, an investigational combination therapy for the treatment of Amyotrophic Lateral Sclerosis. Coya has granted Dr. Reddy’s an exclusive license to commercialize COYA 302, a proprietary co-pack kit containing combination of low dose IL-2 and CTLA-4 Ig (abatacept) in the United States, Canada, the European Union and the United Kingdom for ALS. This Agreement is in addition to the in-licensing agreement with Dr. Reddy’s signed in early 20231. Coya retains the right to commercialize COYA 302 for patients with amyotrophic lateral sclerosis in Japan, Mexico, and each country in South America. Coya will have responsibility for the clinical development of COYA 302 and for seeking regulatory approval for COYA 302 for patients with ALS in the United States. Dr. Reddy’s will make a USD 7.5 million upfront payment to Coya. Upon the first FDA acceptance of an investigational new drug application for COYA 302 for the treatment of ALS, Dr. Reddy’s will pay Coya an additional USD 4.2 million. Upon dosing of the first patient in the first Phase 2 trial of COYA 302 for the treatment of ALS in the United States, Dr. Reddy’s will pay Coya an additional USD 4.2 million. Coya anticipates that the IND filing will be made in the first half of 2024. The Agreement also includes development and regulatory milestones up to USD 40 million should all such development and regulatory milestones be achieved. Coya is eligible to receive sales-based milestone payments of up to USD 677.25 million linked to tiers of cumulative net sales being achieved over several years (over the term of the agreement subject to product commercial exclusivity). Dr. Reddy’s will pay Coya royalties based on a percentage net sales of COYA 302 ranging from low to middle teens. Coya is not a related party to Dr. Reddy’s or its promoters/promoter group. [collapse expanded text] |
Dr. Reddy's Laboratories, Junshi Biosciences | May 2023 | 728.3 | Development and licensing agreement for toripalimab | Shanghai Junshi Biosciences announced a collaboration with Dr Reddy’s Laboratories to develop and … read morecommercialize toripalimab, the anti-PD-1 monoclonal antibody in Latin America, India, South Africa, and at the election of Dr. Reddy’s, also in Australia, New Zealand and other countries. Junshi Biosciences will grant a licence to Dr Reddy’s to develop and exclusively commercialize toripalimab in Brazil, Mexico, Colombia, Argentina, Peru, Chile, Panama, Uruguay, India and South Africa. Dr. Reddy’s may elect to expand the scope of the license to cover Australia, New Zealand and nine other countries. Junshi Biosciences also grants Dr Reddy’s the exclusive right of first negotiation for commercialization, in the event that Junshi Biosciences determines to grant any third party the rights to commercialize two other products as agreed in the agreement in one or more countries within the total 21 countries of Dr Reddy’s Territory3. Junshi Biosciences may receive up to an aggregate of US$728.3 million for upfront payment, potential expansion of Dr. Reddy’s Territory and milestone payment, plus double-digit percentage of royalties on the net sales of products containing toripalimab. [collapse expanded text] |
Aspect Biosystems, Novo Nordisk | Apr 2023 | 725 | Development and licensing agreement for bioprinted tissue therapeutics for diabetes and obesity | Aspect Biosystems and Novo Nordisk announced a collaboration, development, and licence agreement to … read moredevelop bioprinted tissue therapeutics designed to replace, repair, or supplement biological functions inside the body with the aim of delivering a new class of truly disease-modifying treatments for diabetes and obesity. The collaboration will leverage Aspect’s proprietary bioprinting technology and Novo Nordisk’s expertise and technology in stem cell differentiation and cell therapy development and manufacturing. Novo Nordisk will receive an exclusive, worldwide licence to use Aspect’s bioprinting technology to develop up to four products for the treatment of diabetes and/or obesity. Aspect will receive initial payments of 75 million dollars, including an upfront payment, research funding and an investment in the form of a convertible note. Aspect is also eligible to receive up to 650 million dollars in future development, regulatory, commercial and sales milestone payments per product, as well as tiered royalties on future product sales. [collapse expanded text] |
Biomedical Advanced Research and Development Authority, Emergent BioSolutions | Jul 2023 | 704 | Contract service agreement for Ebanga | September 2024 Emergent BioSolutions announced today that it was awarded a contract modification … read moreexecuting an option period by the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, valued at $41.9 million, for drug substance engineering and scale-up process validation, long term stability, and commercial readiness in support of its ongoing scale-up program for Ebanga (ansuvimab-zykl), a licensed treatment for Ebola virus disease July 2023 Emergent BioSolutions was awarded a 10-year contract by the Biomedical Advanced Research and Development Authority valued at up to a maximum of $704 million, for advanced development, manufacturing scale-up, and procurement of Ebanga (ansuvimab-zykl), a licensed treatment for Ebola virus disease. [collapse expanded text] |
AbCellera Biologics, Government of Canada | May 2023 | 700 | Development agreement to advance drug development capabilities and infrastructure that will accelerate innovative medicines to patients | AbCellera announced a CA$701 million co-investment with the Governments of Canada and British … read moreColumbia to build new capabilities and infrastructure to develop innovative antibody-based medicines and strengthen Canada’s leadership in clinical research, manufacturing, and drug development. Over the next eight years, AbCellera plans to invest CA$401 million in the project, and the Governments of Canada and British Columbia will contribute CA$225 million and CA$75 million, respectively. These investments will build new capabilities in Canada to develop, manufacture, and deliver antibody medicines to patients through Phase 1 clinical trials and build expertise in translational science, technical operations, and clinical operations and research. [collapse expanded text] |
CSPC Megalith Biopharmaceutical, Corbus Pharmaceuticals | Feb 2023 | 692.5 | Licensing agreement for CRB-701 | Corbus Pharmaceuticals has entered into an exclusive licensing agreement with CSPC Megalith … read moreBiopharmaceutical for development and commercialization of CRB-701 (SYS6002): a novel clinical stage antibody drug conjugate targeting Nectin-4. The agreement covers exclusive commercialization rights to CRB-701 in the United States, Canada, the European Union (including the European Free Trade Area), the United Kingdom, and Australia. CSPC will retain all rights to SYS6002 in the remaining global markets. The IND for CRB-701 has been cleared by the US FDA. CRB-701 is currently being investigated by CSPC in a Phase 1 dose escalation clinical trial in advanced solid tumors in China. Corbus is planning to bridge data from this Phase 1 trial to support a US clinical trial starting in 2024. Corbus and CSPC will work collaboratively to execute the clinical development of CRB-701 with Corbus responsible for the clinical development in the US and other licensed territories. CSPC will receive an upfront payment of $7.5 million. CSPC will also be eligible to receive royalties on net sales and up to $130 million in potential development and regulatory milestone payments and $555 million in potential commercial milestone payments. [collapse expanded text] |
Roche, Zion Pharmaceuticals | May 2023 | 680 | Development and licensing agreement for ZN-A-1041 | Zion Pharma announced that Roche has acquired the global rights to Zion’s lead program, ZN-A-1041. … read moreZN-A-1041 is an orally administered selective tyrosine kinase inhibitor targeting the Human Epidermal Growth Factor Receptor 2. ZN-A-1041 was designed to be blood-brain-barrier-penetrant, and has the potential to treat or prevent the onset of brain metastases in patients with HER2-positive metastatic breast cancer. After a transition period, Roche will be responsible for the further development, manufacturing, and commercialization of ZN-A-1041 globally. Zion will receive up to $70 million USD in upfront and near-term milestone payments pending achievement of certain milestone events. Zion will also be eligible for up to $610 million USD in additional payments following achievement of certain development, regulatory, and sales-based milestone events by ZN-A-1041, as well as tiered royalties on sales. [collapse expanded text] |
ABVC BioPharma, AiBtl BioPharma | Nov 2023 | 667 | Licensing agreement for CNS drugs with indications of MDD and ADHD | January 2024 ABVC BioPharma announced that the Company and its subsidiary received an aggregate … read moreof 46 million shares from AiBtl BioPharma, as its first milestone payment under a global licensing agreement. The agreement between the Company and AiBtl placed a value of $460 ($10 per share) on such payment. November 2023 ABVC BioPharma entered into a global licensing definitive agreement with AiBtl BioPharma for the Company's CNS drugs with the indications of MDD and ADHD. The agreement has the potential of licensing income worth $467M and royalties up to $200M. [collapse expanded text] |
Abbvie, Capsida Biotherapeutics | Feb 2023 | 665 | Collaboration agreement for targeted genetic medicines for eye diseases with high unmet need | Key Deal Terms Summary: AbbVie and Capsida Biotherapeutics Expanded Collaboration… read moreParties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Considerations
Overall SummaryAbbVie and Capsida have expanded their strategic collaboration to develop genetic medicines targeting serious eye diseases. AbbVie will leverage its ophthalmology expertise, while Capsida will lead capsid discovery and early manufacturing using its AAV engineering platform. Capsida will receive $70 million upfront, with potential milestone payments up to $595 million, plus royalties on future product sales. This agreement strengthens AbbVie’s gene therapy pipeline and reinforces Capsida’s position in AAV-based therapeutics. [collapse expanded text] |
Eli Lilly, PRISM BioLab | Nov 2023 | 660 | Collaboration and licensing agreement for protein-protein interaction target | PRISM BioLab has entered into a License and Collaboration Agreement with Eli Lilly. PRISM and … read moreLilly will collaborate to discover small molecule inhibitors of a PPI target selected by Lilly utilizing PRISM's proprietary PepMetics technology. Lilly has the option to add up to two more targets to the collaboration and is responsible for the clinical development and commercialization of resulting products. PRISM will receive upfront payments and is eligible to receive up to $660 million in pre-clinical, clinical and commercial development milestones payments, as well as royalties on product sales. [collapse expanded text] |
EVOQ Therapeutics, Gilead Sciences | Jan 2023 | 658.5 | Collaboration, option and licensing agreement for immunotherapy products for rheumatoid arthritis and lupus | Gilead Sciences and EVOQ Therapeutics announced a collaboration and licensing agreement to advance … read moreEVOQ’s proprietary technology for the treatment of rheumatoid arthritis and lupus. EVOQ’s NanoDisc technology is designed to enable lymph-targeted delivery of disease-specific antigens and has the potential to change the paradigm for the treatment of autoimmune diseases. Gilead and EVOQ will collaborate on preclinical development. Gilead has the option to exclusively license rights to EVOQ’s NanoDisc technology to pursue product candidates for RA and lupus indications and will be responsible for clinical development and commercialization. EVOQ could potentially receive up to $658.5 million total in upfront, option exercise and milestone payments across all programs, as well as tiered royalties on product sales. [collapse expanded text] |
AbSci, Almirall | Nov 2023 | 650 | Collaboration agreement for treatments for dermatological diseases | Almirall and Absci announced a drug discovery partnership aimed to develop and commercialize AI- … read moredesigned therapeutics to fight chronic and debilitating dermatological diseases. The partnership combines Absci’s Integrated Drug Creation platform with Almirall’s dermatological expertise with the goal of delivering life-changing medicines to patients, marking another step forward in AI drug creation. Absci will apply its de novo generative AI technology to create and commercialize therapeutic candidates for two dermatological targets. In addition to product royalties, Absci is eligible to receive up to approximately $650 million in upfront fees, R&D, and post-approval milestone payments across the two programs if all milestones are successfully completed. [collapse expanded text] |
Neuraxpharm, TG Therapeutics | Aug 2023 | 645 | Licensing and option agreement for BRIUMVI | TG Therapeutics and Neuraxpharm announced an agreement for the ex-US commercialization of BRIUMVI ( … read moreublituximab). BRIUMVI is the first and only anti-CD20 monoclonal antibody approved in the United States and European Union for adult patients with relapsing forms of multiple sclerosis that can be administered in a one-hour infusion, twice a year, following the starting dose. TG Therapeutics will receive an upfront payment of $140 million plus an additional $12.5 million upon launch in the first EU country and is eligible to receive up to an additional $492.5 million in milestone-based payments on achievement of certain launch and commercial milestones. The total deal is valued at up to $645 million in upfront and milestone payments. TG will receive tiered double-digit royalties on net product sales up to 30%. Neuraxpharm will have the exclusive right to commercialize BRIUMVI in territories outside the United States, Canada, and Mexico, which are retained by TG, and excluding certain Asian countries previously partnered. TG Therapeutics retains an option to buy back all rights under the commercialization agreement for a period of two years in the event of a change in control of TG. [collapse expanded text] |
Evotec, Sandoz | May 2023 | 640 | Development, manufacturing, option and licensing agreement for multiple biosimilars | July 2024 Evotec announced that its biologics segment Just - Evotec Biologics has expanded its … read morestrategic partnership with Sandoz Just - Evotec Biologics will receive appropriate remuneration following early scientific validation, with further funding tied to achieving development milestones from 2025 May 2023 Evotec and Sandoz announced that Just - Evotec Biologics launched a multi-year, long-term tech partnership with Sandoz for the immediate development and subsequent manufacturing of multiple biosimilars. The partnership includes an option for the non-exclusive in-licensing of Just - Evotec Biologics' proprietary technology by Sandoz for building its fully-owned S.POD facility (in analogy to Just - Evotec Biologics' state-of-the-art J.POD facilities). Just - Evotec Biologics will receive a double-digit-million upfront and future payments dependent on successful development progress of US$ 640 m as well as additional undisclosed payments dependent on progress into commercial manufacturing and exercising the S.POD option. The partnership sets out highest ambitions for reaching highest quality and lowest cost levels by introducing Just - Evotec Biologics' data-driven, fully integrated design capability and continuous manufacturing technology (J.DESIGN) into the field of biosimilars, exclusive for all molecules in scope. Both parties are closely aligned in their quest for improving access to medicines for patients across the globe. The development of the biosimilars will ramp up over the coming 12-18 months in a highly collaborative fashion at Just - Evotec Biologics' J.POD facilities. In addition, this partnership will set a precedent for Sandoz being able to in-license, non-exclusively, the Just - Evotec Biologics' proprietary J.DESIGN platform, process development and continuous manufacturing technology and build a state-of-the-art, fully owned ‘S.POD' facility in the latter part of this decade. To secure industry leading performance, the Just - Evotec Biologics team will support design, construction, onboarding, and training of the Sandoz team to fully realise the potential of the technology with positive impact on cost, speed, and quality in the field of biosimilars. [collapse expanded text] |
Confo Therapeutics, Eli Lilly | Mar 2023 | 630 | Licensing and option agreement for CFTX-1554 | Confo Therapeutics announced a worldwide licensing agreement with Eli Lilly for Confo’s clinical … read morestage CFTX-1554 and back-up compounds. Lilly will continue the clinical development program beyond Phase 1. In addition, the agreement considers a program to further develop Confo’s existing therapeutic antibody candidates targeting the same receptor. Confo will receive a USD 40M upfront payment from Lilly as well as up to USD 590M in potential milestone payments per program and tiered royalties. Confo maintains a co-investment option to participate in the funding of future development programs after clinical proof-of-concept for additional royalties. [collapse expanded text] |
GenFleet Therapeutics, Verastem | Aug 2023 | 625.5 | Collaboration, option and licensing agreement for programs targeting RAS pathway-driven cancers | December 2023 Verastem Oncology announced a potential best-in-class KRAS G12D oral inhibitor as … read morethe lead program of its discovery and development collaboration with GenFleet Therapeutics. August 2023 Verastem Oncology has entered into a discovery and development collaboration with GenFleet Therapeutics to advance three oncology discovery programs targeting RAS pathway-driven cancers. The collaboration, which builds on the strengths of both Companies in oncology small molecule drug development, enables Verastem Oncology to partner its clinical development and regulatory expertise with GenFleet’s accomplished discovery capabilities. This includes Verastem Oncology’s experience and established network of collaborators, including scientific and clinical experts in RAS biology and RAS pathway-dependent cancers and GenFleet’s accomplishments with its KRAS G12C inhibitor program. The risk-sharing structure of the collaboration is designed to allow Verastem Oncology the flexibility of a milestone-based option to license up to three compounds. The licenses would give Verastem Oncology development and commercialization rights outside of China while GenFleet would retain development and commercialization rights inside of China. The terms of the agreement include combined upfront, research support and option payments to GenFleet of $11.5 million for the first program, with potential total deal size across all three programs up to $625.5 million excluding royalties if Verastem Oncology exercises its in-license options. The collaboration provides Verastem Oncology with exclusive rights to obtain a license to each of the compounds after successful completion of pre-determined milestones in Phase 1 trials. [collapse expanded text] |
Pierre Fabre, Scorpion Therapeutics | Apr 2023 | 618 | Co-development and licensing agreement for STX-721 and STX-241 for EGFR mutant non-small cell lung cancer | Scorpion Therapeutics and Pierre Fabre announced an exclusive collaboration and license agreement … read morefor the co-development of STX-721 and STX-241, two candidates in Scorpion’s franchise of highly-selective, next-generation mutant epidermal growth factor receptor inhibitors. Discovered by Scorpion, STX-721 and STX-241 are potentially best-in-class inhibitors of EGFR mutations and potent treatment options for emergent and unmet medical needs in non-small cell lung cancer. Scorpion will lead clinical development of STX-721 and Pierre Fabre will lead clinical development of STX-241. Scorpion will retain commercialization rights to STX-721 and STX-241 in the United States, Canada and Japan, and Pierre Fabre will be responsible for commercialization activities in all other territories, with a focus on Europe and China. Scorpion will receive a combined $65 million from an upfront payment and the achievement of near-term milestones, and will be eligible to receive up to a total of $553 million in potential milestone payments. Pierre Fabre will pay Scorpion tiered percentage royalties on a licensed product-by-licensed product basis, ranging from mid-single to mid-teens based on annual net sales of each licensed product in territories excluding the United States, Canada and Japan. Scorpion will pay Pierre Fabre tiered percentage royalties based on a licensed product-by-licensed product basis, ranging from low-single to low-double digits on annual net sales of each licensed product in the United States. The companies will share global development expenses based on a pre-specified cost-sharing arrangement. [collapse expanded text] |
Pierre Fabre, Scorpion Therapeutics | Apr 2023 | 618 | Collaboration, licensing and co-development agreement for STX-721 and STX-241 | Scorpion Therapeutics and Pierre Fabre announced an exclusive collaboration and license agreement … read morefor the co-development of STX-721 and STX-241, two candidates in Scorpion’s franchise of highly-selective, next-generation mutant epidermal growth factor receptor inhibitors. Discovered by Scorpion, STX-721 and STX-241 are potentially best-in-class inhibitors of EGFR mutations and potent treatment options for emergent and unmet medical needs in non-small cell lung cancer. Scorpion will lead clinical development of STX-721 and Pierre Fabre will lead clinical development of STX-241. Scorpion will retain commercialization rights to STX-721 and STX-241 in the United States, Canada and Japan, and Pierre Fabre will be responsible for commercialization activities in all other territories, with a focus on Europe and China. Scorpion will receive a combined $65 million from an upfront payment and the achievement of near-term milestones, and will be eligible to receive up to a total of $553 million in potential milestone payments. Pierre Fabre will pay Scorpion tiered percentage royalties on a licensed product-by-licensed product basis, ranging from mid-single to mid-teens based on annual net sales of each licensed product in territories excluding the United States, Canada and Japan. Scorpion will pay Pierre Fabre tiered percentage royalties based on a licensed product-by-licensed product basis, ranging from low-single to low-double digits on annual net sales of each licensed product in the United States. The companies will share global development expenses based on a pre-specified cost-sharing arrangement. [collapse expanded text] |
AstraZeneca, LaNova Medicines | May 2023 | 600 | Licensing agreement for LM-305 | LaNova Medicines has entered into an exclusive license agreement with AstraZeneca Pharmaceuticals … read morefor LM-305, a pre-clinical stage antibody drug conjugate targeting G protein-coupled receptor, class C, group 5, member D (GPRC5D). AstraZeneca will be granted an exclusive global license to research, develop, and commercialize LM-305. LaNova Medicines is eligible to receive an upfront and near-term payments of up to $55 million and additional development and commercial milestone payments of up to $545 million, as well as tiered royalties on net sales worldwide. [collapse expanded text] |
Elevar Therapeutics, Jiangsu Hengrui Pharmaceuticals | Oct 2023 | 600 | Licensing agreement for camrelizumab in combination with rivoceranib for uHCC | Elevar Therapeutics and Jiangsu Hengrui Pharmaceuticals announced a global licensing agreement that … read moregrants Elevar rights to commercialize and develop Hengrui Pharma’s anti-PD-1 antibody camrelizumab in combination with rivoceranib for unresectable hepatocellular carcinoma worldwide, excluding Greater China Region and Korea. Elevar will pay Hengrui Pharma up to $600 million of sales milestones and a double-digit percentage royalty on camrelizumab net sales. The total estimated 10-year payout could be up to $1 billion. [collapse expanded text] |
GSK, Scynexis | Mar 2023 | 593 | Licensing and option agreement for Brexafemme | June 2023 SCYNEXIS announced the achievement of a $25 million performance-based development … read moremilestone under its exclusive license agreement with GSK for ibrexafungerp. The milestone payment follows a development goal for the Phase 3 MARIO study for ibrexafungerp in invasive candidiasis as SCYNEXIS continues executing ongoing ibrexafungerp trials. March 2023 GSK and SCYNEXIS have entered into an exclusive licence agreement for Brexafemme (ibrexafungerp tablets), a US FDA approved, first-in-class antifungal for the treatment of vulvovaginal candidiasis and for reduction in the incidence of recurrent VVC. This exclusive licence agreement gives GSK rights to commercialise Brexafemme for VVC and RVVC while continuing to develop ibrexafungerp, which is in phase III clinical trials for the potential treatment of invasive candidiasis, a life-threatening fungal infection. GSK will make an upfront payment to SCYNEXIS of $90 million, plus additional potential milestone-based payments totalling $503 million. GSK will pay up to $245.5 million if specific development, regulatory, and commercial milestones associated with the IC indication are successfully completed. A further $15 million milestone will be paid upon successful US FDA approval of an additional indication. GSK will pay sales-related milestone payments based on achieving a certain commercial performance of up to $242.5 million, and mid-single digit to mid-teen digit tiered royalties on the totality of sales across all indications (in both cases with the top tier based on achieving net sales greater than $1 billion). GSK will also receive an exclusive licence to develop ibrexafungerp and commercialise Brexafemme in all countries except the greater China region and certain other countries already out-licensed by SCYNEXIS to third parties. SCYNEXIS will continue executing the phase III programme for IC and other ongoing trials. SCYNEXIS retains rights to all other assets derived from enfumafungin. As part of this exclusive licence agreement, GSK has been granted a right of first negotiation to these compounds. [collapse expanded text] |
Cullinan Oncology, Harbour Biomed | Feb 2023 | 588 | Licensing agreement for B7H4 x 4-1BB bispecific immune activator | August 2024 Following review of data from phase 1 study it now plans to discontinue development … read moreHarbour BioMed will get back full rights to CLN-418 but lose chance to cash in on $550 million milestone payments February 2023 Cullinan Oncology has entered into an exclusive license with Harbour BioMed for the development and commercial rights of HBM7008 (CLN-418) in the US. CLN-418/HBM7008 is a B7H4 x 4-1BB bispecific immune activator developed from next-gen heavy chain only antibody (HCAb)-based multi-specific antibody discovery platform HBICE, currently in a Phase 1 clinical study being conducted at US and Australian sites in patients with advanced solid tumors. Cullinan Oncology will pay Harbour BioMed an upfront license fee of $25 million at closing for the exclusive right to develop and commercialize CLN-418/HBM7008 in the US. Harbour BioMed will be eligible to receive up to $148M in development and regulatory milestones plus up to an additional $415M in sales-based milestones as well as tiered royalties up to high teens on potential US commercial sales. [collapse expanded text] |
Abbvie, Anima Biotech | Jan 2023 | 582 | Collaboration, option and licensing agreement for mRNA biology modulators against oncology and immunology targets | AbbVie and Anima Biotech announced a collaboration to discover and develop mRNA biology modulators … read morefor three targets across Oncology and Immunology. Anima will use its mRNA Lightning platform to discover novel mRNA biology modulators against the collaboration targets providing AbbVie exclusive rights to license and further develop and commercialize the programs. Anima will receive an upfront payment of $42 million and may be eligible to receive up to $540 million in option fees and research and development milestones in the aggregate across the three targets, with potential for further commercial milestones as well as tiered royalties on net sales. AbbVie has an option to expand the collaboration with up to three additional targets under the same terms as the initial collaboration, which may increase the potential value of the collaboration. [collapse expanded text] |
AcuraStem, Takeda Pharmaceutical | Sep 2023 | 580 | Licensing agreement for PIKFYVE targeted therapeutics including AS-202 | AcuraStem has entered into a license agreement with Takeda to develop and commercialize AcuraStem's … read morePIKFYVE targeted therapeutics including AS-202, an innovative antisense oligonucleotide for the treatment of Amyotrophic Lateral Sclerosis. Takeda will receive an exclusive, worldwide license to AcuraStem's PIKFYVE program. AcuraStem will receive an upfront and milestone payments totaling up to approximately $580 million if all future clinical, regulatory, and commercial milestones are achieved during the term of the agreement plus tiered royalties on potential net sales of any commercial products resulting from this license. [collapse expanded text] |
Genentech, Kronos Bio | Jan 2023 | 574 | Collaboration and licensing agreement for therapies against transcriptional targets in oncology | Kronos Bio has entered into a discovery collaboration in the field of oncology with Genentech … read morefocused on discovering and developing small-molecule drugs that modulate transcription factor targets selected by Genentech. The partnership will allow Genentech to leverage Kronos Bio’s expertise to identify protein-protein interactions, genetic dependencies and gene expression signatures to better understand and target the oncogenic activity of transcription factors in cancer types of interest. Under the collaboration, researchers at the two companies will collaborate using Kronos Bio’s proprietary drug discovery platform, including the small molecule microarray for hit finding, to build upon research conducted to date by Genentech. Kronos Bio will lead discovery and research activities to a defined preclinical point when Genentech will have the exclusive right to pursue further preclinical and clinical development and commercialization. Kronos Bio will receive an upfront payment of $20 million and be eligible for additional payments, which could total up to $554 million, based on reaching certain milestones, including discovery, preclinical, clinical and commercial milestones, as well as tiered royalties on any potential products that are commercialized as a result of the collaboration. [collapse expanded text] |
Imugene, Precision BioSciences | Aug 2023 | 562 | Licensing and option agreement for azercabtagene zapreleucel | Precision BioSciences announced completion of a strategic transaction with Imugene for global … read morerights to Azercabtagene Zapreleucel (azer-cel), Precision’s lead allogeneic CAR T candidate, for cancer. Imugene will assume ongoing clinical execution for azer-cel in the large B-cell lymphoma population who have relapsed following autologous CAR T treatment. The license also includes an option to develop up to three other cancer research programs in the future. In exchange for global rights to azer-cel for cancer, as well as Precision BioSciences’ CAR T infrastructure and its experienced cell therapy teams, Precision will receive upfront economics valued at $21 million (all figures in USD) consisting of cash and equity. Precision is eligible for an $8 million near-term payment in cash and equity upon successful completion of the phase 1b dosing in the CAR T relapsed LBCL patient population. For azer-cel, Precision is eligible to receive up to $198 million in additional milestone payments and double-digit royalties on net sales. For each additional research program selected by Imugene, Precision is eligible for up to $145 million in milestone payments and tiered royalties on net sales. [collapse expanded text] |
Becton Dickinson, Steris Corporation | Jun 2023 | 540 | Asset purchase agreement for surgical instrumentation platform | BD has signed a definitive agreement to sell its Surgical Instrumentation platform to Steris for $ … read more540 million. The divestiture will include V. Mueller, Snowden-Pencer and Genesis branded products and three manufacturing facilities located in St. Louis, Mo., Cleveland, Ohio and Tuttlingen, Germany. Approximately 360 employees who support this platform will transfer to STERIS upon the completion of the transaction. [collapse expanded text] |
Goldfinch Bio, Karuna Therapeutics | Feb 2023 | 535 | Licensing agreement for TRPC4/5 product candidates | Karuna Therapeutics announced their entry into an exclusive license agreement under which Karuna … read morewill obtain global development, manufacturing, and commercialization rights to Goldfinch Bio’s investigational transient receptor potential canonical 4 and 5 (TRPC4/5) channel candidates, including lead clinical-stage candidate GFB-887. Karuna intends to evaluate these candidates as potential treatments for various psychiatric and neurological conditions, starting with GFB-887 for the treatment of mood and anxiety disorders. Under the terms of the agreement, the assignment estate of Goldfinch Bio will receive a $15 million upfront payment and is eligible to receive up to $520 million in milestone payments for each licensed TRPC4/5 candidate, of which $410 million are related to regulatory approval and commercial sales milestones, as well as a flat low-single-digit royalty on any potential global net sales of each licensed product. [collapse expanded text] |
Astex Pharmaceuticals, Merck and Co | Aug 2023 | 535 | Collaboration and licensing agreement for small molecule candidates with activity towards a tumour suppressor protein for cancer | Astex Pharmaceuticals announced an exclusive worldwide research collaboration and license agreement … read morewith MSD. The goal of the collaboration is to identify small molecule candidates with activity towards a tumour suppressor protein for the treatment of cancer. Astex will apply its fragment-based drug discovery platform to develop compounds targeting multiple forms of the p53 tumour suppressor protein and provide MSD with lead compounds for further optimization and preclinical development. MSD is granted an exclusive global license to research, develop, and commercialise candidates arising under the collaboration. Astex will receive an upfront payment of $35 million and is eligible for milestone payments associated with the achievement of preclinical, clinical, regulatory and sales milestones, totalling approximately $500 million per program, as well as tiered royalties on sales of any products arising from the collaboration. MSD will assume responsibility for funding all future research and development of lead candidates as well as commercialisation of products globally. [collapse expanded text] |
Amgen, TScan Therapeutics | May 2023 | 530 | Collaboration agreement for TargetScan to identify the antigens recognized by T cells in patients with Crohn’s disease | Amgen and TScan Therapeutics announced a multi-year collaboration that will use TScan’s proprietary … read moretarget discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with Crohn’s disease. TScan will receive a $30 million upfront payment and is eligible to earn over $500 million in success-based preclinical, clinical, regulatory and commercial milestones as well as tiered single-digit royalty payments. Amgen will evaluate a variety of modalities to create therapeutics based on targets discovered by TScan and will retain all global development and commercial rights. Amgen also has an option to expand the collaboration to ulcerative colitis, under certain terms. Each party will be responsible for its own research expenses. [collapse expanded text] |
Embark Biotech, Novo Nordisk | Aug 2023 | 516 | Collaboration agreement for pharmaceuticals to treat obesity and related co-morbidities | Novo Nordisk and Embark Biotech have entered a three-year research and development collaboration to … read morediscover and develop novel pharmaceuticals to treat obesity and related co-morbidities. Novo Nordisk receives the full rights to develop and commercialize the lead program, while the Embark shareholders will receive 15 million Euro in an upfront cash payment and are eligible to receive potential development, regulatory, and commercial milestones of up to 456 million Euro. [collapse expanded text] |
Boehringer Ingelheim, Phenomic AI | Nov 2023 | 509 | Collaboration and licensing agreement for novel targets for stroma-rich cancer therapies | Phenomic AI have entered into a strategic collaboration and licensing agreement with Boehringer … read moreIngelheim Pharmaceuticals to discover targets important in stroma-rich cancers. The partners will leverage Phenomic’s expertise in target identification and stromal biology based on its scTx single-cell transcriptomics platform which will greatly enhance Boehringer’s efforts to develop first-in-class medicines to transform the lives of people with cancer by delivering meaningful advances with the ultimate goal to cure a range of cancers. Boehringer Ingelheim has the option to license targets discovered and functionally validated by Phenomic as a basis for novel cancer therapeutics. Boehringer Ingelheim will also be responsible for all non-clinical and clinical development, as well as commercialization of associated cancer therapies. Phenomic will receive upfront and near-term payments of approximately $9 million including research funding and collaboration milestones. Phenomic is also eligible to receive more than USD $500 million in licensing fees as well as clinical, regulatory and commercial milestones in addition to royalties on future product sales. [collapse expanded text] |
Angelini Pharma, JCR Pharmaceuticals | May 2023 | 505.5 | Collaboration and licensing agreement for J-Brain Cargo for treatment of epilepsy | Angelini Pharma and JCR Pharmaceuticals entered into an exclusive global development and … read morecommercialization agreement for the development of novel biologic therapies that applies J-Brain Cargo, blood-brain barrier penetrating technology, for the treatment of epilepsy. JCR and Angelini Pharma will collaboratively lead the discovery and pre-clinical development efforts for the identification of brain-penetrant biologic therapeutics using JCR’s proprietary blood-brain barrier technology, J-Brain Cargo. This technology allows the delivery of biotherapeutics into the central nervous system via a mechanism called receptor-mediated transcytosis. Following the pre-clinical development phase, Angelini Pharma will have an exclusive license option to advance therapeutic candidates identified as part of the collaboration into clinical development and global commercialization outside of Japan. JCR will receive reimbursement of research expenses and an upfront payment. JCR will also be eligible to receive additional payments of up to US$505.5 million upon reaching development and commercial milestones, as well as tiered royalties on post-approval net sales. [collapse expanded text] |
PureTech Health, Royalty Pharma | Mar 2023 | 500 | Royalty financing agreement for KarXT | PureTech Health and Royalty Pharma announced that Royalty Pharma has acquired an interest in … read morePureTech’s royalty in Karuna Therapeutics’ KarXT for up to $500 million, with $100 million in cash up front and up to $400 million in additional payments contingent on the achievement of certain regulatory and commercial milestones. PureTech has sold its right to receive a 3% royalty from Karuna to Royalty Pharma on sales up to $2 billion annually, after which threshold Royalty Pharma will receive 33% and PureTech will retain 67% of the royalty payments. PureTech retains its 3.1% equity ownership in Karuna. Additionally, under its license agreement with Karuna, PureTech retains the right to receive milestone payments upon the achievement of certain regulatory approvals and 20% of sublicense income. [collapse expanded text] |
Ferring Pharmaceuticals, Royalty Pharma | Aug 2023 | 500 | Royalty financing agreement for Adstiladrin | Royalty Pharma and Ferring Pharmaceuticals today announced that Royalty Pharma has acquired a … read moresynthetic royalty on US net sales of Ferring’s Adstiladrin (nadofaragene firadenovec-vncg) for up to US $500 million comprised of an upfront payment of US $300 million and a US $200 million milestone payment. The milestone payment is contingent on certain manufacturing goals that are expected to be achieved in 2025 for the FDA-approved intravesical gene therapy that Ferring will make available next month through an early experience program for the treatment of adult patients with high-risk, Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors. Royalty Pharma is acquiring a 5.1% percentage royalty on net sales of Adstiladrin in the United States, which will increase to 8.0% upon payment of the manufacturing-related milestone. The royalty is expected to end in the early to mid-2030s. [collapse expanded text] |
Top partnering deals of 2022 valued at over US$500m.
Partners | Date | Value, US$m | Subject | Termsheet |
---|---|---|---|---|
Kelun-Biotech Biopharmaceutical, Merck and Co | Dec 2022 | 9475 | Collaboration, option and licensing agreement for seven investigational antibody-drug conjugate candidates for cancer | August 2024 Merck & Co. is agreeing to pay $37.5 million to take up its option on one … read morecandidate while returning the rights to another asset Merck has taken up its option on SKB571 bispecific ADC that Kelun sees primarily as treatment of solid tumors such as lung cancer and gastrointestinal tumors December 2022 Merck & Co and Kelun-Biotech have entered into an exclusive license and collaboration agreement to develop seven investigational preclinical antibody-drug conjugates for the treatment of cancer. Kelun-Biotech has granted Merck exclusive global licenses to research, develop, manufacture and commercialize multiple investigational preclinical ADC therapies and exclusive options to obtain additional licenses to ADC candidates. Kelun-Biotech retains the right to research, develop, manufacture and commercialize certain licensed and option ADCs for mainland China, Hong Kong and Macau. Kelun-Biotech will receive an upfront payment of $175 million from Merck. Kelun-Biotech is also eligible to receive future development, regulatory and sales milestone payments totaling up to $9.3 billion, if Kelun-Biotech does not retain mainland China, Hong Kong and Macau rights for the option ADCs and all candidates achieve regulatory approval, plus tiered royalties on net sales for any commercialized ADC product. Merck also intends to make an equity investment in Kelun-Biotech. [collapse expanded text] |
IGM Biosciences, Sanofi | Mar 2022 | 6305 | Collaboration and licensing agreement for IgM antibody agonists against oncology and immunology/inflammation targets | Key Deal Terms Summary1. Agreement Overview
2. Financial Terms
3. Development & Commercialization Plans
4. Strategic Impact
Overall SummaryIGM Biosciences and Sanofi have refocused their 2022 strategic collaboration, now exclusively targeting immunology/inflammation. IGM retains global rights to the oncology targets originally covered under the agreement, while Sanofi continues to develop immunology/inflammation IgM agonist antibodies. The original deal included $150 million upfront, with over $6 billion in milestone potential across programs. The refocused partnership aligns Sanofi’s resources with its core immunology/inflammation strategy, while IGM retains control over its oncology assets, supporting its long-term pipeline growth. [collapse expanded text] |
Poseida Therapeutics, Roche | Aug 2022 | 6220 | Collaboration, option and licensing agreement for allogeneic CAR-T cell therapies for hematologic malignancies | Key Deal Terms Summary1. Agreement Overview
2. Financial Terms
3. Development & Commercialization Plans
4. Strategic Impact
Overall SummaryPoseida Therapeutics and Roche have entered a strategic global collaboration to advance allogeneic CAR-T therapies for hematologic malignancies. Under the agreement, Poseida will receive $110 million upfront and up to $110 million in near-term milestones, with the potential for up to $6 billion in future milestone payments and tiered royalties into the low double digits. The collaboration combines Poseida’s proprietary genetic engineering technologies with Roche’s expertise in oncology development and commercialization. Poseida will lead early-stage clinical development, while Roche will oversee late-stage trials and global commercialization, positioning both companies at the forefront of next-generation cell therapy innovation. [collapse expanded text] |
Exscientia, Sanofi | Jan 2022 | 5300 | Research agreement for AI-driven pipeline of precision-engineered medicines | Key Deal Terms Summary: Exscientia and Sanofi Collaboration ExpansionParties… read moreInvolved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Considerations
Overall SummarySanofi has expanded its strategic AI-driven drug discovery collaboration with Exscientia by incorporating a new discovery-stage program. Exscientia is eligible for up to $45 million in upfront and research-stage milestones, plus over $300 million in additional milestones and royalties on sales. This expansion strengthens Sanofi’s AI-powered precision medicine efforts, reinforcing Exscientia’s role as a leader in AI-enabled drug discovery. [collapse expanded text] |
Akeso Biopharma, Summit Therapeutics | Dec 2022 | 5070 | Collaboration, licensing and co-promotion agreement for ivonescimab | Key Deal Terms Summary1. License Expansion – June 2024
2. Original License Agreement – December 2022 to January 2023
3. Financial and Strategic Developments
4. Overall SummarySummit Therapeutics has expanded its licensing agreement with Akeso for ivonescimab, now covering Latin America, the Middle East, and Africa alongside its previously licensed territories. The total deal value for the expanded rights is up to $70 million. This builds on their original $5 billion agreement, which included a $500 million upfront payment and potential $4.5 billion in milestones. Akeso retains commercialization rights for China and other regions. The partnership includes royalty payments, strengthened clinical data sharing, and a mutual commitment to accelerating ivonescimab’s global development. [collapse expanded text] |
Arcturus Therapeutics, CSL, Seqirus | Nov 2022 | 4500 | Collaboration and licensing agreement for self-amplifying mRNA vaccines | Key Deal Terms Summary1. Agreement Overview
2. Financial Terms
3. Development & Commercialization Plans
4. Strategic Impact
Overall SummaryArcturus Therapeutics and CSL Seqirus have announced that the European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for ARCT-154, a next-generation mRNA vaccine for COVID-19. The submission is supported by positive Phase 3 data, demonstrating strong efficacy against symptomatic and severe COVID-19 and a superior neutralizing antibody response against Omicron BA.4/5. The approval decision is expected in 2024, with CSL Seqirus leading European commercialization. This milestone strengthens Arcturus' position in the mRNA vaccine space and expands CSL Seqirus' pandemic preparedness portfolio. [collapse expanded text] |
Merck and Co, Orna Therapeutics | Aug 2022 | 3750 | Collaboration and licensing agreement for next generation of RNA technology | Parties Involved
Collaboration… read moreScopeThe collaboration focuses on the discovery, development, and commercialization of multiple programs using Orna’s proprietary circular RNA (oRNA) technology. The programs span vaccines and therapeutics in infectious diseases and oncology. Orna’s oRNA-LNP platform, which includes circular RNA and custom lipid nanoparticles, is at the center of the collaboration due to its enhanced in vivo stability and protein expression capabilities. Rights & Responsibilities
Financial Terms
Regulatory ApprovalThe collaboration is at the discovery and early development stage. No regulatory submissions or approvals have been announced. Overall SummaryMerck and Orna Therapeutics have entered into a broad strategic collaboration to leverage Orna’s next-generation circular RNA (oRNA) platform for the development of vaccines and therapeutics in infectious diseases and oncology. The deal is valued at up to $3.75 billion, including a $150 million upfront payment and $100 million equity investment, and represents a significant step toward advancing novel RNA-based treatments. [collapse expanded text] |
GSK, WaVe Lifesciences | Dec 2022 | 3495 | Collaboration, option and licensing agreement for oligonucleotide therapeutics focusing on novel genetic targets | Parties Involved
… read more Collaboration ScopeThe partnership includes a four-year discovery collaboration leveraging Wave’s PRISM™ oligonucleotide platform and GSK’s genetics and genomics expertise to develop oligonucleotide therapeutics. The agreement spans:- Up to eight preclinical programs advanced by GSK.- Up to three preclinical programs led by Wave.- A global license granted to GSK for WVE-006, Wave’s first-in-class RNA editing program for alpha-1 antitrypsin deficiency (AATD). The collaboration aims to address a broad range of diseases using RNA-targeting modalities, including editing, splicing, and silencing. Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryWave Life Sciences and GSK have entered into a strategic collaboration valued at over $4 billion to co-develop oligonucleotide therapies, with GSK receiving rights to up to eight programs and an exclusive global license for WVE-006, a novel RNA editing candidate for AATD. The deal includes a $170 million upfront payment, and Wave is eligible for milestones and royalties across all partnered programs. This partnership combines Wave’s cutting-edge RNA technologies with GSK’s genetic insights and global reach, significantly advancing the field of RNA-based genetic medicine. [collapse expanded text] |
Biocon, Viatris | Feb 2022 | 3335 | Asset purchase agreement for biosimilars assets | Biocon Biologics has entered into a definitive agreement with its partner Viatris. Biocon … read moreBiologics will acquire Viatris’ biosimilars business to create a unique fully integrated global biosimilars enterprise. Viatris will receive consideration of up to USD 3.335 billion, including cash up to USD 2.335 billion and Compulsorily Convertible Preference Shares in BBL, valued at USD 1 billion. Viatris will receive cash consideration of USD 2 billion on closing of the transaction and up to USD 335 million as additional payments expected to be paid in 2024. Additionally, upon closing of the transaction, BBL will issue USD 1 billion of Compulsorily Convertible Preference Shares to Viatris, equivalent to an equity stake of at least 12.9% in the Company, on a fully diluted basis. BBL Acquires: Viatris’ global commercial infrastructure in developed and emerging markets Viatris’ global biosimilars business with an estimated revenue of USD 875 million and EBITDA of USD 200 million for CY 2022 and estimated to exceed USD 1 billion in revenue next year Viatris’ rights in all biosimilars assets including its in-licensed portfolio and an option to acquire Viatris’ rights in bAflibercept Transition services for an expected two-year period to ensure a seamless transition with partners and continued services to patients and customers [collapse expanded text] |
BioNTech, Pfizer, US Government | Jun 2022 | 3200 | Supply agreement for Omicron-adapted COVID-19 vaccines | Pfizer and BioNTech announced a new vaccine supply agreement with the U.S. government to support … read morethe continued fight against COVID-19. Under the agreement, the U.S. government will receive 105 million doses (30 µg, 10 µg and 3 µg). This may include adult Omicron-adapted COVID-19 vaccines, subject to authorization from the U.S. Food and Drug Administration. The doses are planned to be delivered as soon as late summer 2022 and continue into the fourth quarter of this year. The U.S. government will pay the companies $3.2 billion upon receipt of the first 105 million doses. Under this agreement, the U.S. government also has the option to purchase up to 195 million additional doses, bringing the total number of potential doses to 300 million. [collapse expanded text] |
Bristol-Myers Squibb, Century Therapeutics | Jan 2022 | 3150 | Collaboration, option, licensing and co-promotion agreement for iPSC-derived allogeneic cell therapies | Parties Involved
… read more Collaboration ScopeThe agreement focused on the development and commercialization of up to four iPSC-derived allogeneic cell therapy programs for hematologic malignancies and solid tumors. The initial two programs targeted:- Acute Myeloid Leukemia (AML)- Multiple Myeloma These programs could utilize Century’s iNK (induced natural killer) or gamma delta iT (induced T cell) platforms. Bristol Myers Squibb also held the option to add two additional programs, subject to agreed conditions. Rights & Responsibilities
Financial Terms
Regulatory ApprovalAll programs were in the preclinical stage at the time of signing. No regulatory submissions were announced. Termination
Overall SummaryCentury Therapeutics and Bristol Myers Squibb formed a high-value strategic collaboration in January 2022 to advance iPSC-derived cell therapies for cancer, with a deal value exceeding $3 billion. The partnership combined Century’s next-generation iNK/iT platforms with BMS’s oncology development expertise. Despite the initial promise, the agreement was terminated in December 2024, halting all related development activities. [collapse expanded text] |
Bayer, Cinven | Mar 2022 | 2600 | Asset purchase agreement for environmental science professional business | Bayer and Cinven have entered into a definitive agreement regarding the sale of Bayer’s … read moreEnvironmental Science Professional business for a purchase price of 2.6 billion U.S. dollars. [collapse expanded text] |
Adagene, Sanofi | Mar 2022 | 2517.5 | Collaboration, option and licensing agreement for masked immuno-oncology antibody candidates | Adagene announced a collaboration and exclusive license agreement with Sanofi to generate masked … read moremonoclonal and bispecific antibodies for development and commercialization by Sanofi. Adagene will be responsible for early stage research activities to develop masked versions of Sanofi candidate antibodies, using Adagene’s SAFEbody technology. Sanofi will be solely responsible for later stage research and all clinical, product development and commercialization activities. Sanofi will make an upfront payment of $17.5 million to Adagene and will have the ability to advance two initial Sanofi antibody candidates in the collaboration, followed by an option for two additional candidates. Adagene will be eligible to receive total potential development, regulatory and commercial milestone payments of up to $2.5 billion for advancement of the candidates, which will be exclusively developed and commercialized by Sanofi. Adagene is eligible to also receive tiered royalties on global net sales of approved collaboration products. [collapse expanded text] |
Biogen, Samsung Bioepis, Samsung Biologics | Jan 2022 | 2300 | Asset purchase agreement for Samsung Bioepis joint venture | Biogen have entered into an agreement whereby Samsung Biologics will acquire Biogen’s equity stake … read morein the Samsung Bioepis joint venture for an aggregate consideration of up to USD $2.3 billion. [collapse expanded text] |
Sanofi, Scribe Therapeutics | Sep 2022 | 2265 | Collaboration agreement for CRISPR-based cell therapies for cancer | January 2024 Scribe Therapeutics announced that Sanofi has exercised its option for a second … read moretarget as part of the companies' research collaboration to develop in vivo CRISPR-based therapeutics. July 2023 Scribe Therapeutics announced an expanded collaboration with Sanofi. Sanofi receives an exclusive license to use Scribe’s CRISPR X-Editing (XE) genome editing technologies for the development of in vivo therapies, including sickle cell disease. The agreement follows the launch of the companies’ existing collaboration focused on ex vivo editing of natural killer cell therapies for the treatment of cancer. The in vivo collaboration will leverage Scribe’s precisely engineered CRISPR XE technologies and Sanofi’s capabilities in non-viral delivery to address an initial target for sickle cell disease. Scribe’s proprietary CRISPR by Design approach powers the only platform that uses holistic engineering to transform bacterial immune systems into therapeutically relevant genome editing technologies. By combining Scribe’s novel technologies with Sanofi’s proven expertise in developing and manufacturing therapeutics on a global scale, the companies will seek to advance potentially breakthrough genomic medicines for the in vivo treatment of sickle cell and other diseases. Scribe will receive $40 million in upfront payment and is eligible to potentially receive more than $1.2 billion based on the successful completion of certain development and sales milestones. Scribe will also be eligible to receive tiered royalties that range from high single digits to low double digits on net future sales on any products that may result from this agreement. Scribe has a right to opt-in to development cost sharing, as well as co-promotion and profit and loss sharing in the US on one future program. September 2022 Scribe Therapeutics announced a strategic collaboration with Sanofi US for the use of Scribe’s CRISPR genome editing technologies to enable genetic modification of novel natural killer cell therapies for cancer. The agreement grants Sanofi non-exclusive rights to Scribe’s proprietary CRISPR platform of wholly owned enzymes to create ex vivo NK cell therapies. Scribe’s suite of custom engineering genome editing and delivery tools called CasX-Editors, based on novel foundations such as the CasX enzyme, will support Sanofi’s expanding pipeline of NK cell therapeutics for oncology. Scribe will receive $25 million in upfront payment and be eligible to potentially receive more than $1 billion in payments based on development and commercial milestones, as well as tiered royalties on net future sales on any products that may result from this research agreement. [collapse expanded text] |
Merck and Co, PeptiDream | Dec 2022 | 2100 | Collaboration and licensing agreement for peptide drug conjugates | PeptiDream announced a new multi-target collaboration and license Agreement with Merck & Co … read morefocused on the discovery and development of novel peptide drug conjugates. PeptiDream will provide peptide candidates identified from PeptiDream’s proprietary Peptide Discovery Platform System technology for use as PDCs against targets of interest to MSD. MSD will have exclusive rights to the peptide candidates for conjugation to cytotoxic payloads and will be responsible for all development aspects of any PDC products arising from the collaboration. The new collaboration and license agreement builds upon the long collaborative relationship between the companies, which started with a multi-target discovery and optimization collaboration in April 2015. PeptiDream will receive an upfront payment from MSD and be eligible for payments based on the achievement of specified development, regulatory, and commercial milestones potentially totaling up to $2.1 billion (¥275billion (1USD = 131JPY)). PeptiDream is eligible to receive , of any such products. [collapse expanded text] |
Sanofi, Skyhawk Therapeutics | Jul 2022 | 2054 | Collaboration agreement for small molecules that modulate RNA splicing for challenging oncology and immunology targets | Skyhawk Therapeutics announced the signing of an exclusive worldwide collaboration agreement with … read moreSanofi US to discover and develop novel small molecules that modulate RNA splicing for challenging oncology and immunology targets. Sanofi will pay Skyhawk $54 million upfront. Skyhawk will grant Sanofi exclusive licenses to worldwide intellectual property rights to candidates discovered and developed under the collaboration that are directed to program targets. Following DC status, Sanofi will assume responsibility for further development and commercialization. Skyhawk is also eligible to receive over $2 billion in potential milestone payments, as well as potential royalties on future sales. [collapse expanded text] |
Jnana Therapeutics, Roche | Nov 2022 | 2050 | Collaboration and licensing agreement for small molecule drugs for cancer, immune-mediated and neurological diseases | Jnana Therapeutics has entered into a collaboration and license agreement with Roche for the … read morediscovery of small molecule drugs for the treatment of cancer, immune-mediated and neurological diseases. The collaboration covers multiple targets from a diverse range of target classes to address diseases with high unmet need. Jnana will receive an upfront payment of $50 million, significant near-term milestone payments, and additional potential future payments that could exceed $2 billion, as well as tiered royalties. Jnana will conduct discovery and preclinical activities against multiple cancer, immune-mediated and neurological disease targets, and Roche will be responsible for development and commercialization of any resulting products. [collapse expanded text] |
CytomX Therapeutics, Regeneron Pharmaceuticals | Nov 2022 | 2030 | Research agreement for conditional bispecific therapeutics for cancer | CytomX Therapeutics and Regeneron Pharmaceuticals announced a collaboration and licensing agreement … read moreto create conditionally-activated investigational bispecific cancer therapies utilizing CytomX’s Probody therapeutic platform and Regeneron’s Veloci-Bi bispecific antibody development platform. The collaboration is strategically focused on applying CytomX’s biologic masking strategies to develop investigational Regeneron bispecifics that remain inactive until activated by proteases in the tumor microenvironment. This technology has the potential to widen the therapeutic window and help minimize off-target effects for these next-generation T-cell engaging therapies, potentially addressing tumor types that have historically been unresponsive to immunotherapy. Regeneron and CytomX will collaborate on the discovery activities to identify and validate conditionally active bispecific antibodies. Regeneron will be responsible for funding preclinical and clinical development and commercialization activities. CytomX will receive an upfront payment of $30 million and will be eligible to receive future target nomination payments and preclinical, clinical, and commercial milestones of up to $2 billion. CytomX is also eligible to receive tiered global net sales royalties. [collapse expanded text] |
Code Biotherapeutics, Takeda Pharmaceutical | Feb 2022 | 2000 | Collaboration, option and licensing agreement for 3DNA genetic medicine delivery platform for therapies for rare diseases | Code Biotherapeutics announced a collaboration and option agreement with Takeda to leverage Code … read moreBio’s proprietary targeted 3DNA non-viral genetic medicine delivery platform to design and develop gene therapies for rare disease indications. Takeda and Code Bio will design and develop a targeted gene therapy leveraging Code Bio’s 3DNA platform for a liver-directed rare disease program, plus conduct additional studies for central nervous system-directed rare disease programs. Takeda has the right to exercise options for an exclusive license for four programs. Code Bio will receive double-digit million dollars in upfront, near-term milestone and research funding payments. Code Bio is also eligible to receive future development and commercial milestone payments plus tiered royalties with a potential total deal value over the course of the partnership of up to $2 billion if milestones for all four programs are achieved. Takeda and Code Bio will collaborate on research activities up to candidate selection. After option exercise, Takeda will assume responsibility for further development and commercialization. [collapse expanded text] |
Amgen, Generate Biomedicines | Jan 2022 | 1900 | Collaboration and licensing agreement for protein therapeutics for five clinical targets across several therapeutic areas and multiple modalities | Amgen and Generate Biomedicines announced a research collaboration agreement to discover and create … read moreprotein therapeutics for five clinical targets across several therapeutic areas and multiple modalities. Amgen will pay $50 million in upfront funding for the initial five programs with a potential transaction value of $1.9 billion plus future royalties, and will have the option to nominate up to five additional programs, at additional cost. For each program, Amgen will pay up to $370 million in future milestones and royalties up to low double digits. Amgen will also participate in a future financing round for Generate. Additional terms were not disclosed. [collapse expanded text] |
Bristol-Myers Squibb, GentiBio | Aug 2022 | 1900 | Collaboration and licensing agreement for engineered Treg therapies for inflammatory bowel diseases | GentiBio has entered into a collaboration with Bristol Myers Squibb to develop new engineered Treg … read moretherapies to re-establish immune tolerance and repair tissue in patients living with inflammatory bowel diseases. The collaboration brings together GentiBio's proprietary engineered Treg platform for generating scalable, stable, highly-selective, and durable Tregs with Bristol Myers Squibb's leadership in cell therapies and immunology. During the multi-year collaboration, GentiBio will apply its modular engineered Treg platform and scalable manufacturing process to produce stable and disease-specific engineered Tregs against multiple targets. Bristol Myers Squibb will have the right to develop and advance up to three of the resulting programs into clinical trials. Bristol Myers Squibb made an undisclosed upfront cash payment to GentiBio. GentiBio is eligible to receive development and sales milestone payments of up to $1.9 billion and royalties. [collapse expanded text] |
Lantheus Holding, POINT Biopharma | Nov 2022 | 1800 | Collaboration and licensing agreement for PNT2002 | Lantheus Holdings and POINT Biopharma Global announced a set of strategic collaboration agreements … read morein which Lantheus will license exclusive worldwide rights to POINT’s PNT2002 and PNT2003 product candidates. Upon consummation of the agreements, in exchange for the exclusive worldwide rights, Lantheus will pay a total of $260 million in upfront payments between the two agreements to POINT, with the potential for additional milestone payments of approximately $1.8 billion between the two products based on US Food and Drug Administration approval and net sales and commercial milestones. Lantheus will pay POINT royalties on net sales, beyond certain financial thresholds and subject to conditions, of 20% for PNT2002 and 15% for PNT2003. POINT will fund and complete its Phase 3 SPLASH trial for PNT2002, following which Lantheus will file the New Drug Application in collaboration with POINT. Upon consummation of the agreements, the companies will form joint steering committees to oversee the clinical studies, regulatory filings, manufacturing and commercial readiness for both PNT2002 and PNT2003. POINT will develop commercial production capacity and manufacture clinical and commercial supply for both PNT2002 and PNT2003. Lantheus has the rights to commercialize both assets post regulatory approval. Lantheus will fund the all-cash license of exclusive worldwide rights, excluding certain territories, for PNT2002 and PNT2003 with cash on Lantheus’ balance sheet and committed financing. The milestone-based structure under the agreements allows Lantheus to maintain its attractive financial profile and creates the opportunity to generate strong free cash flow. In exchange for Lantheus receiving exclusive worldwide rights, excluding certain territories, for PNT2002, POINT will receive a $250 million upfront payment, an additional payment up to $250 million upon US regulatory approval, and, once certain return on investment financial thresholds have been achieved and other conditions met, royalties of 20% on net sales, as well as the potential for up to an additional $1.3 billion in various net sales milestone payments. [collapse expanded text] |
Gilead Sciences, Macrogenics | Oct 2022 | 1760 | Collaboration, option and licensing agreement for MGD024 | September 2023 MacroGenics announced that its partner, Gilead Sciences, nominated the first of … read moretwo research programs, leveraging MacroGenics’ DART and TRIDENT platforms for generating bispecific antibodies. This nomination grants Gilead an exclusive option, upon achievement of a pre-defined preclinical milestone, to license worldwide rights to the research program. MacroGenics will receive $15 million related to the nomination of a bispecific research program to be conducted by MacroGenics and funded by Gilead. October 2022 Gilead Sciences and MacroGenics announced an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using MacroGenics’ DART platform, and two additional bispecific research programs. The collaboration agreement grants Gilead the option to license MGD024, a potential treatment for certain blood cancers, including acute myeloid leukemia and myelodysplastic syndromes. MacroGenics will be responsible for the ongoing Phase 1 study for MGD024 during which Gilead may elect to exercise its option to license the program at predefined decision points. The Phase 1 study will include a dose escalation segment and an expansion segment that is intended to evaluate MGD024 as monotherapy and in combination with other therapies across multiple indications. Gilead will pay MacroGenics an upfront payment of $60 million and MacroGenics will be eligible to receive up to $1.7 billion in target nomination, option fees, and development, regulatory and commercial milestones. MacroGenics will also be eligible to receive tiered, double-digit royalties on worldwide net sales of MGD024 and a flat royalty on worldwide net sales of products under the two research programs. [collapse expanded text] |
Jazz Pharmaceuticals, Zymeworks | Oct 2022 | 1760 | Licensing agreement for zanidatamab | December 2022 Jazz Pharmaceuticals and Zymeworks announced that Jazz has exercised its option to … read morecontinue with its exclusive development and commercialization rights to Zymeworks' zanidatamab in key markets, including the US, Europe and Japan, pursuant to the license and collaboration agreement entered into in October 2022. October 2022 Jazz Pharmaceuticals and Zymeworks have entered into an exclusive licensing agreement under which Jazz will acquire development and commercialization rights to Zymeworks' zanidatamab across all indications in the United States, Europe, Japan and all other territories except for those Asia/Pacific territories previously licensed by Zymeworks. Jazz will receive an exclusive license to develop and commercialize zanidatamab in the United States, Europe, Japan and all other territories except for those Asia/Pacific territories that Zymeworks previously licensed to BeiGene. Zymeworks is eligible to receive a $50 million upfront payment, following receipt of the clearance relating to the United States Hart-Scott Rodino Antitrust Improvements Act of 1976 (such clearance, the "HSR Clearance"), and should Jazz decide to continue the collaboration following readout of the top-line clinical data from HERIZON-BTC-01, a second, one-time payment of $325 million. Zymeworks is also eligible to receive up to $525 million upon the achievement of certain regulatory milestones and up to $862.5 million in potential commercial milestone payments, for total potential payments of up to $1.76 billion. Pending approval, Zymeworks is eligible to receive tiered royalties between 10% and 20% on Jazz's net sales. [collapse expanded text] |
Abpro, Celltrion | Sep 2022 | 1750 | Development and licensing agreement for cancer treatment bispecific antibody | Abpro announced a strategic partnership with Celltrion for its cancer molecule ABP 102, an antibody … read moretherapy for patients suffering from HER2+ cancer, including breast, gastric, and pancreatic cancer. Through this global partnership, Abpro will receive payments from Celltrion of up to $1.75 Billion, including an equity investment, development and commercial milestone payments and worldwide profit sharing. Celltrion will be in charge of the development of ABP 102 following the completion of in vitro studies by Abpro and will have world-wide commercialization rights. HER2+ type cancer is implicated in up to 30% of all cases in breast, gastric, pancreatic, and other forms of cancer. [collapse expanded text] |
Eli Lilly, ImmunoGen | Feb 2022 | 1745.5 | Licensing agreement for camptothecin ADC platform | ImmunoGen announced a global, multi-year definitive licensing agreement whereby it granted Eli … read moreLilly exclusive rights to research, develop, and commercialize ADCs directed to targets selected by Lilly based on ImmunoGen's novel camptothecin technology. ImmunoGen retains full rights to the camptothecin platform for all targets not covered by the Lilly license. Lilly will pay ImmunoGen an upfront payment of $13 million, reflecting initial targets selected by Lilly. Lilly may select a pre-specified number of additional targets, with ImmunoGen eligible to receive an additional $32.5 million in exercise fees if Lilly licenses the full number of targets. ImmunoGen is eligible to receive up to $1.7 billion in potential target program exercise fees and milestone payments based on the achievement of pre-specified development, regulatory, and commercial milestones. ImmunoGen is also eligible for tiered royalties as a percentage of worldwide commercial sales by Lilly. Lilly is responsible for all costs associated with research and development. [collapse expanded text] |
Beam Therapeutics, Pfizer | Jan 2022 | 1650 | Collaboration, option and licensing agreement for in vivo base editing programs for range of rare diseases | Pfizer and Beam Therapeutics announced an exclusive four-year research collaboration focused on in … read morevivo base editing programs for three targets for rare genetic diseases of the liver, muscle and central nervous system. The base editing programs to be evaluated as part of the collaboration will leverage Beam’s proprietary in vivo delivery technologies, which use messenger RNA and lipid nanoparticles to deliver base editors to target organs. Combining these technologies with Pfizer’s proven experience in developing and manufacturing medicines and vaccines, this collaboration seeks to advance potentially transformative therapies for patients living with rare diseases. Beam will conduct all research activities through development candidate selection for three undisclosed targets, which are not included in Beam’s existing programs. Pfizer may opt in to exclusive, worldwide licenses to each development candidate, after which it will be responsible for all development activities, as well as potential regulatory approvals and commercialization, for each such candidate. Beam has a right to opt in, at the end of Phase 1/2 studies, upon the payment of an option exercise fee, to a global co-development and co-commercialization agreement with respect to one program licensed under the collaboration pursuant to which Pfizer and Beam would share net profits as well as development and commercialization costs in a 65%/35% ratio (Pfizer/Beam). Beam will receive an upfront payment of $300 million and, assuming Pfizer exercises its opt-in license rights for all three targets, is eligible for development, regulatory and commercial milestone payments for potential total deal consideration of up to $1.35 billion. Beam is also eligible to receive royalties on global net sales for each licensed program. The collaboration has an initial term of four years and may be extended up to one additional year. [collapse expanded text] |
Ipsen, Marengo Therapeutics | Aug 2022 | 1637 | Collaboration and licensing agreement for precision immuno-oncology candidates from STAR platform | Ipsen and Marengo Therapeutics announced a strategic partnership to advance two of Marengo’s … read morepreclinical STAR platform-generated candidates into the clinic. The collaboration will leverage Marengo’s proprietary R&D expertise of a novel mechanism of T cell activation with Ipsen’s global oncology footprint for clinical development and commercialization. Ipsen will make an upfront payment of $45 million, together with potential payments up to a total of $1.592 billion if all milestones are met in addition to tiered sales royalty payments. Marengo will lead the preclinical development efforts and will expense related costs until the submission of an Investigational New Drug application to the U.S. FDA. Ipsen will assume responsibilities for clinical development and commercialization. [collapse expanded text] |
AstraZeneca, Scorpion Therapeutics | Jan 2022 | 1575 | Collaboration, option, licensing, co-development and co-promotion agreement for precision medicines against hard-to-target cancer proteins | Scorpion Therapeutics announced a collaboration with AstraZeneca to discover, develop and … read morecommercialize precision medicines against previously hard-to-target cancer proteins, with the potential to transform oncology treatment. The collaboration focuses on a class of proteins called transcription factors, which control gene expression and can regulate important cellular process including cell growth and survival. To overcome the challenges of targeting transcription factors and to reach underserved patient populations, this collaboration will combine Scorpion’s fully integrated discovery platform with AstraZeneca’s leadership in developing and commercializing precision medicines for cancer treatment. Scorpion will lead discovery and certain preclinical activities. AstraZeneca has the exclusive option to license worldwide rights for up to three drug candidates. AstraZeneca would be responsible for development and commercialization activities worldwide following opt-in, while Scorpion would retain the option to co-develop and co-promote up to two of these programs in the U.S. under certain conditions, including if AstraZeneca exercises three license options. Scorpion will receive an upfront cash payment of $75 million and is eligible to receive up to an additional $1.5 billion in the form of option fees and milestone payments, as well as tiered royalties on net sales ranging from mid-single digit to low-double digits. In the event Scorpion opts-in to co-developing and co-promoting a nominated program, Scorpion will participate in the operating costs and be entitled to a proportionate share of the economics in the U.S., subject to certain adjustments. [collapse expanded text] |
Novartis, Precision BioSciences | Jun 2022 | 1475 | Collaboration agreement for curative treatment for disorders including sickle cell disease | Precision BioSciences has entered into an exclusive worldwide in vivo gene editing research and … read moredevelopment collaboration and license agreement with Novartis Pharma. Precision will develop a custom ARCUS nuclease that will be designed to insert, in vivo, a therapeutic transgene at a “safe harbor” location in the genome as a potential one-time transformative treatment option for diseases including certain hemoglobinopathies such as sickle cell disease and beta thalassemia. Precision will develop an ARCUS nuclease and conduct in vitro characterization, with Novartis then assuming responsibility for all subsequent research, development, manufacturing and commercialization activities. Novartis will receive an exclusive license to the custom ARCUS nuclease developed by Precision for Novartis to further develop as a potential in vivo treatment option for sickle cell disease and beta thalassemia. Precision will receive an upfront payment of $75 million and is eligible to receive up to an aggregate amount of approximately $1.4 billion in additional payments for future milestones. Precision is also eligible to receive certain research funding and, should Novartis successfully commercialize a therapy from the collaboration, tiered royalties ranging from the mid-single digits to low-double digits on product sales. [collapse expanded text] |
GSK, Mersana Therapeutics | Aug 2022 | 1460 | Option, co-development and licensing agreement for XMT-2056 | Mersana Therapeutics announced a global collaboration that provides GSK an exclusive option to co- … read moredevelop and commercialize XMT-2056, an Immunosynthen ADC that targets a novel epitope of HER2. XMT-2056 is designed to activate the innate immune system through STING signaling in both tumor-resident immune cells and in tumor cells. Mersana will receive an upfront option purchase fee of $100 million. Mersana also is eligible to receive up to $1.36 billion in the form of an option exercise payment and development, regulatory and commercial milestone payments if GSK exercises its option. Mersana has retained options to profit-share and to co-promote in the United States. If it exercises its profit-share option, Mersana will be eligible to receive tiered royalties on net sales outside of the United States. If Mersana does not elect to profit-share, it is eligible to receive double-digit tiered royalties on global net sales. [collapse expanded text] |
Astellas Pharma, Sutro Biopharma | Jun 2022 | 1357.5 | Collaboration, licensing and option agreement for immunostimulatory antibody-drug conjugates | Astellas Pharma and Sutro Biopharma announced a worldwide, strategic collaboration and licensing … read moreagreement focused on the discovery and development of novel immunostimulatory antibody-drug conjugates. The collaboration leverages the unique cancer-fighting potential of iADCs as a novel modality, enabled by Sutro’s ability to engineer complex conjugated antibodies, and Astellas’ global oncology R&D expertise. This strategic partnership will engage in the development of iADCs, a next generation modality with the potential for effective and efficient approaches for treatment of cold tumors so as to bring new drug therapies to patients who do not respond to existing therapies. An iADC, which combines an antibody with a small molecule compound that induces immunogenic cell death*2 in addition to an immune activating molecule, has the potential to boost the anti-cancer action. This partnership will enable Astellas and Sutro to mutually leverage strengths in their respective fields to accelerate iADC development for three distinct biological targets; Sutro will engage in research and preclinical studies to identify candidate compounds and then Astellas will pursue clinical development. Sutro has advanced technologies for linking drugs to antibodies and proprietary component parts, including candidate antibodies and linkable cytotoxins and immunostimulatory molecules. For development of iADCs, Astellas will utilize the strength of its global R&D and commercialization capabilities in the area of antibodies and the small molecular components. These iADCs may have the potential to provide new therapeutic options for treatment of cancers for which no broadly effective therapy is currently available. Under the terms of the agreement, Sutro will receive an upfront cash payment of US$90 million to develop iADCs for three biological targets and may be eligible to receive up to US$422.5 million in development, regulatory and commercial milestones for each product candidate, and tiered royalties ranging from low double-digit to mid-teens on worldwide sales of any commercial products that may result from the collaboration, subject to Sutro’s cost and profit sharing option for the United States. Sutro has the option to share in the costs and profits for developing and commercializing product candidates in the United States. If Sutro exercises this option for a particular product candidate, Astellas and Sutro will equally share the costs of such co-development and co-commercialization, with the resulting profits/losses from co-commercialization also shared equally in the United States. [collapse expanded text] |
Royalty Pharma, Theravance Biopharma | Jul 2022 | 1350 | Royalty financing agreement for TRELEGY ELLIPTA | Theravance Biopharma has entered into a definitive agreement to sell all of its units in Theravance … read moreRespiratory Company, representing its 85% economic interest in the sales-based royalty rights on worldwide net sales of GSK's TRELEGY ELLIPTA to Royalty Pharma for over $1.5 billion in potential total value. The transaction is intended to provide near-, mid- and long-term value to the Company with an upfront cash payment of approximately $1.1 billion, up to $250 million in additional milestone payments contingent on the achievement of certain TRELEGY net sales thresholds between 2023 and 2026 and outer year royalties to the Company providing an opportunity to receive an estimated NPV of approximately $200 million. [collapse expanded text] |
Repare Therapeutics, Roche | Jun 2022 | 1325 | Collaboration, licensing, option and co-promotion agreement for Camonsertib (RP-3500) | February 2024 Repare Therapeutics will regain global development and commercialization rights to … read morecamonsertib (RP-3500), a potential best-in-class oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase), following termination of its collaboration agreement with Roche. Roche notified Repare that, effective May 7, 2024, it is terminating its worldwide license and collaboration agreement for the development and commercialization of camonsertib following a review of Roche’s pipeline and evolving external factors. Repare regains full control of all rights for camonsertib, a potential best-in-class inhibitor of ATR. January 2024 Repare Therapeutics announced it has earned a $40 million milestone payment from Roche upon dosing of the first patient with camonsertib (RP-3500 or RG6526) in Roche’s TAPISTRY trial (NCT04589845). TAPISTRY is a Phase 2, global, multicenter, open-label, multi-cohort clinical trial designed to evaluate the safety and efficacy of targeted therapies or immunotherapy in participants with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations. June 2022 Repare Therapeutics has entered into a worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib (also known as RP-3500), a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) for the treatment of tumors with specific synthetic-lethal genomic alterations including those in the ATM gene (Ataxia-Telangiectasia mutated kinase). Roche will assume development of camonsertib with the potential to expand development into additional tumors and multiple combination studies. Repare will receive a $125 million upfront payment, and is eligible to receive up to $1.2 billion in potential clinical, regulatory, commercial and sales milestones, including up to $55 million in potential near-term payments, and royalties on global net sales ranging from high-single-digits to high-teens. The collaboration also provides Repare with the ability to opt-in to a 50/50 U.S. co-development and profit share arrangement, including participation in U.S. co-promotion if U.S. regulatory approval is received. If Repare chooses to exercise its co-development and profit share option, it will continue to be eligible to receive certain clinical, regulatory, commercial and sales milestone payments, in addition to full ex-U.S. royalties. [collapse expanded text] |
Amphista Therapeutics, Bristol-Myers Squibb | May 2022 | 1280 | Collaboration and licensing agreement for targeted protein degradation therapeutics | September 2023 Amphista Therapeutics has achieved the first milestone in the second active … read morediscovery programme under its strategic collaboration and license agreement with Bristol Myers Squibb, triggering a payment for achieving the milestone. May 2023 Amphista Therapeutics announced the delivery of the first discovery milestone under its collaboration and license agreement with Bristol-Myers Squibb, triggering a payment for achieving the milestone. May 2022 Amphista Therapeutics announced a strategic collaboration and license agreement with Bristol-Myers Squibb. Bristol Myers Squibb and Amphista will work collaboratively to discover and develop small molecule protein degraders. Bristol Myers Squibb will be granted a global exclusive license to the degraders developed and will be responsible for further development and commercialization activities. Amphista will receive a $30 million upfront payment, the potential for up to $1.25 billion in performance-based milestone payments and payment for a limited expansion of the collaboration, as well as royalties on global net sales of products. [collapse expanded text] |
Abbvie, Sosei | Aug 2022 | 1280 | Collaboration, option and licensing agreement for small molecules that modulate novel G protein-coupled receptor targets associated with neurological disease | Sosei and AbbVie have entered a new drug discovery collaboration and option-to-license agreement to … read morediscover, develop and commercialize small molecules that modulate novel G protein-coupled receptor targets associated with neurological disease. The new agreement will leverage Sosei Heptares’ StaR technology and structure-based drug design platform and AbbVie’s extensive neuroscience and disease area expertise. The agreement expands the breadth of the ongoing collaboration between Sosei Heptares and AbbVie, building on the first multi-target discovery agreement signed between the companies in June 2020, which is focused on the inflammatory and autoimmune disease areas. Sosei Heptares will conduct and fund R&D activities through the completion of Investigational New Drug-enabling studies. AbbVie has the exclusive option to license up to three programs at this stage and will have responsibility for clinical, regulatory and commercial development thereafter. Sosei Heptares receives an upfront payment of US$40 million on signing and is eligible to receive up to US$40 million in near-term research milestone payments expected over the next three years, as well as further potential option, development and commercial milestones totalling up to US$1.2 billion, plus tiered royalties on global sales. [collapse expanded text] |
Jazz Pharmaceuticals, Werewolf Therapeutics | Apr 2022 | 1275 | Collaboration and licensing agreement for WTX-613 | Jazz Pharmaceuticals and Werewolf Therapeutics have entered into a licensing agreement under which … read moreJazz has acquired exclusive global development and commercialization rights to Werewolf's investigational WTX-613, a differentiated, conditionally-activated interferon alpha (IFNα) INDUKINE molecule. Jazz has secured exclusive global rights to WTX-613. Jazz will make an upfront payment of $15 million to Werewolf, and Werewolf is eligible to receive development, regulatory and commercial milestone payments of up to $1.26 billion. Werewolf is eligible to receive a tiered, mid-single-digit percentage royalty on net sales of WTX-613. [collapse expanded text] |
Gilead Sciences, ViiV Healthcare | Feb 2022 | 1250 | Settlement and licensing agreement for Bictegravir patent | Gilead Sciences has reached a global resolution with ViiV Healthcare for all pending or potential … read moreclaims related to Gilead’s sales of the HIV treatment Biktarvy (bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg tablets). ViiV Healthcare will dismiss all pending lawsuits relating to bictegravir, the novel compound in Biktarvy. Gilead will make a one-time payment of $1.25 billion and an ongoing royalty payment of 3% until 2027 on future sales of Biktarvy and on the bictegravir component of any future bictegravir-containing products sold in the U.S. [collapse expanded text] |
Novartis, Voyager Therapeutics | Mar 2022 | 1250 | Option and licensing agreement for next-generation gene therapy vectors for neurological diseases | March 2023 Voyager Therapeutics announced that Novartis Pharma has exercised its options to … read morelicense novel capsids generated from Voyager’s TRACER capsid discovery platform for use in gene therapy programs against two undisclosed neurologic disease targets. Under the terms of the license option agreement, originally announced in March 2022, Voyager previously received a $54 million upfront payment from Novartis for the option to license capsids for up to three central nervous system targets. With Novartis’ option exercise on two targets, Voyager now receives an additional $25 million option exercise payment and is eligible to receive up to $600 million in associated potential development, regulatory, and commercial milestone payments, as well as mid- to high-single-digit tiered royalties based on net sales of Novartis products incorporating the licensed capsids. In addition, over the next 18 months, Novartis retains the right to expand the agreement to include options to license capsids for up to two additional rare CNS targets, subject to their availability, for a fee of $18 million per target. Under such an expansion, Voyager would be eligible to receive a $12.5 million license option exercise fee for each target exercised, as well as future potential milestone payments of $300 million per target and tiered mid- to high-single digit royalties on products incorporating the licensed capsids. The two Novartis targets licensed under the agreement are distinct from targets in Voyager’s internal and partnered pipeline. Novartis elected not to license a capsid for one CNS target under the original agreement, and all capsid rights with respect to that target are returned to Voyager. Voyager retains global rights to all licensed capsids for use with other targets and to all other applications of its TRACER technology. March 2022 Novartis announced a license option agreement with Voyager Therapeutics for three capsids to use in potential gene therapies for neurological diseases, with options to access capsids for two other targets. Novartis will have the right to evaluate novel capsids from Voyager’s TRACER platform and to exercise options to license capsids for exclusive use in Novartis’ development of AAV gene therapies directed to three targets. Novartis has the right to license capsids for two additional disease targets under the same terms. Voyager will receive an upfront payment, with additional payments for each exercised option, as well as future milestones and sales-based royalties. [collapse expanded text] |
Amgen, LegoChem Biosciences | Dec 2022 | 1250 | Collaboration and licensing agreement for antibody-drug conjugates | LegoChem Biosciences has entered into a research collaboration and license agreement with Amgen, … read morewhereby it granted Amgen rights to research, develop, and commercialize ADCs directed against up to 5 targets selected by Amgen based on LCB’s proprietary ConjuAll ADC technology. LCB is eligible to receive up to USD 1.25 billion including upfront, development and commercial milestone payments, and is also eligible for tiered royalties as a percentage of worldwide commercial sales by Amgen. [collapse expanded text] |
Eli Lilly, PeptiDream | Dec 2022 | 1235 | Research, collaboration and licensing agreement for peptide drug conjugates | PeptiDream have entered into a Research Collaboration and License Agreement with US-based Eli Lilly … read morefocused on the discovery and development of novel peptide drug conjugates. PeptiDream will utilize its proprietary Peptide Discovery Platform System technology to identify high affinity macrocyclic peptide ligands to Lilly-elected targets of interest, capable of delivering a Lilly conjugated payload to certain cells and tissues of interest to Lilly. PeptiDream will lead peptide discovery and optimization efforts, and Lilly will lead payload discovery and optimization efforts. Lilly will be responsible for all development aspects of any PDC products arising from the collaboration. PeptiDream will receive an upfront payment from Lilly as well as be eligible for payments based on the achievement of specified development, regulatory, and commercial milestones potentially totaling up to $1.235 billion (¥163billion). PeptiDream is eligible to receive royalties on net sales of any such products. [collapse expanded text] |
Insilico Medicine, Sanofi | Nov 2022 | 1221.5 | Collaboration agreement for Pharma.AI to advance drug development candidates for up to six new targets | Insilico Medicine announced a multi-year, multi-target strategic research collaboration with Sanofi. … read more
The collaboration will leverage Insilico Medicine’s AI platform, Pharma.AI, to advance drug development candidates for up to six new targets. Sanofi will pay Insilico Medicine a total of up to $21.5 million covering the upfront and target nomination fees to benefit from Insilico’s end-to-end Pharma.AI platform and gain access to a team of interdisciplinary drug discovery scientists to identify, synthesize, and advance high-quality lead therapeutic compounds up to development candidate stage. Additional payments will be made if key research, development, and sales milestones are met, and could total up to $1.2 billion. The collaboration also establishes mid-single to up to low double-digit tiered royalties for any products developed. [collapse expanded text] |
CSPC Megalith Biopharmaceutical, Elevation Oncology | Jul 2022 | 1175 | Licensing agreement for EO-3021 (SYSA1801) | Elevation Oncology has entered into an exclusive license agreement with CSPC Megalith … read moreBiopharmaceutical to develop and commercialize EO-3021 (SYSA1801), a differentiated, clinical stage antibody drug conjugate targeting Claudin18.2, in all global territories outside Greater China (mainland China, Hong Kong, Macau and Taiwan). SYSA1801 is currently being evaluated by CSPC in a Phase 1, dose-escalation clinical trial in China. Elevation Oncology expects to initiate a Phase 1 clinical trial evaluating EO-3021 in the U.S. in 2023. Elevation Oncology will develop and commercialize EO-3021 in all global territories outside of Greater China. CSPC will receive a one-time, upfront payment of $27 million. CSPC will also be eligible to receive up to $148 million in potential development and regulatory milestone payments and up to $1.0 billion in potential commercial milestone payments plus royalties on net sales. [collapse expanded text] |
Jazz Pharmaceuticals, Sumitomo Pharmaceuticals | May 2022 | 1140 | Licensing agreement for DSP-0187 | Jazz Pharmaceuticals and Sumitomo Pharma have entered into an exclusive licensing agreement under … read morewhich Jazz has acquired development and commercialization rights in the United States, Europe and other territories for Sumitomo Pharma's investigational DSP-0187, a potent, highly selective oral orexin-2 receptor agonist with potential application for the treatment of narcolepsy, idiopathic hypersomnia and other sleep disorders. Jazz has designated this molecule JZP441. Jazz will receive an exclusive license to develop and commercialize DSP-0187 throughout the world except for Japan, China and certain other Asia/Pacific countries and regions, where Sumitomo Pharma will retain all development and commercialization rights. Sumitomo Pharma will receive an upfront payment of $50 million, and is eligible to receive development, regulatory and commercial milestone payments of up to $1.09 billion. Pending approval, Sumitomo Pharma is eligible to receive a tiered, low double-digit royalty on Jazz's net sales of DSP-0187. [collapse expanded text] |
Bristol-Myers Squibb, Volastra Therapeutics | Mar 2022 | 1130 | Collaboration and licensing agreement for drug discovery using CINtech platform | Volastra Therapeutics announced a collaboration with Bristol Myers Squibb to discover, develop and … read morecommercialize new medicines. The multi-year collaboration will leverage Volastra’s proprietary CINtech platform, to identify CIN-related, synthetic lethal targets as drug candidates. Volastra will be responsible for conducting various activities for undisclosed targets. For select targets, Volastra will conduct all research activities through development candidate selection and Bristol Myers Squibb may take on the responsibilities for all subsequent development, regulatory and commercialization activities of the development candidates under an exclusive worldwide license. Volastra will receive $30 million in an upfront payment and will also be eligible to receive up to $1.1 billion in development, regulatory and commercial milestone payments. Volastra is entitled to receive royalties on net global sales of any product commercialized by Bristol Myers Squibb resulting from the collaboration. [collapse expanded text] |
Cerevance, Merck and Co | Aug 2022 | 1125 | Collaboration and licensing agreement for discovery of novel targets in Alzheimer’s disease | Cerevance announced a multi-year strategic research collaboration with Merck to identify novel … read moretargets for Alzheimer’s disease utilizing Cerevance’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) technology platform. Cerevance will concurrently out-license one discovery-stage program to Merck as part of the collaboration. Cerevance will receive a $25 million upfront payment and is eligible to receive development and commercial milestone payments totaling approximately $1.1B, in addition to potential royalties on sales of approved products derived from the collaboration. [collapse expanded text] |
ABL Bio, Sanofi | Jan 2022 | 1060 | Collaboration and licensing agreement for ABL301 | ABL Biotechnologies announced an exclusive collaboration and worldwide license agreement with … read moreSANOFI to develop and commercialize ABL301, a pre-clinical stage bispecific antibody targeting alpha-synuclein and IGF1R to treat Parkinson's disease and other potential indications with enhanced blood-brain barrier penetration. ABL will receive $75 million in upfront payments. ABL is eligible to receive up to $985 million based on the achievement of predefined development, regulatory and commercialization milestones, including $45 million in near-term milestones. ABL is also eligible to receive royalties on net sales if the product from the collaboration is commercialized. The transaction will become effective after customary closing conditions are met, such as the HSR clearance. SANOFI will receive worldwide exclusive development and commercialization rights to ABL301. Meanwhile, ABL will lead the preclinical development and Phase 1 clinical trial of ABL301. Thereafter, SANOFI will be responsible for further clinical development, regulatory approval and commercialization of ABL301 worldwide. [collapse expanded text] |
Menarini, NewAmsterdam Pharma | Jun 2022 | 1049.9 | Licensing agreement for obicetrapib | NewAmsterdam Pharma and the Menarini Group announced an exclusive license agreement for the … read morecommercialization of obicetrapib, if approved, in Europe, either as a monotherapy or as part of a fixed dose combination with ezetimibe, for cardiovascular diseases. Obicetrapib is NewAmsterdam’s next-generation oral, low-dose and once-daily cholesteryl ester transfer protein inhibitor therapeutic candidate, for which a promising safety and efficacy profile as an LDL-lowering adjunct to maximally tolerated statin therapy in patients with dyslipidemia has been observed through Phase 2b trials. NewAmsterdam will retain all rights to commercialize obicetrapib, if approved, in the rest of the world, as well as rights to develop certain forms of obicetrapib for other diseases such as Alzheimer’s disease. NewAmsterdam will receive an upfront payment of €115 million, as well as €27.5 million in committed R&D funding, for a total of €142.5 million in committed consideration. NewAmsterdam will be eligible to receive up to €863 million in potential clinical, regulatory and commercial milestones, bringing the total potential deal value to €1,005.5 million. Menarini will pay NewAmsterdam tiered double-digit percentage royalties from the teens to mid-twenties on net sales of obicetrapib in Europe. NewAmsterdam will be responsible for further clinical development of obicetrapib and the parties will cooperate in regulatory activities to secure approval for the product. Menarini will be responsible for all commercialization activities in the licensed territory. [collapse expanded text] |
Bayer, Mammoth Biosciences | Jan 2022 | 1040 | Collaboration, option and licensing agreement for novel gene editing technology | Bayer and Mammoth Biosciences announced a strategic collaboration and option agreement for the use … read moreof Mammoth’s CRISPR systems to develop in vivo gene-editing therapies. Mammoth Biosciences’ groundbreaking gene-editing technology is a key enabling technology, as well as a stand-alone therapeutic modality. It will significantly enhance Bayer’s efforts to develop transformative therapies for patients faster and strengthen the company’s recently established new cell and gene therapy platform. Under the terms of the agreement the two companies will start their collaboration with a focus on liver-targeted diseases. Mammoth Biosciences will receive an upfront payment of USD 40 million and is eligible to receive target option exercise fees as well as potential future payments in the magnitude of more than one billion USD upon successful achievement of certain research, development, and commercial milestones across five preselected in vivo indications with a first focus on liver-targeted diseases. Bayer will pay research funding and tiered royalties up to low double-digit percentage of net sales. The companies are also exploring work on ex vivo projects on a nonexclusive basis. [collapse expanded text] |
Janssen Biotech, Mersana Therapeutics | Feb 2022 | 1040 | Research and licensing agreement for antibody-drug conjugates targeting cancers | Mersana Therapeutics announced a research collaboration and license agreement with Janssen Biotech … read moreto discover novel ADCs for three targets. Janssen will provide proprietary antibodies for three targets. Mersana will apply its expertise and its proprietary Dolasynthen platform to discover novel ADC product candidates. Mersana may leverage Synaffix’s GlycoConnect technology as its preferred site-specific ADC bioconjugation technology. Mersana will collaborate with Janssen on target candidates during preclinical development, with Janssen being solely responsible for clinical development and commercialization. Mersana will receive an upfront payment of $40 million. Mersana is eligible to receive reimbursement of certain costs as well as more than $1 billion in potential milestone payments, plus mid-single-digit to low double-digit percentage royalties on worldwide net sales of ADCs against the selected targets. [collapse expanded text] |
Dren Bio, Pfizer | Jan 2022 | 1025 | Research and licensing agreement for bispecific antibodies for select oncology targets using targeted myeloid engager and phagocytosis platform | Dren Bio has entered into a research collaboration and license agreement with Pfizer. The … read morestrategic collaboration will focus on the discovery and development of therapeutic bispecific antibodies for select oncology targets using Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform. Pfizer made an upfront cash payment of $25 million to Dren Bio, with the Company eligible to potentially receive more than $1 billion of cash in total, including payments for the achievement of future development, regulatory, and commercial milestones. Dren Bio and Pfizer will work together to advance the selected oncology target programs through clinical candidate selection, at which point Pfizer will assume full responsibility for all remaining development, manufacturing, regulatory and commercialization activities. For each target-specific product that is globally licensed by Pfizer, Dren Bio will be eligible to receive tiered royalties on all future net sales during the term of the Agreement. Additionally, under the terms of the agreement, Pfizer also has the right to reserve and subsequently nominate additional oncology targets to license from Dren Bio, subject to additional cash payments and future royalties. Excluding products developed for targets licensed to Pfizer, Dren Bio will retain exclusive global rights for the platform including all other therapeutic targets currently in development as part of its own internal pipeline. [collapse expanded text] |
Atomwise, Sanofi | Aug 2022 | 1020 | Collaboration and licensing agreement for AI-powered drug discovery | Atomwise has established a strategic and exclusive research collaboration with Sanofi that will … read moreleverage its AtomNet platform for computational discovery and research of up to five drug targets. Sanofi will pay Atomwise $20 million upfront to identify, synthesize, and advance lead compounds for up to five targets which will be exclusive to Sanofi. Subsequent payments pegged to key research, development, and sales milestones could total more than $1 billion. In addition, tiered royalties have been established for products developed through the collaboration. [collapse expanded text] |
HIBio, MorphoSys | Jun 2022 | 1015 | Licensing agreement for felzartamab and MOR210 | MorphoSys and Human Immunology Biosciences entered into an equity participation agreement and … read morelicense agreements to allow HIBio to develop and commercialize MorphoSys’ felzartamab, an anti-CD38 antibody, and MOR210, an anti-C5aR1 antibody. HIBio will obtain exclusive rights to develop and commercialize felzartamab and MOR210 across all indications worldwide, with the exception of Greater China for felzartamab and Greater China and South Korea for MOR210. MorphoSys will receive a 15% equity stake in HIBio, along with certain equity earn-in provisions and standard investment rights. MorphoSys will also be represented as a member of HIBio’s Board of Directors. On achievement of development, regulatory and commercial milestones, MorphoSys will be eligible to receive payments from HIBio of up to $1 billion across both programs, in addition to tiered, single- to low double-digit royalties on net sales of felzartamab and MOR210 and will be compensated for ongoing program expenses. HIBio will assume full responsibility for future development and commercialization expenses. MorphoSys also receives an upfront payment of $15 million for MOR210. [collapse expanded text] |
Avista Therapeutics, Roche | Jul 2022 | 1007.5 | Development and licensing agreement for AAV gene therapy vectors for ocular diseases | Avista Therapeutics announced a partnership with Roche to develop novel AAV gene therapy vectors … read morefor the eyes. The partnership aims to apply Avista’s single-cell adeno-associated virus engineering (scAAVengr) platform technology to develop intravitreal AAV capsids matching a capsid profile defined by Roche. Roche has the right to evaluate and license novel capsids from Avista, and will be responsible for conducting preclinical, clinical and commercialization activities for gene therapy programs using these novel capsids, which will be distinct from Avista’s internal pipeline. Avista will receive an upfront payment of $7.5 million and, if successful, is eligible to receive additional payments during the research phase of the partnership, as well as clinical and sales milestone payments and royalties for resulting products with a total potential deal value that may exceed $1 billion. [collapse expanded text] |
Eli Lilly, Evotec | Jan 2022 | 1000 | Collaboration agreement for drug discovery in metabolic diseases with a focus on kidney diseases and diabetes | Evotec has entered into a drug discovery collaboration with Eli Lilly in the field of metabolic … read morediseases with a focus on kidney diseases and diabetes. The collaboration leverages Evotec's extensive experience and track record of delivering in the field of metabolic diseases, as well as its unique and extensive kidney disease patient database, to identify and validate promising novel targets for therapeutic intervention. Evotec will be responsible for the discovery of potential drug candidates for the treatment of diabetes and chronic kidney diseases from targets identified by Lilly or by Evotec. Lilly reserves the right to select up to five programmes developed within this partnership and to continue with any subsequent development, clinical validation and commercialisation. The collaboration initially runs for a term of three years. In addition to an undisclosed upfront payment, Evotec will be eligible to receive success-based discovery development, regulatory and commercial milestone payments of up to US$ 180 m per programme, as well as tiered royalties on net sales of any products resulting from the collaboration, for a potential overall value up to US$ 1 bn. [collapse expanded text] |
Janssen Pharmaceutica NV, Remix Therapeutics | Feb 2022 | 1000 | Collaboration, option and licensing agreement for small molecule therapeutics using REMaster drug discovery platform to modulate RNA processing | Remix Therapeutics announced a strategic collaboration with Janssen Pharmaceutica for the discovery … read moreand development of small molecule therapeutics that modulate RNA processing using Remix's REMaster drug discovery platform. Remix will receive an initial payment of $45 million in cash for upfront and research funding, and may also receive preclinical, clinical, commercial, and sales milestone payments and tiered royalties for any resulting products. Janssen will have exclusive rights to three specific targets with applications in immunology and oncology. Remix will have the ability to opt into a portion of the costs of clinical development on one program in exchange for higher royalties. Remix is eligible to receive total payments potentially exceeding $1 billion, subject to regulatory approvals and other conditions. [collapse expanded text] |
Amphista Therapeutics, Merck and Co | May 2022 | 1000 | Collaboration agreement for targeted protein degradation therapeutics | Amphista Therapeutics announced a strategic collaboration with Merck Healthcare. Merck and … read moreAmphista will work collaboratively to discover and develop small molecule protein degraders for an initial three targets in oncology and immunology indications. Amphista will receive an upfront payment, R&D funding and success-based milestone payments of up to €893.5 million ($1.0 billion*) as well as royalties in the mid-single digit range. [collapse expanded text] |
Regeneron Pharmaceuticals, Sanofi | Jun 2022 | 1000 | Licensing agreement for Libtayo | Regeneron Pharmaceuticals announced its intent to purchase Sanofi's stake in the Regeneron and … read moreSanofi collaboration on Libtayo (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization and manufacturing rights to the medicine. The transaction is subject to merger control clearance outside the United States and is expected to close in the third quarter of 2022. Once the transaction has closed, Regeneron will record 100% of global net sales and expenses for the Libtayo program. Regeneron and Sanofi entered into the Immuno-oncology License and Collaboration Agreement in 2015. Pursuant to this agreement, the companies currently split Libtayo's worldwide operating profits equally and co-commercialize Libtayo in the US, with Sanofi solely responsible for commercialization outside the US. Sanofi will transfer the rights to develop, commercialize and manufacture Libtayo entirely to Regeneron, on a worldwide basis, over the course of a defined transition period. Upon closing of the transaction, Regeneron will make an upfront payment of $900 million to Sanofi, which will be entitled to receive an 11% royalty on worldwide net sales of Libtayo. Sanofi will also be entitled to a $100 million regulatory milestone payment upon the first approval by either the FDA or European Commission of Libtayo in combination with chemotherapy for first-line treatment of certain patients with NSCLC, as well as sales-related milestone payments of up to $100 million in total over the next two years. Regeneron will accelerate reimbursement of the development balance associated with Regeneron and Sanofi's separate Antibody Collaboration. Regeneron will increase from 10% to 20% the share of its profits that are paid to Sanofi to reimburse Sanofi-funded development expenses, until Regeneron's share of the total cumulative development costs incurred under the collaboration has been reached. [collapse expanded text] |
Biomedical Advanced Research and Development Authority, Vir Biotechnology | Oct 2022 | 1000 | Contract service agreement for pandemic preparedness for influenza and other infectious disease threats | Vir Biotechnology announced that the Biomedical Advanced Research and Development Authority has … read moreawarded Vir a multi-year contract with the potential for up to $1 billion to advance the development of a full portfolio of innovative solutions to address influenza and potentially other infectious disease threats. As part of BARDA’s ongoing effort to prepare and respond to public health emergencies, the agency will invest approximately $55 million initially for the ongoing and rapid development of VIR-2482, an investigational prophylactic monoclonal antibody designed to protect against seasonal and pandemic influenza. This includes a Phase 2 pre-exposure prophylaxis trial expected to begin in the second half of 2022 with initial data anticipated in mid-2023. The balance of the award is subject to BARDA exercising up to 12 options in further support of the development of pre-exposure prophylactic antibodies including and beyond VIR-2482 for the prevention of influenza illness or possibly supporting medical countermeasures for other pathogens of pandemic potential. [collapse expanded text] |
Hookipa Pharma, Roche | Oct 2022 | 970 | Collaboration, option and licensing agreement for arenaviral immunotherapy for KRAS-mutated cancers | February 2023 HOOKIPA Pharma has achieved a $10 million non-dilutive milestone payment under its … read morecollaboration agreement with Roche to develop HB-700, a novel arenaviral immunotherapy for KRAS-mutated cancers. The success-based milestone payment reflects the start of the HB-700 manufacturing process to support a Phase 1 clinical trial. HOOKIPA plans to submit an Investigational New Drug Application to the US Food and Drug Administration in the first half of 2024. October 2022 HOOKIPA Pharma announced a strategic collaboration and license agreement with Roche to develop HB-700 for KRAS-mutated cancers and a second undisclosed novel arenaviral immunotherapy. HOOKIPA will conduct research and early clinical development through Phase 1b for HB-700, a novel investigational arenaviral immunotherapy for the treatment of KRAS-mutated cancers. Upon the completion of the Phase 1b trial, Roche has the right to assume development responsibility and to commercialize licensed products across multiple indications upon approval. The agreement also includes an option for Roche to license a second arenaviral cancer immunotherapy. HOOKIPA will receive an upfront payment of $25 million. Roche will have the option to expand the initial collaboration by adding an additional product candidate, whereafter HOOKIPA will receive an additional $15 million payment at option exercise. Including this option payment, HOOKIPA is eligible for research, development and commercialization milestone-based payments for HB-700 and the additional product candidate totaling up to approximately $930 million. Upon commercialization, HOOKIPA is eligible to receive tiered royalties of a high single-digit to mid-teens percentage on the worldwide net sales of HB-700 and the additional product candidate. [collapse expanded text] |
ACADIA Pharmaceuticals, Stoke Therapeutics | Jan 2022 | 967 | Collaboration and licensing agreement for multiple RNA-based treatments for genetic neurodevelopmental diseases | Acadia Pharmaceuticals and Stoke Therapeutics have entered a collaboration to discover, develop and … read morecommercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The collaboration includes SYNGAP1 syndrome, Rett syndrome (MECP2), and an undisclosed neurodevelopmental target of mutual interest. Stoke will receive an upfront payment of $60 million from Acadia and is eligible to receive up to $907 million in milestones as well as royalties on future sales. For the SYNGAP1 program, the two companies will jointly share global research, development and commercialization responsibilities and share 50/50 in all worldwide costs and future profits. Stoke is eligible to receive potential development, regulatory, first commercial sales and sales milestones. For the Rett syndrome (MECP2) and the undisclosed neurodevelopmental program, Stoke will lead research and pre-clinical development activities, while Acadia will lead clinical development and commercialization activities. Acadia will fully fund the research and pre-clinical development activities related to these two targets and Stoke is eligible to receive potential development, regulatory, first commercial sales and sales milestones as well as tiered royalty payments on worldwide sales starting in the mid-single digit range and escalating to the mid-teens based on revenue levels. [collapse expanded text] |
Kelun-Biotech Biopharmaceutical, MSD | Jul 2022 | 936 | Collaboration and licensing agreement for antibody drug conjugate for treatment of solid tumors | Kelun-Biotech has entered into a collaboration and exclusive license agreement with MSD to develop … read morean investigational antibody drug conjugate for the treatment of solid tumors. Kelun-Biotech has granted MSD global, exclusive rights to develop, manufacture and commercialize an investigational ADC. Kelun-Biotech and MSD will also collaborate on the early clinical development of the investigational ADC. Kelun-Biotech will receive an upfront payment of $35mm and is eligible to receive future development, approval and commercial milestone payments totaling up to $901mm, plus tiered royalties on net sales. [collapse expanded text] |
Heidelberg Pharma, Huadong Medicine | Feb 2022 | 930 | Licensing agreement for | Heidelberg Pharma and Huadong Medicine have entered into a strategic partnership with the signing … read moreof an exclusive licensing agreement as well as an investment agreement. The agreements were concluded with wholly owned subsidiaries of Huadong, one of the leading pharmaceutical companies in China with a focus on oncology and ADC research, development and commercialization. Heidelberg Pharma has granted Huadong exclusive development and commercialization rights for HDP-101 (BCMA-ATAC) and HDP-103 (PSMA-ATAC) for Asia 1 and is eligible to receive an upfront payment of USD 20 million (EUR 17.5 million) and milestone payments of up to USD 449 million (EUR 400 million), as well as tiered royalties ranging from single to low double digit percentages for each candidate. Heidelberg Pharma has granted Huadong an exclusive option for the pre-IND research candidates HDP-102 (CD37-ATAC) and HDP-104 (undisclosed target) in Asia 1 with a total deal value of up to USD 461 million (EUR 410 million), plus tiered royalties ranging from single to low double digit percentages for each candidate. Huadong also has right of first negotiation to license the next two ATAC (R) candidates for Asia 1. Huadong becomes the strategic partner in Asia for Heidelberg Pharma's product development. [collapse expanded text] |
Tavros Therapeutics, Vividion Therapeutics | Oct 2022 | 930 | Collaboration agreement for four oncology targets | Tavros Therapeutics and Vividion Therapeutics have entered into a collaboration agreement to … read morediscover or target four oncology targets across an initial five-year term. Tavros will receive $17.5 million in a cash upfront payment from Vividion, and is eligible to receive up to $430.5 million in potential future payments based on the achievement of prespecified preclinical, clinical development, and commercial milestones, as well as low-single-digit royalties on sales of certain potential programs. Vividion has options to pursue up to five additional targets with up to $482 million in potential additional future payments. [collapse expanded text] |
Blueprint Medicines, Sixth Street | Jun 2022 | 910 | Royalty financing agreement for AYVAKIT/AYVAKYT and BLU-263 | Blueprint Medicines announced strategic financing collaboration with Sixth Street. The … read moreagreement with Sixth Street has three parts: $250 million cash upfront in exchange for future AYVAKIT/AYVAKYT and BLU-263 royalties at a rate of 9.75 percent subject to an annual cap of $900 million in net sales and a cumulative cap of 1.45 times invested capital; Up to $400 million in a senior secured credit facility, of which Blueprint Medicines will draw $150 million initially with an additional $250 million available in delayed draw tranches at Blueprint Medicines' election; and $260 million in a potential credit facility to support buy-side business development opportunities, subject to mutual agreement between Sixth Street and Blueprint Medicines. [collapse expanded text] |
BridgeBio Pharma, Bristol-Myers Squibb | May 2022 | 905 | Licensing and option agreement for BBP-398 | BridgeBio Pharma announced an exclusive license with Bristol-Myers Squibb to develop and … read morecommercialize BBP-398, a potentially best-in-class SHP2 inhibitor, in oncology. BridgeBio will receive an upfront payment of $90 million, up to $815 million in development, regulatory and sales milestone payments, and tiered royalties in the low- to mid-teens. BridgeBio will retain the option to acquire higher royalties in the United States in connection with funding a portion of development costs upon the initiation of registrational studies. Based on the terms of the agreement, BridgeBio will continue to lead its ongoing Phase 1 monotherapy and combination therapy trials. Bristol Myers Squibb will lead and fund all other development and commercial activities. [collapse expanded text] |
Cook Medical, Cooper Companies | Feb 2022 | 875 | Asset purchase agreement for reproductive health business | Cook Medical signed a letter of intent with CooperCompanies to sell the entirety of Cook’s … read moreReproductive Health business within the MedSurg division. CooperCompanies will pay $875 million comprised of $675 million at closing and $200 million paid in four $50 million annual installments. [collapse expanded text] |
Fosun Pharmaceutical, Henlius Biotech | Nov 2022 | 840 | Licensing agreement for PD-1 candidate | Shanghai Fosun Pharma has licensed US rights to a PD-1 candidate from Henlius Biotech, in an $840 … read moremillion agreement. Henlius negotiated a contract with Fosun, consisting of a $140 million upfront payment, a one-time $50 million regulatory milestone payment and up to $650 million in sales milestones, plus royalties. The PD-1, serplulimab, was the thirteenth PD-1/L1 inhibitor approved in China. [collapse expanded text] |
Merck KGaA, Mersana Therapeutics | Dec 2022 | 830 | Collaboration and licensing agreement for immunosynthen antibody-drug conjugates | Mersana Therapeutics announced a research collaboration and commercial license agreement with a … read moresubsidiary of Merck KGaA to discover novel Immunosynthen ADCs directed against up to two targets. Immunosynthen, Mersana’s proprietary STING-agonist ADC platform, is designed to generate systemically administered ADCs that locally activate STING signaling in both tumor-resident immune cells and in antigen-expressing tumor cells, unlocking the anti-tumor potential of innate immune stimulation. Mersana will develop novel ADC product candidates against up to two targets utilizing its Immunosynthen platform to conjugate proprietary antibodies from Merck KGaA, Darmstadt, Germany. Mersana will be responsible for certain discovery activities, as well as limited preclinical manufacturing and supply obligations, which will be reimbursed by Merck KGaA. Merck KGaA will be solely responsible for in vitro and in vivo characterization, other preclinical work, and all clinical development and potential commercialization activities relating to any resulting product candidates. Mersana will receive an upfront payment of $30 million. Mersana is also eligible to receive reimbursement of certain costs, up to $800 million in potential regulatory, development and commercial milestone payments, and tiered royalties up to the low double-digit percentages on worldwide net sales of any approved ADCs developed under the agreement. [collapse expanded text] |
Astellas Pharma, GO Therapeutics, Xyphos Biosciences | Jun 2022 | 783.5 | Research and licensing agreement for antibodies for immuno-oncology | Astellas Pharma and GO Therapeutics announced that Xyphos Biosciences and GO have entered into a … read morestrategic research collaboration and license agreement to develop novel Immuno-Oncology therapeutics. Under the terms of the agreement, the two companies will collaborate exclusively to identify novel antibodies with high affinity to two different glycoprotein targets and apply these antibodies to a range of therapeutic modalities. GO will lead the collaboration to discover high-affinity antibodies against the two targets, and Astellas will be responsible for research activities, clinical development and commercialization of the therapeutics derived from the antibodies provided by GO. Xyphos will pay GO Therapeutics US$20.5 million in upfront cash. Milestone and contingency payments could total up to another US$763 million. [collapse expanded text] |
Alexion Pharmaceuticals, AstraZeneca, Neurimmune Therapeutics | Jan 2022 | 760 | Collaboration and licensing agreement for NI006 | Neurimmune has entered into an exclusive global collaboration and license agreement with Alexion, … read moreAstraZeneca's Rare Disease group, to develop NI006, an investigational human monoclonal antibody specifically targeting misfolded transthyretin. NI006 is currently in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). Alexion will be granted an exclusive, worldwide license to develop, manufacture and commercialize Neurimmune's ATTR clinical asset NI006. Neurimmune will receive an upfront payment of $30 million with the potential for additional contingent milestone payments of up to $730 million payable upon achievement of certain development, regulatory and commercial milestones, as well as low-to-mid teen royalties on net sales of any approved medicine resulting from the collaboration. Neurimmune will continue to be responsible for completion of the current Phase 1b clinical study on behalf of Alexion. Alexion will be responsible for further clinical development, manufacturing, and commercialization. [collapse expanded text] |
Capricor Therapeutics, Nippon Shinyaku | Jan 2022 | 735 | Licensing and distribution agreement for CAP-1002 | Capricor Therapeutics has entered into a partnership with Nippon Shinyaku for the exclusive … read morecommercialization and distribution in the United States of Capricor’s lead asset, CAP-1002, for the treatment of Duchenne muscular dystrophy. Capricor will be responsible for the conduct of HOPE-3 as well as the manufacturing of CAP-1002. Nippon Shinyaku will be responsible for the distribution of CAP-1002 in the United States. Capricor will sell commercial product to Nippon Shinyaku and in addition will receive a meaningful, double-digit share of product revenue and additional development and sales-based milestone payments. Capricor will receive an upfront payment of $30 million with potential additional milestone payments of up to $705 million. [collapse expanded text] |
Amgen, Horizon Therapeutics, Q32 Bio | Aug 2022 | 732.5 | Collaboration and option agreement for ADX-914 for treatment of autoimmune diseases | November 2023 Q32 Bio will regain full development and commercial rights to bempikibart ( … read morepreviously known as ADX-914) from Amgen. August 2022 Q32 Bio and Horizon Therapeutics have entered into a collaboration and option agreement to develop ADX-914 for the treatment of autoimmune diseases. Horizon will fund development through completion of the two Phase 2 trials of ADX-914, with Q32 being operationally responsible for the conduct of all program-related activities. Horizon will receive an option to acquire the ADX-914 program, exercisable through a period following completion of the Phase 2 trials. During the option period, Q32 will receive $55 million in the form of initial consideration and staged development funding, of which Horizon expects to recognize as R&D expenses approximately $32.5 million in the third quarter of 2022, and the remainder in 2023. These payments will be included in Horizon's non-GAAP financial measures, including adjusted EBITDA. If Horizon exercises the option, Q32 may be eligible to receive up to an additional $645 million in closing and milestone payments, as well as tiered royalties on net sales, less certain amounts payable under a pre-existing license agreement. [collapse expanded text] |
Eli Lilly, Sosei | Dec 2022 | 731 | Collaboration and licensing agreement for small molecules that modulate novel G protein-coupled receptor targets associated with diabetes and metabolic diseases | Sosei has entered a drug discovery collaboration with Eli Lilly to discover, develop and … read morecommercialize small molecules that modulate novel G protein-coupled receptor targets associated with diabetes and metabolic diseases. This new agreement will leverage Sosei Heptares’ StaR technology and structure-based drug design platform and Lilly’s extensive drug development and commercialization expertise as well as its therapeutic area expertise in diabetes and metabolic diseases. Sosei Heptares will focus its efforts on multiple GPCR targets nominated by Lilly to deliver novel target-selective small molecule hit candidates for further development and commercialization. Sosei Heptares receives an upfront payment of US$37 million on signing and is eligible to receive development and commercial milestones totalling up to US$694 million, plus tiered royalties on global sales. [collapse expanded text] |
Alectos Therapeutics, Biogen | Jun 2022 | 722.5 | Collaboration and licensing agreement for AL01811 | Biogen and Alectos Therapeutics have entered into a license and collaboration agreement to develop … read moreand commercialize a novel preclinical selective GBA2 inhibitor, AL01811, which has first-in-class potential as an oral disease modifying treatment for patients with Parkinson’s disease. This collaboration combines Alectos’ expertise in small-molecule therapeutics with Biogen’s development capabilities in movement disorders. Biogen will make an upfront payment of $15 million to Alectos Therapeutics for an exclusive global license to AL01811 and additional unnamed backup molecules. Alectos is eligible to receive up to $77.5M in potential development payments and $630M in potential commercial payments should the collaboration achieve certain milestones. Alectos is also eligible to receive tiered royalties in the high-single-digits to mid-teens. Moving forward, both companies will collaborate on preclinical activities for AL01811 and, once AL01811 is advanced to the clinic, Biogen will assume sole responsibility for all development, regulatory, manufacturing, and commercial activities and costs. [collapse expanded text] |
Entrada Therapeutics, Vertex Pharmaceuticals | Dec 2022 | 709 | Collaboration agreement for endosomal escape vehicle therapeutics for myotonic dystrophy type 1 | Vertex Pharmaceuticals and Entrada Therapeutics announced a global collaboration focused on … read morediscovering and developing intracellular Endosomal Escape Vehicle (EEV) therapeutics for myotonic dystrophy type 1. The collaboration includes Entrada’s program for DM1, ENTR-701, which is in late-stage preclinical development. Entrada will receive an upfront payment of $224 million, as well as an equity investment of $26 million. Entrada is eligible to receive up to $485 million for the successful achievement of certain research, development, regulatory and commercial milestones, and tiered royalties on future net sales for any products that may result from this collaboration agreement. The agreement includes a four-year global research collaboration whereby Entrada will continue to advance and receive payments for certain research activities related to ENTR-701, as well as additional DM1-related research activities. Vertex will be responsible for global development, manufacturing and commercialization of ENTR-701 and any additional programs stemming from Entrada’s DM1 research efforts. [collapse expanded text] |
Novo Nordisk, Ventus Therapeutics | Sep 2022 | 703 | Development and licensing agreement for peripherally-restricted NLRP3 inhibitors | Ventus Therapeutics has entered into an exclusive worldwide license agreement with Novo Nordisk to … read moredevelop and commercialize candidates from Ventus’ portfolio of peripherally-restricted NLRP3 inhibitors. Novo Nordisk will make an upfront payment of $70 million in cash to Ventus and provide research and development funding. Ventus will be eligible to receive up to an additional $633 million in potential clinical, regulatory, and commercial milestones as well as tiered royalties. In exchange, Novo Nordisk will receive exclusive worldwide rights to develop and commercialize Ventus’ lead NLRP3 inhibitor program for a broad range of diseases, including nonalcoholic steatohepatitis, chronic kidney disease, and other cardiometabolic conditions. Ventus retains the right to develop NLRP3 inhibitors for certain systemic diseases, including specific inflammatory and respiratory diseases. Ventus retains worldwide rights to the company’s distinct brain-penetrant NLRP3 inhibitor program. [collapse expanded text] |
Cybrexa Therapeutics, Exelixis | Nov 2022 | 702.5 | Collaboration and licensing agreement for CBX-12 | Exelixis and Cybrexa Therapeutics have entered into an exclusive collaboration agreement providing … read moreExelixis the right to acquire CBX-12 (alphalex exatecan), a clinical-stage, first-in-class peptide-drug conjugate that utilizes Cybrexa’s proprietary alphalex technology to enhance delivery of exatecan to tumor cells. CBX-12 is designed to increase the efficacy and reduce the toxicity of topoisomerase I inhibition by delivering exatecan, a highly potent, second-generation topoisomerase I inhibitor, directly to the tumor cells. This collaboration underscores Exelixis’ commitment to expanding its clinical pipeline building upon its biotherapeutics and targeted drug therapy expertise. Exelixis will pay Cybrexa an upfront fee of $60 million in exchange for the right to acquire CBX-12 pending certain Phase 1 results and to fund certain development and manufacturing expenses incurred by Cybrexa to advance an agreed development plan. Cybrexa may also be eligible to receive up to an additional $642.5 million, including development, regulatory, and commercial milestone payments, as well as a fee for the acquisition of CBX-12 upon evaluation of a pre-specified clinical data package. [collapse expanded text] |
Eli Lilly, Lilly Institute for Genetic Medicine | Feb 2022 | 700 | Spin out agreement for Lilly Institute for Genetic Medicine | Eli Lilly announced the launch of the Lilly Institute for Genetic Medicine and an investment of … read moreapproximately $700 million to establish a state-of-the-art facility at a new site in the Boston Seaport. This investment – part of the company's strategy to advance RNA based therapeutics – builds on the 2020 acquisition and rapid expansion of Prevail Therapeutics, a gene therapy pioneer based in New York City. Working together, researchers in both Boston and New York will leverage promising RNA and DNA-based technologies to develop therapies with the potential to treat or prevent diseases in a manner that is challenging or not possible with traditional medicines. [collapse expanded text] |
Genentech, Kiniksa Pharmaceuticals | Aug 2022 | 700 | Licensing agreement for vixarelimab | Kiniksa Pharmaceuticals announced a global license agreement with Roche and Genentech for the … read morerights to develop and commercialize vixarelimab, a fully human monoclonal antibody targeting oncostatin M receptor beta (OSMRβ). Kiniksa will receive $100 million in upfront and near-term payments, and is eligible to receive up to approximately $600 million in certain clinical, regulatory, and sales-based milestones, before fulfilling upstream financial obligations. Kiniksa is also eligible to receive royalties on annual net sales. Genentech will obtain rights for the development and commercialization of vixarelimab. [collapse expanded text] |
Lava Therapeutics, Pfizer, Seagen | Sep 2022 | 700 | Licensing agreement for LAVA-1223 | March 2024 LAVA Therapeutics announced that Pfizer has achieved a clinical development milestone … read morefor PF-08046052 (formerly SGN-EGFRd2 /LAVA-1223), prompting the first milestone payment of $7 Million to LAVA. September 2022 Seagen and LAVA Therapeutics announced an exclusive license agreement in which Seagen will work to develop, manufacture and commercialize LAVA-1223. LAVA-1223 is an advanced preclinical asset that utilizes LAVA’s proprietary Gammabody technology to target epidermal growth factor receptor-expressing solid tumors. Seagen will receive an exclusive global license for LAVA-1223 and pay LAVA $50 million upfront; up to approximately $650 million in potential development, regulatory and commercial milestones; and royalties ranging from the single digits to the mid-teens on future sales. The agreement also provides Seagen with the opportunity to exclusively negotiate rights to apply LAVA's proprietary Gammabody platform on up to two additional tumor targets. [collapse expanded text] |
Clovis Oncology, Novartis | Dec 2022 | 680.75 | Asset purchase agreement for FAP-2286 | Clovis has entered into a “stalking horse” purchase and assignment agreement with Novartis … read moreInnovative Therapies to acquire substantially all of the rights of the Company to its pipeline clinical candidate, FAP-2286, as a therapeutic agent for an upfront payment of $50 million and up to an additional $333.75 million upon the successful achievement of specified development and regulatory milestones and $297 million in later sales milestones. [collapse expanded text] |
Eli Lilly, Genesis Therapeutics | May 2022 | 670 | Collaboration agreement for therapies using genesis molecular AI platform | Genesis Therapeutics has entered into a strategic collaboration with Eli Lilly to discover novel … read moretherapies for up to five targets across a range of therapeutic areas. The collaboration will deploy Genesis’ pioneering AI drug discovery platform, which combines 3D structure-aware deep neural networks with cutting-edge molecular simulation. Genesis’ field-leading machine learning models will be utilized by joint teams of engineers and scientists from Genesis and Lilly as they drive toward first-in-class and best-in-class drug candidates. Genesis will partner with Lilly on three initial targets and will receive an upfront payment of $20 million. Lilly will have the option to nominate two more targets for an additional nomination payment per target. Genesis will be eligible to receive up to $670 million total in upfront; target nomination; and preclinical, development, regulatory and sales milestone payments. Genesis is also eligible to receive royalties on net sales. [collapse expanded text] |
Huadong Medicine, Kiniksa Pharmaceuticals | Feb 2022 | 662 | Collaboration and licensing agreement for ARCALYST and mavrilimumab | Kiniksa Pharmaceuticals and Hangzhou Zhongmei Huadong Pharmaceutical, a wholly-owned subsidiary of … read moreHuadong Medicine announced a strategic collaboration to develop and commercialize Kiniksa’s ARCALYST and mavrilimumab in the Asia Pacific Region. Kiniksa will receive $22 million upfront and is eligible to receive up to approximately $640 million in specified development, regulatory and sales-based milestones. Kiniksa is also eligible to receive tiered royalties ranging from the low-teens to the low-twenties on annual net sales. Huadong Medicine will obtain exclusive rights and responsibility for the development and commercialization of ARCALYST and mavrilimumab in the Asia Pacific Region including Greater China, South Korea, Australia, and 18 other countries, but excluding Japan. Kiniksa will otherwise retain all existing development and commercialization rights for both assets. [collapse expanded text] |
Blueprint Medicines, Proteovant Therapeutics | Feb 2022 | 652 | Collaboration, option, licensing and co-promotion agreement for targeted protein degrader therapies | Blueprint Medicines and Proteovant Therapeutics announced a strategic collaboration to advance … read morenovel targeted protein degrader therapies to address important areas of medical need. The collaboration will bring together Proteovant's Artificial Intelligence -enhanced targeted protein degradation platform and Blueprint Medicine's precision medicine expertise to discover novel targeted protein degraders. The companies will jointly research important targets and advance up to two novel protein degrader therapies into development candidates. As a core part of the collaboration, Proteovant's exclusive partner for TPD, VantAI, will deploy its leading AI technologies for degrader generation and optimization. Upon designation of a clinical development candidate, Blueprint Medicines has the exclusive option to develop and commercialize products resulting from the collaboration. Proteovant has the option to co-develop and co-commercialize the second of the two Blueprint Medicines-optioned programs in the U.S. Proteovant will receive a $20 million upfront payment and will be eligible to receive up to an additional $632 million in potential research, development, regulatory and commercialization milestone payments plus tiered royalties from mid- to high-single digits on net sales on the first two program targets, subject to adjustment in specified circumstances. Of the total contingent payments, up to $105 million would be preclinical, clinical development and regulatory milestones and up to $527 million would be approval and sales milestones. Each company will be responsible for its own costs under the research plan. Should Proteovant opt in to the second program, the parties will split profits and losses of that program equally in the U.S. along with development costs and the milestone payments for the program will be reduced accordingly. Proteovant will be eligible to receive milestone payments and royalties on ex-U.S. sales. In addition, the partners may jointly extend the collaboration, with the same structure and financial terms, to two additional program targets through additional funding by Blueprint Medicines. [collapse expanded text] |
Genentech, Jemincare, Roche | Aug 2022 | 650 | Licensing agreement for JMKX002992 | Jemincare Pharmaceutical have entered into an exclusive worldwide license agreement with Roche and … read moreGenentech for the development and commercialization of its androgen receptor degrader, JMKX002992. Genentech will be granted an exclusive license to develop and commercialize the degrader worldwide, and will be fully responsible for the development and commercialization costs. Genentech will pay Jemincare a USD 60 million upfront payment. Jemincare is also entitled to receive up to USD 590 million in additional payments upon achievement of certain development, regulatory and sales-based milestone targets. Jemincare is also entitled to receive tiered royalties on net sales. [collapse expanded text] |
AbSci, Merck and Co | Jan 2022 | 610 | Collaboration, option and licensing agreement for AI-powered Integrated Drug Creation platform | Absci has entered into a research collaboration with Merck using Absci’s AI-powered Integrated Drug … read moreCreation Platform. Absci will deploy its Bionic Protein non-standard amino acid technology to produce enzymes tailored to Merck’s biomanufacturing applications and receive an upfront and certain other milestone payments. Merck has the option to nominate up to three targets and enter into a drug discovery collaboration agreement, and Absci would then be eligible to receive up to $610 million in upfront fees and milestone payments for all three targets, as well as research funding and tiered royalties on sales. [collapse expanded text] |
Juniper Biologics, Kolon Life Science | Apr 2022 | 600 | Licensing agreement for TG-C LD | Juniper Biologics has gained the licensing rights to develop and commercialize TG-C LD (TissueGene- … read moreC low dose) for the treatment of knee osteoarthritis. The $600 million USD licensing deal which covers Asia Pacific, Middle East and Africa was signed with Kolon Life Science, and is Juniper Biologics’ second acquisition in as many months. Juniper Biologics will be responsible for developing and commercializing TG-C LD to medical professionals and hospitals within these regions. Kolon Life Science will be responsible for supporting the development as well as supplying TG-C LD. [collapse expanded text] |
Boehringer Ingelheim, Surrozen | Oct 2022 | 599 | Collaboration and licensing agreement for SZN-413 | Key Deal Terms Summary: Surrozen and Boehringer Ingelheim Collaboration… read moreParties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Considerations
Overall SummarySurrozen and Boehringer Ingelheim have entered a strategic partnership to develop SZN-413, a Wnt agonist therapy for retinal diseases. Boehringer Ingelheim will take the lead on development and commercialization after an initial joint research phase. Surrozen receives a $12.5 million upfront payment, with potential milestone payments up to $586.5 million, plus royalties on future sales. This collaboration reinforces Boehringer Ingelheim’s presence in ophthalmology and leverages Surrozen’s proprietary Wnt-modulating technology to potentially restore retinal health. [collapse expanded text] |
GSK, Spero Therapeutics | Sep 2022 | 591 | Licensing agreement for tebipenem HBr | Parties Involved
… read more Collaboration ScopeGSK has obtained an exclusive license to develop and commercialize tebipenem HBr, a late-stage oral carbapenem antibiotic for complicated urinary tract infections (cUTI), except in Japan and certain other Asian countries, where rights are retained by Meiji Seika. Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryGSK has entered into an exclusive license agreement with Spero Therapeutics to develop and commercialize tebipenem HBr, a potential first-in-class oral carbapenem antibiotic for complicated urinary tract infections. Spero will conduct the Phase 3 trial, while GSK will handle additional development and commercialization outside of Japan and select Asian countries. Spero receives $66M upfront, with up to $525M in potential milestone payments, tiered royalties, and a $9M equity investment from GSK. [collapse expanded text] |
Macrogenics, Synaffix | Feb 2022 | 586 | Licensing and option agreement for GlycoConnect antibody conjugation technology, HydraSpace polar spacer technology, as well as select toxSYN linker-payloads (SYNtecan E, SYNeamicin D and SYNeamicin G) | March 2023 Synaffix has announced the expansion of its license agreement with MacroGenics. … read moreThe expansionincreases the total potential consideration by up to $2.2 billion, plus tiered low to high single-digit royalties on potential net sales of any resulting products. MacroGenics currently has the option to pursue up to seven ADC programs under the expanded deal, which includes three programs from the original collaboration. February 2022 Synaffix has entered into a technology agreement with MacroGenics. MacroGenics will gain access to Synaffix's clinical stage GlycoConnect antibody conjugation technology, HydraSpace polar spacer technology, as well as select toxSYN linker-payloads (SYNtecan E, SYNeamicin D and SYNeamicin G), each designed to enable ADCs with best-in-class efficacy and tolerability. These will be combined with MacroGenics' proprietary antibody and bispecific DART antibody platform technologies to generate next generation ADCs. Synaffix will be eligible to receive up to $586 million in payments spanning upfront and milestone payments across three programs plus royalties on commercial sales. The license rights of MacroGenics for each program will be designated as exclusive or non-exclusive to each program's antibody target (or to the combination of two targets, if bispecific). The first program will commence at signature, with the option to expand the collaboration to a further two programs by March 2023. MacroGenics will be responsible for research, development, manufacturing and commercialization of the ADCs. Synaffix will support MacroGenics' research activities and be responsible for the manufacturing of components that are specifically related to its proprietary GlycoConnect and HydraSpace technologies and the toxSYN linker-payloads. [collapse expanded text] |
Merck KGaA, Proxygen | Jun 2022 | 554 | Collaboration and licensing agreement for molecular glue degraders | Proxygen has entered into a strategic multi-year research collaboration and license agreement with … read moreMerck. Proxygen is eligible to receive up to €495 million ($554 million at the average USD/EUR FX rate of Q1 2022) in continuous R&D funding, upfront and success-based pre-clinical, clinical, regulatory, and commercial milestones, as well as additional royalty payments. Under the terms of the agreement, the companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage. [collapse expanded text] |
Bristol-Myers Squibb, SyntheX | Oct 2022 | 550 | Collaboration agreement for targeted protein degradation therapeutics | SyntheX announced a research collaboration and license agreement with Bristol Myers Squibb to … read morediscover, develop and commercialize novel small molecules using SyntheX's ToRNeDO platform for protein degradation. The collaboration will focus on discovering molecular glue degraders. SyntheX will receive a combined upfront of cash and an investment and is eligible for up to $550 million in performance-based milestone payments, as well as royalties on global net sales of products. [collapse expanded text] |
Leidos, National Institute of Allergy and Infectious Diseases | Mar 2022 | 545 | Contract service agreement for biomedical research | Leidos was awarded a new prime contract to provide biomedical preclinical and development … read morecapabilities to support the National Institute of Allergy and Infectious Diseases. The seven-year, multi-award, indefinite delivery/indefinite quantity contract has an approximate value of up to $545 million across all task areas to be engaged on this program. This project will be funded in whole or in part with federal funds from the NIAID, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93021D00030. [collapse expanded text] |
Abbvie, iSTAR Medical | Jul 2022 | 535 | Development and option agreement for MINIject device device for patients with glaucoma | Key Deal Terms Summary: AbbVie and iSTAR Medical Strategic AllianceParties… read moreInvolved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Considerations
Overall SummaryAbbVie and iSTAR Medical have formed a strategic alliance to advance the development and commercialization of MINIject®, a MIGS device for glaucoma treatment. iSTAR will continue clinical development and commercialization efforts, while AbbVie has secured an exclusive right to acquire iSTAR following the completion of the STAR-V study. The agreement includes a $60 million upfront payment, with potential milestone payments of up to $475 million upon acquisition. This partnership expands AbbVie’s glaucoma portfolio, reinforcing its commitment to innovative interventional eye care solutions. [collapse expanded text] |
Grunenthal, Shionogi | Aug 2022 | 525 | Licensing agreement for resiniferatoxin | Grünenthal and Shionogi have entered into a licensing agreement for Grünenthal's investigational … read moremedicine Resiniferatoxin. Shionogi obtained the exclusive rights to commercialise Grünenthal's asset in Japan for pain associated with osteoarthritis of the knee. Shionogi will obtain the exclusive commercialisation rights for RTX in Japan for a total consideration of up to $ 525 million plus additional sales based payments. Shionogi will pay $ 75 million upon signature, and further milestone payments of $ 70 million prior to regulatory approval. The agreement includes competitive investment commitments for launch and commercialisation. Manufacturing and supply of RTX to Shionogi will be carried out exclusively by Grünenthal. [collapse expanded text] |
Bayer, Grunenthal | Jul 2022 | 508.55 | Asset purchase agreement for Nebido | Grünenthal announced an agreement with Bayer to acquire Nebido, the well-known brand for the … read moretreatment of male hypogonadism and its associated brands for up to € 500 million. The product is approved and successfully commercialized in over 80 countries. Patent protection exists until March 2024 in the EU and until May 2027 in the US. [collapse expanded text] |
Almirall, Simcere Pharmaceuticals | Sep 2022 | 507 | Licensing agreement for SIM0278 | Almirall and Simcere Pharmaceutical have entered into an exclusive licensing agreement for Simcere’ … read mores IL-2 mutant fusion protein (IL-2 mu-Fc) autoimmune drug candidate, SIM0278. Almirall will be granted an exclusive right to develop and commercialise SIM0278 for all indications outside of the Greater China region (Mainland China, Hong Kong, Macau and Taiwan). Simcere will retain all rights to develop and commercialise SIM0278 within Greater China. Simcere will receive a $15 million upfront payment and up to US$492 million in development and commercial milestone payments considering successful achievements in several indications, with an important part as sales milestones, as well as up to low double-digit tiered royalties based upon future global sales. [collapse expanded text] |
Amgen, Plexium | Feb 2022 | 500 | Collaboration and licensing agreement for targeted protein degradation therapeutics | Amgen and Plexium announced an exclusive, worldwide, multi-year research collaboration and license … read moreagreement to identify novel targeted protein degradation therapeutics toward historically challenging drug targets. The multi-year collaboration supports the discovery of novel molecular glue therapeutics leveraging insights from Amgen's expertise in developing multispecific molecules. Under the terms of the agreement, the collaboration will initially focus on two programs with Amgen holding options to add additional programs. Plexium is eligible to receive over $500 million in success-based target access, pre-clinical, clinical, regulatory and commercial milestones, as well as tiered single-digit royalty payments, if all options are exercised. Amgen has a commercial license to each program that advances to a predefined preclinical stage of development and will be responsible for global development and commercialization. The partnership will focus on expanding targeted protein degradation opportunities through discovery of previously unrecognized molecular glues or monovalent degraders. These molecules work through a concept of induced proximity that take advantage of the normal biology of a cell to bring two proteins together to drive protein degradation. This collaboration incorporates Plexium's comprehensive targeted protein degradation platform, powered by a proprietary high-throughput cell-based screening technology that enables the discovery of novel molecular glue therapies. [collapse expanded text] |
Top partnering deals of 2021 valued at over US$500m.
Partners | Date | Value, US$m | Subject | Termsheet |
---|---|---|---|---|
AmerisourceBergen, Walgreens | Jan 2021 | 6500 | Asset purchase agreement for Alliance Healthcare businesses | AmerisourceBergen and Walgreens Boots Alliance announced strategic agreements under which … read moreAmerisourceBergen will acquire the majority of Walgreens Boots Alliance’s Alliance Healthcare businesses for approximately $6.5 billion, comprised of $6.275 billion in cash and 2 million shares of AmerisourceBergen common stock. AmerisourceBergen’s acquisition of Alliance Healthcare will provide even stronger support for pharmacies and pharmacists across the globe and integrated solutions for pharmaceutical manufacturers. Walgreens Boots Alliance will be able to increase its focus on expanding its core retail pharmacy businesses, bringing even greater healthcare offerings to patients and customers and further accelerating its progress on its clear set of strategic priorities. [collapse expanded text] |
Poseida Therapeutics, Takeda Pharmaceutical | Oct 2021 | 3770 | Collaboration, option and licensing agreement for non-viral in vivo gene therapies | May 2023Key Deal Terms SummaryAgreement OverviewFinancial Terms
Development & Commercialization Status
Strategic Impact
Overall SummaryTakeda has opted to terminate its collaboration and license agreement with Poseida, originally valued at up to $3.6 billion, following its exit from AAV gene therapy R&D. The termination is effective July 30, 2023, with Poseida retaining the rights to the gene therapy programs. While no new partnerships have been announced, Poseida may explore new collaborations and is financially positioned to operate through mid-2024. October 2021Key Deal Terms SummaryAgreement Overview
Financial Terms
Development & Commercialization Plans
Strategic Impact
Overall SummaryPoseida Therapeutics and Takeda have partnered to co-develop a series of next-generation, non-viral gene therapies using Poseida’s advanced genetic engineering platforms. The agreement includes an upfront payment, substantial milestone potential up to $3.6 billion, and double-digit royalties. The collaboration strengthens both companies' strategic positions in rare diseases and gene therapy innovation, while offering potential breakthroughs for patients in need. [collapse expanded text] |
Eli Lilly, ProQR Therapeutics | Sep 2021 | 3750 | Collaboration, research and licensing agreement for genetic disorders in the liver and nervous system | Parties Involved
… read more Collaboration ScopeThe collaboration centers on the development of RNA editing-based therapies using ProQR’s Axiomer® platform, which harnesses endogenous ADAR enzymes to introduce targeted RNA edits (A-to-I conversions). The original 2021 agreement focused on up to five targets for liver and nervous system disorders. The 2022 expansion broadens the scope to include additional CNS and PNS targets and introduces potential for correcting or introducing protective variants in disease-relevant transcripts. Rights & Responsibilities
Financial Terms
Regulatory ApprovalNot yet applicable — programs are in preclinical or early research phases. Overall SummaryEli Lilly and ProQR have expanded their strategic RNA editing alliance, originally signed in September 2021, to include additional CNS and PNS targets utilizing ProQR’s Axiomer® platform. The deal reflects growing conviction in ADAR-mediated RNA editing as a potential modality for treating genetic disorders. With a total deal value now reaching $3.75 billion, plus royalties, the collaboration strengthens both firms' positioning in the genetic medicine space, particularly for diseases with high unmet need in the nervous system and liver. [collapse expanded text] |
AstraZeneca, Ionis Pharmaceuticals | Dec 2021 | 3585 | Collaboration, co-development, co-promotion and licensing agreement for eplontersen | July 2023 Ionis Pharmaceuticals has expanded its existing collaboration with AstraZeneca to … read moreinclude exclusive rights for AstraZeneca to commercialize eplontersen in Latin America. Ionis previously granted AstraZeneca exclusive rights to commercialize eplontersen in all other countries outside the US Ionis and AstraZeneca will continue to jointly develop and commercialize eplontersen in the US. The companies are successfully advancing eplontersen by combining Ionis' industry-leading expertise in RNA-targeted therapeutics and deep knowledge of transthyretin amyloidosis with AstraZeneca's global cardiovascular commercial capabilities. AstraZeneca paid Ionis $20 million to license eplontersen in Latin America. Under the terms of the collaboration agreement, Ionis is eligible to receive up to $3.6 billion in milestone and other payments. The collaboration includes territory-specific cost-sharing provisions. Ionis is also eligible to earn royalties in the range of low double-digit to mid-20s percentage depending on region. Ionis and AstraZeneca are seeking regulatory approval for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) in the US and plan to seek regulatory approval in the EU and other parts of the world. The US Food and Drug Administration accepted the New Drug Application for eplontersen for the treatment of ATTRv-PN with a PDUFA action date of Dec. 22, 2023. Eplontersen was granted Orphan Drug Designation in the U.S. December 2021 Ionis Pharmaceuticals has entered into a strategic collaboration agreement with AstraZeneca to develop and commercialize eplontersen, Ionis' investigational antisense medicine for the treatment of transthyretin amyloidosis (ATTR). The companies will develop a global strategy for developing, manufacturing and commercializing eplontersen. A breakdown of responsibilities of the collaboration includes, but is not limited to: Ionis will continue to lead the conduct of the global Phase 3 clinical trials in patients with hereditary ATTR amyloidosis (hATTR) with polyneuropathy (NEURO-TTRansform) and cardiomyopathy (CARDIO-TTRansform). Ionis will manufacture and supply eplontersen for the ongoing clinical trials and process qualifications. AstraZeneca will be responsible for commercial supply, with transition timing to be agreed by both companies. Ionis and AstraZeneca will have shared responsibility for medical affairs and commercial activities in the U.S. AstraZeneca will have an exclusive license for eplontersen outside the U.S. except certain countries in Latin America. Ionis will receive a $200 million upfront payment, up to $485 million in development and approval milestones, and up to $2.9 billion in sales-related milestone payments. The collaboration includes territory-specific development, commercial and medical affairs cost-sharing provisions. Ionis is also eligible to earn royalties in the range of low double-digit to mid-20s percentage depending on region. [collapse expanded text] |
Adaptimmune, Genentech | Sep 2021 | 3300 | Collaboration, licensing, option and co-promotion agreement for targeted allogeneic T-cell therapies | Key Deal Terms Summary1. Agreement Overview
2. Financial Terms
3. Termination Details
4. Development & Commercialization Impact
Overall SummaryAdaptimmune and Genentech’s 2021 strategic collaboration to develop allogeneic T-cell therapies for cancer was terminated in April 2024. The deal initially involved up to $3 billion in milestone payments and a $150 million upfront payment, but no further financial commitments were disclosed upon termination. Adaptimmune remains focused on its late-stage autologous pipeline, with afami-cel expected to launch in 2024. [collapse expanded text] |
Bristol-Myers Squibb, Eisai | Jun 2021 | 3000 | Co-development and co-promotion agreement for MORAb-202 antibody drug conjugate | July 2024 Eisai announced that it has agreed to end its global strategic collaboration with … read moreBristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin formerly known as MORAb-202 due to ongoing portfolio prioritization efforts within Bristol Myers Squibb Eisai now owns all rights to FZEC and will solely conduct global development and commercialization of agent Eisai will accelerate development of agent as a high priority with hope to deliver it to patients as early as possible Eisai plans to refund a part of unused portion of $200 million payment it received towards research and development expenses from Bristol Myers Squibb under the collaboration agreement and record remaining as other income June 2021 Eisai and Bristol-Myers Squibb have entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate. MORAb-202 is Eisai’s first ADC and combines Eisai’s in house developed anti-folate receptor alpha (FRα) antibody, and Eisai’s anticancer agent eribulin, using an enzyme cleavable linker. It is a potential best-in-class FRα ADC with a favorable pharmacology profile and demonstrated single agent activity in patients with advanced solid tumors. Eisai is currently investigating MORAb-202 in FRα-positive solid tumors (inclusive of endometrial, ovarian, lung and breast cancers) in two studies: a Phase 1 clinical study in Japan and a Phase 1/2 clinical study in the United States. The companies are planning to move into the registrational stage of development for this asset as early as next year. Eisai and Bristol Myers Squibb will jointly develop and commercialize MORAb-202 in the following collaboration territories: Japan; China; countries in the Asia-Pacific region; the United States; Canada; Europe, including the European Union and the United Kingdom; and Russia. Bristol Myers Squibb will be solely responsible for developing and commercializing the drug in regions outside of the collaboration territories. Eisai will remain responsible for the manufacturing and supply of MORAb-202 globally. Bristol Myers Squibb will pay $650 million U.S. dollars to Eisai including $200 million U.S. dollars as payment toward Eisai research and development expenses. Eisai is also entitled to receive up to $2.45 billion U.S. dollars in potential future development, regulatory, and commercial milestones. The parties will share profits, research and development and commercialization costs in the collaboration territories and Bristol Myers Squibb will pay Eisai a royalty on sales outside of the collaboration territories. Eisai is expected to book sales of MORAb-202 in Japan, China, countries in the Asia-Pacific region, Europe and Russia. Bristol Myers Squibb is expected to book sales of MORAb-202 in the United States and Canada. [collapse expanded text] |
Roche, Shape Therapeutics | Aug 2021 | 3000 | Collaboration and licensing agreement for AAV-based RNA editing technology for neuroscience and rare disease indications | Key Deal Terms Summary: Shape Therapeutics and Roche CollaborationParties… read moreInvolved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Considerations
Overall SummaryShapeTX and Roche have formed a multi-target strategic collaboration to develop next-generation RNA-based gene therapies for neurodegenerative and rare diseases. ShapeTX will lead preclinical research, while Roche will handle clinical development and commercialization. ShapeTX is eligible for payments exceeding $3 billion, plus tiered royalties on sales. This partnership expands Roche’s gene therapy capabilities while validating ShapeTX’s RNAfix™ and AAVid™ platforms for RNA editing and targeted gene delivery. [collapse expanded text] |
BeiGene, Novartis | Dec 2021 | 2795 | Collaboration, option, licensing and co-promotion agreement for ociperlimab | BeiGene announced an option, collaboration and license agreement with Novartis Pharma to develop, … read moremanufacture and commercialize BeiGene’s investigational TIGIT inhibitor ociperlimab in North America, Europe, and Japan. BeiGene has granted Novartis an exclusive time-based option under which, upon exercise by Novartis prior to late 2023, the companies have agreed to jointly develop ociperlimab, with Novartis responsible for regulatory submissions after a transition period and for commercialization upon regulatory approvals in the licensed territory. During the option period Novartis will conduct and fund additional global clinical trials of ociperlimab in combination with tislelizumab in selected tumor types. In addition, following option exercise, both companies may conduct clinical trials globally to explore combinations of ociperlimab with other cancer treatments. Following approval, BeiGene will co-detail the product in the United States. BeiGene will receive an upfront cash payment of $300 million from Novartis along with an additional payment of $600 or $700 million upon exercise by Novartis of an exclusive time-based option prior to mid-2023 or between then and late-2023, subject to receipt of required antitrust approval. In addition, following option exercise, BeiGene is eligible to receive up to $745 million upon the achievement of regulatory approval milestones, $1.15 billion upon the achievement of sales milestones, and royalties on future sales of ociperlimab in the licensed territory. The licensed territory is the same as the tislelizumab collaboration, the United States, Canada, Mexico, member countries of the European Union, United Kingdom, Norway, Switzerland, Iceland, Liechtenstein, Russia, and Japan. Subject to the terms of the agreement, during the option period, Novartis will initiate and fund additional global clinical trials with ociperlimab and BeiGene has agreed to expand enrollment in two ongoing trials. Additionally, following the option exercise, Novartis has agreed to share development costs of global trials. Following approval, BeiGene has agreed to provide 50 percent of the co-detailing and co-field medical efforts in the United States, and has an option to co-detail up to 25 percent in Canada and Mexico, funded in part by Novartis. Each party retains the worldwide right to commercialize its propriety products in combination with ociperlimab, as is the case with tislelizumab under the parties’ existing agreement. [collapse expanded text] |
Antylia Scientific, Avantor | Sep 2021 | 2700 | Asset purchase agreement for Masterflex bioprocessing business and related assets | Avantor has entered into a definitive agreement to acquire the Masterflex bioprocessing business … read moreand related assets of Antylia Scientific. The all-cash transaction is valued at $2.9 billion, subject to final adjustments at closing. Given anticipated tax benefits from the transaction structure, the net purchase price is approximately $2.7 billion. [collapse expanded text] |
Neurocrine Biosciences, Sosei | Nov 2021 | 2700 | Collaboration and licensing agreement for clinical and preclinical subtype-selective muscarinic M4, M1 and dual M1/M4 receptor agonists | Parties Involved
… read more Collaboration ScopeThe collaboration centers on the development and commercialization of novel, selective muscarinic receptor agonists (targeting M4, M1, and dual M1/M4) for the treatment of schizophrenia, dementia, and other neuropsychiatric disorders. The lead asset is HTL-0016878, a selective M4 agonist, expected to enter Phase 2 studies for schizophrenia in 2022. Additional preclinical assets include selective M1, M4, and dual M1/M4 receptor agonists. Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryNeurocrine Biosciences and Sosei Heptares have established a strategic partnership valued at up to $2.7 billion to develop next-generation selective muscarinic receptor agonists for schizophrenia and neuropsychiatric diseases. The deal gives Neurocrine access to a broad CNS-targeted portfolio, with Sosei retaining Japanese rights for M1 agonists and sharing in the upside through milestones, royalties, and R&D collaboration. The alliance combines Sosei’s GPCR drug design expertise with Neurocrine’s clinical and commercial strength in neuroscience. [collapse expanded text] |
RemeGen, Seagen | Aug 2021 | 2600 | Co-development and licensing agreement for Disitamab Vedotin | Seagen and RemeGen have entered into an exclusive worldwide licensing agreement to develop and … read morecommercialize disitamab vedotin, a novel HER2-targeted ADC. Seagen will make a $200 million upfront payment to exclusively license rights to disitamab vedotin for global development and commercialization, outside of RemeGen’s territory. RemeGen will retain development and commercialization rights for Asia, excluding Japan and Singapore. Seagen will lead global development and RemeGen will fund and operationalize the portion of global clinical trials attributable to its territory. RemeGen will also be responsible for all clinical development and regulatory submissions specific to its territory. Seagen will pay RemeGen up to $2.4 billion in potential total milestone payments based upon the achievement of specified development, regulatory and commercialization goals across multiple indications and products. RemeGen will be entitled to a tiered, high single digit to mid-teen percentage royalty based on net sales of disitamab vedotin in Seagen’s territory. [collapse expanded text] |
Anima Biotech, Takeda Pharmaceutical | Mar 2021 | 2420 | Collaboration, option and licensing agreement for mRNA translation modulators for neurological diseases | Parties Involved
… read more Collaboration ScopeThe collaboration focuses on discovering and developing small molecule modulators of mRNA translation for genetically-defined neurological diseases. Anima will use its Translation Control Therapeutics platform to develop candidates against:- Anima's Huntington’s Disease program targeting HTT (mutant protein translation inhibition)- Two additional Takeda-selected neurological targets Takeda has the exclusive rights to develop and commercialize resulting clinical candidates. The agreement includes an option to expand to three more targets, pending additional terms. Rights & Responsibilities
Financial Terms
Regulatory ApprovalThe collaboration is at the preclinical research stage. No regulatory submissions or approvals have been announced yet. Overall SummaryAnima Biotech and Takeda have entered a strategic collaboration to discover and develop first-in-class small molecule drugs that modulate mRNA translation for neurological diseases, starting with Huntington’s Disease. The partnership could be worth up to $2.42 billion, with $120 million upfront and milestone payments, and options for additional programs and royalties. This collaboration leverages Anima's unique ribosome-targeted platform and Takeda's clinical strength in CNS to tackle previously undruggable targets. [collapse expanded text] |
Arvinas, Pfizer | Jul 2021 | 2400 | Collaboration, co-development and co-promotion agreement for PROTAC protein degrader ARV-471 | Arvinas and Pfizer announced a global collaboration to develop and commercialize ARV-471, an … read moreinvestigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The estrogen receptor is a well-known disease driver in most breast cancers. ARV-471 is currently in a Phase 2 dose expansion clinical trial for the treatment of patients with estrogen receptor (ER) positive / human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) locally advanced or metastatic breast cancer. Pfizer will pay Arvinas $650 million upfront. Separately, Pfizer will make a $350 million equity investment in Arvinas. The companies will equally share worldwide development costs, commercialization expenses, and profits. The agreement is a worldwide co-development and co-commercialization collaboration. ARV-471 is wholly owned by Arvinas and under the financial terms of the agreement, Pfizer will pay Arvinas $650 million upfront. Separately, Pfizer will invest $350 million in Arvinas, receiving approximately 3.5 million newly issued shares of Arvinas common stock, priced at a 30% premium to the 30-day volume weighted average price on July 20, 2021. This represents an equity ownership stake by Pfizer of approximately 7%. Arvinas is also eligible to receive up to $400 million in approval milestones and up to $1 billion in commercial milestones, in addition to sharing profits on ARV-471 worldwide. Arvinas and Pfizer will jointly develop ARV-471 through a robust clinical program designed to position ARV-471 as an endocrine backbone therapy of choice across the breast cancer treatment paradigm, from the adjuvant setting through late-line metastatic disease. [collapse expanded text] |
Kite Pharma, Shoreline Biosciences | Jun 2021 | 2300 | Collaboration and option agreement for allogeneic cell therapies | Kite and Shoreline Biosciences announced a strategic partnership to develop novel cell therapies … read moreacross a variety of cancer targets. The collaboration will leverage Shoreline’s deep expertise in iPSC differentiation and genetic reprogramming in combination with Kite’s extensive cell therapy development, commercialization and manufacturing expertise to develop novel allogeneic candidates for a range of hematologic malignancies. The collaboration will focus initially on chimeric antigen receptor NK targets, with Kite having an option to expand the collaboration to include an iPSC CAR Macrophage program for an undisclosed target to be selected post deal execution. This agreement follows Kite’s investment in Shoreline’s recent Series A financing. Shoreline will receive an upfront payment and will be eligible to receive additional payments totaling over $2.3 billion as well as royalties based on achievement of certain development and commercial milestones. [collapse expanded text] |
BeiGene, Novartis | Jan 2021 | 2200 | Collaboration, co-development, licensing, option and co-promotion agreement for tislelizumab | September 2023 Novartis and BeiGene have mutually agreed to terminate the collaboration and … read morelicense agreement for tislelizumab, a humanized IgG4 anti-PD-1 monoclonal antibody. BeiGene will re-assume all development and commercialization rights for tislelizumab, and Novartis will manufacture tislelizumab. Novartis and BeiGene are committed to working together to develop a transition plan to enable tislelizumab regulatory submissions to continue as planned and ensure smooth transition of activities. BeiGene will provide Novartis with ongoing clinical supply of tislelizumab to support its clinical trials. February 2021 BeiGene announced the closing of the collaboration and license agreement with Novartis Pharma to develop, manufacture, and commercialize BeiGene’s anti-PD-1 antibody tislelizumab in the United States, Canada, Mexico, member countries of the European Union, United Kingdom, Norway, Switzerland, Iceland, Liechtenstein, Russia, and Japan. The companies have agreed to jointly develop tislelizumab in these licensed countries, with Novartis responsible for regulatory submissions after a transition period and for commercialization upon regulatory approvals. In addition, both companies may conduct clinical trials globally to explore combinations of tislelizumab with other cancer treatments, and BeiGene has an option to co-detail the product in North America, funded in part by Novartis. BeiGene will receive an upfront cash payment of $650 million and is eligible to receive up to $1.3 billion upon the achievement of regulatory milestones, $250 million upon the achievement of sales milestones, and royalties on future sales of tislelizumab in the licensed territory. BeiGene will be responsible for funding ongoing clinical trials of tislelizumab, Novartis has agreed to fund new registrational, bridging, or post-marketing studies in its territory, and each party will be responsible for funding clinical trials evaluating tislelizumab in combination with its own or third-party agents. Each party retains worldwide rights to commercialize its proprietary products in combination with tislelizumab. January 2021 BeiGene announced a collaboration and license agreement with Novartis Pharma to develop, manufacture and commercialize BeiGene’s anti-PD-1 antibody tislelizumab in the United States, Canada, Mexico, member countries of the European Union, United Kingdom, Norway, Switzerland, Iceland, Liechtenstein, Russia, and Japan. The Companies have agreed to jointly develop tislelizumab in these licensed countries, with Novartis responsible for regulatory submissions after a transition period and for commercialization upon regulatory approvals. In addition, both companies may conduct clinical trials globally to explore combinations of tislelizumab with other cancer treatments, and BeiGene has an option to co-detail the product in North America, funded in part by Novartis. BeiGene will receive an upfront cash payment of $650 million from Novartis. BeiGene is eligible to receive up to $1.3 billion upon the achievement of regulatory milestones, $250 million upon the achievement of sales milestones, and royalties on future sales of tislelizumab in the licensed territory. BeiGene will be responsible for funding ongoing clinical trials of tislelizumab, Novartis has agreed to fund new registrational, bridging, or post-marketing studies in its territory, and each party will be responsible for funding clinical trials evaluating tislelizumab in combination with its own or third party products. Each party retains the worldwide right to commercialize its propriety products in combination with tislelizumab. [collapse expanded text] |
Primavera Capital Group, Reckitt Benckiser | Jun 2021 | 2200 | Asset purchase agreement for infant formula and child nutrition business | Reckitt Benckiser has entered into a definitive agreement to sell its Infant Formula and Child … read moreNutrition business in China to Primavera Capital Group for an implied enterprise value of US$2.2 billion. [collapse expanded text] |
Alector, GSK | Jul 2021 | 2200 | Collaboration, licensing and co-promotion agreement for AL001 and AL101 | Alector and GlaxoSmithKline announced a strategic global collaboration for the development and … read morecommercialization of two clinical-stage, potential first-in-class monoclonal antibodies (AL001 and AL101) designed to elevate progranulin (PGRN) levels. PGRN is a key regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders, making it one of the most attractive genetically validated targets for the development of new immuno-neurology treatments. The collaboration brings together Alector’s leading immuno-neurology expertise with GSK’s R&D focus on the science of the immune system and human genetics, proven late-stage drug development capabilities and global footprint. Enrollment is currently underway for a pivotal Phase 3 trial for AL001 in people at risk for or with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN). FTD-GRN is a rapidly progressing and severe form of dementia found most frequently in people less than 65 years old at the time of diagnosis and has no approved treatments. AL001 is also currently in a Phase 2 study in symptomatic FTD patients with a mutation in the C9orf72 gene and is planned to enter Phase 2 development for amyotrophic lateral sclerosis (ALS) in the second half of 2021. AL101 is in a Phase 1a clinical trial and is designed to treat patients suffering from more prevalent neurodegenerative diseases, including Parkinson’s disease and Alzheimer’s disease. Alector will receive $700 million in upfront payments. Alector will be eligible to receive up to an additional $1.5 billion in clinical development, regulatory and commercial launch-related milestone payments. Alector will lead the global clinical development of AL001 and AL101 through Phase 2 proof-of-concept. Thereafter, Alector and GSK will share development responsibilities for all late-stage clinical studies for AL001 and AL101 and all costs for global development will be divided between the two companies. The companies will be jointly responsible for commercialization in the U.S. and will share profits and losses. Alector will lead commercial efforts associated with AL001 in orphan indications and GSK will lead the commercialization of AL101 in Alzheimer’s and Parkinson’s disease. Outside the U.S., GSK will be responsible for commercialization of AL001 and AL101 and Alector will be eligible for tiered royalties. [collapse expanded text] |
Alnylam Pharmaceuticals, PeptiDream | Jul 2021 | 2200 | Collaboration and licensing agreement for peptide-siRNA conjugates for targeted delivery of RNAi therapeutics to a broader range of extrahepatic tissues | Alnylam Pharmaceuticals and PeptiDream announced a license and collaboration agreement to discover … read moreand develop peptide-siRNA conjugates to create multiple opportunities to deliver RNAi therapeutics to tissues outside the liver. Through this collaboration, the companies will collaborate to select and optimize peptides for targeted delivery of small interfering RNA (siRNA) molecules to a wide range of cell types and tissues via specific interactions with receptors expressed on the target cells. Alnylam will select a set of receptors for PeptiDream’s peptide discovery platform. PeptiDream will select, optimize, and synthesize peptides for each receptor. Alnylam will then generate peptide-siRNA conjugates and perform in vitro and in vivo studies to support final peptide selection. The collaboration has the potential to yield multiple treatment opportunities by targeting disease causing mRNA transcripts in a wide variety of tissue types. PeptiDream will receive an upfront payment from Alnylam as well as R&D funding over the term of the research collaboration, as provided in the agreement. PeptiDream may also receive payments based on the achievement of specified development, regulatory, and commercial milestones potentially totaling up to $2.2 billion (¥244 billion). PeptiDream is eligible to receive low-to-mid single digit royalties on sales on any such Alnylam products. [collapse expanded text] |
GSK, iTeos Therapeutics | Jun 2021 | 2075 | Co-development, licensing and co-promotion agreement for EOS-448 | iTeos Therapeutics and GlaxoSmithKline announced an agreement to co-develop and co-commercialise … read moreEOS-448, an anti-TIGIT monoclonal antibody currently in phase I development as a potential treatment for patients with cancer. TIGIT, part of the CD226 checkpoint axis, has demonstrated potential as a promising target for the next generation of immuno-oncology therapies based on compelling preclinical data and a phase II randomised clinical trial. With this collaboration GSK is uniquely positioned with access to antibodies that synergistically target all three known CD226 checkpoints - TIGIT, CD96 and PVRIG. iTeos will receive an upfront payment of $625 million. iTeos will be eligible to receive up to an additional $1.45 billion in milestone payments, should the EOS-448 programme achieve certain development and commercial milestones. GSK and iTeos will share responsibility and costs for the global development of EOS-448 and will jointly commercialise and equally split profits in the US. Outside of the US, GSK will receive an exclusive license for commercialisation and iTeos will receive tiered royalty payments. [collapse expanded text] |
Eli Lilly, Kumquat Biosciences, Loxo Oncology | Jul 2021 | 2070 | Collaboration agreement for small molecules that stimulate tumor-specific immune responses | Loxo Oncology and Kumquat Biosciences announced an exclusive collaboration focused on the discovery, … read moredevelopment and commercialization of potential novel small molecules that stimulate tumor-specific immune responses. Through the multi-year collaboration, Kumquat will utilize its small molecule immuno-oncology platform to discover novel clinical candidates and Lilly has the option to select a certain number of drug candidates for further development and commercialization worldwide, excluding Greater China. Kumquat has retained development and commercialization rights in Greater China for each of the drug candidates selected by Lilly, subject to Lilly's option to co-commercialize in Greater China. Kumquat has the option to co-develop and co-commercialize a certain number of the drug candidates selected by Lilly in the U.S. Kumquat will receive an aggregate of $70 million consisting of a cash upfront payment and an equity investment. Kumquat is eligible to receive over $2 billion in potential milestone payments based on the achievement of preclinical, development and future commercial milestones, as well as royalties on sales of commercialized products resulting from the collaboration. [collapse expanded text] |
MorphoSys, Royalty Pharma | Jun 2021 | 2025 | Royalty financing agreement for Tremfya | Royalty Pharma and MorphoSys announced a $2.025 billion strategic funding partnership as part of … read moreMorphoSys’ $1.7 billion acquisition of Constellation Pharmaceuticals. This partnership is expected to fuel the expansion of the combined company’s capabilities to help enable the development and potential approvals of important cancer treatments. This funding partnership is anchored by Royalty Pharma’s acquisition of MorphoSys’ rights to receive future royalties on Janssen’s Tremfya (guselkumab). Tremfya is an anti interleukin (IL)-23, approved for the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis and is also in clinical development for ulcerative colitis and Crohn’s disease. In 2020, Tremfya generated sales of $1.347 billion. Royalty Pharma will also acquire the rights to receive royalties and certain milestone payments on four attractive development-stage therapies: Gantenerumab, an anti-amyloid-beta monoclonal antibody, in Phase 3 development for Alzheimer’s disease by Roche. Royalty Pharma will purchase the rights to receive 60% of MorphoSys’ future royalties on gantenerumab. Otilimab, a fully human monoclonal antibody that inhibits granulocyte-macrophage colony-stimulating factor (GMCSF), in Phase 3 development for rheumatoid arthritis by GlaxoSmithKline. Royalty Pharma will purchase the rights to receive 80% of MorphoSys’ future royalties and 100% of its future milestones on otilimab. Pelabresib, a bromodomain and extra-terminal (BET) inhibitor for myelofibrosis, in Phase 3 development by Constellation. Royalty Pharma will purchase the rights to receive 3% of future net sales of pelabresib. CPI-0209, a second-generation enhancer of zeste homolog 2 (EZH2) inhibitor, in Phase 2 development for hematological malignancies and solid tumors by Constellation. Royalty Pharma will purchase the rights to receive 3% of future net sales of CPI-0209. [collapse expanded text] |
BridgeBio Pharma, Helsinn Therapeutics, QED Therapeutics | Mar 2021 | 2000 | Co-development, licensing and co-promotion agreement for Infigratinib in oncology | March 2022 Helsinn and BridgeBio Pharma announced an update to their existing strategic … read morecollaboration to develop, manufacture and commercialize infigratinib for oncology indications. Helsinn will gain an exclusive license to commercialize infigratinib in the U.S. and will be responsible for developing, manufacturing and commercializing infigratinib in oncology indications worldwide except for achondroplasia or any other skeletal dysplasias and except in mainland China, Hong Kong and Macau. BridgeBio will be eligible to receive regulatory and commercial milestone payments as well as tiered royalties on adjusted net sales from Helsinn. BridgeBio will retain all rights to develop, manufacture and commercialize infigratinib in skeletal dysplasia, including achondroplasia. March 2021 QED Therapeutics and Helsinn Group announced a global collaboration and licensing agreement to further develop and commercialize QED Therapeutics’ FGFR1-3 inhibitor, infigratinib, in oncology and all other indications except for skeletal dysplasias (including achondroplasia). Completion of the Agreement is subject to regulatory review and customary closing conditions, which are expected to occur in the second quarter of 2021. BridgeBio will retain all rights to infigratinib in skeletal dysplasia, including achondroplasia. Subject to U.S. Food and Drug Administration approval, QED and Helsinn will co-commercialize infigratinib in oncology indications in the U.S. and will share profits and losses on a 50:50 basis. Helsinn will have exclusive commercialization rights and lead commercialization for infigratinib in non-skeletal dysplasia indications outside of the U.S., excluding China, Hong Kong and Macau, which are covered by BridgeBio’s strategic development and commercialization collaboration with LianBio. BridgeBio will be eligible to receive more than $2 billion in upfront, regulatory and commercial milestones, as well as tiered royalties on adjusted net sales from Helsinn Group. BridgeBio and Helsinn Group intend to pursue an ambitious co-development plan in oncology indications, including clinical investigation underway in first-line cholangiocarcinoma and adjuvant urothelial cancer. This plan will be underpinned by close collaboration among the parties, with the aim of developing new treatments for patients with FGFR-driven cancers. As infigratinib heads toward potential approval and commercialization in a range of oncology indications, Helsinn’s unique integrated licensing business model will enable its distribution to reach patients globally. [collapse expanded text] |
Covestro, DSM | Apr 2021 | 1896 | Asset purchase agreement for resins and functional materials and associated businesses | Royal DSM announced the completion of the sale of its Resins & Functional Materials and … read moreassociated businesses to Covestro for an equity value of €1.6 billion. The proposed sale of RFM was first announced on 30 September 2020. The transaction covers DSM's Resins & Functional Materials businesses, including DSM Niaga, DSM Additive Manufacturing, and the coatings activities of DSM Advanced Solar. [collapse expanded text] |
Artiva Biotherapeutics, Merck and Co | Jan 2021 | 1881 | Collaboration, option and licensing agreement for CAR-NK cell therapies | Artiva Biotherapeutics has entered into an exclusive worldwide collaboration and license agreement … read morewith Merck to develop novel chimeric antigen receptor (CAR)-NK cell therapies targeting solid tumor-associated antigens. The collaboration will leverage Artiva’s off-the-shelf allogeneic NK cell manufacturing platform, along with its proprietary CAR-NK technology. The collaboration initially includes two CAR-NK programs with an option for a third, none of which are in Artiva’s current or planned pipeline. The agreement provides that Artiva will develop the CAR-NK programs through the first GMP manufacturing campaign and IND preparation, followed by transfer to Merck for clinical and commercial development. Artiva will receive a $30 million upfront payment for the first two programs and an additional $15 million payment if Merck exercises its option for a third program. Artiva is also eligible to receive future development and commercial milestones of up to $612 million per program and royalties are payable by Merck on worldwide sales of any product derived from the collaboration. Merck agreed to provide research funding to Artiva for each of the programs under the collaboration. [collapse expanded text] |
Abbvie, Regenxbio | Sep 2021 | 1750 | Collaboration, co-promotion, licensing and manufacturing agreement for RGX-314 | AbbVie and REGENXBIO announced a partnership to develop and commercialize RGX-314, a potential one- … read moretime gene therapy for the treatment of wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases. RGX-314 is currently being evaluated in patients with wet AMD in a pivotal trial utilizing subretinal delivery, and in patients with wet AMD and DR in two separate Phase II clinical trials utilizing in-office suprachoroidal delivery. REGENXBIO will be responsible for completion of the ongoing trials of RGX-314. AbbVie and REGENXBIO will collaborate and share costs on additional trials of RGX-314, including the planned second pivotal trial evaluating subretinal delivery for the treatment of wet AMD and future trials. AbbVie will lead the clinical development and commercialization of RGX-314 globally. REGENXBIO shall participate in U.S. commercialization efforts as provided under a mutually agreed upon commercialization plan. Vie will pay REGENXBIO a $370 million upfront payment with the potential for REGENXBIO to receive up to $1.38 billion in additional development, regulatory and commercial milestones. REGENXBIO and AbbVie will share equally in profits from net sales of RGX-314 in the U.S. AbbVie will pay REGENXBIO tiered royalties on net sales of RGX-314 outside the U.S. REGENXBIO will lead the manufacturing of RGX-314 for clinical development and U.S. commercial supply, and AbbVie will lead manufacturing of RGX-314 for commercial supply outside the U.S. [collapse expanded text] |
Eli Lilly, Foghorn Therapeutics, Loxo Oncology | Dec 2021 | 1680 | Co-development and co-promotion agreement for oncology targets using Gene Traffic Control platform | February 2024 Foghorn Therapeutics announced that Lilly has selected FHD-909, a first-in-class … read moreoral BRM selective inhibitor, for clinical development. Lilly plans to file an IND for FHD-909 in Q2 2024. The primary target patient population is BRG1 mutated non-small cell lung cancer. December 2021 Loxo Oncology at Lilly and Foghorn Therapeutics announced a strategic collaboration to create novel oncology medicines by applying Foghorn’s proprietary Gene Traffic Control platform. The collaboration includes a co-development and co-commercialization agreement for Foghorn’s selective BRM oncology program and an additional undisclosed oncology target. In addition, the collaboration includes three additional discovery programs using Foghorn’s proprietary Gene Traffic Control platform. Foghorn will receive upfront consideration of $300 million in cash for the collaboration agreement and an equity investment by Lilly of $80 million in Foghorn common shares at a price of $20 per share. For the BRM-selective program and the additional undisclosed target program, Foghorn will lead discovery and early research activities, while Lilly will lead development and commercialization activities with participation from Foghorn in operational activities and cost sharing. Foghorn and Lilly will share 50/50 in the U.S. economics, and Foghorn is eligible to receive royalties on ex-U.S. sales starting in the low double-digit range and escalating into the twenties based on revenue levels. For the additional discovery programs, Foghorn will lead discovery and early research activities. Foghorn may receive up to a total of $1.3 billion in potential development and commercialization milestones. Foghorn will have an option to participate in a percentage of the U.S. economics and is eligible to receive tiered royalties from the mid-single digit to low-double digit range on sales outside the U.S. that may be exercised after the successful completion of the dose-finding toxicity studies. [collapse expanded text] |
Eli Lilly, Loxo Oncology, Merus | Jan 2021 | 1660 | Collaboration agreement for T-cell re-directing bispecific antibodies | Loxo Oncology at Lilly and Merus announced a research collaboration and exclusive license agreement … read morethat will leverage Merus' proprietary Biclonics platform along with the scientific and rational drug design expertise of Loxo Oncology at Lilly to research and develop up to three CD3-engaging T-cell re-directing bispecific antibody therapies. Merus will lead discovery and early stage research activities while Loxo Oncology at Lilly will be responsible for additional research, development and commercialization activities. Merus will receive an upfront cash payment of $40 million, as well as an equity investment by Lilly of $20 million in Merus common shares. Merus is also eligible to receive up to $540 million in potential development and commercialization milestones per product, for a total of up to approximately $1.6 billion for three products, as well as tiered royalties ranging from the mid-single to low-double digits on product sales should Lilly successfully commercialize a therapy from the collaboration. [collapse expanded text] |
Eli Lilly, Lycia Therapeutics | Aug 2021 | 1635 | Collaboration and licensing agreement for lysosomal targeting chimera degraders | Eli Lilly and Lycia Therapeutics announced a multi-year research collaboration and licensing … read moreagreement focused on the discovery, development and commercialization of novel targeted therapeutics using Lycia's proprietary lysosomal targeting chimera, or LYTAC, protein degradation technology. Under the terms of the agreement, the companies will utilize Lycia's LYTAC platform to discover and develop novel degraders for up to five targets that aim to address key unmet medical needs in Lilly's therapeutic areas of focus, including immunology and pain. Lilly will be solely responsible for preclinical and clinical development of candidates and receives an exclusive worldwide license to commercialize potential medicines resulting from the agreement. Lycia will receive an upfront payment of $35 million. The company is also eligible to receive over $1.6 billion in potential milestone payments based on the achievement of prespecified preclinical, development and commercial milestones, as well as tiered royalties from mid-single to low double-digits on sales resulting from the agreement. [collapse expanded text] |
Astellas Pharma, Dyno Therapeutics | Dec 2021 | 1618 | Collaboration, option and licensing agreement for next-generation AAV gene therapy vectors for skeletal and cardiac muscle | Astellas Pharma and Dyno Therapeutics announced an option and license agreement was signed on … read moreNovember 23 to develop next-generation adeno-associated virus vectors for gene therapy directed to skeletal and cardiac muscle using Dyno's CapsidMap platform. Dyno will design novel AAV capsids with improved functional properties for gene therapy, while Astellas will be responsible for conducting preclinical, clinical and commercialization activities, including manufacturing, of gene therapy product candidates using the novel capsids. Dyno will receive an $18 million upfront payment and be eligible to receive additional payments during the research phase of the collaboration as well as clinical and sales milestone payments and royalties for any resulting products. The aggregate potential value of future milestone and royalty payments to Dyno exceeds $235 million per product and over $1.6 billion in total value. [collapse expanded text] |
Agenus Bio, Bristol-Myers Squibb | May 2021 | 1560 | Licensing and co-promotion agreement for AGEN1777 anti-TIGIT bispecific antibody program | August 2024 Agenus announced in SEC filing that Bristol Myers Squibb is returning rights to … read morebiotech for its proprietary TIGIT bispecific antibody program and their 2021 licensing agreement December 2023 Agenus has triggered the second development milestone payment under its global licensing agreement with Bristol Myers Squibb Company for BMS-986442, an Fc-enhanced bispecific TIGIT antibody. Agenus will receive a $25 million cash payment from Bristol Myers Squibb with the dosing of the first patient in the phase 2 dose expansion portion of the ongoing CA115-001 clinical trial of BMS-986442. May 2021 Bristol Myers Squibb and Agenus have entered into a definitive agreement under which Bristol Myers Squibb will be granted a global exclusive license to Agenus’ proprietary bispecific antibody program, AGEN1777, that blocks TIGIT and a second undisclosed target. AGEN1777 is an Fc-enhanced antibody in late preclinical development designed to target major inhibitory receptors expressed on T and NK cells to improve anti-tumor activity. In preclinical studies this approach has shown significant potential in tumor models where anti-PD-1 or anti-TIGIT monospecific antibodies alone are ineffective. Bristol Myers Squibb will become solely responsible for the development and any subsequent commercialization of AGEN1777 and its related products worldwide. Agenus will receive a $200 million upfront payment and up to $1.36 billion in development, regulatory and commercial milestones in addition to tiered double-digit royalties on net product sales. Agenus will retain options to conduct clinical studies under the development plan, to conduct combination studies with certain other Agenus pipeline assets, and also, upon commercialization, to co-promote AGEN1777 in the US. [collapse expanded text] |
Alpine Immune Sciences, Horizon Therapeutics | Dec 2021 | 1560 | Collaboration and licensing agreement for protein-based therapies for autoimmune and inflammatory diseases | Alpine Immune Sciences and Horizon Therapeutics announced an exclusive license and collaboration … read moreagreement for the development and commercialization of up to four preclinical candidates generated from Alpine’s unique discovery platform. The overall agreement includes licensing of a lead, potential first-in-class preclinical candidate, as well as a research collaboration to jointly generate additional novel candidates. These candidates include previously undisclosed multi-specific fusion protein-based therapeutic candidates for autoimmune and inflammatory diseases. Horizon will make an upfront payment to Alpine of $25 million as well as an equity investment in Alpine of $15 million at a 25 percent premium to the 30-day volume-weighted average share price. Alpine is eligible to receive up to $381 million per program, or approximately $1.52 billion in total, in future success-based payments related to development, regulatory and commercial milestones as well as tiered royalties on global net sales. Alpine will advance candidate molecules to pre-defined preclinical milestones. Horizon will then assume responsibility for development and commercialization activities and costs. [collapse expanded text] |
Eli Lilly, Regor Therapeutics | Dec 2021 | 1550 | Collaboration, option and licensing agreement for therapies for metabolic disorders | Eli Lilly and Regor Therapeutics have entered into a multi-year research collaboration and … read morelicensing agreement to discover, develop and commercialize novel therapies for metabolic disorders. Lilly will have a license to select Regor intellectual property with an option to extend the license. Lilly will be responsible for clinical development, manufacturing and commercialization worldwide, except for People's Republic of China, Macau, Hong Kong and Taiwan, where Regor will maintain these rights and responsibilities. The agreement will allow each company the opportunity to fully leverage both parties' existing compounds and technologies globally to maximize patient treatment choice. Regor will receive an upfront payment of up to $50 million, which partially includes an equity investment by Lilly in Regor, subject to the parties entering into standard equity agreements. The company is also eligible to receive up to $1.5 billion in potential payments based on the achievement of prespecified preclinical, clinical development and commercial milestones, as well as tiered royalties from low-single to low-double digits on sales resulting from the agreement. [collapse expanded text] |
Altaris Capital Partners, Perrigo | Mar 2021 | 1500 | Asset purchase agreement for generics business | Perrigo has reached a definitive agreement to sell its Generic Rx Pharmaceuticals business to … read moreAltaris Capital Partners for total consideration of $1.55 billion, including $1.5 billion in cash, subject to customary adjustments. As part of the consideration, Altaris will also assume more than $50 million in potential R&D milestone payments and contingent purchase obligations with third-party Rx partners. [collapse expanded text] |
Novartis, UCB | Dec 2021 | 1500 | Co-development, option and co-promotion agreement for UCB0599 and UCB7853 | UCB has entered into a global co-development and co-commercialization agreement with Novartis … read morecovering UCB0599, a potential first in class, small molecule, alpha-synuclein misfolding inhibitor currently in Phase 2 clinical development, and upon completion of the ongoing Phase 1 program, an opt-in to co-develop UCB7853, an anti-alpha-synuclein antibody, both in Parkinson's Disease (PD). Under the terms of the agreement, the parties will co-develop and co-fund the further global development of UCB0599. Novartis also have the right to "opt-in" to engage in global co-development of UCB7853 upon completion of a Phase 1 study currently being run by UCB. Further clinical development would then also be jointly funded and managed. UCB will receive an upfront payment of US$150 million and is eligible to receive further potential payments with a total consideration approaching US$1.5 billion upon receipt of certain regulatory approvals and satisfying certain development and sales related milestones. If approved, commercial responsibilities will be split, with UCB being the marketing authorization holder and commercial lead in Europe and Japan, and Novartis in the US and all other territories. [collapse expanded text] |
Macrogenics, ZAI Laboratory | Jun 2021 | 1485 | Collaboration, option and licensing agreement for bispecific antibodies in oncology | MacroGenics and Zai Lab have entered into an exclusive collaboration and license agreement … read moreinvolving up to four immuno-oncology molecules. The first collaboration program covers a lead research molecule that incorporates MacroGenics’ DART platform and binds CD3 and an undisclosed target that is expressed in multiple solid tumors. The next-generation CD3 component of the DART bispecific molecule has been designed to minimize cytokine-release syndrome while maintaining anti-tumor cytolytic activity. The second collaboration program will cover a target to be designated by MacroGenics. For both molecules, Zai receives commercial rights in Greater China, Japan, and Korea and MacroGenics receives commercial rights in all other territories. For the lead molecule, Zai Lab receives an option upon reaching a predefined clinical milestone to convert the regional arrangement into a global 50/50 profit share. Zai Lab also obtains exclusive, global licenses from MacroGenics to develop, manufacture and commercialize two additional molecules. For the four programs, each company will contribute intellectual property to generate either CD3- or CD47-based bispecific antibodies. MacroGenics receives initial consideration from Zai Lab of $55 million, including an upfront payment of $25 million and an equity investment of $30 million in MacroGenics’ common stock at $31.30 per share. In addition, MacroGenics is eligible to receive up to $1.4 billion in potential development, regulatory and commercial milestone payments for the four programs. If products from the collaboration are commercialized, MacroGenics would also receive royalties on annual net sales in Zai Lab’s territories. [collapse expanded text] |
Genentech, Pieris Pharmaceuticals | May 2021 | 1420 | Collaboration and licensing agreement for locally delivered respiratory and ophthalmology therapies that leverage Anticalin technology | Pieris has entered into a multi-program research collaboration and license agreement with Genentech … read moreto discover, develop and commercialize locally delivered respiratory and ophthalmology therapies that leverage Pieris' proprietary Anticalin technology. The research collaboration will enable Pieris to combine its robust discovery engine with Genentech's targets, as well as its preclinical and clinical development expertise, to create novel therapies for the treatment of respiratory and ophthalmological diseases. These two focus areas of the collaboration are uniquely suited to the advantages offered by the small size of Anticalin proteins when delivered locally. Pieris will receive $20 million as an upfront payment and may be eligible to receive more than $1.4 billion in additional milestone payments across multiple programs, as well as tiered royalties for commercialized programs. Pieris will be responsible for discovery research and early preclinical development of the programs, and Genentech will be responsible for IND-enabling activities, clinical development, and commercialization of those programs. Genentech will also have the option to select additional targets in return for an option exercise fee. The collaboration does not include any of Pieris' internal programs. [collapse expanded text] |
Obsidian Therapeutics, Vertex Pharmaceuticals | Apr 2021 | 1375 | Collaboration, option and licensing agreement for therapies that regulate gene editing | Vertex Pharmaceuticals and Obsidian Therapeutics have entered into a strategic research … read morecollaboration and licensing agreement focused on the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The collaboration leverages Obsidian’s cytoDRiVE platform technology to discover gene-editing medicines whose therapeutic activity can be precisely controlled using small molecules and Vertex’s established scientific and clinical capabilities in small molecule, cell and genetic therapies to more rapidly bring these approaches to patients. Obsidian will use its cytoDRiVE technology to develop novel regulated gene editing therapy candidates for multiple serious diseases. Obsidian grants Vertex the exclusive option to license worldwide rights to candidates discovered and developed under the collaboration. Following Vertex’s exercise of its options, Vertex will be responsible for further preclinical and clinical development and commercialization. Vertex will pay Obsidian up to $75 million in upfront payments and research milestones that may be paid during the research term, including an equity investment in Obsidian. Obsidian is eligible to receive up to $1.3 billion in potential payments based upon the successful achievement of specified research, development, regulatory, and commercial milestones across up to five potential programs. Vertex will pay tiered royalties on future net sales on any products that may result from this collaboration. Specific diseases that are the subject of this collaboration are not disclosed. [collapse expanded text] |
Bristol-Myers Squibb, Molecular Templates | Feb 2021 | 1370 | Collaboration, option and licensing agreement for next generation engineered toxin bodies for cancer | Molecular Templates has entered into a worldwide strategic research collaboration with Bristol- … read moreMyers Squibb to discover and develop multiple novel therapies designed for specific oncology targets. The collaboration will seek to discover new molecules utilizing MTEM’s next generation engineered toxin body (ETB) platform. ETBs represent a new class of targeted therapeutics that act through differentiated mechanisms of actions including the ability to force receptor internalization, deliver therapeutic payloads, and directly kill targeted cells through the enzymatic inactivation of ribosomes. MTEM will conduct research activities for the discovery of next generation ETBs for multiple targets, of which the first target has been selected by Bristol Myers Squibb. Bristol Myers Squibb will have the option to obtain an exclusive worldwide license to develop and commercialize ETBs directed to each selected target. Following the exercise of the option, Bristol Myers Squibb would be solely responsible for developing and commercializing the licensed ETBs. Bristol Myers Squibb will make an up-front payment of $70 million to MTEM. MTEM is also eligible to receive near-term and development, regulatory and sales milestone payments of up to approximately $1.3 billion as well as tiered royalty payments on future sales. [collapse expanded text] |
F-Star Therapeutics, Janssen Biotech | Oct 2021 | 1367.5 | Licensing agreement for multiple next generation bispecific antibody therapeutics | f-Star has entered into a license and collaboration agreement with Janssen Biotech. F-star will … read moregrant Janssen a worldwide, exclusive royalty-bearing license to research, develop, and commercialize up to five novel bispecific antibodies directed to Janssen therapeutic targets using F-star’s proprietary Fcab and mAb2 platforms. Janssen will be responsible for all research, development, and commercialization activities under the agreement. F-star is entitled to receive upfront fees of $17.5 million, near-term fees and potential further milestones of up to $1.35 billion. F-star is also eligible to receive potential tiered mid-single digit royalties on annual net sales. [collapse expanded text] |
Dunad Therapeutics, Novartis | Nov 2021 | 1324 | Collaboration, option and licensing agreement for next-generation oral targeted protein degrader therapies | Dunad Therapeutics has entered a strategic collaboration and license agreement with Novartis to … read moregenerate orally bioavailable covalent and protein degrading small molecule drugs. Dunad will apply its tunable and highly selective platform to generate novel covalent and targeted protein degrading small molecule drugs focusing on up to four drug targets agreed with Novartis. Dunad will also be responsible for program execution up to lead optimization. Novartis will contribute target and ligand knowledge as well as access to unique assays and models and will fully fund the research collaboration. Novartis has an exclusive option to develop and commercialize products resulting from the research programs directed against up to four drug targets. Upon exercise of this option, Novartis will assume responsibility for future development, manufacturing and global commercialization of the small molecule therapeutic products generated against the agreed targets. Dunad will receive $24 million in an upfront payment and equity investment, as well as significant research funding. Dunad will also be eligible for milestone payments that could aggregate to up to $1.3 billion and royalties. Alongside the equity investment of Novartis, and the founding investor Epidarex Capital, BioGeneration Ventures (BGV) is joining Dunad as a new investor. Oskar Slotboom, General Partner at BGV, has joined Dunad's Board of Directors. [collapse expanded text] |
Artios Pharma, Novartis | Apr 2021 | 1320 | Collaboration and licensing agreement for next generation DDR cancer therapies | Artios Pharma announced a global research collaboration with Novartis to discover and validate next … read moregeneration DDR targets to enhance Novartis' Radioligand Therapies. Artios and Novartis will perform target discovery and validation, and Novartis will select up to three exclusive DDR targets, and receive worldwide rights on these targets to be utilized with its RLT’s. Novartis will make an up-front payment of US$20 million and provide near term research funding to support the collaboration. Artios will be eligible to receive discovery, development, regulatory and sales-based milestones, in addition to royalty payments on net sales of products commercialized by Novartis. The collaboration does not include Artios’ lead programs, ART0380, which is currently in clinical development, or ART4215, a first-in-class Pol Theta inhibitor. [collapse expanded text] |
Jiangsu Hansoh Pharmaceutical, Silence Therapeutics | Oct 2021 | 1316 | Collaboration, option and licensing agreement for therapeutics leveraging mRNAi GOLD platform | July 2023 Silence Therapeutics will receive a $4.0 million cash payment from Hansoh … read morePharmaceutical following the achievement of two undisclosed preclinical milestones. April 2022 Silence Therapeutics will receive a $2.0 million cash payment from Hansoh Pharmaceutical Group following the achievement of an undisclosed preclinical milestone. October 2021 Silence Therapeutics and Hansoh Pharmaceutical announced a collaboration to develop siRNAs for three undisclosed targets leveraging Silence’s proprietary mRNAi GOLD platform. Hansoh will have the exclusive option to license rights to the first two targets in Greater China, Hong Kong, Macau and Taiwan following the completion of phase 1 studies. Silence will retain exclusive rights for those two targets in all other territories. Silence will be responsible for all activities up to option exercise and will retain responsibility for development outside the China region post phase 1 studies. Hansoh will also have the exclusive option to license global rights to a third target at the point of IND filing. Hansoh will be responsible for all development activities post option exercise for the third target. Hansoh will make a $16 million upfront payment and Silence is eligible to receive up to $1.3 billion in additional development, regulatory and commercial milestones. Silence will also receive royalties tiered from low double-digit to mid-teens on Hansoh net product sales. [collapse expanded text] |
Janssen Biotech, Xencor | Oct 2021 | 1313 | Collaboration, licensing and co-promotion agreement for Plamotamab and XmAb CD28 bispecific antibody combinations for B-cell malignancies | Xencor announced an exclusive collaboration and worldwide license agreement with Janssen Biotech to … read moredevelop and commercialize plamotamab and novel XmAb B-cell targeting bispecific antibodies that are designed to conditionally activate T cells through the CD28 co-stimulatory receptor. Plamotamab is a CD20 x CD3 XmAb bispecific antibody and is currently completing a Phase 1 dose-escalation study in patients with CD20-expressing hematologic malignancies. Janssen will receive worldwide exclusive development and commercialization rights to plamotamab, whether as a monotherapy or in combination regimens. Xencor will collaborate with Janssen on further clinical development of plamotamab with Janssen paying 80% and Xencor paying 20% of costs, including those for a subcutaneous formulation anticipated to enter clinical trials in 2022. In parallel, Xencor will continue, at its own expense, a previously announced clinical collaboration to evaluate the combination of plamotamab, tafasitamab and lenalidomide in patients with B-cell lymphoma, including a Phase 2 trial in relapsed or refractory diffuse large B-cell lymphoma anticipated to start in late 2021 or early 2022. Further, Xencor will apply its XmAb bispecific Fc technology to create and characterize XmAb CD28 bispecific antibody candidates against B-cell targets during a two-year joint research collaboration, and Janssen will have an exclusive worldwide license to develop selected molecules in combination with plamotamab and other agents, such as CD3 bispecific antibodies. Xencor will receive an upfront payment of $100 million, and Johnson & Johnson Innovation will purchase $25 million of newly issued shares of Xencor common stock. Xencor will be eligible to receive up to $1.188 billion in potential development, regulatory and sales milestone payments, as well as tiered royalties on net sales of products developed under the agreement, ranging from mid-teen to low-twenties percentages for products containing plamotamab and plamotamab/CD28 bispecific antibody combinations. Separate terms apply to CD28 bispecific antibodies commercialized outside of a plamotamab combination, where Xencor retains an option to co-fund development costs in exchange for higher royalties and the right to co-detail such products in the United States. [collapse expanded text] |
Biogen, Capsigen | May 2021 | 1307 | Collaboration and licensing agreement for AAV capsids for targeted CNS and neuromuscular disorders | Biogen and Capsigen have entered into a strategic research collaboration to engineer novel adeno- … read moreassociated virus capsids that have the potential to deliver transformative gene therapies that address the underlying genetic causes of various CNS and neuromuscular disorders. Capsigen’s proprietary TRADE platform and associated technologies will be utilized with the aim to create and identify novel AAV capsids tailored to meet disease-specific transduction profiles. Capsids are the protein coat that protects and facilitates delivery of the virus’ genetic payload into host cells. The collaboration will leverage Capsigen’s capsid engineering expertise and Biogen’s discovery, development, manufacturing and commercialization capabilities with the goal to accelerate delivery of gene therapies to patients in need. Capsigen will apply its vector engineering approaches to develop novel capsids designed to meet highly customized, disease-specific transduction profiles. Biogen will receive an exclusive license under Capsigen’s proprietary technology for an undisclosed number of CNS and neuromuscular disease targets. Capsigen will receive a $15 million upfront payment and is eligible to receive up to $42 million in potential research milestones and up to an additional $1.25 billion in potential development and commercial payments should the collaboration programs achieve certain developmental milestones and sales thresholds. Capsigen is also eligible to receive royalties on future net sales of products that incorporate capsids resulting from the collaboration. [collapse expanded text] |
Ensoma, Takeda Pharmaceutical | Feb 2021 | 1250 | Collaboration and licensing agreement for Engenious vectors for up to five rare disease indications | Ensoma has entered into a strategic collaboration with Takeda Pharmaceutical. The agreement … read moregrants Takeda an exclusive worldwide license to Ensoma’s Engenious vectors for up to five rare disease indications. Takeda will make an equity investment of $10 million in Ensoma’s Series A Preferred Stock with the potential for $100 million in upfront and preclinical research payments. In total, assuming success for five programs, Ensoma is eligible to receive up to $1.25 billion from Takeda, including additional development and commercialization milestone payments and up to low double-digit royalties on net sales of each product. Takeda is granted an exclusive worldwide license to Ensoma’s Engenious vector technology platform for up to five rare genetic disease indications. Ensoma will conduct preclinical research activities for the Takeda programs, and both parties will share in responsibilities leading to submission of Investigational New Drug applications. Takeda will lead development activities thereafter. [collapse expanded text] |
Eli Lilly, MiNA Therapeutics | May 2021 | 1250 | Research and licensing agreement for drug candidates using small activating RNA technology platform | Eli Lilly and MiNA Therapeutics announced a global research collaboration to develop novel drug … read morecandidates using MiNA's proprietary small activating RNA (saRNA) technology platform. MiNA will utilize its saRNA platform to research up to five targets selected by Lilly that aim to address diseases across Lilly's key therapeutic focus areas. Lilly will be responsible for preclinical and clinical development of candidates and will retain exclusive commercialization rights for any products resulting from the collaboration. MiNA will receive a $25 million upfront payment and is eligible to receive potential development and commercialization milestones up to a total of $245 million per target, as well as tiered royalties from the low-single to low-double digits on product sales resulting from the collaboration. [collapse expanded text] |
Amgen, Kyowa Hakko Kirin | Jun 2021 | 1250 | Co-development, licensing and co-promotion agreement for KHK4083 | Amgen and Kyowa Kirin announced an agreement to jointly develop and commercialize KHK4083, which is … read moreKyowa Kirin's potential first-in-class, Phase 3-ready anti-OX40 fully human monoclonal antibody in development for the treatment of atopic dermatitis, with potential in other autoimmune diseases. Amgen will lead the development, manufacturing, and commercialization for KHK4083 for all markets globally, except Japan, where Kyowa Kirin will retain all rights. Kyowa Kirin will co-promote KHK4083 with Amgen in the U.S. and have opt-in rights to co-promote KHK4083 in certain other markets outside the U.S., including in Europe and Asia. Amgen will make a $400 million up-front payment to Kyowa Kirin and future contingent milestone payments potentially worth up to an additional $850 million, as well as significant royalty payments on future global sales. Kyowa Kirin and Amgen will share global development costs, except in Japan, and U.S. commercialization costs. Amgen will consolidate sales for KHK4083 in all markets globally, except for Japan. Amgen also will leverage unique data from its deCODE Genetics subsidiary to inform the potential use of KHK4083 in indications beyond atopic dermatitis. [collapse expanded text] |
Biohaven Pharmaceuticals, Pfizer | Nov 2021 | 1240 | Collaboration and licensing agreement for Rimegepant and Zavegepant | Biohaven Pharma and Pfizer announced a strategic commercialization arrangement for rimegepant in … read moremarkets outside of the United States upon approval. Rimegepant is commercialized as Nurtec ODT in the U.S., and is indicated for the acute treatment of migraine attacks with or without aura and the preventive treatment of episodic migraine in adults. An application for the approval of rimegepant is currently under review by the European Medicines Agency and several additional regulatory authorities outside of the U.S. Biohaven would remain primarily responsible for further clinical development of rimegepant and the parties will cooperate in regulatory activities to secure approval for the product. Biohaven will continue to solely commercialize Nurtec ODT in the U.S and Pfizer would commercialize rimegepant, upon approval, in all regions outside the U.S. Pfizer gains rights outside of the U.S. to zavegepant, a third generation, high affinity, selective and structurally unique, small molecule CGRP receptor antagonist, currently being studied in an intranasal delivery and a soft-gel formulation in Phase 3 clinical trials for migraine indications. Biohaven and Pfizer are entering into a collaboration and license agreement and related sublicense agreement pursuant to which Pfizer will acquire rights to commercialize rimegepant and zavegepant outside of the U.S. Biohaven will continue to lead research and development globally and Pfizer would execute commercialization globally, outside of the U.S. Pfizer will make an upfront payment of $500 million, consisting of $150 million cash and $350 million in the purchase of Biohaven equity at a 25 percent market premium. Biohaven is also eligible to receive up to $740 million in milestones. In addition to the tiered double-digit royalties owed to Biohaven on net sales outside of the U.S., Pfizer will compensate Biohaven for the related royalties on net sales outside of the U.S. owed under the Company's license and funding agreements with Bristol-Myers Squibb Company and Royalty Pharma. As noted above, in connection with the transaction, Pfizer will make a $350 million investment in the common shares of Biohaven. [collapse expanded text] |
Bristol-Myers Squibb, Exscientia | May 2021 | 1200 | Collaboration and licensing agreement for AI to accelerate the discovery of small molecule therapeutic drug candidates | August 2021 Exscientia announced that Bristol-Myers Squibb has elected to in-license an immune- … read moremodulating drug candidate created by Exscientia. Exscientia has two active collaborations with Bristol Myers Squibb, which together focus on multiple therapeutic areas, including oncology and immunology. Bristol Myers Squibb will be responsible for clinical and commercial development of the drug candidate. Exscientia will receive a $20 million option exercise fee with the potential for additional development milestones as well as tiered royalties on any product sales. May 2021 Exscientia has entered into a collaboration agreement with Bristol-Myers Squibb. This collaboration has the potential to add to the Bristol Myers Squibb drug pipeline whilst enhancing Exscientia’s portfolio of shared assets. The collaboration will use AI to accelerate the discovery of small molecule therapeutic drug candidates in multiple therapeutic areas, including oncology & immunology. The agreement includes up to $50 million in upfront funding, up to $125 million in near to mid-term potential milestones, and additional clinical, regulatory and commercial payments that take the potential value of the deal beyond $1.2 billion. Exscientia will also receive tiered royalties on net sales of any marketed drug products resulting from the collaboration. [collapse expanded text] |
Merck and Co, US Government | Jun 2021 | 1200 | Supply agreement for Molnupiravir | Merck has entered into a procurement agreement with the United States government for molnupiravir ( … read moreMK-4482). Through the agreement, if molnupiravir receives Emergency Use Authorization or approval by the U.S. Food and Drug Administration, Merck will receive approximately $1.2 billion to supply approximately 1.7 million courses of molnupiravir to the United States government. Merck has been investing at risk to support development and scale-up production of molnupiravir and expects to have more than 10 million courses of therapy available by the end of 2021. [collapse expanded text] |
Novo Nordisk, Prothena | Jul 2021 | 1200 | Asset purchase and licensing agreement for PRX004 and ATTR Amyloidosis Programme | Prothena and Novo Nordisk have entered into a definitive purchase agreement under which Novo … read moreNordisk has acquired Prothena’s clinical stage antibody PRX004 and broader ATTR amyloidosis programme. Novo Nordisk will initially focus on the clinical development of PRX004 in ATTR cardiomyopathy - an underdiagnosed and potentially fatal form of ATTR amyloidosis characterised by build-up of amyloid deposits in cardiac tissue. Novo Nordisk acquires Prothena’s wholly-owned subsidiary and gains full worldwide rights to the intellectual property and related rights of Prothena’s ATTR amyloidosis business and pipeline. Prothena is eligible to receive development and sales milestone payments totalling up to 1.2 billion US dollars including 100 million dollars in upfront and near-term clinical milestone payments. [collapse expanded text] |
Arbor Biotechnologies, Vertex Pharmaceuticals | Aug 2021 | 1200 | Collaboration agreement for ex vivo engineered cell therapies | Vertex Pharmaceuticals and Arbor Biotechnologies announced a collaboration to enhance efforts in … read moredeveloping ex vivo engineered cell therapies, using Arbor’s proprietary CRISPR gene-editing technology for select diseases. Vertex will receive rights to use Arbor’s technology to research and develop ex vivo engineered cell therapies towards Vertex’s goal of generating fully differentiated, insulin-producing hypoimmune islet cells for the treatment of type 1 diabetes, for next-generation approaches in sickle cell disease and beta thalassemia, and for the treatment of other diseases. Arbor will receive an upfront cash payment and is eligible to receive up to $1.2 billion in potential payments based upon the successful achievement of specified research, development, regulatory and commercial milestones across up to seven potential programs. Vertex will pay tiered royalties on future net sales on any products that may result from this collaboration. Vertex will also make an investment in Arbor in the form of a convertible note. [collapse expanded text] |
Government of Japan, Merck and Co, Ridgeback Biotherapeutics | Nov 2021 | 1200 | Supply agreement for Molnupiravir | Merck & Co and Ridgeback Biotherapeutics announced that the Japanese government will purchase, … read moreupon authorization or approval, approximately 1.6 million courses of molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine. Merck is developing molnupiravir in collaboration with Ridgeback Biotherapeutics. Under the agreement, if molnupiravir receives authorization or approval by Japan’s Pharmaceuticals and Medical Devices Agency, Merck will supply approximately 1.6 million courses of molnupiravir to the Japanese government for approximately $1.2 billion including applicable taxes. In anticipation of results from the Phase 3 MOVe-OUT clinical trial, and the potential for regulatory authorization or approval, Merck has been investing at risk to support development and scale-up production of molnupiravir and expects to produce 10 million courses of treatment by the end of 2021, with at least 20 million courses to be produced in 2022. [collapse expanded text] |
Biond Biologics, Sanofi | Jan 2021 | 1125 | Licensing agreement for BND-22 | Key Deal Terms SummaryMarch 20251. Agreement Overview2. Financial Terms
3. Development & Commercialization Plans
4. Strategic Impact
Overall SummaryBiond Biologics has regained full rights to BND-22 (SAR444881) following Sanofi’s strategic R&D reprioritization. Positive Phase 1 data demonstrated favorable safety and efficacy, leading to ongoing Phase 2 trials in cholangiocarcinoma, NSCLC, and CRC. Biond will now assume full control over BND-22’s future development and may seek strategic partners to advance the program. The decision underscores BND-22’s potential as a novel ILT2-targeting immune checkpoint inhibitor in the evolving oncology landscape. January 2021Key Deal Terms Summary1. Agreement Overview
2. Financial Terms
3. Development & Commercialization Plans
4. Strategic Impact
Overall SummaryBiond Biologics and Sanofi have entered into a global licensing agreement for BND-22, an immune checkpoint inhibitor targeting ILT2. Sanofi gains exclusive worldwide rights, while Biond leads the Phase 1a clinical trial before transferring development and commercialization to Sanofi. Biond will receive $125M upfront, over $1B in milestone payments, and tiered double-digit royalties. The deal strengthens Sanofi’s oncology pipeline with a first-in-class ILT2-targeting immunotherapy, while validating Biond’s innovative immuno-oncology platform. [collapse expanded text] |
Fibrogen, HiFiBio | Jun 2021 | 1125 | Licensing and option agreement for next-generation therapies for cancer and autoimmune disease | December 2021 FibroGen and HiFiBiO Therapeutics announced an extension of their partnership with … read moreFibroGen’s exercise of an exclusive license option for HiFiBiO’s anti-CCR8 monoclonal antibody program (HFB1011). HiFiBiO will receive a $35 million upfront payment from FibroGen in addition to potential clinical, regulatory, and commercial milestones. HiFiBiO will also be eligible to receive royalties based upon net sales. FibroGen will have the sole right to develop all products in the CCR8 program worldwide. The development candidate is expected to enter clinical development in 2023. June 2021 FibroGen and HiFiBiO Therapeutics announced a partnership covering three HiFiBiO programs. FibroGen will make a $25 million upfront payment to HiFiBiO, as well as payments upon option exercise. HiFiBiO may receive up to a total of an additional $1.1B in future option, clinical, regulatory, and commercial milestone payments across all three programs. HiFiBiO will also be eligible to receive royalties based upon worldwide net sales. FibroGen exclusively licensed all products in the Galectin-9 program and will have sole right to develop them worldwide. The lead product candidate in the Galectin-9 program is expected to enter clinical development in the first quarter of 2023. FibroGen has also obtained exclusive options to license all product candidates in HiFiBiO’s CXCR5 and CCR8 programs. Each option may be independently exercised following delivery of program-specific data to be generated by HiFiBiO. If an option is exercised, FibroGen will have the sole right to develop products from that program worldwide. The lead product candidates from the CXCR5 and CCR8 programs are expected to enter clinical development by the middle of 2023. [collapse expanded text] |
Selecta Biosciences, Takeda Pharmaceutical | Oct 2021 | 1124 | Licensing agreement for next-generation gene therapies for lysosomal storage disorders | Selecta Biosciences has entered into a strategic licensing agreement with Takeda Pharmaceutical to … read moredevelop targeted, next-generation gene therapies for two indications within the field of lysosomal storage disorders. The collaboration leverages Selecta’s ImmTOR platform to enable redosing of transformative therapies. Selecta is entitled to receive an undisclosed upfront payment and up to $1.124 billion in future additional payments over the course of the partnership that are contingent on the achievement of development or commercial milestones or Takeda’s election to continue its activities at specified development stages. Selecta is also eligible for tiered royalties on future commercial sales. [collapse expanded text] |
Coherus Biosciences, Junshi Biosciences | Feb 2021 | 1110 | Co-development, option and licensing agreement for Toripalimab, JS006, JS018-1 | January 2022 Coherus BioSciences and Shanghai Junshi Biosciences announced that Coherus has … read moreinitiated the process to exercise its option to license JS006, Junshi Biosciences’ TIGIT-targeted antibody, in the United States and Canada, expanding the companies’ 2021 immuno-oncology collaboration agreement. Coherus will pay Junshi Biosciences $35 million upfront, up to $255 million in development regulatory and sales milestones, and an 18% royalty on net product revenue, subject to terms and conditions agreed between the parties. February 2021 Junshi Biosciences announced a collaboration with Coherus BioSciences for the development and commercialization of toripalimab, Junshi Biosciences’ anti-PD-1 antibody, in the United States and Canada. Junshi Biosciences will receive up to an aggregate of US$1.11 billion of upfront payment, exercise fee and milestone payments from Coherus for the grant of the license of toripalimab and the two option programs (if exercised). Junshi Biosciences and Coherus will co-develop toripalimab, and Coherus will be responsible for all commercial activities in US and Canada. Junshi Biosciences has also granted Coherus options to JS006 (an anti-TIGIT antibody) and JS018-1 (a next generation engineered IL-2 cytokine), as well as first negotiation rights to two early-stage checkpoint inhibitor antibodies. Coherus has also acquired options or first negotiation rights to four of Junshi Biosciences’ novel oncology molecules. The Companies may develop toripalimab in combination with one or more of these four compounds, and potentially with other cancer drugs: An option to JS006, an antibody targeting TIGIT, a clinically validated immune inhibitory checkpoint. Anti-TIGIT antibodies have demonstrated significant synergistic anti-tumor activity in combination with anti-PD-1 antibodies. JS006 is expected to enter global clinical development later this year. The option term expires prior to initiation of Phase 2 development. An option to JS018-1, a next-generation engineered IL-2 cytokine designed to inhibit stimulation of regulatory T cells while retaining stimulatory activity on effector T-cells and natural killer (“NK”) cells. The option term expires prior to initiation of Phase 2 development. First negotiation rights to two undisclosed early-stage novel oncology programs directed against immune checkpoint molecules. Junshi Biosciences will grant Coherus exclusive rights to toripalimab in the United States and Canada as well as options in these territories to Junshi Biosciences’ JS006 and JS018-1. Coherus will also have first negotiation rights to two undisclosed preclinical immuno-oncology programs. Junshi Biosciences will receive an upfront payment of US$150 million. For toripalimab, Junshi Bioscience will receive 20% royalty on the annual net sales of toripalimab and up to an aggregate $380 million in one-time payments for the achievement of various milestones. For JS006 and JS108-1, Junshi Biosciences will receive an opt-in payment of $35 million per program. Additionally, for each program, Junshi Biosciences will receive 18% royalty on the annual net sales and up to an aggregate $255 million for the achievement of various milestones. The Companies will collaborate on the development of toripalimab and other licensed compounds, and Coherus will pay for a portion of these co-development activities up to a maximum of US$25 million per licensed compound per year. [collapse expanded text] |
Debiopharm, Merck KGaA | Mar 2021 | 1071.5 | Licensing and co-development agreement for xevinapant | Debiopharm announced an exclusive license agreement with Merck KGaA for the development and … read morecommercialization of xevinapant (Debio 1143). Xevinapant, a potent, oral of Inhibitor of Apoptosis Proteins (IAP) antagonist, is the only medicine in its class in late-stage clinical development and has the potential to be first in class. Xevinapant is currently being investigated in the pivotal Phase III TrilynX study for previously untreated high-risk locally advanced squamous cell carcinoma of the head and neck (LA SCCHN), in combination with platinum-based chemotherapy and standard fractionation intensity-modulated radiotherapy. Given their strong commercial footprint in the field of head and neck cancer, Merck KGaA is the partner of choice to leverage our outstanding phase II data and make xevinapant a transformative therapy for cancer patients. Merck KGaA receives exclusive rights to develop and commercialize xevinapant worldwide, including in the U.S. Merck KGaA will also co-fund with Debiopharm the ongoing Phase III registrational TrilynX study, a global double-blind, placebo-controlled, 700-patient randomized clinical trial to evaluate the efficacy and safety of xevinapant vs. placebo when added to definitive chemoradiotherapy (CRT) in cisplatin-eligible patients with high-risk LA SCCHN. Debiopharm to receive €188 million upfront and up to €710 million in milestone, as well as royalty payments. [collapse expanded text] |
Baring Private Equity Asia, Boston Scientific, Lumenis | Mar 2021 | 1070 | Asset purchase agreement for surgical business | Boston Scientific has entered into a definitive agreement with an affiliate of Baring Private … read moreEquity Asia to acquire the global surgical business of Lumenis for an upfront cash payment of $1.07 billion, subject to closing adjustments. BPEA will retain ownership of the Lumenis global aesthetics and ophthalmology businesses. [collapse expanded text] |
Boehringer Ingelheim, Enara Bio | Jan 2021 | 1047 | Collaboration, option and licensing agreement for targeted cancer immunotherapies, leveraging Dark Antigen discovery platform | January 2024 Enara Bio announced that Boehringer Ingelheim has exercised its option to license a … read morenumber of cancer antigens discovered and validated through the ongoing collaboration using Enara Bio’s Dark Antigen discovery platform, EDAPT. January 2021 Boehringer Ingelheim and Enara Bio have entered into a strategic collaboration and licensing agreement to research and develop novel targeted cancer immunotherapies, leveraging Enara Bio’s Dark Antigen discovery platform. This new collaboration combines Boehringer Ingelheim’s approach to tackle cancer through pairing leading science with innovative immune-oncology platforms, such as oncolytic viruses and cancer vaccines, with Enara Bio’s expertise in cancer antigen identification. The aim is to provide potential new therapies for patients with difficult to treat lung and gastrointestinal cancers. Boehringer Ingelheim has the option to license Dark Antigens discovered and validated by Enara Bio. Boehringer Ingelheim will also be responsible for all non-clinical and clinical development, as well as commercialization of associated cancer immunotherapies, including therapeutic vaccines and T-cell redirecting biologics. Enara Bio retains rights to use any discovered antigens for use in cell therapy-based products. Enara Bio is eligible to receive an upfront payment, together with research/preclinical milestones and licensing fees for each tumor type that is explored. Enara Bio is also eligible to receive more than EUR 876 million in clinical, regulatory and commercial milestones, in addition to royalties on future product sales. [collapse expanded text] |
Arrowhead Pharmaceuticals, GSK | Nov 2021 | 1030 | Licensing agreement for ARO-HSD | April 2023 Arrowhead Pharmaceuticals earned a $30 million milestone payment from GSK following … read morethe start of GSK’s Phase 2b trial of GSK4532990, formerly called ARO-HSD, an investigational RNA interference therapeutic for the treatment of patients with non-alcoholic steatohepatitis. November 2021 Arrowhead Pharmaceuticals entered into an exclusive license agreement with GlaxoSmithKline under which GSK will develop and commercialize ARO-HSD, Arrowhead’s investigational RNA interference therapeutic in a Phase 1/2 trial that is currently being developed as a treatment for patients with nonalcoholic steatohepatitis. Arrowhead will receive an upfront payment of $120 million and is eligible for additional payments of $30 million at the start of Phase 2 and $100 million upon achieving a successful Phase 2 trial readout and the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial read out positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to Arrowhead of up to $190 million at first commercial sale, and up to $590 million in sales-related milestone payments. Arrowhead is further eligible to receive tiered royalties on net product sales. GSK will receive an exclusive license to develop and commercialize ARO-HSD in all territories except Greater China, which will be retained by Arrowhead. GSK will be wholly responsible for further clinical development and commercialization, outside of Greater China. [collapse expanded text] |
LegoChem Biosciences, SOTIO | Nov 2021 | 1027.5 | Collaboration and licensing agreement for ADC technology for up to five therapeutic programs targeting distinct tumor-associated antigens | November 2022 SOTIO Biotech has exercised its first of five exclusive, target-specific options … read morewith LegoChem Biosciences for antibody-drug conjugate SOT106, which is currently being evaluated in preclinical studies across a multitude of solid tumor indications. The exercise of the first option triggers an undisclosed milestone payment by SOTIO to LCB. November 2021 SOTIO Biotech announced an exclusive, target-specific license and option agreement with LegoChem Biosciences. SOTIO will obtain rights to deploy LCB’s ADC technology for up to five therapeutic programs targeting distinct tumor-associated antigens. The deal enables SOTIO to combine its proprietary antibodies with LCB’s ADC technology platform in order to deliver novel therapeutics for the treatment of solid tumors and includes LCB’s proprietary conjugation technology ConjuAll and potent linker-payload platform including multiple different payloads. LCB is eligible to receive upfront and potential milestone payments worth up to $1027.5 million, payable based on certain developments and regulatory achievements, plus royalties on net sales. The deal includes upfront and near-term milestones worth up to $29.5 million, subject to exercise of the options and achievement of success-based milestones. No further financial details are disclosed. [collapse expanded text] |
Genentech, Ribometrix | Jan 2021 | 1025 | Collaboration and licensing agreement for RNA-targeted small molecule therapeutics against several targets | Ribometrix announced a strategic collaboration with Genentech to discover and develop novel RNA- … read moretargeted small molecule therapeutics against several targets. Ribometrix will apply its proprietary discovery platform to identify and optimize small molecule compounds that modulate RNA function by targeting three-dimensional (3D) RNA structures. Ribometrix and Genentech will collaborate on the discovery and preclinical development of programs. Genentech will be responsible for further development and commercialization. Genentech will pay Ribometrix a $25 million upfront payment, and in return will receive exclusive rights to several predefined targets including an exclusive global license for the development and commercialization of molecules under this collaboration. Ribometrix will also be eligible to receive potential milestone payments exceeding $1 billion as well as tiered royalties on future global net sales of products that result from the collaboration. [collapse expanded text] |
Exicure, Ipsen | Aug 2021 | 1020 | Collaboration, option and licensing agreement for targeting rare neurodegenerative disorders | December 2022 Exicure announced the termination of its collaboration agreement with Ipsen … read moreBioPharm. Ipsen retains the right to re-enter into the collaboration with Exicure in Huntington’s Disease and Angelman’s Syndrome. August 2021 Ipsen and Exicure have signed an exclusive collaboration agreement to research, develop, and commercialize novel Spherical Nucleic Acids (SNAs) as potential investigational treatments for Huntington’s disease and Angelman syndrome. Ipsen will receive exclusive options to license SNA-based therapeutics arising from two collaboration programs for Huntington’s disease and Angelman syndrome. Ipsen will pay Exicure a cash upfront payment of $20m upon closing and Exicure will be responsible for discovery and certain pre-clinical development activities. In the event Ipsen exercises its option, Ipsen will be responsible for further development and commercialization of the licensed products. Exicure will receive a $20m upfront payment and is eligible to receive up to $1B in option exercise fees and milestone payments should Ipsen opt into both programs, as well as tiered royalties. [collapse expanded text] |
Cardinal Health, Cordis, Hellman & Friedman | Mar 2021 | 1000 | Asset purchase agreement for Cordis business | Cardinal Health has signed a definitive agreement to sell its Cordis business to Hellman & … read moreFriedman for approximately $1 billion, which includes buyer's assumption of certain liabilities and seller's retention of certain working capital accounts. The transaction is expected to close in the first half of Cardinal Health's fiscal year 2022, subject to customary closing conditions and regulatory clearances. [collapse expanded text] |
Eureka Therapeutics, Memorial Sloan Kettering Cancer Center, Sanofi | Jul 2021 | 1000 | Licensing agreement for non-CAR use of a novel, human binding domain targeting GPRC5D | Eureka Therapeutics and Memorial Sloan Kettering Cancer Center entered into a license agreement … read morewith Sanofi for the non-CAR use of a novel, human binding domain targeting GPRC5D (G Protein-Coupled Receptor Family C Group 5 Member D). The GPRC5D binding domain was discovered using Eureka’s proprietary E-ALPHA antibody discovery platform and developed under a collaboration agreement between Eureka and MSK. Sanofi has exclusive rights to the GPRC5D binder for non-CAR use. Eureka and MSK are eligible to receive an upfront payment and over $1 billion of potential development, regulatory and sales milestone payments. Eureka and MSK are also eligible to receive tiered royalties on net sales. [collapse expanded text] |
GSK, Vir Biotechnology | Nov 2021 | 1000 | Supply agreement for Sotrovimab | GlaxoSmithKline and Vir Biotechnology announced US government contracts totaling approximately $1 … read morebillion to purchase sotrovimab, an investigational monoclonal antibody for the early treatment of COVID-19, which the US Food and Drug Administration granted Emergency Use Authorization in May 2021. GSK will supply these doses to the US government by December 17, 2021, enabling further expanded nationwide access to sotrovimab for patients. In addition to the doses that will be supplied this year, the US government will have the option to purchase additional doses through March 2022. [collapse expanded text] |
Omeros, Rayner Surgical | Dec 2021 | 1000 | Asset purchase and licensing agreement for OMIDRIA franchise | February 2023 Omeros announced that Rayner Surgical has paid the $200 million milestone payment … read moredue to Omeros under the Asset Purchase Agreement, dated December 1, 2021, pursuant to which Omeros sold its ophthalmology product OMIDRIA to Rayner in December of 2021. December 2021 Omeros has entered into a definitive agreement for the sale of OMIDRIA to Rayner Surgical Group. Expected to close on or before December 31, 2021, the transaction includes an upfront payment of $125 million with an additional $200 million in a commercial milestone payment. Omeros will also retain its accounts receivable balance at the closing, which was $34 million at the end of last quarter. Together with substantial royalties to be paid by Rayner to Omeros on net sales of OMIDRIA, the transaction is valued in excess of $1 billion. Rayner will pay Omeros royalties on both U.S. and ex-U.S. net sales of OMIDRIA. In the U.S., the royalty rate will be 50 percent of U.S. net sales until the earlier of either January 1, 2025 or payment of the $200-million commercial milestone, after which Omeros will receive royalties of 30 percent of U.S. net sales for the life of OMIDRIA’s U.S. patent estate. The commercial milestone payment is triggered if separate payment for OMIDRIA is secured for a continuous period of at least four years. Outside of the U.S., Omeros will receive a 15-percent royalty rate on OMIDRIA net sales throughout the applicable patent life on a country-by-country basis. [collapse expanded text] |
Eli Lilly, Rigel Pharmaceuticals | Feb 2021 | 960 | Co-development, co-promotion and licensing agreement for R552 | Eli Lilly and Rigel Pharmaceuticals announced a global exclusive license agreement and strategic … read morecollaboration to co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications including autoimmune and inflammatory diseases. Lilly will also lead all clinical development of brain penetrating RIPK1 inhibitors in central nervous system diseases. Lilly will pay an upfront cash payment to Rigel of $125 million. Rigel may also be eligible to receive up to $835 million in potential development, regulatory, and commercial milestone payments, as well as tiered royalties ranging from the mid-single digit to high-teens that will vary depending upon Rigel's clinical development investment. Lilly and Rigel will co-develop R552 at specified contribution levels. Lilly will be responsible for all costs of global commercialization for R552, and Rigel will have the right to co-commercialize R552 in the U.S. Lilly will be solely responsible for all clinical development and commercialization of brain penetrating RIPK1 inhibitors in CNS indications. [collapse expanded text] |
Beijing InnoCare Pharma, Biogen | Jul 2021 | 937.5 | Collaboration and licensing agreement for Orelabrutinib | Biogen and InnoCare Pharma have entered into a license and collaboration agreement for … read moreorelabrutinib, an oral small molecule Bruton’s tyrosine kinase inhibitor (BTKi) for the potential treatment of multiple sclerosis. Orelabrutinib is a covalent BTKi with high selectivity and the ability to cross the blood-brain barrier, and is currently being studied in a multi-country, placebo-controlled Phase 2 trial in relapsing-remitting MS. Biogen will have exclusive rights to orelabrutinib in the field of MS worldwide and certain autoimmune diseases outside of China (including Hong Kong, Macau and Taiwan), while InnoCare will retain exclusive worldwide rights to orelabrutinib in the field of oncology and certain autoimmune diseases in China (including Hong Kong, Macau and Taiwan). InnoCare will receive a $125 million upfront payment and is eligible to receive up to $812.5 million in potential development milestones and potential commercial payments should the collaboration achieve certain development, commercial milestones and sales thresholds. InnoCare is also eligible to receive tiered royalties in the low to high teens on potential future net sales of any product resulting from the collaboration. [collapse expanded text] |
Nykode Therapeutics, Regeneron Pharmaceuticals | Nov 2021 | 925 | Collaboration and licensing agreement for vaccines against cancer and infectious diseases | Nykode Therapeutics has entered into a license and collaboration agreement with Regeneron for the … read morediscovery, development and commercialization of potential new vaccines for cancer and infectious diseases. The agreement includes five distinct programs, three within cancer and two within infectious diseases. Each of these may include several vaccine candidates, all of which being eligible for milestone and royalty payments. The vaccines will combine Regeneron’s unique antigen selection expertise andinnovative VelociSuite in vivo models with Nykode Therapeutics’ modular vaccine platform and expertise in vaccine design. Nykode Therapeutics will be responsible for vaccine generation and characterization, as well as product supply through the end of Phase 1 trials. Regeneron will be responsible for antigen identification, preclinical and clinical development, manufacturing (from the end of Phase 1 trials) and commercialization. Nykode Therapeutics will receive a USD 30 million upfront payment and a USD 20 million equity investment at a premium of 20% on a 30-day volume weightedaverage price of the Nykode Therapeutics share for the last 30 trading days before the effective date of the agreement. Nykode Therapeutics will potentially be eligible to receive more than USD 875 million in milestone payments, plus high single-digit to low double-digit tiered royalties on sales of commercialized products arising from the collaboration, bringing the total potential value of the agreement to more than USD 925 million, plus royalties. Regeneron will cover costs for research, as well as potential clinical, regulatory, manufacturing and commercialization activities. [collapse expanded text] |
Chi-Med, Hutchmed, Inmagene Biopharmaceuticals | Jan 2021 | 920 | Development, option and licensing agreement for drug candidates for immunological diseases | January 2024 Inmagene Biopharmaceuticals exercised the option to obtain an exclusive, worldwide … read moreand royalty-bearing license for IMG-007, a non-depleting humanized anti-OX40 mAb, and IMG-004, an oral non-covalent and reversible BTK inhibitor, with the right to sublicense through multiple tiers. The option was exercised pursuant to a collaboration between Inmagene and HUTCHMED announced in 2021 to develop and commercialize a portfolio of drug candidates for I&I diseases. January 2021 Hutchison China MediTech and Inmagene Biopharmaceuticals announced a strategic partnership to further develop four novel preclinical drug candidates discovered by Chi-Med for the potential treatment of multiple immunological diseases. Funded by Inmagene, the companies will work together to move the drug candidates towards investigational new drug submission. If successful, Inmagene will then move the drug candidates through global clinical development. Chi-Med grants Inmagene exclusive options to four drug candidates solely for the treatment of immunological diseases. Should Inmagene exercise the option, it will have the right to further develop, manufacture and commercialize that specific drug candidate worldwide, with Chi-Med retaining first right to co-commercialization in mainland China. For each of the drug candidates, Chi-Med will be entitled to development milestones of up to US$95 million and up to US$135 million in commercial milestones, as well as up to double-digit royalties upon commercialization. [collapse expanded text] |
Bristol-Myers Squibb, Immatics Biotechnologies | Dec 2021 | 920 | Licensing, option and co-promotion agreement for TCR bispecific program IMA401 | September 2024 Collaboration with Bristol Myers Squibb for the co-development of IMA401 has … read moreended due to ongoing portfolio prioritization efforts within Bristol Myers Squibb Existing collaboration and license agreement signed in December 2021 will terminate effective December 12, 2024 IMA401 development and commercialization rights will be reverted to Immatics Immatics is not obligated to refund Bristol Myers Squibb any part of the $150 million upfront received under the collaboration and is not required to make any future milestone payments to Bristol Myers Squibb Parties will engage in a wind-down period as stipulated under the collaboration agreement Immatics has been responsible for conducting the ongoing Phase 1 clinical trial Immatics intends to advance IMA401 further through clinical development December 2021 Immatics and Bristol Myers Squibb have entered into a license, development and commercialization agreement for Immatics’ TCR Bispecific candidate, IMA401. Immatics will receive an upfront payment of $150 million as well as up to $770 million in development, regulatory and commercial milestone payments, in addition to tiered double-digit royalty payments on net sales of IMA401. Immatics retains the options to co-fund US development in exchange for enhanced US royalty payments and/or to co-promote IMA401 in the US. [collapse expanded text] |
Immusoft, Takeda Pharmaceutical | Oct 2021 | 900 | Collaboration, option and licensing agreement for cell therapies for rare neurometabolic disorders | Immusoft has signed a research collaboration and license option agreement with Takeda … read morePharmaceutical to discover, develop and commercialize transformative cell therapies in rare inherited metabolic disorders with central nervous system manifestations and complications using Immusoft’s Immune System Programming technology platform, which modifies a patient’s B cells and instructs the cells to deliver gene-encoded therapies. The collaboration will focus on delivering protein therapeutics across the blood-brain barrier, a promising area of Immusoft’s research, which has the potential to enable the treatment of diseases with high unmet need. Immusoft will receive an undisclosed upfront payment and research funding support. The company is also eligible to receive future option fees and milestone payments with a total potential value of more than $900 million if all options are exercised and all milestones are achieved over the course of the partnership. Takeda has options to exclusively license the programs at the preclinical stage and Immusoft is eligible for tiered royalties on future products resulting from the partnership. Takeda would be responsible for further preclinical and clinical development, and commercialization. [collapse expanded text] |
Otsuka, Sumitomo Dainippon Pharma, Sunovion Pharmaceuticals | Sep 2021 | 890 | Collaboration, co-development agreement for four compounds: ulotaront (SEP-363856), non-racemic ratio of amisulpride enantiomers (SEP-4199), SEP-378614 and SEP-380135 | Sunovion Pharmaceuticals, Sumitomo Dainippon Pharma and Otsuka Pharmaceutical have entered into a … read moreworldwide license agreement for the joint development and commercialization of four compounds: ulotaront (SEP-363856), non-racemic ratio of amisulpride enantiomers (SEP-4199), SEP-378614 and SEP-380135. Otsuka Pharmaceutical Development & Commercialization will jointly lead, together with Sunovion, the effort to advance the research and development program worldwide, as well as plan for future commercial activities. This collaboration recognizes that there is a great need for novel treatments in the area of neuropsychiatric medicine development. The companies are focused on working together on solutions to address these areas of unmet medical need by advancing four promising compounds―ulotaront (SEP-363856), SEP-4199, SEP-378614 and SEP-380135―that address serious neuropsychiatric disorders. The goal of the co-development programs is to contribute to changing the course of serious medical conditions and provide new treatment options to patients and healthcare providers globally. Upon the completion of the agreement, in addition to an upfront payment of USD 270 million, Sunovion is eligible for development milestone payments of up to USD 620 million for the four compounds and relevant sales milestone payments. Sunovion and Otsuka will share profits from the four compounds, as well as all expenses for clinical studies, applications for approval, and commercialization in each country. Additional details regarding terms of the agreement are not being disclosed. [collapse expanded text] |
Bolt Biotherapeutics, Genmab | Jun 2021 | 880 | Collaboration, co-development and co-promotion agreement for antibodies and bispecific antibody engineering technologies in combination with Boltbody immune-stimulating antibody conjugate technology platform | Genmab and Bolt Biotherapeutics have entered into an oncology research and development … read morecollaboration. Together, the companies will evaluate Genmab antibodies and bispecific antibody engineering technologies in combination with Bolt’s proprietary Boltbody immune-stimulating antibody conjugate technology platform, with the goal of discovering and developing next-generation, immune-stimulatory, antibody-based conjugate therapeutics for the treatment of cancer. This research collaboration will evaluate multiple bispecific ISAC concepts to identify up to three clinical candidates for development. Genmab will fund the research, along with the preclinical and clinical development of these candidates through clinical proof of concept. Genmab will pay Bolt an upfront payment of USD 10 million. Genmab will also make a USD 15 million equity investment in Bolt. Bolt is eligible to receive total potential milestone payments of up to USD 285 million per therapeutic candidate exclusively developed and commercialized by Genmab, along with tiered royalties. Genmab will fully fund pre-clinical and early clinical development of all candidates. If a candidate is co-developed, development costs will be split 50:50 between the two companies, and the companies will be solely responsible for commercialization costs in their respective territories and shall pay each other royalties on product sales. [collapse expanded text] |
CYTOVIA Therapeutics, Cellectis, CytoLynx Therapeutics | Feb 2021 | 875 | Collaboration agreement for TALEN gene-edited iPSC NK and CAR-NK cells | November 2021 Cytovia Therapeutics and Cellectis have expanded their collaboration of TALEN gene- … read moreedited iPSC-derived NK and CAR-NK cells to include new CAR target and development in China by Cytovia’s joint venture entity, CytoLynx Therapeutics. The amended financial terms include an equity stake totaling $20 million in Cytovia stock as well as up to $805 million of development, regulatory, and sales milestones and single-digit royalty payments on the net sales of all partnered products commercialized by Cytovia. February 2021 Cytovia Therapeutics and Cellectis have entered into a strategic research and development collaboration to develop TALEN gene-edited iPSC NK and CAR-NK cells. The financial terms of the partnership include up to $760 million of development, regulatory, and sales milestones from Cytovia to Cellectis for the first 5 TALEN gene-edited iPSC-derived NK products. Cellectis will also receive single-digit royalty payments on the net sales of all partnered products commercialized by Cytovia. Cellectis will receive an equity stake of $15 million in Cytovia stock or an upfront cash payment of $15 million if certain conditions are not met by December 31, 2021, as well as an option to invest in future financing rounds. Cellectis will develop custom TALEN, which Cytovia will use to edit iPSCs. Cytovia will be responsible for the differentiation and expansion of the gene-edited iPSC master cell bank into NK cells and will conduct the pre-clinical evaluation, clinical development, and commercialization of the mutually-agreed-upon selected therapeutic candidates. Cellectis is granting Cytovia a worldwide license to its TALEN gene-editing technology, enabling Cytovia to modify NK cells addressing multiple gene targets for therapeutic use in several cancer indications. [collapse expanded text] |
Appia Bio, Kite Pharma | Aug 2021 | 875 | Collaboration agreement for allogeneic cell therapies for cancer | Kite Pharma and Appia Bio announced a collaboration and license agreement to research and develop … read moreHSC-derived cell therapies directed toward hematological malignancies. Kite and Appia Bio will develop chimeric antigen receptor (CAR)-engineered invariant natural killer T (CAR-iNKT) cells using Appia Bio’s ACUA technology platform for allogeneic cell therapy. Appia Bio will be responsible for preclinical and early clinical research of two HSC-derived CAR-iNKT product candidates engineered with CARs provided by Kite. Appia Bio will receive an upfront payment, an equity investment, and additional milestone payments for a total value of up to $875 million as well as tiered royalties. Kite will be responsible for the development, manufacturing, and commercialization of the product candidates identified through the collaboration. [collapse expanded text] |
Ovid Therapeutics, Takeda Pharmaceutical | Mar 2021 | 856 | Development and licensing agreement for soticlestat | Takeda Pharmaceutical and Ovid Therapeutics announced that Takeda has entered into an exclusive … read moreagreement under which Takeda will secure global rights at closing from Ovid to develop and commercialize the investigational medicine soticlestat (TAK-935/OV935) for the treatment of developmental and epileptic encephalopathies, including Dravet syndrome and Lennox-Gastaut syndrome. Under the new exclusive agreement, all global rights to soticlestat have been secured by Takeda from Ovid. Takeda will assume sole responsibility for further worldwide development and commercialization, and Ovid will no longer have any financial obligation to Takeda under the original collaboration agreement, including for milestone payments or any future development and commercialization costs. Ovid will receive an upfront payment of $196 million at closing and is eligible to receive up to an additional $660 million upon achieving development, regulatory and sales milestones. Ovid will receive tiered royalties beginning in the low double-digits and up to 20 percent on sales of soticlestat, if approved and commercialized. [collapse expanded text] |
BAKX Therapeutics, Ipsen | Jul 2021 | 850 | Collaboration and licensing agreement for BKX-001 | Ipsen and BAKX Therapeutics have signed an exclusive worldwide-collaboration agreement to research, … read moredevelop, manufacture and commercialize BKX-001 as a potential treatment for leukemia, lymphoma and solid tumors. Ipsen will pay BAKX Therapeutics $14.5m upon closing, comprising an equity investment and an upfront payment, followed by up to $837.5m in milestone payments. The companies would also share equally costs and profits. [collapse expanded text] |
Gilead Sciences, Gritstone Bio | Feb 2021 | 785 | Collaboration, option and licensing agreement for prime-boost vaccine platform for human immunodeficiency virus | Gilead Sciences and Gritstone Oncology have entered into a collaboration, option and license … read moreagreement to research and develop a vaccine-based immunotherapy as part of Gilead’s efforts to find a curative treatment for human immunodeficiency virus (HIV) infection. Gilead and Gritstone will develop an HIV-specific therapeutic vaccine using Gritstone’s proprietary prime-boost vaccine platform, comprised of self-amplifying mRNA (SAM) and adenoviral vectors, with antigens developed by Gilead. Gilead will make a $60 million payment at closing, consisting of a $30 million upfront cash payment and a $30 million equity investment at a premium. Gilead will be responsible for conducting a Phase 1 study for the HIV-specific therapeutic vaccine and holds an exclusive option under the collaboration to obtain an exclusive license to develop and commercialize the HIV-specific therapeutic vaccine beyond Phase 1. Gritstone is also eligible to receive up to an additional $725 million if the option is exercised and if certain clinical, regulatory and commercial milestones are achieved, as well as mid single-digit to low double-digit tiered royalties on net sales upon commercialization. [collapse expanded text] |
Cidara Therapeutics, Janssen Pharmaceuticals | Apr 2021 | 780 | Development and licensing agreement for CD388 and other influenza antiviral conjugates | Cidara Therapeutics has entered into an exclusive worldwide license and collaboration agreement … read morewith Janssen Pharmaceuticals to develop and commercialize Cidara’s Cloudbreak antiviral conjugates for the prevention and treatment of seasonal and pandemic influenza. This agreement was facilitated by Johnson & Johnson Innovation. Cidara will be responsible for the development and manufacturing of the first influenza AVC, CD388, into the clinic and through Phase 2 clinical development, and Janssen will be responsible for late-stage development, manufacturing, registration and global commercialization. Cidara will receive an upfront payment of $27 million and Janssen will fund all future research, development, manufacturing and commercialization for CD388. In addition to the upfront payment, Cidara is eligible to receive up to an aggregate of $753 million in budgeted R&D funding and in development, regulatory and commercial milestones, plus tiered royalties on worldwide sales in the mid to high single digits. Cidara has the option to co-detail CD388 in the U.S. [collapse expanded text] |
IQVIA, Q2 Solutions, Quest Diagnostics | Apr 2021 | 760 | Asset purchase agreement for minority share in Q2 Solutions | Quest Diagnostics announced the sale of its minority share in Q2 Solutions to IQVIA for $760 … read moremillion in an all-cash transaction. [collapse expanded text] |
Halozyme Therapeutics, ViiV Healthcare | Jun 2021 | 740 | Collaboration and licensing agreement for ENHANZE drug delivery technology to enable development of "ultra-long-acting" medicines for HIV | ViiV Healthcare and Halozyme Therapeutics announced a global collaboration and license agreement … read morethat gives exclusive access to Halozyme's ENHANZE drug delivery technology, recombinant human hyaluronidase PH20 enzyme (rHuPH20), for specific targets used in the treatment and prevention of HIV. ViiV Healthcare will make an upfront payment of $40 million to Halozyme for the exclusive license to four HIV small and large molecule targets and is obligated to make potential future payments of up to $175 million in development and commercial milestones per target, subject to achievement of specified development and commercial milestones, including certain specified sales milestones. Halozyme will also be entitled to receive mid-single digit royalties on sales of commercialised medicines using the technology. The license gives ViiV exclusive use of Halozyme's proprietary rHuPH20 technology for four, specific HIV medicine targets that will expand opportunities for development of nearly all of ViiV's pipeline assets. These assets are integrase inhibitors, reverse transcriptase inhibitors limited to nucleoside reverse transcriptase inhibitors (NRTI) and nucleoside reverse transcriptase translocation inhibitors (NRTTIs), capsid inhibitors and broadly neutralising monoclonal antibodies (bNAbs), that bind to the gp120 CD4 binding site. [collapse expanded text] |
Eli Lilly, Verge Genomics | Jul 2021 | 719 | Collaboration and licensing agreement for therapies for amyotrophic lateral sclerosis | Verge Genomics announced a three-year collaboration with Eli Lilly to research and develop novel … read moretherapies for the treatment of amyotrophic lateral sclerosis. Verge will receive up to $25 million in upfront, equity investment and potential near-term payments, with additional milestone value of $694 million and potential downstream royalties. Verge will apply its all-in-human platform to discover and validate new targets for ALS. The all-in-human platform is based on a proprietary collection of patient brain transcriptomes across a variety of neurodegenerative diseases. Through its application, the all-in-human platform provides insights into novel causal disease mechanisms in genetically segmented patient populations, and enables the discovery of therapeutic targets. Based on these insights, Verge will apply its human-based discovery capabilities to validate targets. Lilly will select up to four targets identified by Verge with plans to advance through clinical development and commercialization. [collapse expanded text] |
Boehringer Ingelheim, Twist Bioscience | Sep 2021 | 710 | Collaboration and licensing agreement for antibody libraries to discover therapeutic antibodies against multiple targets | Twist Bioscience announced a broad-based research collaboration with Boehringer Ingelheim to use … read moreTwist’s proprietary antibody libraries to discover therapeutic antibodies against multiple targets provided by Boehringer Ingelheim. Twist Biopharma will utilize its “Library of Libraries,” a panel of synthetic antibody phage display libraries derived only from sequences that exist in the human body, to identify potential therapeutic antibody candidates. Twist and Boehringer Ingelheim will work together to validate and optimize any resulting new antibody candidates, which could be researched against a range of therapeutic areas. Boehringer Ingelheim retains exclusive worldwide rights to develop and commercialize any therapeutic antibodies discovered as part of the collaboration. Twist will receive an upfront payment for each program entry. Twist has the potential to earn up to a total of $710 million in success-based clinical, regulatory and commercial milestone payments for the multiple target discovery programs. [collapse expanded text] |
Arrowhead Pharmaceuticals, Horizon Therapeutics | Jun 2021 | 700 | Collaboration and licensing agreement for RNAi therapeutic for uncontrolled gout | Arrowhead Pharmaceuticals and Horizon Therapeutics announced a global collaboration and license … read moreagreement for ARO-XDH, a previously undisclosed discovery-stage investigational RNA interference (RNAi) therapeutic being developed by Arrowhead as a potential treatment for people with uncontrolled gout. Arrowhead will conduct all activities through preclinical stages of development of the siRNA therapeutic. Horizon will receive a worldwide exclusive license to the therapeutic and will be wholly responsible for clinical development and commercialization. Arrowhead will receive $40 million as an upfront payment from Horizon and is eligible to receive up to $660 million in potential development, regulatory and commercial milestones, and is further eligible to receive royalties in the low- to mid-teens range on net product sales. [collapse expanded text] |
Mammoth Biosciences, Vertex Pharmaceuticals | Oct 2021 | 691 | Development agreement for in vivo gene-editing therapies for serious diseases | Vertex Pharmaceuticals and Mammoth Biosciences announced a partnership to develop in vivo gene- … read moreediting therapies for two genetic diseases using Mammoth’s next-generation CRISPR systems. Mammoth Biosciences will receive upfront payments of $41 million, including an investment in the form of a convertible note, and is eligible to receive up to $650 million in potential future payments based upon the successful achievement of prespecified research, development and commercial milestones across two potential programs. Vertex will pay tiered royalties on future net sales on any products that may result from this collaboration. [collapse expanded text] |
Orifarm, Takeda Pharmaceutical | Mar 2021 | 670 | Asset purchase agreement for portfolio of OTC products | Takeda Pharmaceutical announced the completion of its sale of a portfolio of select products to … read moreOrifarm Group for a total value of up to $670 million USD. The portfolio includes approximately 130 over-the-counter (OTC) and prescription pharmaceutical products sold in Europe, and two manufacturing sites located in Denmark and Poland. This divestment agreement was first announced in April 2020. [collapse expanded text] |
Cell Cure Neurosciences, Genentech, Lineage Cell Therapeutics, Roche | Dec 2021 | 670 | Collaboration and licensing agreement for OpRegen RPE cell therapy | Key Deal Terms Summary: Lineage and Genentech Collaboration AgreementParties… read moreInvolved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Considerations
Overall SummaryLineage has entered into a worldwide exclusive license agreement with Genentech for the development and commercialization of OpRegen, an RPE cell therapy targeting advanced dry AMD with GA. Genentech will assume clinical development and commercialization, while Lineage will complete ongoing clinical activities and manufacturing support. The agreement includes a $50 million upfront payment, up to $620 million in milestones, and tiered double-digit royalties on future sales. This collaboration strengthens Genentech’s ophthalmology pipeline and supports Lineage’s regenerative medicine platform. [collapse expanded text] |
Senti Biosciences, Spark Therapeutics | Apr 2021 | 645 | Collaboration, option and licensing agreement for gene circuit technology to development of next-generation precision gene therapies directed toward specific cell types | Key Deal Terms Summary: Spark Therapeutics and Senti Bio CollaborationParties… read moreInvolved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Considerations
Overall SummarySpark Therapeutics and Senti Bio have established a strategic collaboration to develop precision gene therapies for CNS, eye, and liver diseases. The partnership will integrate Senti Bio’s gene circuit technology with Spark’s gene therapy research and development capabilities. Senti Bio is eligible for potential payments exceeding $645 million, along with royalties on future product sales. This collaboration reinforces Spark’s position as a leader in gene therapy while advancing Senti Bio’s synthetic biology-driven approach to next-generation therapeutics. [collapse expanded text] |
Flame Biosciences, NovaRock Biotherapeutics | Aug 2021 | 640 | Licensing agreement for NBL-012 and NBL-015 | NovaRock Biotherapeutics have entered into an exclusive license agreement and strategic partnership … read morewith Flame Biosciences. NovaRock has granted Flame Biosciences the exclusive rights to NBL-015 outside of Greater China (including mainland China, Hong Kong, Macau, and Taiwan). Flame shall be responsible for the development, regulatory approval, and commercialization of NBL-015. NovaRock will, at Flame Biosciences's expense, collaborate with Flame on the discovery and preclinical development of two new bispecific antibodies based on NovaRock's NovaTE bi-specific antibody technology platform and subsequently grant Flame Biosciences the exclusive rights to further develop, manufacture and commercialize the Licensed Products. The lead product candidates from this collaboration are expected to enter clinical development in late 2023. NovaRock will receive an upfront payment of US$7.5 million and is eligible to receive development milestone payments of up to US$172.5 million subject to achievement of the development milestone events. NovaRock is also eligible to receive sales milestone payments of up to US$460 million subject to the achievement of the sales milestone events and royalties based on a certain percentage of the net sales of the Licensed Products in the Territory. [collapse expanded text] |
Pfizer, Voyager Therapeutics | Oct 2021 | 630 | Option and licensing agreement for TRACER AAV capsids to enable neurologic and cardiovascular gene therapy programs | October 2022 Voyager Therapeutics announced that Pfizer has exercised its option to license a … read morenovel capsid generated from Voyager’s TRACER capsid discovery platform to help enable a potential gene therapy program against an undisclosed rare neurologic disease target. Under the terms of the license option agreement, originally announced in October 2021, Voyager previously received a $30 million upfront payment and is entitled to receive a $10 million option exercise payment. Voyager is eligible to receive potential future development, regulatory and commercialization milestone payments of up to $115 million, sales milestones of up to $175 million, and mid- to high-single-digit tiered royalties in connection with Pfizer’s use of its capsid in development and commercialization of a gene therapy for a rare neurologic target. October 2021 Voyager Therapeutics announced an agreement through which Pfizer may exercise options to license novel capsids generated from Voyager’s RNA-driven TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) screening technology as part of Pfizer’s efforts to develop, manufacture, and commercialize gene therapies, utilizing two undisclosed transgenes to treat certain neurologic and cardiovascular diseases. Pfizer will have the right to evaluate novel capsids selected for central nervous system and cardiac tropisms from Voyager’s TRACER platform and to exercise options to license capsids for exclusive use in Pfizer’s development of AAV gene therapies incorporating two undisclosed transgenes. These transgenes will be distinct from those planned for Voyager’s internal pipeline. Voyager will retain global rights to all licensed capsids for use with other transgenes and to all other applications of its TRACER technology. Voyager will receive $30 million upfront and is entitled to receive up to $20 million in exercise fees for two options, exercisable by Pfizer within 12 months of signing. Voyager will be eligible to earn up to $580 million in total development, regulatory, and commercial milestones associated with licensed products incorporating the two undisclosed Pfizer transgenes together with a Voyager licensed capsid. Voyager is also eligible to receive mid- to high-single-digit tiered royalties based on net sales of Pfizer’s products incorporating the licensed capsids. [collapse expanded text] |
Celltrion, Department of Defense | Sep 2021 | 626 | Supply agreement for COVID-19 point-of-care rapid antigen test kits | Celltrion announced that the Defense Logistics Agency under the Department of Defense has awarded … read moreCelltrion USA a procurement contract for its DiaTrustTM COVID-19 Ag Rapid Test. The DLA estimates its order volume to be as much as $626 million considering the change in demand by the COVID-19 community transmission rate in the U.S. [collapse expanded text] |
Blueprint Medicines, ZAI Laboratory | Nov 2021 | 615 | Collaboration and licensing agreement for BLU-945 and BLU-701 | Blueprint Medicines and Zai Lab announced an exclusive collaboration and license agreement for the … read moredevelopment and commercialization of BLU-945 and BLU-701 for the treatment of patients with epidermal growth factor receptor -driven non-small cell lung cancer in Greater China, including mainland China, Hong Kong, Macau and Taiwan. By combining Blueprint Medicines' precision therapy expertise with Zai Lab's development capabilities and established lung cancer franchise in Greater China, the collaboration aims to accelerate global development of BLU-945 and BLU-701 while addressing significant medical needs in China, where 40-50 percent of patients with NSCLC are believed to harbor EGFR mutations. Blueprint Medicines will retain all rights to BLU-945 and BLU-701 in the rest of the world. Blueprint Medicines will receive an upfront cash payment of $25 million and will be eligible to receive up to $590 million in potential development, regulatory and sales-based milestone payments, and tiered royalties on a product-by-product basis ranging from the low-teens to mid-teens on annual net sales of BLU-945 and BLU-701 in Greater China, subject to adjustment in specified circumstances. In addition, Zai Lab will be responsible for all the development costs for BLU-945 and BLU-701 occurring in Greater China and will receive the rights to develop and exclusively commercialize BLU-945 and BLU-701 in the region. [collapse expanded text] |
Genentech, Novome Biotechnologies | Nov 2021 | 605 | Collaboration agreement for targets against inflammatory bowel disease | Novome Biotechnologies announced a multi-year research collaboration and licensing agreement with … read moreGenentech to use Novome’s proprietary Genetically Engineered Microbial Medicines platform to discover, engineer and develop bacterial strains that express and deliver specific therapeutically relevant molecules to targets in the human intestinal tract to treat diseases such as Inflammatory Bowel Disease. Novome will have responsibility for research activities up to initiation of IND-enabling preclinical studies for this multi-target collaboration. Genentech will be responsible for clinical development of candidates and commercialization of potential medicines resulting from the collaboration. Novome will receive an upfront payment of $15 million. The Company is also eligible to receive up to $590 million in potential milestone payments based on the achievement of prespecified development and commercial milestones, as well as tiered royalties on sales resulting from the agreement. Novome retains rights to develop its own, wholly-owned IBD candidates utilizing targets outside of those included in the collaboration. [collapse expanded text] |
Incyte, Syndax Pharmaceuticals | Sep 2021 | 602 | Collaboration, licensing, option and co-promotion agreement for Axatilimab | Syndax Pharmaceuticals and Incyte have entered into an exclusive worldwide collaboration and … read morelicense agreement to develop and commercialize axatilimab, Syndax's anti-CSF-1R monoclonal antibody. Syndax and Incyte are seeking to develop axatilimab as a backbone therapy for patients with cGVHD as well as in additional immune-mediated diseases where CSF-1R-dependent monocytes and macrophages are believed to contribute to organ fibrosis. Syndax recently completed a Phase 1/2 trial of axatilimab in patients with cGVHD. Data from the Phase 1 portion of the trial highlighting the tolerability and high response rate of axatilimab in cGVHD patients refractory to multiple therapeutic agents were reported during an oral presentation at the American Society of Hematology Annual Meeting in December 2020. Updated results from the Phase 1 portion and preliminary results from the Phase 2 expansion portion of the study, which evaluated 1 mg/kg of axatilimab every two weeks, are expected to be presented at a medical meeting in the fourth quarter of 2021. Incyte will lead global commercial activities for axatilimab across all indications. The companies will participate in a 50:50 profit share in the US, and Syndax will receive double-digit royalties on sales outside of the US Syndax will retain the option to co-promote axatilimab for any approved indications in the US. Syndax will receive an upfront payment of $117 million plus a $35 million equity investment, which will be purchased at $24.62 per share, a 30% premium to the volume weighted average price over the 10 days prior to September 24, 2021. Syndax will also be eligible to receive up to an additional $450 million in potential regulatory, development and commercial milestone payments. The companies will share development costs associated with global and US-specific trials for all agreed upon trials at a rate of 55% (Incyte) and 45% (Syndax), with Incyte responsible for 100% of future development costs for trials that are specific to ex-US countries. Syndax will fund the initial development of axatilimab in IPF and Incyte will have the option to co-fund late-stage development for this indication. [collapse expanded text] |
Genevant Sciences, Takeda Pharmaceutical | Mar 2021 | 600 | Collaboration and licensing agreement for nucleic acid therapeutics for liver fibrosis | Genevant Sciences has entered into a global collaboration and license agreement with Takeda … read morePharmaceutical for the discovery, development and commercialization of LNP-delivered nucleic acid therapeutics directed to previously inaccessible drug targets in hepatic stellate cells to treat liver fibrosis. Genevant is initially eligible to receive up to $600 million in upfront and milestone payments, plus royalties on future product sales. Takeda has exclusive rights to Genevant’s LNP technology for a specified number of selected hepatic stellate cells targets. [collapse expanded text] |
Intellia Therapeutics, SparingVision | Oct 2021 | 600 | Collaboration, licensing and co-promotion agreement for ocular therapies using CRISPR/Cas9 technology | Key Deal Terms Summary: Intellia Therapeutics and SparingVision Collaboration… read moreParties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Considerations
Overall SummaryIntellia and SparingVision have entered a strategic collaboration to develop CRISPR/Cas9-based gene editing therapies for ocular diseases. SparingVision will lead R&D efforts, while Intellia retains U.S. commercialization options for two targets. Intellia will also receive a 10% equity stake in SparingVision and potential milestone payments exceeding $200 million per product, along with royalties on product sales. This partnership strengthens Intellia’s presence in ophthalmology while enabling SparingVision to pioneer gene editing-based vision-saving treatments. [collapse expanded text] |
Carestream Health, Envista | Dec 2021 | 600 | Asset purchase agreement for intra-oral scanner business | Envista has entered into a definitive agreement to acquire Carestream Dental's Intra-Oral Scanner ( … read moreIOS) business for $600 million. [collapse expanded text] |
Heartseed, Novo Nordisk | Jun 2021 | 598 | Collaboration, licensing and co-promotion agreement for HS-001 | Heartseed and Novo Nordisk have entered into an exclusive worldwide collaboration and licence … read moreagreement for development, manufacturing and commercialisation of Heartseed’s lead asset HS-001. Novo Nordisk gains exclusive rights to develop, manufacture and commercialise HS-001 worldwide except in Japan. Heartseed will maintain the rights to solely develop HS-001 in Japan and Novo Nordisk has the rights to co-commercialise the product in Japan with Heartseed with 50/50 profit and cost sharing. Heartseed is eligible to receive payments totalling up to 598 million US dollars including 55 million dollars in upfront and near-term milestone payments. Heartseed is also eligible to receive tiered high single-digit to low double-digit royalties of annual net sales outside of Japan. [collapse expanded text] |
Genfit, Ipsen | Dec 2021 | 592.6 | Collaboration and licensing agreement for Elafibranor | Ipsen and GENFIT have entered into a long-term strategic partnership for global collaboration … read morebetween the two companies. The agreement gives Ipsen exclusive worldwide license to develop, manufacture and commercialize GENFIT’s investigational treatment elafibranor, for people living with Primary Biliary Cholangitis. The partnership also gives Ipsen access to future clinical programs led by GENFIT and combines GENFIT’s scientific expertise and proprietary technologies in liver disease with Ipsen’s development and commercialization capabilities. To underscore the long-term commitment represented by this partnership, Ipsen will also purchase newly issued GENFIT equity representing 8% post-issuance through a €28m investment in GENFIT, becoming one of the largest shareholders. Ipsen will pay GENFIT up to €480m, comprising upfront cash payment of €120m, as well as regulatory, commercial, and sales-based milestone payments up to €360m, plus tiered double-digit royalties of up to 20%. Ipsen also becomes a shareholder of GENFIT through the purchase of 3,985,239 newly issued shares representing 8% of GENFIT S.A. after issuance, via a €28m investment. The new shares will be issued pursuant to the twentieth resolution of GENFIT’s 30 June 2021 shareholders’ meeting and will be subject, upon issuance, to a lock-up period ending, in the event of positive ELATIVE results, on the earlier of the date on which the EMA makes a formal recommendation to the European Commission for the marketing authorisation of elafibranor in PBC or the date on which the U.S. FDA grants approval of elafibranor in PBC. Issuance of the new shares is expected to take place on or about December 22, 2021. In addition, the Board of Directors of GENFIT will propose at the next shareholders’ meeting that Ipsen becomes a board member. [collapse expanded text] |
CANbridge Pharmaceuticals, LogicBio Therapeutics | Apr 2021 | 591 | Collaboration, option and licensing agreement for gene therapy programs | CANbridge Pharmaceuticals has entered into a strategic collaboration and licensing agreement with … read moreLogicBio Therapeutics. The agreement includes a worldwide license to develop, manufacture and commercialize gene therapy candidates for treatments for Fabry and Pompe diseases, based on LogicBio’s adeno-associated virus (AAV) sL65, the first capsid produced from the LogicBio sAAVy platform. The agreement also includes options for the development of AAV sL65-based treatments for two additional indications. AAV sL65 has unique liver-targeting properties, the potential to overcome limited potency and immunogenicity issues, and is more efficient to manufacture, potentially resulting in higher yields, making it a valuable strategic addition to the CANbridge’s gene therapy program. CANbridge is also granted an option to an exclusive license for LB-001, an investigational in-vivo gene editing technology based on GeneRide platform for the potential treatment of methylmalonic acidemia (MMA), in Greater China (China, Taiwan, Hong Kong and Macau). LogicBio is eligible to receive an upfront payment of $10 million for the exclusive worldwide license to support the development of two gene therapy candidates for Fabry and Pompe diseases. In addition, the agreement grants options for two additional undisclosed gene therapy programs, based on AAV sL65, and an option to an exclusive license for LB-001 in Greater China. Upon exercising the option for LB-001, CANbridge would assume responsibility and costs for all future development in the territory, including regulatory and commercial activities and, potentially, manufacturing. The agreement also includes payments, including opt-in fees triggered upon the exercise of these options, as well as clinical, regulatory, and commercial milestone payments for up to $581 million, and up to double-digit royalties on net sales. [collapse expanded text] |
China Grand Pharmaceutical, ITM Isotopen Technologien | Dec 2021 | 587 | Licensing agreement for ITM-11 (n.c.a. 177Lu-edotreotide) and ITM-41 (n.c.a. 177Lu-zoledronate) and diagnostic TOCscan (68Ga-edotreotide) | February 2022 ITM Isotope Technologies Munich and Grand Pharmaceutical announced that ITM and a … read moresubsidiary of GP have entered into a definitive agreement under which GP will make a EUR 25 million (USD 28 million) equity investment in ITM. The agreement will further deepen the strategic collaboration between the two companies and support ITM to further expanding its broad pipeline of precision oncology treatments and diagnostics in Greater China. December 2021 ITM Isotope Technologies and Grand Pharmaceutical have entered into an exclusive licensing agreement for GP to develop, manufacture and commercialize ITM’s oncological radiopharmaceutical candidates, ITM-11 (n.c.a. 177Lu-edotreotide) and ITM-41 (n.c.a. 177Lu-zoledronate) as well as the diagnostic TOCscan (68Ga-edotreotide) in the territory of mainland China, Hong Kong, Macau and Taiwan. ITM grants GP an exclusive license for the named products in the licensed territory and will support the supply of the pharmaceutical materials needed to conduct clinical and commercial activities. GP will be responsible for clinical development, regulatory activities and commercialization of these products in the licensed geographies. ITM is eligible for a significant upfront payment as well as potential aggregate regulatory and commercial milestone payments totalling up to approximately EUR 520 million in addition to tiered royalties. [collapse expanded text] |
Akebia Therapeutics, Cyclerion Therapeutics | Jun 2021 | 585 | Licensing agreement for Praliciguat | Cyclerion Therapeutics has entered into an exclusive, global license agreement with Akebia … read moreTherapeutics for the development and commercialization of praliciguat, an oral sGC stimulator. Akebia has obtained an exclusive license to research, develop and commercialize praliciguat globally and will be solely responsible for these activities going forward. Cyclerion is eligible to receive up to $225M in pre-commercial milestones, including up to $15M in the first 18 months. Total potential future development, regulatory, and commercialization milestone payments could result in up to $585M. Cyclerion is also eligible to receive tiered, sales-based royalties ranging from single-digit to high-teen percentages. [collapse expanded text] |
Everest Medicines, SinoMab Bioscience, Suzhou Sinovent Pharmaceuticals | Sep 2021 | 561 | Licensing agreement for XNW1011 | Everest Medicines has entered into an exclusive licensing agreement with Suzhou Sinovent … read morePharmaceuticals and SinoMab BioScience to develop, produce and commercialize XNW1011 (referred as "SN1011" by SinoMab), a covalent reversible Bruton's tyrosine kinase inhibitor, globally for the treatment of renal diseases. Everest will pay Sinovent and SinoMab USD $12 million in initial upfront payments and up to $549 million as future development, regulatory, and commercial milestone payments, as well as high single-digit to low double-digit royalties on global net sales. The agreement will also include full technology transfer of the current manufacturing process to Everest to support future development and commercialization. [collapse expanded text] |
Alligator Bioscience, Orion | Aug 2021 | 550 | Research, option and licensing agreement for bispecific antibody cancer therapeutics | November 2024 Orion Corporation and Alligator Bioscience AB have agreed on conversion previously … read moregranted royalty-bearing license to Orion Corporation to two bispecific antibodies that companies have been successfully developing in collaboration using Alligator’s RUBY bispecific format to perpetual, fully paid, royalty-free license Orion will continue to develop these antibodies, which are currently in late-stage pre-clinical development, without any obligation to pay any milestone payments or royalties to Alligator In connection with amendment Orion pays Alligator a one-time payment of EUR 3.5 million July 2023 Alligator Bioscience announced that Technical Feasibility in the second program under the research collaboration and license agreement with Orion, which aims to discover and develop new bispecific antibody cancer therapeutics, has been achieved. May 2023 Alligator Bioscience announced that Orion has selected bispecific lead antibodies and is exercising its option to develop these molecules under the existing research collaboration and license agreement between the two companies. Alligator will continue to generate additional data in order for Orion to select the final development candidate over the coming months. Upon exercise, the development option is conditional upon a milestone payment to Alligator. January 2023 Alligator Bioscience announced an expansion to its research collaboration and license agreement with Orion to discover and develop together new bispecific antibody cancer therapeutics. The collaboration has been expanded to add the development of a second bispecific antibody using Alligator’s proprietary bispecific RUBY platform, where Alligator will provide validated monospecific binders for one target and Orion will do the same for the other target. August 2021 Alligator Bioscience has entered into a research collaboration and license agreement with Orion to discover and develop together new bispecific antibody cancer therapeutics The research collaboration will focus on the discovery of novel bispecific antibodies directed towards immuno-oncology targets selected by Orion. The agreement covers an option to develop three bispecific antibodies. Alligator Bioscience will employ its proprietary phage display libraries and RUBY bispecific platform to develop immuno-oncology product candidates based on design criteria identified by Orion. During the initial research period of the collaboration, Alligator Bioscience will receive an upfront payment and research support payments. Alligator Bioscience is eligible for development, approval and sales milestone payments of up to 469 million euros, in addition to royalties if Orion exercises its options to continue development and commercialization of the resulting product candidates. [collapse expanded text] |
American Type Culture Collection (ATCC), National Institute of Allergy and Infectious Diseases | Nov 2021 | 545 | Contract service agreement for research capabilities in infectious, immunologic and allergic diseases | ATCC has been awarded a seven-year, Indefinite Delivery/Indefinite Quantity contract with a ceiling … read morevalue of $545 million by the National Institute of Allergy and Infectious Diseases. With this contract, ATCC will support NIAID’s Division of Clinical Research, Division of Intramural Research and Vaccine Research Center with rapid response capabilities to infectious disease issues, such as COVID-19, as well as provide quality services across basic science, preclinical, clinical, assay development and vaccine production. [collapse expanded text] |
Nestle Health Science, Seres Therapeutics | Jul 2021 | 525 | Licensing and co-promotion agreement for SER-109 | Seres Therapeutics has entered into an agreement with Nestlé Health Science to jointly … read morecommercialize SER-109, Seres’ investigational oral microbiome therapeutic for recurrent Clostridioides difficile infection (CDI), in the United States and Canada. If approved, SER-109 would become the first-ever FDA-approved microbiome therapeutic. Nestlé Health Science will utilize its global pharmaceutical business Aimmune Therapeutics and will assume the role of lead commercialization party. Seres will receive license payments of $175 million up front, and an additional $125 million upon FDA approval of SER-109. The agreement also includes sales target milestones which, if achieved, could total up to $225 million. Seres will be responsible for development and pre-commercialization costs in the U.S. Upon commercialization, Seres will be entitled to an amount equal to 50% of the commercial profits. The agreement to co-commercialize SER-109 in the U.S. and Canada represents the expansion of an existing strategic collaboration between the companies. Nestlé Health Science already has commercial rights to Seres’ investigational treatments for CDI and inflammatory bowel disease outside of the U.S. and Canada, and with this expansion, Nestlé Health Science becomes Seres’ global collaborator in SER-109. [collapse expanded text] |
Merck and Co, Synthekine | Nov 2021 | 525 | Collaboration and licensing agreement for surrogate cytokine agonist platform for cytokine therapeutics | Synthekine has entered into a worldwide research collaboration and license agreement with Merck & … read moreamp; Co. The collaboration will leverage Synthekine’s proprietary surrogate cytokine agonist platform to discover, develop, and commercialize novel cytokine therapeutics. Synthekine is responsible for initial research efforts in collaboration with Merck, and Merck will have exclusive rights to develop, manufacture and commercialize surrogate cytokine agonists for up to two cytokine targets. Initially, the collaboration will focus on a target that has the potential to treat autoimmune diseases. Merck will make an upfront payment and will make an additional one-time payment if it designates a second target. Synthekine will be eligible for up to $525 million in development, regulatory and commercialization milestones, as well as tiered royalties on net sales, for each target. Merck will provide research funding to Synthekine for programs under the collaboration. [collapse expanded text] |
Beijing Tide Pharmaceutical, Graviton Bioscience | Feb 2021 | 517.5 | Licensing agreement for ROCK2 inhibitor TDI01 | Graviton Bioscience and Beijing Tide Pharmaceutical announced the signing of an exclusive license … read moreagreement for TDI01. The agreement grants development and commercialization rights for TDI01 to Graviton in all territories, excluding China. Graviton will make an upfront payment and additional amounts for development, regulatory and sales milestone payments for all programs, as well as royalties on net sales and an option for a revenue-sharing arrangement for certain developed products. The aggregate amount of upfront, development, regulatory and sales milestone payments is up to USD 517.5 million. [collapse expanded text] |
KSQ Therapeutics, Takeda Pharmaceutical | Jan 2021 | 500 | Collaboration, option and licensing agreement for novel immuno-oncology therapies | May 2023 KSQ Therapeutics has expanded its strategic collaboration with Takeda to research and … read morevalidate novel tumor-intrinsic targets. Takeda will provide KSQ with an upfront payment and an investment in the double-digit millions of dollars. KSQ is also eligible to receive up to $510 million in future payments if all milestones are achieved during the term of the agreement, plus royalties on potential net sales of any commercial product resulting from the collaboration. January 2021 KSQ Therapeutics has entered into a broad strategic collaboration with Takeda Pharmaceutical Company to research, develop and commercialize novel immune-based therapies for cancer. KSQ has granted Takeda an exclusive, worldwide, royalty-bearing license to develop, manufacture and commercialize cell and non-cell therapy products that modulate targets identified using KSQ’s CRISPRomics technology. The deal includes two T-cell targets previously identified and validated by KSQ, with the potential to introduce two additional T-cell targets to the collaboration. The companies will also collaborate to discover and develop therapeutics that modulate natural killer cell targets to be identified through the collaboration. Under the terms of the agreement, upfront and potential preclinical milestones have the potential to exceed $100 million. KSQ will be eligible for additional option payments along with development and commercialization milestone payments. Depending on the target, these option and milestone payments can reach up to more than $400 million per program. KSQ is also eligible to receive tiered royalties on net sales of each approved product. KSQ and Takeda can collaborate on IND-enabling activities, with clinical development led by Takeda to explore multiple modalities. Takeda will assume responsibility for funding all development and commercialization activities. KSQ will have the option to participate in cost/profit sharing on one of the two products based on the T-cell targets previously identified and validated by KSQ, in the U.S. and retain royalties on all ex-U.S. sales for that product. [collapse expanded text] |
GSK, Sandoz | Feb 2021 | 500 | Asset purchase and supply agreement for cephalosporin antibiotics business | Sandoz has signed an agreement to acquire GSK’s cephalosporin antibiotics business, reinforcing its … read moreleading global position in antibiotics. The agreement includes the global rights to three established brands (Zinnat, Zinacef and Fortum)) in more than 100 markets. It excludes the rights in the US, Australia and Germany to certain of those brands, which were previously divested by GSK, and in India, Pakistan, Egypt, Japan (to certain of the brands) and China, which will be retained by GSK. Sandoz will pay GSK USD 350 million at closing, plus additional milestone payments of up to USD 150 million, subject to the terms of the transaction. Closing of the transaction is expected in the second half of 2021, subject to customary closing conditions including regulatory approvals. Once the transaction is completed, GSK will supply Zinnat to Sandoz under a manufacturing and supply agreement, while supporting a transfer of the related manufacturing operations to Sandoz. We expect this process to last for approximately four years from the close of the transaction onwards. [collapse expanded text] |
Amathus Therapeutics, Merck and Co | Mar 2021 | 500 | Collaboration and option agreement for small molecule therapeutic candidates for neurodegenerative diseases | Amathus Therapeutics announced a strategic collaboration with Merck to develop novel small molecule … read moretherapeutic candidates for neurodegenerative diseases. Amathus will be responsible for identifying and progressing novel chaperone activators through preclinical discovery. Merck has the option to acquire Amathus Therapeutics and its pipeline of mitochondrial targeted candidates for the treatment of neurodegenerative disorders and renal diseases. Amathus will receive an upfront payment from Merck and, upon Merck’s exercise of its option, will be eligible for milestone payments associated with the successful development of candidates in excess of $500 million per program. Upon exercise of its option, Merck will be solely responsible for clinical development and commercialization. [collapse expanded text] |
BridGene Biosciences, Takeda Pharmaceutical | Mar 2021 | 500 | Collaboration and licensing agreement for up to five drug discovery programs harnessing IMTAC Chemoproteomics platform | March 2023 BridGene Biosciences has achieved a significant milestone in its collaboration with … read moreTakeda. The collaboration between BridGene and Takeda is based on BridGene's proprietary IMTAC (Isobaric Mass Tagged Affinity Characterization) chemoproteomics platform, which is used to identify targets and small molecules for Takeda to develop into therapeutic candidates for clinical development. BridGene is entitled to receive an undisclosed milestone payment. March 2021 BridGene Biosciences announced a strategic research collaboration and licensing agreement with Takeda Pharmaceutical. Under the collaboration, the parties will establish up to five drug discovery programs, harnessing BridGene's proprietary IMTAC (Isobaric Mass Tagged Affinity Characterization) Chemoproteomics platform to identify targets and small molecule drug candidates for Takeda to develop into therapeutic candidates and pursue into clinical development. BridGene with its chemoproteomics platform can identify small molecule interactions with a wide variety of proteins in living cells. BridGene will receive from Takeda a one-time upfront payment for access to its IMTAC technology. For any validated targets selected by Takeda, Takeda will receive an exclusive license to research, develop and commercialize any drug candidates that result from the research programs. BridGene will then be eligible to receive potential preclinical, clinical and commercial milestone payments that could exceed $500 million, as well as royalties from future sales of commercialized drugs resulting from the collaboration. [collapse expanded text] |
Amyris, DSM Nutritional Products | Mar 2021 | 500 | Supply agreement for flavor and fragrance ingredients | Amyris has signed and closed an agreement with DSM Nutritional Products for the exclusive rights to … read moresupply Amyris's product portfolio of flavor and fragrance ingredients. Amyris will continue to develop, scale and manufacture future molecules with its existing partners and DSM. The total transaction value is estimated at over $500 million from short and long-term contributions with approximately 1/3 as an upfront payment at closing, more than 1/3 from potential earn-out payments based on milestones over the three year period from 2022 through 2024, and the remainder attributable to a 15-year manufacturing agreement between Amyris and DSM and the expected value of developing and scaling a pipeline of new F&F molecules through collaboration agreements. Amyris will continue to develop, scale-up and produce all existing ingredients in its F&F portfolio with the support of DSM and Amyris's current F&F partners. Amyris's F&F partners have extended their current R&D collaboration agreements by 15 years to accelerate the development of future F&F ingredients. DSM will be responsible for the commercial relationship with Amyris's current partners. The parties expect that the combination of DSM's market reach and Amyris's proprietary synthetic biology and fermentation platform will accelerate the industry's transition to clean, sustainable chemistry. [collapse expanded text] |
ObsEva, Organon | Jul 2021 | 500 | Licensing agreement for Ebopiprant (OBE022) | Organon and ObsEva have entered into an agreement whereby Organon will license the global … read moredevelopment, manufacturing and commercial rights to ebopiprant (OBE022). Ebopiprant is an investigational, orally active, selective prostaglandin F2α (PGF2α) receptor antagonist being evaluated as a potential treatment for preterm labor by reducing inflammation and uterine contractions. Organon will gain exclusive worldwide rights to develop and commercialize ebopiprant. ObsEva is entitled to receive tiered double-digit royalties on commercial sales as well as up to $500 million in upfront and milestone payments including $25 million to be paid at signing, up to $90 million in development and regulatory milestones and up to $385 million sales based milestones. [collapse expanded text] |
Top partnering deals of 2020 valued at over US$500m.
Partners | Date | Value, US$m | Subject | Termsheet |
---|---|---|---|---|
Artios Pharma, Merck KGaA | Dec 2020 | 6910 | Collaboration, option and licensing agreement for multiple precision oncology drugs | Key Deal Terms Summary1. Agreement Overview
2. Financial Terms
3. Development & Commercialization Plans
4. Strategic Impact
Overall SummaryArtios Pharma and Merck KGaA have formed a three-year global strategic collaboration to develop novel precision oncology drugs targeting nucleases. Artios will receive an upfront payment of $30 million, with the potential to earn up to $860 million per target plus double-digit royalties if Merck KGaA opts into exclusive development of up to eight targets. The collaboration enhances Merck KGaA’s oncology pipeline while reinforcing Artios’ position in the DDR space. [collapse expanded text] |
AstraZeneca, Daiichi Sankyo | Jul 2020 | 6000 | Development and licensing agreement for DS-1062 | Key Deal Terms Summary1. Collaboration Overview
2. Financial Terms
3. Commercialization and Strategic Impact
4. DS-1062 Drug Profile
5. Implications and Future Developments
Overall SummaryDaiichi Sankyo and AstraZeneca have expanded their ADC collaboration with a $6 billion deal for DS-1062, a TROP2-directed ADC in phase 1 clinical development for lung and breast cancers. AstraZeneca will pay $1 billion upfront, with up to $5 billion in milestone payments, and the companies will share costs and profits globally, excluding Japan. The agreement strengthens AstraZeneca’s oncology pipeline while positioning DS-1062 as a potential leading therapy in multiple cancers. [collapse expanded text] |
Merck and Co, Seattle Genetics | Sep 2020 | 4200 | Collaboration, co-development and licensing agreement for ladiratuzumab vedotin | Seattle Genetics and Merck announced a strategic oncology collaboration. The companies will … read moreglobally develop and commercialize Seattle Genetics’ ladiratuzumab vedotin, an investigational antibody-drug conjugate (ADC) targeting LIV-1, which is currently in phase 2 clinical trials for breast cancer and other solid tumors. The collaboration will pursue a broad joint development program evaluating ladiratuzumab vedotin as monotherapy and in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) in triple-negative breast cancer, hormone receptor-positive breast cancer and other LIV-1-expressing solid tumors. Seattle Genetics will receive a $600 million upfront payment and Merck will make a $1.0 billion equity investment in 5.0 million shares of Seattle Genetics common stock at a price of $200 per share. Seattle Genetics is eligible for progress-dependent milestone payments of up to $2.6 billion. Seattle Genetics and Merck will collaborate and equally share costs on the global development of ladiratuzumab vedotin and other LIV-1-targeting ADCs. The companies have agreed to jointly develop and share future costs and profits for ladiratuzumab vedotin on a 50:50 basis worldwide. Merck will pay Seattle Genetics $600 million upfront and make a $1.0 billion equity investment in 5.0 million shares of Seattle Genetics common stock at a price of $200 per share. In addition, Seattle Genetics will be eligible to receive up to $2.6 billion in milestone payments, including $850 million in development milestones and $1.75 billion in sales milestones. The companies will jointly develop and commercialize ladiratuzumab vedotin and equally share profits worldwide. The companies will co-commercialize in the U.S. and Europe. Seattle Genetics will be responsible for marketing applications for approval in the U.S. and Canada, and will record sales in the U.S., Canada and Europe. Merck will be responsible for marketing applications for approval in Europe and in countries outside the U.S. and Canada, and will record sales in countries outside the U.S., Europe and Canada. Including the upfront payment, equity investment proceeds and potential milestone payments, Seattle Genetics is eligible to receive up to $4.2 billion. [collapse expanded text] |
Myovant Sciences, Pfizer | Dec 2020 | 4200 | Collaboration, option, licensing and co-promotion agreement for Relugolix | Key Deal Terms Summary1. Agreement Overview
2. Financial Terms
3. Clinical Data & Efficacy
4. Safety & Tolerability
5. Development & Commercialization Plans
Overall SummaryThe Phase 3 SPIRIT Extension Study demonstrated that relugolix combination therapy provided significant, sustained pain relief for endometriosis-related pain over one year, with minimal bone mineral density loss. The positive safety and efficacy profile will support a New Drug Application submission to the FDA in H1 2021. Pfizer and Myovant continue their strategic collaboration, with Pfizer committing up to $4.2 billion in payments, reflecting confidence in relugolix’s commercial potential. [collapse expanded text] |
Alteogen | Jun 2020 | 3881 | Licensing agreement for Hybrozyme technology to enable subcutaneous administration of biologic products | Alteogen has entered into a non-exclusive, global license agreement with a Top Ten Pharmaceutical … read moreCompany, to use ALT-B4, Alteogen’s novel hyaluronidase- derived utilizing the Hybrozyme technology. ALT-B4 is a proprietary recombinant human hyaluronidase enzyme that enables large-volume subcutaneous administration of biologics that would otherwise be administered as an IV injection. Alteogen has granted worldwide rights for TTPC to develop multiple products in combination with ALT-B4. Alteogen will receive an initial payment of USD 16 Million and is also eligible to receive additional milestones upon TTPC’s achievement of specified development, regulatory and sales milestones, totaling up to USD 3.865 Billion for the initial products under this agreement. TTPC may in the future elect to develop additional products in combination with ALT-B4 upon achievement of the pre-specified milestone. Alteogen will be responsible for regulatory development and commercial supply of ALT-B4. [collapse expanded text] |
Abbvie, Genmab | Jun 2020 | 3800 | Collaboration, co-development, licensing and co-promotion agreement for bispecific antibody products, including epcoritamab | Deal Summary: AbbVie & GenmabParties Involved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryThis collaboration leverages AbbVie’s global oncology expertise and ADC technology with Genmab’s bispecific antibody platforms to advance novel cancer treatments. The $750 million upfront payment and $3.15 billion potential milestone payments highlight the deal’s financial significance. The joint commercialization strategy for epcoritamab and shared rights for additional antibody candidates ensure both companies benefit from the collaboration's success in hematologic and solid tumors. [collapse expanded text] |
PeptiDream, Takeda Pharmaceutical | Dec 2020 | 3500 | Collaboration and licensing agreement for peptide drug conjugates for neuromuscular diseases | July 2021 PeptiDream and Takeda Pharmaceutical announced an expansion of its research … read morecollaboration and exclusive license agreement to create peptide-drug conjugates (PDCs) for several central nervous system (CNS) targets, which play importantroles in chronic neurodegenerative diseases. PeptiDream is eligible to receive up to approximately $3.5 billion (JPY 390.3 billion) in total as upfront and potential preclinical, development, launch, and sales-based milestones. PeptiDream is also eligible to receive royalties on net sales of any product resulting from the collaboration. December 2020 PeptiDream and Takeda Pharmaceutical have agreed to a collaborative research and exclusive license agreement to create peptide-drug conjugates (PDCs) for neuromuscular diseases. Despite advances in the understanding of neuromuscular diseases, the broad biodistribution required to target key tissues throughout the body that contribute to disease remains a key challenge for drug development. The agreement aims to address these challenges by conjugating peptides developed by PeptiDream and JCR Pharmaceuticals that bind to the transferrin receptor to specific drug payloads selected by Takeda to improve their profile of tissue distribution for treating neuromuscular diseases. PeptiDream will receive an upfront payment from Takeda. PeptiDream may also receive milestone payments based on the achievements of specified pre-clinical research and clinical trial achievements. Financial terms of the collaboration were not disclosed. [collapse expanded text] |
Biogen, Sage Therapeutics | Nov 2020 | 3125 | Collaboration and licensing agreement for therapies in depression and movement disorders | Key Deal Terms Summary1. Agreement Overview
2. Financial Terms
3. Development & Commercialization Plans
4. Strategic Impact
Overall SummarySage Therapeutics announced the termination of Biogen’s rights to SAGE-324, following negative Phase 2 results in essential tremor. The termination will be effective in February 2025, with Sage regaining full ownership of the asset. Sage and Biogen remain partners on zuranolone (ZURZUVAE®), ensuring continued collaboration in postpartum depression. Sage plans to explore other potential indications for SAGE-324 but did not disclose financial implications of the termination. [collapse expanded text] |
Fate Therapeutics, Janssen Biotech | Apr 2020 | 3100 | Collaboration, option, licensing and co-promotion agreement for iPSC-derived cell-based cancer immunotherapies | Parties Involved
Collaboration ScopeThe original April 2020 collaboration aimed to co-develop up to four iPSC-derived CAR NK and CAR T-cell therapies targeting tumor-associated antigens in hematologic malignancies and solid tumors. Fate was to apply its iPSC product platform using Janssen’s proprietary antigen-binding domains, with Fate advancing candidates through IND filing, after which Janssen would have exclusive development and commercialization rights. Rights & Responsibilities
Financial Terms
Termination Details
Regulatory Approval
Overall SummaryFate Therapeutics and Janssen entered a high-value global collaboration in April 2020 to develop off-the-shelf iPSC-derived CAR NK and T-cell therapies, with a potential value of over $3 billion. Despite achieving early milestones, the partnership was terminated in January 2023 after the parties failed to align on revised terms. Fate subsequently reprioritized its pipeline, focused on next-generation multiplexed CAR cell therapies, and confirmed a three-year operational runway with approximately $475 million in cash and receivables as of year-end 2022. [collapse expanded text] |
Bristol-Myers Squibb, Repare Therapeutics | May 2020 | 3065 | Collaboration agreement for SNIPRx synthetic lethal discovery platform to identify multiple oncology drug candidates | Repare Therapeutics has entered into an exclusive, worldwide research collaboration with Bristol … read moreMyers Squibb. Under the terms of the agreement, the companies will leverage Repare’s proprietary, CRISPR-enabled genome-wide synthetic lethal target discovery platform, SNIPRx, to jointly identify multiple synthetic lethal precision oncology targets for drug candidates. Repare will grant BMS exclusive worldwide rights to develop and commercialize therapeutics for select validated synthetic lethal precision oncology targets discovered under the collaboration. BMS will make an upfront payment of $65 million which includes a $15 million equity investment in Repare. Repare will be eligible to receive up to approximately $3 billion in license fees, discovery, development, regulatory and sales-based milestones, in addition to royalty payments on net sales of each product commercialized by BMS. [collapse expanded text] |
WuXi Biologics | Feb 2020 | 3000 | Manufacturing agreement for vaccine products | WuXi Biologics announced that WuXi Vaccines has entered into a strategic partnership with a global … read morevaccine leader and signed a 20-year vaccine manufacturing contract valued approximately $3 billion USD, pursuant to which WuXi Vaccines will build a dedicated facility and supply a commercial vaccine products for the global market. WuXi Vaccines will build an integrated vaccine manufacturing facility including drug substance manufacturing (DS), drug product manufacturing (DP), Manufacture Science and Technology Labs (MS&T) as well as Quality Control labs (QC). The facility will be dedicated to manufacture one of its partner's vaccine products for the global market. The new facility is expected to be operational in 2022. [collapse expanded text] |
Bristol-Myers Squibb, Schrodinger | Nov 2020 | 2755 | Collaboration agreement for computational platform and drug discovery capabilities | Schrödinger announced a discovery collaboration with Bristol Myers Squibb to discover, develop, and … read morecommercialize therapeutics in multiple disease areas. The multi-year collaboration will combine Schrödinger’s leading physics-based computational platform and drug discovery capabilities with Bristol Myers Squibb's expertise in development and commercialization to advance small molecule therapeutics for targets in oncology, immunology, and neurological disorders. The collaboration includes two of Schrödinger’s early-stage programs and additional undisclosed targets. Schrödinger will be responsible for the discovery of development candidates for each of the targets under the collaboration. Bristol Myers Squibb will then be responsible for the development, manufacturing, and commercialization of the candidates. Bristol Myers Squibb will pay Schrödinger $55 million upfront, and Schrödinger will also be eligible to receive up to $2.7 billion in preclinical, development, regulatory and sales-based milestone payments. Schrödinger is entitled to receive royalties on net sales of each product commercialized by Bristol Myers Squibb. Schrödinger has agreed to grant Bristol Myers Squibb exclusive worldwide rights to develop and commercialize the development candidates generated by the collaboration. [collapse expanded text] |
Biogen, Sangamo Therapeutics | Feb 2020 | 2720 | Collaboration and licensing agreement for gene regulation therapies for Alzheimer’s, Parkinson’s, neuromuscular, and other neurological diseases | March 2023 Biogen notified Sangamo of its termination for convenience, effective June 15, 2023, … read moreof the Collaboration and License Agreement by and between Biogen and Sangamo dated February 26, 2020, pursuant to which Biogen and Sangamo were engaged in programs to research and develop gene regulation therapies to treat neurological diseases. Biogen has indicated to Sangamo that the termination relates to a recent strategic review. Sangamo will investigate alternative options to advance the neurological disease programs that were subject to the Biogen Agreement, including potential development internally or with a collaboration partner, dependent on the outcome of a broader strategic review of its pre-clinical pipeline of therapies to treat patients suffering from central nervous system disorders. February 2020 Biogen and Sangamo Therapeutics have executed a global licensing collaboration agreement to develop and commercialize ST-501 for tauopathies including Alzheimer’s disease, ST-502 for synucleinopathies including Parkinson’s disease, a third undisclosed neuromuscular disease target, and up to nine additional undisclosed neurological disease targets. The companies will leverage Sangamo’s proprietary zinc finger protein (ZFP) technology delivered via adeno-associated virus (AAV) to modulate the expression of key genes involved in neurological diseases. Biogen has exclusive global rights to ST-501 for tauopathies including Alzheimer’s disease, ST-502 for synucleinopathies including Parkinson’s disease, and a third undisclosed neuromuscular disease target. In addition, Biogen has exclusive rights to nominate up to nine additional undisclosed targets over a target selection period of five years. Sangamo will perform early research activities, costs for which will be shared by the companies, aimed at the development of the combination of proprietary CNS delivery vectors and ZFP-TFs targeting therapeutically relevant genes. Biogen will then assume responsibility and costs for the investigational new drug-enabling studies, clinical development, related regulatory interactions, and global commercialization. Sangamo will be responsible for GMP manufacturing activities for the initial clinical trials for the first three products of the collaboration and plans to leverage its in-house manufacturing capacity. Biogen will assume responsibility for GMP manufacturing activities beyond the first clinical trial for each of the first three products. Sangamo will receive $350 million comprised of $125 million in a license fee payment and $225 million from the sale of new Sangamo stock, or approximately 24 million shares at $9.21 per share. Sangamo may receive up to $2.37 billion in other development, regulatory, and commercial milestone payments, including up to $925 million in pre-approval milestone payments and up to $1,445 million in first commercial sale and other sales-based milestone payments. Sangamo will also be eligible to receive from Biogen tiered high single digit to sub-teen double-digit royalties on potential net commercial sales of products arising from the collaboration. [collapse expanded text] |
Genzyme, Nurix Therapeutics, Sanofi | Jan 2020 | 2555 | Collaboration, option, co-development and co-promotion agreement for targeted protein degradation therapies | Nurix Therapeutics announced a global strategic collaboration with Sanofi to discover, develop and … read morecommercialize a pipeline of innovative targeted protein degradation drugs for patients with challenging diseases in multiple therapeutic areas. Nurix will utilize its proprietary drug discovery platform, DELigase, that integrates its DNA-encoded libraries (DEL) and its unparalleled portfolio of E3 ligases to create small molecules designed to induce degradation of three specified drug targets, with an option by Sanofi to expand to a total of five targets. Sanofi will have exclusive rights and be responsible for clinical development and commercialization of drug candidates resulting from the work while Nurix will retain the option to co-develop and co-promote up to two products in the United States under certain conditions. The collaboration excludes Nurix’s lead degradation programs for which Nurix retains all rights. Nurix will receive an upfront payment of $55 million and subsequent payments upon expansion of the number of targets to be included in the collaboration. In addition, Nurix will be eligible to receive up to approximately $2.5 billion in total payments based on the successful completion of certain research, pre-clinical, clinical, regulatory and sales milestones. For those programs that Nurix exercises its option to co-develop and co-promote, the parties will split U.S. profits and losses evenly and Nurix will be eligible to receive royalties on ex-U.S. net sales on all optioned products. [collapse expanded text] |
Astex Pharmaceuticals, Merck and Co, Taiho | Jan 2020 | 2550 | Collaboration, licensing, option and co-promotion agreement for small molecule inhibitors against several drug targets including KRAS oncogene | Merck announced an exclusive worldwide research collaboration and license agreement with Taiho … read morePharmaceutical and Astex Pharmaceuticals focused on the development of small molecule inhibitors against several drug targets, including the KRAS oncogene, which are currently being investigated for the treatment of cancer. Merck, Taiho and Astex will combine preclinical candidates and their data with knowledge and expertise from their respective research programs. In exchange for providing Merck an exclusive global license to their small molecule inhibitor candidates, Taiho and Astex will receive an aggregate upfront payment of $50 million and will be eligible to receive approximately $2.5 billion contingent upon the achievement of preclinical, clinical, regulatory and sales milestones for multiple products arising from the agreement, as well as tiered royalties on sales. Merck will fund research and development and will be responsible for commercialization of products globally. Taiho has retained co-commercialization rights in Japan and an option to promote in specific areas of South East Asia. [collapse expanded text] |
Sanofi-Pasteur, Translate Bio | Mar 2020 | 2329 | Collaboration agreement for mRNA vaccine candidate against COVID-19 | June 2021 Translate Bio has achieved a manufacturing milestone under the collaboration with … read moreSanofi Pasteur related to its influenza mRNA vaccine program. Translate Bio will receive a $50 million payment from Sanofi Pasteur for the successful manufacture, release, and delivery of clinical drug product to supply Sanofi Pasteur’s Phase 1 influenza clinical trial which is anticipated to begin in the coming weeks. The Phase 1 clinical trial will evaluate a monovalent influenza vaccine candidate and will inform the next steps of the mRNA-based influenza vaccine program. July 2020 Translate Bio announced the closing of a previously announced expansion of the collaboration and licensing agreement with Sanofi Pasteur to develop mRNA vaccines for all infectious disease pathogens. Translate Bio will receive $425 million in upfront payment and common stock equity investment and overall is eligible to receive up to $1.9 billion of potential milestones and other payments as well as tiered royalties on worldwide sales of developed vaccines. Sanofi received exclusive worldwide rights for infectious disease mRNA vaccines. Sanofi will pay for all costs during the collaboration term. March 2020 Sanofi Pasteur and Translate Bio collaborate to develop a novel mRNA vaccine for COVID-19. This collaboration leverages an existing agreement from 2018 between the two companies to develop mRNA vaccines for infectious diseases. [collapse expanded text] |
Skyhawk Therapeutics, Vertex Pharmaceuticals | Dec 2020 | 2240 | Collaboration agreement for small molecules that modulate RNA splicing for serious diseases | Skyhawk Therapeutics and Vertex Pharmaceuticals announced a strategic research collaboration and … read morelicensing agreement aimed at the discovery and development of novel small molecules that modulate RNA splicing for the treatment of serious diseases. Vertex will pay Skyhawk $40 million upfront. Skyhawk will grant Vertex options to exclusively license worldwide intellectual property rights to candidates discovered and developed under the collaboration that are directed to program targets. Following Vertex’s exercise of its options, Vertex will be responsible for further development and commercialization. Skyhawk is also eligible to receive up to $2.2 billion in potential milestone payments, as well as potential royalties on future sales. [collapse expanded text] |
Kymera Therapeutics, Sanofi | Jul 2020 | 2150 | Collaboration and option agreement for protein degrader therapies | Kymera Therapeutics has entered into a multi-program strategic collaboration with Sanofi to develop … read moreand commercialize first-in-class protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases. The companies will also partner on a second earlier stage program. Kymera will receive $150 million in cash upfront and may receive more than $2 billion in potential development, regulatory and sales milestones, as well as significant royalty payments. Kymera retains the option to participate in US development and commercialization for both programs. This includes the ability to participate equally in the costs, profits and losses after opt-in, and to co-promote partnered products in the US. Sanofi will make an upfront payment of $150 million in cash to Kymera for global rights to develop its small molecule IRAK4 protein degraders in inflammation and immunology indications, and a second earlier stage undisclosed program. IRAK4 is believed to play a key role in multiple immune-inflammatory diseases, including hidradenitis suppurativa, atopic dermatitis and rheumatoid arthritis. Kymera will advance the IRAK4 program through Phase 1 clinical trials; Sanofi will assume clinical development and commercialization responsibilities thereafter. Sanofi will lead all clinical development activities for the second program. Kymera will have the option to participate in the development of both programs in the US during clinical development. Kymera will retain global rights to its IRAK4 program in oncology indications. [collapse expanded text] |
Biogen, Denali Therapeutics | Aug 2020 | 2150 | Collaboration, licensing, co-development and co-promotion agreement for LRRK2 program for Parkinson’s disease and Certain TV platform-enabled programs for neurodegenerative diseases | Parties Involved
… read more Collaboration ScopeThe collaboration encompasses two major initiatives:
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryBiogen and Denali have built a multi-faceted strategic partnership aimed at advancing treatments for Parkinson’s and Alzheimer’s disease. The collaboration includes a co-development and commercialization arrangement for BIIB122, a first-in-class LRRK2 inhibitor, and a licensed program (ATV:Aβ) that leverages Denali’s TV platform to enable effective blood-brain barrier delivery of anti-amyloid antibodies. The deal is valued at over $1 billion in upfront and equity payments, with substantial milestones and royalties tied to the success of these and potential future programs. [collapse expanded text] |
Genentech, Roche, UCB | Jul 2020 | 2120 | Collaboration and licensing agreement for UCB0107 antibody treatment for people living with Alzheimer's Disease | October 2024 UCB has regained all global rights to bepranemab from Roche/Genentech July … read more2020 UCB announced an agreement to enter into a world-wide, exclusive license agreement with Roche and Genentech for the global development and commercialization of UCB0107 in Alzheimer's Disease. The transaction remains subject to obtaining antitrust clearance and other customary closing conditions. UCB will provide an exclusive, world-wide license to Roche and Genentech to develop and commercialize UCB0107 in AD. UCB will receive an initial upfront payment of US $120 million. UCB will fund and perform a proof-of-concept study in AD and, upon availability of the results of that study, Genentech has the right to progress with the development or return full rights back to UCB. After Genentech's decision to proceed with further clinical development, UCB will be eligible to receive further potential cost reimbursement, development and sales milestone payments as well as royalties with a total potential consideration approaching US $2 billion upon receipt of certain regulatory approvals and satisfying certain clinical and sales milestones. [collapse expanded text] |
Innovent Biologics, Roche | Jun 2020 | 2100 | Collaboration agreement for multiple products including cellular therapies and bispecific antibodies | Innovent Biologics announced a strategic research and development collaboration with Roche covering … read moremultiple cell therapies and bispecific antibodies. The collaboration will focus on the discovery, clinical development and commercialization of bispecific antibodies and multiple cell therapies and will be directed to the treatment of hematological and solid cancers. Innovent will pay upfront, development and commercial milestone payments, and royalties, to non-exclusively access certain Roche technologies that enable the discovery and development of specific 2:1 T-cell bispecific antibodies (TCB) and the universal CAR-T platform. Innovent will create, develop, manufacture, and commercialize the products. Roche retains an option right to license each product for ex-China development and commercialization. Should Roche exercise all of its options, it will pay option exercise payments totaling $140 million plus additional development, approval, and sales milestone payments up to $1.96 billion if all products are successfully developed and commercialized. Roche will pay double-digit up to mid teen percentage royalties on each product. [collapse expanded text] |
Bristol-Myers Squibb, Insitro | Oct 2020 | 2070 | Collaboration, option and licensing agreement for treatments for amyotrophic lateral sclerosis and frontotemporal dementia | Insitro has entered into a five-year, discovery collaboration with Bristol Myers Squibb focused on … read morethe discovery and development of novel therapies for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia. Insitro will apply its proprietary platform, the insitro Human (ISH) platform, to create induced pluripotent stem cell (iPSC) derived disease models for ALS and FTD. The ISH platform applies machine learning, human genetics and functional genomics to generate and optimize predictive in vitro models and drive therapeutic discovery and development. Through its application, the ISH platform will provide insights into disease progression, identify coherent patient segments and discover candidate targets. Based on these insights, insitro will apply its machine-learning-enabled therapeutics discovery capabilities to advance programs. Bristol Myers Squibb will have the option to select a number of targets identified by insitro to advance through clinical development and commercialization. insitro will receive $50 million in an upfront payment and will be eligible to receive an additional $20 million in near term operational milestones and up to an aggregate of more than $2 billion in discovery, development, regulatory and commercial milestones in addition to royalty payments on net product sales. Bristol Myers Squibb will be responsible for clinical development as well as regulatory submissions and commercialization activities. [collapse expanded text] |
Affimed Therapeutics, Roivant Sciences | Nov 2020 | 2060 | Collaboration and licensing agreement for Innate Cell Engagers (ICE) for multiple cancer targets | Affimed and Roivant Sciences have entered into a licensing and strategic collaboration agreement to … read moredevelop and commercialize novel ICE molecules in oncology. The collaboration grants Roivant a license to the preclinical molecule AFM32. The collaboration will also leverage Affimed’s proprietary Redirected Optimized Cell Killing (ROCK) platform to generate ICE molecules against targets not included in Affimed’s current pipeline. Affimed will receive $60 million in upfront consideration, comprised of $40 million in cash and pre-paid R&D funding, and $20 million of newly issued shares in Roivant. Affimed could receive further short-term proceeds in the form of option fees contingent on the commencement of additional programs contemplated under the agreement. The company is eligible to receive up to an additional $2 billion in milestones over time upon achievement of specified development, regulatory and commercial milestones, as well as tiered royalties on net sales. Pursuant to the agreement, Affimed will be primarily responsible for driving the discovery and research phases of molecule development through filing of the IND. Roivant will be responsible for clinical development and commercialization worldwide, and Affimed retains an option for co-promotion. [collapse expanded text] |
CSL Behring, UniQure | Jun 2020 | 2050 | Licensing agreement for AMT-061 (etranacogene dezaparvovec) | uniQure and CSL Behring have entered into a licensing agreement providing CSL Behring with … read moreexclusive global rights to etranacogene dezaparvovec, uniQure’s investigational gene therapy for patients with hemophilia B. Etranacogene dezaparvovec consists of an AAV5 viral vector carrying a gene cassette with the patent-protected Padua variant of Factor IX (FIX-Padua). uniQure will receive a $450 million upfront cash payment and be eligible to receive up to $1.6 billion in payments based on regulatory and commercial milestones. uniQure will also be eligible to receive tiered double-digit royalties in a range of up to a low-twenties percentage of net product sales arising from the collaboration. [collapse expanded text] |
Neurocrine Biosciences, Takeda Pharmaceutical | Jun 2020 | 2015 | Collaboration and licensing agreement for therapies for psychiatric disorders | January 2025 Key Deal Terms of the Neurocrine-Takeda Amendment for Osavampator … read moreExclusive Rights and Territory Split Financial Structure Development and Commercialization June 2020 Key Deal Terms of the Neurocrine Biosciences and Takeda CollaborationExclusive Licensing Agreement Clinical Assets Financial Terms Development & Commercialization Preclinical Programs |
Incyte, MorphoSys | Jan 2020 | 2000 | Collaboration, licensing and co-promotion agreement for Tafasitamab | MorphoSys and Incyte have entered into a collaboration and license agreement to further develop and … read morecommercialize MorphoSys' proprietary anti-CD19 antibody tafasitamab (MOR208) globally. Tafasitamab is an Fc-engineered antibody against CD19 currently in clinical development for the treatment of B cell malignancies. MorphoSys and Incyte will co-commercialize tafasitamab in the U.S., while Incyte has exclusive commercialization rights outside of the U.S. MorphoSys will receive an upfront payment of $750 million and, in addition, Incyte will make an equity investment into MorphoSys of $150 million in new American Depositary Shares (ADS) of MorphoSys at a premium to the share price at signing of the agreement. Depending on the achievement of certain developmental, regulatory and commercial milestones, MorphoSys will be eligible to receive milestone payments amounting to up to $1.1 billion. MorphoSys will also receive tiered royalties on ex-U.S. net sales of tafasitamab in a mid-teens to mid-twenties percentage range of net sales. In the U.S., MorphoSys and Incyte will co-commercialize tafasitamab, with MorphoSys leading the commercialization strategy and booking all revenues from sales of tafasitamab. Incyte and MorphoSys will be jointly responsible for commercialization activities in the U.S. and will share profits and losses on a 50:50 basis. Outside the U.S., Incyte will have exclusive commercialization rights, and will lead the commercialization strategy and book all revenues from sales of tafasitamab, paying MorphoSys royalties on ex-U.S. net sales. Furthermore, the companies will share development costs associated with global and U.S.-specific trials at a rate of 55% (Incyte) to 45% (MorphoSys); Incyte will cover 100% of the future development costs for trials that are specific to ex-U.S. countries. Both parties have agreed to co-develop tafasitamab broadly in relapsed/refractory diffuse large B cell lymphoma (r/r DLBCL), frontline DLBCL as well as additional indications beyond DLBCL, such as follicular lymphoma (FL), marginal zone lymphoma (MZL) and chronic lymphocytic leukemia (CLL). Incyte will be responsible for initiating a combination study of its investigational PI3K-delta inhibitor parsaclisib and tafasitamab in r/r B cell malignancies. Further, Incyte will be responsible for leading any potential registration-enabling studies in CLL and a phase 3 trial in r/r FL/MZL. MorphoSys will continue to be responsible for its currently ongoing clinical trials of tafasitamab in non-Hodgkin lymphoma (NHL), CLL, r/r DLBCL and frontline DLBCL. The parties will share responsibility in starting additional global trials, and Incyte intends to pursue development in additional territories including Japan and China. MorphoSys recently submitted a Biologics License Application (BLA) for tafasitamab, in combination with lenalidomide, to the U.S. Food and Drug Administration (FDA) for the treatment of r/r DLBCL; the FDA decision regarding a potential approval is expected by mid-2020. The submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in r/r DLBCL is planned for mid-2020. [collapse expanded text] |
Alnylam Pharmaceuticals, Blackstone Medical | Apr 2020 | 2000 | Royalty financing agreement to facilitate RNAi therapeutics | Parties Involved
Collaboration ScopeThe partnership supports the development and advancement of RNAi therapeutics targeting cardiometabolic diseases, specifically:- Vutrisiran for ATTR amyloidosis with cardiomyopathy- ALN-AGT for hypertension This agreement is part of a broader $2 billion strategic financing collaboration established in April 2020, which also includes royalty monetization, corporate debt, equity investment, and R&D funding. Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryBlackstone and Alnylam entered a $2 billion strategic collaboration to accelerate Alnylam’s RNAi therapeutic programs, with $150 million specifically allocated to R&D for cardiovascular candidates vutrisiran and ALN-AGT. The partnership includes a mix of royalty monetization, debt financing, and equity investment, allowing Alnylam to pursue a self-sustaining financial model without future equity dilution. The deal supports Alnylam’s leadership in RNAi while advancing therapies for diseases with significant unmet medical needs. [collapse expanded text] |
Agios Pharmaceuticals, Les Laboratoires Servier | Dec 2020 | 2000 | Asset purchase agreement for oncology business | Servier has entered into an agreement for the acquisition of Agios Pharmaceuticals' oncology … read morebusiness including its commercial, clinical and research-stage oncology portfolio for up to $2 billion, including an upfront payment of $1.8 Billion and a potential $200 million in regulatory milestone, plus royalties. The transaction has been approved by both companies' respective boards of directors. [collapse expanded text] |
BioNTech, Pfizer, US Government | Jul 2020 | 1950 | Supply agreement for mRNA-based SARS-CoV-2 vaccine | Pfizer and BioNTech announced the execution of an agreement with the U.S. Department of Health and … read moreHuman Services and the Department of Defense to meet the U.S. government’s Operation Warp Speed program goal to begin delivering 300 million doses of a vaccine for COVID-19 in 2021. Under the agreement, the U.S. government will receive 100 million doses of BNT162, the COVID-19 vaccine candidate jointly developed by Pfizer and BioNTech, after Pfizer successfully manufactures and obtains approval or emergency use authorization from U.S. Food and Drug Administration. The U.S. government will pay the companies $1.95 billion upon the receipt of the first 100 million doses, following FDA authorization or approval. The U.S. government also can acquire up to an additional 500 million doses. [collapse expanded text] |
BioNTech, Pfizer, US Government | Dec 2020 | 1950 | Supply agreement for additional doses of COVID-19 vaccine | Pfizer and BioNTech announced a second agreement with the U.S. government to supply an additional … read more100 million doses of the companies’ COVID-19 Vaccine from production facilities in the U.S. This agreement brings the total number of doses to be delivered to the U.S. to 200 million. The companies expect to deliver the full 200 million doses to Operation Warp Speed (OWS) by July 31, 2021. Consistent with the original agreement announced in July 2020, the U.S. government will pay $1.95 billion for the additional 100 million doses. [collapse expanded text] |
Abbvie, I-mab | Sep 2020 | 1940 | Collaboration and licensing agreement for differentiated anti-CD47 monoclonal antibody lemzoparlimab (TJC4) | September 2023 I-Mab received a notice on September 21, 2023, from AbbVie Global Enterprises … read moreterminating the license and collaboration agreement between the parties dated September 3, 2020, and subsequently amended on August 15, 2022, relating to certain CD47 antibody compounds and products. The termination of the Collaboration Agreement in its entirety by AbbVie is based on the previous program discontinuation and AbbVie’s strategic decision. The termination will take effect on November 20, 2023. As a result, the Company will regain the full global rights to develop and commercialize certain CD47 compounds and products under the Collaboration Agreement, including lemzoparlimab. The termination will not affect the upfront and milestone payments of $200 million that the Company has received from AbbVie. September 2020 AbbVie and I-Mab have signed a broad, global collaboration agreement for the development and commercialization of lemzoparlimab (also known as TJC4), an innovative anti-CD47 monoclonal antibody internally discovered and developed by I-Mab for the treatment of multiple cancers. In addition, the two partners have the potential to expand the collaboration to additional transformative therapies. The collaboration established today provides AbbVie with an exclusive global license, excluding greater China, to develop and commercialize lemzoparlimab. Both companies will collaborate to design and conduct further global clinical trials to evaluate lemzoparlimab in multiple cancers. I-Mab retains all rights to develop and to commercialize lemzoparlimab in mainland China, Macau and Hong Kong. The collaboration also allows for potential collaboration on future CD47-related therapeutic agents. Each party will have the opportunity subject to further licenses to explore each other's related programs in their respective territories. The companies will share manufacturing responsibilities with AbbVie being the primary manufacturer for global supply. The collaboration will accelerate I-Mab's establishment of commercial production operations in China. AbbVie will pay I-Mab $180 million in an upfront payment to exclusively license lemzoparlimab, along with $20 million in a milestone payment based on the Phase 1 results, for a total of $200 million. I-Mab will be eligible to receive up to $1.74 billion in success-based milestone payments for lemzoparlimab, of which $840 million are based on clinical development and regulatory approval milestones, with the remainder based on commercial milestones. Upon commercialization of lemzoparlimab, AbbVie will also pay tiered royalties from low-to-mid teen percentages on global net sales outside of greater China. [collapse expanded text] |
Arcus Biosciences, Gilead Sciences | May 2020 | 1900 | Collaboration, co-development and co-promotion agreement for next-generation cancer immunotherapies | January 2024 Gilead Sciences and Arcus Biosciences announced an amendment to their collaboration … read moreagreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21.00 per share. The equity investment and collaboration amendment enable accelerated growth of the companies’ joint development programs that span multiple indications. Additionally, Johanna Mercier, Chief Commercial Officer at Gilead Sciences, will join the Arcus Board, bringing Gilead’s total director designees to three. The amendment also includes governance enhancements enabling streamlined decision-making and reflecting the continued growth of the collaboration. May 2023 Gilead Sciences and Arcus Biosciences have expanded the previously announced research collaboration focused on oncology to include therapies for the treatment of inflammatory diseases. The expanded collaboration builds upon Gilead’s growing presence in inflammatory disease and serves as a step towards broadening Arcus’ capabilities and portfolio beyond oncology and into inflammation. Arcus will receive an upfront payment of $35 million and will initiate research programs against up to four targets jointly selected by the parties that are applicable to inflammatory diseases. Gilead may exercise an option to license each program at two separate, prespecified time points. If Gilead exercises its option at the earlier time point for the first two target programs, Arcus would be eligible to receive up to $420 million in option and milestone payments and tiered royalties for each optioned program. For any other option exercise by Gilead for the four target programs, the parties would have rights to co-develop and share global development costs and to co-commercialize and share profits in the United States for optioned programs. November 2021 Gilead Sciences and Arcus Biosciences announced that Gilead has exercised its options to three programs in Arcus’s clinical-stage portfolio, including both anti-TIGIT molecules, domvanalimab and AB308, as well as etrumadenant and quemliclustat. Arcus will receive option payments totaling $725 million. The parties will co-develop and share the global costs related to these programs. If the optioned molecules achieve regulatory approval, Gilead and Arcus will co-commercialize and equally share profits in the U.S. Gilead will hold exclusive rights outside the U.S., subject to any rights of Arcus’s existing collaboration partners, and Gilead will pay to Arcus tiered royalties. With Gilead’s early option exercises for all three programs, Gilead and Arcus amended the 2020 Agreement, including as follows: Arcus may be required to operationalize at least 50% of the clinical studies, with costs to be shared by Gilead and Arcus. The royalties payable by Gilead to Arcus on sales for these three programs outside of the U.S. were slightly reduced. The reduced royalties range from the mid-teens to the low twenties. Arcus will lead the discovery and early development of drug candidates against two novel research targets jointly selected by the parties. Upon closing of the transaction for all three programs, the $100 million option continuation payment due in 2022 will not be made by Gilead. May 2020 Gilead Sciences and Arcus Biosciences have entered into a 10-year partnership to co-develop and co-commercialize current and future therapeutic product candidates in Arcus’s pipeline. The agreement will also provide ongoing funding to support Arcus’s research and development programs. Arcus will receive $375 million upon closing, consisting of a $175 million upfront payment and a $200 million equity investment from Gilead. Arcus is eligible to receive up to $1.225 billion in opt-in and milestone payments with respect to its current clinical product candidates. Gilead will gain access to Arcus’s current and future investigational immuno-oncology products through the agreement, as Gilead continues to expand its presence in the field. This includes immediate rights to zimberelimab, as well as the right to opt-in to all other current Arcus clinical candidates, which include AB154, AB928 and AB680, upon payment of an opt-in fee that ranges from $200 million to $275 million per program, after delivery of a qualifying data package. If Gilead opts-in to the AB154 program, Arcus is eligible to receive up to $500 million in potential future U.S. regulatory approval milestones. Gilead will receive the right to opt-in to all other programs that emerge from Arcus’s research portfolio over the next 10 years, upon payment of an opt-in fee of $150 million per program after Arcus’s delivery of a qualifying data package. Upon Gilead’s exercise of its option for a program, unless Arcus opts out according to terms of the agreement, the companies will co-develop and share global development costs and will co-commercialize and share profits in the United States. Gilead will obtain exclusive rights to commercialize any optioned programs outside of the U.S., subject to any rights of Arcus’s existing partners, and for which Gilead will pay to Arcus tiered royalties ranging from high-teens to low twenties. Gilead will further provide ongoing research and development support of up to $400 million over the collaboration term. Gilead will have the right to appoint two individuals to Arcus’s Board of Directors upon closing of the transaction. Gilead’s $200 million equity investment will be at a price per share of $33.54. Additionally, Gilead will have the right to purchase additional shares from Arcus, up to a maximum of 35% of the outstanding voting stock of Arcus over the course of the next five years, at a 20% premium at the time Gilead exercises such option, or, if greater, at the initial purchase price per share. [collapse expanded text] |
Dyno Therapeutics, Roche | Oct 2020 | 1800 | Collaboration and licensing agreement for AAV gene therapy vectors for CNS diseases and liver-directed therapies | Dyno Therapeutics announced a collaboration and license agreement with Roche to apply Dyno’s … read moreCapsidMap platform for the development of next-generation adeno-associated virus (AAV) vectors for gene therapies for central nervous system (CNS) diseases and liver-directed therapies for the portfolio of both Roche and Spark Therapeutics, a member of the Roche Group. Dyno will be responsible for the design of novel AAV capsids with improved functional properties for gene therapy, while Roche and Spark Therapeutics will be responsible for conducting preclinical, clinical and commercialization activities for gene therapy product candidates using the novel capsids. Dyno will receive an undisclosed upfront payment and if successful, is eligible to receive additional payments during the research phase of the collaboration as well as clinical and sales milestone payments and royalties for any resulting products. The aggregate potential value of future milestone payments to Dyno may exceed $1.8 billion. [collapse expanded text] |
Gilead Sciences, Pionyr Immunotherapeutics | Jun 2020 | 1745 | Option agreement to acquire Pionyr Immunotherapeutics | March 2023 Pionyr and Gilead Sciences have mutually agreed to change their 2020 exclusive option … read moreagreements. Gilead has waived its exclusive option to acquire Pionyr and certain other rights under the 2020 agreements. Gilead will retain its 49% equity stake in Pionyr as well as its right, under certain conditions, to review new data as it emerges. Pionyr is now free to pursue fundraising and partnering opportunities as part of its ongoing strategy. June 2020 Gilead Sciences announced that for $275 million the company will acquire a 49.9 percent equity interest in Pionyr Immunotherapeutics, and an exclusive option to purchase the remainder of Pionyr. Pionyr’s shareholders may receive up to an additional $1.47 billion in option exercise fees and future milestone payments. Pionyr’s shareholders will receive $275 million upon closing. Gilead will receive 49.9 percent of the common stock of Pionyr and an exclusive option to purchase the remaining equity. Gilead may exercise its exclusive option upon completion of Phase 1b studies for PY314 and PY159, or at an earlier time if Gilead chooses to do so, for a $315 million option exercise fee and up to $1.15 billion in potential future milestone payments. Gilead will provide Pionyr with additional funding for the PY314 and PY159 clinical programs, as well as ongoing research and development programs. Gilead will have the right to nominate one individual to Pionyr’s Board of Directors upon closing of the transaction. Gilead and the other stockholders of Pionyr will jointly select and nominate one independent individual to Pionyr’s Board of Directors. [collapse expanded text] |
Bicycle Therapeutics, Genentech | Feb 2020 | 1730 | Collaboration and licensing agreement for Bicycle-based immuno-oncology therapies | July 2022 Bicycle Therapeutics announced that Genentech has exercised its second option to … read moreinitiate a new program, expanding the exclusive strategic collaboration agreement with Bicycle to discover, develop and commercialize novel Bicycle-based immuno-oncology therapies. October 2021 Bicycle Therapeutics announced that Genentech has exercised an option to initiate a new program, expanding the exclusive strategic collaboration agreement with Bicycle to discover, develop and commercialize novel Bicycle®-based immuno-oncology therapies. February 2020 Bicycle Therapeutics has entered into a strategic collaboration agreement with Genentech to discover, develop and commercialize novel Bicycle-based immuno-oncology therapies. By entering into this early discovery collaboration with Genentech, Bicycle will be exploring its technology on a wider range of immuno-oncology targets, combining the expertise of both companies. Bicycle brings its proprietary discovery platform, which allows rapid screening of novel targets to identify Bicycles and the ability to readily conjugate these together to create novel molecules that may overcome the potential limitations of other modalities. Genentech brings to the collaboration its knowledge of immuno-oncology drug discovery and emerging target biology, as well as its development and commercialization expertise. Genentech and Bicycle will collaborate on the discovery and pre-clinical development of novel Bicycle-based immunotherapies against multiple targets. Bicycle will be responsible for discovery research and early pre-clinical development up to candidate selection, and Genentech will be responsible for further development and commercialization upon the selection of candidates. None of Bicycle’s wholly owned oncology pipeline, including its immuno-oncology candidates, are included in the collaboration. Bicycle will receive a $30 million upfront payment. The upfront payment and potential discovery, development, regulatory and commercial-based milestone payments could total up to $1.7 billion. Bicycle will also be eligible to receive tiered royalties on Bicycle-based medicines commercialized by Genentech. [collapse expanded text] |
Blueprint Medicines, Genentech, Roche | Jul 2020 | 1702 | Collaboration, licensing and co-promotion agreement for Pralsetinib | Blueprint Medicines has entered into a global collaboration with Roche and Genentech to develop and … read morecommercialize pralsetinib, an investigational once-daily oral precision therapy for the treatment of people with cancer driven by oncogenic RET alterations, including non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), other thyroid cancers and other solid tumors. Blueprint Medicines and Genentech will co-commercialize pralsetinib in the U.S. and Roche will obtain exclusive commercialization rights for pralsetinib outside of the U.S., excluding Greater China. The companies also plan to expand development of pralsetinib in multiple treatment settings and explore development of a next-generation RET inhibitor as part of this collaboration. The collaboration combines Blueprint Medicines' pralsetinib and precision therapy expertise with Roche's global reach, integrated personalized healthcare capabilities and portfolio of cancer therapies. Marketing applications for pralsetinib are submitted or planned for RET fusion-positive NSCLC, RET mutation-positive MTC and RET fusion-positive thyroid cancer in the U.S., Europe and other geographies. Blueprint Medicines will grant Roche an exclusive worldwide license excluding Greater China and the U.S., and a co-exclusive license in the U.S. to develop and commercialize pralsetinib. In addition, Roche will have the right to opt in to a next-generation RET compound co-developed under the collaboration. Blueprint Medicines will receive $775 million in upfront payments, including a cash payment of $675 million and an equity investment by Roche of $100 million in Blueprint Medicines' common stock at a purchase price of $96.57 per share. Blueprint Medicines will be eligible to receive up to an additional $927 million in contingent payments, including specified development, regulatory and sales-based milestones for pralsetinib and any licensed product containing a next-generation RET compound. In the U.S., Blueprint Medicines and Genentech will work together to co-commercialize pralsetinib, with the companies equally sharing responsibilities, profits and losses. In addition, Blueprint Medicines is eligible to receive tiered royalties ranging from high-teens to mid-twenties on annual net sales of pralsetinib outside the U.S. Blueprint Medicines and Roche have agreed to co-develop pralsetinib globally in RET-altered solid tumors, including NSCLC, MTC and other thyroid cancers, as well as other solid tumors. The companies will share global development expenses based on pre-specified cost-sharing. [collapse expanded text] |
Astellas Pharma, CytomX Therapeutics | Mar 2020 | 1680 | Collaboration, licensing, option and co-promotion agreement for Probody T-cell engaging bispecific therapies for cancer | March 2024 First clinical candidate in its TCB agreement with Astellas has entered into GLP … read moretoxicology studies which triggers a $5 million payment to CytomX The clinical candidate is the first PROBODY® TCB molecule under this alliance to progress into a GLP toxicology study CytomX and Astellas are also collaborating on additional conditionally activated TCB programs with CytomX eligible to receive future preclinical, clinical and commercial milestones CytomX retains a cost share and co-commercialization option on a select number of targets. January 2023 CytomX Therapeutics achieved a clinical candidate milestone under its TCB agreement with Astellas Pharma US. The clinical candidate is the first Probody TCB molecule to progress in the collaboration and will trigger a $5 million dollar milestone payment to CytomX. CytomX and Astellas are also collaborating on additional conditionally activated TCB programs with CytomX eligible to receive future preclinical, clinical and commercial milestones. CytomX retains a cost share and co-commercialization option on a select number of targets. March 2020 CytomX Therapeutics and Astellas Pharma have entered into a strategic collaboration agreement focused on the discovery, research, development and commercialization of novel T-cell engaging bispecific antibodies targeting CD3 and tumor cell surface antigens for the treatment of cancer. The parties will utilize CytomX’s Probody therapeutic technology platform, as well as its proprietary bispecific formats and CD3 modules. CytomX and Astellas will collaborate on several initial programs. CytomX will lead research and discovery activities, up to clinical candidate selection, that will be funded by Astellas. Astellas will lead and fund preclinical and clinical development and commercialization activities. Astellas will make an upfront cash payment of $80 million to CytomX with CytomX eligible to receive future preclinical, clinical and commercial milestones of over $1.6 billion. CytomX is also eligible to receive tiered royalties on global net sales that range from high-single digits to mid-teens. For a specified number of targets, prior to the initiation of the first pivotal clinical trial for a product directed toward such target, CytomX may exercise an option to co-fund a pre-determined portion of clinical development costs. For these products, CytomX is eligible to receive a pre-specified portion of profits in the United States and tiered low-double digit to mid-teen percentage royalties on net sales outside of the United States. CytomX may later elect to co-commercialize the products directed toward such targets in the United States. [collapse expanded text] |
Affinia Therapeutics, Vertex Pharmaceuticals | Apr 2020 | 1600 | Collaboration, option and licensing agreement for AAV capsids for genetic therapies | Vertex Pharmaceuticals and Affinia Therapeutics have entered into a strategic research … read morecollaboration to engineer novel adeno-associated virus (AAV) capsids to deliver transformative genetic therapies to people with serious diseases. Affinia Therapeutics’ proprietary AAVSmartLibrary and associated technology provides capsids for improved tissue tropism, manufacturability and pre-existing immunity. The collaboration will leverage Affinia Therapeutics’ capsid engineering expertise and Vertex’s scientific, clinical and regulatory capabilities to accelerate the development of genetic therapies for people affected by Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and cystic fibrosis (CF). Affinia Therapeutics will apply its vector design and engineering technologies to develop novel capsids with improved properties. The agreement provides Vertex an exclusive license under Affinia Therapeutics’ proprietary technology and intellectual property (IP) in DMD and DM1 with an exclusive option to license rights for CF and an additional undisclosed disease. The scope of the agreement covers all genetic therapy modalities in these diseases. Affinia Therapeutics will be eligible to receive over $1.6 billion in upfront and development, regulatory and commercial milestones, including $80 million in upfront payments and research milestones that will be paid during the research term, plus tiered royalties on future net global sales on any products that result from the collaboration. Affinia Therapeutics will be responsible for the discovery of capsids that meet certain pre-determined criteria. Vertex will be responsible for and will fund the design and manufacturing of genetic therapies incorporating the selected capsids, preclinical and clinical development efforts, and commercialization of any approved products in the licensed diseases. [collapse expanded text] |
Novavax, UK Government | Jul 2020 | 1600 | Contract service agreement for vaccine for COVID-19 | Novavax has been selected to participate in Operation Warp Speed, a U.S. government program that … read moreaims to begin delivering millions of doses of a safe, effective vaccine for COVID-19 in 2021. Novavax has been awarded $1.6 billion by the federal government to complete late-stage clinical development, including a pivotal Phase 3 clinical trial; establish large-scale manufacturing; and deliver 100 million doses of NVX‑CoV2373, Novavax’ COVID-19 vaccine candidate, as early as late 2020. NVX‑CoV2373 consists of a stable, prefusion protein made using its proprietary nanoparticle technology and includes Novavax’ proprietary Matrix‑M adjuvant. Novavax will demonstrate it can rapidly stand up large-scale manufacturing and transition into ongoing production, including the capability to stockpile and distribute large quantities of NVX-CoV2373 when needed. The agreement will fund the late-stage clinical studies necessary to determine the safety and efficacy of NVX-CoV2373, including a pivotal Phase 3 clinical trial with up to 30,000 subjects beginning in the fall of 2020. [collapse expanded text] |
Gilead Sciences, Tizona Therapeutics | Jul 2020 | 1550 | Option agreement for Tizona | Gilead Sciences announced that it will invest $300 million to acquire a 49.9 percent equity … read moreinterest in Tizona Therapeutics. Gilead will also receive an exclusive option to acquire the remainder of Tizona for up to an additional $1.25 billion, including an option exercise fee and potential future milestone payments. Gilead can exercise its option to acquire the remainder of Tizona following the readout of a Phase 1b study of Tizona’s investigational antibody, TTX-080, or earlier if Gilead decides to do so. TTX-080, discovered by Tizona, is a potential first-in-class medicine that targets HLA-G, a novel and emerging immune checkpoint expressed across multiple tumor types. The expression pattern of HLA-G often appears distinct from that of PD-(L)1, suggesting potential utility to address tumors that do not respond to current anti-PD-(L)1 treatments and to deepen responses in tumors that are sensitive to anti-PD-(L)1 therapies. Tizona equity holders will receive $300 million upon closing. Gilead will obtain a 49.9 percent equity stake and an exclusive option to purchase the remaining equity exercisable following the completion of Phase 1b studies for TTX-080, or earlier if Gilead chooses. Tizona equity holders will be eligible to receive up to $1.25 billion in an option exercise fee and potential future milestone payments. Gilead will also provide funding to support Tizona’s ongoing research and development to advance its novel pipeline. Gilead will have the right to appoint two individuals to Tizona’s Board of Directors upon closing of the transaction. [collapse expanded text] |
Amunix, Hoffmann La Roche, Roche | Jan 2020 | 1540 | Licensing agreement for technology platform, XTEN, to discover and develop non-oncology therapeutics | Amunix Pharmaceuticals has provided a technology license to F. Hoffmann-La Roche and Hoffmann-La … read moreRoche to utilize Amunix’s technology platform, XTEN, to discover and develop non-oncology therapeutics against certain undisclosed targets. This agreement builds on Amunix’s previous technology assessment with Roche focused on using XTEN, a proprietary unstructured polypeptide, to extend drug half-life. Amunix will receive a $40 million upfront payment from Roche. Amunix may also receive up to $1.5 billion in payments from Roche associated with the achievement of certain developmental and sales milestones, plus royalties on sales of commercialized products. [collapse expanded text] |
Gilead Sciences, Second Genome | Apr 2020 | 1538 | Collaboration, option and licensing agreement for biomarker and inflammatory bowel disease drug discovery | Gilead Sciences & Second Genome Strategic Collaboration SummaryParties… read moreInvolved
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryGilead Sciences and Second Genome have entered a strategic four-year collaboration to advance IBD drug discovery and biomarker identification through microbiome insights. Second Genome will use its Microbiome Analytics Platform™ to help stratify patients and optimize potential treatments. Gilead will receive worldwide rights to up to five programs and exclusive biomarker rights. Second Genome will receive $38 million upfront, with the potential for up to $300 million per program in milestone payments, plus low double-digit royalties on approved products. [collapse expanded text] |
Moderna, US Government | Aug 2020 | 1525 | Supply agreement for mRNA Vaccine Against COVID-19 (mRNA-1273) | Moderna announced that the US government has secured 100 million doses of mRNA-1273 as part of the … read moreUS government’s goal of securing early access to safe and effective COVID-19 vaccines for the American people. The award of up to $1.525 billion is for the manufacturing and delivery of 100 million doses of mRNA-1273 including incentive payments for timely delivery of the product. With the previous award of up to $955 million from BARDA for the development of mRNA-1273 to licensure, today’s announcement brings the U.S. government commitments for early access to mRNA-1273 to up to $2.48 billion. Under the terms of the agreement, the U.S. government, as a part of Operation Warp Speed, will also have the option to purchase up to an additional 400 million doses of mRNA-1273 from Moderna. The U.S. government has announced that consistent with its commitment to free access to COVID-19 vaccines, Americans will receive mRNA-1273 at no cost for the vaccine itself. [collapse expanded text] |
Aro Biotherapeutics, Ionis Pharmaceuticals | Jan 2020 | 1400 | Collaboration and licensing agreement for cell-specific delivery of antisense oligonucleotides | October 2020 Aro Biotherapeutics announced today that Ionis Pharmaceuticals has exercised an … read moreoption to acquire a license to an undisclosed antisense oligonucleotide (ASO)-Centyrin drug conjugate. January 2020 Aro Biotherapeutics has entered a licensing and collaboration agreement with Ionis Pharmaceuticals through which Ionis will use Aro’s CENTYRIN technology to develop targeted cell- and tissue- specific delivery of antisense oligonucleotides (ASOs). Under the terms of the agreement, the companies will collaborate to create unique ASO-Centyrin conjugates that are designed to achieve tissue specific, therapeutically effective gene knockdown in extra-hepatic tissues with systemic administration. Under the terms of the agreement, the two companies have agreed to jointly work towards advancing a defined number of ASO-Centyrin drug conjugates. Aro will be responsible for Centyrin discovery and will collaborate with Ionis to create lead ASO-Centyrin drug conjugates for further development. Ionis will be responsible for development and will have global commercialization rights for each ASO-Centyrin drug conjugate. The parties will also collaborate on additional discovery programs. Aro will receive an upfront cash payment, funding to support R&D efforts, and payments associated with the achievement of specific development and commercial milestones, up to $1.4B. In addition, Aro will receive royalties on net sales. [collapse expanded text] |
Eli Lilly, Precision BioSciences | Nov 2020 | 1395 | Collaboration and licensing agreement for ARCUS genome editing platform for in vivo therapies for genetic disorders | Eli Lilly and Precision BioSciences announced a research collaboration and exclusive license … read moreagreement to utilize Precision's proprietary ARCUS genome editing platform for the research and development of potential in vivo therapies for genetic disorders, with an initial focus on Duchenne muscular dystrophy (DMD) and two other undisclosed gene targets. Genome editing technologies enable precise editing of the DNA of a living organism, opening up the possibility of correcting genetic problems at their source. ARCUS is a unique, proprietary, and versatile genome editing platform with attributes including specificity, ability to make a variety of efficient edits (knock-in, knock-out, and repair), and small size, thereby enabling a range of therapeutic editing. The platform is derived from a natural genome-editing enzyme called I-CreI, a homing endonuclease that can be optimized to control for potency and specificity. Precision will receive an upfront cash payment of $100 million, as well as an equity investment by Lilly of $35 million in Precision's common stock. Precision is also eligible to receive up to $420 million in potential development and commercialization milestones per product, as well as tiered royalties ranging from the mid-single digits to low-teens on product sales should Lilly successfully commercialize a therapy from the collaboration. Precision will lead pre-clinical research and IND-enabling activities, with Lilly then assuming responsibility for clinical development and commercialization. Lilly will have the right to select up to three additional gene targets for this collaboration. Precision can co-fund clinical development of one product in exchange for an increased royalty rate on co-funded product sales. [collapse expanded text] |
Mesoblast, Novartis | Nov 2020 | 1305 | Collaboration, licensing and option agreement for acute respiratory distress syndrome cell therapy | December 2021 Mesoblast was notified by Novartis that it has chosen to terminate the agreement … read morewith Mesoblast prior to closing. Mesoblast remains highly focused on executing on our short term objective to bring remestemcel-L to market for patients with acute respiratory distress syndrome due to COVID19. November 2020 Mesoblast has entered into an exclusive worldwide license and collaboration agreement with Novartis for the development, manufacture and commercialization of Mesoblast’s mesenchymal stromal cell (MSC) product remestemcel-L, with aninitial focus on the development of the treatment of acute respiratory distress syndrome (ARDS), including that associated with COVID-19. Novartis will make a US$50 million upfront payment including US$25 million in equity. From the initiation of a Phase 3 trial in all-cause ARDS, Novartis will fully fund global clinical development for all-cause ARDS and potentially other respiratory indications. Mesoblast may receive a total of US$505 million pending achievement of precommercialization milestones for ARDS indications. Mesoblast may receive additional payments post-commercialization of up to US$750 million based on achieving certain sales milestones and tiered double-digit royalties on product sales. Mesoblast will retain full rights and economics for remestemcel-L for graft versus host disease (GVHD), and Novartis has an option to, if exercised, become the commercial distributor outside of Japan. For most non-respiratory indications, the parties may co-fund development andcommercialization on a 50:50 profit-share basis. Mesoblast will be responsible for clinical and commercial manufacturing and Novartis will purchase commercial product under agreed pricing terms. Novartis will reimburse Mesoblast up to US$50 million on the achievement of certain milestones related to the successful implementation of its next-generation manufacturing processes using its proprietary media and three-dimensional bioreactors aimed at delivering substantial manufacturing efficiencies. Novartis will be responsible for any capital expenditure required to meet increased capacity requirements for manufacture of remestemcel-L. November 2020 Novartis entered into an exclusive worldwide license and collaboration agreement with Mesoblast to develop, commercialize and manufacture remestemcel-L for the treatment of acute respiratory distress syndrome (ARDS), including that associated with COVID-19. ARDS is an area of significant unmet need, with an approximate 40% mortality rate with current standard of care, which includes prolonged ICU treatment and mechanical ventilation. As the potential first ARDS therapy, remestemcel-L will use mesenchymal stromal cells (MSCs), a cell-based platform technology, to treat this deadly condition and improve outcomes. Remestemcel-L is currently being studied in COVID-19-related ARDS in an ongoing 300-patient Phase III study. Novartis intends to initiate a Phase III study in non-COVID-19-related ARDS after the anticipated closing of the license agreement and successful completion and outcome of the current study. Novartis will acquire the exclusive worldwide rights to develop, commercialize and manufacture remestemcel-L for ARDS, and will obtain access to an innovative cell-therapy platform with a range of potential applications in severe respiratory conditions and beyond. Novartis will make a $25 million upfront payment and invest $25 million in Mesoblast equity with additional payments and royalties due on achievement of agreed development, regulatory and commercial milestones. Novartis will provide certain support to enable commercial manufacturing scale-up. Novartis has the option, if exercised, to distribute remestemcel-L for graft versus host disease (GVHD) (outside Japan). Both parties have rights to co-fund development and commercialization for other non-respiratory indications. [collapse expanded text] |
CStone Pharmaceuticals, EQRx | Oct 2020 | 1300 | Licensing agreement for sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1) | CStone Pharmaceuticals announced an agreement to out-license ex-Greater China rights for two key … read morelate-stage immuno-oncology assets, sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1), to EQRx, a biopharmaceutical company with an innovative business model that will allow these drugs to be competitively positioned in global markets against established treatments for the target indications. CStone will receive an upfront payment of US$150 million and up to US$1.15 billion in milestone payments for both drugs as well as separate tiered royalties. EQRx will obtain exclusive rights to lead global development and commercialization worldwide, excluding Mainland China, Taiwan, Hong Kong and Macau. CStone retains rights to CS1003 in Greater China, where it can continue to pursue development as a monotherapy or as part of its combination strategy for this drug. [collapse expanded text] |
Apellis Pharmaceuticals, Swedish Orphan Biovitrum | Oct 2020 | 1245 | Co-development and licensing agreement for systemic Pegcetacoplan in rare diseases | Apellis Pharmaceuticals and Swedish Orphan Biovitrum announced a strategic collaboration to … read moreaccelerate the advancement of systemic pegcetacoplan, a targeted C3 therapy, for the treatment of multiple rare diseases with high unmet need that impact more than 275,000 patients globally. Sobi will receive global co-development and exclusive ex-US commercialization rights for systemic pegcetacoplan. Apellis retains U.S. commercialization rights for systemic pegcetacoplan and worldwide commercial rights for ophthalmological pegcetacoplan, which is being evaluated by Apellis in two fully enrolled Phase 3 studies in geographic atrophy (GA). Pegcetacoplan targets excessive activation of C3 in the complement cascade, part of the body’s immune system, which can lead to the onset and progression of many serious diseases. Apellis and Sobi plan to jointly advance the clinical development of systemic pegcetacoplan in five parallel registrational programs across hematology, nephrology, and neurology. These include new registrational programs in cold agglutinin disease (CAD) and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA), both of which are expected to start in 2021. By controlling complement activation centrally, pegcetacoplan offers the potential to become a transformative new therapy in several rare diseases where patients have few or no treatment options today. Apellis and Sobi will co-develop systemic pegcetacoplan in the following rare diseases: Hematology – Paroxysmal nocturnal hemoglobinuria (PNH), CAD, and HSCT-TMA Nephrology – Immune complex membranoproliferative glomerulonephritis (IC-MPGN) and C3 glomerulopathy (C3G) Neurology – Amyotrophic lateral sclerosis (ALS) Sobi will make an upfront payment of $250 million to Apellis and up to $915 million in other regulatory and commercial milestone payments, and will contribute $80 million in reimbursement payments over a four-year period for research and development to support the initial development plan, which includes ongoing studies in PNH, IC-MPGN/C3G, and ALS and new studies in CAD and HSCT-TMA. Apellis will also be eligible for tiered double-digit royalties on sales ranging from high teens to high twenties. Sobi intends to finance these payments with available funds. Sobi will receive reimbursement payments for the costs incurred by Sobi in connection with the CAD and HSCT-TMA trials that Sobi will conduct. The parties have agreed to split costs 50/50 for any future global studies beyond the initial development plan. Apellis will be responsible for all regulatory and commercial activities in the United States and the ongoing Marketing Authorization Application review for PNH in the European Union, which will be subsequently transferred to Sobi. Sobi will be responsible for regulatory and commercial activities for systemic pegcetacoplan in ex-US markets. The co-development of systemic pegcetacoplan will be overseen by a joint development committee, and the commercial strategy will be overseen by a joint commercial committee. [collapse expanded text] |
Eli Lilly, Evox Therapeutics | Jun 2020 | 1220 | Collaboration and licensing agreement for DeliverEX platform for RNA interference and antisense oligonucleotide drug payloads for neurological disorders | Evox Therapeutics announced a research collaboration and license agreement with Eli Lilly to … read moreleverage Evox's proprietary DeliverEX platform to develop and deliver RNA interference (RNAi) & antisense oligonucleotide (ASO) drug payloads for the potential treatment of neurological disorders. During this research collaboration and five-target license agreement, Evox will be responsible for exosome engineering in order to achieve brain/CNS-targeting, drug loading and analytics and some in vitro assay development, as well as material supply for initial in vivo studies. Any resulting candidate handover and technology transfer to Lilly will occur after pre-clinical proof of concept studies have been completed. Evox will receive a $20 million cash up-front payment, research funding over three years, as well as a $10 million investment from Lilly in exchange for a convertible bond from the Company. Evox will also be eligible for potential pre-clinical and clinical development, regulatory and commercial milestones of up to approximately $1.2 billion, as well as tiered royalties up to low double digits on net sales of products arising from the collaboration. [collapse expanded text] |
Accent Therapeutics, AstraZeneca | Jun 2020 | 1155 | Collaboration, option and licensing agreement for therapeutics targeting RNA-modifying proteins (RMPs) for treatment of cancer | Accent Therapeutics and AstraZeneca will collaborate to discover, develop and commercialize … read moretransformative therapeutics targeting RNA-modifying proteins (RMPs) for the treatment of cancer. The collaboration combines Accent’s expertise as a leader in the biology, target identification and drug discovery of RMP-targeting therapies with AstraZeneca’s industry leading expertise in oncology. Accent will be responsible for research and development activities for a nominated preclinical program through to the end of Phase I clinical trials. Following completion of Phase I, AstraZeneca will lead development and commercialization activities for the nominated program, with Accent having the option to jointly develop and commercialize with AstraZeneca in the US. AstraZeneca will also have the exclusive option to license worldwide rights to two further preclinical discovery programs, for which Accent will conduct certain preclinical activities. Accent will receive an upfront payment of $55 million and, in the event that Accent elects to jointly develop the nominated program, is eligible to receive up to $1.1 billion in additional success-based payments across all programs in the form of option fees and milestone payments, as well as tiered royalties on net sales ranging from mid-single digit to low-double digits. In the event Accent opts into co-developing and co-commercializing the nominated program, profits and losses will be split in the US. [collapse expanded text] |
GSK, Immatics Biotechnologies | Feb 2020 | 1150 | Development, licensing and option agreement for novel adoptive cell therapies | November 2022 On October 24, 2022, GSK provided Immatics with notice of its decision to … read moreterminate their collaboration. Initially announced on February 20, 2020, the terms of the agreement included a €45 Million (~$50 Million) upfront payment to Immatics and the potential for additional milestone and royalty payments in return for access to two of Immatics’ TCR-T programs. As communicated to Immatics, GSK’s decision was made unrelated to the programs and the progress achieved in the collaboration to date. The termination will be effective on December 26, 2022. February 2020 Immatics Biotechnologies has entered into a strategic collaboration agreement with GSK to develop novel adoptive cell therapies targeting multiple cancer indications. The companies will collaborate on the identification, research and development of next-generation T-Cell Receptor (TCR) Therapeutics with a focus on solid tumors. The parties will initially develop autologous T-cell therapies with the option to add allogeneic cell therapies using Immatics’ ACTallo approach. The companies intend to utilize proprietary TCRs identified by Immatics’ XCEPTOR TCR discovery platform and directed against two proprietary targets, which were discovered and validated by Immatics’ XPRESIDENT technology. Immatics will receive an upfront payment of €45 Million (~$50 million) for two initial programs and is eligible to receive over $550M in development, regulatory and commercial milestone payments for each product as well as additional royalty payments. GSK obtains an option to select additional target programs to include in the collaboration. For each additional program, Immatics is entitled to option, milestone and royalty payments. Immatics will have primary responsibility for the development and validation of the TCR Therapeutics up to designation of a clinical candidate. GSK will assume sole responsibility for further worldwide development, manufacturing and commercialization of the TCR Therapeutics with the possibility for Immatics to co-develop one or more TCR Therapeutics including the conduct of the first-in-human clinical trial upon GSK’s request. [collapse expanded text] |
Adrestia, GSK | Dec 2020 | 1150 | Collaboration agreement for disease balancing platform | GSK is entering into a multi-year agreement with Adrestia on up to five strategic, collaborative … read moreprojects. Adrestia will be eligible to receive up to $230M (£172M) from each project in post-option milestone payments, plus royalties, subject to development and commercialisation progress, across multiple arising products. In addition to the Series A investment for an equity stake, GSK is also making an upfront payment for the collaborative projects. The collaboration will combine Adrestia’s world leading, synthetic viability platform with GSK’s deep scientific expertise in human genetics, functional genomics, screening, and bioinformatics. [collapse expanded text] |
CureVac, GSK | Jul 2020 | 1106 | Collaboration agreement for mRNA-based vaccines and monoclonal antibodies targeting infectious disease pathogens | GlaxoSmithKline and CureVac announced the signing of a strategic collaboration agreement for the … read moreresearch, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The collaboration complements GSK’s existing mRNA capabilities with CureVac’s integrated mRNA platform. The companies will combine their mRNA expertise on development opportunities across a range of infectious disease pathogens, selected with the potential to best leverage the advantages of this platform technology, while addressing significant unmet medical need and economic burden. CureVac’s existing COVID-19 mRNA and rabies vaccines research programmes are not included in the collaboration. GSK will make an equity investment in CureVac of £130m (€150m), representing close to a 10% stake, an upfront cash payment of £104m (€120m) and a one-time reimbursable payment of £26m (€30m) for manufacturing capacity reservation, upon certification of CureVac’s commercial scale manufacturing facility currently under construction in Germany. CureVac will be eligible to receive development and regulatory milestone payments of up to £277m (€320m), commercial milestone payments of up to £329m (€380m) and tiered royalties on product sales. GSK will fund R&D activities at CureVac related to the development projects covered by the collaboration. CureVac will be responsible for the preclinical- and clinical-development through Phase 1 trials of these projects, after which GSK will be responsible for further development and commercialization. CureVac will be responsible for the GMP manufacturing of the product candidates, including for commercialization, and will retain commercialization rights for selected countries for all product candidates. [collapse expanded text] |
Abpro | Mar 2020 | 1100 | Licensing agreement for two bispecific antibodies, ABP-100 and ABP-201 | Abpro announced the formation of a strategic partnership to advance two bispecific antibodies in … read morekey Asian markets including Greater China, Japan, and South Korea. The strategic partnership was formed with Abpro Bio. Abpro has granted an exclusive license to Abpro Bio to develop and commercialize two of Abpro’s bispecific antibody candidates: ABP-100 and ABP-201. ABP-100 is in development for immuno-oncology with initial indications including gastric, breast and endometrial cancers. ABP-201 is in development for ophthalmology with initial indications inclusive of Wet AMD (age-related macular degeneration) and diabetic macular edema. The collaboration will also leverage Abpro’s proprietary DiversImmune antibody platform for generating novel molecules. Abpro will lead global clinical development of the bi-specific candidates and work closely with Abpro Bio. Key terms of the agreement include: Abpro will receive from Abpro Bio up to $1.1 billion in total payments, including a $30 million upfront equity investment, and an additional $1.05 billion based on clinical milestones, post-approval payments, and royalties as ABP-100 and ABP-201 progress through the clinical development and regulatory approval processes in Greater China, Japan, and South Korea. Abpro Corporation’s two co-founders, Ian Chan and Eugene Chan, as well as Robert S. Langer, PhD, Institute Professor at MIT, will join the Board of Abpro Bio Ltd. [collapse expanded text] |
SurgCenter Development, Tenet Healthcare | Dec 2020 | 1100 | Asset purchase agreement for portfolio of surgery centers | Tenet Healthcare will acquire a portfolio of up to 45 ambulatory surgery centers from SurgCenter … read moreDevelopment. The Portfolio will be operated by Tenet’s United Surgical Partners International (USPI) subsidiary as part of its industry-leading ambulatory surgery platform. Under the terms of the transaction, the Company will purchase majority interests in up to 45 centers by fully acquiring SCD’s interests, and partially acquiring interests from physician partners, for approximately $1.1 billion in cash and the assumption of approximately $18 million of center-level debt. [collapse expanded text] |
GSK, Vir Biotechnology | Apr 2020 | 1095 | Collaboration, option and co-development agreement for COVID-19 and potential future coronavirus outbreaks | February 2023 VIR BIOTECHNOLOGY announced that the research collaboration agreement established … read morewith GSK in 2020 has been amended to reflect that Vir will continue its ongoing efforts to discover, develop and advance next-generation solutions for COVID-19 and other potential coronavirus outbreaks, independently or with other partners. Together, the Companies will continue working to ensure ongoing access to sotrovimab for patients around the world, where authorized, and to develop new therapies for influenza and other respiratory diseases. Vir retains the sole rights to continue advancing next-generation solutions arising from the collaborative coronavirus vaccine and antibody programs, subject to tiered low- to mid-single digit royalties to GSK. The Companies continue to collaborate on sotrovimab and VIR-7832, as well as a portfolio of other respiratory disease programs. February 2021 GlaxoSmithKline and Vir Biotechnology have signed a binding agreement to expand their existing collaboration to include the research and development of new therapies for influenza and other respiratory viruses. The expanded collaboration, which builds on the agreement signed in 2020 to research and develop therapies for coronaviruses, provides GSK exclusive rights to collaborate with Vir on the development of potential best-in-class monoclonal antibodies (mAbs) for the prevention or treatment of influenza. These include VIR-2482, an intramuscularly administered investigational mAb designed as a universal prophylactic for influenza A that has completed a Phase 1 trial, as well as next-generation antibodies for the prevention or treatment of influenza during a three-year research period. GSK will have the exclusive option to co-develop VIR-2482 after Vir completes and reports Phase 2 trial outcomes, and will share development costs on the development of all other influenza mAbs. As part of the new collaboration agreement, the companies will also engage in two additional research programs. The first is an expansion of their current functional genomics collaboration to develop potential pan-coronavirus therapeutics to now include other respiratory virus targets. Under the second program, the companies will collaborate to develop up to three neutralizing monoclonal antibodies identified using Vir’s antibody technology platform to target non-influenza pathogens during a three-year research period. GSK will make an upfront payment of $225 million and a further equity investment in Vir of $120 million. Vir will continue to fund the development of VIR-2482 through completion of Phase 2 trials, after which time, if GSK exercises its option to co-develop VIR-2482, it will pay an option fee of $300 million. Following option exercise for VIR-2482, and for each other program in the expanded collaboration, the companies will share the development costs and related profits associated with this agreement. GSK will also pay Vir up to $200 million based on the successful delivery of pre-defined regulatory milestones. April 2020 GlaxoSmithKline and Vir Biotechnology have signed a binding agreement to enter into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration will use Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventative options to help address the current COVID-19 pandemic and future outbreaks. The companies will leverage GSK’s expertise in functional genomics and combine their capabilities in CRISPR screening and artificial intelligence to identify anti-coronavirus compounds that target cellular host genes. They will also apply their combined expertise to research SARS-CoV-2 and other coronavirus vaccines. The collaboration will also utilise Vir’s CRISPR screening and machine learning approach to identify cellular targets whose inhibition can prevent viral infection. Vir has identified multiple potential targets against flu and other respiratory pathogens, as well as hepatitis B virus, and will now focus on SARS-CoV-2. Additionally, the companies have also agreed to conduct research into SARS-CoV-2 and other coronavirus vaccines by coupling GSK’s vaccines technologies and expertise with Vir’s ability to identify neutralising epitopes that are present across entire viral families. These efforts will be additive to other initiatives GSK is advancing to develop a potential vaccine for COVID-19. In addition, to gain access to Vir’s technology, GSK will make an equity investment in Vir of $250 million, priced at $37.73, a 10% premium to the closing share price on Friday, March 27, 2020. [collapse expanded text] |
Atomwise, Bridge Biotherapeutics | Mar 2020 | 1080 | Collaboration agreement for Pellino inhibitor pipeline using AI | Atomwise and Bridge Biotherapeutics announced a research collaboration to launch up to 13 small … read moremolecule programs across multiple therapeutic areas using structure-based AI technology for drug discovery. Atomwise will use its AI technology and homology modeling capabilities to evaluate Pellino E3 ubiquitin ligases and their interactions with target protein substrates. Atomwise and Bridge will rapidly cycle through the design and testing of potent small molecule compounds, evaluating billions of possibilities that will selectively inhibit Pellino proteins. Atomwise will receive upfront, milestone, and royalty payments upon success of each research program. Based upon historical averages for small molecule drugs, Atomwise estimates that it could receive up to $1.08B (including royalties) with success in all research programs. [collapse expanded text] |
Abbvie, Frontier Medicines | Dec 2020 | 1055 | Collaboration and option agreement for therapies and E3 degraders against difficult-to-drug targets | January 2023 Frontier Medicines announced the second and third programs under the company's … read moreglobal partnership with AbbVie have advanced into lead generation. These programs harness novel E3 Ligases for targeted protein degradation, through the discovery of small molecules from The Frontier Platform. January 2022 Frontier Medicines announced the first target for the development of a small molecule inhibitor is advancing into the lead generation phase under the company’s global partnership with AbbVie. December 2020 AbbVie and Frontier Medicines announced a global strategic collaboration to discover, develop and commercialize a pipeline of innovative small molecule therapeutics against high-interest, difficult-to-drug protein targets. AbbVie and Frontier will utilize Frontier's proprietary chemoproteomics platform to identify small molecules for programs directed to novel E3 ligases and certain oncology and immunology targets. Whereas conventional drug discovery methodologies have been primarily successful against a relatively discrete set of target classes, chemoproteomics-based screening in relevant cellular contexts has the potential to enable targeting of a significantly broader range of proteins. By selecting certain immunology and oncology targets for the collaboration that are considered well validated but to date, inaccessible, the collaboration has the potential to develop highly differentiated and efficacious therapeutics. AbbVie will pay Frontier an upfront cash payment of $55 million, and Frontier is eligible to receive additional milestone payments. AbbVie will reimburse Frontier's R&D costs through defined stages of pre-clinical development. The companies will collaborate on the research and pre-clinical development of programs directed against E3 ligase, immunology and oncology targets. Upon successful completion of defined stages of pre-clinical development, AbbVie will assume full responsibility for global development and commercialization activities and costs for the programs. Frontier will retain an option to share development activities and expenses for certain oncology programs through the completion of Phase 2. Frontier will be eligible to receive success-based development and commercial milestone payments that could potentially exceed $1 billion, in addition to royalty payments on commercialized products. AbbVie retains the right to expand the collaboration in the future by exercising options to a defined number of additional targets. The collaboration excludes all of Frontier's internal programs for which Frontier retains exclusive global rights. [collapse expanded text] |
Bayer, Recursion | Sep 2020 | 1050 | Collaboration, option and licensing agreement for digital drug discovery and therapies for fibrotic diseases | November 2023 Bayer and Recursion Pharmaceuticals have updated the focus of their research … read morecollaboration to precision oncology. The oncology-focused collaboration will leverage Bayer’s small molecule compound library and expertise in biology and medicinal chemistry as well as Recursion’s purpose-built artificial intelligence-guided drug discovery platform. This strategic shift will enable Bayer to utilize Recursion’s capabilities to initiate and advance the identification of novel therapeutic targets for challenging oncology indications with high unmet need. Under the terms of the agreement, the companies may initiate up to seven oncology programs and Recursion is eligible to receive potential, success-based, future payments of up to $1.5 billion plus royalties on net sales. Bayer will gain the option to exclusively license novel therapeutics derived from the research activities. December 2021 Recursion announced expansion of the company's existing strategic collaboration in fibrosis with Bayer. The expanded collaboration will include Recursion's powerful inferential search capabilities based on its growing maps of human cellular biology, giving Bayer the ability to further accelerate the work already underway in expanding the universe of novel fibrotic hypotheses. Recursion and Bayer may now work on more than a dozen programs in total of relevance to fibrotic disease. All projects will remain subject to the previously agreed upon economics, where each potential program could generate more than $100 million in commercial milestone payments plus royalties on future sales. September 2020 Bayer and Recursion Pharmaceuticals have entered into a strategic collaboration agreement. The partnership will leverage Recursion’s purpose-built artificial intelligence-guided drug discovery platform and Bayer’s small molecule compound library and deep scientific expertise to discover and develop new treatments for fibrotic diseases of the lung, kidney, heart and more. In addition, Leaps by Bayer, the impact investment arm of Bayer, is leading Recursion’s Series D financing with an investment of USD 50 million. Under the terms of the agreement, the parties may initiate more than ten programs with possible development and commercial milestone payments of more than USD 100 million per program plus royalties on future sales. Bayer will gain the option to exclusively license novel therapeutics derived from the research activities. Bayer will contribute with its small molecule compound library and expertise in biology and medicinal chemistry. In addition to the USD 50 million equity investment, Recursion will receive an upfront payment of USD 30 million. [collapse expanded text] |
Arrowhead Pharmaceuticals, Takeda Pharmaceutical | Oct 2020 | 1040 | Co-development and co-promotion agreement for ARO-AAT for alpha-1 antitrypsin-associated liver disease | Takeda Pharmaceutical and Arrowhead Pharmaceuticals announced a collaboration and licensing … read moreagreement to develop ARO-AAT, a Phase 2 investigational RNA interference (RNAi) therapy in development to treat alpha-1 antitrypsin-associated liver disease (AATLD). ARO-AAT is a potential first-in-class therapy designed to reduce the production of mutant alpha-1 antitrypsin protein, the cause of AATLD progression. Takeda and Arrowhead will co-develop ARO-AAT which, if approved, will be co-commercialized in the United States under a 50/50 profit-sharing structure. Outside the U.S., Takeda will lead the global commercialization strategy and receive an exclusive license to commercialize ARO-AAT with Arrowhead eligible to receive tiered royalties of 20-25% on net sales. Arrowhead will receive an upfront payment of $300 million and is eligible to receive potential development, regulatory and commercial milestones up to $740 million. [collapse expanded text] |
Janux Therapeutics, Merck and Co | Dec 2020 | 1001 | Collaboration agreement for candidates for immuno-oncology using T cell engager (TRACTr) technology | Janux Therapeutics announced a strategic collaboration and license agreement with Merck to discover, … read moredevelop and commercialize innovative, next generation T cell engager immunotherapies for the treatment of cancer. The goal of the collaboration is to use Janux’s proprietary Tumor Activated T Cell Engager (TRACTrTM) technology to engineer novel, T cell engager drug candidates directed against two cancer targets selected by Merck. Merck has received an exclusive worldwide license to products and intellectual property developed from this collaboration. Janux will be eligible to earn up to $500.5 million per target in upfront and milestone payments plus royalties on sales of any product derived from the collaboration. Merck will fund research and development performed under the collaboration. [collapse expanded text] |
Boehringer Ingelheim, Enleofen Bio | Jan 2020 | 1000 | Licensing agreement for preclinical interleukin-11 (IL-11) platform | Boehringer Ingelheim and Enleofen Bio announced the acquisition of worldwide exclusive rights to … read moreEnleofen’s preclinical interleukin-11 (IL-11) platform by Boehringer Ingelheim to develop first-in-class therapies across a broad range of fibro-inflammatory diseases. The new partnership combines Boehringer Ingelheim’s leading expertise and comprehensive pipeline in fibrotic diseases with Enleofen’s world-leading expertise in IL-11 biology and the company’s extensive range of therapeutic antibodies targeting this pathway. The acquisition of the IL-11 program from Enleofen strengthens Boehringer Ingelheim’s pipeline portfolio, which combines approaches that are effective across multiple fibrotic diseases with disease-specific approaches to achieve greater therapeutic effect and builds on the experience gained with nintedanib in fibrotic lung diseases. Boehringer Ingelheim will be solely responsible for the clinical, regulatory and commercial development of the licensed therapies. Enleofen may receive earn out payments in excess of one billion USD per product in upfront and success-based development and commercialization milestones. [collapse expanded text] |
Jnana Therapeutics, Roche | Jul 2020 | 1000 | Collaboration agreement for regulators of cellular metabolism to treat immune-mediated and neurological diseases | Jnana Therapeutics announced a strategic, multi-target collaboration and license agreement with … read moreRoche for the discovery of small molecule drugs directed at the solute carrier family of metabolite transporters as a broad, innovative approach for modulating cellular metabolism to treat immune-mediated and neurological diseases. Jnana will partner with Roche on discovery and preclinical development for a broad set of targets across immunology and neuroscience, which Roche will further develop and commercialize exclusively. Jnana will receive an upfront payment of $40 million in cash, and may receive research funding, preclinical, development and commercialization milestone payments, as well as royalties. The aggregate value of potential future payments to Jnana can exceed $1 billion. [collapse expanded text] |
Kiadis Pharma, Sanofi | Jul 2020 | 986.7 | Licensing agreement for K-NK-cell programs | Kiadis Pharma announced the exclusive license of Kiadis’ previously undisclosed K-NK004 program to … read moreSanofi. The agreement covers Kiadis’ proprietary CD38 knock out (CD38KO) K-NK therapeutic for combination with anti-CD38 monoclonal antibodies, including Sarclisa, Sanofi’s recently approved therapy for patients with multiple myeloma. Sanofi has obtained exclusive rights to use Kiadis’ K-NK platform for two undisclosed pre-clinical programs. Kiadis will receive a €17.5 million up front payment and will be entitled to receive up to €857.5 million upon Sanofi’s achievement of preclinical, clinical, regulatory and commercial milestones. Kiadis will also receive up to low double-digit royalties based on commercial sales of approved products resulting from this agreement. [collapse expanded text] |
Boehringer Ingelheim, Click Therapeutics | Sep 2020 | 960 | Collaboration, development and licensing agreement for CT-155 | December 2022 Boehringer Ingelheim and Click Therapeutics announced the launch of an expanded … read morecollaboration for the development and commercialization of a second prescription-based digital therapeutic. The companies will collaborate to develop and commercialize a novel mobile application, which combines multiple clinically validated therapeutic interventions for use alone and in combination with pharmaceutical therapy to help people with schizophrenia achieve positive clinical outcomes. The partnership aims to provide additional treatment options to those living with schizophrenia, where there remains a significant unmet need due to lack of access to psychosocial intervention therapies. The companies are pursuing this new therapy after recognizing that a comprehensive treatment strategy for schizophrenia would benefit from a multi-product approach. Click Therapeutics will receive an upfront payment, funding for research and development activities as well as clinical, regulatory and commercial milestone payments up to a total of USD 460 million, plus tiered royalties. September 2020 Boehringer Ingelheim and Click Therapeutics have entered into a collaboration for the development and commercialization of a prescription-based digital therapeutic. It will utilize cognitive and neurobehavioral mechanisms delivered through Click’s proprietary engagement platform with the goal of reducing cognitive deficits and impaired social functioning in patients with schizophrenia. Together the two companies will join their expertise to develop a novel mobile application, CT-155, which combines multiple clinically validated therapeutic interventions to help schizophrenia patients modify their behavior to achieve positive clinical outcomes alone and in combination with pharmaceutical therapy options. The partnership aims to provide better tools and resources to those living with schizophrenia, where there remains a huge unmet need due to lack of access to psychosocial intervention therapies. Click Therapeutics will be primarily responsible for research and development activities, and will support Boehringer Ingelheim as it undertakes worldwide commercialization activities. Click Therapeutics will receive under the terms of the partnership agreement an upfront payment and funding for research and development activities as well as clinical, regulatory and commercial milestones representing a total deal value of over USD 500 million. Click Therapeutics will receive tiered royalties on annual net sales of CT-155 worldwide. [collapse expanded text] |
Aligos Therapeutics, Merck and Co | Dec 2020 | 916 | Research, collaboration and licensing agreement for oligonucleotide therapy for NASH | January 2022 Aligos Therapeutics has expanded its ongoing collaboration agreement with Merck & … read moreamp; Co to discover and develop oligonucleotide therapies for non-alcoholic steatohepatitis. That agreement has now been expanded to include the in-license by Merck of an early-stage program with respect to a second undisclosed NASH target on which Aligos has previously been working independently and separately from Merck. In addition, under this expanded arrangement, Merck has the ability of adding an additional third target of interest in the cardiometabolic/fibrosis space to the collaboration. Aligos will receive a payment from Merck for the in-license of the program directed at a second undisclosed NASH target. Aligos will receive an additional payment upon designation of a third target for the collaboration. With respect to each target in the collaboration, Aligos will be eligible to receive up to ~$460M in development and commercialization milestones as well as tiered royalties on net sales. Aligos is primarily responsible for designing, synthesizing and evaluating the oligonucleotide candidates and delivering optimized lead molecules. Thereafter, Merck is responsible for subsequent research, clinical development and commercialization. December 2020 Aligos Therapeutics has entered into an Exclusive License and Research Collaboration Agreement with Merck under which Merck and Aligos will apply Aligos’ oligonucleotide platform technology to discover, research, optimize and develop oligonucleotides directed against a non-alcoholic steatohepatitis (NASH) target and up to one additional target of interest in the cardiometabolic/fibrosis space. Aligos will receive an upfront payment from Merck as well as an additional payment upon designation of a second target for the collaboration. With respect to each collaboration target, Aligos will be eligible for up to $458M in development and commercialization milestones as well as tiered royalties on net sales. Aligos will be primarily responsible for designing, preparing and evaluating the oligonucleotide molecules and delivering optimized lead molecules, and Merck will be responsible for subsequent research, clinical development and commercialization efforts. [collapse expanded text] |
Carmine Therapeutics, Takeda Pharmaceutical | Jun 2020 | 900 | Collaboration, option and licensing agreement for rare disease gene therapies using novel red blood cell extracellular vesicles platform | Carmine Therapeutics has signed a research collaboration agreement with Takeda Pharmaceutical to … read morediscover, develop and commercialize transformative non-viral gene therapies for two rare disease targets using Carmine's REGENT technology, based on red blood cell extracellular vesicles. Takeda has committed a $5M convertible loan in support of the development of Carmine's novel REGENT platform. Carmine will receive an upfront payment, research funding support and is eligible for over $900M in total milestone payments plus tiered royalties. Takeda has an option to license the programs following the completion of pre-clinical proof of concept studies and would be responsible for clinical development and commercialization. [collapse expanded text] |
Adaptimmune, Astellas Pharma, Universal Cells | Jan 2020 | 897.5 | Co-development and co-promotion agreement for stem-cell derived allogeneic T-cell therapies | Astellas Pharma, through its wholly-owned subsidiary Universal Cells, and Adaptimmune Therapeutics … read morehave entered into a co-development and co-commercialization agreement to bring new stem-cell derived allogeneic T-cell therapies to people with cancer. Astellas and Adaptimmune will agree on up to three targets and co-develop T-cell therapy candidates directed to those targets. These targets will exclude target specific T-cell products in pre-clinical or clinical trials or those developed for other partners at Adaptimmune. The collaboration will leverage Adaptimmune's target identification and validation capabilities for generating target-specific T-cell Receptors (TCRs), chimeric antigen receptors (CARs), and HLA-independent TCRs that recognize surface epitopes independently of the HLA profile of the tumor cell. The collaboration will also utilize Astellas’ Universal Donor Cell and Gene Editing Platform it obtained through the acquisition of Seattle-based Universal Cells. Astellas will fund research up until completion of a Phase 1 trial for each candidate. Upon completion of the Phase 1 trial for each candidate, Astellas and Adaptimmune will elect whether to progress with co-development and co-commercialization of the candidate, or to allow the other Party to pursue the candidate independently through a milestone and royalty bearing licence, with the agreement allowing for either company to opt out. The companies will each have a co-exclusive licence covering the co-development and co-commercialization of the product candidates within the field of T-cell therapy. If a candidate is developed by one company only, the appropriate licences will become exclusive to the continuing party. Astellas will also have the right to select two targets and develop allogeneic cell therapy candidates independently. Astellas will have sole rights to develop and commercialize these products, subject to necessary licenses and the payment of milestones and royalties. Adaptimmune may receive up to $897.5 million in payments, including: An upfront payment of $50 million. Development milestones totalling up to $73.75 million for each product if the collaboration product discovered in this partnership is co-developed and commercialized by both companies Up to $147.5 million in milestone payments per product and up to $110 million in sales milestones for products developed unilaterally by Astellas. Adaptimmune will receive research funding of up to $7.5 million per year. Adaptimmune would receive tiered royalties on net sales in the mid-single to mid-teen digits. Astellas may receive up to $552.5 million, including: Up to $147.5 million in milestone payments per product and up to $110 million in sales milestones for products developed unilaterally by Adaptimmune. Astellas would receive tiered royalties on net sales in the mid-single to mid-teen digits. To the extent that Astellas and Adaptimmune co-develop and co-commercialize any T-cell therapy, they will equally share the costs of such co-development and co-commercialization, with the resulting profits from co-commercialization also shared equally. Further details governing co-development and co-commercialization will be articulated in a product-specific commercialization agreement. [collapse expanded text] |
Merck and Co, Zymeworks | Jul 2020 | 891 | Research and licensing agreement for multispecific antibodies | Zymeworks and Merck have signed a new license agreement granting Merck the right to develop … read moreadditional multispecific antibody therapeutic candidates using Zymeworks’ Azymetric and EFECT platforms. Zymeworks will provide Merck a worldwide, royalty-bearing license to research, develop and commercialize up to three new multispecific antibodies toward Merck’s therapeutic targets. Zymeworks will receive an undisclosed upfront payment and if each of the three programs yield an approved product, Zymeworks is eligible to receive up to US$411 million in option exercise fees and clinical development and regulatory approval milestone payments and up to US$480 million in commercial milestone payments, as well as tiered royalties on worldwide sales. Merck will also receive a worldwide, royalty-bearing license to research, develop and commercialize up to three multispecific antibodies in the animal health field in exchange for additional milestone payments and tiered royalties. [collapse expanded text] |
Evox Therapeutics, Takeda Pharmaceutical | Mar 2020 | 882 | Collaboration and option agreement for multi-target collaboration is focussed on developing up to five novel protein replacement and mRNA therapies | Evox Therapeutics announced the signing of a rare disease-focused partnership with Takeda … read morePharmaceutical. The multi-target collaboration is focussed on developing up to five novel protein replacement and mRNA therapies, including Evox's preclinical programme in Niemann-Pick disease type C (NPC) and a second new programme directed at another undisclosed rare disease. As part of the deal, Takeda also has the option to select up to three additional rare disease targets. The partnership with Takeda enables Evox to continue advancing its proprietary exosome-based targeting and delivery technology, while also leveraging Takeda's extensive development and clinical expertise to advance these partnered programmes into the clinic. Evox will be eligible to receive up to $44 million in upfront, near-term milestone payments and research funding. Evox is eligible to receive approximately $882 million in upfront, development, and commercial milestone payments from Takeda. Evox will also receive tiered royalties on net sales of each product. Evox will be primarily responsible for research and development activities for each programme until IND-enabling studies and for manufacturing up to and including Phase 1 clinical trials. Takeda will reimburse Evox for manufacturing costs incurred after the pre-clinical handover of the programmes. [collapse expanded text] |
Eli Lilly, Sitryx | Mar 2020 | 880 | Collaboration and licensing agreement for immunometabolic medicines | Eli Lilly announced an exclusive global licensing and research collaboration with Sitryx. The … read morecollaboration will study up to four novel preclinical targets identified by Sitryx that could lead to potential new medicines for autoimmune diseases. Sitryx will receive an upfront payment of $50 million and Lilly will make a $10 million equity investment in Sitryx. Sitryx will be eligible to receive potential development milestones up to $820 million, as well as commercialization milestones and royalty payments on potential sales in the mid- to high-single digit range. In return, Sitryx will grant Lilly an exclusive, worldwide license to develop and commercialize up to four novel immunometabolism targeted therapeutics, including Sitryx's two lead projects. Lilly and Sitryx will establish a 5-year research collaboration to support the development of the therapeutics, with Sitryx responsible for drug discovery, while Lilly will fund and manage the clinical development and commercial phase of the collaboration. [collapse expanded text] |
Hanmi Pharmaceutical, Merck and Co | Aug 2020 | 870 | Licensing agreement for Efinopegdutide | Merck and Hanmi Pharmaceutical have entered into an exclusive licensing agreement for the … read moredevelopment, manufacture and commercialization of efinopegdutide (formerly HM12525A), Hanmi’s investigational once-weekly glucagon-like peptide-1 (GLP-1)/glucagon receptor dual agonist, for the treatment of nonalcoholic steatohepatitis (NASH). Merck will be granted an exclusive license to develop, manufacture and commercializeefinopegdutidein the United States and globally. Hanmi will receive an upfront payment of $10 million and is eligible to receive milestone payments up to $860 million associated with the development, regulatory approval and commercialization of efinopegdutide,as well as double-digit royalties on sales of approved product. Hanmi retains an option to commercialize efinopegdutide in Korea. [collapse expanded text] |
Abbvie, Alpine Immune Sciences | Jun 2020 | 865 | Development, option and licensing agreement for ALPN-101 | December 2023 Alpine Immune Sciences has amended the previously announced 2020 option and … read morelicense agreement with AbbVie for acazicolcept. Key terms of the amended agreement: Company will stop enrollment under the amended agreement in the phase 2 study of acazicolcept in systemic lupus erythematosus within 30 days. Currently enrolled patients will be allowed to complete the study. Patients who are currently in the screening process and meet eligibility requirements will be allowed to enter and complete the study. Final analysis will be conducted after the last patient completes the study protocol which is expected to occur by the end of 2024. AbbVie retains an exclusive option to obtain an exclusive worldwide license to acazicolcept which is exercisable by AbbVie at any time and will expire 90 days from delivery of an agreed upon data package by the Company to AbbVie. The previously disclosed option exercise fee of $75 million has been reduced to $10 million and the remaining pre-option development milestone has been removed.Potential future development, commercial, and sales-based milestones and sales-based royalties have been reduced by 25 percent from the originally agreed upon amounts. Company has received $105 million in non-refundable upfront and milestone payments to-date as part of the option and license agreement. June 2020 Alpine Immune Sciences and AbbVie announced an exclusive worldwide option and license agreement for ALPN-101, a first-in-class dual CD28/ICOS costimulation antagonist. Alpine will receive an upfront payment of $60 million, and will also be eligible to receive up to an aggregate of $805 million for exercise of the option and success-based development, regulatory and commercial milestones. Alpine is eligible to receive tiered royalties on net sales of ALPN-101. AbbVie will receive an option to an exclusive license for ALPN-101. During the option period, Alpine will conduct a phase 2 study in systemic lupus erythematosus. Upon exercise of the option, AbbVie will conduct all future clinical development, manufacturing and commercialization activities for ALPN-101. [collapse expanded text] |
Hypera Pharma, Takeda Pharmaceutical | Mar 2020 | 825 | Asset purchase agreement for over-the-counter and prescription pharmaceutical products | Takeda Pharmaceutical has entered into an agreement to divest a portfolio of select non-core … read moreproducts exclusively in Latin America to Hypera for a total value of $825M USD. The portfolio includes over-the-counter and prescription pharmaceutical products sold in Brazil, Mexico, Argentina, Colombia, Ecuador, Panama and Peru, which are part of Takeda’s Growth & Emerging Markets Business Unit. The non-core products in this latest transaction generated revenues of approximately $215 million USD in Fiscal Year 2018, driven by sales of key products such as Neosaldina, Nesina, and Dramin. Takeda has entered into an agreement to divest the rights, title, and interest to the products in a portfolio of approximately 18 select OTC and prescription pharmaceutical assets sold in Brazil, Mexico, Argentina, Colombia, Ecuador, Panama and Peru - to Hypera Pharma for a total value of $825M USD. Takeda anticipates that approximately 300 commercial employees supporting the divested assets will be given the opportunity to transition over to Hypera Pharma at the close of this transaction. Takeda and Hypera Pharma have also entered into a manufacturing and supply agreement under which Takeda will continue to manufacture these products and supply them to Hypera Pharma. The transaction is expected to close in the second half of 2020, subject to the satisfaction of customary closing conditions. Until then, Takeda remains the owner of these products and responsible for ensuring patient access to them. [collapse expanded text] |
GSK, Surface Oncology | Dec 2020 | 815 | Licensing agreement for SRF813, a fully human IgG1 antibody targeting PVRIG (also known as CD112R) | Surface Oncology announced an agreement for GSK to exclusively license worldwide development and … read morecommercial rights to Surface Oncology’s preclinical program SRF813, a fully human IgG1 antibody targeting PVRIG (also known as CD112R), an inhibitory protein expressed on natural killer cells (NK cells) and T cells. GSK will make an $85 million upfront payment. Surface Oncology may receive up to an additional $730 million in future milestone payments, as well as be eligible to receive tiered royalties on global net sales. [collapse expanded text] |
GSK, Surface Oncology | Dec 2020 | 815 | Licensing agreement for SRF813, a fully human IgG1 antibody targeting PVRIG (also known as CD112R) | Surface Oncology announced an agreement for GSK to exclusively license worldwide development and … read morecommercial rights to Surface Oncology’s preclinical program SRF813, a fully human IgG1 antibody targeting PVRIG (also known as CD112R), an inhibitory protein expressed on natural killer cells (NK cells) and T cells. GSK will make an $85 million upfront payment. Surface Oncology may receive up to an additional $730 million in future milestone payments, as well as be eligible to receive tiered royalties on global net sales. [collapse expanded text] |
Gilead Sciences, Jounce Therapeutics | Sep 2020 | 805 | Licensing agreement for JTX-1811/GS-1811 program | December 2022 Gilead Sciences and Jounce Therapeutics amended their existing license agreement … read morefor GS-1811 (formerly JTX-1811), enabling Gilead to buy out remaining contingent payments potentially due under the license agreement executed in August 2020. As part of the transaction, certain operational obligations of the parties related to GS-1811, an anti-CCR8 antibody, set forth in the license agreement have also been terminated. Gilead will acquire certain related intellectual property, including all outstanding rights of Jounce to GS-1811, pursuant to the transaction agreement. GS-1811, a potentially first-in-class immunotherapy, is designed to selectively deplete immunosuppressive tumor-infiltrating T regulatory cells in the tumor microenvironment and is currently in Phase 1 clinical development as a possible treatment for patients with solid tumors. November 2022 Jounce Therapeutics announced earning a $15.0 million clinical milestone payment from Gilead Sciences under the exclusive license agreement for GS-1811, an anti-CCR8 antibody for which Gilead has exclusive rights to develop and commercialize. GS-1811 (formerly JTX-1811) is designed to selectively deplete immunosuppressive tumor-infiltrating T regulatory cells in the tumor microenvironment. June 2021 Jounce Therapeutics announced the US Food and Drug Administration’s clearance of its Investigational New Drug application for JTX-1811, an anti-CCR8 antibody, for which Gilead Sciences, has exclusive rights to develop and commercialize. The IND clearance triggers a $25.0 million milestone payment to Jounce. September 2020 Gilead Sciences announced an agreement with Jounce Therapeutics to exclusively license its JTX-1811 program. JTX-1811 is a monoclonal antibody designed to selectively deplete immunosuppressive tumor-infiltrating T regulatory (TITR) cells. Gilead will make a $85 million upfront payment to, and a $35 million equity investment at a premium in, Jounce upon closing. Jounce may receive up to an additional $685 million in future clinical, regulatory and commercial milestone payments. Jounce will also be eligible to receive royalties ranging from high single digit to mid-teens based upon worldwide sales, subject to certain adjustments. Jounce will lead development of JTX-1811 through IND clearance, and thereafter, Gilead will have the sole right to develop JTX-1811. [collapse expanded text] |
Eli Lilly, Seed Therapeutics | Nov 2020 | 800 | Research agreement for therapeutic benefit through targeted protein degradation | Seed Therapeutics has entered into a research collaboration and license agreement with Eli Lilly to … read morediscover and develop new chemical entities that could produce therapeutic benefit through targeted protein degradation. Seed Therapeutics will receive a $10 million upfront cash payment to fund research, as well as a $10 million equity investment from Lilly. Seed Therapeutics will also be eligible to receive up to approximately $780 million in potential pre-clinical and clinical development, regulatory and commercial milestones, as well as tiered royalties on net sales of products that result from the collaboration. [collapse expanded text] |
Boston Scientific, Laboratoire Serb, Stark Investments | Dec 2020 | 800 | Asset purchase agreement for BTG Specialty Pharmaceuticals business | Boston Scientific has entered into a definitive agreement with Stark International, and SERB to … read moresell its BTG Specialty Pharmaceuticals business for $800 million in cash. The agreement includes the transfer of five facilities and approximately 280 employees globally. [collapse expanded text] |
Novartis, Sangamo Therapeutics | Jul 2020 | 795 | Collaboration, option and licensing agreement for genomic medicines for autism and other neurodevelopmental disorders | March 2023 Novartis Institutes for BioMedical Research notified Sangamo Therapeutics of its … read moretermination for convenience, effective June 11, 2023 of the Collaboration and License Agreement by and between Novartis and Sangamo dated July 27, 2020, pursuant to which Novartis and Sangamo were engaged in programs to research gene regulation therapies to treat three neurodevelopment disorders. Novartis has indicated to Sangamo that the termination relates to a recent strategic review. Sangamo will investigate alternative options to advance the neurodevelopmental disorder programs that were subject to the Novartis Agreement, including potential development internally or with a collaboration partner, dependent on the outcome of a broader strategic review of its pre-clinical pipeline of therapies to treat patients suffering from central nervous system disorders. July 2020 Sangamo Therapeutics has executed a global licensing collaboration agreement with Novartis to develop and commercialize gene regulation therapies to address three neurodevelopmental targets, including autism spectrum disorder (ASD) and other neurodevelopmental disorders. The collaboration will leverage Sangamo’s propriety genome regulation technology, zinc finger protein transcription factors (ZFP-TFs), to aim to upregulate the expression of key genes involved in neurodevelopmental disorders. Under the terms of the agreement, over a three-year collaboration period, Novartis has exclusive rights to ZFP-TFs targeted to three undisclosed genes which are associated with neurodevelopmental disorders, including ASD and intellectual disability. Novartis also has the option to license Sangamo’s proprietary AAVs. Sangamo is responsible for certain research and associated manufacturing activities, all of which will be funded by Novartis, and Novartis assumes responsibility for additional research activities, investigational new drug-enabling studies, clinical development, related regulatory interactions, manufacturing and global commercialization. Novartis will pay Sangamo a $75 million upfront license fee payment within thirty days. Sangamo is eligible to earn up to $720 million in other development and commercial milestone payments, including up to $420 million in development milestones and up to $300 million in commercial milestones. Sangamo is also eligible to receive from Novartis tiered high single-digit to sub-teen double-digit royalties on potential net commercial sales of products arising from the collaboration. [collapse expanded text] |
Aspen Pharmacare Canada, Mylan Laboratories | Sep 2020 | 761 | Asset purchase agreement for thrombosis business | Mylan announced an agreement to acquire the related intellectual property and commercialization … read morerights of Aspen Pharmacare Holdings thrombosis business in Europe for EUR 641.9 million, subject to customary closing conditions and European regulatory clearances. The transaction is expected to be immediately accretive to Mylan upon closing and is anticipated to be accretive to VIATRIS upon the completion of Mylan's previously announced combination with Upjohn that is expected to close in the fourth quarter of 2020. Upon closing of the transaction, Mylan expects to fund an upfront payment of EUR 263.2 million to Aspen from existing cash. Also, Mylan expects to utilize cash generated from operations to make the final deferred payment of EUR 378.7 million on June 25, 2021. The portfolio consists of well-established injectable anticoagulants sold in Europe under the brand names, and variations of the brand names, Arixtra, Fraxiparine, Mono-Embolex and Orgaran. [collapse expanded text] |
Genentech, Relay Therapeutics | Dec 2020 | 760 | Collaboration, licensing, option and co-promotion agreement for RLY-1971 | July 2024 Roche’s Genentech has ended its SHP2 inhibitor pact returning rights to Relay … read moreTherapeutics after paying more than $120 million into alliance Genentech paid $75 million upfront to license Relay’s SHP2 inhibitor, a molecule variously called RLY-1971, migoprotafib or GDC-1971 Outlay reflected company’s belief in promise of pairing molecule with its KRAS G12C inhibitor GDC-6036 $45 million in milestones later, Genentech has decided to terminate the R&D alliance without cause, depriving Relay of chance to pocket another $675 million in success-based milestones December 2020 Relay Therapeutics has entered into a worldwide license and collaboration agreement with Genentech for the development and commercialization of RLY-1971, a potent inhibitor of SHP2. Genentech will assume development of RLY-1971 with the potential to expand into multiple combination studies including with Genentech’s investigational inhibitor of KRAS G12C, GDC-6036. Relay Therapeutics will receive $75 million in an upfront payment and is eligible to receive $25 million in additional near-term payments. Relay Therapeutics also has the right to opt in to a 50/50 U.S. profit/cost share on RLY-1971. If Relay elects to opt in, then Relay will be eligible to receive 50 percent of profits from U.S. sales and up to $410 million in additional ex-U.S. commercialization and sales-based milestone payments, as well as royalties on ex-U.S. net sales. If Relay Therapeutics elects not to opt in, then Relay will be eligible to receive up to $695 million in additional development, commercialization and sales-based milestones, as well as royalties on global net sales, anticipated to be in the low-to-mid-teens. In the event of regulatory approval of both RLY-1971 and GDC-6036 in combination, Relay Therapeutics is eligible to receive additional royalties. Relay Therapeutics retains the right to combine RLY-1971 with its selective FGFR2 and mutant-selective PI3Kα programs. [collapse expanded text] |
BioNTech, Pfizer | Mar 2020 | 748 | Co-development and distribution agreement for potential COVID-19 vaccine | April 2020 BioNTech and Pfizer disclosed additional details of their collaboration to advance … read morecandidates from BioNTech’s mRNA vaccine program, previously announced on March 17, 2020. Collaboration aims to rapidly advance multiple COVID-19 vaccine candidates into human clinical testing based on BioNTech’s proprietary mRNA vaccine platforms, with the objective of ensuring rapid worldwide access to the vaccine, if approved. The collaboration will leverage Pfizer’s broad expertise in vaccine research and development, regulatory capabilities, and global manufacturing and distribution network. The two companies plan to jointly conduct clinical trials for the COVID-19 vaccine candidates initially in the United States and Europe across multiple sites. BioNTech and Pfizer intend to initiate the first clinical trials as early as the end of April 2020, assuming regulatory clearance. During the clinical development stage, BioNTech and its partners will provide clinical supply of the vaccine from its GMP-certified mRNA manufacturing facilities in Europe. BioNTech and Pfizer will work together to scale-up manufacturing capacity at risk to provide worldwide supply in response to the pandemic. BioNTech and Pfizer will also work jointly to commercialize the vaccine worldwide (excluding China, which is already covered by BioNTech’s collaboration with Fosun Pharma) upon regulatory approval. Pfizer will pay BioNTech $185 million in upfront payments, including a cash payment of $72 million and an equity investment of $113 million. BioNTech is eligible to receive future milestone payments of up to $563 million for a potential total consideration of $748 million. Pfizer and BioNTech will share development costs equally. Initially, Pfizer will fund 100 percent of the development costs, and BioNTech will repay Pfizer its 50 percent share of these costs during the commercialization of the vaccine. March 2020 Pfizer and BioNTech have agreed to a letter of intent regarding the co-development and distribution (excluding China) of a potential mRNA-based coronavirus vaccine aimed at preventing COVID-19 infection. The companies have executed a Material Transfer and Collaboration Agreement to enable the parties to immediately start working together. The collaboration aims to accelerate development of BioNTech’s potential first-in-class COVID-19 mRNA vaccine program, BNT162, which is expected to enter clinical testing by the end of April 2020. The rapid advancement of this collaboration builds on the research and development collaboration into which Pfizer and BioNTech entered in 2018 to develop mRNA-based vaccines for prevention of influenza. The companies expect to utilize multiple research and development sites from both companies, including in the United States and Germany, to house the activities identified by the collaboration agreement. The companies will begin collaborating immediately. They will finalize details of the agreement regarding financial terms, and all activities related to development, manufacturing and potential commercialization over the next few weeks. [collapse expanded text] |
Selecta Biosciences, Swedish Orphan Biovitrum | Jun 2020 | 730 | Licensing agreement for SEL-212 | Swedish Orphan Biovitrum and Selecta Biosciences have entered into a strategic licensing agreement … read morefor the product candidate SEL-212. SEL-212 is a combination of Selecta’s tolerogenic ImmTOR immune tolerance platform and a therapeutic uricase enzyme (pegadricase) that is designed to durably control serum uric acid, reduce immunogenicity, and allow for repeated monthly dosing for the treatment of chronic refractory gout. Sobi will assume responsibility for development, regulatory, and commercial activities for SEL-212 in all markets outside of China. Sobi will make initial payments to Selecta of USD 100 million, which include USD 75 million up-front license fee and USD 25 million in a private placement of shares of Selecta common stock. Selecta is eligible to receive potential milestone payments of up to USD 630 million from Sobi, which are dependent upon specific regulatory and development targets having been met, as well as sales thresholds. Selecta is eligible to receive tiered double-digit royalties on net sales. Sobi and Selecta have entered into a share purchase agreement, pursuant to which Sobi will invest USD 25 million in a private placement of 5,416,390 shares of Selecta common stock at a purchase price of USD 4.62 per share (representing a 20% premium to the volume weighted average price over the 10 days prior to signing). [collapse expanded text] |
Genentech, Nykode Therapeutics, Vaccibody | Oct 2020 | 715 | Collaboration and licensing agreement for VB10.NEO, individualized neoantigen cancer vaccines | June 2023 Nykode Therapeutics has expanded the clinical collaboration and supply agreement with … read moreRoche to cover evaluation of VB10.16, Nykode’s wholly owned off-the-shelf therapeutic cancer vaccine candidate, in combination with Roche’s cancer immunotherapy atezolizumab in patients with advanced cervical cancer who have progressed on pembrolizumab plus chemotherapy +/- bevacizumab as first line treatment. The VB-C-04 trial is expected to be initiated in the U.S. in the fourth quarter of 2023 with registrational intent, which provides a potential fast-to-market path. Nykode will sponsor and fund the planned clinical trial, and Roche will provide atezolizumab. Nykode retains all commercial rights to VB10.16 worldwide. October 2020 Vaccibody has entered into an exclusive worldwide license and collaboration agreement with Genentech for the development and commercialization ofDNA-based individualized neoantigen vaccines for the treatment of cancers. Vaccibody will conduct development through the end of Phase 1b and Genentech will be responsible for development and commercialization thereafter. The transaction will combine Genentech’s global cancer immunotherapy research, development and commercial leadership with Vaccibody’s targeted DNA-based vaccine platform to realize a potential new treatment paradigm of individualized cancer vaccines. Vaccibody will receive USD 200 million in initial upfront and near-term payments. Additionally, Vaccibody will be eligible to receive up to a furtherUSD 515 million in potential payments and milestones, plus low double-digit tiered royalties on sales of commercialized products arising from the partnership. Following completion of the Phase 1b study, Genentech will have responsibility and bear all costs for clinical, regulatory, manufacturing and commercialization activities. Genentech and Vaccibody will progress Vaccibody’s investigationalproduct, VB10.NEO, into clinical trials in the U.S. and in Europe. VB10.NEO, an individualized DNA-based neoantigen vaccine, uniquely targets encoded antigens to antigen presenting cells which are essential for generating potent T cell responses required for cancer therapy. The vaccine is designed to be produced on-demand according to the neoantigen profile of an individual patient. Neoantigens are proteins generated by tumor-specific mutations not present in normal tissues, and are thus an attractive target for cancer immunotherapy asthey may be recognized as foreign by the immune system. [collapse expanded text] |
Biogen, Pfizer | Jan 2020 | 710 | Licensing agreement for PF-05251749 | Biogen announced an agreement to acquire from Pfizer PF-05251749, a novel CNS-penetrant small … read moremolecule inhibitor of casein kinase 1 (CK1), for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases. Biogen plans to develop the Phase 1 asset for the treatment of Sundowning in Alzheimer’s disease (AD) and Irregular Sleep Wake Rhythm Disorder (ISWRD) in Parkinson’s disease (PD). The purchase will include an upfront payment of $75 million with up to $635 million in potential additional development and commercialization milestone payments, as well as tiered royalties in the high single digits to sub-teens. [collapse expanded text] |
Celsius Therapeutics, Les Laboratoires Servier | Dec 2020 | 700 | Collaboration, option and licensing agreement for identification and validation of novel colorectal cancer drug targets | Servier and Celsius Therapeutics announced a strategic collaboration focused on the identification … read moreand validation of novel colorectal cancer drug targets. Celsius will analyze hundreds of samples from defined CRC patient populations using its proprietary single-cell genomics platform and will work to identify and validate new drug targets during the three-year research period. Servier will receive an exclusive option to research, develop, and commercialize products directed to up to three of the targets. Celsius would receive an upfront payment and research funding, and would be eligible to receive over $700 million in potential discovery, development, and commercialization milestone payments, along with tiered royalties. [collapse expanded text] |
Kyowa Hakko Kirin, MEI Pharma | Apr 2020 | 682.5 | Co-development, co-promotion and licensing agreement for ME-401 | MEI Pharma and Kyowa Kirin have entered into a global license, development and commercialization … read moreagreement to further develop and commercialize MEI's ME-401, an oral, once-daily, investigational drug-candidate, selective for phosphatidylinositol 3-kinase delta (PI3Kδ), in clinical development for the treatment of B-cell malignancies. MEI and Kyowa Kirin will co-develop and co-promote ME-401 in the U.S., with MEI booking all revenue from U.S. sales. Kyowa Kirin has exclusive commercialization rights outside of the U.S. Under the terms of the agreement, which substantially retains and consolidates the terms of the 2018 license agreement between MEI and Kyowa Kirin to develop and commercialize ME-401 in Japan, MEI will receive a $100 million upfront payment from Kyowa Kirin. MEI is also eligible to receive up to $582.5 million in additional payments from Kyowa Kirin depending on the achievement of certain U.S. and ex-U.S. development, regulatory and commercial milestones. If approved by FDA in the U.S., MEI and Kyowa Kirin will co-promote ME-401, with MEI booking all revenue from sales. MEI and Kyowa Kirin will share U.S. profits and costs (including development costs) on a 50-50 basis. Outside the U.S., Kyowa Kirin will have exclusive commercialization rights, lead commercialization and book all revenues from sales of ME-401. Kyowa Kirin will pay MEI escalating tiered royalties on ex-U.S. sales starting in the teens. Kyowa Kirin will be responsible for all incremental ex-U.S. clinical development costs and all ex-U.S. regulatory, CMC and commercial costs. The companies have agreed to a development plan designed to broadly evaluate ME-401 in patients with various B-cell malignancies, including in combination with other agents. [collapse expanded text] |
Laborie Medical Technologies, Urotronic | Oct 2020 | 680 | Option and licensing agreement for Optilume | Laborie Medical Technologies entered into a multi-faceted, strategic partnership with Urotronic to … read moresupport regulatory approval of Optilume, a drug-coated balloon (DCB) technology for use in urethral strictures and benign prostatic hyperplasia (BPH). LABORIE will invest $15 million USD in Urotronic's Series C financing along with $5 million USD from current shareholders and secure an option to acquire all rights to Optilume. Under the terms of the option agreement, LABORIE can acquire a perpetual, exclusive license to the Optilume Urethral Strictures device, upon FDA approval, for $165 million. LABORIE also has an option to acquire the Company, upon FDA approval of the Optilume BPH device, for $350 million upfront plus another $150 million in earnouts if certain sales milestones are reached. This strategic partnership with Urotronic demonstrates LABORIE's continued commitment to expand the use of less invasive treatments and improve outcomes for patients suffering from urological disorders. [collapse expanded text] |
Elevar Therapeutics, Oasmia Pharmaceutical | Mar 2020 | 678 | Licensing agreement for Apealea | Elevar Therapeutics announced an agreement with Oasmia Pharmaceutical to obtain global rights for … read moreApealea, except in Nordics, Russia, and certain countries in Eastern Europe. Elevar and Oasmia have created a joint development committee for Apealea to expand approvals in Ovarian cancer worldwide while driving development in additional indications. Although the full terms of the deal have not been disclosed, Oasmia will receive an upfront payment of $20M and up to $658M in additional regulatory and sales milestones. [collapse expanded text] |
Atara Biotherapeutics, Bayer | Dec 2020 | 670 | Collaboration and licensing agreement for mesothelin-targeted CAR T-cell therapies for solid tumors | May 2022 Atara Biotherapeutics announced that it received notification of Bayer’s intention to … read moreend the exclusive worldwide licensing agreement for next-generation mesothelin-directed CAR T-cell therapies. December 2020 Bayer and Atara Biotherapeutics announced an exclusive worldwide license agreement and research, development and manufacturing collaboration for mesothelin-directed CAR T-cell therapies for the treatment of solid tumors. The agreement includes the development candidate ATA3271, an armored allogeneic T-cell immunotherapy, and an autologous version, ATA2271, for high mesothelin-expressing tumors such as malignant pleural mesothelioma and non-small-cell lung cancer. The licensed technology leverages Atara's novel, proprietary Epstein-Barr Virus (EBV) T-cell platform combined with CAR T technologies targeting mesothelin to improve efficacy, persistence, safety, and durability of response. Atara will lead IND (Investigational New Drug)-enabling studies and process development for ATA3271 while Bayer will be responsible for submitting the IND and subsequent clinical development and commercialization. Atara will continue to be responsible for the ongoing ATA2271 phase 1 study, for which an IND filing has been accepted and the clinical trial has been initiated. Atara will receive an upfront payment of USD 60 million and is eligible to receive payments from Bayer upon achievement of certain development, regulatory and commercialization milestones totaling USD 610 million, as well as tiered royalties up to low double-digit percentage of net sales. As part of the transaction, Atara will also provide translational and clinical manufacturing services to be reimbursed by Bayer. In addition, for a limited period of time, Bayer has a non-exclusive right to negotiate a license for additional Atara CAR T product candidates. [collapse expanded text] |
Empirico, Ionis Pharmaceuticals | Jan 2020 | 660 | Collaboration agreement for Discovery and development of novel antisense oligonucleotide therapeutics | Empirico has entered into a strategic collaboration with Ionis Pharmaceuticals. During the … read morethree-year collaboration, Empirico will utilize its Precision Insights Platform, which incorporates huge biological data sets, human genetics and advanced algorithmic approaches, to identify therapeutic targets for indications and tissues that are amenable to Ionis’ industry-leading antisense technology. Ionis can advance up to ten targets identified by Empirico and assume responsibility for all preclinical and clinical development activities. Empirico and Ionis will also work together to incorporate human genetics evidence into ongoing efforts with existing Ionis programs, including work on target validation, indication and biomarker selection, and patient stratification. Ionis has made a $10 million equity investment in Empirico, with additional near-term commitments of up to $30 million based on operational and preclinical milestones. Empirico will be eligible to receive in excess of $620 million for the achievement of clinical development, regulatory and commercial milestones, and royalties on net sales. Empirico also has the option to license, develop, and commercialize an Ionis development candidate directed toward a collaboration target for which Ionis will receive milestone payments and royalties on net sales. [collapse expanded text] |
PTC Therapeutics, Royalty Pharma | Jul 2020 | 650 | Royalty financing agreement for Risdiplam | Royalty Pharma announced an agreement with PTC Therapeutics to acquire a portion of PTC’s royalty … read moreinterest in risdiplam for a one-time payment of $650 million. [collapse expanded text] |
Astellas Pharma, KaliVir Immunotherapeutics | Dec 2020 | 634 | Development and licensing agreement for VET2-L2 novel oncolytic virus | KaliVir Immunotherapeutics and Astellas Pharma entered into a worldwide licensing agreement for the … read moreresearch, development, and commercialization of VET2-L2, an intravenously administered oncolytic virus for Immuno-Oncology, as well as a research collaboration to generate a Second Product, a follow-on virus. This collaboration, which combines KaliVir's expertise in the development of oncolytic viruses with Astellas' capabilities in advanced drug development and its global business experience, will enable both parties to develop new Immuno-Oncology therapies. Astellas will pay to KaliVir up to US$56 million in the form of an upfront payment and other payments to support research and preclinical activities related to VET2-L2 and the Second Product. Astellas may pay up to US$307 million and up to US$271 million for development, regulatory and commercialization of VET2-L2 and Second Product, respectively. Astellas also may make royalty payments on net sales of each licensed product. [collapse expanded text] |
Biomedical Advanced Research and Development Authority, Emergent BioSolutions, US Government | Jun 2020 | 628 | Contract service agreement for COVID-19 vaccine development and manufacturing | Emergent BioSolutions has been issued a task order under an existing contract with the Biomedical … read moreAdvanced Research and Development Authority to deploy its contract development and manufacturing (CDMO) capacities, capabilities, and expertise to support the U.S. government’s efforts to accelerate delivery of COVID-19 vaccines. This task order, valued at approximately $628 million, is being issued under the company’s 2012 contract with BARDA that established Emergent’s Baltimore Bayview facility as a Center for Innovation in Advanced Development and Manufacturing (CIADM) for pandemic preparedness, and expands the partnership to include investments in Emergent’s Baltimore Camden and Rockville facilities, creating a U.S.-based manufacturing supply chain for pharmaceutical and biotechnology innovators of COVID-19 vaccine candidates. Under the task order, Emergent will deploy its molecule-to-market CDMO offering, committing manufacturing capacity, valued at approximately $542.7 million, for production of COVID-19 vaccine candidates through 2021. This award secures, on behalf of leading COVID-19 vaccine innovators that are supported by the U.S. government, capacity for drug substance manufacturing at the company’s Baltimore Bayview facility and for drug product manufacturing at the Baltimore Camden and Rockville locations. The task order also includes an investment of approximately $85.5 million for the rapid expansion of Emergent’s viral and non-viral CDMO drug product fill/finish capacity at the Baltimore Camden and Rockville facilities. [collapse expanded text] |
Esperion Therapeutics, Otsuka | Apr 2020 | 610 | Development and licensing agreement for NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) Tablets | Esperion have entered into a collaboration agreement with Otsuka Pharmaceutical for the development … read moreand commercialization of NEXLETOL and NEXLIZET tablets in Japan. Both medicines were recently approved in both the US and EU. The collaboration advances the commitment of both companies to provide cost-effective, oral, once-daily, non-statin LDL-cholesterol (LDL-C) lowering medicines for hypercholesterolemia patients in Japan. This development and commercialization collaboration combines Esperion’s expertise in lipid management with Otsuka’s deep cardiovascular drug development and commercialization expertise in Japan. Esperion will grant Otsuka exclusive rights to NEXLETOL and NEXLIZET tablet development and commercialization in Japan. Otsuka will be responsible for all development, regulatory, and commercialization activities in Japan. Otsuka will fund all Japan-specific development costs associated with the program. Esperion estimates this amount to total up to $100 million over the next few years. Esperion will receive an upfront cash payment of $60 million as well as up to an additional $450 million in total development and sales milestones. Esperion will also receive tiered royalties from 15 percent to 30 percent on net sales in Japan. [collapse expanded text] |
Gilead Sciences, Kite Pharma, Kyverna Therapeutics | Jan 2020 | 587.5 | Collaboration and licensing agreement for engineered T cell therapies | Kyverna has entered into a strategic collaboration and license agreement with Gilead to develop … read moreengineered T cell therapies for the treatment of autoimmune disease based on Kyverna's synthetic Treg platform and synNotch technology from Kite. Kyverna will be responsible for conducting research activities and initial clinical studies through proof-of-concept and Gilead will be granted an option, upon the exercise of which Gilead will be solely responsible for further clinical development and commercialization efforts for these programs. Gilead will make to Kyverna an upfront payment of $17.5 million and Kyverna may earn an additional $570 million in development and commercialization milestones. Kyverna will also continue to advance its platform and develop proprietary programs beyond the Gilead collaboration. [collapse expanded text] |
LEO Pharma, Microbio Shanghai, Oneness Biotech | Apr 2020 | 570 | Licensing agreement for FB825 | LEO Pharma has signed a worldwide exclusive licensing agreement with Oneness Biotech and Microbio … read moreShanghai covering the development and commercialization of the novel Atopic Dermatitis (AD) and Allergic Asthma drug candidate, FB825. LEO Pharma will make an upfront payment of USD 40 million and offer milestone payments up to USD 530 million, followed by a tiered high single-digit to double-digit royalties. Oneness will be responsible for executing the Phase 2a study for Atopic Dermatitis in the United States and Microbio Shanghai will execute the Phase 2a study for allergic asthma in China. LEO Pharma will assume all the development responsibilities after the Phase 2a studies. [collapse expanded text] |
Cheplapharm Arzneimittel, Takeda Pharmaceutical | Sep 2020 | 562 | Asset purchase agreement for cardiovascular, metabolic and anti-inflammatory therapeutic products | Takeda Pharmaceutical has entered into an agreement to divest a portfolio of select non-core … read moreprescription pharmaceutical products sold predominantly in Europe and Canada to Cheplapharm. Takeda will receive an upfront payment of approximately $562 million USD, subject to customary legal and regulatory closing conditions. The portfolio to be divested to Cheplapharm is comprised of non-core prescription pharmaceutical products in a variety of therapeutic categories sold predominantly in Europe and Canada. This includes Cardiovascular/Metabolic and Anti-Inflammatory products along with Calcium. The portfolio generated FY 2019 net sales of approximately $260 million USD. While the products included in the sale address key patient needs in these countries, they are outside of Takeda’s five key business areas. There are no anticipated employee transfers in connection with this transaction. The transaction is expected to close by the end of Fiscal Year 2020 (ending March 2021), subject to the satisfaction of customary closing conditions and receipt of required regulatory clearances. Until then, the products will continue to be made available to patients and manufactured and supplied by Takeda. [collapse expanded text] |
AstraZeneca, Samsung Biologics | Sep 2020 | 545.6 | Manufacturing and supply agreement for drug substance | December 2021 Samsung Biologics continues its strategic biopharmaceutical manufacturing … read morecollaboration with AstraZeneca. The partnership is based on an expanded deal this year in May 2021 which followed the signing of a long-term strategic agreement made in September 2020. Under the agreement, valued at approximately $380 million up from the initial $331 million for the production of drug substance and drug product, Samsung Biologics manufactures AstraZeneca's COVID-19 long-acting antibody (LAAB) combination, AZD7442, and will start to manufacture a cancer immunotherapy product from next year. September 2020 Samsung Biologics and AstraZeneca announced a long-term supply agreement, valued at approximately $330.8 million. Samsung Biologics will provide large-scale commercial manufacturing for drug substance in its Plant 3 as well as drug product to support AstraZeneca's biologics therapeutics, which could be increased to $545.6 million. By leveraging Samsung Biologics' robust expertise and capabilities in the manufacturing of high-quality biopharmaceuticals, this new partnership will enable AstraZeneca to expand its biologics manufacturing capabilities into Asia Pacific. According to AstraZeneca, this collaboration agreement is also expected to accelerate Korean bio-health innovation. [collapse expanded text] |
Assembly Biosciences, BeiGene | Jul 2020 | 540 | Collaboration and licensing agreement for ABI-H0731, ABI-H2158 and ABI-H3733 | Assembly Biosciences and BeiGene have entered into a collaboration in China for Assembly’s … read moreportfolio of three clinical-stage core inhibitor candidates for the treatment of patients with chronic hepatitis B virus (HBV) infection. Assembly has granted BeiGene exclusive rights to develop and commercialize ABI-H0731, ABI-H2158 and ABI-H3733 in China, including Hong Kong, Macau, and Taiwan. ABI-H0731 and ABI-H2158 are both in ongoing Phase 2 clinical trials and ABI-H3733 is in Phase 1 development. BeiGene will be responsible for development, regulatory submissions, and commercialization in China. Assembly retains full worldwide rights outside of the partnered territory for the Company’s HBV portfolio. Assembly will receive an upfront cash payment of $40 million and is eligible to receive up to approximately $500 million in potential development, regulatory and net sales milestone payments pending successful development and commercialization of the licensed candidates. Assembly is eligible to receive tiered royalties of net sales. BeiGene will contribute initial funding for clinical development in China, after which the development costs for the territory will be shared equally by the parties. [collapse expanded text] |
EQRx, Jiangsu Hansoh Pharmaceutical | Jul 2020 | 535 | Collaboration and licensing agreement for Almonertinib | Hansoh Pharmaceutical announced a strategic collaboration and licensing agreement for almonertinib … read morewith EQRx. EQRx will be responsible for the development and commercialization of almonertinib in the United States, Europe, Japan and all other global markets outside of Greater China, and Hansoh Pharma will continue its development and commercialization of almonertinib in Greater China. EQRx and Hansoh will seek to jointly conduct global studies to further expand the potential of almonertinib as a monotherapy and in combination therapy settings. Hansoh will receive approximately $100 million in upfront payment and development and regulatory milestones, with additional undisclosed commercial milestones as well as royalty payments. [collapse expanded text] |
BridgeBio Pharma, LianBio | Aug 2020 | 531.5 | Collaboration agreement for targeted oncology drug candidates | BridgeBio Pharma is partnering with LianBio. The partnership marks the first major expansion of … read moreBridgeBio’s pipeline into Asian markets. This strategic relationship will initially focus on two of BridgeBio’s targeted oncology drug candidates, FGFR inhibitor infigratinib, currently in Phase 3 development for FGFR-driven tumors and Phase 1-ready SHP2 inhibitor BBP-398, for tumors driven by RAS and receptor tyrosine kinase mutations. The agreement also provides LianBio with preferential future access in the territory to more than 20 drug development candidates currently owned or controlled by BridgeBio. This collaboration is designed to advance and accelerate BridgeBio’s programs in China and other major Asian markets, allowing BridgeBio to quickly bring innovation to large numbers of patients with high unmet need. LianBio will receive commercial rights in China and selected Asian markets and participate in clinical development activities for infigratinib (housed in BridgeBio affiliate QED) and BBP-398 (housed in BridgeBio affiliate Navire). BridgeBio’s near-term economics includes a total of $26.5 million in upfront and milestone payments. BridgeBio will receive up to $505 million in future milestone payments, tiered royalty payments from single- to double-digits on net sales of both products in licensed territories. BridgeBio will increase its equity interest via investment in LianBio and BridgeBio CEO Neil Kumar has been appointed to the LianBio board of directors. [collapse expanded text] |
Supernus Pharmaceuticals, US WorldMeds | Apr 2020 | 530 | Asset purchase agreement for CNS portfolio | Supernus Pharmaceuticals has entered into a definitive agreement under which Supernus will acquire … read morethe CNS portfolio of US WorldMeds. With the acquisition, Supernus adds three established and marketed products in the U.S. market with a product candidate in late-stage development: APOKYN (apomorphine hydrochloride) injection is used, as needed, to provide rapid, reliable, and robust control of body movements in people with Parkinson’s disease (PD) when they experience an off episode. An off episode, also called hypomobility, may include symptoms such as muscle stiffness, slow movements, and difficulty starting movements. MYOBLOC® (rimabotulinumtoxinB) injection is the first and only approved botulinum toxin Type B injectable indicated for the treatment of cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia in adults, and the treatment of chronic sialorrhea in adults. XADAGO® (safinamide) tablets is a monoamine oxidase type B (MAO-B) inhibitor indicated as a daily adjunctive treatment to levodopa/carbidopa in patients with PD experiencing off episodes. Apomorphine Infusion Pump is a product candidate for the continuous treatment of motor fluctuations (“on‐off” episodes) in PD patients whose motor control is unsatisfactory with oral levodopa and at least one other noninvasive PD therapy. New Drug Application (NDA) submission is expected in the second half of 2020 with potential launch, if approved by the FDA, in the second half of 2021. Total consideration of $530 million consists of an upfront cash payment of $300 million plus regulatory and commercial milestone cash payments up to $230 million. All cash consideration will be funded through existing balance sheet cash. [collapse expanded text] |
Navitor Pharmaceuticals, Supernus Pharmaceuticals | Apr 2020 | 525 | Co-development and option agreement for mTORC1 Activator NV-5138 | Supernus Pharmaceuticals and Navitor Pharmaceuticals announced a joint development and option … read moreagreement for Navitor’s mTORC1 activator, NV-5138. Supernus and Navitor will jointly conduct a Phase II clinical program for NV-5138 in TRD. Supernus will pay the costs of Phase II development up to $50 million, plus certain costs associated with nonclinical development and formulation. In addition, Navitor has granted Supernus an exclusive option to license or acquire NV-5138 in all world territories, excluding Greater China, prior to initiation of a Phase III clinical program. In exchange for the option to license or acquire NV-5138, Navitor will receive an upfront payment of $25 million, composed of a $10 million option fee and a $15 million equity investment representing approximately 13% ownership in Navitor. Total payments, exclusive of royalty payments on net sales of NV-5138 and development costs under the agreement, have the potential to reach $410 million to $475 million, which includes the upfront payment of $25 million, an additional license or acquisition fee depending on whether Supernus ultimately licenses or acquires NV-5138, and subsequent clinical, regulatory and sales milestone payments. Supernus also will have the first right of refusal for any compound with a similar mechanism of action on mTORC1 as NV-5138 in the central nervous system. In conjunction with the equity investment, Jack Khattar, President and CEO of Supernus, will join the Board of Directors of Navitor. [collapse expanded text] |
ACADIA Pharmaceuticals, Vanderbilt University | May 2020 | 525 | Research and licensing agreement for drug candidates targeting the muscarinic M1 receptor for range of central nervous system | ACADIA Pharmaceuticals and Vanderbilt University announced an exclusive worldwide license agreement … read moreto develop and commercialize novel drug candidates targeting the muscarinic M1 receptor with the potential to treat a range of central nervous system (CNS) disorders. The collaboration will focus on positive allosteric modulators (PAMs) of the M1 receptor. The WCNDD has been developing highly selective PAMs of the M1 subtype of muscarinic acetylcholine receptor, which may represent a novel approach for improving cognitive function and other neuropsychiatric symptoms in patients suffering from CNS disorders. The agreement includes a lead compound currently in Phase 1 testing, as well as compounds currently in preclinical development and compounds generated in an ongoing discovery program. Vanderbilt University will receive $10 million upfront and is eligible for potential milestone payments of up to $515 million and tiered royalties. [collapse expanded text] |
Merck KGaA, Novartis | Oct 2020 | 524 | Licensing agreement for anti-ADAMTS5 nanobody for osteoarthritis | Merck has entered into an out-licensing agreement with Novartis for the development of M6495, an … read moreanti-ADAMTS5 Nanobody for the potential treatment of osteoarthritis (OA). Merck will out-license to Novartis the Phase II-ready asset M6495 for further evaluation in OA patients. Merck will receive an upfront payment of € 50 million with the potential of receiving a further € 400 million related to delivering on certain development and commercial milestones and royalties on future net sales. Novartis will assume full responsibility for the development and commercialization of the M6495 program. [collapse expanded text] |
Pfizer, eFFECTOR Therapeutics | Jan 2020 | 507 | Collaboration, licensing, option and co-promotion agreement for small-molecule inhibitors of eukaryotic initiation factor 4E (eIF4E) | eFFECTOR Therapeutics and Pfizer announced an exclusive worldwide license and collaboration … read moreagreement to develop small-molecule inhibitors of eukaryotic initiation factor 4E (eIF4E), a key oncogenic driver located downstream from both the RAS and PI3K signaling pathways. eIF4E is an effector protein that is activated in a variety of human cancers and is linked to poor prognosis and resistance to certain therapies. eFFECTOR will receive a $15 million payment upfront, and will be eligible for additional potential $492M in R&D funding, development and sales milestone payments. eFFECTOR will receive royalties on sales of any products that may result from this collaboration if the program reaches commercialization and has an option to enter into a co-promotion and profit and loss share arrangement in the United States. [collapse expanded text] |
Engitix, Takeda Pharmaceutical | Aug 2020 | 500 | Collaboration and licensing agreement for anti-fibrotic therapies in advanced liver diseases | April 2022 Engitix entered into an agreement with Takeda to expand an existing collaboration to … read morenow include the discovery and development of novel therapeutics for fibrostenotic inflammatory bowel disease, including Crohn’s disease and ulcerative colitis. Engitix and Takeda will collaborate in the confirmation and validation of targets and the preclinical development of therapeutics in IBD using Engitix’s unique extracellular matrix discovery platform. Takeda will have exclusive rights to develop and commercialise certain clinical candidates generated against validated targets arising from the collaboration. Engitix will receive an upfront payment, with additional near-term payments based on the confirmation and functional validation of selected targets. Engitix will be eligible to receive a total of up to approximately $300 million for the achievement of preclinical, development, regulatory and commercial milestones over the course of the partnership, as well as further royalty payments based on sales of commercialised products. This agreement builds on the collaboration between the companies announced in mid-2020 for the discovery and development of novel therapeutics for advanced fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH). August 2020 Engitix entered into a licensing and collaboration agreement with Takeda Pharmaceutical Company to discover and develop novel therapeutics for advanced fibrotic liver diseases, including non-alcoholic steatohepatitis. Engitix and Takeda will collaborate in the confirmation and validation of targets and preclinical development of therapeutics in liver fibrosis using Engitix’s unique extracellular matrix (ECM) discovery platform. Takeda will have exclusive rights to develop and commercialise clinical candidates generated against validated targets derived from the collaboration. Engitix will receive an upfront payment, with additional near-term payments based on the confirmation and functional validation of selected targets. Engitix will be eligible to receive more than $500 million for the achievement of preclinical, development, regulatory and commercial milestones, as well as further royalty payments upon sales of commercialised products. [collapse expanded text] |
Merck and Co, Yumanity Therapeutics | Jun 2020 | 500 | Collaboration and licensing agreement for treatments for neurodegenerative diseases | July 2023 Kineta announced the achievement of a development milestone which triggers a $5 … read moremillion payment from its research and development collaboration with Merck. This collaboration, focused on the discovery and development of novel candidates for the treatment of amyotrophic lateral sclerosis, originated from an agreement between Yumanity Therapeutics and Merck. January 2022 Yumanity achieves research milestone in its collaboration with Merck; Yumanity to receive $5 million milestone payment. June 2020 Yumanity Therapeutics has entered into a strategic research collaboration and license agreement with Merck focused on accelerating the development of new treatments for neurodegenerative diseases. Merck will gain exclusive rights to two novel Yumanity pipeline programs for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar dementia (FTLD). Yumanity and Merck will collaborate to advance the two preclinical programs during the research term, after which Merck has the right to continue clinical development and commercialization. Yumanity will receive an upfront payment and is eligible to receive milestone payments totaling approximately $500M associated with the successful development of marketed products for pipeline programs, as well as royalties on net sales. Merck is also joining existing Yumanity investors (Fidelity Management & Research Company, Redmile Group, Pfizer Ventures, Alexandria Venture Investments, Tony Coles, and Dolby Family Ventures) by participating in a Series C round of financing. [collapse expanded text] |
Top partnering deals of 2019 valued at over US$500m.
Partners | Date | Value, US$m | Subject | Termsheet |
---|---|---|---|---|
Amgen, Celgene | Aug 2019 | 13400 | Asset purchase agreement for Otezla | Bristol-Myers Squibb announced that Celgene in connection with its merger agreement with Bristol- … read moreMyers Squibb, has entered into an agreement with Amgen under which Amgen would acquire the global rights to OTEZLA (apremilast) for $13.4 billion in cash. Bristol-Myers Squibb previously announced the decision to divest OTEZLA in connection with the ongoing regulatory approval process for the Company’s pending merger with Celgene. The closing of the acquisition covered by the agreement with Amgen is contingent on Bristol-Myers Squibb and Celgene entering into a consent decree with the Federal Trade Commission (FTC) in connection with their pending merger, the closing of the pending merger, and the satisfaction of other customary closing conditions. Amgen will acquire OTEZLA and related intellectual property, including any patents that primarily cover apremilast, as well as other assets and liabilities related to OTEZLA. The agreement includes the transfer of Celgene employees primarily dedicated to OTEZLA. [collapse expanded text] |
Bayer Animal Health, Elanco | Aug 2019 | 7600 | Asset purchase agreement for animal health business | Elanco Animal Health has entered into an agreement with Bayer to acquire its animal health business … read morein a transaction valued at US$7.6 billion. The transaction, which is subject to regulatory approval and other customary closing conditions, creates the second largest animal health leader while strengthening and accelerating the company’s proven Innovation, Portfolio and Productivity (IPP) strategy. The transaction will double Elanco’s Companion Animal business, advancing the company’s intentional portfolio mix transformation and creating a balance between its Food Animal and Companion Animal segments. Elanco expects the combined organization to continue to deliver mid-single digit revenue growth, while accelerating achievement of adjusted gross margin goals and delivering double digit adjusted EBITDA margin growth. Elanco will finance the transaction through both cash and equity. Bayer will receive $5.32 billion in cash, subject to customary purchase price adjustments, and $2.28 billion or approximately 68 million Elanco Animal Health common shares. This represents a 70 percent to 30 percent cash-to-equity mix. Stock received by Bayer is subject to a 7.5 percent symmetrical collar centered on Elanco’s volume-weighted average price for the 30 trading days ended August 6, 2019 of $33.60. Elanco has secured a bridge commitment for the cash portion of the consideration. It intends to fund the cash consideration through a combination of new debt and equity. At close, Elanco expects its gross debt to adjusted EBITDA leverage ratio to be ~5x, including the benefit of expected cost synergies. The strong cash flow generation profile of the combined businesses will allow Elanco to de-lever rapidly to below 3x gross debt to adjusted EBITDA by the end of 2022. The transaction is expected to close in mid-2020, subject to regulatory approvals and other customary closing conditions. [collapse expanded text] |
AstraZeneca, Daiichi Sankyo | Mar 2019 | 6900 | Collaboration, development and licensing agreement for Trastuzumab Deruxtecan (DS-8201) | Daiichi Sankyo has entered into a global development and commercialization agreement with … read moreAstraZeneca for Daiichi Sankyo's lead antibody drug conjugate (ADC), [fam-] trastuzumab deruxtecan (DS-8201), currently in pivotal development for multiple HER2 expressing cancers including breast and gastric cancer, and additional development in non-small cell lung and colorectal cancer. Daiichi Sankyo and AstraZeneca will jointly develop and commercialize [fam-] trastuzumab deruxtecan as a monotherapy or a combination therapy worldwide, except in Japan where Daiichi Sankyo will maintain exclusive rights. Daiichi Sankyo will be solely responsible for manufacturing and the supply of [fam-] trastuzumab deruxtecan. AstraZeneca will pay Daiichi Sankyo an upfront payment of $1.35 billion. Contingent payments of up to $5.55 billion include $3.8 billion for achievement of future regulatory milestones and other contingencies, as well as sales-related milestones of up to $1.75 billion. Total payments under the agreement have the potential to reach up to $6.90 billion. Daiichi Sankyo and AstraZeneca will share equally development and commercialization costs as well as profits from [fam-] trastuzumab deruxtecan worldwide, except for Japan. Daiichi Sankyo is expected to book sales in U.S., certain countries in Europe, and certain other markets where Daiichi Sankyo has affiliates. AstraZeneca is expected to book sales in all other markets worldwide, including China, Australia, Canada and Russia. [collapse expanded text] |
Galapagos, Gilead Sciences | Jul 2019 | 6325 | Collaboration agreement for discovery platform and pipeline | Gilead Sciences and Galapagos have entered into a 10-year global research and development … read morecollaboration. Gilead will gain access to an innovative portfolio of compounds, including six molecules currently in clinical trials, more than 20 preclinical programs and a proven drug discovery platform. Galapagos will receive a $3.95 billion upfront payment and a $1.1 billion equity investment from Gilead. Galapagos will use the proceeds to expand and accelerate its research and development programs. Gilead will receive an exclusive product license and option rights to develop and commercialize all current and future programs in all countries outside Europe. Gilead and Galapagos have agreed to amend certain terms in the agreement governing filgotinib, the candidate being advanced for rheumatoid arthritis and other inflammatory diseases to provide a broader commercialization role for Galapagos in Europe. The collaboration will allow for closer scientific partnership between the companies. Gilead will have access to Galapagos’ established research base, which includes more than 500 scientists, and to Galapagos’ unique platform, which utilizes disease-related, human primary cell-based assays to discover and verify novel drug targets. Gilead will also nominate two individuals to Galapagos’ Board of Directors following the closing of the transaction. Gilead gains rights to GLPG1690, Galapagos’ Phase 3 candidate for idiopathic pulmonary fibrosis. Gilead also receives option rights for GLPG1972, a Phase 2b candidate for osteoarthritis, in the United States. Both GLPG1690 and GLPG1972 are first-in-class compounds and could offer important mid- and late-stage pipeline opportunities for Gilead. Gilead receives option rights on all of Galapagos’ other current and future clinical programs outside of Europe. Galapagos will fund and lead all discovery and development autonomously until the end of Phase 2. After the completion of a qualifying Phase 2 study, Gilead will have the option to acquire an expanded license to the compound. If the option is exercised, Gilead and Galapagos will co-develop the compound and share costs equally. Gilead will maintain option rights to Galapagos’ programs through the 10-year term of the collaboration and for up to an additional three years thereafter for those programs that have entered clinical development prior to the end of the collaboration term. If GLPG1690 is approved in the United States, Gilead will pay Galapagos an additional $325 million milestone fee. For GLPG1972, Gilead has the option to pay a $250 million fee to license the compound in the United States after the completion of the ongoing Phase 2b study in osteoarthritis. If certain secondary efficacy endpoints are met, Gilead would pay up to an additional $200 million. Following opt in, Galapagos would be eligible to receive up to $550 million in regulatory and commercial milestones. For all other programs resulting from the collaboration, Gilead will make a $150 million opt-in payment per program and will owe no subsequent milestones. Galapagos will receive tiered royalties ranging from 20-24% on net sales of all Galapagos products licensed by Gilead as part of the agreement. [collapse expanded text] |
Novartis, Takeda Pharmaceutical | May 2019 | 5300 | Asset purchase agreement for Xiidra | Novartis has entered into an agreement with Takeda Pharmaceutical to acquire the assets associated … read morewith Xiidra (lifitegrast ophthalmic solution) 5% worldwide. Xiidra is the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease. The transaction would bolster the Novartis front-of-the-eye portfolio and ophthalmic leadership. Closing of the transaction is expected in second half of 2019, subject to customary closing conditions including regulatory approvals. On closing, Novartis plans a smooth transition of operations and integration of Xiidra into its pharmaceuticals portfolio. Deal terms include a USD 3.4 billion upfront payment with potential milestone payments of up to USD 1.9 billion. As part of the agreement, Novartis will be taking on approximately 400 employees associated with the product. [collapse expanded text] |
GSK, Merck KGaA | Feb 2019 | 4174 | Co-development and co-promotion agreement for M7824 | September 2021 Merck announced a mutual decision with GSK to terminate their agreement on … read morebintrafusp alfa, effective September 30, 2021. February 2019 GlaxoSmithKline and Merck KGaA have entered into a global strategic alliance to jointly develop and commercialise M7824 (bintrafusp alfa*). M7824 is an investigational bifunctional fusion protein immunotherapy that is currently in clinical development, including potential registration studies, for multiple difficult-to-treat cancers. This includes a Phase II trial to investigate M7824 compared with pembrolizumab as a first-line treatment in patients with PD-L1 expressing advanced non-small cell lung cancer (NSCLC). Merck KGaA will receive an upfront payment of €300 million (£260 million) and is eligible for potential development milestone payments of up to €500 million (£440 million) triggered by data from the M7824 lung cancer programme. Merck KGaA will also be eligible for further payments upon successfully achieving future approval and commercial milestones of up to €2.9 billion (£2.5 billion). The total potential deal value is up to €3.7 billion (£3.2 billion). Both companies will jointly conduct development and commercialisation with all profits and costs from the collaboration being shared equally on a global basis. [collapse expanded text] |
Abpro, NJCTTQ | Feb 2019 | 4000 | Development agreement for multiple novel bispecific antibodies | Abpro and NJCTTQ have entered into an agreement to develop multiple novel bispecific antibody … read moretherapies in immuno-oncology, including best-in-class T-cell engagers. The collaboration leverages Abpro’s proprietary DiversImmuneTM antibody discovery platform. Abpro is eligible to receive up to $4 billion, including $60 million in near-term R&D funding, plus potential milestones and royalties. Abpro will retain all commercial rights for any approved molecules in geographies outside of China and Thailand, while NJCTTQ will retain rights in China. Abpro and NJCTTQ will collaborate globally to pursue pre-clinical and clinical development efforts and, ultimately, commercialization. [collapse expanded text] |
Amgen, BeiGene | Oct 2019 | 3950 | Collaboration agreement for oncology in China | Amgen has entered into a strategic collaboration with BeiGene that will significantly accelerate … read moreAmgen's plans to expand its oncology presence in China, the world's second-largest pharmaceutical market. BeiGene is a research-based, oncology-focused biotechnology company with an established and highly experienced team in China, including a 700-person commercial organization and a 600-person clinical development organization. As part of the collaboration: Amgen will acquire a 20.5% stake in BeiGene for approximately $2.7 billion in cash. This represents a purchase price of $174.85 per BeiGene American Depositary Share on NASDAQ, a 36% premium to BeiGene's 30-day volume-weighted average share price as of Oct. 30, 2019. Amgen will nominate one person to serve on BeiGene's Board of Directors. BeiGene will commercialize XGEVA (denosumab), KYPROLIS (carfilzomib) and BLINCYTO (blinatumomab) in China during which time the parties will equally share profits and losses. Two of these products will revert to Amgen, one after five years and one after seven years. Following the commercialization period, BeiGene will have the right to retain one product and will be entitled to receive royalties on sales in China for an additional five years on the products not retained. XGEVA was launched in China in September of this year; KYPROLIS and BLINCYTO are both in Phase 3 trials in China. Amgen and BeiGene will collaborate to advance 20 medicines from Amgen's innovative oncology pipeline in China and globally. BeiGene will share global research and development costs and contribute up to $1.25 billion to advance these medicines. Amgen will pay royalties to BeiGene on the sales of these products outside of China, with the exception of AMG 510, Amgen's first-in-class KRASG12C inhibitor that is being studied as a potential treatment for solid tumors. Amgen anticipates utilizing data from clinical trials conducted in China to advance the development of its oncology portfolio globally. Of the 20 oncology medicines in development, BeiGene will assume commercial rights in China for seven years after launch for those that receive approval in China, including AMG 510. After this time, BeiGene will retain rights to up to six of these products in China, excluding AMG 510, while rights on remaining products revert to Amgen. Amgen and BeiGene will share profits in China equally on these products until the rights revert to Amgen, after which Amgen will pay royalties to BeiGene on sales in China for a period of five years after reversion. Amgen will continue to commercialize its non-oncology product portfolio in China. Earlier this year, Amgen launched its first-ever product in China, Repatha (evolocumab), an LDL cholesterol-lowering treatment proven to reduce the risk of heart attacks and stroke. Amgen expects to launch a number of other non-oncology medicines in China over the next several years, including Prolia (denosumab), which reduces the risk of fracture in postmenopausal women with osteoporosis. XGEVA, KYPROLIS and BLINCYTO, as well as the medicines in Amgen's oncology pipeline, will be manufactured at Amgen's existing facilities. Amgen will purchase its equity stake in BeiGene with available cash and expects to retain its investment grade credit rating. [collapse expanded text] |
Bristol-Myers Squibb, Celgene, Immatics Biotechnologies | Aug 2019 | 3050 | Collaboration, option, co-development and co-promotion agreement for adoptive cell therapies | Parties Involved
Collaboration ScopeThe initial 2019 collaboration focused on the discovery and development of autologous TCR-T therapies against solid tumor targets identified by Immatics. Under this agreement:- Immatics would develop and validate TCR-T product candidates up to the lead candidate stage.- Bristol Myers Squibb (BMS) could opt in and assume global development, manufacturing, and commercialization. The collaboration was expanded in June 2022 to include:- A new multi-program partnership to develop allogeneic, off-the-shelf gamma delta TCR-T and/or CAR-T cell therapies using Immatics’ ACTallo® platform.- An additional autologous TCR-T target added to the original agreement. However, as of December 2024, the two expansions (from 2022) were terminated effective March 12, 2025, while the original 2019 collaboration remains intact. Rights & ResponsibilitiesImmatics:- Responsible for target discovery, TCR identification, and preclinical development through lead candidate stage.- Eligible for milestones and royalties upon BMS opt-in.- Led preclinical work for allogeneic ACTallo® programs.- Held the ACTallo® platform IP and know-how. Bristol Myers Squibb:- Held exclusive global license rights upon opt-in for each program.- Assumed responsibility for clinical development and commercialization post-opt-in.- Controlled development of its own two ACTallo® programs, with the option to expand.- Exercised its first opt-in in May 2023 for a novel TCR-T program targeting solid tumors. Financial Terms2019 Agreement (autologous TCR-T programs):- Upfront Payment: $75 million- Per Program Potential: - Up to $505 million in option, development, regulatory, and commercial milestone payments - Tiered royalties on global net sales- Immatics retained co-development/co-funding rights on selected programs 2022 Expansion (ACTallo® allogeneic platform):- Upfront Payment: $60 million- Up to $700 million per BMS-owned program in development, regulatory, and commercial milestones- Tiered royalties: up to low double-digit percentages- Option to jointly develop up to four additional programs per company- An added autologous TCR-T program with a $20 million upfront payment May 2023 Opt-in:- BMS exercised its first option, triggering: - $15 million option payment to Immatics - Immatics remains eligible for up to $490 million in remaining milestones and tiered royalties Regulatory Approval
Overall SummaryImmatics and Bristol Myers Squibb entered a strategic TCR-T cell therapy collaboration in 2019, with $75 million upfront and potential >$1.5 billion in milestones and royalties. The partnership was expanded in 2022 to include an allogeneic ACTallo® platform, with $60 million upfront and up to $700 million per program, plus a $20 million payment for an additional autologous TCR-T target. However, in December 2024, both 2022 expansions were terminated, effective March 2025, leaving the original 2019 agreement in place. BMS’s first opt-in, announced in May 2023, secured rights to a novel TCR-T product targeting solid tumors, keeping the collaboration active under the original framework. [collapse expanded text] |
Altavant Sciences, Enzyvant Science, Myovant Sciences, Roivant Sciences, Sumitomo Dainippon Pharma, Sumitovant Biopharma, Urovant Sciences | Sep 2019 | 3000 | Collaboration, option and asset purchase agreement for biopharmaceutical companies | December 2019 Sumitovant Biopharma unveiled as a new, global biopharmaceutical company through … read morethe closing of the transaction previously announced on October 31, 2019 between Sumitomo Dainippon Pharma and Roivant Sciences. October 2019 Sumitomo Dainippon Pharma and Roivant Sciences have signed a definitive agreement for the creation of a novel and broad Strategic Alliance and to form a new company owned and supported by Sumitomo Dainippon Pharma. September 2019 Sumitomo Dainippon Pharma and Roivant Sciences have entered into the Memorandum for the creation of a novel and broad Alliance to include the transfer to Sumitomo Dainippon Pharma of Roivant's ownership interests in 5 of their biopharmaceutical companies ("Vants"), with options to acquire up to 6 additional Vants, and access to Roivant's proprietary technology platforms, DrugOme and Digital Innovation. Roivant will collaborate with Sumitomo Dainippon Pharma with the continued involvement of Roivant's senior leaders to ensure the success of the Alliance. Sumitomo Dainippon Pharma will take an equity stake of over 10% of shares outstanding in Roivant. Pursuant to the Memorandum, the Sumitomo Dainippon-Roivant Alliance, a new entity to be wholly owned by Sumitomo Dainippon Pharma, is expected to assume Roivant's ownership interests in Myovant Sciences (women's health and prostate cancer), Urovant Sciences (urinary diseases), Enzyvant Therapeutics (pediatric rare diseases), Altavant Sciences (respiratory rare diseases), and one additional company to be specified before the execution of the definitive agreement. Sumitomo Dainippon Pharma will also gain options to acquire Roivant's ownership interests in up to 6 additional biopharmaceutical Vants. These 11 Vants collectively have more than 25 innovative clinical programs, with multiple potential product launches expected from 2020 to 2022. Sumitomo Dainippon Pharma plans to support the Vants in the Alliance by leveraging the potential benefits of scale and other advantages associated with Sumitomo Dainippon Pharma's global commercial infrastructure such as market access and drug distribution. Roivant also plans to continue to support the six Vants subject to the option. Sumitomo Dainippon and Roivant will further collaborate with the goal of successfully progressing each of the Vants' ongoing programs. Sumitomo Dainippon Pharma will gain key elements of Roivant's proprietary technology platform, including the DrugOme, which assists in accelerating pipeline acquisition and clinical development, and Digital Innovation, which uses technology to improve business processes. These platforms will continue to be used by Roivant under separate contract for other Vants as well as future business activities. Sumitomo Dainippon Pharma also expects to enter contract agreements with Roivant Health technology Vants, including Datavant and Alyvant, to support its own ongoing and future clinical and commercialization activities and maximize the value of its product portfolio, including products in the Sumitomo Dainippon-Roivant Alliance. [collapse expanded text] |
Roche, Sarepta Therapeutics | Dec 2019 | 2850 | Licensing and option agreement for SRP-9001 (AAVrh74.MHCK7.micro-dystrophin) gene therapy | Parties Involved
… read more Collaboration ScopeThe agreement grants Roche exclusive commercial rights outside the United States to SRP-9001, Sarepta’s investigational gene therapy for Duchenne muscular dystrophy (DMD). SRP-9001 delivers a micro-dystrophin-encoding gene to muscle tissue to enable expression of the micro-dystrophin protein, which is missing or defective in individuals with DMD. Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummarySarepta and Roche entered into a landmark licensing agreement granting Roche exclusive ex-U.S. rights to SRP-9001, Sarepta’s investigational micro-dystrophin gene therapy for Duchenne muscular dystrophy. The deal includes $1.15 billion upfront ($750M cash + $400M equity), potential $1.7 billion in milestones, and mid-teen royalties. Sarepta will continue to lead global development and manufacturing, while Roche commercializes outside the U.S., with both companies sharing global development costs equally. This partnership aims to accelerate access to SRP-9001 globally while providing strategic resources for Sarepta’s broader gene therapy pipeline. [collapse expanded text] |
Gilead Sciences, Nurix Therapeutics | Jun 2019 | 2345 | Collaboration, option and licensing agreement for protein degradation drugs for cancer and other diseases | April 2024 Two-year extension of ongoing research collaboration intended to generate multiple … read moreadditional clinical candidates Nurix will receive a $15.0 million extension fee, and will remain eligible for up to an additional $73.5 million in potential preclinical research milestones and licensing fees, and up to $1.7 billion in potential future development, regulatory, and sales milestones as well as royalties on future products Nurix continues to retain co-development and 50/50 profit sharing options on up to two programs in the United States March 2023 Gilead Sciences and Nurix Therapeutics announced that Gilead has exercised its option to exclusively license Nurix’s investigational targeted protein degrader molecule NX‑0479. This bivalent degrader, designated GS-6791, is the first development candidate resulting from the previously announced Nurix-Gilead collaboration to discover, develop, and commercialize a pipeline of innovative targeted protein degradation therapies. Under the terms of the parties’ Collaboration, Option and License Agreement, for the NX-0479 option that Gilead is exercising, Nurix will receive an option exercise payment of $20 million and potentially could receive up to an additional $425 million in clinical, regulatory, and commercial milestone payments, as well as up to low double-digit tiered royalties on product net sales. June 2019 Gilead Sciences and Nurix Therapeutics announced a global strategic collaboration to discover, develop and commercialize a pipeline of innovative targeted protein degradation drugs for patients with cancer and other challenging diseases. Nurix will utilize its proprietary drug discovery platform to identify novel agents that utilize E3 ligases to induce degradation of specified drug targets and Gilead will have an option to license drug candidates directed to up to five targets resulting from the work. Nurix will retain the option to co-develop and co-detail up to two programs in the United States. The collaboration excludes Nurix’s lead degradation program, for which Nurix retains all rights. Nurix will receive an upfront payment of $45 million and will be eligible to receive up to approximately $2.3 billion in total additional payments based on the successful completion of certain research, pre-clinical, clinical, regulatory and commercialization milestones as well as up to low double-digit tiered royalties on net sales. For those programs that Nurix opts in to co-develop and co-detail, the parties will split development costs as well as profits and losses 50/50 for the U.S., and Nurix will be eligible to receive royalties on ex-U.S. sales and reduced milestone payments. [collapse expanded text] |
Adaptive Biotechnologies, Genentech | Jan 2019 | 2300 | Collaboration and licensing agreement for neoantigen directed T-cell therapies for cancer | Adaptive Biotechnologies entered into a worldwide collaboration and license agreement with … read moreGenentech to develop, manufacture and commercialize novel neoantigen directed T-cell therapies for the treatment of a broad range of cancers. The collaboration will combine Genentech’s global cancer immunotherapy research and development leadership with Adaptive’s proprietary T-cell receptor (TCR) discovery and immune profiling platform (TruTCR) to accelerate a transformational new treatment paradigm of tailoring cellular therapy for each patient’s individual cancer. Adaptive will utilize the investigational TCR discovery platform to identify the optimal TCRs to most effectively target each patient’s neoantigens for treatment. Genentech will engineer and manufacture a personalized cellular medicine to deliver to each patient. The goal is to harness the vast majority of therapeutically relevant, patient-specific neoantigens and advance the next generation of cellular therapies in oncology. Adaptive will receive $300 million in an initial upfront payment and may be eligible to receive more than $2 billion over time, including payments upon achievement of specified development, regulatory and commercial milestones, and royalties on sales. Genentech will have responsibility for clinical, regulatory, and commercialization efforts, and Adaptive will be responsible for patient-specific screening on a global basis. Adaptive will continue to use its TCR discovery and immune profiling platform to collaborate in the development of cellular therapies in other disease areas, including autoimmune conditions and infectious diseases. [collapse expanded text] |
Mallinckrodt Pharmaceuticals, Silence Therapeutics | Jul 2019 | 2116 | Collaboration and licensing agreement for RNAi therapeutics for complement-mediated diseases | March 2023 Silence Therapeutics announced it will be acquiring back exclusive worldwide rights … read moreto two siRNA drug targets under the collaboration agreement with Mallinckrodt Pharmaceuticals for complement-mediated diseases. Silence will not make any upfront payment to get the two assets back and Mallinckrodt is eligible to receive future success-based milestones and low single digit royalties on net sales if the projects advance. Silence will gain rights back to two undisclosed preclinical complement targets. SLN501, the C3 targeting program will remain under the collaboration agreement. October 2019 Silence Therapeutics announced the triggering of the first $2 million in research milestones for SLN500 under the collaboration with Mallinckrodt Pharmaceuticals, a global biopharmaceutical company. This milestone relates to the completion of specific pre-clinical aspects of the SLN500 programme and highlights the rapid progress which has been achieved and the close working relationship between the two companies since the collaboration was entered into on 18 July 2019. Under the terms of the agreement, Mallinckrodt has options to license up to two additional complement-targeted assets in Silence’s preclinical complement-directed RNAi development program. Silence continues to work with Mallinckrodt to actively assess the two additional complement-targeted assets and further updates will be made in due course. July 2019 Mallinckrodt and Silence Therapeutics announced a collaboration that will allow the companies to develop and commercialize RNAi drug targets designed to inhibit or 'silence' the complement cascade, a group of proteins that are involved in the immune system and that play a role in the development of inflammation. These proteins are known to contribute to the pathogenesis of many diseases, including autoimmune diseases. Mallinckrodt will obtain an exclusive worldwide license to Silence's C33 complement asset, SLN500, with options to license up to two additional complement-targeted assets in Silence's preclinical complement-directed RNAi development program. Silence will be responsible for preclinical activities, and for executing the development program of each asset until the end of Phase 1, after which Mallinckrodt will assume clinical development and responsibility for global commercialization. Mallinckrodt has agreed to provide Silence with an upfront payment of $20 million. Silence is also eligible to receive up to $10 million in research milestones for SLN500 and for each optioned asset, in addition to funding for Phase 1 clinical development including GMP4 manufacturing. Silence will fund all other preclinical activities. The collaboration provides for potential added clinical and regulatory milestone payments of up to $100 million for SLN500, as well as commercial milestone payments of up to $563 million for SLN500. Should Mallinckrodt opt to license one or two additional assets, Silence could receive up to $703 million in similar clinical, regulatory, and commercial milestone payments per asset. Silence would also receive tiered, low double-digit to high-teen royalties on net sales for SLN500 and each optioned asset. The companies will work together to develop and commercialize this RNAi therapeutic target, with the possibility of additional assets, and will form a Joint Steering Committee to guide the asset's development program. Silence's proprietary technology is a highly specific and modular platform designed to inhibit or 'silence' the expression of disease-causing genes. The technology is appropriate to target any number of genes; however, the collaboration focuses on the complement cascade, which is implicated in a number of autoimmune diseases. [collapse expanded text] |
Gilead Sciences, Goldfinch Bio | May 2019 | 2059 | Collaboration, option, co-promotion and licensing agreement for therapies for kidney disease | Gilead Sciences and Goldfinch Bio announced a strategic collaboration to discover, develop and … read morecommercialize a pipeline of innovative therapeutics for diabetic kidney disease (DKD) and certain orphan kidney diseases. Gilead has exclusive options to license worldwide rights to certain products directed toward targets emerging from Goldfinch’s proprietary Kidney Genome Atlas (KGA), a comprehensive registry of patients with kidney diseases integrating genomic, transcriptomic and proteomic data with patient clinical profiles. In addition, Goldfinch will apply its biology platform of human induced pluripotent stem cell-derived kidney cells and kidney organoids to validate targets and support discovery and development of products to which Gilead will have exclusive option rights. Through sequencing the DNA of a large cohort of diabetic patients with and without kidney disease, Goldfinch will expand the scope of the KGA beyond orphan kidney diseases to include DKD. In addition to target identification and validation, Goldfinch will lead discovery and development activities prior to exercise of exclusive option rights by Gilead, at which time Gilead will be responsible for the development and commercialization of optioned products. Goldfinch retains the option to lead development and co-promote optioned products directed to specific kidney disease targets. The collaboration does not include Goldfinch’s existing programs, GFB-887 and GFB-024, for which Goldfinch will retain all rights. Goldfinch will receive $55 million in upfront payments, which includes a $5 million equity investment, and an additional $54 million to support the development of the KGA platform for DKD. Goldfinch is also eligible to receive up to $1.95 billion in potential payments for the first five collaboration programs based on the successful achievement of research, development, regulatory and commercial milestones, and tiered royalties on sales of potential products originating from the collaboration. Goldfinch retains the option to equally share in U.S. profits for certain optioned products in certain pre-defined kidney indications. Development costs for profit share products will be shared among the two parties in a manner commensurate with product rights. [collapse expanded text] |
Neurocrine Biosciences, Voyager Therapeutics | Jan 2019 | 1815 | Collaboration and licensing agreement for Parkinson’s Disease and Friedreich’s Ataxia | February 2021 Voyager Therapeutics announced that Neurocrine Biosciences provided notice of … read moretermination of the Parkinson’s disease portion of the collaboration agreement, effective August 2, 2021. The Friedreich’s ataxia program and two discovery programs that are also part of the agreement are not impacted and remain under active collaboration. June 2019 The ex-U.S. rights to VY-FXN01 are transferred from Voyager to Neurocrine Biosciences under the terms of the collaboration agreement between Voyager and Neurocrine Biosciences announced in January 2019. January 2019 Neurocrine Biosciences and Voyager Therapeutics announced the formation of a strategic collaboration focused on the development and commercialization of Voyager’s gene therapy programs, VY-AADC for Parkinson’s disease and VY-FXN01 for Friedreich’s ataxia, as well as rights to two programs to be determined. This collaboration combines Neurocrine Biosciences’ expertise in neuroscience, drug development and commercialization with Voyager’s innovative gene therapy programs targeting severe neurological diseases. Neurocrine Biosciences has agreed to pay Voyager $165 million in cash including a $115 million upfront payment and a $50 million equity investment at a Voyager per share price of $11.96. Voyager will also receive funding from Neurocrine Biosciences for all costs incurred on these collaboration programs as described below. In addition, Voyager may be entitled to earn up to $1.7 billion in development, regulatory and commercial milestone payments across the four programs. Under terms of the agreement for VY-AADC for Parkinson’s disease: Neurocrine Biosciences has agreed to fund the clinical development of the Phase 2-3 pivotal program for VY-AADC. After the data readout of the Phase 2 RESTORE-1 trial, Voyager has the option to either: (1) co-commercialize VY-AADC with Neurocrine Biosciences in the U.S. under a 50/50 cost- and profit-sharing arrangement and receive milestones and royalties based on ex-U.S. sales, or (2) grant Neurocrine Biosciences full global commercial rights in exchange for milestone payments and royalties based on global sales. Under terms of the agreement for VY-FXN01 for Friedreich’s ataxia: Neurocrine Biosciences has agreed to fund the development through the Phase 1 clinical trial of VY-FXN01. After the data readout of the Phase 1 trial, Voyager has the option to either: (1) co-commercialize VY-FXN01 with Neurocrine Biosciences in the U.S. under a 60/40 cost- and profit-sharing arrangement, or (2) grant Neurocrine Biosciences full U.S. commercial rights in exchange for milestone payments and royalties based on U.S. sales. Sanofi Genzyme retains an option for ex-U.S. rights to VY-FXN01 following the data readout of the Phase 1 trial. Under terms of the agreement for the two programs to be determined: Neurocrine Biosciences has agreed to fund the development of these programs to be determined and Voyager will have the right to earn milestone payments and royalties based on global sales. [collapse expanded text] |
Neurocrine Biosciences, Xenon Pharmaceuticals | Dec 2019 | 1775 | Collaboration, research and licensing agreement for XEN901 | January 2022 Xenon Pharmaceuticals announced that its collaboration to develop treatments for … read moreepilepsy with Neurocrine Biosciences achieved a regulatory milestone, which has triggered an aggregate payment of $15.0 million to Xenon. The U.S. Food and Drug Administration accepted Neurocrine’s protocol amendment that expands the study population to include subjects aged between 2 and 11 years in the ongoing Phase 2 randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of NBI-921352 in pediatric patients with SCN8A developmental and epileptic encephalopathy (SCN8A-DEE). Xenon will receive an aggregate of $15.0 million from Neurocrine Biosciences in the form of a $6.75 million payment in cash and a $8.25 million equity investment at a Xenon per share price of $31.855, calculated as a 15% premium to Xenon’s 30-day trailing volume weighted average price. September 2021 Xenon Pharmaceuticals announced that its collaboration to develop treatments for epilepsy with Neurocrine Biosciences achieved a regulatory milestone with the approval of a clinical trial application in Europe, triggering an aggregate payment of $10.0 million to Xenon. October 2019 Neurocrine Biosciences and Xenon Pharmaceuticals announced a license and collaboration agreement to develop first-in-class treatments for epilepsy. Neurocrine Biosciences gains an exclusive license to XEN901, a clinical stage selective Nav1.6 sodium channel inhibitor with potential in SCN8A developmental and epileptic encephalopathy (SCN8A-DEE) and other forms of epilepsy, including focal epilepsy. Neurocrine Biosciences gains an exclusive license to pre-clinical compounds for development, including selective Nav1.6 inhibitors and dual Nav1.2/1.6 inhibitors. The agreement also includes a multi-year research collaboration to discover, identify and develop additional novel Nav1.6 and Nav1.2/1.6 inhibitors. Neurocrine Biosciences will be responsible for development costs associated with the programs and the agreement will be subject to the following terms: Upfront License Payment: Xenon will receive $50 million, including a $30 million upfront payment in cash and a $20 million equity investment by Neurocrine Biosciences at a Xenon per share price of $14.196. XEN901 Investigational New Drug (IND) Milestone: Xenon will receive up to $25 million upon the U.S. Food and Drug Administration (FDA) acceptance of an IND for XEN901, with 55% of the amount in the form of an equity investment in Xenon at a 15% premium to Xenon’s 30-day trailing volume weighted average price at that time. Collaboration Milestones: Xenon may also be entitled to receive up to approximately $1.7 billion in additional development, regulatory and commercial milestone payments related to XEN901 and other licensed Nav1.6 or Nav1.2/1.6 inhibitor products. XEN901 Royalties: Xenon will have the right to receive a tiered royalty ranging from the low double-digits to mid-teen percentage in the U.S. and a tiered royalty at slightly lower rates outside the U.S. based upon aggregate global net sales. Other Product Royalties: Xenon will have the right to receive a tiered royalty for other Nav1.6 and Nav1.2/1.6 inhibitor products ranging from the mid-single to low double-digits in the U.S. and a tiered royalty at slightly lower rates outside the U.S. based upon aggregate global net sales. Xenon Co-Fund Option: Xenon retains an option to co-fund 50% of the U.S. development costs of XEN901 or another product candidate in exchange for increased U.S. royalties, reaching 20% of U.S. net sales at the highest royalty tier for XEN901. Funded Collaboration: Neurocrine Biosciences will fund all clinical developments costs associated with the development of product candidates under the collaboration (subject to Xenon’s Co-Fund Option) and will also fund a research collaboration up to 3 years with a minimum of 10 FTEs (full time equivalents) at Xenon. Xenon will be responsible for certain pre-clinical and a portion of certain near term manufacturing costs under the collaboration. Neurocrine Biosciences anticipates filing an IND application with the FDA in the middle of 2020 in order to start a proposed clinical trial for XEN901 in SCN8A-DEE patients. [collapse expanded text] |
GSK, Lyell Immunopharma | Oct 2019 | 1750 | Collaboration agreement for cancer cell therapies | GlaxoSmithKline announced a five-year collaboration with Lyell Immunopharma to develop new … read moretechnologies to improve cell therapies for cancer patients. The collaboration will apply Lyell’s technologies to further strengthen GSK’s cell therapy pipeline, including GSK3377794, which targets the NY-ESO-1 antigen that is expressed across multiple cancer types. The collaboration will also build on GSK’s world-leading manufacturing platform and expertise for cell and gene therapy that delivered the world’s first approved ex vivo gene therapy (Strimvelis) for ADA-SCID in 2016. GSK has granted patents and pending patent applications related to its stable cell line technology and has a long-standing collaboration with Miltenyi Biotec to improve quality and scale of output to meet the needs of larger patient populations. [collapse expanded text] |
Dicerna Pharmaceuticals, Roche | Oct 2019 | 1670 | Collaboration and licensing agreement for DCR-HBVS for treatment of chronic hepatitis B virus infection | Dicerna Pharmaceuticals announced a research collaboration and licensing agreement with Roche to … read moredevelop novel therapies for the treatment of chronic hepatitis B virus (HBV) infection using Dicerna’s proprietary GalXC RNAi platform technology. The collaboration will focus on worldwide development and commercialization of DCR-HBVS, Dicerna’s investigational therapy in Phase 1 clinical development. The collaboration also includes the discovery and development of therapies targeting multiple additional human and viral genes associated with HBV infection using the technology platforms of both companies. Dicerna will receive $200 million in an initial upfront payment and may be eligible to receive up to an additional $1.47 billion over time for the achievement of specified development, regulatory and commercial milestones. Dicerna may be eligible to receive royalties based on potential product sales of DCR-HBVS. Dicerna retains an option to co-fund pivotal development of DCR-HBVS worldwide, which if exercised, entitles Dicerna to receive enhanced royalties and co-promote products including DCR-HBVS in the U.S. Dicerna and Roche also agreed to collaborate on the research and development of additional therapies targeting multiple human and viral genes implicated in chronic HBV infection, using technology from both companies, for which Dicerna is eligible to receive additional milestones and royalties on any potential products. [collapse expanded text] |
Akcea Therapeutics, Ionis Pharmaceuticals, Pfizer | Oct 2019 | 1550 | Licensing agreement for AKCEA-ANGPTL3-LRx | January 2022 Pfizer and Ionis Pharmaceuticals announced the discontinuation of the Pfizer-led … read moreclinical development program for vupanorsen (PF-07285557), an investigational antisense therapy that was being evaluated for potential indications in cardiovascular risk reduction and severe hypertriglyceridemia. Pfizer made this decision after a thorough review of data from the global Phase 2b, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, 8-arm parallel-group study of vupanorsen in statin-treated participants with dyslipidemia — also known as TaRgeting ANGPTL3 with an aNtiSense oLigonucleotide in AdulTs with dyslipidEmia (TRANSLATE-TIMI 70). Pfizer will return development rights to vupanorsen to Ionis, from which it licensed the investigational therapy in a worldwide exclusive agreement in November 2019. November 2019 Akcea Therapeutics and Pfizer have entered into a worldwide exclusive licensing agreement for AKCEA-ANGPTL3-LRx, an investigational antisense therapy being developed to treat patients with certain cardiovascular and metabolic diseases. Akcea and Ionis will receive a $250 million upfront license fee, which will be split equally between the two companies. Akcea will settle its $125 million obligation to Ionis in Akcea common stock. The companies are also eligible to receive development, regulatory and sales milestone payments of up to $1.3 billion and tiered, double-digit royalties on annual worldwide net sales following marketing approval of AKCEA-ANGPTL3-LRx. Future milestone payments and royalties will be split equally between Akcea and Ionis. Pfizer is responsible for all development and regulatory activities and costs beyond those associated with the ongoing Phase 2 study. Prior to regulatory filing for marketing approval, Akcea has the right, at its option to participate in certain commercialization activities with Pfizer in the U.S. and certain additional markets on pre-defined terms and based on meeting pre-defined criteria. [collapse expanded text] |
Abbvie, Voyager Therapeutics | Feb 2019 | 1538 | Collaboration, option and licensing agreement for vectorized antibodies for Parkinson's disease and other synucleinopathies | August 2020 Voyager Therapeutics announced the termination of its tau and alpha-synuclein … read morevectorized antibody collaborations with AbbVie. Voyager retains full rights to the vectorization technology and certain novel vectorized antibodies developed as part of the collaborations. February 2019 AbbVie and Voyager Therapeutics announced an exclusive, global strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed at pathological species of alpha-synuclein for the potential treatment of Parkinson's disease and other diseases (synucleinopathies) characterized by the abnormal accumulation of misfolded alpha-synuclein protein. Voyager will perform research and preclinical development work to vectorize antibodies directed against alpha-synuclein that are designated by AbbVie, after which AbbVie may select one or more vectorized antibodies to advance into IND-enabling studies and clinical development. Voyager will be responsible for the research, IND-enabling and Phase 1 clinical activities and costs. Following completion of Phase 1 clinical development, AbbVie has an option to license the vectorized alpha-synuclein antibody program for further clinical development and global commercialization for indications including Parkinson's disease and other synucleinopathies. Voyager will receive an upfront cash payment of $65 million and has the potential to earn up to $245 million in preclinical and Phase 1 option payments. Voyager is also eligible to receive up to an additional $728 million in potential development and regulatory milestone payments for each alpha-synuclein vectorized antibody compound. Voyager is eligible to receive tiered royalties on the global commercial net sales of each alpha-synuclein vectorized antibody and may also earn up to a total of $500 million in commercial milestones. [collapse expanded text] |
Atomwise, Jiangsu Hansoh Pharmaceutical | Sep 2019 | 1500 | Collaboration agreement to design and discover potential drug candidates for up to eleven undisclosed target proteins in multiple therapeutic areas | April 2020 Hansoh Pharma and Atomwise announced the expansion of their strategic partnership for … read moreAI-accelerated drug discovery. Expansion of the partnership immediately follows completion of their first hit-discovery collaboration, which successfully identified and experimentally confirmed several novel hit compounds for a previously challenging oncology target in only 4 months. September 2019 Atomwise announced a collaboration with Hansoh Pharmaceutical to design and discover potential drug candidates for up to eleven undisclosed target proteins in multiple therapeutic areas. Scientific teams from Atomwise and Hansoh Pharma will collaborate closely on the programs. The combination of Atomwise’s AI technology and medicinal chemistry and protein structure expertise, and Hansoh Pharma’s fully integrated research and development, manufacturing and commercial capabilities has the potential to dramatically increase success and compress timelines for drug discovery and clinical development. Under the terms of the collaboration, Atomwise will receive undisclosed technology access fees, option exercise fees, royalties, and income based on sublicensing or sale of assets created under the collaboration. Based on historical average revenues for small molecule drugs, the total potential value of the deal to Atomwise with success in all projects could reach US$1.5 billion. Hansoh Pharmaceutical and Atomwise have announced a collaboration to design and discover potential drug candidates for up to eleven undisclosed target proteins in multiple therapeutic areas. Scientific teams from Atomwise and Hansoh Pharma will work closely together on the programs. The combination of complementary expertise and technologies has the potential to dramatically increase success and compress timelines for drug discovery and clinical development. Atomwise will receive undisclosed technology access fees, option exercise fees, royalties, and income based on sublicensing or sale of assets created under the collaboration. Based on historical average revenues for small molecule drugs, the total potential value of the deal to Atomwise with success in all projects could be in excess of blockbuster potential. Hansoh Pharma will receive rights for development and commercialization in all fields and geographies. [collapse expanded text] |
Alteogen | Dec 2019 | 1386 | Licensing agreement for Hybrozyme technology to enable subcutaneous administration of biologic products | Alteogen has entered into a non-exclusive global license agreement with a top 10 Global … read morePharmaceutical Company to use ALT-B4, Alteogen’s novel hyaluronidase-derived technology called Hybrozyme technology. Alteogen has granted worldwide rights for GPC to develop and commercialize multiple products in combination with Hybrozyme technology while Alteogen will be responsible for the clinical and commercial supply of ALT-B4 materials. Alteogen will receive an initial payment of USD 13 million and is also eligible to receive additional milestones upon GPC’s achievement of specified development, regulatory and sales milestones, totaling up to USD 1.373 billion. [collapse expanded text] |
Boehringer Ingelheim, Bridge Biotherapeutics | Jul 2019 | 1274 | Collaboration and licensing agreement for BBT-877 | Boehringer Ingelheim and Bridge Biotherapeutics are entering into a new collaboration and license … read moreagreement with the goal of developing Bridge Biotherapeutics’s autotaxin inhibitor BBT-877 for patients with fibrosing interstitial lung diseases, including IPF. BBT-877 is currently in Phase I clinical studies and is anticipated to enter Phase II testing within the next 12 months. Both companies will initially focus on developing the compound for the treatment of IPF, an area of high-unmet medical need and one of the key focus areas of Boehringer Ingelheim. Bridge Biotherapeutics will receive upfront and near term payments of EUR 45 million and is eligible to receive up to more than EUR 1.1 billion in potential payments based upon the successful achievement of specified development, regulatory, and commercial milestones and staggered, up to double digit royalties. [collapse expanded text] |
Sosei Heptares, Takeda Pharmaceutical | Aug 2019 | 1226 | Research, development and licensing agreement for molecules that modulate G protein-coupled receptor targets | Sosei has entered into a strategic multi-target partnership with Takeda Pharmaceutical Company to … read morediscover, develop and commercialize novel molecules, including small molecules and biologics, that modulate G protein-coupled receptor targets. Under the terms of the agreement, the partnership will combine the proprietary GPCR-focused structure-based drug design capabilities at Sosei Heptares with Takeda's extensive discovery, development and therapeutic area expertise directed towards multiple GPCR targets nominated by Takeda. The nominated targets represent new therapeutic intervention points across a range of diseases. The collaboration will initially focus on high-priority gastrointestinal targets, but the agreement includes the potential expansion into other therapeutic areas. Sosei Heptares is eligible to receive up to $26 million in upfront and near-term payments, in addition to research funding over the term of the agreement, plus future development, commercialization and net sales-based milestone payments that may exceed $1.2 billion. Sosei Heptares is also eligible to receive tiered royalties on net sales of any licensed products by Takeda resulting from the partnership. Takeda receives exclusive global rights to develop and commercialize therapeutic agents for each novel target through specified pharmacological approaches in the collaboration. [collapse expanded text] |
Amgen, Hummingbird Bioscience | Sep 2019 | 1200 | Collaboration, option and licensing agreement for antibody therapeutics | Hummingbird Bioscience has announced a multi-target collaboration to co-discover novel antibody … read moretherapeutics with Amgen. This partnership brings together Hummingbird’s proprietary drug discovery platform with Amgen’s disease expertise and drug development capabilities. Amgen will provide Hummingbird with two of its proprietary targets and allows for further expansion of up to 10 additional targets over a 6-year period upon which Hummingbird will apply its proprietary Rational Antibody Discovery platform to create novel therapeutic antibodies. Amgen has an exclusive option to license rights to the resulting antibodies from each project. Hummingbird will receive upfront and research payments and, upon entry into a license agreement, is also eligible to receive downstream clinical and commercial milestone payments of up to $100 million per program plus royalties. Additional financial details are not being disclosed. [collapse expanded text] |
Codiak BioSciences, Jazz Pharmaceuticals | Jan 2019 | 1156 | Collaboration and licensing agreement for engineered exosomes to create therapies for cancers | Jazz Pharmaceuticals and Codiak BioSciences have entered into a strategic collaboration agreement … read morefocused on the research, development and commercialization of exosome therapeutics to treat cancer. Codiak granted Jazz an exclusive, worldwide, royalty-bearing license to develop, manufacture and commercialize therapeutic candidates directed at five targets to be developed using Codiak's engEx precision engineering platform for exosome therapeutics. The targets focus on oncogenes that have been well validated in hematological malignancies and solid tumors but have been undruggable with current modalities, including NRAS and STAT3. Codiak is responsible for the execution of pre-clinical and early clinical development of therapeutic candidates directed at all five targets through Phase 1/2 proof of concept studies. Following the conclusion of the applicable Phase 1/2 study, Jazz will be responsible for future development, potential regulatory submissions and commercialization for each product. Codiak has the option to participate in co-commercialization and cost/profit-sharing in the U.S. and Canada on up to two products. Jazz will pay Codiak an upfront payment of $56 million. Codiak is eligible to receive up to $20 million in preclinical development milestone payments across all five programs. Codiak is also eligible to receive milestone payments totaling up to $200 million per target based on Investigational New Drug application acceptance, clinical and regulatory milestones, including approvals in the U.S., European Union and Japan, and sales milestones. Codiak is also eligible to receive tiered royalties on net sales of each approved product, with percentages ranging from mid-single digits in the lowest tier to high teens in the highest tier. [collapse expanded text] |
Alnylam Pharmaceuticals, Regeneron Pharmaceuticals | Apr 2019 | 1150 | Collaboration agreement for RNAi therapeutics focused on ocular and CNS diseases | Alnylam Pharmaceuticals and Regeneron Pharmaceuticals announced a collaboration to discover, … read moredevelop and commercialize new RNA interference (RNAi) therapeutics for a broad range of diseases by addressing disease targets expressed in the eye and central nervous system (CNS), in addition to a select number of targets expressed in the liver. The collaboration will leverage both companies’ scientific and technological expertise and will build on Alnylam’s recent preclinical data showing potent and highly durable delivery of RNAi therapeutics to achieve target gene silencing in the eye and CNS. The collaboration will also benefit from Regeneron’s industry-leading VelociSuite technologies and capabilities from the Regeneron Genetics Center (RGC). Alnylam will work exclusively with Regeneron to discover RNAi therapeutics for eye and CNS diseases. Regeneron will lead development and commercialization for all programs targeting eye diseases, with Alnylam entitled to potential milestone and royalty payments. The companies will jointly advance and alternate leadership on CNS programs, with the lead party retaining global development and commercial responsibility. For CNS programs, both companies will have the option at candidate selection to participate equally in potential future profits of programs led by the other party. The collaboration also includes a select number of RNAi therapeutic programs designed to target genes expressed in the liver, which can influence a wide variety of diseases throughout the body. These programs include a planned joint effort evaluating anti-C5 antibody-siRNA combinations for C5 complement-mediated diseases including evaluating the combination of Regeneron’s pozelimab (REGN3918), currently in Phase 1 development, with Alnylam’s cemdisiran, currently in Phase 2 development. Alnylam will retain control of cemdisiran monotherapy development, and Regeneron will lead combination development. The parties will equally share investment and potential future profits on the monotherapy program, and Alnylam will receive royalties on any potential combination product sales. For all other alliance liver programs, the parties will alternate leadership and participate equally in potential profits. The companies will continue their previously-announced collaboration to identify RNAi therapeutics for the chronic liver disease nonalcoholic steatohepatitis (NASH) based on novel RGC findings. Alnylam retains broad global rights to all of its other unpartnered liver-directed clinical and preclinical pipeline programs. Regeneron has agreed to make a $400 million upfront payment to Alnylam and to purchase $400 million of Alnylam equity at a price per share of $90.00 (4.44 million common shares), based on the volume-weighted average price over the last fifteen-trading-day period. Alnylam is eligible to receive up to an additional $200 million in milestone payments upon achievement of certain criteria during early clinical development for the eye and CNS programs. The companies plan to advance programs directed to 30 targets and introduce many into clinical development during the initial five-year discovery period, which includes an option to extend. For each program, Regeneron will provide Alnylam with $2.5 million in funding at program initiation and an additional $2.5 million at lead candidate identification, translating to the potential for approximately $30 million in annual discovery funding to Alnylam as the alliance reaches steady state. [collapse expanded text] |
PHC Holdings, Thermo Fisher Scientific | Jan 2019 | 1140 | Asset purchase agreement for anatomical pathology business | PHC Holdings has signed a definitive agreement with Thermo Fisher Scientific to acquire Thermo … read moreFisher’s Anatomical Pathology business for approximately US$ 1.14 billion. [collapse expanded text] |
Kymera Therapeutics, Vertex Pharmaceuticals | May 2019 | 1070 | Collaboration, option and licensing agreement for targeted protein degradation medicines for serious diseases | Vertex Pharmaceuticals and Kymera Therapeutics have entered into a four-year strategic research and … read moredevelopment collaboration to advance small molecule protein degraders against multiple targets. The collaboration will leverage Kymera’s expertise in targeted protein degradation and its proprietary Pegasus drug discovery platform and Vertex’s scientific, clinical, and regulatory capabilities to accelerate the development of first-in-class medicines for people with serious diseases. Vertex will pay Kymera $70 million upfront including an equity investment in the company. Kymera will conduct research activities in multiple targets under the collaboration. Upon designation of a clinical development candidate, Vertex has the option to exclusively license molecules against the designated target. Kymera is also eligible to receive more than $1 billion in potential payments based upon the successful achievement of specified research, development, regulatory, and commercial milestones for up to six programs optioned as part of the collaboration. Vertex will pay tiered royalties on future net sales on any products that may result from this collaboration. [collapse expanded text] |
Bavarian Nordic, GSK | Oct 2019 | 1066 | Licensing agreement for rabies and tick-borne encephalitis vaccines | GlaxoSmithKline announced the divestment of travel vaccines Rabipur (tradename Rabavert in the US) … read morefor the prevention of rabies, and Encepur for the prevention of tick-borne encephalitis, to Bavarian Nordic. GSK will receive an upfront payment of approximately EUR301 million (£259m) and will also receive milestone payments of EUR495 million and additional proceeds from the sale of inventory over the course of the supply arrangements for a total consideration of up to EUR 955m. The value of inventory at the anticipated closing date is estimated to be EUR 159 million. EUR 25m (£22m) of the total consideration is conditional upon future sales performance of the two vaccines. Milestones are payable upon successful technology transfer, marketing authorisation transfers and the fulfilment of GSK’s supply commitments until Bavarian Nordic obtains regulatory approval to manufacture the vaccines. To ensure supply continuity both vaccines will continue to be manufactured primarily at GSK’s Marburg site in Germany until full production is transferred to Bavarian Nordic. The staged technology transfer is expected to commence in Q1 2020 with completion anticipated within 5 years. [collapse expanded text] |
Gilead Sciences, Insitro | Apr 2019 | 1050 | Collaboration, option and licensing agreement for therapies for nonalcoholic steatohepatitis | Gilead Sciences and insitro have entered into a strategic collaboration to discover and develop … read moretherapies for patients with nonalcoholic steatohepatitis (NASH). insitro’s proprietary platform will be utilized to create disease models for NASH and discover targets that have an influence on clinical progression and regression of the disease. The insitro Human (ISH) platform applies machine learning, human genetics and functional genomics to generate and optimize unique in vitro models and drive therapeutic discovery and development. The ISH platform will provide insights into disease progression, suggest candidate targets, and predict patient responses to potential therapeutic interventions. Gilead can advance up to five targets identified through this collaboration and will be responsible for chemistry and development against these targets. insitro will receive an upfront payment of $15 million, with additional near-term payments up to $35 million based on operational milestones. insitro will be eligible to receive up to $200 million for the achievement of preclinical, development, regulatory and commercial milestones for each of the five Gilead targets; and up to low double-digit tiered royalties on net sales. For programs where insitro opts in, it will have the right to co-develop and co-detail in the U.S., receive a profit share in China and receive milestone payments and royalties on other ex-U.S. sales. [collapse expanded text] |
Genentech, Sosei, Sosei Heptares | Jul 2019 | 1026 | Collaboration and licensing agreement for medicines that modulate G protein-coupled receptor targets | October 2023 Sosei will receive a US$3.75 million milestone payment under the 2019 multi-target … read moreResearch Collaboration and License Agreement with Genentech. The discovery-based payment is related to progression of a potential first-in-class project targeting an undisclosed G protein-coupled receptor. Genentech will now be responsible for further development and commercialization of this potential new medicine. July 2019 Sosei has entered into a multi-target research collaboration and license agreement with Genentech to discover and develop novel medicines (new small molecules and/or biologics) that modulate G protein-coupled receptor (GPCR) targets of interest to Genentech. The collaboration will combine the proprietary GPCR-focused structure-based drug design capabilities at Sosei Heptares with Genentech's discovery, development and therapeutic area expertise directed towards multiple GPCR targets nominated by Genentech. The nominated targets represent promising new therapeutic intervention points across a range of diseases. Genentech will be responsible for developing and commercializing potential new medicines for each novel target and will have exclusive global rights to these agents. Sosei Heptares is eligible to receive US$26 million in upfront and near-term payments, in addition to future milestone payments that may exceed US$1 billion for achieving pre-specified research, development and commercialization events. Sosei Heptares is also eligible to receive royalty payments on the net sales of potential future medicines resulting from the collaboration. [collapse expanded text] |
Cytovant Sciences, MediGene | Apr 2019 | 1010 | Collaboration and licensing agreement for research-stage T cell immunotherapy targeting NY-ESO-1 as well as a DC vaccine targeting WT-1 and PRAME | Cytovant has entered into a multi-program license and collaboration agreement with Medigene. … read moreMedigene has granted Cytovant exclusive licenses to develop, manufacture, and commercialize Medigene's research-stage T cell immunotherapy targeting NY-ESO-1 as well as a DC vaccine targeting WT-1 and PRAME, in Greater China, South Korea, and Japan. Cytovant and Medigene have entered into a strategic collaboration and discovery agreement for T-cell receptor (TCR) immunotherapies for two additional targets. Medigene will be responsible for the generation and delivery of the TCR constructs using its proprietary TCR discovery and isolation platform. Following this research collaboration period, Cytovant will assume sole responsibility for the development and commercialization of these TCR therapies in the relevant countries. The TCRs to be generated by Medigene will be tailored specifically to Asian patients. Medigene will receive an overall upfront payment of USD 10 million as well as potential development, regulatory, and commercial milestone payments which in aggregate could total over USD 1 billion for the four products across multiple indications. Medigene will be eligible to receive royalty payments on net sales of the products in a low double-digit percentage in the relevant countries. Cytovant will reimburse all R&D costs incurred by Medigene within the collaboration. [collapse expanded text] |
Dermelix Biotherapeutics, Exicure | Feb 2019 | 1002 | Development and licensing agreement for spherical nucleic acid therapeutics in rare genetic skin diseases | Exicure and Dermelix Biotherapeutics announced a license and development agreement to advance SNA … read moretherapeutics in rare genetic skin diseases. Dermelix licensed worldwide rights to research, develop, and commercialize Exicure’s technology for the treatment of Netherton Syndrome and up to five additional rare skin indications. Dermelix will initially develop a targeted therapy for the treatment of Netherton Syndrome (NS). Exicure will receive an upfront payment of $1 million at closing of the transaction and will receive an additional $1 million upon the exercise of each of the five options granted to Dermelix. Exicure will be responsible for conducting the early stage development for each indication up to IND enabling toxicology studies. Dermelix will assume subsequent development, commercial activities and financial responsibility. Exicure is eligible to receive potential payments following the achievement of certain clinical, regulatory, and commercial milestones of approximately $166 million per indication in each of six indications. Exicure will receive low double-digit royalties on annual net sales for SNA therapeutics developed. [collapse expanded text] |
Mersana Therapeutics, Synaffix | Jan 2019 | 1000 | Licensing agreement for GlycoConnect site-specific ADC technology | November 2021 Synaffix announced the expansion of its license agreement with Mersana … read moreTherapeutics. Mersana will expand its access to Synaffix's GlycoConnect site-specific ADC bioconjugation technology for six additional ADC targets. The license rights granted to Mersana are tied to specific ADC targets to be selected and provide non-exclusive access to deploy GlycoConnect site-specific ADC bioconjugation technology against the specified targets. Synaffix is eligible to receive upfront and milestone payments on a per-target basis with a total potential deal value exceeding $1 billion plus royalties. January 2019 SynAffix has entered into a license agreement with Mersana Therapeutics. This agreement provides Mersana access to Synaffix’s industry-leading site-specific GlycoConnect ADC technology that has consistently demonstrated an ability to improve both the safety and the efficacy profiles of ADC product candidates. Synaffix is eligible to receive upfront and milestone payments on a per-target basis with a projected total deal value of $295 million, plus royalties. Mersana has been granted a non-exclusive license to incorporate GlycoConnect into one of its ADC development candidates, as well as an option to expand to additional programs. This agreement follows a research collaboration between the two companies that was centered around multiple product candidates. [collapse expanded text] |
Centrexion, Eli Lilly | May 2019 | 997.5 | Licensing agreement for CNTX-0290 | Eli Lilly announced a license agreement to acquire the exclusive worldwide rights for CNTX-0290 … read morefrom Centrexion Therapeutics. CNTX-0290, is a novel, small molecule somatostatin receptor type 4 (SSTR4) agonist that is currently being studied in Phase 1 clinical testing as a potential non-opioid treatment for chronic pain conditions. Lilly will pay Centrexion an upfront payment of $47.5 million and Centrexion may be eligible for up to $575 million in potential development and regulatory milestones. If CNTX-0290 is successfully commercialized, Centrexion would be eligible for up to $375 million in potential sales milestones and tiered royalties ranging from the high-single to low-double digits. Lilly and Centrexion may also elect at a later date to co-promote CNTX-0290 in the U.S. [collapse expanded text] |
Celgene, Facit, Triphase Accelerator | Jan 2019 | 980 | Collaboration, option and licensing agreement for therapeutic targeting WDR5 protein for treatment of blood cancers including leukemia | Triphase Accelerator, FACIT, announced a new strategic collaboration with Celgene for a first-in- … read moreclass preclinical therapeutic targeting the WDR5 protein for the treatment of blood cancers including leukemia. Triphase is a drug development company advancing novel compounds through Phase 2 proof-of-concept, including the WDR5 program. Celgene has the option to acquire TRPH-395 from Triphase Accelerator. Celgene will pay an upfront of US$40M and upon exercise of the option, Celgene will pay up to US$940M in contingent development, regulatory and sales milestones. Additional payments for sales-based royalties are also possible. [collapse expanded text] |
C4 Therapeutics, Roche | Jan 2019 | 900 | Collaboration and option agreement for degrader-based medicines | C4 Therapeutics announced the transformation of its ongoing research and development partnership … read morewith Roche focusing on new cancer treatments based on C4T’s targeted protein degradation technology. C4T will lead efforts from discovery through defined preclinical or early clinical milestones, depending on the program. Upon C4T reaching these milestone events, Roche will have exclusive options for worldwide rights to continue development and commercialize drugs from these programs. C4T will have the option to co-develop and co-promote in the U.S. on selected programs. C4T will receive a significant upfront payment and near-term preclinical milestones. Upon success C4T may also receive royalties and potential clinical, regulatory, and commercial milestone payments totaling over $900 million. [collapse expanded text] |
Jazz Pharmaceuticals, PharmaMar | Dec 2019 | 900 | Licensing and supply agreement for Lurbinectedin | PharmaMar and Jazz Pharmaceuticals have entered into an exclusive license agreement for … read morelurbinectedin in the United States. PharmaMar will receive an upfront payment of $200 million with potential regulatory milestone payments of up to $250 million upon the achievement of accelerated and/or full regulatory approval of lurbinectedin by FDA within certain timelines. PharmaMar is also eligible to receive up to $550 million in potential commercial milestone payments, as well as incremental tiered royalties on future net sales of lurbinectedin ranging from the high teens up to 30 percent. PharmaMar may receive additional payments on approval of other indications. PharmaMar retains production rights for lurbinectedin and will supply the product to Jazz. [collapse expanded text] |
Daiichi Sankyo, Esperion Therapeutics | Jan 2019 | 900 | Licensing agreement for bempedoic acid | January 2024 Esperion Therapeutics and Daiichi Sankyo Europe GmbH announced a $125 million … read moreamendment to their collaboration, which includes an amicable resolution to their commercial dispute and certain other adjustments to enhance the long-term value of their products. DSE has agreed to pay Esperion $100 million in mid-January ahead of an anticipated Type II(a) variation approval by the European Medicines Agency for NILEMDO (bempedoic acid) Tablet and NUSTENDI (bempedoic acid and ezetimibe) Tablet. DSE will make an additional $25 million payment to Esperion in the calendar quarter immediately following EMA's decision on the pending application. The legal action pending in the United States District Court for the Southern District of New York will be dismissed. The parties also agreed, as part of the resolution: for Esperion to transition to DSE manufacturing and supply responsibilities in Europe and other territories, resulting in significant cost savings and efficiencies for both companies. to expand their collaboration in Europe and other territories, to include the potential development and commercialization of a triple formulation product comprising bempedoic acid, ezetimibe and a statin, which could represent significant long-term value for the collaboration. for DSE to now lead all regulatory communications with the EMA regarding the pending applications. January 2019 Esperion Therapeutics have entered into a licensing agreement with Daiichi Sankyo Europe providing DSE with exclusive rights to commercialize bempedoic acid and the bempedoic acid / ezetimibe combination pill in the European Economic Area and Switzerland. The agreement combines Esperion Therapeutics’ first-in-class ATP Citrate Lyase (ACL) inhibitor, bempedoic acid, with Daiichi Sankyo’s European commercial capabilities which includes more than 1000 professionals dedicated to the commercialization of cardiovascular (CV) products, as well as synergies with their existing portfolio of novel oral anticoagulant and antiplatelet products. This agreement seeks to distribute bempedoic acid and the bempedoic acid / ezetimibe combination pill to the millions of patients in these geographies that need additional low-density lipoprotein cholesterol (LDL-C) lowering after maximum tolerated statin therapy. Esperion will grant Daiichi Sankyo Europe exclusive commercialization rights to bempedoic acid and the bempedoic acid / ezetimibe combination pill in the European Economic Area and Switzerland. Daiichi Sankyo Europe will be responsible for commercialization in the territories. Esperion will receive an upfront cash payment of $150 million as well as $150 million upon first commercial sales in the territory. Esperion is also eligible to receive a substantial additional regulatory milestone payment upon the grant of the Marketing Authorization in the EU for the CV Risk Reduction Label, depending on the range of relative risk reduction in the CLEAR Outcomes study. Esperion is eligible to receive additional sales milestone payments. Esperion will receive substantial tiered royalties on net territory sales. [collapse expanded text] |
Biogen, Fujifilm | Mar 2019 | 890 | Asset purchase agreement for biologics site | Biogen has entered into a share purchase agreement with FUJIFILM under which Fujifilm will acquire … read morethe shares of Biogen’s subsidiary, which holds Biogen’s biologics manufacturing operations in Hillerød, Denmark, for up to $890 million in cash, subject to minimum purchase commitment guarantees and other contractual terms. The approximately 800 employees at the Hillerød subsidiary are expected to continue employment under Fujifilm ownership. As part of the proposed transaction, Biogen also announced today that it will enter into manufacturing services agreements with Fujifilm. Following the completion of the transaction, Fujifilm will use the Hillerød site to produce commercial products for Biogen, such as TYSABRI, as well as other third-party products. [collapse expanded text] |
Boehringer Ingelheim, Yuhan Corporation | Jul 2019 | 870 | Collaboration and licensing agreement for dual agonist (GLP1R/FGF21R agonist) for NASH | Boehringer Ingelheim and Yuhan announced a collaboration and license agreement for the development … read moreof a first-in-class dual agonist for the treatment of NASH and related liver diseases that combines GLP-1 and FGF21 activity in one molecule. The collaboration brings together Yuhan Corporation’s expertise in FGF21 biology, obesity and NASH with Boehringer Ingelheim’s pharmaceutical expertise and commitment to bringing innovative medicines to patients with cardiometabolic diseases. Yuhan Corporation will receive an upfront and near term payments of USD 40 million and is eligible to receive up to USD 830 million in potential milestone payments plus tiered royalties on future net sales. [collapse expanded text] |
Evotec, Takeda Pharmaceutical | Sep 2019 | 850 | Collaboration agreement for small molecule drug discovery | Evotec announced a strategic, multi-year drug discovery collaboration with Takeda Pharmaceutical. … read moreUnder the collaboration, the parties aim to establish at least five drug discovery programmes with the goal of Evotec delivering clinical candidates for Takeda to pursue into clinical development. The collaboration combines Evotec’s ability to effectively drive fully integrated drug discovery programmes with Takeda’s strategic insights into transformative therapeutic approaches in Takeda’s four core therapeutic areas: Oncology, Gastroenterology, Neuroscience and Rare Diseases, as well as Takeda’s development and commercialisation expertise. Evotec will leverage its industry-leading discovery platform to validate therapeutic hypotheses and advance small molecule programmes with Takeda having options to assume responsibility at lead series and upon Evotec delivering a pre-clinical candidate. Takeda will pay Evotec a one-time, upfront fee to access its platforms. Evotec is eligible to receive pre-clinical, clinical, and commercial milestones that can total in excess of $ 170 m per programme as well as tiered royalties on future sales. [collapse expanded text] |
IFM Therapeutics, Novartis | Sep 2019 | 840 | Collaboration and option agreement for suite of immunotherapies that inhibit the cGAS/STING pathway | December 2021 IFM Therapeutics announced that IFM Due, an IFM subsidiary company, has extended … read moreits collaboration and exclusive option agreement with Novartis to develop immunotherapies that inhibit the cGAS-STING pathway to treat a range of serious inflammatory and autoimmune diseases. September 2019 IFM Therapeutics announced that IFM Due, an IFM subsidiary company, has reached a collaboration and exclusive option agreement with Novartis to develop a suite of immunotherapies that inhibit the cGAS/STING pathway to treat a range of serious inflammatory and autoimmune diseases. Novartis will make fixed payments sufficient to fully finance IFM Due's research and development costs for the cGAS/STING program in exchange for the option to acquire the IFM Due subsidiary. Upon option exercise, IFM Due's shareholders will be entitled to consideration in aggregate value of up to $840 million, including an upfront payment upon option closing and other contingent consideration. [collapse expanded text] |
Everest Medicines, Immunomedics | Apr 2019 | 835 | Licensing agreement for sacituzumab govitecan | August 2022 The licensing agreement will be terminated. April 2019 Immunomedics and … read moreEverest Medicines announced an exclusive license agreement to develop, register, and commercialize sacituzumab govitecan in Greater China, South Korea and certain Southeast Asian countries. Immunomedics will receive an upfront payment of $65 million and an additional $60 million based on U.S. FDA approval of sacituzumab govitecan in metastatic triple-negative breast cancer. Everest will develop and commercialize the product in various global and local indications across the Territory. The Company is eligible to receive development and sales milestone payments of up to $710 million, as well as escalating tiered royalties that begin in the mid-teens based on net sales within the Territory. Everest Medicines will be responsible for all costs associated with the clinical development and commercialization of sacituzumab govitecan in the Territory, while a Joint Steering Committee will be established between the companies to oversee the overall strategy and priorities. [collapse expanded text] |
Ligand Pharmaceuticals, Royalty Pharma | Mar 2019 | 827 | Royalty financing for Promacta | Ligand Pharmaceuticals and Royalty Pharma announce the sale of Ligand’s Promacta-related … read moreintellectual property rights licensed to Novartis, including the royalty stream on worldwide net sales of Promacta to Royalty Pharma for $827 million in cash. Promacta (eltrombopag) is known as Revolade outside the U.S. and is marketed worldwide by Novartis. This transaction is expected to close on Wednesday, March 6, 2019. Highlights of the transaction to monetize the Promacta royalty include: Provides substantial cash payment for Ligand’s leading royalty asset. Ligand’s 2019 revenues are now expected to be approximately $118 million and 2019 adjusted diluted EPS to be approximately $32.25, compared to the previous guidance of $6.05. Proceeds to be reinvested by Ligand primarily to 1) acquire assets that can generate long-term revenue streams, fully-funded Shots on Goal and technology platforms to drive future deal making and 2) share repurchases to increase the per share profits and cash-flow for the existing business. Ligand will enter the second quarter of 2019 with highly-diversified and high-growth revenue streams, more than 200 Shots on Goal fully funded by partners, three major technology platforms to drive new licensing and over $3.5 billion of potential contract payments with existing partners. At the close of the transaction, Ligand estimates it will have over $1.4 billion of cash. In addition, the long-term growth potential for the OmniAb platform is accelerating, given R&D progress by partners and new licensing transactions. [collapse expanded text] |
Janssen Pharmaceuticals, Locus Biosciences | Jan 2019 | 818 | Collaboration and licensing agreement for CRISPR-Cas3 bacteriophage therapeutics | Locus Biosciences has entered into an exclusive collaboration and license agreement with Janssen … read morePharmaceuticals to develop, manufacture and commercialize CRISPR-Cas3-enhanced bacteriophage ("crPhage™") products targeting two key bacterial pathogens for the potential treatment of infections of the respiratory tract and other organ systems. Johnson & Johnson Innovation LLC facilitated the transaction. Locus will receive $20 million in initial payments, and is eligible to receive up to a total of $798 million in potential future development and commercial milestone payments, and royalties on any product sales. [collapse expanded text] |
Astellas Pharma, Pandion Therapeutics | Oct 2019 | 795 | Collaboration and licensing agreement for locally acting immunomodulators for autoimmune diseases of pancreas | Pandion Therapeutics and Astellas Pharma announced the signing of a License and Collaboration … read moreAgreement directed toward the research, development, and commercialization of locally acting immunomodulators for autoimmune diseases of the pancreas. The collaboration will allow the parties to combine Pandion’s modular biologics and functional immunology expertise with Astellas' advanced therapeutics development and global commercialization capabilities for the treatment of autoimmune diseases. Pandion will be responsible for design and discovery of bispecific drug candidates based on Pandion's proprietary modular immune effector and tissue tether platform and Astellas will be responsible for conducting preclinical, clinical and commercialization activities for the selected candidates developed during the collaboration. Pandion could receive up to $45 million as upfront and payments related to research and preclinical activities. If Astellas develops and commercializes multiple candidates for multiple pancreatic autoimmune diseases, Pandion is potentially eligible to receive more than $750 million in future development and commercial milestone payments from Astellas. Pandion may also receive royalties on worldwide net sales of any commercial products developed through the collaboration. [collapse expanded text] |
Rheos Medicines, Roche | Dec 2019 | 792.5 | Collaboration, option and licensing agreement for medicines in immunometabolism | Rheos Medicines has entered into a worldwide exclusive collaboration, option and license agreement … read morewith Roche to discover, develop and commercialize novel therapeutics in the field of immunometabolism. Rheos will conduct an exclusive research effort to identify novel targets in immunometabolism that modify the fate or function of certain human immune cells. Rheos will also be responsible for drug discovery efforts under the collaboration. Roche will receive an option to exclusively license a defined number of programs emerging from the collaboration. For certain products within the collaboration, Rheos and Roche could share worldwide development and US commercial rights. Rheos will receive an upfront cash payment of $42.5 million upon execution and will be eligible to receive up to approximately $90 million for specified research and preclinical development milestones as well as option fees. Rheos will also be eligible to receive up to an additional approximately $660 million in specified development, regulatory and sales related milestones across the programs and tiered royalties on net sales. For those products for which Rheos and Roche could share development and commercial rights Rheos will be entitled to additional financial compensation within the US and ex- US commensurate with the share of its financial investment in development and commercialization. [collapse expanded text] |
Gilead Sciences, Yuhan Corporation | Jan 2019 | 785 | Co-development and licensing agreement for treatments for advanced fibrosis due to NASH | October 2024 Gilead has “mutually agreed” to terminate its collaboration and license agreement … read morewith South Korean biotech Yuhan for a pair of MASH therapie Gilead has lost $15 million upfront payment January 2019 Gilead Sciences and Yuhan have entered into a licensing and collaboration agreement to co-develop novel therapeutic candidates for the treatment of patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH). Gilead will acquire global rights to develop and commercialize novel small molecules against two undisclosed targets in all countries, with the exception of the Republic of Korea where Yuhan will retain certain commercialization rights. Yuhan and Gilead will jointly conduct preclinical research, and Gilead will be responsible for global clinical development. Gilead will also be responsible for commercialization worldwide, outside of Yuhan’s rights in the Republic of Korea. Yuhan will receive an upfront payment of $15 million and is eligible to receive up to an additional $770 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on future net sales. This agreement builds on the companies’ existing commercial collaboration to support the promotion of Gilead’s medicines in the Republic of Korea. [collapse expanded text] |
Dicerna Pharmaceuticals, Novo Nordisk | Nov 2019 | 757.5 | Collaboration, co-development, co-promotion and licensing agreement for therapies for the treatment of liver-related cardio-metabolic diseases using GalXC RNAi platform technology | Dicerna Pharmaceuticals and Novo Nordisk announced an agreement to discover and develop novel … read moretherapies for the treatment of liver-related cardio-metabolic diseases using Dicerna’s proprietary GalXC RNAi platform technology. The collaboration plans to explore more than 30 liver cell targets and may deliver multiple clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity, and rare diseases. Dicerna will conduct and fund discovery and preclinical development to clinical candidate selection for each liver cell target, and Novo Nordisk will be responsible for all further development. The agreement represents a significant investment by Novo Nordisk to secure access to Dicerna’s proprietary GalXC RNAi platform, which complements its existing technology base. The collaboration provides Novo Nordisk with the capability to inhibit hepatocyte targets involved in disease regulation and has the potential to generate a number of clinical development candidates. The agreement enables each company to co-develop and co-commercialize product candidates discovered under the collaboration. Novo Nordisk will lead programs targeting cardio-metabolic disorders and other indications with Dicerna having the option to opt into two programs during clinical development. Dicerna retains rights to initiate two new orphan liver disease programs for which Novo Nordisk can opt in. For all co-development programs, the companies will share in the profit/loss of net sales of products consistent with each company’s contribution to co-development costs. Dicerna will receive: An upfront payment of USD 175 million. A USD 50 million equity investment in Dicerna at a premium. USD 25 million annually during each of the first three years of the collaboration, contingent on Dicerna delivering RNAi molecules for a defined number of targets. Up to USD 357.5 million per target in development, regulatory, and commercialization milestone payments, plus tiered royalties on product sales ranging from the mid-single-digits to mid-teens. [collapse expanded text] |
Danaher, Sartorius Stedim Biotech | Oct 2019 | 750 | Asset purchase agreement for life science portfolio | Sartorius Stedim Biotech has agreed to acquire parts of Danaher’s Life Science portfolio as part of … read morea broader transaction between Danaher and Sartorius Group, SSB’s major shareholder. The total purchase price is approximately $750 million in cash of which about a quarter will be allocated to the businesses purchased by SSB. T he final purchase price allocation will be subject to the closing process. The businesses to be acquired by SSB had combined sales turnover of approximately $70 million in 2018 and strong double-digit profit margins. They employ approximately 110 people worldwide. The proposed transaction is expected to be completed in the first quarter of 2020 and is subject to customary closing conditions and the successful acquisition of the GE Biopharma business by Danaher. [collapse expanded text] |
Janssen Biotech, XBiotech | Dec 2019 | 750 | Asset purchase agreement for Bermekimab | Janssen Biotech has entered a definitive agreement to acquire all rights to the investigational … read morecompound bermekimab from XBiotech. Bermekimab is an anti-IL-1alpha monoclonal antibody (mAb) in Phase 2 development for the treatment of atopic dermatitis and hidradenitis suppurativa. It is the only antibody targeting IL-1a currently in clinical development and has the potential for superior efficacy and safety compared to the current standard of care. Janssen will assume responsibility for the clinical program, working closely with XBiotech as it completes the ongoing Phase 2 studies in atopic dermatitis and hidradenitis suppurativa. Janssen will pay XBiotech a purchase price of $750 million for the rights to bermekimab; should Janssen pursue bermekimab indications outside of dermatology, XBiotech may be eligible to receive additional payments upon the receipt of certain commercialization authorizations. [collapse expanded text] |
Abbvie, Allergan, Exicure | Nov 2019 | 750 | Collaboration, option and licensing agreement for SNA-based treatments for hair loss disorders | December 2022 Exicure announced the termination of its collaboration agreement with AbbVie. … read moreExicure regains the ability to independently develop medicines targeting hair loss disorders, Angelman syndrome, and Huntington’s disease. November 2019 Allergan Pharmaceuticals International and Exicure have entered into a global collaboration agreement to discover and develop novel treatments for hair loss disorders based on Exicure’s proprietary SNA technology. Allergan will receive exclusive access and options to license SNA-based therapeutics arising from two collaboration programs related to the treatment of hair loss disorders. Exicure will receive an upfront payment of $25 million and will conduct discovery and development in two collaboration programs for hair loss disorders. In the event that Allergan exercises an option, Allergan will be responsible for clinical development and commercialization of the licensed products. Exicure will be eligible to receive development and regulatory milestones of up to $97.5 million per program and commercial milestones of up to $265 million per program. Exicure will also be eligible to receive tiered royalties on worldwide net product sales of mid-single digit to mid-teens percentages on worldwide net product sales. [collapse expanded text] |
Janssen Biotech, Morphic Therapeutic | Feb 2019 | 745 | Collaboration agreement for novel integrin therapeutics | January 2023 Morphic Holding received notice from Janssen Pharmaceuticals that Janssen has … read moreelected to terminate the Research Collaboration and Option Agreement between Janssen and Morphic Therapeutic dated February 15, 2019. Janssen exercised its right to terminate the Collaboration Agreement for convenience. The termination will be effective within sixty days of January 13, 2023. Under the terms of the Collaboration Agreement, Morphic granted Janssen exclusive license options on certain product candidates directed at multiple targets. The termination follows Janssen’s delivery of notice to the Company that it did not intend to exercise its options on the first two integrin targets under the Collaboration Agreement due to lack of target validation in the specific disease of Janssen’s interest. Effective upon the termination of the Collaboration Agreement, all rights and licenses granted thereunder shall immediately terminate. January 2021 Morphic Therapeutic announced the expansion of its research and development collaboration with Janssen Pharmaceuticals. The collaboration expansion involves the initiation of work on a third integrin target, with the collaboration scope to include activating antibodies against this new target. The agreement was facilitated by Johnson & Johnson Innovation. Morphic will receive a milestone payment for initiating work on the third target. As part of the expansion any new product candidates will be subject to milestones and royalties. February 2019 Morphic Therapeutic has entered into a research and development collaboration with Janssen Biotech to discover and develop novel integrin therapeutics for patients with conditions not adequately addressed by current therapies. Johnson & Johnson Innovation LLC facilitated the transaction. The collaboration focuses on several undisclosed integrin targets and will explore both inhibitors and activators of integrin function. Under the terms of the agreement, the companies will collaborate through preclinical development to identify and advance candidates. Upon completing Investigational New Drug enabling studies, Janssen may exclusively option the licensed compounds, and then Janssen will be responsible for global clinical development and commercialization. Janssen will pay Morphic an undisclosed upfront payment and will fund research activities. Morphic will receive from Janssen multiple preclinical development, clinical and commercial milestone payments totaling over $725 million if such milestones are achieved. Morphic will also receive royalties on worldwide net sales for any products resulting from the collaboration. [collapse expanded text] |
Arvinas, Bayer | Jun 2019 | 740 | Joint venture and development agreement for proteolysis-targeting chimera candidates for humans and plants | Bayer announced a collaboration with Arvinas. The new life science research partnership … read moreuniquely leverages the full potential of Arvinas' novel PROTAC technology, coupled with leading expertise of Bayer in health and agriculture to develop innovations for the benefit of patients and farmers. Bayer will form an exclusive joint venture as the first company to explore the PROTAC technology in agriculture for crop protection, and at the same time, establish a target-based pharmaceutical research collaboration with Arvinas. Bayer will make an equity investment to sustain its commitment for the technology. Within the framework of the joint venture, the exploration of novel molecular targets to address weeds, insects and/or diseases that threaten crops worldwide will be pioneered. As the technology degrades targets rather than inhibiting them, it offers a completely new category of crop protection applications in agriculture. In addition, PROTACs have the potential to revive crop protection mechanisms that have become ineffective due to resistance. Under the framework of the joint venture, Bayer has committed more than $55 million over six years to translate the new protein degradation technology in agro chemistry and to build an agro-specific PROTAC IP portfolio. Arvinas will receive an upfront payment and pharmaceutical R&D support over the next four years, as well as a direct equity investment. These investments, combined, will exceed $60 million. Bayer will own the rights to novel lead structures generated in the course of the collaboration. As programs progress through research, development, and commercialization, Arvinas is eligible to receive pre-defined development milestones of over $685 million and commercial royalties. [collapse expanded text] |
Boehringer Ingelheim, Lupin Limited | Sep 2019 | 720 | Development and licensing agreement for MEK inhibitor compound (LNP3794) as a potential targeted therapy for patients with difficult-to-treat cancers | Boehringer Ingelheim and Lupin announced a licensing, development and commercialization agreement … read morefor Lupin’s MEK inhibitor compound (LNP3794) as a potential targeted therapy for patients with difficult-to-treat cancers. The partnership aims to develop Lupin’s lead MEK inhibitor compound in combination with one of Boehringer Ingelheim’s innovative KRAS inhibitors for patients with gastrointestinal and lung cancers harboring a broad range of oncogenic KRAS mutations. The collaboration has a strategic goal to focus on patients with gastrointestinal or lung cancers defined by KRAS mutations, sub-populations that currently need more effective therapeutic options. Lupin will receive an upfront payment of $20 million and potential additional payments for successful achievement of defined clinical, regulatory and commercial milestones for a total deal value of more than $700 million. Lupin will be entitled to receive double-digit royalties on the sales of the product. [collapse expanded text] |
Ribometrix, Vertex Pharmaceuticals | Sep 2019 | 720 | Collaboration, development, option and licensing agreement for RNA-targeted small molecule therapeutics | Vertex Pharmaceuticals and Ribometrix have entered into a strategic collaboration to discover and … read moredevelop novel RNA-targeted small molecule therapeutic candidates for serious diseases. The collaboration will combine Ribometrix’s proprietary discovery platform for identifying and optimizing small molecule therapeutics that modulate RNA function by targeting three-dimensional (3D) RNA structures with Vertex’s scientific, clinical and regulatory capabilities for up to three therapeutic programs, including one ongoing discovery program from Ribometrix. Vertex will pay Ribometrix approximately $20 million upfront, which includes an equity investment in the company. Ribometrix will undertake two discovery programs with Vertex, and Vertex has an option to add a third program. Following discovery and optimization of novel therapeutic molecules, Vertex has the option to take an exclusive global license for the development and commercialization of molecules for that program. Ribometrix is eligible to receive more than $700 million in total potential payments based upon the successful achievement of specified research, development, regulatory and commercial milestones as part of the collaboration. Vertex will pay tiered royalties on future net global sales on any products that result from the collaboration. [collapse expanded text] |
AgonOx, Talem Therapeutics | Sep 2019 | 720 | Joint venture agreement for antibody therapeutics to target T cell mediated anti-tumor activity | Talem Therapeutics has entered into an LOI to form a Joint Venture as it partners in the continued … read moredevelopment of antibody therapeutics to target T cell mediated anti-tumor activity, with AgonOx. This partnership will advance two of AgonOx's top 10 candidates to emerge from its translational science platform focused on modulation of the tumor microenvironment and, if commercialized, may result in approximately $720 million USD comprised of licensing fees, as well as development and commercial milestones in addition to royalties on worldwide sales. Talem will leverage the internal development capabilities of ImmunoPrecise, including high throughput, rapid identification of candidates through single cell interrogation, as well as accessing synthetic and natural immune phage libraries, and its bispecific platform, Abthena. All of these technologies integrate seamlessly with IPA's integrated Artemis Intelligence Metadata (AIM) capabilities to enable rapid turnaround on additional outputs in therapeutic optimization, stability, affinity, and manufacturability. Both companies will aid in the functional analyses of the candidates, while AgonOx also pulls from its experience in pre-clinical and clinical development, built, in part, on access to physicians and relevant samples through their alignment with the Earl A. Chiles Research Institute at the Providence Cancer Institute. [collapse expanded text] |
StrideBio, Takeda Pharmaceutical | Mar 2019 | 710 | Collaboration and licensing agreement for gene therapies for neurological diseases | StrideBio announced the signing of a collaboration and license agreement with Takeda Pharmaceutical … read moreto develop in vivo AAV based therapies for Friedreich's Ataxia (FA) and two additional undisclosed targets. These programs aim to utilize novel AAV capsids developed by StrideBio to improve potency, evade neutralizing antibodies and enhance specific tropism to tissues including the central nervous system. StrideBio will be responsible for AAV capsid development, non-clinical development and manufacturing of preclinical candidates to be selected for advancement into clinical studies. Takeda will be responsible for clinical development and commercialization of selected candidates arising from the collaboration. A total of three targets are specified under the collaboration, with the initial target being Friedreich's Ataxia. StrideBio is eligible to receive approximately $30 million in upfront and near term pre-clinical milestones, as well as an additional $680 million in future development and commercial milestones from Takeda. StrideBio will also receive royalties on worldwide net sales of any commercial products developed through the collaboration. Further financial terms were not disclosed. [collapse expanded text] |
Alexion Pharmaceuticals, Zealand Pharma | Mar 2019 | 695 | Collaboration agreement for peptide therapies for complement-mediated diseases | Alexion Pharmaceuticals and Zealand Pharma announced a collaboration to discover and develop novel … read morepeptide therapies for complement-mediated diseases. Peptides offer a number of advantages, including being highly selective and potent, allowing low dosage volumes for ease of administration, and having the potential to treat a broad range of complement-mediated diseases. The agreement provides Alexion with exclusive worldwide licenses, as well as development and commercial rights, for up to four targets within the complement pathway. Alexion and Zealand will enter into an exclusive collaboration for the discovery and development of subcutaneously delivered peptide therapies directed to up to four complement pathway targets. Zealand will lead the joint discovery and research efforts through the preclinical stage, and Alexion will lead development efforts beginning with IND filing and Phase 1 studies. The agreement provides Alexion with exclusive worldwide licenses and commercial rights to the peptide therapies developed in the collaboration. Zealand will receive an immediate upfront payment of $25 million for the first target, with Alexion making a concurrent $15 million equity investment in Zealand Pharma at a premium to the market price as of the collaboration effective date. For the lead target, the agreement provides the potential for development-related milestones of up to $115 million, as well as up to $495 million in sales-related milestones and the potential for high single- to low double-digit royalty payments. Each of the three subsequent targets can be selected for an option fee of $15 million and has the potential for additional development milestones and sales milestones and royalty payments at a reduced price to the lead target. [collapse expanded text] |
Pfizer, Vivet Therapeutics | Mar 2019 | 686.8 | Collaboration and option agreement for VTX-801 treatment for Wilson disease | Vivet Therapeutics and Pfizer announced that Pfizer has acquired a 15% equity interest in Vivet and … read moresecured an exclusive option to acquire all outstanding shares. Pfizer and Vivet will collaborate on the development of VTX-801, Vivet’s proprietary treatment for Wilson disease. Pfizer paid approximately €45 million (US$51 million) upon signing and may pay up to €560 million (US$635.8 million) inclusive of the option exercise payment and subject to certain clinical, regulatory, and commercial milestones. Pfizer can exercise its option to acquire 100% of Vivet following the company’s delivery of certain data from the Phase I/II clinical trial for VTX-801. Pfizer senior executive Monika Vnuk, M.D., Vice President, Worldwide Business Development, will join Vivet’s Board of Directors. Other terms of the transaction were not disclosed. [collapse expanded text] |
STADA Arzneimittel, Takeda Pharmaceutical | Nov 2019 | 660 | Asset purchase agreement for OTC product portfolio | STADA Arzneimittel has agreed to acquire a portfolio of selected products from Takeda … read morePharmaceutical for a total value of $660 Million USD. The portfolio of approximately 20 selected over-the-counter (‘OTC’) and prescription pharmaceutical assets sold inter alia in Russia, Georgia, Azerbaijan, Belarus, Kazakhstan, and Uzbekistan will be divested to. The portfolio includes OTC-vitamins and food supplements, plus selected products within the cardiovascular, diabetes, general medicine, and respiratory therapeutic areas. Included in the transaction is the key product Cardiomagnyl, a well-known name and category leader in Russia, which is used to prevent blood clots, as well as the newer, patent-protected Nesina (for type II diabetes treatment) and Edarbi (angiotensin II receptor blocker for blood pressure control). [collapse expanded text] |
Affibody, Alexion Pharmaceuticals | Mar 2019 | 650 | Co-development, option and co-promotion agreement for anti-FcRn Affibody molecule, ABY-039 | Alexion Pharmaceuticals and Affibody announced a partnership to co-develop ABY-039 for rare … read moreImmunoglobulin G (IgG)-mediated autoimmune diseases. Currently in Phase 1 development, ABY-039 is a bivalent antibody-mimetic that targets the neonatal Fc receptor (FcRn). ABY-039 has been specifically designed to combine Affibody’s protein therapeutics platform (Affibody molecules) and Albumod technology to achieve a long half-life, which, along with its small size provides the potential for less frequent, convenient, at-home subcutaneous administration. Alexion will provide Affibody with an upfront payment of $25 million, with the potential for additional development- and sales-based milestones of up to $625 million and tiered low double-digit royalty payments. Alexion will lead joint clinical development of ABY-039 and commercialization activities. Affibody has the option to co-promote ABY-039 in the U.S. and will lead clinical development for an undisclosed indication. [collapse expanded text] |
Cidara Therapeutics, Mundipharma | Sep 2019 | 640 | Co-development and licensing agreement for Rezafungin | Cidara Therapeutics and Mundipharma have entered into a strategic partnership to develop and … read morecommercialize rezafungin for the treatment and prevention of invasive fungal infections. Rezafungin is a novel, once-weekly echinocandin antifungal being developed for the first-line treatment of candidemia and invasive candidiasis as well as for the prophylaxis of invasive fungal infections in patients undergoing allogeneic blood and marrow transplantation, for which no new therapies have been approved in over 13 years. The partnership agreement follows Cidara’s recent announcement of the successful completion of its STRIVE B Phase 2 trial. Under the terms of the agreement, in exchange for granting Mundipharma exclusive commercialization rights to rezafungin outside the U.S. and Japan, Cidara will receive a $30 million upfront payment and Mundipharma will make a $9 million equity investment in Cidara. Cidara will also receive an additional $42 million in near-term funding to support the global Phase 3 ReSTORE and ReSPECT trials for the treatment and prevention of fungal infections. Cidara is eligible to receive development, regulatory and commercial milestone payments, representing a total potential transaction value of $568 million plus double-digit royalties. Cidara will continue to lead the ongoing global Phase 3 development programs for rezafungin with the support of Mundipharma. The companies may pursue additional indications or formulations of rezafungin. [collapse expanded text] |
GSK, SpringWorks Therapeutics | Jun 2019 | 625 | Collaboration agreement to evaluate nirogacestat in combination with belantamab mafodotin in patients with relapsed or refractory multiple myeloma | September 2022 SpringWorks Therapeutics has entered into an expanded global, non-exclusive … read morelicense and collaboration agreement with GSK for nirogacestat, SpringWorks’ investigational oral gamma secretase inhibitor, in combination with Blenrep (belantamab mafodotin-blmf), GSK’s antibody-drug conjugate targeting B-cell maturation antigen. SpringWorks will receive a $75 million equity investment from GSK, with shares of common stock priced at a premium to the 30-day volume-weighted average share price on September 2, 2022. SpringWorks will also be eligible to receive up to $550 million in additional payments based on reaching certain development and commercial milestones. SpringWorks will retain full commercial rights to nirogacestat and will be responsible for global commercialization of nirogacestat. June 2019 SpringWorks Therapeutics has entered into a clinical trial collaboration agreement with GlaxoSmithKline to evaluate SpringWorks Therapeutics’ investigational gamma secretase inhibitor (GSI), nirogacestat, in combination with GlaxoSmithKline’s investigational anti-B-cell maturation antigen (BCMA) antibody-drug conjugate (ADC), belantamab mafodotin (formerly GSK2857916), in patients with relapsed or refractory multiple myeloma. GlaxoSmithKline will sponsor and conduct the adaptive Phase 1b study to evaluate the safety, tolerability and preliminary efficacy of the combination, and will assume all development costs associated with the study. GlaxoSmithKline and SpringWorks Therapeutics will also form a joint development committee to manage the clinical study. [collapse expanded text] |
Astellas Pharma, Frequency Therapeutics | Jul 2019 | 625 | Licensing agreement for FX-322 | Astellas Pharma and Frequency Therapeutics have entered into an exclusive license agreement to … read moredevelop and commercialize Frequency’s regenerative therapeutic candidate, FX-322, for the treatment of sensorineural hearing loss, the most common type of hearing loss. Astellas will be responsible for the development and commercialization of FX-322 outside of the U.S. and Frequency will be responsible for U.S. development and commercialization. The companies will be jointly responsible for conducting global clinical studies and coordinating commercial launch activities. Frequency will receive an upfront payment of $80 million and may also receive up to an additional $545 million based on development and commercial milestones, as well as royalties on any future product sales in the licensed territory. [collapse expanded text] |
Cantex Pharmaceuticals, Chimerix | Jul 2019 | 617.5 | Licensing agreement for CX-01 for acute myeloid leukemia | Chimerix announced the completion of an exclusive worldwide license of CX-01 from Cantex … read morePharmaceuticals. Chimerix intends to move quickly into Phase 3 development of CX-01 for the treatment of Acute Myeloid Leukemia (AML) in the first-line setting. CX-01 has received Fast Track and Orphan Drug Designations from the U.S. Food and Drug Administration for the treatment of AML. Chimerix has exclusive worldwide rights to develop and commercialize CX-01. Chimerix will make an upfront payment of $30 million to Cantex. Chimerix has issued 10 million shares of Chimerix common stock to Cantex. Cantex is eligible for regulatory and commercial milestones of up to $587.5 million, and tiered royalties starting at 10%. [collapse expanded text] |
Eli Lilly, ImmuNext | Mar 2019 | 605 | Collaboration and licensing agreement for new medicines for autoimmune diseases by regulating immune cell metabolism | Eli Lilly and ImmuNext announced a global licensing and research collaboration focused on the study … read moreof a preclinical novel target that could lead to potential new medicines for autoimmune diseases by regulating immune cell metabolism. ImmuNext will receive an upfront payment of $40 million, and is eligible to receive up to approximately $565 million in development and commercialization milestones, as well as tiered royalties ranging from the mid-single to low-double digits on product sales. ImmuNext will grant Lilly an exclusive, worldwide license to develop and commercialize the novel immunometabolism target. Lilly and ImmuNext will establish a 3-year research collaboration to support the target's development. [collapse expanded text] |
Blackstone, FerGene, Ferring Pharmaceuticals | Nov 2019 | 570 | Joint venture agreement for nadofaragene firadenovec (rAd-IFN/Syn3), an investigational novel gene therapy | Ferring Pharmaceuticals and Blackstone Life Sciences announced the joint investment of over $570 … read moremillion USD in nadofaragene firadenovec (rAd-IFN/Syn3), an investigational novel gene therapy in late stage development for patients with high-grade, Bacillus Calmette-Guérin (BCG) unresponsive, non-muscle invasive bladder cancer (NMIBC). FerGene, a new gene therapy company and Ferring subsidiary, has been created to potentially commercialize nadofaragene firadenovec in the US and to advance the global clinical development. FerGene’s goal is to bring this promising therapy to a patient population which has seen little improvement in their standard of care over the past twenty years. Blackstone will invest $400 million USD and Ferring will invest up to $170 million USD in FerGene. Ferring will also potentially launch and commercialize nadofaragene firadenovec outside of the US. [collapse expanded text] |
Atomwise, Eli Lilly | Jun 2019 | 560 | Collaboration agreement for AI driven drug discovery | Atomwise announced a multi-year agreement with Eli Lilly to apply Atomwise’s patented artificial … read moreintelligence (AI) technology in support of Lilly’s preclinical drug discovery efforts. The companies will collaborate on up to ten drug targets selected by Lilly, with the goal of accelerating the time it takes to identify and develop potential new medicines. Atomwise could receive up to $1 million per target in discovery milestones and will be eligible for up to $550 million in potential development and commercialization milestones inclusive of all targets. Atomwise will have the option to develop compounds from the collaboration that Lilly chooses not to advance into clinical testing. [collapse expanded text] |
Molecular Templates, Vertex Pharmaceuticals | Nov 2019 | 560 | Collaboration, option and licensing agreement for targeted conditioning regimens that may enhance hematopoietic stem cell transplant process | Vertex Pharmaceuticals and Molecular Templates have entered into a strategic research collaboration … read moreto discover and develop novel targeted conditioning regimens that may enhance the hematopoietic stem cell transplant process, including transplants conducted as part of treatment with ex vivo CRISPR/Cas9 gene editing therapies such as CTX001. CTX001 is currently being evaluated in two ongoing Phase 1/2 studies in patients with transfusion-dependent beta thalassemia and severe sickle cell disease, where a hematopoietic stem cell transplant is required as part of treatment with CTX001. The collaboration will seek to discover a new conditioning regimen utilizing MTEM’s engineered toxin body (ETB) platform, which is designed to specifically target and remove specific cells to enable successful engraftment of new cells. MTEM will conduct research activities for the use of ETBs for up to two targets selected by Vertex. The initial research will be focused on discovering a novel conditioning regimen using MTEM’s ETB technology platform. In addition, Vertex has an option to select a second target as part of the collaboration. Upon designation of a clinical development candidate that emerges from the research efforts, Vertex has the option to exclusively license molecules against the designated target. Vertex will have exclusive rights to develop molecules that emerge from the research program for any indication. Vertex will make an up-front payment of $38 million to MTEM, including an equity investment. MTEM is also eligible to receive future development, regulatory and sales milestones and option payments of up to $522 million (across two targets) and tiered royalty payments on future sales. [collapse expanded text] |
Alexion Pharmaceuticals, Caelum Biosciences | Jan 2019 | 560 | Development, option and licensing agreement fro CAEL-101 for light chain (AL) amyloidosis | Caelum Biosciences has signed a strategic agreement with Alexion Pharmaceuticals to advance the … read moredevelopment of CAEL-101 for light chain (AL) amyloidosis. CAEL-101 is a first-in-class amyloid fibril targeted therapy designed to improve organ function by reducing or eliminating amyloid deposits in patients with AL amyloidosis. Alexion will acquire a minority equity interest in Caelum and an exclusive option to acquire the remaining equity in the company based on Phase 2 data for pre-negotiated economics. Alexion will make payments to Caelum totaling up to $60 million, including the purchase price for the equity and milestone-dependent development funding payments. The collaboration also provides for potential additional payments of up to $500 million, including the upfront and regulatory and commercial milestone payments, in the event Alexion exercises the acquisition option. The collaboration will leverage Alexion’s expertise in rare disease antibody development and commercial franchise in hematology. Alexion and Caelum will collaborate on the design of the ongoing development program for CAEL-101. Caelum will be responsible for conducting the development program through the end of Phase 2 and for manufacturing CAEL-101. [collapse expanded text] |
Bayer, Beiersdorf | May 2019 | 550 | Asset purchase agreement for Coppertone | Beiersdorf entered into a definitive agreement with Bayer for the purchase of Bayer’s sun care … read morebusiness marketed under the Coppertone brand for a purchase price of USD 550 million. [collapse expanded text] |
Department of Health and Human Services, Emergent BioSolutions | Jun 2019 | 535 | Contract service and supply agreement for vaccinia immune globulin intravenous (VIGIV) in support of smallpox preparedness | Emergent BioSolutions announced a contract award by the Office of the Assistant Secretary for … read morePreparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) valued at approximately $535 million over 10 years for the continued supply of Vaccinia Immune Globulin Intravenous (VIGIV) into the U.S. Strategic National Stockpile (SNS) in support of smallpox preparedness. [collapse expanded text] |
Blueprint Medicines, Clementia Pharmaceuticals, Ipsen | Oct 2019 | 535 | Development and licensing agreement for BLU-782 | Ipsen and Blueprint Medicines have entered into an exclusive, worldwide license agreement for the … read moredevelopment and commercialization of BLU-782, an oral, highly selective investigational ALK2 inhibitor being developed for the treatment of fibrodysplasia ossificans progressiva (FOP). The agreement enhances Ipsen’s Rare Diseases portfolio and advances Blueprint Medicines’ goal of rapidly and efficiently developing BLU-782 as a potential treatment for patients with FOP. Ipsen has demonstrated its commitment to leadership in this complex ultra-rare genetic disorder through the ongoing late-stage clinical development of palovarotene, an investigational retinoic acid receptor gamma (RARγ) agonist. With the addition of BLU-782, which recently completed dosing in a Phase 1 study in healthy volunteers, Ipsen has the potential to offer the broadest possible suite of treatment options for patients with FOP. Subject to the terms of the license agreement, Blueprint Medicines will be eligible to receive up to $535 million in upfront, milestone and other payments, including an upfront cash payment of $25 million and up to $510 million in potential milestone payments related to specified development, regulatory and sales-based milestones for licensed products in up to two indications, including FOP. Ipsen will pay Blueprint Medicines tiered percentage royalties ranging from the low- to mid-teens on worldwide aggregate annual net sales of licensed products, subject to adjustment in specified circumstances under the license agreement. [collapse expanded text] |
Arvelle Therapeutics, SK Biopharmaceuticals | Feb 2019 | 530 | Development and licensing agreement for Cenobamate | SK Biopharmaceuticals and Arvelle Therapeutics have entered into an exclusive licensing agreement … read morefor Arvelle to develop and commercialize cenobamate in Europe. Cenobamate is a novel, small molecule investigational antiepileptic drug for the potential treatment of partial-onset seizures in adult patients. SK Biopharmaceuticals will receive an upfront payment of $100 million and is eligible to receive up to $430 million upon achievement of certain regulatory and commercial milestones in addition to royalties on net sales generated in Europe. SK Biopharmaceuticals will have an option to obtain a significant equity stake in Arvelle and will also retain commercial rights for all non-European territories. [collapse expanded text] |
Celgene, Jounce Therapeutics | Jul 2019 | 530 | Licensing agreement for JTX-8064 | Jounce Therapeutics announced an update on its strategic collaboration with Celgene. Under the … read moreterms of a new license agreement, Celgene has licensed worldwide rights to JTX-8064, a highly-selective, potential first-in-class antibody that targets the LILRB2 receptor on macrophages. Jounce retains full worldwide rights to its pipeline beyond JTX-8064, including vopratelimab, JTX-4014 and all discovery programs, as Jounce and Celgene have also entered into a mutual agreement to terminate their original strategic collaboration agreement. Under the terms of the new license agreement for JTX-8064, Jounce receives a $50.0 million non-refundable license fee and is eligible to receive from Celgene up to $480 million in development, regulatory and commercial milestone payments, as well as royalties on potential worldwide sales. Celgene will be responsible for all development and commercialization of JTX-8064. [collapse expanded text] |
Halozyme Therapeutics, argenx | Feb 2019 | 530 | Collaboration and licensing agreement for ENHANZE technology | October 2020 Halozyme Therapeutics and argenx are expanding their existing global collaboration … read moreand license agreement that was signed in February 2019. Under the newly announced expansion, argenx gained the ability to exclusively access Halozyme's ENHANZE drug delivery technology for three additional targets upon nomination for a total of up to six targets under the existing and newly expanded collaboration. To date, argenx has nominated two targets including the human neonatal Fc receptor FcRn and complement component C2. May 2019 Halozyme Therapeutics announced that argenx has selected a second target under the collaboration and license agreement the companies announced in February 2019. February 2019 argenx and Halozyme Therapeutics announced a global collaboration and license agreement that enables use by argenx of Halozyme's ENHANZE drug delivery technology to develop multiple subcutaneous product formulations for current or future argenx product candidates. The agreement provides argenx exclusive access to ENHANZE for any product targeting the human neonatal Fc receptor FcRn, including argenx's lead asset efgartigimod (ARGX-113) and up to two additional targets, potentially shortening drug administration time, reducing healthcare practitioner time, and offering additional flexibility and convenience for patients. argenx will pay an upfront payment of $30 million to Halozyme, $10 million per target for future target nominations and potential future payments of up to $160 million per selected target subject to achievement of specified development, regulatory and sales-based milestones. Halozyme will also receive mid-single digit royalties on sales of commercialized products. [collapse expanded text] |
Ardelyx, Kyowa Hakko Kirin | Nov 2019 | 520.5 | Research, option and licensing agreement for identification and design of compounds to two undisclosed targets | Ardelyx and Kyowa Kirin announced the expansion of their partnership with a new agreement. The … read morecompanies have established a two-year research collaboration, whereby Ardelyx will execute a research plan, in which Kyowa Kirin will also join, to advance two of Ardelyx's ongoing research programs focused on the identification and design of compounds to two undisclosed targets. Kyowa Kirin will pay Ardelyx $10 million ($5 million a year for two years) to support the ongoing research. Following the end of the research period, Kyowa Kirin will have the option to license any candidates nominated by the companies for further development and commercialization in certain specified territories, with additional commitments payable to Ardelyx of up to $10.5 million in upfronts and up to $500 million in development and sales milestones. The research collaboration will be governed by a joint research committee. Additional terms were not disclosed. [collapse expanded text] |
NovImmune, Swedish Orphan Biovitrum | Jun 2019 | 516.4 | Asset purchase agreement for emapalumab and related assets | Swedish Orphan Biovitrum has signed an agreement to acquire, from Novimmune’s shareholders, a newly … read moreestablished company owning emapalumab and related assets, giving Sobi access to world-class R&D capabilities in the field of Immunology. The acquisition means that the previously announced exclusive licence agreement with Novimmune will be superseded. Through the acquisition of emapalumab, Sobi gains access to: All assets relating to emapalumab including intellectual property, patent rights, data and know-how All relevant and highly experienced employees involved in the clinical and biopharmaceutical development of emapalumab Options for the shared financial rights to NI-1701 and NI-1801, two product candidates in the field of immuno-oncology A priority review voucher within the US Food & Drug Administration’s priority review programme, which offers companies investing in orphan drugs a cost reduction for the application fee for future products and shortens the review period. The voucher can be used or sold by Sobi. The consideration for the acquisition is CHF 515 M (SEK 4,897 M), of which CHF 400 M was previously committed in the exclusive licence agreement for emapalumab. The acquisition is expected to be earnings neutral in 2019 and completed during Q3 2019, subject to customary closing conditions. [collapse expanded text] |
Abbvie, Harpoon Therapeutics | Nov 2019 | 510 | Collaboration, option and licensing agreement for HPN217 | September 2023 Harpoon Therapeutics announced that AbbVie has notified the company that it will … read morenot exercise the exclusive license option of the parties’ Development and Option Agreement in connection with Harpoon’s HPN217 program, which targets B cell maturation antigen, or BCMA. The Agreement, which will terminate effective October 12, 2023, granted AbbVie an option to a worldwide, exclusive license to the HPN217 program. The program has been and will remain exclusively owned by Harpoon, and the company plans to complete the ongoing Phase 1 clinical trial with data to support the next phase of development. November 2019 Harpoon Therapeutics and AbbVie announced an exclusive worldwide option and license transaction for HPN217, Harpoon’s B cell maturation antigen (BCMA)-targeting Tri-specific T cell Activating Construct (TriTAC), and an expansion of their existing discovery collaboration for up to six additional targets. These agreements build upon the discovery collaboration established by the two companies in October 2017 and are expected to advance and broaden the use of Harpoon’s proprietary TriTAC platform. The TriTAC platform produces novel T cell engagers targeting both solid tumors and hematologic malignancies. Harpoon granted to AbbVie an option to license worldwide exclusive rights to HPN217. Harpoon will be responsible for development of HPN217 through Phase 1/2 clinical trials. Upon exercise of the option, AbbVie will conduct all future clinical development, manufacturing and commercialization activities. AbbVie may exercise its option to license HPN217 after completion of the Phase 1/2 clinical trial. The license and option agreement represents a potential transaction value of up to $510 million in upfront, option and milestone payments, plus royalties on global commercial sales. Under the terms of the expanded discovery collaboration agreement, AbbVie will receive worldwide exclusive rights to develop and commercialize two new TriTAC molecules engineered for two selected targets. AbbVie has the option to select up to four additional targets for a total of up to six new targets. For each selected target under the Amended Discovery agreement, Harpoon is eligible to receive up to $310 million in upfront and potential development, regulatory and commercial milestone payments, plus royalties on global commercial sales. Consistent with the existing discovery collaboration agreement, Harpoon and AbbVie will conduct certain initial research and discovery activities for each designated target, after which AbbVie will be solely responsible for further development and commercialization efforts. [collapse expanded text] |
HemoShear, Horizon Pharma plc | Jan 2019 | 500 | Collaboration agreement for drug discovery in gout | September 2022 HemoShear Therapeutics has earned a milestone payment for the advancement of … read morepotential lead product candidates against a second target for the treatment of gout under its collaboration with Horizon Therapeutics. This milestone marks the fifth payment that HemoShear has earned in accordance with the Horizon exclusive drug discovery agreement established in January 2019. HemoShear received an upfront payment and R&D funding, and Horizon received exclusive access to HemoShear's proprietary disease modeling platform, to discover potential new therapeutics for gout. Successful development and commercialization of multiple therapies by Horizon would make HemoShear eligible to receive milestone payments of potentially more than $500 million plus royalties. Further financial terms were not disclosed. September 2021 HemoShear Therapeutics has earned a milestone payment for the advancement of potential lead product candidates for the treatment of gout under its collaboration with Horizon Therapeutics. This milestone marks the fourth payment that HemoShear has earned, following previous payments for the identification and validation of two novel gout drug targets in accordance with the Horizon exclusive drug discovery agreement established in January 2019. HemoShear received an upfront payment and R&D funding, and Horizon received exclusive access to HemoShear's proprietary disease modeling platform, to discover new therapeutics for gout. Successful development and commercialization of multiple therapies by Horizon will make HemoShear eligible to receive milestone payments of potentially more than $500 million plus royalties. Further financial terms were not disclosed. April 2021 HemoShear Therapeutics has identified a second drug target for the treatment of gout under its collaboration with Horizon Therapeutics that was established in January 2019. Leveraging its proprietary REVEAL-Tx disease modeling platform, HemoShear has earned two milestone payments to date in accordance with the Horizon exclusive drug discovery agreement. Each milestone acknowledges the validation of a novel drug target and its advancement to a subsequent stage in Horizon's early discovery pipeline. July 2020 HemoShear Therapeutics has achieved a research milestone in its collaboration with Horizon Therapeutics to discover and develop novel therapeutics for gout. In fewer than 18 months, HemoShear's team has made significant progress and the company will receive an undisclosed milestone payment in accordance with the agreement with Horizon, which was executed in January 2019. January 2019 Horizon Pharma and HemoShear Therapeutics announced a collaboration to discover and develop novel therapeutics for gout. HemoShear will receive upfront payments and R&D funding, and Horizon will receive exclusive access to HemoShear’s proprietary disease modeling platform to discover new therapeutics for gout. Successful development and commercialization of multiple therapies by Horizon will make HemoShear eligible to receive milestone payments of potentially more than $500 million plus royalties. Further financial terms were not disclosed. [collapse expanded text] |
Top partnering deals of 2018 valued at over US$500m.
Partners | Date | Value, US$m | Subject | Termsheet |
---|---|---|---|---|
GSK, Novartis | Mar 2018 | 13000 | Asset purchase agreement for consumer healthcare business | GlaxoSmithKline has reached an agreement with Novartis for the buyout of Novartis’ 36.5% stake in … read moretheir Consumer Healthcare Joint Venture for $13 billion (£9.2 billion). The Consumer Healthcare Joint Venture was formed as part of the three-part transaction between GSK and Novartis which was approved by shareholders in 2014. Last year, GSK’s Consumer Healthcare business reported sales of £7.8 billion and since 2015 sales have grown 4% on a 3 year CAGR basis (2015-2017 at 2014 CER) with an overall improvement in operating margins from 11.3% in 2015 to 17.7% in 2017. Under the terms of the original transaction, Novartis has the right, exercisable from 2 March 2018 to 2 March 2035 to require GSK to purchase its stake (or specified tranches of it) in the Joint Venture. This put option, in both size and possible timing, creates inherent uncertainty for the Group’s capital planning. The new agreement to buy-out Novartis’ stake removes this uncertainty and improves the Group’s ability to plan allocation of capital to its other priorities. [collapse expanded text] |
Gilead Sciences, Tango Therapeutics | Oct 2018 | 6345 | Collaboration agreement for immuno-oncology treatments for patients with cancer | Key Deal Terms SummaryAgreement Overview
Financial Terms
Development & Commercialization Plans
Strategic Impact
Overall SummaryGilead Sciences and Tango Therapeutics have expanded their strategic oncology collaboration to accelerate the discovery and development of immune evasion therapies. The agreement increases target scope from five to fifteen, with Gilead securing worldwide option rights for seven years. Tango retains co-development rights for up to five programs in the U.S. The financial structure includes $125 million upfront, a $20 million equity investment, and up to $410 million per program in milestone payments. The collaboration strengthens Gilead’s immuno-oncology strategy while allowing Tango to further develop its proprietary discovery platform. [collapse expanded text] |
Eisai, Merck and Co | Mar 2018 | 5760 | Co-development and co-promotion agreement for LENVIMA (lenvatinib mesylate) | Eisai and Merck have agreed upon a strategic collaboration for the worldwide co-development and co- … read morecommercialization of LENVIMA (lenvatinib mesylate), an orally available tyrosine kinase inhibitor discovered by Eisai. Eisai and Merck will develop and commercialize LENVIMA jointly, both as monotherapy and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab). Eisai will book LENVIMA product sales globally, as monotherapy and in combination, and Merck and Eisai will share gross profits equally. Per the agreement, the companies will also jointly initiate new clinical studies evaluating the LENVIMA/KEYTRUDA combination to support 11 potential indications in six types of cancer (endometrial cancer, non-small cell lung cancer, hepatocellular carcinoma, head and neck cancer, bladder cancer and melanoma), as well as a basket trial targeting multiple cancer types. Gross profits from LENVIMA product sales globally will be shared equally by Eisai and Merck. Expenses incurred during co-development, including for studies evaluating LENVIMA as monotherapy, will be shared equally by the two companies. Merck will pay Eisai an upfront payment of $300 million U.S. dollars and up to $650 million U.S. dollars for certain option rights through 2020 (Eisai’s financial year: fiscal year ended March 2021), as well as $450 million U.S. dollars as reimbursement for research and development expenses. In addition, Eisai is eligible to receive up to $385 million U.S. dollars associated with the achievement of certain clinical and regulatory milestones and a maximum of up to $3.97 billion U.S. dollars for the achievement of milestones associated with sales of LENVIMA. Assuming the achievement of all development and commercial goals for all indications, the total amount of upfront, option and regulatory and sales milestone payments has the potential to reach up to $5.76 billion U.S. dollars. [collapse expanded text] |
Affimed Therapeutics, Genentech | Aug 2018 | 5096 | Collaboration agreement for NK Cell engager-based immunotherapeutics for multiple cancer targets | Affimed has entered into a strategic collaboration agreement with Genentech to develop and … read morecommercialize novel NK cell engager-based immunotherapeutics to treat multiple cancers. Affimed will apply its proprietary Redirected Optimized Cell Killing (ROCK®) platform, which enables the generation of both NK cell and T cell-engaging antibodies, to discover and advance innate immune cell engager-based immunotherapeutics of interest to Genentech. The collaboration includes candidate products generated from Affimed's ROCK platform and multiple undisclosed solid and hematologic tumor targets. Affimed and Genentech will collaborate on the discovery, early research and late-stage research phases. Genentech will be responsible for clinical development and commercialization worldwide. Affimed will receive $96 million in an initial upfront payment and other near-term committed funding. Affimed may be eligible to receive up to an additional $5.0 billion over time, including payments upon achievement of specified development, regulatory and commercial milestones, and royalties on sales. [collapse expanded text] |
Dicerna Pharmaceuticals, Eli Lilly | Oct 2018 | 3700 | Collaboration and licensing agreement for GalXC RNAi technology platform to progress new drug targets | November 2021 Dicerna Pharmaceuticals announced that Eli Lilly has declared proof of principle … read morefor the first two targets in the companies’ exclusive relationship in neurodegeneration and pain, under the companies’ global research and licensing collaboration. This milestone triggers two single-digit multimillion-dollar milestone payments to Dicerna, which the Company expects to receive in the fourth quarter of 2021. October 2018 Eli Lilly and Dicerna Pharmaceuticals announced a global licensing and research collaboration focused on the discovery, development and commercialization of potential new medicines in the areas of cardio-metabolic disease, neurodegeneration and pain. The companies will utilize Dicerna's proprietary GalXC RNAi technology platform to progress new drug targets toward clinical development and commercialization. In addition, the partners will collaborate to move beyond the current technical paradigm in order to generate next-generation oligonucleotide therapeutic agents. Dicerna will receive an upfront payment of $100 million, as well as an equity investment of $100 million at a premium. Dicerna is also eligible to receive up to approximately $350 million per target in development and commercialization milestones, as well as tiered royalties ranging from the mid-single to low-double digits on product sales. Dicerna will work exclusively with Lilly in the neurodegeneration and pain fields, and on select targets in cardio-metabolic diseases. The two companies anticipate collaborating on more than ten targets. [collapse expanded text] |
Bristol-Myers Squibb, Nektar Therapeutics | Feb 2018 | 3630 | Collaboration and licensing agreement for NKTR-214 | Parties Involved
… read more Collaboration ScopeThe partnership centers on joint development and commercialization of bempegaldesleukin (bempeg/NKTR-214), a CD122-preferential IL-2 pathway agonist, in combination with Opdivo (nivolumab) and Opdivo plus Yervoy (ipilimumab). Initially launched in February 2018, the collaboration was amended in January 2020 to expand the scope of registrational trials. The programs now include:- Three original registrational trials in metastatic melanoma, cisplatin-ineligible metastatic urothelial cancer, and metastatic RCC- Two additional registrational trials in adjuvant melanoma and muscle-invasive bladder cancer- A Phase 1/2 study evaluating bempeg + nivolumab + axitinib in first-line RCC- A separate BMS-funded Phase 1/2 study in first-line NSCLC Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryNektar and Bristol-Myers Squibb entered a strategic collaboration in 2018 to co-develop and commercialize bempegaldesleukin (NKTR-214) in combination with Opdivo and Yervoy, with a major amendment in 2020 to expand registrational efforts. BMS committed a total $1.85B upfront, with up to $1.78B in milestones, and the partners will share profits and costs with Nektar retaining major commercial rights and economics for NKTR-214. The program spans more than 20 indications and supports development in high-unmet need oncology settings. [collapse expanded text] |
Kite Pharma, Sangamo Therapeutics | Feb 2018 | 3160 | Collaboration agreement for zinc finger nuclease (ZFN) technology platform for next-generation ex vivo cell therapies in oncology | Kite and Sangamo Therapeutics have entered into a worldwide collaboration using Sangamo's zinc … read morefinger nuclease (ZFN) technology platform for the development of next-generation ex vivo cell therapies in oncology. Kite will use Sangamo's ZFN technology to modify genes to develop next-generation cell therapies for autologous and allogeneic use in treating different cancers. Allogeneic cell therapies from healthy donor cells or from renewable stem cells would provide a potential treatment option that can be accessed directly within the oncology infusion center, thus reducing the time to infusion for patients. Sangamo will receive an upfront payment of $150 million and is eligible to receive up to $3.01 billion in potential payments, aggregated across 10 or more products utilizing Sangamo's technology, based on the achievement of certain research, development, regulatory and successful commercialization milestones. Sangamo would also receive tiered royalties on sales of potential future products resulting from the collaboration. Kite will be responsible for all development, manufacturing and commercialization of products under the collaboration, and will be responsible for agreed upon expenses incurred by Sangamo. [collapse expanded text] |
Cellectis, Pfizer | Jun 2018 | 2855 | Collaboration agreement for Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in oncology | Pfizer and Cellectis have entered into a global strategic collaboration to develop Chimeric Antigen … read moreReceptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets. Cellectis’ CAR-T platform technology provides a proprietary, allogeneic approach (utilizing engineered T-cells from a single donor for use in multiple patients) to developing CAR-T therapies that is distinct from other autologous approaches (engineering a patient’s own T-cells to target tumor cells). Pfizer has exclusive rights to pursue development and commercialization of CAR-T therapies, in the field of oncology, directed at a total of fifteen targets selected by Pfizer. Both companies will work together on preclinical research and Pfizer will be responsible for the development and potential commercialization of any CAR-T therapies for the Pfizer-selected targets. In addition, the agreement provides for a total of twelve targets selected by Cellectis. Both companies will work together on preclinical research on four Cellectis-selected targets and Cellectis will work independently on eight additional targets. Cellectis will be responsible for clinical development and commercialization of CAR-T therapeutics for the Cellectis-selected targets. Pfizer has right of first refusal to the four Cellectis-selected targets. Cellectis will receive an upfront payment of $80 million, as well as funding for research and development costs associated with Pfizer-selected targets and the four Cellectis-selected targets within the collaboration. Cellectis is eligible to receive development, regulatory and commercial milestone payments of up to $185 million per Pfizer product. Cellectis is also eligible to receive tiered royalties on net sales of any products that are commercialized by Pfizer. Additionally, Pfizer will be entering into an equity agreement to purchase approximately 10% of the Cellectis capital through newly issued shares at 9.25 Euro per share, pending Cellectis shareholder approval. Approval by two-thirds of the votes cast by voting Cellectis shareholders is required for the issuance. Shareholders of Cellectis representing 52.8% of its voting rights have already undertaken to vote in favor of the issuance. In the event the sale of equity is not approved by the Cellectis shareholders, Pfizer has the option to terminate the collaboration agreement. [collapse expanded text] |
Genmab, Immatics Biotechnologies | Jul 2018 | 2804 | Collaboration, licensing, option and co-promotion agreement for bispecific immunotherapies to target multiple cancer indications | Genmab has entered into a research collaboration and exclusive license agreement with privately … read moreowned Immatics Biotechnologies to discover and develop next-generation bispecific immunotherapies to target multiple cancer indications. The deal strengthens Genmab’s position in immuno-oncology by combining Genmab's proprietary technologies and antibody know-how with Immatics' XPRESIDENT targets and T-cell receptor (TCR) capabilities. Genmab will receive an exclusive license to three proprietary targets from Immatics, with an option to license up to two additional targets at predetermined economics. The companies will conduct joint research, funded by Genmab, on multiple antibody and/or TCR-based bispecific therapeutic product concepts. Genmab may elect to progress any resulting product candidates, and will be responsible for development, manufacturing and worldwide commercialization. For any products that are commercialized by Genmab, Immatics will have an option to limited co-promotion efforts in selected countries in the EU. Genmab will pay Immatics an upfront fee of USD 54 million and Immatics is eligible to receive up to USD 550 million in development, regulatory and commercial milestone payments for each product, as well as tiered royalties on net sales. [collapse expanded text] |
Ethicon Endo-Surgery, Fortive, Johnson & Johnson | Jun 2018 | 2800 | Asset purchase agreement for Advanced Sterilization Products (ASP) business | Johnson & Johnson has received a binding offer from Fortive to acquire its Advanced … read moreSterilization Products (ASP) business, a division of Ethicon, for an aggregate value of approximately $2.8 billion, consisting of $2.7 billion of cash proceeds from Fortive and $0.1 billion of retained net receivables. ASP is a global leader in innovative infection prevention solutions with 2017 net revenue of approximately $775 million. [collapse expanded text] |
Les Laboratoires Servier, Shire Pharmaceuticals | Apr 2018 | 2400 | Asset purchase agreement for oncology business | Shire has entered into a definitive agreement with Servier to sell its Oncology business for $2.4 … read morebillion. Shire's Oncology business includes in-market products ONCASPAR (pegaspargase), a component of multi-agent treatment for acute lymphoblastic leukemia (ALL) and ex-U.S. rights to ONIVYDE (irinotecan pegylated liposomal formulation), a component of multi-agent treatment for metastatic pancreatic cancer post gemcitabine-based therapy. The portfolio also includes Calaspargase Pegol (Cal-PEG), which is under FDA review for the treatment of ALL and early stage immuno-oncology pipeline collaborations. Servier has agreed to acquire Shire's Oncology business for a total consideration of $2.4 billion, in cash, upon completion. In 2017, the Oncology business generated revenues of $262 million. The total consideration represents a revenue multiple of 9.2 times 2017 revenues. The transaction covers the transfer of Shire's Oncology business including in-market products ONCASPAR (pegaspargase), a component of multi-agent treatment for acute lymphoblastic leukemia (ALL) and ex-U.S. rights to ONIVYDE (irinotecan pegylated liposomal formulation), a component of multi-agent treatment for metastatic pancreatic cancer post gemcitabine-based therapy. The portfolio also includes Calaspargase Pegol (Cal-PEG), which is under FDA review for the treatment of ALL, and early stage immuno-oncology pipeline collaborations. The gross assets that are the subject of the transaction are approximately $1.6 billion and the profits attributable to the assets being transferred are approximately $140 million, excluding depreciation, amortization and other direct and indirect costs. [collapse expanded text] |
Takeda Pharmaceutical, WAVE Life Sciences | Feb 2018 | 2290 | Collaboration and option agreement for antisense oligonucleotides for genetically-defined neurological diseases | October 2024 Wave Life Sciences were notified by Takeda Pharmaceutical that Takeda did not … read moreintend to exercise and therefore elected to terminate its option for the Huntingtin target under the parties’ Collaboration and License Agreement dated February 19, 2018 HTT was last active collaboration target under Collaboration Agreement, the Collaboration Agreement expired with immediate effect Takeda has paid Wave approximately $260 million October 2021 WAVE Life Sciences announced an amendment to its ongoing collaboration with Takeda Pharmaceutical which immediately discontinues the discovery research component of the collaboration that provided Takeda with the right to license multiple preclinical programs for central nervous system indications over a four-year research term. Takeda will pay Wave $22.5 million for collaboration-related research and preclinical expenses. The amendment announced today allows Wave to advance CNS programs independently or enter partnerships in the CNS field outside of the three specified targets, which are part of the ongoing late-stage collaboration between the companies. February 2018 Takeda Pharmaceutical has entered into a research, development and commercial collaboration and multi-program option agreement with Wave Life Sciences to develop antisense oligonucleotides for genetically-defined neurological diseases. This partnership supports Takeda’s externalization strategy, which focuses on collaborations that complement its internal pipeline of programs, and represents the next generation of innovative therapies to treat diseases with no current treatment options. The first component of the collaboration with Wave will focus on programs targeting Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS) (commonly referred to as Lou Gehrig’s disease), frontotemporal dementia (FTD) and spinocerebellar ataxia type 3 (SCA3). Wave is developing oligonucleotide therapeutics to target diseases that have been historically difficult to treat with small molecules or biologics. Their molecules are designed to reduce the expression of disease-promoting proteins or to transform the production of dysfunctional mutant proteins into the production of functional proteins, with the potential of treating the targeted disease. The first component of this collaboration will investigate the following potential therapies with the option to co-develop and co-commercialize after demonstration of clinical proof of mechanism: WVE-120101 and WVE-120102, which selectively target mutant huntingtin and are currently in Phase 1b/2a clinical trials for the treatment of HD WVE-3972-01, which targets C9ORF72 and is expected to be evaluated in clinical studies for the treatment of ALS and FTD beginning in Q4 2018 Program targeting ATXN3 for the treatment of SCA3 The second component of the collaboration provides Takeda with the rights to exclusively license multiple preclinical programs targeting other neurological disorders including Alzheimer’s disease and Parkinson’s disease. At any one time during a four-year term, the companies may collaborate on up to six preclinical programs. Under terms of the two-component agreement, Takeda will make an initial payment of $110 million to Wave and purchase $60 million of Wave’s ordinary shares at $54.70 per share. Takeda will also fund at least $60 million of Wave research over a four-year period to advance multiple preclinical targets selected by and licensed to Takeda. The first component of the agreement grants Takeda with the option to co-develop and co-commercialize the following nucleic acid investigational therapies upon Wave demonstrating proof of mechanism in initial clinical studies: WVE-120101 and WVE-120102, which selectively target the mutant allele of the huntingtin (HTT) gene and are currently in Phase 1b/2a clinical trials for the treatment of HD WVE-3972-01, which targets the C9ORF72 gene and is expected to be evaluated in clinical studies for the treatment of ALS and FTD beginning in Q4 2018Program targeting the ATXN3 gene for the treatment of SCA3 Upon opt-in by Takeda on any individual program, Wave will receive an opt-in payment and will lead manufacturing and joint clinical co-development activities; Takeda will lead joint co-commercial activities in the United States and all commercial activities outside of the United States. Global costs and potential profits will be shared 50:50 and Wave will be eligible to receive development and commercial milestone payments. The second component of the strategic collaboration provides Takeda with the right to license multiple preclinical programs for CNS indications, including Alzheimer’s disease and Parkinson’s disease. During a four-year term, the companies may collaborate on up to six preclinical targets at any one time. Takeda will fund at least $60 million of Wave’s preclinical activities and reimburse Wave for agreed-upon additional expenses. Assuming Takeda advances six programs that achieve regulatory approval and commercial milestones, Wave will be eligible to receive more than $2 billion in cash milestone payments, of which more than $1 billion would be in precommercial milestone payments. Wave is also eligible to receive tiered high single-digit to mid-teen royalty payments on global commercial sales of each licensed program. [collapse expanded text] |
AstraZeneca, Swedish Orphan Biovitrum | Nov 2018 | 2255 | Licensing agreement for Synagis (palivizumab) and MEDI8897 | April 2023 Sanofi has simplified its contractual arrangements relating to the development and … read morecommercialization of Beyfortus (nirsevimab) in the United States. Sobi will terminate its participation agreement with AstraZeneca, and Sanofi and AstraZeneca will update the Collaboration Agreement so that Sanofi has full commercial control of nirsevimab in the US. Sanofi has simultaneously entered into a direct royalty agreement with Sobi to share a portion of U.S. net sales from nirsevimab. November 2018 Swedish Orphan Biovitrum has entered into agreements to acquire the perpetual rights to Synagis (palivizumab) in the US from AstraZeneca and to participate in 50 per cent of the future earnings of the candidate drug MEDI8897 in the US. The total upfront consideration corresponds to USD 1,500 M (SEK 13.6 B[1]), consisting of USD 1,000 M (SEK 9.1 B) in cash and USD 500 M (SEK 4.5 B) equivalent in newly issued Sobi shares. In addition, deferred and contingent payments depending on certain conditions may be payable, in amounts as further set out below. The upfront consideration payable at closing of the acquisition will be USD 1,500 M (SEK 13.6 B) consisting of cash and newly issued Sobi common shares. Sobi will also pay USD 20 M (SEK 181 M) in cash, per year, for the three years 2019-2021 as consideration for MEDI8897. Sobi may pay up to USD 470 M (SEK 4.3 B) for Synagis sales-related milestones from 2026 onwards, plus, USD 175 M (SEK 1.6 B) following submission of the Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for MEDI8897. The agreement also includes potential net payments of approximately USD 110 M (SEK 1.0 B) on achievement of other MEDI8897 profit and development-related milestones. MEDI8897 associated payments, if payable, are expected from 2023 onwards. Following completion of the acquisition, AstraZeneca will hold 8.1 per cent of the total shares and votes in Sobi. AstraZeneca has undertaken not to sell the shares received as consideration for a period of 12 months, and not to acquire additional shares in Sobi for a period of 18 months, following the closing date of the acquisition. The upfront cash consideration payable will amount to USD 1,000 M (SEK 9.1 B) and the share consideration will consist of 24,193,092 newly issued Sobi shares, corresponding to a value of USD 500 M (SEK 4.5 B) based on the daily volume weighted average price paid for the Sobi common share on Nasdaq Stockholm during a period of five trading days immediately prior to entering into the agreement concerning the acquisition. The board of directors of Sobi will at closing of the acquisition exercise the authorisation granted by the Annual General Meeting in May 2018 to issue the Sobi shares. [collapse expanded text] |
Sanofi-Pasteur, Translate Bio | Jun 2018 | 2250 | Collaboration and licensing agreement for mRNA vaccines | June 2020 Sanofi Pasteur and Translate Bio have agreed to expand their existing 2018 … read morecollaboration and license agreement to develop mRNA vaccines for infectious diseases. The expansion of this agreement will further unite Translate Bio’s expertise and knowledge from more than 10 years of mRNA research and development with Sanofi’s leadership in vaccine research and development. Translate Bio will receive a total upfront payment of $425 million, consisting of a $300 million cash payment and a private placement common stock investment of $125 million at $25.59 per share representing a 50 percent premium to the 20-day moving average share price prior to signing. Translate Bio will also be eligible for potential future milestones and other payments up to $1.9 billion, including $450 million of milestones under the 2018 agreement. Of these potential milestones and other payments, approximately $360 million are anticipated over the next several years, inclusive of COVID-19 vaccine development milestones. Translate Bio is also eligible to receive tiered royalty payments based upon worldwide sales of the developed vaccines. Sanofi Pasteur will pay for all costs during the collaboration term. Sanofi Pasteur will receive exclusive worldwide rights for infectious disease vaccines. Translate Bio is using its mRNA platform to discover, design and manufacture vaccine candidates and Sanofi Pasteur is providing its deep vaccine expertise to advance vaccine candidates into and through further development. Translate Bio will also transfer technology and processes to allow Sanofi Pasteur to develop and manufacture mRNA vaccines for infectious diseases. The teams are currently evaluating multiple COVID-19 vaccine candidates in vivo for immunogenicity and neutralizing antibody activity to support lead candidate selection and the companies have the goal of initiating a first-in-human clinical trial in the fourth quarter of 2020. The companies are also advancing an mRNA vaccine development candidate against influenza through preclinical studies with clinical trial initiation anticipated in mid-year 2021. Additional mRNA vaccine development programs under the collaboration include another viral pathogen and a bacterial pathogen. June 2018 Translate Bio announced a multi-year research and development collaboration and exclusive licensing agreement with Sanofi Pasteur to develop mRNA vaccines for up to five undisclosed infectious disease pathogens. Translate Bio and Sanofi Pasteur will jointly conduct research and development activities to advance mRNA vaccines during an initial three-year research term. Sanofi Pasteur will make an upfront payment of $45 million to Translate Bio. Translate Bio is eligible to receive up to $805 million in payments, which also includes certain development, regulatory and sales-related milestones across several vaccine targets, and option exercise fees if Sanofi Pasteur exercises its option related to development of vaccines for additional pathogens. Translate Bio is also eligible to receive tiered royalty payments associated with worldwide sales of the developed vaccines. Sanofi Pasteur will pay for all costs during the research term and will receive exclusive worldwide commercialization rights. Translate Bio will be responsible for clinical manufacture and will be entitled to additional payments under a separate supply agreement to be established. [collapse expanded text] |
AC Immune, Eli Lilly | Dec 2018 | 1905.2 | Collaboration and licensing agreement for Morphomer tau aggregation inhibitors for Alzheimer’s disease and other neurodegenerative diseases | AC Immune and Eli Lilly have signed a license and collaboration agreement to research and develop … read moretau aggregation inhibitor small molecules for the potential treatment of Alzheimer’s disease (AD) and other neurodegenerative diseases. The collaboration combines AC Immune’s proprietary Morphomer platform technology with Lilly’s clinical development expertise and commercial capabilities in central nervous system disorders. The collaboration will focus primarily on AC Immune’s lead molecule, ACI-3024, which has demonstrated tau aggregation inhibition in preclinical models. AC Immune will receive an upfront payment of CHF80 million as well as $50 million in exchange for a note, convertible to equity at a premium. AC Immune is also eligible to receive CHF60 million in potential near-term development milestones, as well as other potential development, regulatory and commercial milestones up to approximately CHF1.7 billion, and tiered royalty payments in the low double digits. AC Immune will conduct the initial Phase 1 development of the Morphomer tau aggregation inhibitors, while Lilly will fund and conduct further clinical development. Lilly will receive worldwide commercialization rights for the tau aggregation inhibitors in the area of Alzheimer’s disease. AC Immune has retained certain development rights in orphan indications and co-development and co-promotion options in certain indications outside AD. [collapse expanded text] |
Arrowhead Pharmaceuticals, Janssen Pharmaceuticals | Oct 2018 | 1900 | Collaboration agreement for RNAi therapeutics directed against additional targets using Targeted RNAi Molecule (TRiM) platform | September 2021 Arrowhead Pharmaceuticals earned a $10 million milestone payment from Janssen … read morePharmaceuticals. The milestone payment was earned after Janssen dosed the fifth patient in a Phase 1 clinical study of ARO-JNJ1, an investigational RNAi therapeutic candidate which utilizes Arrowhead’s proprietary Targeted RNAi Molecule (TRiM™) platform. October 2018 Arrowhead entered into a research collaboration and option agreement with Janssen to potentially collaborate for up to three additional RNA interference (RNAi) therapeutics against new targets to be selected by Janssen. Arrowhead is also eligible to receive approximately $1.9 billion in option and milestone payments for the collaboration agreement related to up to three additional targets. Arrowhead is further eligible to receive tiered royalties up to mid teens on product sales. October 2018 Janssen and Arrowhead agreed to a research collaboration to develop RNAi therapeutics directed against additional targets using Arrowhead's proprietary Targeted RNAi Molecule (TRiM) platform. If Janssen exercises its option for such RNAi therapeutics, Arrowhead will be eligible to receive additional payments. [collapse expanded text] |
Akcea Therapeutics, Ionis Pharmaceuticals | Mar 2018 | 1880 | Development and licensing agreement for TTR technology | Ionis Pharmaceuticals and Akcea Therapeutics announced an exclusive, worldwide license by Ionis to … read moreAkcea for inotersen and AKCEA-TTR-LRx, formerly IONIS-TTR-LRx, in a transaction potentially worth up to approximately $1.7 billion to Ionis plus profit sharing payments. This transaction strengthens the companies' ability to successfully launch inotersen upon approval by leveraging the commercial preparations carried out by Ionis along with Akcea's commercial infrastructure and capabilities. The newly combined Akcea team is preparing to launch inotersen in the U.S. and EU following planned approvals in mid-2018 to treat people with hereditary transthyretin amyloidosis, or hATTR, a systemic, progressive and fatal disease. The companies are also developing AKCEA-TTR-LRx for hereditary and wild-type forms of ATTR. AKCEA-TTR-LRx is planned to enter clinical development in 2018. As part of the collaboration, the inotersen commercial team is joining Akcea, enabling a seamless and rapid transition in the ongoing launch preparations for inotersen. Sarah Boyce, currently Ionis' chief business officer, will join Akcea as president and take a seat on the Akcea board of directors upon closing. Akcea will pay Ionis an upfront licensing fee of $150 million, payable in shares of common stock priced by reference to a recent trading average. Akcea will have rights to commercialize inotersen and AKCEA-TTR-LRx globally. To support commercialization of inotersen, Ionis will purchase $200 million of Akcea common stock priced by reference to a recent trading average. Upon closing this transaction, Ionis' ownership in Akcea will increase by 7%, from 68% to 75%, totaling 64,114,545 shares. Regulatory approval of inotersen and AKCEA-TTR-LRx in the U.S. and EU will trigger milestone payments to Ionis of $50 million and $40 million, respectively, with additional milestone payments due upon approval of both programs in various other geographies. The license fee and initial milestone payments may be payable in Akcea common stock at fair market value. Commercial profits and losses from inotersen will be split 60% to Ionis and 40% to Akcea until the first commercial sales of AKCEA-TTR-LRx, after which the profits and losses will be shared 50/50. The costs of the development of AKCEA-TTR-LRx and the profits from its commercialization will be shared 50/50. The license for the two drugs also includes various sales milestone payments of up to nearly $1.3 billion. [collapse expanded text] |
Arrowhead Pharmaceuticals, Janssen Pharmaceuticals | Oct 2018 | 1850 | Licensing agreement for ARO-HBV | February 2023 Arrowhead Pharmaceuticals has gained rights to ARO-PNPLA3, formerly called JNJ- … read more75220795, which was part of a 2018 research collaboration and option agreement between Arrowhead and Janssen Pharmaceuticals. ARO-PNPLA3 is an investigational RNA interference therapeutic developed using Arrowhead’s proprietary TRiM platform and designed to reduce liver expression of patatin-like phospholipase domain containing 3 (PNPLA3) as a potential treatment for patients with non-alcoholic steatohepatitis. ARO-PNPLA3 is currently in a Phase 1 clinical study. PNPLA3 has strong genetic and preclinical validation as a driver of fat accumulation and damage in the livers of patients who carry the common I148M mutation. October 2018 Arrowhead Pharmaceuticals entered into a license and collaboration agreement with Janssen Pharmaceuticals to develop and commercialize ARO-HBV. Arrowhead will receive $175 million as an upfront payment. Johnson & Johnson Innovation – JJDC will make a $75 million equity investment in Arrowhead at a price of $23.00 per share of Arrowhead common stock. Arrowhead is eligible to receive up to approximately $1.6 billion in milestone payments for the HBV license agreement, including a $50 million milestone payment linked to a Phase 2 study. Arrowhead is further eligible to receive tiered royalties up to mid teens on product sales. October 2018 Janssen Pharmaceuticals has entered into an agreement with Arrowhead Pharmaceuticals for an exclusive, worldwide license to develop and commercialize ARO-HBV, a Phase 1/2 subcutaneous, ribonucleic acid interference (RNAi) therapy candidate being investigated for the treatment of chronic hepatitis B viral infection. Arrowhead will complete the ongoing Phase 1/2 clinical trial for ARO-HBV, a next-generation RNAi therapy candidate which is designed to silence HBV gene products by specifically targeting two regions of the HBV genome. Janssen will lead the clinical development from Phase 2b onwards. Arrowhead will receive an initial upfront payment, potential development and commercial milestone payments and potential future royalties. Separately, Johnson & Johnson Innovation - JJDC, Inc., will make an equity investment in Arrowhead. [collapse expanded text] |
Agenus Bio, Gilead Sciences | Dec 2018 | 1850 | Collaboration agreement for immuno-oncology therapies | April 2022 Agenus announced receipt of a $5M clinical milestone payment for AGEN2373 ( … read moreconditionally active CD137 agonist). AGEN2373 is being evaluated in a Phase 1b combination study with botensilimab (Fc-enhanced anti-CTLA-4), in melanoma patients who had relapsed on, or were refractory to, prior anti-PD-1 therapy. December 2018 Gilead Sciences and Agenus have entered into an immuno-oncology (I-O) partnership focused on the development and commercialization of up to five novel immuno-oncology therapies. Agenus will receive $150 million upon closing, which includes a $120 million upfront cash payment and a $30 million equity investment. The agreement also includes approximately $1.7 billion in potential future fees and milestones. Gilead will receive worldwide exclusive rights to AGEN1423, which has an estimated IND filing by year-end 2018. Gilead will also receive the exclusive option to license two additional programs: AGEN1223 and AGEN2373. Agenus has filed the IND for AGEN1223 and has a planned IND filing for AGEN2373 in the first half of 2019. Agenus will be responsible for developing the option programs up to the option decision points, at which time Gilead may acquire exclusive rights to the programs on option exercise. For one of the option programs, Agenus will have the right to opt-in to shared development and commercialization in the U.S. Gilead will also receive right of first negotiation for two additional, undisclosed preclinical programs. [collapse expanded text] |
Cilag AG, argenx | Dec 2018 | 1800 | Collaboration and licensing agreement for cusatuzumab (ARGX-110) | June 2021 Cilag announced its decision not to continue the collaboration and license agreement … read morewith argenx for cusatuzumab, an investigational therapeutic antibody that targets CD70. The decision is based upon Janssen's review of all available cusatuzumab data and in consideration of the evolving standard of care for the treatment of acute myeloid leukemia (AML). Final results from Janssen's clinical studies of cusatuzumab will be presented in the future. Janssen will work with argenx to transition the cusatuzumab program back to argenx. Patients currently enrolled in ongoing cusatuzumab clinical trials will continue to be supported through treatment and follow-up. December 2018 argenx announced an exclusive, global collaboration and license agreement for cusatuzumab (ARGX-110), a highly differentiated anti-CD70 SIMPLE Antibody, with Cilag. Janssen will pay argenx $300 million in an upfront payment and JJDC will purchase $200 million (1,766,899) of newly issued shares representing 4.68% of argenx’s outstanding shares at a price of €100.02 per share ($113.19). argenx will be eligible to receive potentially up to $1.3 billion in development, regulatory and sales milestones, in addition to tiered, double-digit royalties. Janssen will be responsible for commercialization worldwide. argenx retains the option to participate in commercialization efforts in the U.S., where the companies have agreed to share economics 50/50 on a royalty basis and outside the U.S., Janssen will pay double-digit sales royalties to argenx. [collapse expanded text] |
Merck and Co, Sutro Biopharma | Jul 2018 | 1660 | Collaboration and licensing agreement for immune-modulating therapies for cancer and autoimmune disorders | September 2021 Sutro Biopharma announced that Merck & Co has extended the research term for … read morethe first cytokine derivative program under the 2018 Merck Agreement, for an additional two years. The research extension is intended to facilitate completion of preclinical research and development activities for a second candidate, which has a novel design and approach. As part of this extension, Sutro is eligible to receive up to $10 million. March 2020 Sutro Biopharma announced that Merck has extended the research term of the collaboration's first cytokine-derivative program by one year, which includes a payment to Sutro of an undisclosed amount. Sutro's collaboration with Merck was announced in July 2018 to develop therapeutics for cancer and autoimmune disorders. July 2018 Sutro Biopharma has signed a collaboration and licensing agreement with Merck to discover and develop novel immune-modulating therapies for cancer and autoimmune disorders. The research and development activities will leverage Sutro's proprietary cell-free protein synthesis and site-specific conjugation platforms, which facilitate precision design and rapid empirical optimization of protein conjugates, to discover and develop best-in-class immune-modulating cytokine derivatives for both oncology and autoimmune indications. Sutro will be primarily responsible for preclinical research and Merck will gain exclusive worldwide rights to therapeutic candidates derived from the collaboration. Sutro will receive an upfront payment of $60 million and is eligible for milestone payments totaling up to $1.6 billion associated with the development and sale of all therapeutic candidates and all possible indications identified under the collaboration, as well as tiered royalties on the sale of products. [collapse expanded text] |
Bristol-Myers Squibb, Taisho Pharmaceutical | Dec 2018 | 1600 | Asset purchase agreement for consumer health business | Bristol-Myers Squibb announced that Taisho Pharmaceutical has offered to purchase Bristol-Myers … read moreSquibb’s UPSA consumer health business for $1.6 billion. UPSA develops and delivers important consumer medicines for patients in France, across Europe and additional countries. Taisho is the largest over-the-counter (OTC) drug company in Japan, with over a century of experience in this field. Taisho holds a leading presence in anti-inflammatory analgesic, cold and flu and hair growth segments in Japan and Southeast Asia. The potential transaction is anticipated to be completed during the first half of 2019, subject to regulatory approvals and satisfaction of certain other customary closing conditions. The offer by Taisho is structured in the form of a “put option” agreement. Under the terms of the agreement, the offer is subject to Bristol-Myers Squibb’s exercise of the put option following information and consultation processes with relevant employee representative bodies. Upon exercise of the put option, Bristol-Myers Squibb and Taisho would execute a definitive stock and assets purchase agreement following which Taisho would acquire all of the issued and outstanding shares of capital stock of UPSA SAS, as well as Bristol-Myers Squibb’s assets and liabilities relating to the UPSA product portfolio. Assuming completion, Bristol-Myers Squibb estimates the potential transaction would be approximately ($0.04) dilutive to 2019 earnings. [collapse expanded text] |
Bristol-Myers Squibb, Celgene, Prothena | Mar 2018 | 1545 | Collaboration agreement for novel therapies for neurodegenerative diseases | July 2023 Prothena announced that Bristol Myers Squibb exercised its option under the global … read moreneuroscience research and development collaboration to obtain the exclusive worldwide commercial rights for PRX005 and will pay Prothena $55 million. PRX005, which is designed to be a best-in-class anti-tau antibody, specifically targets an area within the microtubule binding region (MTBR) of tau for the potential treatment of Alzheimer’s disease. March 2018 Prothena announced a global collaboration with Celgene to develop new therapies for a broad range of neurodegenerative diseases. The multi-year research and development collaboration is focused on three proteins implicated in the pathogenesis of several neurodegenerative diseases, including tau, TDP-43 and an undisclosed target. For each of the programs, Celgene has an exclusive right to license clinical candidates in the U.S. at the investigational new drug (IND) filing and if exercised, would also have a right to expand the license to global rights at the completion of Phase 1. Following the exercise of global rights, Celgene will be responsible for funding all further global clinical development and commercialization. Prothena will receive a $100 million upfront payment and a $50 million equity investment by Celgene, plus future potential exercise payments and regulatory and commercial milestones for each licensed program. Prothena will also receive additional royalties on net sales of any resulting marketed products. Prothena will receive an upfront payment and equity investment, and is eligible to receive exercise payments and regulatory and commercial milestones, plus additional royalties on net sales based on the following collaboration deal terms: Prothena will receive an upfront payment of $100 million. Celgene will make a $50 million equity investment in Prothena by subscribing to approximately 1.2 million of Prothena’s ordinary shares at $42.57 per shareFor programs reaching commercialization, Prothena will receive tiered royalties on net sales. The targets encompassed in this collaboration are implicated in the pathogenesis of several neurodegenerative diseases for which there are no current disease modifying therapies, including the following: Tau, a protein implicated in diseases including Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), chronic traumatic encephalopathy (CTE) and other tauopathies. Prothena has identified antibodies targeting novel epitopes on the tau protein with the ability to block misfolded tau from binding to cells and to inhibit cell-to-cell transmission, preventing downstream functional toxic effects. TDP-43, a protein implicated in diseases including amytrophic lateral sclerosis (ALS) and the most common subtype of FTD, behavioral variant FTD (bvFTD), a proportion of AD and other TDP-43 proteinopathies. Prothena has generated antibodies that target multiple epitopes on the TDP-43 protein and is using proprietary in vitro screening methodology to select those that may be the most potent and efficacious in inhibiting toxicity and cell-to-cell transmission of misfolded TDP-43 species. [collapse expanded text] |
Gilead Sciences, Scholar Rock | Dec 2018 | 1530 | Collaboration agreement for therapies for fibrotic diseases | Gilead Sciences and Scholar Rock have entered into a strategic collaboration to discover and … read moredevelop highly specific inhibitors of transforming growth factor beta (TGFβ) activation for the treatment of fibrotic diseases. Gilead has exclusive options to license worldwide rights to product candidates that emerge from three Scholar Rock TGFβ programs: inhibitors that target activation of latent TGFβ1 with high affinity and specificity, inhibitors that selectively target activation of latent TGFβ1 localized to extracellular matrix, and a third TGFβ discovery program. Scholar Rock is responsible for antibody discovery and preclinical research through product candidate nomination, after which, upon exercising the option for a program, Gilead will be responsible for the program’s preclinical and clinical development and commercialization. Scholar Rock retains exclusive worldwide rights to discover, develop, and commercialize certain TGFβ inhibitors for oncology and cancer immunotherapy. Scholar Rock will receive $80 million in upfront payments, comprised of $50 million cash and $30 million purchase of Scholar Rock Holding Corporation common stock. Scholar Rock will receive a one-time milestone payment of $25 million upon the successful completion of specific preclinical studies and be eligible to receive up to an additional $1,425 million in potential payments aggregated across all three programs based on the successful achievement of certain research, development, regulatory and commercialization milestones. Scholar Rock would also receive high single-digit to low double-digit tiered royalties on sales of potential future products originating from the collaboration. [collapse expanded text] |
Boehringer Ingelheim, OSE Immunotherapeutics | Apr 2018 | 1387.8 | Collaboration and licensing agreement for OSE-172 | Boehringer Ingelheim and OSE Immunotherapeutics announced a collaboration and exclusive worldwide … read morecollaboration and license agreement to jointly develop OSE-172, a SIRP-alpha antagonist targeting myeloid lineage cells. Boehringer Ingelheim has acquired the global rights to develop, register and commercialize OSE-172, a monoclonal antibody targeting SIRP-alpha which is expressed in myeloid lineage cells, as part of their continued commitment to research and innovation in immuno-oncology. OSE Immunotherapeutics will receive a €15 million upfront payment from Boehringer Ingelheim, and potential additional short-term milestones of up to €15 million upon initiation of a phase 1 clinical study. OSE Immunotherapeutics stands to receive more than €1.1 billion upon reaching pre-specified development, commercialization and sales milestones, plus royalties on worldwide net sales. [collapse expanded text] |
Mologen, Oncologie | Aug 2018 | 1308.9 | Assignment and co-development agreement for lefitolimod | MOLOGEN signed a term sheet outlining the framework for a global assignment of all intellectual … read moreproperty and other rights in MOLOGEN’s lead compound lefitolimod to ONCOLOGIE and an expansion of the existing global co-development agreement between MOLOGEN and ONCOLOGIE. The potential total deal value would be over €1 billion plus low double digit royalties on net sales, representing an attractive upside for MOLOGEN. MOLOGEN would receive a near-term consideration of €23 million. This transaction would secure the major part of the funding for the pivotal IMPALA study until read-out, projected for 2020. The term sheet envisages that all rights to MOLOGEN’s immunotherapeutic agent lefitolimod, including intellectual property (IP) and know-how, will be transferred to ONCOLOGIE. MOLOGEN would receive short-term as well as development and sales milestone payments. ONCOLOGIE would be solely responsible for all development, manufacturing and commercialization activities relating to lefitolimod globally and bear the corresponding expenses. Under the co-development agreement, MOLOGEN would carry out certain manufacturing activities to supply the clinical medication. ONCOLOGIE would also obtain a Right of First Refusal to license the optioned products, EnanDIM and MGN1601 – but excluding the MIDGE technology. With such a transaction, MOLOGEN would secure most of the funds needed for the completion of IMPALA. The remaining part would be raised through further capital measures. A substantial and long-term upside of attractive development payments, as well as sales milestones and royalties, remains with MOLOGEN. This agreement would allow the project to be almost entirely funded until the read-out of the pivotal IMPALA study which is expected in 2020. The transaction is still subject to the agreement of the parties in a definitive transaction documentation. In addition to finalizing the IMPALA study, the co-development agreement would provide an opportunity to fully realize the potential of lefitolimod in combination with other immuno-oncology drugs and in additional indications outside the colorectal cancer (CRC) maintenance setting. Success in additional indications would bring in additional milestones and royalties representing substantial value for MOLOGEN. As consideration for the global assignment of all rights to lefitolimod and the provision of the co-development services, MOLOGEN would receive short-term as well as development and sales milestone payments comprising the following elements: First of all, to fund the further development of lefitolimod, MOLOGEN would receive a near-term consideration in the aggregated amount of €23 million consisting of (1) an initial purchase price of the global rights in the amount of €3 million due at the signing of the definitive transaction documents, (2) subsequent quarterly cash payments reflecting MOLOGEN’s budgeted expenses for such quarters in a total amount of €7 million, and (3) a commitment by ONCOLOGIE to run several clinical trials designed to expand the clinical setting for lefitolimod beyond the IMPALA indication in the amount of €9 million. (4) a commitment of ONCOLOGIE to invest a total amount of €4 million into two zero interest mandatory convertible bonds (“MCB”) with a term of five years and a nominal value of €2 million each. Such MCBs would be issued by MOLOGEN to ONCOLOGIE without subscription rights of the existing shareholders backed by the existing conditional capital 2018. The initial conversion price will correspond to the 10-days volume weighted average (stock) price (Xetra) immediately preceding the Company’s decision to actually issue the respective MCB plus a 30% premium. The first MCB is envisaged to be issued by 31 August 2018. The second MCB is envisaged to be issued at the time of signing of the final contract. ONCOLOGIE would place an amount of €5 million, including the €2 million for the second note and €3 million for the global assignment of all intellectual property, in an escrow account within twenty days of signing the term sheet. The subscription of the first MCB also discharges ONCOLOGIE’s equity investment obligation in the amount of €2 million under the existing co-development agreement announced on 13 February 2018. The funds referred to under (1), (2) and (4) above (i.e. a total amount of €14 million) will be used for the completion of the IMPALA trial until read-out including the preparation of the production upscale. In addition, ONCOLOGIE would invest a minimum of additional €9 million in combination studies as part of the co-development agreement beyond IMPALA. Secondly, ONCOLOGIE would be responsible for all future development activities, including regulatory interactions and production of drug material to support the future commercialization of lefitolimod. Thirdly, the parties agreed on development and commercialization milestones. They would be due upon reaching predefined development steps as well as market approval. MOLOGEN would be eligible to receive up to approximately €200 million in development and regulatory milestone payments based on IMPALA success, and on the success of additional indications that the parties intend to further explore. After registration of lefitolimod in major territories, additional commercial milestones could add up to more than €900 million depending on potential future sales. Furthermore, ONCOLOGIE would pay MOLOGEN tiered royalties on a low double-digit percentage average with a peak rate of 16%. In case of a licensing by ONCOLOGIE to a third party outside Greater China, MOLOGEN is entitled to receive 35% of all licensing receipts in condition of a positive read-out of the IMPALA study and otherwise 30% but not less than 50% of the agreed milestones and royalties for territories outside Greater China. In the event Oncology would commercialize lefitolimod on their own or by licensees in the Greater China territory, MOLOGEN would receive 100% of the agreed milestone payments and royalties. The parties have agreed on a three months exclusivity period to negotiate the definitive transaction documentation. A condition for the closing of the assignment of all rights in lefitolimod is the further funding of ONCOLOGIE in a mid-double-digit million amount. [collapse expanded text] |
Janssen Biotech, Yuhan Corporation | Nov 2018 | 1255 | Collaboration and licensing agreement for Lazertinib lung cancer therapy | Yuhan has entered into a license and collaboration agreement with Janssen Biotech to develop … read moreLazertinib, a novel clinical-stage therapeutic candidate for the treatment of patients with non-small cell lung cancer (NSCLC). Yuhan will receive an upfront payment of $50 million and is eligible to receive up to $1,205 million in potential development and commercial milestone payments, along with tiered double-digit royalties on future net sales. Janssen will assume responsibility for development, manufacturing and commercialization with exclusive worldwide rights to Lazertinib excluding the Republic of Korea, where the rights are retained by Yuhan. The two companies will collaborate on global clinical trials evaluating Lazertinib both in monotherapy and combination regimens, trials are anticipated to begin in 2019. [collapse expanded text] |
Pieris Pharmaceuticals, Seagen, Seattle Genetics | Feb 2018 | 1230 | Collaboration and licensing agreement for multiple targeted bispecific immuno-oncology treatments for solid tumors and blood cancers | January 2023 Pieris Pharmaceuticals has achieved a $5 million milestone from Seagen. The … read moremilestone is based on dosing the first patient in a Seagen-sponsored phase 1 study of SGN-BB228 (PRS-346), a novel bispecific antibody-Anticalin molecule (Mabcalin) that is designed to provide a potent costimulatory bridge between tumor-specific T cells and CD228 expressing tumor cells. March 2021 Pieris announced that Seagen has made a strategic equity investment in Pieris as part of an ongoing collaboration between the companies. In addition, the companies have entered into a clinical trial collaboration agreement to evaluate the safety and efficacy of combining Pieris' cinrebafusp alfa (PRS-343), a 4-1BB/HER2 bispecific, with Seagen's TUKYSA (tucatinib), a small-molecule tyrosine kinase HER2 inhibitor, for the treatment of gastric cancer patients expressing lower HER2 levels (IHC2+/ISH- & IHC1+) as part of the upcoming phase 2 study to be conducted by Pieris. The companies have also amended their existing immuno-oncology collaboration agreement around joint development and commercial rights for the second of up to three products in the alliance. Under the amended and restated agreement, Pieris' option to co-develop and co-commercialize the second of three programs in the collaboration has been amended to provide it with a co-promotion option in the United States, with Seagen solely responsible for the development and overall commercialization of that program. Under the co-promotion option, Pieris will also be entitled to increased royalties from that program in the event that it chooses to exercise the option. In connection with the amendment, on March 24, 2021, in a private placement transaction, Seagen made an equity investment of $13 million in Pieris through the purchase of 3,706,174 newly issued shares of Pieris common stock at a price of $3.51 per share. February 2018 Pieris Pharmaceuticals and Seattle Genetics have entered into a collaboration and license agreement with the goal of developing multiple targeted bispecific immuno-oncology treatments for solid tumors and blood cancers. The collaboration leverages the expertise and core technologies of both companies to develop novel Antibody-Anticalin fusion proteins. Pieris' proprietary suite of agonistic costimulatory Anticalin proteins, when fused to a tumor-targeting antibody, can activate the immune system preferentially in the tumor microenvironment. Seattle Genetics, through its industry-leading work in the field of antibody-drug conjugates (ADCs), has a substantial portfolio of cancer targets and tumor-specific monoclonal antibodies from which programs will be selected for the collaboration. The bispecific drug candidates in this alliance will be designed to enable the patient's immune cells to specifically attack tumors. Seattle Genetics will pay Pieris a $30 million upfront fee, tiered royalties on net sales up to low double-digits, and up to $1.2 billion in total success-based payments across three product candidates. The companies will pursue multiple Antibody-Anticalin fusion proteins during the research phase, and Seattle Genetics has the option to select up to three therapeutic programs for further development. Prior to the initiation of a pivotal trial, Pieris may opt into global co-development and US commercialization of the second program and share in global costs and profits on a 50/50 basis. Seattle Genetics will solely develop, fund and commercialize the other two programs. [collapse expanded text] |
Arena Pharmaceuticals, United Therapeutics | Nov 2018 | 1200 | Licensing agreement for Ralinepag | Arena Pharmaceuticals and United Therapeutics have entered into a global license agreement for … read moreArena's Phase 3 investigational drug candidate, ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension (PAH). Arena will grant United Therapeutics exclusive, worldwide rights to develop, manufacture and commercialize ralinepag. Arena will receive up to $1.2 billion, including an upfront payment of $800 million and potential milestone payments totaling up to $400 million based on the achievement of certain regulatory events. Arena will receive low double-digit tiered royalties on annual net sales of ralinepag. [collapse expanded text] |
Denali Therapeutics, Sanofi | Nov 2018 | 1125 | Collaboration agreement for RIPK1 inhibitor molecules for neurological and systemic inflammatory diseases | Denali Therapeutics will collaborate with Sanofi on the development of multiple RIPK1 inhibitor … read moremolecules with the potential to treat a range of neurological and systemic inflammatory diseases. The two lead molecules DNL747 and DNL758 target a critical signaling protein known as the receptor-interacting serine/threonine-protein kinase 1 (RIPK1) in the TNF receptor pathway, which regulates inflammation and cell death in tissues throughout the body. The companies plan to study DNL747 in Alzheimer’s disease, amyotrophic lateral sclerosis and multiple sclerosis, and DNL758 in systemic inflammatory diseases such as rheumatoid arthritis and psoriasis. Sanofi will make an upfront cash payment to Denali of $125 million, with future development and commercial milestone payments that could exceed $1 billion. Sanofi and Denali will share commercial profits and losses from DNL747 in the U.S. and China equally, while Denali will receive a royalty from Sanofi for other territories for DNL747 and worldwide for DNL758. Phase 1b and 2 clinical development costs for DNL747 will be fully funded by Sanofi for MS, ALS, and other neurological indications, except in Alzheimer’s disease, which will be funded by Denali. Phase 3 trials for all neurological indications will be jointly funded by Sanofi (70%) and Denali (30%). Sanofi will fully fund the clinical development costs for DNL758 in systemic inflammatory diseases. The collaboration also includes additional pre-clinical RIPK1 inhibitor molecules. [collapse expanded text] |
Abbvie, Voyager Therapeutics | Feb 2018 | 1119 | Collaboration and option agreement for vectorized antibodies directed against tau for Alzheimer’s disease | August 2020 Voyager Therapeutics announced the termination of its tau and alpha-synuclein … read morevectorized antibody collaborations with AbbVie. Voyager retains full rights to the vectorization technology and certain novel vectorized antibodies developed as part of the collaborations. February 2018 Voyager Therapeutics and AbbVie have entered into an exclusive strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed against tau for the treatment of Alzheimer’s disease and other neurodegenerative diseases. This collaboration combines AbbVie’s monoclonal antibody expertise, global clinical development and commercial capabilities with Voyager’s gene therapy platform and expertise that enables generating adeno-associated viral (AAV) vectors for the treatment of neurodegenerative diseases. This collaboration seeks to develop a potential one-time treatment using Voyager’s gene therapy platform to reduce tau pathology through the delivery of an AAV vector antibody that encodes the genetic instructions to produce anti-tau antibodies within the brain. Voyager will perform research and preclinical development of vectorized antibodies directed against tau, after which AbbVie may select one or more vectorized antibodies to proceed into IND-enabling studies and clinical development. Voyager will be responsible for the research, IND-enabling and Phase 1 studies activities and costs. Following completion of Phase 1 clinical development, AbbVie has an option to license the vectorized tau antibody program and would then lead further clinical development and global commercialization for tauopathies, including Alzheimer’s disease and other neurodegenerative diseases. Voyager has an option to share in the costs of clinical development for higher royalty rates. Voyager will receive an upfront cash payment of $69 million as well as up to $155 million in potential preclinical and Phase 1 option payments. Voyager is eligible to receive up to $895 million in development and regulatory milestones for each vectorized tau antibody compound and is eligible to receive tiered royalties on the global commercial net sales of the vectorized antibodies for tauopathies, including Alzheimer’s disease and other neurodegenerative diseases. [collapse expanded text] |
Galapagos, MorphoSys, Novartis | Jul 2018 | 1111 | Licensing agreement for MOR106 | Galapagos and MorphoSys have entered into a worldwide, exclusive agreement with Novartis Pharma … read morecovering the development and commercialization of their joint program MOR106. Upon the signing of the agreement, all future research, development, manufacturing and commercialization costs for MOR106 will be borne by Novartis. This includes the ongoing Phase 2 IGUANA trial in atopic dermatitis patients as well as a planned Phase 1 study to evaluate the safety and efficacy of a subcutaneous formulation of MOR106 in healthy volunteers and AtD patients. MorphoSys and Galapagos will conduct additional trials to support development of MOR106 in AtD. Novartis will explore the potential of MOR106 in additional indications other than AtD. In addition to the funding of the current and future MOR106 program by Novartis, MorphoSys and Galapagos will jointly receive an upfront payment of EUR 95 million (USD 111 million). Pending achievement of certain developmental, regulatory, commercial and sales-based milestones, MorphoSys and Galapagos would jointly be eligible to receive significant milestone payments, potentially amounting up to approximately EUR 850 million (USD 1 billion), in addition to tiered royalties on net commercial sales in the range of up to low-teens to low-twenties. Under the terms of their 2008 agreement, Galapagos and MorphoSys will share all payments equally (50/50). [collapse expanded text] |
Anima Biotech, Eli Lilly | Jul 2018 | 1094 | Collaboration agreement for translation inhibitors for several target proteins | Anima Biotech announced an agreement with Eli Lilly for the discovery and development of … read moretranslation inhibitors for several target proteins by using Anima's Translation Control Therapeutics platform. The multi-year agreement is structured as an exclusive collaboration around several undisclosed Lilly targets. Anima will use its technology platform to discover lead candidates that are translation inhibitors of the Lilly targets. Lilly will be responsible for clinical development and commercialization of products resulting from the collaboration. Anima will receive $30 million in upfront payments and $14 million in research funding. Anima is eligible to receive up to $1.05 billion if all future development and commercial milestones are achieved. Anima will additionally be entitled to low to mid single-digit tiered royalties on sales of any Lilly products resulting from the collaboration. [collapse expanded text] |
PureTech Health, Roche | Jul 2018 | 1036 | Collaboration agreement for milk-derived exosome platform technology for the oral administration of antisense oligonucleotide platform | PureTech Health has entered into a multiyear collaboration with F. Hoffmann-La Roche and Hoffmann- … read moreLa Roche to advance PureTech’s milk-derived exosome platform technology for the oral administration of Roche’s antisense oligonucleotide platform. PureTech Health will receive up to $36 million, including upfront payments, research support, and early preclinical milestones. PureTech Health will be eligible to potentially receive development milestone payments of over $1 billion and additional sales milestones and royalties for an undisclosed number of products. [collapse expanded text] |
Janssen Biotech, Janssen Pharmaceuticals, Theravance | Feb 2018 | 1000 | Collaboration, option and licensing agreement for Pan-JAK inhibitor drug candidate for inflammatory bowel disease | December 2021 In August 2021, the Company completed a Phase 2b/3 induction and maintenance study … read moreof izencitinib in ulcerative colitis and announced that the study did not meet its primary endpoint. In November 2021, the Company announced that it voluntarily discontinued its Phase 2 study of izencitinib in Crohn’s disease. On December 17, 2021, the Company received notice from Janssen terminating the Janssen Agreement, effective as of January 16, 2022. February 2018 Theravance Biopharma has entered into a global co-development and commercialization agreement with Janssen Biotech for TD-1473 and related back-up compounds for inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. Theravance Biopharma will receive an upfront payment of $100 million and will be eligible to receive up to an additional $900 million in potential payments, if Janssen elects to remain in the collaboration following the completion of certain Phase 2 activities, as described below. Theravance Biopharma together with Janssen will jointly develop and commercialize TD-1473 in inflammatory intestinal diseases, with the two companies sharing profits in the US and expenses related to a potential Phase 3 program (67% to Janssen; 33% to Theravance Biopharma). Theravance Biopharma would receive double-digit tiered royalties on ex-US sales. [collapse expanded text] |
Biogen, Ionis Pharmaceuticals | Apr 2018 | 1000 | Collaboration agreement for antisense drug candidates for range of neurological diseases | Biogen and Ionis Pharmaceuticals have expanded their strategic collaboration through a new ten-year … read morecollaboration agreement to develop novel antisense drug candidates for a broad range of neurological diseases. This collaboration capitalizes on Biogen’s expertise in neuroscience research and drug development and Ionis’ leadership in RNA targeted therapies with the goal of developing a broad pipeline of investigational therapies. It builds upon a productive collaboration that produced SPINRAZA, the first and only approved treatment for patients with spinal muscular atrophy. Biogen will pay Ionis $1 billion in cash, which will include $625 million to purchase 11,501,153 shares of Ionis common stock at a price of $54.34 per share, at an approximately 25% cash premium, and a $375 million upfront payment. Biogen will have the option to license therapies arising out of this collaboration and will be responsible for their development and commercialization. Biogen may pay milestone payments, license fees and royalties on net sales. The companies plan to advance programs for a broad range of neurological diseases for which few treatment options exist today. Disease areas include dementia, neuromuscular diseases, movement disorders, ophthalmology, diseases of the inner ear, and neuropsychiatry. Biogen will have the first choice of neurology targets on which to exclusively collaborate with Ionis. In this collaboration, Ionis will be responsible for the identification of antisense drug candidates based on selected targets, while Biogen will be responsible for and pay for non-clinical studies, clinical development, manufacturing, and commercialization. [collapse expanded text] |
Abbvie, Lupin Pharmaceuticals | Dec 2018 | 977 | Development and licensing agreement for MALT1 inhibitors | AbbVie has licensed Lupin’s MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein … read more1) inhibitor program. AbbVie gains exclusive global rights to develop and commercialize Lupin’s MALT1 inhibitors. MALT-1 is a protein involved in T-cell and B-cell lymphocyte activation and AbbVie intends to pursue development across a range of hematological cancers, many with limited current treatment options. AbbVie will pay Lupin an upfront payment of US$ 30 million for an exclusive license to the program. Upon successful completion of regulatory, development and commercial milestones, Lupin is eligible to receive total milestone payments of up to US$ 947 million. Lupin will be entitled to receive a double-digit royalty on the sales of the product and will retain commercial rights to the program in India. [collapse expanded text] |
Genentech, Lodo Therapeutics | May 2018 | 969 | Collaboration agreement for genome mining and biosynthetic cluster assembly platform to identify novel molecules | Lodo Therapeutics has formed a strategic drug discovery collaboration with Genentech. Genentech … read morewill utilize Lodo Therapeutics’ proprietary genome mining and biosynthetic cluster assembly platform to identify novel molecules with therapeutic potential against multiple disease-related targets of interest to Genentech. Lodo will receive an undisclosed upfront payment and is eligible to receive research, development and commercialization milestone payments up to $969 million based on achievement of certain predetermined milestones. Lodo is eligible to receive tiered-royalties on sales of certain products resulting from the collaboration. [collapse expanded text] |
AstraZeneca, Grunenthal | Oct 2018 | 922 | Asset purchase agreement for Nexium and Vimovo | AstraZeneca has agreed to divest the prescription medicine rights to Nexium (esomeprazole) in … read moreEurope, as well as the global rights (excluding the US and Japan) to Vimovo (naproxen/esomeprazole) to Grünenthal. The medicines are outside AstraZeneca’s three main therapy areas of Oncology, Cardiovascular, Renal & Metabolism and Respiratory. Nexium has lost compound patent protection in the majority of global markets. Vimovo is patent protected in most European markets until 2025. The divestment is expected to complete in 2018. For Nexium, Grünenthal will make an upfront payment of $700 million upon completion. AstraZeneca may also receive future milestones and sales-related payments of up to $90 million. For Vimovo, Grünenthal will make an upfront payment of $115 million on completion. AstraZeneca may also receive future milestones and sales-related payments of up to $17 million. Upfront and milestone payments will be reported as Other Operating Income in the Company’s financial statements. AstraZeneca will continue to commercialise Nexium in all markets outside Europe, where the Company retains the rights. On completion of the agreements, AstraZeneca will not retain any ownership rights to Vimovo globally, or to Nexium in Europe. [collapse expanded text] |
Cue Biopharma, LG Life Sciences | Nov 2018 | 905 | Collaboration, option, licensing, co-development and co-promotion agreement for Immuno-STAT biologics in oncology | January 2022 Cue Biopharma along with LG Chem Life Sciences announced that a key milestone in … read morethe selection of a clinical product candidate has been reached in their collaboration for CUE-102, an Immuno-STAT biologic, jointly developed to selectively target WT1-expressing cancers. The milestone represents significant progress for the CUE-102 program and an important achievement in generating promising preclinical activity and data to be shared with the FDA as part of an investigational New Drug filing that is planned for the first quarter of 2022. Cue Biopharma will receive a $3 million milestone payment from LG Chem Life Sciences, the life sciences division of LG Chem. December 2018 Cue Biopharma along with LG Chem Life Sciences announced the selection of Wilms’ Tumor 1 (WT1) as the target antigen for CUE-102, pursuant to the partners’ strategic research and development agreement. November 2018 Cue Biopharma has entered Into a multi-target strategic collaboration with LG Chem Life Sciences to develop multiple Immuno-STAT biologics focused in the field of oncology. The collaboration provides LG Chem with the rights to develop and commercialize, in Asia, Cue Biopharma’s lead product, CUE-101, as well as Immuno-STAT biologics that target T cells against two additional cancer antigens. Cue Biopharma will engineer the selected Immuno-STATs for up to three alleles, while LG Chem will leverage its experience in biologics manufacturing to establish a quality chemistry, manufacturing and controls process for development and commercialization of the selected candidates. LG Chem will also retain the right to elect one additional Immuno-STAT biologic within two years of the agreement for a worldwide development and commercialization license, and Cue Biopharma will retain an option to co-develop and co-commercialize the additional program worldwide. Cue Biopharma retains rights to develop and commercialize all assets included in the agreement in the United States and in global markets outside of Asia. LG Chem will make an undisclosed upfront payment as well as a $5M equity investment at a 20% premium. Cue Biopharma will be eligible to receive up to an additional $400M in research, development, regulatory and sales milestone payments with tiered royalties on sales of collaboration products in the LG Chem territory. LG Chem will further contribute to the collaboration by providing Cue Biopharma with research funding, CMC process development and potentially additional downstream manufacturing capabilities, including clinical and commercial supply for the collaboration products. LG Chem in return will receive royalties on sales of collaboration products in Cue Biopharma's territories outside of Asia. If LG Chem elects the option for an additional program worldwide, Cue Biopharma will receive an undisclosed payment and be eligible to receive greater than $500M in fees and milestone payments. Cue Biopharma will also receive tiered royalties on future global sales. In addition, prior to the first pivotal trial for the optional Immuno-STATs, Cue Biopharma will have the option to elect worldwide co-development rights for the additional program. [collapse expanded text] |
Axovant Gene Therapies, Oxford BioMedica, Sio Gene Therapies | Jun 2018 | 842.5 | Licensing agreement for OXB-102 | January 2022 Oxford BioMedica was informed on Monday 31 January by Sio Gene Therapies that Sio … read moreintends to return the global rights for AXO-Lenti-PD and that they intend to cease work on this gene therapy programme in Parkinson’s Disease. This follows Sio’s announcement today about the resignation of their CEO where Sio also indicates a constraint on resource requirements that has caused Sio to deprioritise the programme. All rights shall be returned to Oxford Biomedica at no cost to the Company. June 2018 Oxford BioMedica has entered into an exclusive worldwide licensing agreement with Axovant Sciences to develop and commercialise OXB-102, a gene therapy developed by Oxford BioMedica for Parkinson’s disease utilising the LentiVector platform. Oxford BioMedica will receive a $30 million upfront payment (approximately £22 million) including $5 million as pre-payment for manufacturing activities related to OXB-102, now renamed, AXO-Lenti-PD. Oxford BioMedica is also eligible to receive $55 million upon the achievement of specified development milestones and $757.5 million upon the achievement of specified regulatory and sales milestones, with 7% to 10% tiered royalties on net sales of AXO-Lenti-PD. Axovant Sciences, a clinical-stage biopharmaceutical company dedicated to advancing treatments for patients with life-altering neurologic conditions and a member of the Roivant family of companies, will fund all clinical development costs and manufacturing process development and scale-up activities for AXO-Lenti-PD. The agreement also allows for both parties to put in place a clinical and commercial supply agreement for GMP manufacturing of AXO-Lenti-PD at Oxford BioMedica. Roivant remains committed to Axovant’s success and are excited about the scientific potential of AXO-Lenti-PD. Axovant will be able to harness the full Roivant drug development platform to ensure its rapid development. [collapse expanded text] |
Arvinas, Pfizer | Jan 2018 | 830 | Collaboration and licensing agreement for PROTAC (PROteolysis TArgeting Chimeras) platform | Arvinas announced a research collaboration and license agreement with Pfizer for the discovery and … read moredevelopment of drug candidates using Arvinas' proprietary PROTAC (PROteolysis TArgeting Chimeras) Platform, a novel technology used to create small molecule therapeutics aimed at degrading disease-causing cellular proteins. The multi-year agreement covers the discovery and development of potential PROTAC clinical candidates designed to degrade several key disease-causing proteins in multiple therapeutic areas. Arvinas will drive discovery efforts, and Pfizer will be accountable for clinical development and commercialization of any products that may result from this collaboration. Arvinas may receive up to $830 million in upfront and potential development and commercialization milestone payments upon achievement of specified preclinical, clinical and commercial milestones. In addition, Arvinas may be entitled to receive tiered royalties based on global product sales on any products that may result from this collaboration. [collapse expanded text] |
Boehringer Ingelheim, Xynomic Pharmaceuticals | Dec 2018 | 800 | Licensing agreement for BI 860585 | Xynomic Pharmaceuticals has been granted an exclusive, worldwide license to develop, manufacture … read moreand commercialize BI 860585, a phase 2 ready mTORC1/2 inhibitor, from Boehringer Ingelheim. Total payments of Xynomic associated with the licensing agreement, including an upfront payment, regulatory milestone payments and potential royalties, will be up to $800 million. [collapse expanded text] |
LEO Pharma, PellePharm | Nov 2018 | 760 | Collaboration and licensing agreement for unmet medical needs across various skin diseases | LEO Pharma and PellePharm announced a strategic development and commercialization collaboration to … read moreaddress unmet medical needs across various skin diseases with no approved treatments, advancing innovation and access to potential therapies for patients with life-altering conditions, such as Gorlin Syndrome and High Frequency Basal Cell Carcinoma (BCC), two distinct and rare forms of skin cancer. LEO Pharma has initially committed $70 million comprised of equity financing and financial R&D support to fund the global Phase 3 trial for patidegib topical gel 2% for the prevention and treatment of Gorlin Syndrome, with LEO Pharma securing an option to acquire all shares in PellePharm. PellePharm and its stockholders could receive up to an additional $690 million including merger consideration, and regulatory and commercial milestone payments. PellePharm stockholders are eligible to receive a double-digit royalty after achieving certain commercial milestones. The agreement establishes a joint development committee with PellePharm maintaining responsibility for global development and LEO Pharma supporting in an advising role. Both companies will jointly drive commercialization planning, and Anders Kronborg, chief financial officer of LEO Pharma, will join PellePharm’s board of directors. [collapse expanded text] |
Ionis Pharmaceuticals, Roche | Oct 2018 | 759 | Collaboration and licensing agreement for IONIS-FB-L Rx for complement-mediated diseases | July 2022 Ionis Pharmaceuticals announced that Roche will license and advance IONIS-FB-LRx, an … read moreinvestigational antisense medicine, into a Phase 3 clinical study in patients with immunoglobulin A nephropathy (IgAN). IgAN is a rare and serious condition that often leads to chronic kidney disease and renal failure. Roche's decision to advance the program comes after positive data from a Phase 2 clinical study in which IONIS-FB-LRx met its primary endpoint of change in 24-hour urinary protein at 29 weeks compared to baseline. Roche will lead and be responsible for the Phase 3 study of IONIS-FB-LRx in patients with IgAN and for future global development, regulatory and commercialization activities. IONIS-FB-LRx is also being evaluated in GOLDEN (NCT03815825), a Phase 2 clinical study to determine whether the medicine can slow or halt the progression of geographic atrophy due to age-related macular degeneration, or AMD. Ionis will receive $55 million from Roche for licensing IONIS-FB-LRx for IgAN and achieving a development milestone in the GOLDEN study. October 2018 Ionis Pharmaceuticals announced a collaboration with Roche to develop IONIS-FB-LRx for the treatment of complement-mediated diseases. This collaboration will leverage Ionis' leadership in RNA-targeted therapeutics to develop IONIS-FB-LRx targeting Factor B (FB) for a broad range of diseases. The first indication the two companies will pursue is the treatment of patients with Geographic Atrophy (GA), the advanced stage of dry age-related macular degeneration (AMD). A Phase 2 study in patients with GA is planned to begin in early 2019. Ionis will receive a $75 million upfront payment. Ionis is eligible to receive up to $684 million in development, regulatory and sales milestone payments and license fees. Ionis also has the potential to receive tiered royalties that range from the high teens to twenty percent on sales from the product when commercialized. Ionis is responsible for conducting a Phase 2 study in patients with dry AMD and exploring the drug in a rare severe renal indication. Roche has the option to license IONIS-FB-LRx at the completion of the studies. U Upon licensing, Roche will be responsible for all global development and commercialization activities. [collapse expanded text] |
Roivant Sciences, iNtRON Biotechnology | Nov 2018 | 757.5 | Licensing and option agreement for SAL200 and anti-Gram-positive endolysin programs—including anti-VRE and anti-TB biologics | Roivant Sciences and iNtRON Biotechnology have entered into a global licensing agreement for SAL200, … read morea novel investigational biologic for the treatment of infectious diseases caused by antibiotic-resistant staphylococci. This licensing deal is worth a total of US$667.5M inclusive of milestone payments, with royalties on net sales in the low double digits. iNtRON Bio will receive an upfront payment upon execution of the agreement and subsequent milestone payments for development, regulatory, and sales-driven events. This agreement also provides Roivant with the option to license iNtRON Bio's non-clinical stage, anti-Gram-positive endolysin programs—including anti-VRE and anti-TB biologics—for an additional consideration of up to US$45M each. Roivant also has the first right of offer for iNtRON Bio's anti-Gram-negative platform. [collapse expanded text] |
BeiGene, Zymeworks | Nov 2018 | 722 | Research and licensing agreement for Azymetric and EFECT platforms | Zymeworks and BeiGene have entered into a license to Zymeworks' proprietary Azymetric and EFECT … read moreplatforms to develop and commercialize globally up to three other bispecific antibodies using the platforms. Zymeworks and BeiGene entered into a separate research and license agreement for Zymeworks’ proprietary Azymetric and EFECT platforms, under which BeiGene will have global rights to research, develop and commercialize up to three bispecific antibody therapeutics directed to targets selected by BeiGene. BeiGene will be responsible for all research, development, and commercial activities under this agreement. Under the terms of the research and license agreement for the Azymetric and EFECT platforms, Zymeworks will receive an upfront payment of US$20 million and is eligible to receive up to an aggregate of US$702 million in development and commercial milestone payments for up to three bispecific product candidates developed under the agreement. In addition, Zymeworks will be eligible to receive tiered royalties on future global sales of bispecific products developed by BeiGene under the agreement. [collapse expanded text] |
Dragonfly Therapeutics, Merck and Co | Oct 2018 | 695 | Collaboration, option and licensing agreement for TriNKET platform to develop drug candidates for solid tumors | November 2021 Dragonfly Therapeutics announced that Merck has licensed its second TriNKET … read moreimmunotherapy candidate from Dragonfly. Merck licensed its first TriNKET immunotherapy candidate from Dragonfly in November 2020. Merck and Dragonfly's collaboration, initially focused on a number of solid tumor targets, began in October 2018. The companies expanded their collaboration last year with a multi-target agreement to develop and commercialize additional natural killer cell engager immunotherapies in oncology, infectious disease and immune disorders. Merck has exercised its option to license exclusive worldwide intellectual property rights on its second immunotherapy candidate developed using the TriNKET technology platform and Dragonfly has received an undisclosed payment associated with this milestone. December 2020 Dragonfly Therapeutics announced that Merck has licensed its first TriNKET immunotherapy candidate from Dragonfly. Merck and Dragonfly's collaboration, initially focused on a number of solid tumor targets, began in October 2018. Earlier this year, the companies expanded their collaboration with a multi-target agreement to develop and commercialize additional natural killer cell engager immunotherapies in oncology, infectious disease and immune disorders. Under the agreement Merck has exercised its option to license exclusive worldwide intellectual property rights on its first immunotherapy candidate developed using the TriNKET technology platform and Dragonfly has received an undisclosed payment associated with this milestone. March 2020 Dragonfly Therapeutics announced an expansion of its strategic collaboration with Merck to discover, develop and commercialize a number of Dragonfly's candidate natural killer cell engager immunotherapies for oncology, infectious disease, and immune disorders. Dragonfly will grant Merck, through a subsidiary, the option to license exclusive worldwide intellectual property rights to multiple candidates developed using Dragonfly's TriNKET technology platform for a number of new targets. Merck will pay Dragonfly approximately $47.5 million upfront. Dragonfly is eligible to receive additional payments associated with development, regulatory and sales milestones as well as potential royalties on sales of approved product. October 2018 Dragonfly Therapeutics announced a strategic collaboration with Merck to discover, develop and commercialize innovative immunotherapies for patients with solid tumor cancers. The collaboration grants Merck the option to license exclusive worldwide intellectual property rights to products developed using Dragonfly's TriNKET technology platform for a number of solid-tumor programs, with the potential to earn Dragonfly up to $695 million in up front and milestone payments per program as well as royalties on sales of approved products. [collapse expanded text] |
Enterome Bioscience, Takeda Pharmaceutical | Oct 2018 | 690 | Co-development, licensing and co-promotion agreement for EB8018 | ENTEROME has entered into a global licensing, co-development and co-promotion agreement with Takeda … read morePharmaceutical. The agreement covers Enterome's lead investigational drug candidate EB8018 in patients with Crohn's disease, with the potential to expand to other gastrointestinal (GI) disorders and liver diseases. Enterome will receive an upfront payment of $50 million and a commitment from Takeda to make a future equity investment in the Company. Enterome is also eligible to receive up to $640 million for achieving specified clinical development, regulatory and commercial milestones with EB8018. In addition, Enterome and Takeda will co-develop EB8018 under the joint agreement and, if approved, the product will be co-promoted in the US under a profit/cost sharing structure. Takeda will receive an exclusive license to commercialize EB8018 outside of the US, and Enterome will be eligible to receive royalties on net sales generated in these territories. [collapse expanded text] |
Metavant, Poxel, Roivant Sciences | Feb 2018 | 675 | Development and licensing agreement for Imeglimin | January 2021 POXEL announced that, as part of the previously communicated decision by Metavant … read morenot to advance Imeglimin into a Phase 3 program for strategic reasons, its partnership agreement with Metavant will be terminated, effective January 31, 2021. Metavant will return all rights to Imeglimin to Poxel, as well as all data, materials, and information, including FDA regulatory filings, related to the program. Metavant is not entitled to any payment from Poxel as part of the return of the program. February 2018 Roivant Sciences and POXEL announced the signing of a strategic development and license agreement for imeglimin, an investigational oral therapy which has been developed by Poxel for the potential treatment of type 2 diabetes, in the U.S., Europe, and all other countries not covered by Poxel’s existing agreement in East and Southeast Asia. This partnership enables Roivant to add an innovative late-stage development program to its pipeline and Poxel gains a strategic development and licensing agreement for imeglimin beyond the company’s partnership with Sumitomo Dainippon Pharma. Poxel is entitled to receive an upfront payment of $35 million (approximately €28 million) and Roivant will invest $15 million (approximately €12 million) in Poxel through a subscription to 1,431,399 newly-issued ordinary shares at €8.5 per share. Poxel is entitled to receive potential future development and regulatory milestone payments and sales-based payments of up to $600 million (approximately €486 million) subject to the successful clinical development and commercialization of imeglimin. Furthermore, after launch Poxel will be entitled to double-digit royalties on net sales. Roivant will be responsible for development and commercialization costs and Poxel will contribute $25 million (approximately €20 million) to the development program. The parties will decide on a potential co-promotion prior to commercialization. [collapse expanded text] |
Molecular Templates, Takeda Pharmaceutical | Sep 2018 | 662.5 | Co-development agreement for protein-based oncology therapy | Molecular Templates announced an agreement with Takeda Pharmaceutical for the joint development of … read moreCD38-targeted engineered toxin bodies (ETBs) for the treatment of patients with diseases such as multiple myeloma. The lead development candidate is a CD38-targeted ETB that resulted from a previous discovery collaboration between the two companies. The parties developed preclinical stage ETBs targeting CD38 under the prior discovery collaboration. Takeda and Molecular Templates will further develop the ETBs for the treatment of multiple myeloma under this new license, development and commercialization agreement. Takeda will make an upfront payment of $30 million and Molecular Templates is eligible to receive development, regulatory and commercial milestone payments of up to $632.5 million if Molecular Templates exercises its co-development option or $337.5 million if Molecular Templates does not exercise or opts out of its co-development option. Takeda has also agreed to pay royalties on sales of the commercial product developed through the collaboration. Molecular Templates and Takeda will share equally in the development costs. [collapse expanded text] |
Aduro BioTech, Eli Lilly | Dec 2018 | 632 | Research, collaboration and licensing agreement for immunotherapies | Eli Lilly and Aduro Biotech announced a research collaboration and exclusive license agreement for … read moreAduro’s cGAS-STING Pathway Inhibitor program for the research and development of novel immunotherapies for autoimmune and other inflammatory diseases. Aduro’s cGAS-STING Pathway Inhibitor program aims to discover and develop inhibitors of the intracellular stimulator of interferon genes (STING) pathway, which can modulate the immune response associated with various autoimmune diseases. Lilly will gain access to novel molecules from Aduro that are designed to inhibit the cGAS-STING pathway. The companies will collaborate to advance these molecules, as well as others from Lilly, into clinical development. Aduro will receive an upfront payment of $12 million and will be eligible for development and commercial milestones up to approximately $620 million per product, as well as royalty payments in the single to low-double digits should Lilly successfully commercialize a therapy from the collaboration. Aduro will receive research funding during the research term and has the option to co-fund the clinical development of each product in exchange for an increase in royalty payments. Lilly will be responsible for all costs of global commercialization. [collapse expanded text] |
ABL Bio, TRIGR Therapeutics | Dec 2018 | 595 | Licensing agreement for TR009 | TRIGR Therapeutics and ABL Bio have entered into a collaboration and license agreement for TR009 ( … read moreformerly known as ABL001 or NOV1501), an ABL developed bispecific antibody candidate targeting two important angiogenic factors, VEGF and DLL4. The license agreement is exclusive and global, excluding the Republic of Korea for all oncology indications and excluding the Republic of Korea and Japan for all ophthalmology indications. This agreement is in addition to the recently announced agreement whereby TRIGR licensed pre-clinical immune engaging bispecific antibodies from ABL. TRIGR is responsible for global Phase 2 and subsequent clinical development and commercialization activities for TR009 for all oncology indications. ABL will receive an upfront payment of $5 million and is eligible to receive up to $405 million in regulatory and sales milestones and royalties on oncology sales of TR009 outside of the Republic of Korea. For ophthalmology indications, TRIGR is responsible for all development and commercialization within its territories. ABL is eligible to receive up to $185 million in milestone payments and royalties on TR009 ophthalmology sales outside of the Republic of Korea and Japan. [collapse expanded text] |
Biogen, Pfizer | Mar 2018 | 590 | Licensing agreement for PF-04958242 | Biogen announced an agreement to acquire from Pfizer PF-04958242, a first-in-class, Phase 2b ready … read moreAMPA receptor potentiator for cognitive impairment associated with schizophrenia (CIAS). The purchase will include an upfront payment of $75 million with up to $515 million in additional development and commercialization milestone payments, as well as tiered royalties in the low to mid-teen percentages. AMPA receptors mediate fast excitatory synaptic transmission in the central nervous system, a process which can be disrupted in a number of neurological and psychiatric diseases, including schizophrenia. [collapse expanded text] |
Sage Therapeutics, Shionogi | Jun 2018 | 575 | Collaboration and licensing agreement for SAGE-217 | Sage Therapeutics and Shionogi have entered into a strategic collaboration for the clinical … read moredevelopment and commercialization of SAGE-217 for the treatment of major depressive disorder (MDD) and other indications in Japan, Taiwan and South Korea. Sage received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for SAGE-217 in MDD in February 2018, and recently announced an expedited development plan for SAGE-217 in the U.S. with a pivotal Phase 3 placebo-controlled trial in patients with MDD expected to commence this year, and an ongoing placebo-controlled trial in women with PPD, now also designated a pivotal trial. The goal of the collaboration is to accelerate development of a potentially groundbreaking medicine to patients in key Asian markets. Shionogi will be responsible for all clinical development, regulatory filings and commercialization of SAGE-217 for MDD, and potentially other indications, in Japan, Taiwan and South Korea. Shionogi will make an upfront payment to Sage of $90 million, and Sage will be eligible to receive additional development and commercial milestones of up to $485 million. Sage will receive tiered royalties on sales of SAGE-217 in Japan, Taiwan and South Korea, if development efforts are successful, with tiers averaging in the greater than 20 percent range, subject to other terms of the agreement. Shionogi has also granted Sage certain rights to co-promote SAGE-217 in Japan across all indications. Sage maintains exclusive rights to develop and commercialize SAGE-217 outside of Japan, Taiwan and South Korea. [collapse expanded text] |
AliveGen, Biogen | Jul 2018 | 562.5 | Asset purchase agreement for ALG-801 and ALG-802 | Biogen has acquired ALG-801 (Phase 1a) and ALG-802 (preclinical) from AliveGen. ALG-801 (now … read moreknown as BIIB110) and ALG-802 represent novel ways of targeting the myostatin pathway, which is one of the most thoroughly studied approaches for muscle enhancement. BIIB110 and ALG-802 are recombinant proteins that act as ActRIIB ligand traps to inhibit myostatin pathway signaling, and their targeted mechanism of action may result in greater efficacy and improved safety compared to other myostatin approaches. We initially plan to study BIIB110 and ALG-802 in multiple neuromuscular indications including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis. The acquisition includes an upfront payment of $27.5 million, and Biogen may pay up to $535 million in additional potential development and commercialization milestones across both assets and multiple indications. [collapse expanded text] |
Gilead Sciences, Japan Tobacco | Nov 2018 | 559 | Amended and restated licensing agreement for HIV integrase inhibitor (JTK-303) | Effective in December 2018, we entered into an agreement with Japan Tobacco to acquire the rights … read moreto market and distribute certain products in our HIV portfolio in Japan and to expand our rights to develop and commercialize elvitegravir to include Japan. We are responsible for the marketing of the products as of January 1, 2019. Under the terms of the agreement, we are obligated to pay Japan Tobacco $559 million in cash, of which $194 million was paid as an up-front payment and the remaining $365 million was reflected in Other accrued liabilities on our Consolidated Balance Sheets at December 31, 2018. We recognized an intangible asset of $550 million reflecting the estimated fair value of the marketing-related rights acquired from Japan Tobacco with the remaining $9 million recorded as Prepaid and other current assets on our Consolidated Balance Sheets. The intangible asset will be amortized over nine years, representing the period over which the majority of the benefits are expected to be derived from the applicable products in our HIV portfolio. The amortization expense will be classified as selling expense and recorded as Selling, general and administrative expenses on our Consolidated Statements of Income.Termination of the agreement may be on a product or country basis and will depend on the circumstances, including material breach by either party or expiry of royalty payment term. We may also terminate the entire agreement without cause. [collapse expanded text] |
Gilead Sciences, Japan Tobacco | Dec 2018 | 559 | Licensing and distribution agreement for HIV products | Gilead entered into an agreement with Japan Tobacco to acquire the rights to market and distribute … read morecertain products in our HIV portfolio in Japan and to expand our rights to develop and commercialize elvitegravir to include Japan. We are responsible for the marketing of the products as of January 1, 2019. Under the terms of the agreement, we are obligated to pay Japan Tobacco $559 million in cash, of which $194 million was paid as an up-front payment and the remaining $365 million was reflected in Other accrued liabilities on our Consolidated Balance Sheets at December 31, 2018. We recognized an intangible asset of $550 million reflecting the estimated fair value of the marketing-related rights acquired from Japan Tobacco with the remaining $9 million recorded as Prepaid and other current assets on our Consolidated Balance Sheets. The intangible asset will be amortized over nine years, representing the period over which the majority of the benefits are expected to be derived from the applicable products in our HIV portfolio. The amortization expense will be classified as selling expense and recorded as Selling, general and administrative expenses on our Consolidated Statements of Income. Termination of the agreement may be on a product or country basis and will depend on the circumstances, including material breach by either party or expiry of royalty payment term. We may also terminate the entire agreement without cause. [collapse expanded text] |
ABL Bio, TRIGR Therapeutics | Jul 2018 | 554.3 | Collaboration and licensing agreement for pipeline of novel therapeutic antibodies to treat cancer | TRIGR Therapeutics and ABL Bio entered into a binding agreement for TRIGR to license the global … read morecommercial rights to ABL Bio’s pipeline of novel therapeutic antibodies to treat cancer. These therapeutic antibodies include ‘blood-brain barrier (BBB)’ penetrating bispecific antibodies (BsAb) (VEGF/undisclosed BBB target BsAb, undisclosed target/undisclosed BBB target BsAb); immune cell engaging bispecific antibodies (4-1BB/undisclosed target BsAb, 4-1BB/ undisclosed target BsAb); and a monoclonal antibody against undisclosed target. TRIGR will pay a total upfront fee of USD $4.3 million to license global rights (except for South Korea) to 5 antibodies currently under development by ABL Bio. ABL Bio will also receive research, regulatory and sales-based milestones of more than USD $550 million in total plus royalties. TRIGR shall share the licensing revenue with ABL Bio in the event of out-licenses to a 3rd party. [collapse expanded text] |
Revolution Medicines, Sanofi | Jul 2018 | 550 | Development and licensing agreement for targeted therapies based on biology of cellular enzyme SHP2 | December 2022 Revolution Medicines announced that Sanofi has provided notice of termination of … read morethe parties’ global SHP2 development and commercialization collaboration. Following termination, Revolution Medicines will regain all global rights granted to Sanofi under the agreement, including decision-making regarding research and development, and rights to all commercial proceeds from RMC-4630, a SHP2 inhibitor drug candidate in development for the treatment of patients with certain RAS-addicted cancers. The companies plan to collaborate to transition all Sanofi’s rights and obligations related to RMC-4630 back to Revolution Medicines over the first half of 2023. July 2018 Sanofi and REVOLUTION Medicines announced an exclusive worldwide partnership to develop and commercialize targeted therapies, based on the biology of the cellular enzyme SHP2, for patients with non-small lung cancer and other types of cancer carrying certain mutations. This collaboration builds on precision oncology discoveries by REVOLUTION Medicines and preclinical development of RMC-4630, the company’s lead small molecule inhibitor of SHP2, and will apply Sanofi’s expertise in oncology research and drug development. In the collaboration, the companies will jointly develop SHP2 inhibitors, which are designed to reduce cell growth signaling that is overactive in cancer. Both parties will contribute to the research and development program, with REVOLUTION Medicines continuing to lead research and early clinical development, and Sanofi leading later development activities for the program. The companies expect to begin first-in-human clinical trials with RMC-4630 in the second half of 2018. REVOLUTION Medicines will receive an upfront fee of $50 million, and Sanofi will cover R&D costs for the joint SHP2 program. Sanofi will receive an exclusive worldwide license for global commercialization of any approved products targeting SHP2, subject to a U.S. co-promote option for REVOLUTION Medicines. The companies will enter into a 50/50 profit and loss share arrangement in the U.S., and REVOLUTION Medicines will receive a tiered royalty reaching mid-double digits on sales in other markets. REVOLUTION Medicines could also receive more than $500 million in development and regulatory milestone payments. [collapse expanded text] |
Allergan, Almirall | Aug 2018 | 550 | Asset purchase agreement for medical dermatology portfolio | Almirall announced the acquisition of a portfolio of five products from Allergan's Medical … read moreDermatology unit in the United States, conditional to the clearance by the relevant authorities. It comprises a balanced portfolio of mature and growth brands, Aczone (dapsone), Tazorac (tazarotene), Azelex (azelaic acid) and Cordran Tape (fludroxycortide), as well as Seysara (sarecycline), a new, innovative first in class tetracycline-derived antibiotic with anti-inflammatory properties for the treatment of moderate to severe acne vulgaris, in patients 9 years of age and older, with a best-in-class safety profile. The acquisition has been announced for a cash consideration of $550 MM at closing. The transaction is subject to be approved by antitrust authorities in the US. Almirall does not envisage any significant obstacles to closing by Q4 2018. Strategic and straight forward transaction in one single geography. [collapse expanded text] |
Amgen, Molecular Partners | Dec 2018 | 547 | Collaboration agreement for immuno-oncology | Amgen and Molecular Partners announced a collaboration and license agreement for the clinical … read moredevelopment and commercialization of MP0310 (FAP x 4-1BB). MP0310 is a preclinical molecule designed to locally activate immune cells in the tumor by binding to FAP on tumor stromal cells (localizer) and co-stimulating T cells via 4-1BB (immune modulator). Amgen obtains exclusive global development and commercial rights for MP0310. The parties will jointly evaluate MP0310 in combination with Amgen`s oncology pipeline products, including its investigational BiTE (bispecific T cell engager) molecules. Molecular Partners retains certain rights to develop and commercialize its proprietary DARPin pipeline products in combination with MP0310. Molecular Partners will receive an upfront payment of $50 million and is eligible to receive up to $497 million in development, regulatory and commercial milestone payments, as well as double-digit, tiered royalties up to the high teens. The parties will share the clinical development costs in defined percentages for the first three indications subject to certain conditions. For all additional clinical trials, Amgen is responsible for all development costs. [collapse expanded text] |
Cara Therapeutics, Vifor-Fresenius Medical Care Renal Pharma | May 2018 | 540 | Licensing agreement for KORSUVA injection | Cara Therapeutics has licensed worldwide rights, except in the U.S., Japan and South Korea, to … read morecommercialize KORSUVA (CR845/difelikefalin) injection for the treatment of chronic kidney disease-associated pruritus (CKD-aP) in dialysis patients to Vifor Fresenius Medical Care Renal Pharma. Cara will receive an upfront payment in the amount of $50 million in cash and an equity investment of $20 million to acquire Cara common stock at a price of approximately $17/share. Cara will also be eligible to receive additional payments of up to $470 million, which includes $30 million in regulatory and up to $440 million in tiered commercial milestones that are all sales related. Cara is also eligible to receive tiered royalties based on net sales of KORSUVA injection in the licensed territories. VFMCRP will have the exclusive rights to commercialize KORSUVA injection for the treatment of CKD-aP in dialysis patients ex-U.S. except in Japan and South Korea. Cara retains full development and commercialization rights for KORSUVA injection for the treatment of CKD-aP in the U.S. except in the dialysis clinics of Fresenius Medical Care North America (FMCNA), where VFMCRP and Cara will promote KORSUVA injection under a profit-sharing arrangement based on net FMCNA clinic sales recorded by Cara. FMCNA is the largest kidney dialysis provider in the U.S. and treated approximately 38% of U.S. dialysis patients in 2017. Cara will solely promote KORSUVA injection in all non-FMC clinics in the U.S. and retain all profits from those sales. [collapse expanded text] |
AstraZeneca, Luye Pharma Group | May 2018 | 538 | Licensing agreement for Seroquel and Seroquel XR | AstraZeneca has entered into an agreement with Luye Pharma for the sale and licence of the rights … read moreto Seroquel and Seroquel XR in the UK, China and other international markets, including Brazil, Australia, Saudi Arabia, Mexico, South Korea, Thailand, Argentina, Malaysia and South Africa. The transaction is part of AstraZeneca’s strategy to focus on its three main therapy areas of Oncology, Cardiovascular, Renal & Metabolism and Respiratory. Seroquel, used primarily to treat schizophrenia and bipolar disease, has lost its compound patent protection globally; the Seroquel XR formulation patents have now also expired in the vast majority of markets. AstraZeneca partnered the rights to Seroquel and Seroquel XR in Japan and Venezuela under prior agreements. Luye Pharma will pay $538m in consideration including $260m immediately following closure of the transaction. In addition, a milestone is payable on the successful transition of certain activities to Luye. AstraZeneca will continue to manufacture and supply Seroquel and Seroquel XR to Luye Pharma during a transition period. The upfront and future payments will be reported as Other Operating Income in the Company’s financial statements. [collapse expanded text] |
Genentech, Microbiotica | Jun 2018 | 534 | Collaboration agreement for precision metagenomics microbiome platform to analyse patient samples | Microbiotica & Genentech Strategic Collaboration SummaryParties Involved… read more
Collaboration Scope
Rights & Responsibilities
Financial Terms
Regulatory Approval
Overall SummaryMicrobiotica and Genentech have entered a multi-year collaboration to advance microbiome-based biomarker discovery and drug development for IBD. Microbiotica will use its precision metagenomics microbiome platform to analyze patient samples from Genentech’s investigational IBD trials, aiming to identify microbiome biomarker signatures, novel drug targets, and live bacterial therapeutics. Microbiotica will receive an undisclosed upfront payment and is eligible for up to $534 million in milestone payments, plus royalties on product sales. Genentech will retain exclusive rights to proprietary discoveries and has an option to license assets developed by Microbiotica. [collapse expanded text] |
Ligand Pharmaceuticals, Roivant Sciences | Mar 2018 | 533.8 | Licensing agreement for LGD-6972 | Ligand Pharmaceuticals announced the signing of a license agreement granting Roivant Sciences … read moreexclusive global rights to develop and commercialize LGD-6972, Ligand’s glucagon receptor antagonist (GRA). Ligand will receive upfront license fees, and is eligible to receive clinical and regulatory milestone payments as well as sales-based milestone payments and royalties. Roivant will be responsible for all costs related to the program, effective immediately. [collapse expanded text] |
Kineta, Pfizer | Dec 2018 | 520 | Collaboration and licensing agreement for cancer immunotherapies | Kineta Immuno-Oncology has entered into a strategic research collaboration with Pfizer to develop … read moreRIG-I agonist immunotherapies for the treatment of cancer. The research collaboration and license agreement grants to Pfizer the exclusive rights to KIO's RIG-I screening platform and related compounds and technologies. The companies will collaborate to develop and test small molecule agonists that target RIG-I, an innate immunostimulatory pathway that can elicit immunogenic cell death (ICD) in tumors, providing both direct tumor cell killing and enhanced anti-tumor immune responses. KIO will receive a $15 million upfront payment and will be eligible to receive up to $505 million in potential research, development and sales milestone payments. KIO is eligible to receive tiered royalties on net sales. Pfizer will fund RIG-I target-related research conducted by Kineta for an initial period of three years, after which Pfizer will be responsible for further development and commercialization of product candidates. [collapse expanded text] |
Top partnering deals of 2017 valued at over US$500m.
Partners | Date | Value, US$m | Subject | Termsheet |
---|---|---|---|---|
AstraZeneca, Merck and Co | Jul 2017 | 8500 | Collaboration agreement for Lynparza in combination with PD-1 inhibitors | AstraZeneca and Merck announced a deal to use AstraZeneca’s PARP inhibitor Lynparza in combination … read morewith PD-1 inhibitors developed by both companies. Lynparza, which has been approved in the United States for the treatment of one type of ovarian cancer, will be combined with AstraZeneca’s Imfrinzi and Merck’s Keytruda. The companies said they will work independently to combine Lynparza with their own PD-1 inhibitors, but will work together in combination with other drugs. Additionally, the companies will work together to test Lynparza in combinations with other undisclosed drugs, the companies said this morning. PARP stands for poly ADP ribose polymerase, which is an enzyme many cancer cells are more dependent upon than regular, healthy cells are. Additionally, the two companies will work together to develop and commercialize AstraZeneca’s selumetinib, an oral MEK inhibitor. AstraZeneca is currently developing selumetinib for multiple indications including thyroid cancer. Under terms of the deal between Merck and AstraZeneca, the U.S. company will pay AstraZeneca up to $8.5 billion for the deal. Merck will provide its transatlantic partner with $1.6 billion in upfront funding, as well as $750 million for certain license options. AstraZeneca could earn an additional $6.15 billion from future regulatory and sales milestones. [collapse expanded text] |
Cardinal Health, Medtronic | Apr 2017 | 6100 | Asset purchase agreement for patient monitoring & recovery divisio | Medtronic plc announced that it has entered into a definitive agreement with Cardinal Health Inc. … read moreto sell its Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses within the Patient Monitoring & Recovery (PMR) division of its Minimally Invasive Therapies Group (MITG). The transaction is expected to close in Medtronic's second quarter of its fiscal year 2018, subject to receipt of customary regulatory approvals and satisfaction of other customary closing conditions. Under the terms of the definitive agreement, Medtronic will receive $6.1 billion in cash, subject to certain adjustments, with total after-tax proceeds estimated to be approximately $5.5 billion. Medtronic intends to allocate $1 billion of the after-tax proceeds for incremental share repurchases in FY18, with the balance used to reduce its debt. This deployment of proceeds is consistent with Medtronic's near-term capital allocation strategy, improves the company's debt leverage ratio, and enables future investments in higher growth and higher margin opportunities. The company remains committed to a capital allocation policy that balances returns to its shareholders with reinvestment in its businesses. [collapse expanded text] |
Ablynx, Sanofi | Jul 2017 | 2917.2 | Collaboration and licensing agreement for Nanobody-based therapeutics | Ablynx has entered into a research collaboration and global exclusive licensing agreement with … read moreSanofi initially focused on developing and commercialising Nanobody-based therapeutics for the treatment of various immune-mediated inflammatory diseases. This collaboration gives Sanofi access to certain Nanobodies in Ablynx's existing portfolio as well as to Ablynx's scientists and proprietary Nanobody platform. Sanofi gains exclusive global rights to certain multi-specific Nanobodies against selected targets, with options for similar rights to additional targets, for a total of eight potential Nanobody product candidates. The financial terms include an upfront payment of €23 million to Ablynx, comprised of license and option fees. In addition, Ablynx will receive research funding, estimated to amount to €8 million for the initially selected targets. Upon exercise of options to additional targets, Sanofi will pay Ablynx further option exercise fees and research funding. Sanofi will be responsible for the development, manufacturing and commercialisation of any products resulting from this agreement. Ablynx will be eligible to receive development, regulatory and commercial milestone payments of up to €2.4 billion plus tiered royalties up to low double digits on the net sales of any products originating from the collaboration. [collapse expanded text] |
Perrigo, Royalty Pharma | Mar 2017 | 2850 | Royalty financing for Tysabri (natalizumab) | Perrigo has completed the divestiture of its rights to the royalty stream from global net sales of … read morethe multiple sclerosis drug Tysabri (natalizumab) to RPI Finance Trust, an affiliate of Royalty Pharma. The transaction comprises a total consideration of $2.2 billion in cash and up to $650 million in royalties earned if global net sales of Tysabri meet specific thresholds in 2018 and 2020. RPI will acquire all of Perrigo's rights to receive Tysabri royalty payments from and after January 1, 2017, which Perrigo has under an agreement with Biogen. [collapse expanded text] |
AstraZeneca, Pieris Pharmaceuticals | May 2017 | 2157.5 | Collaboration, option and licensing agreement for PRS-060 | July 2023 AstraZeneca has informed the Pieris of its decision to terminate the parties' R&D … read morecollaboration agreement and hand back elarekibep along with discontinuing the remaining discovery program. May 2017 Pieris announced a strategic collaboration in respiratory diseases with AstraZeneca to develop novel inhaled drugs that leverage Pieris' Anticalin platform, including its lead preclinical drug candidate, PRS-060. Anticalin molecules are engineered proteins which can mimic antibodies by binding to sites either on other proteins or on small molecules. They are smaller than monoclonal antibodies, offering the potential of direct delivery to the lung. Pieris will be responsible for advancing its preclinical lead candidate, PRS-060, into Phase 1 clinical trials in 2017. PRS-060 is an Anticalin against interleukin-4 receptor alpha (IL-4Ra) with potential in asthma. AstraZeneca will fund all clinical development and subsequent commercialization programs and Pieris has the option of co-development and co-commercialization in the US from Phase 2a onwards. In addition, the parties will collaborate to progress four additional novel Anticalins against undisclosed targets for respiratory diseases with Pieris having the option to co-develop and co-commercialize in the US two of these programs. AstraZeneca will make an upfront and near term milestone payments to Pieris in the amount of $57.5 million -- $45 million USD of upfront payments and $12.5 million USD for the initiation of the PRS-060 Phase 1 trial. Pieris has the potential to receive development-dependent milestones and eventual commercial payments for all products not exceeding $2.1 billion as well as tiered royalties on the sales of any potential products commercialized by AstraZeneca. For programs co-developed by Pieris, the Company stands to receive increased royalties or a gross margin share on worldwide sales equal, dependent on the level of investment to which Pieris commits. [collapse expanded text] |
Immunomedics, Seattle Genetics | Feb 2017 | 1965 | Licensing and development agreement for sacituzumab govitecan (IMMU-132) | Seattle Genetics, Inc. , a global biotechnology company, announced a development and license … read moreagreement with Immunomedics, Inc. under which Seattle Genetics would receive exclusive worldwide rights to develop, manufacture and commercialize sacituzumab govitecan (IMMU-132). Sacituzumab govitecan is an antibody-drug conjugate (ADC) targeted to TROP-2, which is expressed in several solid tumors including cancers of the breast, lung and bladder. Sacituzumab govitecan is in a phase 1/2 trial for patients with triple negative breast cancer (TNBC), as well as multiple other solid tumors. Upon closing of the transactions contemplated by the development and license agreement, Immunomedics would receive an upfront payment of $250 million. In addition, Seattle Genetics would pay development, regulatory and sales-dependent milestone payments across multiple indications and geographic regions of up to a total maximum of approximately $1.7 billion, as well as tiered double-digit royalties. The closing of the transactions contemplated by the development and license agreement is subject to customary conditions, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. In addition, for a limited period of time, Immunomedics has the right to continue discussions with a small number of parties that previously expressed interest in licensing sacituzumab govitecan. If a third party provides Immunomedics with a financially superior licensing offer, Seattle Genetics has the right to match any such offer, and if it decides not to match, Immunomedics has the right to accept the superior offer and terminate the proposed development and license agreement upon payment of a termination fee to Seattle Genetics. Concurrent with the transaction, Seattle Genetics is purchasing approximately $15 million of common stock, representing a 2.8 percent stake in Immunomedics. Seattle Genetics has also been granted the right to purchase an additional 8,655,804 shares of common stock at a price of $4.90 per share for a defined period. The equity purchase and rights are not subject to closing of the development and license agreement. [collapse expanded text] |
Bristol-Myers Squibb, Halozyme Therapeutics | Sep 2017 | 1865 | Collaboration agreement for ENHANZE drug-delivery technology | Bristol-Myers Squibb and Halozyme Therapeutics announced a global collaboration and license … read moreagreement to develop subcutaneously administered Bristol-Myers Squibb immuno-oncology medicines using Halozyme’s ENHANZE drug-delivery technology. Halozyme will receive an initial $105 million for access to the ENHANZE technology. Bristol-Myers Squibb has designated multiple immuno-oncology targets including programmed death 1 (PD-1) and has an option to select additional targets within five years from the effective date. The collaboration may extend to a maximum of 11 targets. Halozyme has the potential to earn milestone payments of up to $160 million for each of the nominated collaboration targets and additional milestone payments for combination products, subject to achievement of specified development, regulatory and sales-based milestones. In addition, Bristol-Myers Squibb will pay Halozyme royalties on sales of products using the ENHANZE technology developed under the collaboration. [collapse expanded text] |
CureVac, Eli Lilly | Oct 2017 | 1800 | Collaboration agreement for mRNA cancer vaccines | Eli Lilly and CureVac have announced a global immuno-oncology collaboration focused on the … read moredevelopment and commercialization of up to five potential cancer vaccine products based on CureVac's proprietary RNActive technology. The companies will use messenger RNA (mRNA) technology that targets tumor neoantigens for a more robust anti-cancer immune response. CureVac will receive an upfront payment of $50 million and an equity investment of €45 million. CureVac is also eligible to receive more than $1.7 billion in development and commercialization milestones if all five vaccines are successfully developed, plus tiered royalties on product sales. Lilly is responsible for target identification, clinical development and commercialization. CureVac will be responsible for mRNA design, formulation and manufacturing of clinical supply and retains the option to co-promote the vaccine products in Germany. CureVac's proprietary RNActive technology will be used to deliver mRNA that ultimately directs the human immune system to target the encoded neoantigens. These tumor-specific neoantigens instruct the patient's existing immune system to mount a selective and potent response to eradicate the cancer. [collapse expanded text] |
DuPont, FMC | Mar 2017 | 1600 | Asset purchase agreement for Health & Nutrition business | DuPont announced that it has entered into a definitive agreement with FMC Corporationto divest a … read moreportion of DuPont's Crop Protection business, including certain research and development capabilities, and to acquire substantially all of FMC's Health & Nutrition business. The transaction includes consideration to DuPont of $1.6 billion to reflect the difference in the value of the assets, including cash of $1.2 billion and working capital of $425 million. Under the terms of the agreement, FMC will acquire DuPont's Cereal Broadleaf Herbicides and Chewing Insecticides portfolios including Rynaxypyr®, Cyazypyr® and Indoxacarb. As part of the transaction agreement, DuPont will acquire FMC's Health & Nutrition business, which generated more than $700 million in revenues in 2016 from two main segments: texturants as food ingredients and pharmaceutical excipients. [collapse expanded text] |
Bayer, Loxo Oncology | Nov 2017 | 1550 | Collaboration and licensing agreement for Larotrectinib and LOXO-195 | Loxo Oncology has entered into a global collaboration with Bayer to develop and commercialize … read morelarotrectinib and LOXO-195, Loxo Oncology’s franchise of highly selective TRK inhibitors for patients with TRK fusion cancers. Loxo Oncology will receive a $400M upfront payment. Loxo Oncology is eligible for $450M in milestone payments upon larotrectinib regulatory approvals and first commercial sale events in certain major markets and an additional $200M in milestone payments upon LOXO-195 regulatory approvals and first commercial sale events in certain major markets. Loxo Oncology will lead global development activities and United States (U.S.) regulatory activities. Bayer will lead ex-U.S. regulatory activities, and worldwide commercial activities. Globally, Loxo Oncology and Bayer will share development costs on a 50/50 basis. In the U.S., where Loxo Oncology and Bayer will co-promote the products, the parties will share commercial costs and profits on a 50/50 basis. Bayer will pay Loxo Oncology a $25M milestone upon achieving a certain U.S. net sales threshold. Outside of the U.S., where Bayer will commercialize, Bayer will pay Loxo Oncology tiered, double-digit royalties on net sales, and sales milestones totaling $475M. Bayer will book revenues worldwide. [collapse expanded text] |
Amgen, CytomX Therapeutics | Oct 2017 | 1455 | Collaboration agreement for immuno-oncology | Amgen and CytomX Therapeutics have entered into a strategic collaboration in immuno-oncology. … read moreThe companies will co-develop a CytomX Probody T-cell engaging bispecific against the Epidermal Growth Factor Receptor (EGFR), a highly validated oncology target expressed on multiple human cancer types. Probody T-cell engaging bispecifics are antibody constructs capable of directing cytotoxic T-cells in tumor microenvironments. In preclinical studies, CytomX's Probody versions of EGFRxCD3 bispecific therapeutics induced tumor regressions and increased the therapeutic window for this high potential cancer target. Amgen and CytomX will co-develop a Probody T-cell engaging bispecific against EGFRxCD3 with CytomX leading early development. Amgen will lead later development and commercialization with global late-stage development costs shared between the two companies. Amgen will make an upfront payment of $40 million and purchase $20 million of CytomX common stock. CytomX will be eligible to receive up to $455 million in development, regulatory and commercial milestones for the EGFR program. Amgen will lead global commercial activities with CytomX able to opt into a profit share in the U.S. and receive tiered, double-digit royalties on net product sales outside of the U.S. Amgen will also receive exclusive worldwide rights to develop and commercialize up to three additional, undisclosed targets. Should Amgen ultimately pursue all of these targets, CytomX will be eligible to receive up to $950 million in additional upfront and milestone payments and high single-digit to mid-double digit royalty payments on any resulting products. CytomX will also receive the rights from Amgen to an undisclosed preclinical T-cell engaging bispecific program; Amgen is eligible to receive milestones and royalty payments on any resulting products from this CytomX program. [collapse expanded text] |
Janssen Biotech, Zymeworks | Nov 2017 | 1452 | Licensing agreement for six bispecific antibodies | Zymeworks has executed a licensing agreement with Janssen Biotech. Zymeworks will provide … read moreJanssen with a worldwide, royalty-bearing license to research, develop, and commercialize up to six bispecific antibodies directed to Janssen therapeutic targets using Zymeworks’ Azymetric and EFECT platforms. Janssen will be responsible for all research, development, and commercial activities under the licensing agreement. Zymeworks will receive an upfront payment of US$50 million and is eligible to potentially receive up to US$282 million in development and up to US$1.12 billion in commercial milestone payments, and tiered royalties on potential sales. Janssen also has the option to develop two additional bispecific programs under the agreement subject to a future option payment. [collapse expanded text] |
Dermira, Genentech, Roche | Aug 2017 | 1410 | Licensing agreement for Lebrikizumab | Dermira has entered into a licensing agreement with F. Hoffmann-La Roche Ltd and Genentech. … read moreDermira will obtain exclusive, worldwide rights to develop and commercialize lebrikizumab, a monoclonal antibody targeting interleukin 13 (IL-13), for atopic dermatitis and all other indications, except Roche will retain certain rights, including exclusive rights to develop and promote lebrikizumab for interstitial lung diseases, such as idiopathic pulmonary fibrosis. Dermira will make an initial payment of $80 million to Roche and payments totaling $55 million in 2018. Dermira will also be obligated to make additional payments upon the achievement of certain milestones, comprising $40 million upon the initiation of Dermira’s first Phase 3 clinical study, up to $210 million upon the achievement of regulatory and first commercial sale milestones in certain territories and up to $1.025 billion based on the achievement of certain thresholds for net sales of lebrikizumab for indications other than interstitial lung disease. Upon potential regulatory approval, Dermira will make royalty payments representing percentages of net sales that range from the high single-digits to the high teens. [collapse expanded text] |
Alnylam Pharmaceuticals, Vir Biotechnology | Oct 2017 | 1310 | Collaboration and licensing agreement for RNAi therapeutics for infectious diseases | April 2020 Vir Biotechnology and Alnylam Pharmaceuticals announced an expansion to their broad … read moremulti-target existing collaboration for the development and commercialization of RNAi therapeutics for infectious diseases, including SARS-CoV-2, the virus that causes the disease COVID-19. This expansion includes up to three additional targets focused on host factors for SARS-CoV-2, including ACE2 and TMPRSS2, both of which are considered critical for viral entry, with the potential for an additional host target to emerge from Vir’s functional genomics work. Pursuant to an amendment to the collaboration agreement, the companies will utilize Alnylam’s recent advances in lung delivery of novel conjugates of siRNA – the molecules that mediate RNAi – together with Vir’s infectious disease expertise and established capabilities, to bring forward up to three additional host factor-targeting development candidates (DCs) to treat SARS-CoV-2 and potentially other coronaviruses as well. The two named targets include angiotensin converting enzyme-2 (ACE2) and transmembrane protease, serine 2 (TMPRSS2). ACE2 is known to be the viral entry receptor for SARS-CoV-2 and other coronaviruses, while TMPRSS2 is believed to cleave the SARS-CoV-2 spike protein to facilitate cellular attachment. The third target is expected to emerge from Vir’s ongoing functional genomics efforts to identify novel host factors pertinent to coronaviral infection and targetable by siRNA, mAbs or small molecules. As part of the original collaboration to advance investigational RNAi therapeutics to treat disease caused by coronavirus infection, Alnylam has designed and synthesized over 350 siRNAs targeting highly conserved regions of the SARS-CoV-2 genome. Lead siRNAs have recently been identified by scientists at Alnylam and are now being further evaluated by scientists at Vir for anti-viral activity in support of DC selection. Upon DC selection, Vir will lead development efforts – working closely with Alnylam to generate the data required to enable the potential for rapid commencement of clinical studies. Under the collaboration and license agreement, as amended, in addition to leading development of selected DCs, Vir will lead commercialization of any products emerging from the collaboration that gain regulatory approval. At clinical proof of concept, Alnylam will have an option to share equally in any profits and losses associated with the development and commercialization of each coronavirus program. Alternatively, Alnylam may elect to earn development and commercialization milestones and royalties on net sales of any products resulting from the collaboration in amounts agreed upon for each coronavirus program. These additional targets expand the companies’ collaboration and license agreement announced in 2017, and the subsequent amendment to that agreement announced in March 2020, to now develop novel siRNAs for up to nine infectious disease targets in total, including hepatitis B virus in the Vir-2218 (ALN-HBV02) program currently in Phase 1/2 studies. October 2017 Alnylam Pharmaceuticals announced an exclusive licensing agreement with Vir Biotechnology for the development and commercialization of RNAi therapeutics for infectious diseases, including chronic hepatitis B virus (HBV) infection. As part of this agreement, the companies will advance Alnylam's HBV program and also initiate a research collaboration for the development and advancement of up to four additional RNAi therapeutic programs for the treatment of other infectious diseases with high unmet needs. As part of the agreement, Alnylam will lead ALN-HBV02 to IND filing, with Vir then progressing ALN-HBV02 through human proof of concept (POC); the companies will co-fund the program through this point. Subsequently, Vir will fund and conduct all development through completion of Phase 2 studies. Thereafter, Alnylam retains the right to opt into a profit-sharing arrangement prior to the start of Phase 3. In connection with the companies' research collaboration for up to four additional infectious disease programs, Vir will fund all research and development costs, while Alnylam retains a product-by-product option on each program to opt into a profit-sharing arrangement following human POC. Under the terms of the agreement, Alnylam will receive an upfront payment, comprised of cash and shares of Vir common stock. Alnylam is also eligible to receive more than $1 billion in potential milestone payments related to the successful advancement of ALN-HBV02 and other infectious disease programs, as well as tiered royalties on products ultimately commercialized by Vir under the collaboration, should Alnylam elect to decline its co-development and profit share option on a per-product basis. [collapse expanded text] |
L'Oreal, Valeant Pharmaceuticals | Jan 2017 | 1300 | Asset purchase agreement for CeraVe, AcneFree and AMBI skincare brands | Valeant Pharmaceuticals has agreed to sell its CeraVe, AcneFree and AMBI skincare brands to L'Oréal … read morefor $1.3 billion in cash. Valeant will use the proceeds from the sale to permanently repay term loan debt under its Senior Credit Facility. CeraVe, AcneFree and Ambi will become part of L'Oréal's Active Cosmetics Division, which includes brands such as La Roche-Posay, Vichy and SkinCeuticals, L'Oréal said in a statement on its website. The CeraVe brand portfolio offers a range of advanced skincare products, including cleansers, moisturizers, sunscreens, healing ointments and a dedicated baby line. The AcneFree brand portfolio offers a full range OTC cleansers and acne treatments in the U.S. introduced to the market in 1966. The AMBI brand portfolio offers a range of skincare products formulated for the needs of multicultural consumers that includes creams, cleansers and moisturizers in the face and body category. [collapse expanded text] |
Biogen, Forward Pharma | Jan 2017 | 1250 | Settlement and licensing agreement for IP rights to multiple sclerosis products | Biogen announced that it had signed a settlement and license deal with Danish company Forward … read morePharma with a $1.25 billion cash payment. The licensing agreement gives Biogen an irrevocable license to Forward’s intellectual property. In addition, Biogen will pay Forward royalties on net sales of Biogen products for multiple sclerosis (MS) that are covered by a Forward patent and that have dimethyl fumarate (DMF) as an active pharmaceutical ingredient. Oral arguments for a patent trial began in late November 2016. The two companies are dueling over Biogen’s multiple sclerosis drug Tecfidera. If Forward won the patent cases, it would receive royalties on all sales of all of Biogen’s drugs for MS that are covered by the patents. Once the License Agreement is executed, Biogen will pay a non-refundable cash package of $1.25 billion. If specific requirements are met, Biogen will also pay Forward future royalties on net sales of its MS drugs covered by Forward’s patent and that have DMF as an ingredient. [collapse expanded text] |
BeiGene, Bristol-Myers Squibb, Celgene | Jul 2017 | 1243 | Collaboration and licensing agreement for BGB-A317 | Celgene entered into a strategic collaboration to develop and commercialize BeiGene's … read moreinvestigational anti-programmed cell death protein 1 (PD-1) inhibitor, BGB-A317, for patients with solid tumor cancers in the United States, Europe, Japan and rest of world outside Asia. BeiGene will retain exclusive rights for the development and commercialization of BGB-A317 for hematological malignancies globally and for solid tumors in Asia (with the exception of Japan). BeiGene will acquire Celgene's commercial operations in China and gain an exclusive license to commercialize Celgene's approved therapies in China - ABRAXANE, REVLIMID and VIDAZA. BeiGene will acquire Celgene's operations in China. BeiGene will also license and assume commercial responsibility for Celgene's approved therapies in China, consisting of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound), REVLIMID (lenalidomide) and VIDAZA (azacitidine). BeiGene is granted licensing rights in China to CC-122, under the same terms and conditions as the approved commercial products. CC-122 is a next generation CelMOD currently in development by Celgene for lymphoma and hepatocellular carcinoma. BeiGene plans to expand manufacturing and commercial operations in China in preparation for the potential approvals of BGB-A317 and future innovative therapies developed by BeiGene in greater China. Celgene will maintain a strategic and R&D presence in China dedicated to long-term commercial activities, regulatory affairs and clinical development of new therapies in the country. Celgene will also continue supporting BeiGene with management of the REVLIMID Risk Minimization Program. BeiGene will receive upfront licensing fees totaling $263 million, and in addition Celgene will acquire an equity stake in BeiGene by purchasing 32.7 million, or 5.9 percent, of BeiGene's ordinary shares at $4.58 per share, or $59.55 per BeiGene's American Depositary Shares (ADS), representing a 35% premium to an 11-day volume-weighted average price of BeiGene's ADS. BeiGene is eligible to receive up to $980 million in development, regulatory and sales milestone payments and royalties on future sales of BGB-A317. [collapse expanded text] |
Arrys Therapeutics, AskAt | Dec 2017 | 1200 | Licensing agreement for AAT-007 and AAT-008 | AskAt announced a worldwide licensing agreement in immuno-oncology with Arrys Therapeutics for two, … read morestructurally different Prostaglandin E2 receptor 4 (EP4) antagonists [AAT-007 and AAT-008]. AskAt will receive upfront, development, and commercial milestone payments potentially exceeding (US) $1.2 billion, in addition to sales royalties. This Agreement covers all territories except China. [collapse expanded text] |
Johnson & Johnson Innovation, Protagonist Therapeutics | May 2017 | 1179 | Collaboration agreement for gastrointestinal diseases treatment | May 2019 Protagonist Therapeutics announced the expansion of its worldwide license and … read morecollaboration agreement with Janssen Biotech for the co-development and commercialization of PTG-200, Protagonist's first-in-class, oral peptide IL-23 receptor antagonist, for all indications including inflammatory bowel disease (IBD). The expanded agreement builds upon Protagonist's ongoing development collaboration with Janssen on PTG-200 and triggers a $25 million milestone payment to Protagonist. The new agreement expands the scope of the original collaboration with Janssen established in 2017 by supporting efforts towards second generation IL-23 receptor antagonists. Protagonist will receive a $25 million milestone payment triggered on signing of the amendment and will be eligible to receive over $1.0 billion in additional research, development, regulatory and sales milestones. As part of the new research collaboration, Janssen will pay certain costs and milestones related to advancing pre-clinical candidates through Phase 1 studies, including funding a number of full time equivalent employees (FTEs) at Protagonist for a set period of time. Protagonist will continue to receive clinical development, regulatory and commercial milestones if Janssen elects to retain its license following completion of Phase 2a and/or Phase 2b studies with PTG-200 and/or second generation compounds. Janssen will receive exclusive, worldwide rights to develop and commercialize PTG-200 and any second-generation compounds derived from the research collaboration, and Protagonist will receive tiered royalties on net product sales. Protagonist Therapeutics and Janssen will jointly conduct the development of PTG-200 through completion of Phase 2 clinical proof-of-concept (POC) in Crohn's disease. Janssen will be responsible for further development and commercialization activities beyond Phase 2 development. According to the terms of the agreement, Protagonist will have the right to co-detail PTG-200 and second generation compounds derived from the collaboration in the U.S. market. May 2017 Investors in Protagonist Therapeutics are excited after Janssen inked a collaboration deal worth nearly $1 billion to develop the company’s treatment for a variety of gastrointestinal diseases, including Crohn’s and inflammatory bowel syndrome. The two companies are joining forces to develop and market PTG-200, Protagonist's first-in-class, oral peptide Interleukin-23 receptor antagonist. The drug is currently in preclinical studies and is expected to being in Phase I clinical trials in the second half of 2017. If Janssen moves the drug into a Phase IIb trial, Protagonist could earn an additional $125 million. They could earn an additional $200 million if Janssen takes the drug into a Phase III trial, according to the Form 8-K. Under terms of the deal Johnson & Johnson Innovation (JNJ), the pharma giant’s investment arm, will provide $50 million in upfront financing for the drug’s development, with another $94 million in potential milestones. Protagonist Therapeutics and Janssen will jointly conduct the development of PTG-200 through Phase II clinical proof-of-concept in Crohn's disease, after which time Janssen will be responsible for development and commercialization. Per the terms of the agreement, Protagonist will have the right to co-detail PTG-200 in the United States. [collapse expanded text] |
Janssen Pharmaceuticals, PeptiDream | Apr 2017 | 1150 | Development agreement for peptide-based therapies to target multiple metabolic and cardiovascular targets | Janssen Pharmaceuticals and Peptidream will develop peptide-based therapies to target multiple … read moremetabolic and cardiovascular targets. The two companies will used PeptiDream’s proprietary Peptide Discovery Platform System (PDPS) technology to identify macrocyclic/constrained peptides against the metabolic and cardiovascular targets identified by Janssen. The companies also plan to optimize hit peptides into therapeutic peptides or small molecule products. PeptiDream’s proprietary Peptide Discovery Platform System enables the production of highly diverse non-standard peptide libraries with high efficiency which then can be developed into peptide-based or small molecule-based therapeutics, according to company information. The agreement between the two companies is worth up to $1.15 billion, the companies said, when clinical development, commercialization and sales milestones are factored into the deal. In addition, PeptiDream is eligible to receive royalties on sales of any products that arise from the collaboration. Under terms of the deal, PeptiDream will receive an undisclosed upfront payment, as well as research funding. Janssen will have the right to develop and commercialize all compounds resulting from the collaboration. [collapse expanded text] |
Bayer, PeptiDream | Nov 2017 | 1100 | Collaboration agreement for macrocyclic/constrained peptides against multiple targets | PeptiDream has entered into a multi-target discovery collaboration with Germany-based Bayer. … read morePeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) technology to identify macrocyclic/constrained peptides against multiple targets of interest selected by Bayer, and to optimize hit peptides into therapeutic peptides or small molecule products. Bayer also holds an exercisable option to negotiate for an extension of the license to peptide-drug conjugate (PDC), diagnostic, bioimaging, and agricultural use and applications. Bayer will have the right to develop and commercialize all compounds resulting from the collaboration. PeptiDream would receive an undisclosed upfront payment and research funding and is eligible to receive preclinical, clinical, and commercialization milestone payments potentially totaling up to $1.11 billion (¥124.5 billion). In addition, PeptiDream is eligible to receive royalties on sales of any products that arise from the collaboration. [collapse expanded text] |
Cooper Companies, Teva Pharmaceutical Industries | Sep 2017 | 1100 | Asset purchase agreement for PARAGARD IUD | The Cooper Companies has entered into a definitive asset purchase agreement with Teva … read morePharmaceutical Industries to acquire the global rights and business of its PARAGARD Intrauterine Device (IUD) in a $1.1 billion cash transaction. [collapse expanded text] |
Cooper Surgical, Teva Pharmaceutical Industries | Sep 2017 | 1100 | Asset purchase agreement for PARAGARD | Teva Pharmaceutical has entered into a definitive agreement under which CooperSurgical will acquire … read morePARAGARD (intrauterine copper contraceptive), a product within its global Women’s Health business, in a $1.1 billion cash transaction. This transaction includes Teva’s manufacturing facility in Buffalo, NY, which produces PARAGARD® exclusively. [collapse expanded text] |
Ipsen, Merrimack Pharmaceuticals, Shire Pharmaceuticals | Jan 2017 | 1025 | Asset purchase agreement for cancer drugs | Merrimack Pharmaceuticals announced it was selling off some of its assets to France-based Ipsen or … read morea deal that could hit $1.025 billion, refocusing its pipeline programs, and completing laying off 80 percent of its staff. Ipsen is paying Merrimack an upfront fee of $575 million in cash. Another $450 million is possible in regulatory approval-based milestone payments. It also picks up Merrimack’s generic version of doxorubicin hydrochloride (HCL) liposome injection (generic DOXIL) for ovarian cancer, AIDS-related Kaposi’s sarcoma and multiple myeloma. [collapse expanded text] |
Ipsen, Merrimack Pharmaceuticals, PharmaEngine, Shire Pharmaceuticals | Apr 2017 | 1025 | Asset purchase and licensing agreement for ONIVYDE (irinotecan liposome injection) in combination with fluorouracil and leucovorin | Ipsen announced that it has completed its acquisition of global oncology assets from Merrimack … read morePharmaceuticals, in Cambridge, MA., focusing on ONIVYDE® (irinotecan liposome injection) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy, in combination with fluorouracil and leucovorin.1,2 Ipsen has gained exclusive commercialization rights for the current and potential future indications for ONIVYDE® in the U.S., as well as the current licensing agreements with Shire for commercialization rights ex-U.S. and PharmaEngine for Taiwan. The acquisition also includes the Merrimack commercial and manufacturing infrastructure for ONIVYDE®, and generic doxorubicin HCl liposome injection. Along with this acquisition, Ipsen will continue to advance the clinical development program for ONIVYDE®. Financial terms of the acquisition include an upfront cash payment of $575 million to Merrimack Pharmaceuticals, and up to $450 million upon the approval of potential additional indications for ONIVYDE® in the U.S. [collapse expanded text] |
Sawai Pharmaceuticals, Upsher-Smith | Apr 2017 | 1005 | Asset purchase agreement for generic pharmaceuticals business | Sawai Pharmaceutical Co. Ltd., a leading Japanese generic pharmaceuticals manufacturer, and Upsher- … read moreSmith Laboratories, Inc., an established generics manufacturer based in Minnesota, U.S., announced the signing of an agreement for Sawai to purchase the generic pharmaceuticals business of Upsher-Smith, from its parent, ACOVA, Inc Under the agreement signed, Sawai will purchase all the equity interest in the generic pharmaceuticals business of Upsher-Smith from ACOVA, for consideration of $1.05 billion. The transaction will be financed by bank loans and available cash. [collapse expanded text] |
Vir Biotechnology, Visterra | Oct 2017 | 1000 | Collaboration, licensing and option agreement for Hierotope platform technology | Visterra has entered into a research collaboration, exclusive license, and option agreement with … read moreVir Biotechnology to develop and commercialize select programs for infectious diseases derived from Visterra’s Hierotope platform technology. The strategic collaboration will combine Visterra’s novel platform for designing and engineering antibody-based biological medicines against unique disease targets with Vir’s specialized expertise in innovative research and development for infectious diseases. Visterra’s Hierotope platform utilizes proprietary computational tools and technologies to identify specific epitopes that are critical to the function of the antigen and to design and engineer precision antibody-based biological medicines to target these epitopes that are difficult to address by traditional techniques. Vir will exclusively license from Visterra up to five research programs for infectious diseases: VIS-FLX, a long-acting monoclonal antibody being developed for the prevention of influenza A in high-risk individuals; VIS-RSV, a bispecific monoclonal antibody for the treatment of respiratory syncytial virus, or RSV, that is designed to both neutralize the virus and prevent its pro-inflammatory activity; VIS-FNG, a bispecific monoclonal antibody for the treatment of severe fungal infections that targets fungal glycans common among most human fungi, including Candida, Aspergillus and Cryptococcus; and Vir may further expand their license by up to two additional infectious disease research programs. In conjunction with the collaboration, Visterra has received from Vir an upfront payment, and will receive funding of costs incurred by Visterra related to the licensed programs. Visterra will be responsible for the development of the Vir licensed programs up to a pre-determined stage, and then Vir will assume further development of these candidates. At the point when Vir assumes development responsibilities, Visterra will be eligible to receive future development, regulatory and sales milestone payments per Vir licensed program. Visterra will also be eligible to receive tiered royalties related to worldwide net sales of products developed under the collaboration. Under additional terms of the collaboration, Visterra has granted Vir an option to a minority financial interest in VIS410, a monoclonal antibody in development for the treatment of hospitalized patients with influenza A. Following exercise of the option, Vir may also elect to co-promote VIS410 in select territories. In total, Visterra is eligible to receive over $1 billion in payments from development, regulatory, and sales milestones, and is also eligible to receive royalties on future product sales from licensed programs. [collapse expanded text] |
CRISPR Therapeutics, Vertex Pharmaceuticals | Dec 2017 | 1000 | Co-development and co-promotion agreement for CTX001 | April 2021 Vertex Pharmaceuticals and CRISPR Therapeutics announced that the companies have … read moreamended their collaboration agreement to develop, manufacture and commercialize CTX001, an investigational CRISPR/Cas9-based gene editing therapy that is being developed as a potentially curative therapy for sickle cell disease and transfusion-dependent beta-thalassemia. With this revised agreement, Vertex will deploy the breadth of its established global capabilities and proven experience in manufacturing, development, regulatory, and commercialization to maximize the potential for CTX001 to transform the lives of tens of thousands of patients in the U.S., Europe and other countries. CRISPR Therapeutics will continue to support the development of CTX001 and invest in further innovation to maximize its potential. Vertex will lead global development, manufacturing and commercialization of CTX001 with support from CRISPR Therapeutics. Vertex will be responsible for 60% of program costs and will receive 60% of profits from future sales of CTX001 worldwide, representing a 10% increase in program economics compared to the previous agreement. CRISPR will be responsible for 40% of costs and will receive 40% of profits. CRISPR will receive a $900 million upfront payment, with potential for a $200 million payment upon the first regulatory approval of CTX001. June 2019 Vertex and CRISPR Therapeutics have expanded their collaboration and entered into an exclusive licensing agreement to discover and develop gene editing therapies for the treatment of DMD and DM1. Vertex will pay $175 million upfront for the exclusive worldwide rights to CRISPR Therapeutics’ existing and future intellectual property including foundational CRISPR/Cas9 technology, novel endonucleases, single and double cut guide RNAs, and AAV vectors for DMD and DM1 gene editing products. For the DMD program, Vertex is responsible for all research, development, manufacturing, and commercialization activities and all related costs. For the DM1 program, Vertex and CRISPR will share research costs for specified guide RNA research to be conducted by CRISPR, and Vertex is responsible for all other research, development, manufacturing, and commercialization costs. CRISPR Therapeutics is eligible to receive payments of up to $1 billion inclusive of the upfront and potential future payments based upon the successful achievement of specified research, development, regulatory, and commercial milestones for the DMD and DM1 programs. Vertex will pay tiered royalties on future net sales on any products that may result from this collaboration. At IND filing, CRISPR has the option to forego the DM1 milestones and royalties to co-develop and co-commercialize all DM1 products globally. December 2017 Vertex Pharmaceuticals and CRISPR Therapeutics announced that the companies will co-develop and co-commercialize CTX001, an investigational gene editing treatment, as part of the companies’ previously announced collaboration aimed at the discovery and development of new gene editing treatments that use the CRISPR/Cas9 technology. CTX001 represents the first gene-based treatment that Vertex exclusively licensed from CRISPR Therapeutics as part of the collaboration. For CTX001, CRISPR and Vertex will equally share all research and development costs and profits worldwide. [collapse expanded text] |
Amag Pharmaceuticals, EndoCeutics | Feb 2017 | 985 | Licensing agreement for Intrarosa (prasterone) | AMAG Pharmaceuticals, Inc.and Endoceutics, Inc. announced that they have entered into an exclusive … read morelicense agreement that provides AMAG with U.S. commercial rights to Intrarosa™ (prasterone). Intrarosa is the only FDA-approved, locally administered, daily, non-estrogen product for the treatment of moderate-to-severe dyspareunia (pain during intercourse), a common symptom of vulvar and vaginal atrophy (VVA), due to menopause. Under the terms of the license agreement, AMAG will receive the right to commercialize and develop Intrarosa in the U.S. for the treatment of VVA and FSD. At closing, AMAG will pay Endoceutics $50 million of total upfront consideration and issue Endoceutics 600,000 unregistered shares of AMAG common stock. In addition, AMAG will pay Endoceutics up to $10 million upon delivery of adequate launch quantities of Intrarosa and $10 million upon the first anniversary of the effective date of the agreement. Endoceutics will be entitled to certain sales milestone payments, including a first sales milestone payment of $15 million, which would be triggered when Intrarosa annual net U.S. sales exceed $150 million, and a second milestone payment of $30 million, which would be triggered when annual net U.S. sales exceed $300 million. Should annual net U.S. sales exceed $500 million, there are additional sales milestone payments of up to $850 million, which would be triggered at various sales thresholds. AMAG will also pay Endoceutics tiered royalties as a percent of Intrarosa net sales ranging from the mid-teens (for calendar year net sales up to $150 million) to the mid-twenties (for any calendar year net sales that exceed $1 billion). At closing, AMAG and Endoceutics will also enter into a supply agreement, under which Endoceutics will supply Intrarosa to AMAG. AMAG has also committed to co-fund a Phase 3 clinical program, which would be conducted by Endoceutics to support regulatory approval of Intrarosa for the treatment of certain types of FSD in post-menopausal women. The direct costs of the potential FSD label expansion study will be shared equally by the parties and capped at up to $20 million for AMAG. The transaction does not include the transfer of any Endoceutics employees or facilities. [collapse expanded text] |
Janssen Biotech, Protagonist Therapeutics | Aug 2017 | 950 | Licensing and collaboration agreement for PTG-200 | December 2023 Protagonist Therapeutics announced it has earned a $10 million milestone payment … read morefollowing the dosing of the third patient in ANTHEM-UC, a Phase 2b trial to evaluate the safety and effectiveness of JNJ-2113 compared with placebo in participants with moderately to severely active ulcerative colitis. With this additional payment, the Company has now earned $60 million in payments in the fourth quarter of 2023 for milestones achieved in the JNJ-2113 Phase 2b and Phase 3 clinical programs led by the Company's collaboration partner, Janssen Biotech. March 2022 Protagonist Therapeutics announced earning a $25 million milestone payment from its collaboration with Janssen Biotech following dosing of the third patient in the Phase 2b FRONTIER 1 clinical trial of PN-235 (JNJ-77242113). October 2021 Protagonist Therapeutics will receive a $7.5 million milestone payment from Janssen Biotech triggered by the completion of the clinical data collection-related Phase 1 activities for PN-235 (JNJ-2113). This investigational drug candidate is one of the three IL-23 receptor antagonists that are part of Protagonist's collaboration agreement with Janssen, which provides for concurrent development of multiple oral IL-23 receptor antagonists against a broad range of indications. July 2021 Protagonist Therapeutics announced its entry into an amended collaboration agreement with Janssen Biotech relating to research, development, manufacture and commercialization of multiple oral Interleukin (IL)-23 receptor antagonist drug candidates. The compounds currently in development are PTG-200, an oral IL-23 receptor antagonist in Phase 2 development for the treatment of Crohn's disease (CD), and PN-232 and PN-235, two second-generation oral IL-23 receptor antagonist candidates. PN-232 and PN-235 are currently in Phase 1 clinical development. The amended agreement provides for the concurrent development of multiple oral IL-23 receptor antagonists against a broad range of indications. As such, certain development milestones have been reconfigured based on multiple drug candidates advancing in parallel. Protagonist remains eligible to potentially receive approximately $900 million in future development and sales milestones, in addition to the $80 million in payments already received under the original agreement. Royalty rates remain unchanged. Janssen will have the right to continue research on IL-23 receptor antagonists developed during the collaboration for three years from the closing of the Restated Agreement. Under the terms of the Restated Agreement, Janssen will conduct all future studies beyond those that are currently ongoing with PTG-200, PN-232 and PN-235 and will be solely financially responsible for any such studies. Accordingly, Protagonist's development and expense obligations will be limited to its relative share of the currently ongoing studies with these candidates. With this revised agreement, Janssen will continue to deploy the breadth of its established global capabilities and proven experience toward further clinical development of these assets. Janssen retains exclusive, worldwide rights to develop and commercialize PTG-200, PN-232, PN-235 and any other second-generation compounds derived from the research collaboration conducted under the Original Agreement, or Janssen's further research under the Restated Agreement. Protagonist will have the right to co-detail up to two licensed products in ulcerative colitis (UC) and CD in the U.S. market. August 2017 Protagonist Therapeutics has closed the worldwide license and collaboration transaction for PTG-200 with Janssen Biotech. Following closure of the transaction, Protagonist received the upfront payment of $50 million originally announced by the two companies as part of the agreement on May 30, 2017. The agreement provides Janssen Biotech with a worldwide license for the co-development and commercialization of PTG-200, Protagonist's first-in-class, oral peptide IL-23 receptor antagonist for all indications including inflammatory bowel disease (IBD). PTG-200 is expected to enter Phase 1 clinical testing before the end of 2017. [collapse expanded text] |
Valeant Pharmaceuticals, iNova Pharmaceuticals | Jun 2017 | 930 | Asset purchase agreement for business | Valeant Pharmaceuticals International, Inc. announced it has entered into an agreement to sell its … read moreiNova Pharmaceuticals business to a company jointly owned by funds advised and managed by Pacific Equity Partners and The Carlyle Group for $930 million in cash. iNova, which markets a diversified portfolio of prescription and over-the-counter products in several areas, such as weight management, pain management, cardiology and cough and cold, operates in more than 15 countries around the world. iNova holds leading market positions in Australia and South Africa and also has an established platform in Asia. Valeant will maintain a strong footprint in these countries primarily through its Bausch + Lomb franchise. Valeant will use proceeds from the sale to permanently repay term loan debt under its Senior Secured Credit Facility. In this transaction, Goldman, Sachs & Co. served as financial advisor to Valeant, and Baker McKenzie acted as legal advisor to Valeant. [collapse expanded text] |
Incyte, Macrogenics | Oct 2017 | 900 | Collaboration and licensing agreement for MGA012 | November 2020 MacroGenics announced that $25 million in milestones have been achieved under its … read moreexclusive global collaboration and license agreement with Incyte for retifanlimab, an investigational anti-PD-1 monoclonal antibody designed by MacroGenics and licensed to Incyte (as INCMGA0012). The milestones were triggered by clinical and regulatory activities related to the further advancement of the molecule, including the recent initiation of POD1UM-303, Incyte’s Phase 3 global study in patients with metastatic squamous cell anal carcinoma (SCAC). September 2020 MacroGenics announced that a $15 million milestone payment has been triggered under its exclusive global collaboration and license agreement with Incyte for retifanlimab (MGA012), an investigational anti-PD-1 monoclonal antibody designed by MacroGenics and licensed to Incyte (as INCMGA00012). The milestone was triggered by the initiation of the Phase 3 POD1UM-304 clinical trial, evaluating the efficacy and safety of retifanlimab with platinum-based chemotherapy in patients with metastatic squamous and non-squamous non-small cell lung cancer (NSCLC). October 2017 Incyte and MacroGenics have entered into an exclusive global collaboration and license agreement for MacroGenics’ MGA012, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1). Incyte has obtained exclusive worldwide rights for the development and commercialization of MGA012 in all indications, while MacroGenics retains the right to develop its pipeline assets in combination with MGA012. Upon closing, Incyte will pay MacroGenics an upfront payment of $150 million. Incyte will receive worldwide rights to develop and commercialize MGA012 in all indications. Per the terms of the collaboration, MacroGenics will also be eligible to receive up to $420 million in potential development and regulatory milestones, and up to $330 million in potential commercial milestones. If MGA012 is approved and commercialized, MacroGenics would be eligible to receive royalties, tiered from 15 percent to 24 percent, on future sales of MGA012 by Incyte. Under the terms of the collaboration, Incyte will lead global development of MGA012. MacroGenics retains the right to develop its pipeline assets in combination with MGA012, with Incyte commercializing MGA012 and MacroGenics commercializing its asset(s), if any such potential combinations are approved. In addition, MacroGenics retains the right to manufacture a portion of both companies’ global clinical and commercial supply needs of MGA012. MacroGenics intends to utilize its commercial-scale GMP facility, which is expected to be fully operational in 2018. [collapse expanded text] |
Bavarian Nordic, Janssen Pharmaceuticals | Jul 2017 | 879 | Collaboration and licensing agreement for MVA-BN technology (updated) | May 2022 Janssen Pharmaceutical announced the termination of its collaboration and license … read moreagreements with Bavarian Nordic that leverage Bavarian Nordic’s MVA-BN (Modified Vaccinia Ankara - Bavarian Nordic) technology to develop potential vaccines against the hepatitis B virus and human papillomaviruses. Janssen remains committed to its strong collaboration with Bavarian Nordic in the quest to prevent and cure infectious diseases – with collaborations in HIV and Ebola still ongoing. August 2017 Bavarian Nordic announced the closing of the transaction with Janssen Pharmaceuticals regarding the license and collaboration agreement entered into on July 27, 2017. The transaction has been cleared under the Hart-Scott-Rodino Antitrust Improvements Act. July 2017 Bavarian Nordic announced an additional worldwide exclusive license and collaboration agreement with Janssen Pharmaceuticals. This new collaboration grants Janssen the exclusive rights to Bavarian Nordic’s MVA-BN technology for two additional programs, targeting vaccines against hepatitis B virus and the human immunodeficiency virus. Janssen will provide an upfront payment of $10 million USD, and Johnson & Johnson Innovation will provide $33 million USD in an equity investment by subscription of new Bavarian Nordic shares. Bavarian Nordic will be eligible to receive milestone payments based upon the achievement of specified development, regulatory and sales milestones up to a total of $836 million USD, in addition to tiered royalties on future sales. With the addition of programs targeting HBV and HIV-1, the companies are now collaborating on four product development programs combining Bavarian Nordic’s MVA-BN technology with Janssen’s AdVac technology platform. Further details on the subscription of shares will be announced separately. [collapse expanded text] |
Department of Defense, Toshiba Medical Systems Corporation | Feb 2017 | 827.6 | Contract service agreement for radiology systems, accessories and training | Toshiba Medical Systems won a 5-year $827.6 million fixed-price, indefinite delivery and quantity … read morecontract with the US Department of Defense. The contract will position Toshiba Medical to provide radiology systems, accessories and training to the DoD, including the Air Force, Navy, Army, Marine Corps and federal civilian agency. [collapse expanded text] |
Ionis Pharmaceuticals, Janssen Biotech | Nov 2017 | 805 | Licensing agreement for IONIS-JBI2-2.5 Rx | Ionis Pharmaceuticals has licensed a second orally delivered Generation 2.5 antisense drug to … read moreJanssen Biotech for which Ionis earned $5 million. IONIS-JBI2-2.5Rx is designed to locally reduce the production of an undisclosed target in the gastrointestinal (GI) tract for the treatment of a GI autoimmune disease. Jansen will now assume all global development, regulatory, and commercialization responsibilities for IONIS-JBI2-2.5Rx for GI diseases. Ionis is eligible to receive nearly $800 million in development, regulatory and sales milestone payments and license fees. In addition, Ionis will receive tiered royalties that on average are double-digits on sales from any product that is successfully commercialized. IONIS-JBI1-2.5Rx, the first collaboration target, was licensed to Janssen last year and Janssen has assumed all global development, regulatory and commercialization responsibilities related to this drug. [collapse expanded text] |
Genzyme, Principia Biopharma, Sanofi | Nov 2017 | 805 | Licensing agreement for PRN2246 | October 2018 Principia Biopharma announced the achievement of $10 million in additional … read moremilestones related to successful development activities conducted by Principia as part of the clinical development of PRN2246. PRN2246, also known as SAR442168, is a Bruton’s tyrosine kinase (BTK) inhibitor that crosses the human blood-brain barrier and modulates immune cell function in the brain for the potential treatment of central nervous system (CNS) diseases. PRN2246 is being developed under a collaboration agreement with Sanofi. November 2017 Sanofi will develop Principia Biopharma's experimental oral treatment that shows promise in multiple sclerosis (MS) and, potentially, other central nervous system (CNS) diseases. Under the license agreement, Sanofi will develop Principia's Bruton's tyrosine kinase (BTK) inhibitor (PRN2246), which was designed to access the brain and spinal cord by crossing the blood-brain barrier and impact immune cell and brain cell signalling. PRN2246 is currently in clinical development. Principia will grant Sanofi an exclusive, worldwide license to develop and commercialize PRN2246. Sanofi will pay Principia a $40 million upfront payment, future milestone payments that could total $765 million and royalties on product sales. Principia has the option to co-fund Phase 3 development, in exchange for either increased royalties on worldwide product sales or a profit and loss sharing arrangement in the United States. [collapse expanded text] |
Autifony Therapeutics, Boehringer Ingelheim | Dec 2017 | 798.8 | Collaboration agreement for voltage gated potassium channel modulator platform | May 2019 Autifony Therapeutics announced that the second milestone has successfully been … read moreachieved under Autifony’s agreement with Boehringer Ingelheim. This comes less than four months after achievement of the first milestone, and shortly after the companyannounced positive clinical data from its ketamine challenge study. Boehringer Ingelheim acquired an exclusive option to purchase Autifony’s Kv3.1/3.2 positive modulator platform in December 2017. Further details of the milestone were not disclosed. Included in the agreement is the lead molecule, AUT00206, which is currently under evaluation in a Phase Ib clinical trial in patients with schizophrenia. Further molecules are also showing significant promise with potential to treat other CNS disorders in areas of unmet medical need, such as hearing disorders and Fragile X syndrome. December 2017 Boehringer Ingelheim and Autifony Therapeutics have signed an agreement about certain aspects of Autifony’s voltage gated potassium channel modulator platform. Boehringer Ingelheim now has an exclusive option to purchase Autifony’s Kv3.1/3.2 positive modulator platform. Included in the agreement is the lead compound AUT00206, a novel, orally active small molecule that is currently being evaluated in two Phase Ib studies, including one in patients with schizophrenia. Boehringer Ingelheim will pay Autifony a €25 million upfront fee, with the possibility of further payments of up to €17.5 million during the option period based on achievement of short term milestones. The total potential transaction may sum up to €627.5 million upon reaching development and pre-commercialisation milestones once Boehringer Ingelheim has exercised its option. Further financial details were not disclosed. [collapse expanded text] |
Department of Defense, Fujifilm medical systems | Aug 2017 | 768 | Contract service agreement for Digital Imaging Network-PACS project | FUJIFILM Medical Systems U.S.A., Inc., a leading provider of diagnostic imaging products and … read moremedical informatics solutions, announced that it has earned a new 10-year contract with a maximum value of $768 million as part of the Digital Imaging Network-PACS (DIN-PACS) IV project from the U.S. Department of Defense (DoD) and the U.S. Department of Veterans Affairs. Specifically, U.S. government healthcare providers can now purchase and install various technologies from Fujifilm’s Synapse enterprise imaging portfolio including Synapse 5 PACS, Synapse Mobility Enterprise Web Viewer, Synapse 3D, Synapse CV (Cardiovascular) and Synapse VNA (Vendor Neutral Archive). Fujifilm’s technology will play a significant role in the MHS Genesis transition—a project that will replace the current electronic health system (EHR) used by the DoD and Veterans Affairs. Specifically, MHS GENESIS integrates inpatient and outpatient best-of-suite solutions that connect medical and dental information across the continuum of care, from point of injury to the military treatment facility. MHS GENESIS will support the availability of electronic health records for more than 9.4 million DoD beneficiaries and approximately 205,000 Military Health System personnel globally. It enables the application of standardized workflows, integrated healthcare delivery, and data standards for the improved and secure electronic exchange of medical and patient data. With a 5-year base period and a 5-year renewal option, the Fujifilm systems covered under the DIN-PACS IV contract are now available to the DoD, the U.S. Department of Veterans Affairs, and other federal agencies are eligible to purchase from DIN-PACS IV, including Indian Health Services. To date, 29 facilities have already installed Fujifilm Synapse systems globally. Enterprise Imaging is rapidly evolving as a necessary organizational priority for health systems across the globe and Fujifilm’s Synapse portfolio is the most comprehensive solution available today. Fujifilm’s Synapse solutions under the DIN-PACS IV contract provide core technology to allow U.S. government healthcare organizations to deploy an Enterprise Imaging strategy that addresses modern IT architecture needs, security, cost savings, operational efficiencies, physician needs, improved outcomes and diagnostic imaging excellence. [collapse expanded text] |
Aspen Pharmacare Canada, AstraZeneca | Aug 2017 | 766 | Licensing agreement for anaesthetic products | Aspen Pharmacare Canada completed the transfer of Canadian commercialisation rights associated with … read morefive of AstraZeneca's anaesthetic products, significantly expanding Aspen's product portfolio. The products included in this transaction are: DIPRIVAN 1%® (propofol) Short-acting intravenous sedative/anaesthetic for injection.NAROPIN® (ropivacaine hydrochloride) Local anaesthesia solution for injection.SENSORCAINE® (bupivacaine hydrochloride) Short-acting local or regional anaesthetic for injection.XYLOCAINE®/XYLOCARD® (lidocaine hydrochloride) Local anaesthesia, solution for injection, formulations for topical anaesthesia and injectable anti-arrhythmic.EMLA CREAM®/EMLA PATCH ® (lidocaine + prilocaine) Topical anaesthetic, cream and patch. All marketing and commercialisation of the newly-acquired anaesthesia products will continue seamlessly through the efforts of the Aspen team, building on the strong anaesthesia heritage established by AstraZeneca. The originator of these brands, AstraZeneca, will continue to manufacture these products for Aspen for the foreseeable future, ensuring product consistency for the marketplace. [collapse expanded text] |
KalVista Pharmaceuticals, Merck and Co | Oct 2017 | 761.1 | Collaboration and option agreement for KVD001 | February 2020 KalVista Pharmaceuticals announced that the option agreement between KalVista and … read moreMerck related to intravitreal diabetic macular edema (DME) candidate KVD001 and future oral DME molecules has expired. Merck paid a $37 million non-refundable upfront fee to KalVista. This agreement with Merck only covered the investigational intravitreal candidate, KVD001, and future oral plasma kallikrein inhibitor programs for DME. With the option expiration, KalVista has no obligations to Merck, and retains full ownership of all of its DME intellectual property in addition to its oral hereditary angioedema (HAE) portfolio. KalVista intends to continue to aggressively pursue its efforts to develop multiple best-in-class oral plasma kallikrein therapies for HAE, as well as additional programs focused on other proteases. October 2017 KalVista Pharmaceuticals has entered into a collaboration agreement with Merck, through a subsidiary, for KVD001, the Company’s investigational intravitreal (IVT) injection candidate currently in development for potential treatment of diabetic macular edema (DME), as well as future oral DME compounds based upon plasma kallikrein inhibition. KalVista has granted to Merck certain rights including an option to acquire KVD001 through a period following completion of the Phase 2 proof-of-concept trial that KalVista intends to commence later this year. KalVista also has granted to Merck a similar option to acquire investigational orally delivered molecules for DME that KalVista will continue to develop as part of its ongoing research and development activities. As consideration for the agreement, Merck will pay to KalVista a $37 million non-refundable upfront fee. KalVista is further eligible to receive payments associated with the exercise of the options by Merck and the achievement of milestones for each program that potentially total up to $715 million. KalVista also will receive tiered royalties on net sales for therapeutic candidates commercialized under this agreement. KalVista will fund and retain control over the planned Phase 2 clinical trial of KVD001 as well as development of the investigational oral DME compounds through Phase 2, unless Merck exercises its options earlier. In addition to the collaboration, KalVista has entered into a separate $9.1 million private placement transaction with Merck under which Merck has acquired 1,070,589 shares of KalVista, representing a 9.9% ownership stake, at a price of $8.50 per share. This private placement closed concurrent with execution of the Option Agreement. [collapse expanded text] |
Calithera Biosciences, Incyte | Jan 2017 | 750 | Research and licensing agreement for experimental small molecule arginase inhibitor CB-1158 in hematology and oncology | Shares of Calithera Biosciences (CALA) are up more than 30 percent this morning after inking a … read moreresearch and licensing deal potentially worth up to $750 million with Delaware-based Incyte Corporation (INCY). Incyte and Calithera will combine forces to develop Calithera’s experimental small molecule arginase inhibitor CB-1158 in hematology and oncology. CB-1158 is currently being studied in a monotherapy dose escalation trial and additional studies are expected to evaluate CB-1158 in combination with immuno-oncology agents, including anti-PD-1 therapy. Under terms of the deal Calithera will receive $53 million in upfront money. That includes $45 million in cash and an $8 million equity investment by Incyte. When milestones and potential royalties are factored in, the deal could be worth about $750 million for Calithera. Incyte will receive worldwide rights to develop and commercialize CB-1158 in hematology and oncology and Calithera will retain certain rights to research, develop and commercialize certain other arginase inhibitors in certain orphan indications. Incyte will fund 70 percent of global development and Calithera will be responsible for the remaining 30 percent. [collapse expanded text] |
MedImmune, Sanofi-Pasteur, Swedish Orphan Biovitrum | Mar 2017 | 739.9 | Development and licensing agreement for MEDI8897, nirsevimab | April 2023 Sanofi has simplified its contractual arrangements relating to the development and … read morecommercialization of Beyfortus (nirsevimab) in the United States. Sobi will terminate its participation agreement with AstraZeneca, and Sanofi and AstraZeneca will update the Collaboration Agreement so that Sanofi has full commercial control of nirsevimab in the US. Sanofi has simultaneously entered into a direct royalty agreement with Sobi to share a portion of US net sales from nirsevimab. With respect to territories outside the US, the existing Collaboration Agreement between AstraZeneca and Sanofi continues to govern that relationship. The new and updated contractual agreements do not impact nirsevimab registration and launch in the US, where all parties remain committed to making Beyfortus available for all infants in time for the 2023/24 RSV season. March 2017 MedImmune and Sanofi Pasteur announced an agreement to develop and commercialise MEDI8897 jointly. MEDI8897 is a monoclonal antibody for the prevention of lower respiratory tract illness caused by respiratory syncytial virus. MEDI8897 is currently in a Phase IIb clinical trial in pre-term infants who are ineligible for Synagis, the current standard of care medicine, and the development plan includes a proposed Phase III trial in healthy full-term and late pre-term infants. Sanofi Pasteur will make an upfront payment of €120 million and pay up to €495 million upon achievement of certain development and sales-related milestones. The two companies will share all costs and profits equally. MedImmune and AstraZeneca will continue to lead all development activity through initial approvals, and AstraZeneca will retain MEDI8897 manufacturing activities. Sanofi-Pasteur will lead commercialisation activities for MEDI8897. [collapse expanded text] |
Department of Defence, Hologic | Apr 2017 | 721.1 | Contract service agreement for radiology systems | Hologic has won a maximum $721.1 million firm-fixed-price contract for radiology systems from the … read moreUS Department of Defense, according to a DoD release published yesterday. The 5-year base indefinite-delivery, indefinite-quantity contract comes with one 5-year option period, according to the DoD release. [collapse expanded text] |
Bristol-Myers Squibb, Roche | Apr 2017 | 710 | Licensing agreement for BMS-986168 anti-eTau compound | Bristol-Myers Squibb has entered into agreement to license BMS-986168, an anti-eTau compound in … read moredevelopment for Progressive Supranuclear Palsy (PSP), to Biogen. Biogen will pay to Bristol-Myers Squibb an upfront payment of $300 million with potential milestone payments of up to $410 million. Biogen also will assume all remaining obligations to the former stockholders of iPierian, Inc. related to Bristol-Myers Squibb’s acquisition of the company in 2014. [collapse expanded text] |
CVC Capital Partners, Teva Pharmaceutical Industries | Sep 2017 | 703 | Asset purchase agreement for women’s health business | Teva has entered into a definitive agreement under which CVC Capital Partners Fund VI will acquire … read morea portfolio of products within its global women’s health business across contraception, fertility, menopause and osteoporosis for $703 million in cash. The portfolio of products, which is marketed and sold outside of the U.S., includes Ovaleap, Zoely, Seasonique, Colpotrophine, Actonel and additional products. [collapse expanded text] |
IBA Molecular Imaging, Mallinckrodt Pharmaceuticals | Jan 2017 | 690 | Asset purchase agreement for molecular imaging business | Mallinckrodt has closed the sale of its global Nuclear Imaging business to IBA Molecular for … read moreapproximately $690 million before tax, including up-front and contingent considerations and the assumption of long-term obligations. Mallinckrodt's action to divest Nuclear Imaging continues the company's strategy to transform its portfolio with specialty pharmaceutical assets that are durable, innovative and have significant volume growth potential. The total consideration of approximately $690 million (before tax) consists of approximately $574 million of up-front consideration, the assumption of approximately $39 million of long-term obligations, and approximately $77 million of contingent consideration. [collapse expanded text] |
Alexion Pharmaceuticals, Halozyme Therapeutics | Dec 2017 | 680 | Licensing agreement for ENHANZE technology | Alexion Pharmaceuticals and Halozyme Therapeutics announced a collaboration and license agreement … read morethat enables Alexion to use Halozyme’s ENHANZE drug-delivery technology in the development of subcutaneous formulations for their portfolio of products. The agreement provides Alexion with the opportunity for exclusive development of up to four targets, including a next generation subcutaneous formulation of ALXN1210 (ALXN1210 SC), the company’s investigational long-acting C5 complement inhibitor, to potentially further extend the dosing interval of ALXN1210 SC to once every two weeks or once per month. Halozyme will receive an initial $40 million with the potential to earn additional payments of up to $160 million for each target developed, subject to achievement of specified development, regulatory and sales-based milestones. Halozyme will also receive mid-single digit royalties on sales of commercialized products. [collapse expanded text] |
Foundation Consumer Healthcare, Teva Pharmaceutical Industries | Sep 2017 | 675 | Asset purchase agreement for emergency contraception products | Teva has entered into a definitive agreement under which Foundation Consumer Healthcare will … read moreacquire Plan B One-Step and Teva’s value brands of emergency contraception, Take Action, Aftera, and Next Choice One Dose for $675 million in cash. [collapse expanded text] |
Abbvie, Principia Biopharma | Jun 2017 | 672.5 | Development and licensing agreement for oral immunoproteasome inhibitors | AbbVie (NYSE: ABBV), a global biopharmaceutical company, and Principia Biopharma Inc., a private, … read moreclinical-stage biopharmaceutical company, announced that they have entered a collaboration for the development of oral immunoproteasome inhibitors. The collaboration is aimed at developing first-in-class oral therapies that bring the power of proteasome inhibition safely into the field of immunology. The collaboration contemplates the creation and development of orally bioavailable, selective inhibitors of the immunoproteasome subunits to target autoimmunity. AbbVie and Principia will collaborate on research and pre-clinical studies. Upon successful completion, AbbVie will be responsible for ongoing clinical development and commercialization of viable compounds resulting from the partnership. Financial terms were not disclosed. [collapse expanded text] |
Janssen Biotech, Legend Biotech | Dec 2017 | 600 | Collaboration and licensing agreement for LCAR-B38M | April 2022 Legend Biotech announced the achievement of a $50 million milestone under its … read morecollaboration agreement with Janssen Biotech for ciltacabtagene autoleucel (cilta-cel), now marketed in the United States under the brand name CARVYKTI. Cilta-cel is a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy. February 2022 Legend Biotech has achieved two milestones under its collaboration agreement with Janssen Biotech for ciltacabtagene autoleucel (cilta-cel), resulting in aggregate payments to Legend Biotech of $50 million. Cilta-cel is a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy. December 2017 Janssen Biotech has entered into a worldwide collaboration and license agreement with Legend Biotech to develop, manufacture and commercialize a chimeric antigen receptor T-cell drug candidate, LCAR-B38M, which specifically targets the B-cell maturation antigen. LCAR-B38M is currently accepted for review by the China Food and Drug Administration and in the planning phase of clinical studies in the United States for multiple myeloma. The companies have entered into a 50/50 percent cost-sharing/profit-split arrangement, except in Greater China, where Janssen and Legend have a 30/70 percent cost-sharing/profit-split arrangement. Janssen will make an upfront payment of $350 million that will be recorded in the fourth quarter and additional payments based upon the achievement of certain development, regulatory and sales milestones. [collapse expanded text] |
Biocon, Equillium | May 2017 | 595 | Collaboration and licensing agreement for Itolizumab | December 2019 Equillium and Biocon have expanded their collaboration and license agreement for … read moreitolizumab to grant Equillium exclusive rights for developing and commercializing itolizumab in Australia and New Zealand. May 2017 Equillium entered into a collaboration and license agreement with Biocon, as amended in September 2018, or the Biocon License, pursuant to which Biocon granted us an exclusive license in the United States and Canada, or the Equillium Territory, to develop, make, have made, use, sell, have sold, offer for sale, import and otherwise exploit EQ001 and any pharmaceutical composition or preparation containing or comprising EQ001, or collectively, a Biocon Product, that uses Biocon technology or Biocon know-how. However, unless we achieve certain regulatory and development milestones within a specific time period, the licensed rights, other than development rights, are limited to the fields of orphan indications and the treatment of asthmatic conditions. We also have the right to sublicense through multiple tiers to third parties, provided such sublicenses comply with the terms of the Biocon License and we provide Biocon a copy of each sublicense agreement within 30 days of execution. Under the Biocon License, we granted back to Biocon a license to use our technology and know-how related to EQ001 and Biocon Products in certain countries outside of the Equillium Territory. In consideration of the rights granted to us by Biocon, we have issued to Biocon an aggregate of 2,316,134 shares of our common stock. In addition, we are obligated to pay Biocon up to an aggregate of $30 million in regulatory milestone payments upon the achievement of certain regulatory approvals and up to an aggregate of $565 million in sales milestone payments upon the achievement of first commercial sale of product and specified levels of product sales. We are also required to pay quarterly tiered royalties based on a percentage from the mid-single digits to sub-teen double digits of net sales of Biocon Products, subject to adjustments in certain circumstances. Biocon is also required to pay us royalties at comparable percentages for sales of EQ001 outside of the Equillium Territory if the approvals in such geographies included or referenced our data, including data from certain of our clinical trials, subject to adjustments in certain circumstances. Under the Biocon License, net sales are calculated on a country-by-country basis and are subject to adjustments, including whether the Biocon Product is sold in the form of a combination product. The Biocon License will continue until the expiration of all royalty obligations, unless terminated earlier. Our royalty obligations expire on a product-by-product and country-by-country basis upon the later of ten years from the first commercial sale of such Biocon Product in such country, the expiration of regulatory exclusivity, and the expiration of the last-to-expire Biocon patent covering such Biocon Product in such country. We may terminate the Biocon License unilaterally, with or without reason, upon 120 days’ prior written notice and either party may terminate the Biocon License in the event of the other party’s material breach of the Biocon License that remains uncured for 90 days after receipt of notice from the non-breaching party. Upon termination by us unilaterally or by Biocon for our material breach, Biocon will retain its license to use our intellectual property related to EQ001 and Biocon Products in certain countries outside the Equillium Territory, and we also will grant Biocon a non-exclusive license, and a right of first negotiation to an exclusive license, to use our intellectual property related to EQ001 and Biocon Products in the Equillium Territory. Further, we are subject to certain diligence obligations related to development, commercialization and funding activities and if we fail to comply with these obligations Biocon may, in certain circumstances, terminate the Biocon License and, in certain other circumstances, such failure may result in the permitted fields of use for licensed Biocon Products being limited to orphan indications and the treatment of asthmatic conditions. [collapse expanded text] |
Les Laboratoires Servier, Pieris Pharmaceuticals | Jan 2017 | 570.3 | Collaboration and licensing agreement for bispecific therapeutic programs | Pieris and Servier Forge signed a broad collaboration deal focused on immuno-oncology. The … read morecollaboration will begin with five bispecific therapeutic programs. The lead program is Pieris’ PRS-332, a potential best-in-class PD-1-targeting bispecific checkpoint inhibitor. The two companies will develop it jointly and divide commercial rights by geography. Pieris will hold commercial rights in the U.S. Servier will hold commercial rights for the rest of the world. The four remaining programs aren’t specified, but may combine antibodies from Servier’s portfolio with one or more of Pieris’ proprietary Anticalin protein platforms. The companies have the option to expand the deal up to three more therapeutic programs. In addition, Pieris has the option to co-develop and retain marketing rights in the U.S. for up to three programs beyond PRS-332. Servier, otherwise, will be responsible for developing and commercializing the four other programs globally. Piereis will receive about $31.3 million (US) as an upfront payment. The company may also receive FTE funding for certain projects, an option fee if it’s expanded, and development-dependent and commercial milestone payments for PRS-332, as well as each additional program. Various milestones for PRS-332 could reach $338 million, and about $201 million for each of the other programs. Preclinical and clinical development costs for any co-developed programs will be split. Pieris is eligible for tiered royalties up to low double digits on sales of any products in the Servier territories. Pieris technology allows for the engineering of simultaneous checkpoint inhibition on the same cell. PRS-332 is a novel PD-1 based bispecific made up of an anti-PD-1 antibody that is linked to an Anticalin protein that targets an undisclosed checkpoint target. [collapse expanded text] |
Torrent Pharmaceuticals, Unichem | Nov 2017 | 558 | Asset purchase agreement for 120 brands and manufacturing facility | Torrent Pharmaceuticals to would buy more than 120 brands of Unichem Laboratories in India and … read moreNepal and its manufacturing plant at Sikkim. The deal, valued at 36 billion rupees ($558 million), will be funded by internal accruals and bank borrowing. The acquisition is expected to close by the end of 2017. [collapse expanded text] |
Agenus Bio, Incyte | Feb 2017 | 536 | Amendment to Development and licensing agreement for Retrocyte Display antibody discovery platform | Incyte Corporation and Agenus Inc.announced that the companies have amended the License, … read moreDevelopment and Commercialization Agreement that was originally entered into January 9, 2015. The amended agreement converts the ongoing GITR and OX40 antibody programs from co-funded development and profit-sharing arrangements to royalty-bearing programs, with Incyte now responsible for funding and conducting global development and commercialization. Should candidates from either of these two programs be approved, Agenus would now become eligible to receive 15 percent royalties on global net sales of each approved product. The ongoing TIM-3 and LAG-3 antibody programs remain royalty-bearing programs, at tiered rates of 6 to 12 percent, with Incyte retaining exclusive world-wide clinical development and commercial responsibilities. Pursuant to the amended agreement, Agenus will receive today accelerated milestone payments of $20 million from Incyte related to the clinical development of INCAGN1876 (anti-GITR agonist) and INCAGN1949 (anti-OX40 agonist). Across all programs in the collaboration, Agenus will now be eligible to receive up to a total of $510 million in future potential development, regulatory and commercial milestones. The parties have also entered into a separate Stock Purchase agreement whereby Incyte will purchase 10 million shares of Agenus common stock today at $6 per share. [collapse expanded text] |
Alpine Immune Sciences, Kite Pharma | Oct 2017 | 535 | Collaboration agreement for next generation CAR-T and TCRs | Alpine Immune Sciences has extended the research term of its worldwide research and license … read moreagreement with Kite. The research collaboration and license agreement, initiated in October 2015, grants Kite an exclusive license to two Alpine programs from Alpine’s Transmembrane Immunomodulatory Protein (TIP) program. The license allows Kite to further engineer these candidates into chimeric antigen receptor (CAR-T) and T cell receptor (TCR) product candidates. The research term extension does not change the $535 million in up front and potential regulatory milestones payable to Alpine in the original agreement or royalties Alpine may earn on potential future sales of Kite products incorporating Alpine’s TIP technology. Kite will continue to have access to two programs from Alpine’s TIP technology for use in CAR-T and TCRs during the extended research term. [collapse expanded text] |
Amgen, Immatics Biotechnologies | Jan 2017 | 530 | Licensing and collaboration agreement for T-cell engaging bispecific immunotherapies for multiple cancers | Amgen and Tuebingen, Germany-based Immatics Biotechnologies GmbH, announced that they would … read morecollaborate on a research and licensing program to develop next-generation, T-cell engaging bispecific immunotherapies for multiple cancers. As part of the deal, Immatics’ XPRESIDENT target discovery and T-cell receptor (TCR) platform will be used with Amgen’s validated Bispecific T-cell Engager (BiTE) technology to create new cancer drugs. Amgen will handle clinical development, manufacturing and commercialization. Amgen is paying Immatics $30 million upfront. Immatics will be eligible for more than $500 million in various milestone payments for each program, as well as double-digit tiered royalties on net sales. T-cell engaging bispecifics redirect the T-cell response toward cancer cells that express specific cancer antigens. [collapse expanded text] |
HanAll Pharmaceuticals, Roivant Sciences | Dec 2017 | 502.5 | Licensing agreement for HL161BKN | HanAll BioPharma has licensed rights to its drug that blocks pathogenic antibody recycling that … read morecauses autoimmune disease to Switzerland-based biotech startup Roivant Sciences in a deal worth US$502.5 million. Roivant Sciences will have exclusive rights to develop and commercialize HanAll Biopharma’s drug candidate HL161BKN in North America, Latin America, EU, Middle East and North Africa. Roivant Sciences is paying the Korean firm US$30 million upfront, US$20 million for drug development expenditure. It has also earmarked US$452.5 million for potential milestone payments, as well as double-digit royalties on sales. [collapse expanded text] |
Boehringer Ingelheim, Xynomic Pharmaceuticals | Oct 2017 | 502 | Development and licensing agreement for BI 882370 | Xynomic Pharma has acquired exclusive global rights to develop, manufacture and commercialize BI … read more882370, a 2nd-generation RAF inhibitor, from Boehringer Ingelheim. Xynomic will pay upfront, milestone and royalty payments up to approximately $502 million. [collapse expanded text] |
ImmuNext, Sanofi | Jan 2017 | 500 | Development and research agreement for novel antibody to treat autoimmune diseases | Sanofi and ImmuNext, Inc., announced an agreement focused on the development of a novel antibody … read morewith the potential to treat a range of autoimmune diseases including Lupus and Multiple Sclerosis. Under the terms of the agreement, ImmuNext will grant Sanofi an exclusive, worldwide license to develop and commercialize INX-021, a CD40L monoclonal antibody in preclinical development that suppresses the activity of a cellular pathway that is overactive in many autoimmune diseases. In addition, Sanofi and ImmuNext will initiate a research collaboration to support clinical trials. Potential milestone payments to ImmuNext under the agreement could total $500 million. ImmuNext is also eligible to receive tiered royalties up to double digits on sales of products. [collapse expanded text] |
Department of Defense, Zoll Medical | Dec 2017 | 500 | Contract service agreement for vital signs monitors | Zoll Medical has received a $400 million contract from the Defense Logistics Agency to supply vital … read moresigns monitors to the U.S. Army and U.S. Air Force. The Defense Department said the contract has a one-year base period and five one-year option periods and that Zoll will perform work in Massachusetts through June 27, 2021. The contract was awarded through a competitive procurement process with three bids received. [collapse expanded text] |
Top partnering deals of 2016 valued at over US$500m.
Partners | Date | Value, US$m | Subject | Termsheet |
---|---|---|---|---|
Canon, Toshiba | Mar 2016 | 5900 | Asset purchase agreement for medical unit | Canon Inc. agreed to buy Toshiba Corp.’s medical equipment unit for 665.5 billion yen ($5.9 billion) … read moreas the world’s biggest maker of cameras seeks new growth. The deal will be funded by existing cash and borrowings. Canon had 654 billion yen of cash and equivalents as of Dec. 31 with total debt of 1.6 billion yen, according to data compiled by Bloomberg. [collapse expanded text] |
Bristol-Myers Squibb, Celgene, Evotec | Dec 2016 | 5505 | Collaboration, option and licensing agreement for neurodegenerative disease drug discovery | July 2023 Evotec announced that Bristol Myers Squibb has exercised its option to enter into an … read moreexclusive global licence agreement. The licence covers selected late-stage discovery programmes that were developed and progressed within the collaboration. Bristol Myers Squibb has selected an undisclosed number of programmes that were rapidly developed and progressed using Evotec’s precision medicine platforms for further development within the expanded collaboration. Evotec receives a $ 40 m payment and is eligible to earn performance milestone payments, as well as tiered royalties up to low double-digit percentages on product sales. March 2023 Evotec has extended and expanded its strategic neurodegeneration partnership with Bristol Myers Squibb. The initial partnership proved highly productive in generating a promising pipeline of discovery to clinical-stage programmes. Based on this success, Bristol Myers Squibb and Evotec extend and expand this partnership for additional 8 years with the goal to further broaden and deepen the strategic alliance. May 2022 Evotec has extended and expanded its partnership with Bristol Myers Squibb in targeted protein degradation. Aim of the eight-year extension is to develop a broad pipeline of molecular glue degraders which are small, drug-like compounds. Evotec's proprietary EVO panOmics and EVO panHunter platforms as well as AI/ML-based drug discovery and development platforms will be leveraged. Evotec receives an upfront payment of $200m and expects to obtain further performance-based, near-term and programme-based milestone payments, resulting in a deal potential of $5bn with additional tiered royalties on product sales. January 2020 Evotec received a US$ 6 m payment from Bristol-Myers Squibb following the decision to expand the collaboration to include additional cell lines. May 2019 Evotec announced that its strategic alliance with Celgene has been expanded to include a new cell type triggering a payment of $9.0m to Evotec. May 2018 Evotec will receive a $ 6 m payment from Celgene following Celgene's decision to expand the collaboration to include additional cell lines. October 2017 Evotec announced that its strategic alliance with Celgene has reached a first milestone triggering revenues of $5.0m to Evotec, which are recognised in the third quarter of 2017. The milestone is due to the successful completion of a screening campaign using Evotec's induced pluripotent stem cell ("iPSC")-based screening platform. This milestone has been achieved under an agreement between Evotec and Celgene, signed only in December 2016. The goal of this collaboration is to identify disease-modifying therapeutics for a broad range of neurodegenerative diseases by leveraging Evotec's unique iPSC platform. December 2016 Evotec and Celgene have entered into a strategic drug discovery and development collaboration to identify disease-modifying therapeutics for a broad range of neurodegenerative diseases. Initial disease areas of focus will include Amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, and multiple other neurodegenerative disorders. Evotec will receive an upfront payment of $ 45 m. Celgene holds exclusive options to in-license worldwide rights to Evotec programmes developed from the company's compound library. Evotec may be eligible to receive up to $ 250 m in milestones as well as up to low double-digit royalties on in-licensed programmes. As part of the collaboration, Celgene may also elect to screen compounds from its proprietary CELMoD library using Evotec's iPSC platform to evaluate activity in models of neurodegenerative diseases. The initial term of the collaboration is five years. [collapse expanded text] |
GTCR Golder Rauner, TerSera Therapeutics | Feb 2016 | 3850 | Sin out agreement for TerSera Therapeutics | GTCR, a leading private equity firm, has entered into a partnership with Ed Fiorentino to form … read moreTerSera Therapeutics LLC . The new company will focus on acquiring specialty pharmaceutical companies and products as part of a strategy to build a leading company in the industry. Initial target acquisition opportunities include products which are already approved or currently marketed, as well as late-stage development assets. GTCR's investment in TerSera will be made from GTCR Fund XI, a private equity fund with $3.85 billion of limited partner equity capital commitments. [collapse expanded text] |
Allergan, Sosei, Sosei Heptares | Apr 2016 | 3340 | Collaboration and licensing agreement for subtype-selective muscarinic receptor agonists | January 2021 Sosei is to regain the worldwide rights to its muscarinic agonist programs. … read moreThe program was licensed to Allergan in April 2016, and Allergan was acquired by AbbVie in May 2020. This decision to return worldwide rights was based on business decisions regarding AbbVie's pipeline strategy and not on any efficacy, safety or other data related to the collaboration programs. As a result of this process, AbbVie has notified Sosei Heptares that it will be returning to Sosei Heptares all assets in development under the program, together with all associated intellectual property licensed by Sosei Heptares to Allergan, and all clinical and preclinical data generated under the partnership. April 2016 Sosei announced that its wholly-owned subsidiary, Heptares Therapeutics has entered into a definitive agreement with Allergan under which Allergan will license exclusive global rights to a broad portfolio of novel subtype-selective muscarinic receptor agonists in development for the treatment of major neurological disorders, including Alzheimer’s disease. Heptares will receive an upfront payment of $125 million and is eligible to receive contingent milestone payments of up to approximately $665 million associated with the successful Phase 1, 2 and 3 clinical development and launch of the first three licensed compounds for multiple indications and up to approximately $2.5 billion associated with achieving certain annual sales thresholds during the several years following launch. Heptares is eligible to receive up to double-digit tiered royalties on net sales of all products resulting from the partnership. Allergan is also committing up to $50 million to a research and development program to be conducted jointly by Allergan and Heptares aimed at advancing multiple candidates through Phase 2 clinical studies. Allergan will be responsible for the development of licensed compounds upon initiation of Phase 2b studies and for subsequent manufacturing and commercialization of the products. The agreement covers first-in-class selective small molecule agonists targeting muscarinic M1 and M4 receptors in the brain, discovered using Heptares’ proprietary StaR technology platform. Allergan will receive exclusive rights to a broad clinical and preclinical portfolio of M1, M4 and dual M1/M4 agonists, including HTL9936 and HTL18318, selective M1 agonists currently in Phase 1 clinical development. [collapse expanded text] |
Incyte, Merus | Dec 2016 | 2300 | Collaboration agreement for bispecific antibody technology | Incyte and Merus have entered into a global, strategic collaboration agreement focused on the … read moreresearch, discovery and development of bispecific antibodies utilizing Merus’ proprietary Biclonics® technology platform. The Collaboration and License Agreement grants Incyte the exclusive rights for up to eleven bispecific antibody research programs, including two of Merus’ current preclinical immuno-oncology discovery programs. Incyte has agreed to pay Merus an upfront payment of $120 million. In addition, Incyte has agreed to purchase 3.2 million shares of Merus stock at $25 per share, for a total equity investment of $80 million. The parties have agreed to collaborate on the development and commercialization of up to 11 bispecific antibody programs. For one current preclinical program, Merus will retain all rights to develop and commercialize approved products in the United States, and Incyte will develop and commercialize approved products arising from the program outside the United States. Following any regulatory approval of a product candidate for this particular pre-clinical program, each company has agreed to pay the other tiered royalties ranging from 6 to 10 percent on net sales of products in their respective territories. Merus also has the option to co-fund development of product candidates arising from two other programs. For any program for which Merus exercises its co-development option, Merus would be responsible for 35 percent of global development costs in exchange for a 50 percent share of U.S. profits and losses and tiered royalties ranging from 6 to 10 percent on ex-U.S. sales by Incyte for these programs. Merus also has the right to elect to provide up to 50 percent of detailing activities for product candidates arising from one of these programs in the United States. For each of the other eight programs, Incyte has agreed to independently fund all development and commercialization activities. For these programs, Merus will be eligible to receive potential development, regulatory and sales milestone payments of up to $350 million per program, which could result in an aggregate milestone opportunity of approximately $2.8 billion if all development, regulatory and sales milestones are achieved across all such eight other programs in all territories. Merus will also be eligible to receive tiered royalties ranging from 6 to 10 percent on global sales of any approved products under these eight programs. Merus will retain rights to both of its clinical candidates and MCLA-158, as well as its technology platform and future programs emerging from Merus’ platform that are outside the scope of this agreement. [collapse expanded text] |
Biogen, University of Pennsylvania | May 2016 | 2000 | Collaboration agreement for gene therapy and gene editing technologies | Biogen announced a broad collaboration and alliance with the University of Pennsylvania to advance … read moregene therapy and gene editing technologies. The expansive research and translational development collaboration has multiple objectives, but will primarily focus on the development of therapeutic approaches that target the eye, skeletal muscle and the central nervous system (CNS). Another important aspect of the alliance will focus on validating next-generation gene transfer technology using adeno-associated virus (AAV) gene delivery vectors. The collaboration will also explore the expanded use of genome editing technology -- the insertion, deletion or replacement of DNA in the genome of an organism -- as a potential therapeutic platform. This collaboration with Penn reinforces Biogen’s commitment to gene therapy and rare diseases. Under this broad research and development alliance, Penn will combine its extensive gene therapy resources and expertise to develop therapeutic candidates under the various collaboration programs using both existing and newly developed AAV vectors and will also aid in the development of new manufacturing approaches needed to support commercialization of gene therapy products. Biogen will in turn, leverage both its therapeutic area and target identification expertise and drug development capabilities to help advance the collaboration programs into the clinic and toward approval. In addition to developing AAV gene replacement programs, the collaboration will also explore new therapeutic targets using both next-generation AAV vectors and genome editing technologies. Under the terms of the agreement, Penn may receive up to $2 billion in research funding, options and milestone payments. Biogen will make an upfront payment to Penn of $20 million with an additional $62.5 million committed to fund R&D costs extending over the next three to five years in seven distinct preclinical research and development programs conducted by the Wilson and Bennett laboratories. Each program may trigger milestones that range from $77.5 million to $137.5 million per product as well as royalties payable on net sales of products. Biogen also receives an option to license next generation AAV vectors for certain indications from Penn, for Biogen’s use outside of the collaboration. [collapse expanded text] |
Nestle Health Science, Seres Therapeutics | Jan 2016 | 1900 | Collaboration agreement for product candidates for Clostridium difficile infection and inflammatory bowel disease | Seres Therapeutics has entered into an agreement with Nestlé Health Science for the development and … read morecommercialization outside of the United States and Canada for its product candidates in development for Clostridium difficile infection (CDI) and inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease. The agreement will support the expansion of Seres’ portfolio in markets outside of the United States and Canada and provide substantial financial support for Seres’ ongoing research and development. Seres retains full commercial rights to its entire portfolio of product candidates in the United States and Canada, where the company plans to build its own commercial organization. Seres granted Nestlé Health Science commercial rights in global markets outside of the United States and Canada to SER-109 and SER-262 for CDI, and SER-287 and SER-301 for IBD. The U.S. Food and Drug Administration (FDA) has granted SER-109 Orphan Drug, as well as Breakthrough Therapy, designations. In exchange for commercial rights, Nestlé Health Science agreed to provide Seres with an upfront payment of $120 million in cash and a series of contingent payments for development and sales milestones and tiered royalties on sales ranging from the high single digits percentages up to the high teens for all products. Nestlé Health Science agreed to contribute to certain development efforts, including 33 percent of expenses for potential global Phase 3 studies for SER-287, SER-301 and SER-262. The full potential value of the up-front payment, milestones and royalties payable by Nestlé Health Science is over $1.9 billion, assuming all products receive regulatory approval and are successfully commercialized. Seres expects to receive a total of $30 million in milestone payments in 2016 associated with the planned initiation of a Phase 1b study for SER-262 in primary CDI and the anticipated start of the Phase 3 trial for SER-109 in recurrent CDI. The upfront payment to be received under the agreement is expected to help fund the late-stage development of Seres’ lead programs, and drive the continued growth of Seres’ pipeline in a variety of conditions where addressing the microbiome could be an effective clinical strategy. Preclinical product candidates currently being investigated at Seres include promising new indications in infectious, inflammatory and metabolic diseases, including rare genetic diseases and immuno-oncology indications. [collapse expanded text] |
Grifols, Hologic | Dec 2016 | 1850 | Asset purchase agreement for NAT donor screening unit | Hologic has entered into a definitive agreement to sell its share of its blood screening business … read moreto Grifols, for gross proceeds of $1.85 billion in cash. The transaction has been approved by the boards of directors of both companies. [collapse expanded text] |
Baxalta, Symphogen | Jan 2016 | 1775 | Collaboration agreement for immuno-oncology | Baxalta and Symphogen announced a broad strategic immuno-oncology collaboration. Baxalta and … read moreSymphogen will advance novel therapeutics against six checkpoint targets, with the first program to enter clinical studies in 2017. On a product-by-product basis, following successful completion of Phase 1 clinical trials, Baxalta will have exclusive option rights to complete late-stage development and worldwide commercialization. Symphogen will receive an upfront payment of $175 million (€160 million) from Baxalta in exchange for the exclusive option rights for six checkpoint therapies. Symphogen will be responsible for performing R&D through Phase 1 clinical trials at its own expense. The agreement holds a total potential value up to €1.4 billion ($1.6 billion) in option fees and milestones over the long-term, in addition to royalties on worldwide sales. Additional terms, including therapeutic targets, were not disclosed. [collapse expanded text] |
Baxalta, Precision BioSciences | Feb 2016 | 1705 | Collaboration agreement for allogeneic chimeric antigen receptor (CAR) T cell therapies | Baxalta and Precision BioSciences announced a global collaboration to develop a broad series of … read moreallogeneic chimeric antigen receptor (CAR) T cell therapies directed towards areas of major unmet need in multiple cancers. Baxalta and Precision BioSciences will develop CAR T therapies for up to six unique targets, with the first program expected to enter clinical studies in late 2017. Precision BioSciences will be responsible for performing early-stage research activities up to Phase 2, following which Baxalta has the exclusive right to opt in for late-stage development and commercialization. Precision BioSciences will receive an upfront payment of $105 million from Baxalta, with additional option fees, developmental, clinical, regulatory, and sales milestones, potentially totaling up to $1.6 billion, in addition to royalties on worldwide sales. Precision also has the right to participate in the development and commercialization of any licensed products resulting from the collaboration through a 50/50 co-development and co-promotion option in the United States. Additional terms and initial targets were not disclosed. [collapse expanded text] |
Baxalta, Les Laboratoires Servier, Precision BioSciences | Feb 2016 | 1606.3 | Development, option and licensing agreement for hematological cancer targets beyond CD19 and two solid tumor targets to its CAR T | September 2020 Precision BioSciences in collaboration with Servier have added two additional … read morehematological cancer targets beyond CD19 and two solid tumor targets to its CAR T development and commercial license agreement. Under the terms of the existing development and commercial license agreement between Servier and Precision, Servier has selected two hematological and two solid tumor targets beyond those already in Precision’s allogeneic CAR T pipeline. Precision intends to leverage its proprietary ARCUS genome editing platform and CAR T development and manufacturing expertise for early-stage research and development activities, including Investigational New Drug (IND) filing through the manufacturing of initial clinical trial material for a Phase 2 study. Servier has the right to opt in for late-stage development and commercialization, and Precision has the right to participate in the development and commercialization of any licensed products resulting from the collaboration through a 50/50 co-development and co-promotion option in the United States. With the addition of these new targets, Precision expects to receive milestone payments in 2020 and 2021. Precision is also eligible for option fees, clinical, regulatory, and sales milestones in addition to royalties on product sales. February 2016 Precision Biosciences entered into the Servier Agreement as subsequently amended, with predecessor entities of Servier. Pursuant to this agreement, we have agreed to develop allogeneic chimeric antigen receptor T cell therapies for up to six unique antigen targets, the first of which was selected at the inception of the agreement. Upon selection of an antigen target, we perform early-stage research and development on individual T cell modifications for the selected target, develop the resulting therapeutic product candidates through Phase 1 clinical trials and manufacture clinical trial material for use in Phase 2 clinical trials. We received an upfront payment of $105.0 million under the Servier Agreement. At Phase 2 readiness for any product candidate covered by the Servier Agreement, Servier may exercise a commercial option to proceed with development and commercialization of the product candidate, subject to option fees. Following the exercise of any such commercial option, Servier must use commercially reasonable efforts to develop and commercialize the product candidate. We have the ability to receive total payments, including the upfront payment, option fees and milestone payments, in the aggregate across all six targets that may be selected, of up to approximately $1.6 billion. This includes up to $1.5 billion in milestone payments, consisting of up to $401.3 million in development milestone payments and up to $1.1 billion in commercial milestone payments. We are also entitled to receive tiered royalties ranging from the mid-single digit percentages to sub-teen percentages on worldwide net sales of any products developed under the Servier Agreement, subject to customary potential reductions. Servier’s obligation to pay royalties to us expires on a country-by-country and licensed product-by-licensed product basis upon the latest of (1) the expiration of the last to expire valid claim of all Precision patents covering a licensed product, (2) expiration of all regulatory exclusivity with respect to a licensed product in the applicable country of sale, and (3) the expiration of 10 years following the first commercial sale of such licensed product in such country. We also have the right to participate in the development and commercialization of any licensed products resulting from the collaboration through a 50/50 co-development and co-promotion option in the United States, subject to our payment of an option fee, which is exercisable after Servier’s commercial option exercise. So long as Servier holds a commercial license with respect to any particular licensed product, we may not develop, manufacture or commercialize any engineered human T cells with chimeric antigen receptors for use in humans directed to the same antigen target as the target of that licensed product. Unless terminated earlier, the Servier Agreement expires upon the first to occur of (1) the expiration of the period in which Servier may nominate antigen targets, if there are no included targets under the agreement, (2) the expiration of the period in which Servier may exercise a commercial option on a licensed product candidate, if no commercial options have been exercised by Servier, or (3) the expiration of the last to expire royalty term for the licensed products and satisfaction of all of Servier’s payment obligations under the agreement. Servier has the right to terminate the agreement for convenience, either in its entirety or on a target-by-target or product-by-product basis, by providing advance notice to us. We may terminate immediately upon notice to Servier if Servier (itself or through the use of certain affiliates or a third party) or any sublicensee initiates or participates in a patent challenge against our patents licensed by Servier under the agreement. In addition, the Servier Agreement may be terminated (a) by either party for the other party’s material breach that remains uncured as specified in the agreement, (b) by either party upon the occurrence of certain insolvency-related events of the other party and (c) upon mutual agreement of the parties in the event either party suffers an event of force majeure as specified in the agreement. If Servier terminates the agreement for our uncured material breach of provisions in the agreement that restrict development, manufacture or commercialization of engineered human T cells with chimeric antigen receptors for use in humans directed to a target selected by Servier, certain licenses we grant to Servier will become royalty-free, fully paid-up, perpetual and irrevocable with respect to the licensed product candidates and licensed products directed to the target that was the subject of such breach, and Servier will be deemed to have previously exercised its commercial option for any then-existing licensed product candidates directed to such target. [collapse expanded text] |
AstraZeneca, Pfizer | Aug 2016 | 1575 | Asset purchase agreement for antibiotics business | Pfizer announced it was buying part of AstraZeneca (AZN)’s antibiotics business. Pfizer is … read morebuying the rights to commercialize and develop AstraZeneca’s late-stage small molecule antibiotics business in most global markets outside the U.S. That includes already approved antibiotics Merrem, Zinforo and Zavicefta, and two that are in clinical development, ATM-AVI and CXL. Allergan controls the North American rights to four of the drugs. Pfizer is acquiring the North American rights to Merem. Pfizer is paying AstraZeneca $550 million when the deal closes, and another $175 million in January 2019. Also, Pfizer may pay up to $250 million in various commercial, manufacturing and regulatory milestones, as well as up to $600 million in sales-related payments, in addition to recurring, double-digit royalties on any future sales of Zaficefta and ATM-AVI in specific markets. The deal does not include AstraZeneca’s biological anti-infective drugs portfolio, or last year’s spinout of early-stage antibiotic development, Entasis Therapeutics. [collapse expanded text] |
Allergan, MedImmune | Oct 2016 | 1520 | Licensing agreement for MEDI2070 | January 2020 AstraZeneca will recover the global rights to brazikumab (formerly MEDI2070), a … read moremonoclonal antibody targeting IL23, from Allergan. Brazikumab is currently in a Phase IIb/III programme in Crohn’s disease (CD)1 and a Phase IIb trial in ulcerative colitis (UC).2 AstraZeneca and Allergan will terminate their existing license agreement and all rights to brazikumab will revert to AstraZeneca. The transaction is expected to complete in the first quarter of 2020, subject to regulatory approvals associated with AbbVie’s proposed acquisition of Allergan and its timely completion. October 2016 AstraZeneca announced that its biologics research-and-development unit, MedImmune, inked a licensing deal with Dublin-based Allergan for MEDI2070. MEDI2070 is an IL-23 monoclonal antibody that is presently in a Phase IIb trial for moderate-to-severe Crohn’s disease. It is also expected to start a Phase II trial for ulcerative colitis. As a result, AstraZeneca will pay Amgen a third of all payments and royalties it receives from Allergan. Amgen is also eligible for a single-digit inventor royalty. As part of the deal, Allergan is paying AstraZeneca an upfront fee of $250 million. Various milestone payments could hit up to $1.27 billion, and any approved therapeutics will include tiered royalties. MedImmune will continue an ongoing Phase IIa trial of the drug in Crohn’s disease to completion, then transition the Phase IIb trial to Allergan. [collapse expanded text] |
Bacit, Cancer Research UK, Syncona Partners, Wellcome Trust | Nov 2016 | 1200 | Collaboration agreement for biotech champion | Cancer Research UK is aligning with the Wellcome Trust, Syncona and BACIT to create an up to £1 … read morebillion company to invest in life sciences, with a significant allocation to oncology, subject to approval from BACIT shareholders. [collapse expanded text] |
Cerulean Pharma, Novartis | Oct 2016 | 1200 | Co development agreement for nanoparticle-drug conjugates | Novartis has signed an agreement with Cerulean Pharma, worth a potential $1.2 billion depending on … read moremilestones met, to co-develop nanoparticle-drug conjugates (NDCs). The combination will see Cerulean create NDCs that specifically attack tumour cells, which could then be used in conjunction with Novartis’ compounds. The deal is broken down into $5 million upfront whilst Novartis will fund five full-time employees to work on the development of NDCs at Cerulean. [collapse expanded text] |
Dermavant Sciences, Portola Pharmaceuticals | Dec 2016 | 1143.1 | Licensing agreement for Cerdulatinib | Dermavant Sciences has entered into an exclusive worldwide licensing agreement with Portola … read morePharmaceuticals for the development and commercialization of cerdulatinib in topical applications beyond oncology. Under the terms of the agreement with Dermavant, Portola retains full rights to all non-topical formulations of cerdulatinib, including oral formulations. [collapse expanded text] |
Proximagen Neuroscience, Saniona | Jan 2016 | 1130 | Collaboration agreement for therapeutics for neurological disorders | January 2018 Saniona and Proximagen have initiated lead optimization in their ongoing drug … read morediscovery and development collaboration. January 2016 Saniona and Proximagen have entered into a drug discovery and development collaboration. This collaboration will focus on research of new small molecule therapeutics for neurological disorders, using Saniona’s expertise in ion channels and related technology platforms. Proximagen is granted exclusive worldwide rights to develop, manufacture and commercialise medicines identified through the collaboration. For Saniona, the total potential value of pre-commercial milestone payments is up to US$30 million. While Proximagen is granted exclusive worldwide rights to develop, manufacture and commercialise medicines identified through the collaboration, Saniona will receive upfront and research funding during the research period. Saniona expects to report approximately US$1.1 million in upfront and research funding under this agreement in 2016. Furthermore, Saniona will receive milestone payments upon the achievement of certain research, development and regulatory milestones. The potential value of the milestone payments is up to US$30 million. In addition, Saniona will receive tiered royalties on net sales of any potential products commercialised by Proximagen as a result of this collaboration. [collapse expanded text] |
Abbott Laboratories, St Jude Medical, Terumo | Oct 2016 | 1120 | Asset purchase agreement for Angio-Seal, Femoseal vascular closure products and Vado Steerable Sheath | Abbott and St. Jude Medical announced an agreement in principle to sell certain products to Terumo … read moreCorporation. The transaction reflects a purchase price of approximately $1.12 billion and is subject to the successful completion of Abbott's acquisition of St. Jude Medical and antitrust regulatory approvals. Abbott, St. Jude Medical and Terumo are bound by the terms of an exclusivity agreement. The divestiture is an all-cash transaction and will include the products globally for St. Jude Medical's Angio-Seal and Femoseal vascular closure products and Abbott's Vado® Steerable Sheath. Abbott will retain its vascular closure products, which include the Perclose ProGlide® Suture-Mediated Closure System, StarClose SE® Vascular Closure System and Prostar® XL Percutaneous Vascular Surgical System. Following Abbott's acquisition of St. Jude Medical, the combined business will compete in nearly every area of the cardiovascular market and hold top positions in high-growth segments, including atrial fibrillation, structural heart and heart failure, as well as a leading position in the high-growth neuromodulation market. [collapse expanded text] |
US Government | Sep 2016 | 1100 | Grant award for $1.1 billion for Zika funding | Congress late Wednesday approved federal funding that will provide $1.1 billion to fight the Zika … read morevirus, along with money necessary to keep the government running through Dec. 9. [collapse expanded text] |
Akebia Therapeutics, Otsuka | Dec 2016 | 1030 | Collaboration and licensing agreement for Vadadustat | April 2017 Akebia Therapeutics, Inc. and Otsuka Pharmaceutical Co., Ltd. announced that they … read morehave expanded their collaboration for vadadustat by entering into a collaboration and license agreement for Europe, China and other territories. Vadadustat is an oral hypoxia-inducible factor (HIF) stabiliser currently in Phase 3 development for the treatment of anaemia associated with chronic kidney disease (CKD). December 2016 Akebia Therapeutics and Otsuka Pharmaceutical have entered into a collaboration and license agreement in the U.S. for vadadustat, an oral hypoxia-inducible factor (HIF) stabilizer currently in development for the treatment of anemia associated with chronic kidney disease (CKD). The collaboration provides capital for the global development program for vadadustat, and commercial resources for a U.S. launch of vadadustat upon approval by the Food and Drug Administration. Akebia will receive $265 million in committed funds plus development and commercial milestones, representing a total transaction value that could exceed $1 billion. The companies intend to contribute equally to commercialization efforts and share equally all costs and revenue in the U.S. Akebia will continue to lead the ongoing global Phase 3 development program for vadadustat. Otsuka will pay $265 million or more in committed capital. This includes a payment of $125 million upon signing and a payment of approximately $35 million in the first quarter of 2017. The agreement also provides for Otsuka to pay $105 million or more of the costs of the global development program for vadadustat. Additionally, Otsuka will pay potential development and commercial milestones up to $765 million. [collapse expanded text] |
2seventy bio, Bluebird Bio, MediGene | Sep 2016 | 1015 | Collaboration agreement for T cell receptor immunotherapies | January 2023 Medigene has received a $3 million milestone payment from its partner 2seventy bio … read moreas part of its T cell receptor agreement in cancer immunotherapy, and which may lead to further potential milestone payments in the future. This payment follows the strategic alliance between 2seventy bio and JW Therapeutics with the initial focus on the development of 2seventy bio’s MAGE-A4 program which employs a highly potent TCR discovered in collaboration with Medigene’s proprietary end-to-end technology platform. May 2018 Medigene announced the significant expansion of its successful strategic alliance with bluebird bio focusing on the research and development of T cell receptor-modified T cell (TCR-T) immunotherapies for the treatment of cancer. Under the revised terms of the agreement, the number of target antigen/MHC restriction combinations for the discovery of specific TCR lead candidates by Medigene will be increased from four to six. As part of this contractual expansion, Medigene will receive an additional one-time payment of USD 8 million. R&D funding for all work performed by Medigene in this collaboration will grow proportionally to address the broader scope of the collaboration. In addition, the aggregate amount of all potential development and commercial milestones as well as royalty payments has been significantly increased in line with the extended number of TCR projects. If successfully developed and marketed through several indications and markets, Medigene could receive up to USD 250 million in milestone payments per TCR program in addition to tiered royalty payments on net sales up to a double-digit percentage. Following the amendment of the agreement, Medigene anticipates receiving an additional payment of USD 1 million associated with the first collaboration project under the agreement. September 2016 Medigene and bluebird bio struck a collaborative deal to develop T cell receptor (TCR) immunotherapies against four targets that could be worth more than $1 billion. In an announcement this morning, the companies said the collaboration will combine Medigene’s TCR technology with bluebird’s lentiviral-based gene therapies, T cell immunotherapy expertise and gene editing capabilities. Under the terms of the agreement, Medigene will be responsible for the generation and delivery of the TCRs using its TCR isolation and characterization platform. Following the collaborative preclinical development, bluebird bio will assume sole responsibility for the clinical development and commercialization of the TCR product candidates, the companies said. Additionally, bluebird will receive an exclusive license for the intellectual property covering the resulting TCRs. As part of the deal, Medigene will receive an upfront payment of $15 million from bluebird. Additional clinical and commercial milestone payments could be total more than $1 billion for Medigene. Additionally, Medigene will receive R&D funding for all work performed in the collaboration and is eligible for tiered royalty payments on net sales up to a double-digit percentage. [collapse expanded text] |
Blueprint Medicines, Roche | Mar 2016 | 1010 | Licensing and collaboration agreement for five small molecule therapeutics targeting kinases in cancer immunotherapy | Blueprint Medicines has entered into a worldwide collaboration and exclusive license agreement with … read moreF. Hoffmann-La Roche Ltd and Hoffmann-La Roche for the discovery, development and commercialization of up to five small molecule therapeutics targeting kinases believed to be important in cancer immunotherapy. Under the terms of the agreement, Blueprint Medicines will receive an upfront cash payment of $45 million and will be eligible to receive up to an additional approximately $965 million in contingent option fees and milestone payments related to specified research, preclinical, clinical, regulatory and sales-based milestones across all five potential programs. Of the total contingent payments, up to approximately $215 million are for option fees and milestone payments for research, preclinical and clinical development events prior to licensing across all five potential programs. In addition, the agreement provides for specified royalties and cost sharing, which are described in more detail below. Immunokinases are intracellular targets known to regulate numerous aspects of immune response and represent an important opportunity for potentially innovative approaches to enhance the immune system's ability to recognize and eradicate tumor cells. This collaboration seeks to develop new mechanisms of modulating the tumor immune response by targeting immunokinases with the goal of enhancing response rates and broadening the utility of using cancer immunotherapies to treat additional cancer types. The collaboration provides for the worldwide development and commercialization of immunokinases in the field of cancer immunotherapy for up to five small molecule drug candidates as single products or possibly in combination with Roche's portfolio of therapeutics. Roche's rights are structured as an option, triggered upon achievement of Phase I proof-of-concept, for an exclusive license to each drug candidate developed under the collaboration. Blueprint Medicines will be primarily responsible for preclinical research and conduct of clinical development for each program prior to any exercise of Roche's option for such program. If Roche exercises an option for a program, Roche will be responsible for subsequent global development for that program through registrational clinical trials. For up to three of the five programs, if Roche exercises its option, Roche will receive worldwide commercialization rights for the licensed product. For up to two of the five programs, if Roche exercises its option, Blueprint Medicines will retain commercialization rights in the United States for the licensed product, and Roche will receive commercialization rights outside of the United States for such licensed product. Blueprint Medicines will also retain worldwide rights to any drug candidates for which Roche elects not to exercise the applicable option. For any licensed product for which Roche retains worldwide commercialization rights, Blueprint Medicines will be eligible to receive tiered royalties ranging from low double-digits to high-teens on future net sales of the licensed product. For any licensed product for which Blueprint Medicines retains commercialization rights in the United States, Blueprint Medicines and Roche will be eligible to receive tiered royalties ranging from mid-single-digits to low double-digits on future net sales in the other party's respective territories in which it commercializes the licensed product. Blueprint Medicines and Roche will share the costs of Phase 1 development for each collaboration target. In addition, Roche will be responsible for post-Phase 1 development costs for each licensed product for which it retains global commercialization rights, and Blueprint Medicines and Roche will share post-Phase 1 development costs for each licensed product for which Blueprint Medicines retains commercialization rights in the United States. [collapse expanded text] |
Mylan Pharmaceuticals, Renaissance Acquisition Holdings | May 2016 | 1000 | Asset purchase agreement for topicals-focused specialty and generics business | Mylan announced an agreement to acquire the non-sterile, topicals-focused specialty and generics … read morebusiness of Renaissance Acquisition Holdings, LLC for $950 million in cash at closing, plus additional contingent payments of up to $50 million, subject to customary adjustments. The Business will bring Mylan a complementary portfolio of approximately 25 branded and generic topical products, an active pipeline of approximately 25 products, and an established U.S. sales and marketing infrastructure targeting dermatologists. The Business also brings Mylan an integrated manufacturing and development platform and a leading topicals-focused contract development and manufacturing organization. [collapse expanded text] |
ICU Medical, Pfizer | Oct 2016 | 1000 | Asset purchase agreement for Hospira Infusion Systems | February 2017 ICU Medical Inc.announced that it has completed its acquisition of the Hospira … read moreInfusion Systems business from Pfizer Inc. The Hospira Infusion Systems business includes IV pumps, solutions, and devices that, when combined with the company’s existing businesses, makes ICU Medical one of the world’s leading pure-play infusion therapy companies. The Hospira Infusion Systems acquisition complements ICU Medical’s existing business to create a company with a complete IV therapy product portfolio from solutions to pumps to non-dedicated infusion sets. October 2016 Pfizer announced it was selling its global infusion therapy business, Hospira Infusion Systems (HIS) to ICU Medical for $1 billion in cash and stock. Part of the reason Pfizer sold these assets is related to regulatory requirements over the Hospira acquisition. Under the new deal, Pfizer will receive about $400 million in newly issued shares of ICU common stock and $600 million in cash. [collapse expanded text] |
AstraZeneca, Bicycle Therapeutics | Dec 2016 | 1000 | Collaboration agreement for bicyclic peptides (Bicycles) | May 2018 Bicycle Therapeutics is expanding its collaboration with AstraZeneca to include … read moreadditional targets in respiratory and cardio-metabolic diseases. The original collaboration was signed in late 2016 and with the expansion has a potential value in excess of $1 billion. Under the terms of the collaboration Bicycle is responsible for identifying Bicycles for an undisclosed number of respiratory, cardiovascular and metabolic disease targets specified by AstraZeneca, while AstraZeneca is responsible for further development and product commercialization. The expansion provides additional disease targets and triggers an undisclosed milestone payment to Bicycle. December 2016 Bicycle Therapeutics has entered into a collaboration with AstraZeneca for the identification and development of bicyclic peptides (Bicycles) for the treatment of respiratory, cardiovascular and metabolic diseases. Bicycle is responsible for identifying Bicycles for an undisclosed number of targets specified by AstraZeneca while AstraZeneca is responsible for further development and product commercialization. If all planned programmes reach the market, Bicycle will be eligible for over $1 billion in payments, including an upfront payment, future R&D funding, development, regulatory and commercialization milestone payments. Bicycle would also be entitled to receive royalties on sales of products resulting from the collaboration. [collapse expanded text] |
Bristol-Myers Squibb, PsiOxus Therapeutics | Dec 2016 | 936 | Licensing agreement for NG-348 | December 2017 PsiOxus Therapeutics announced that the Clinical Trial Application for NG-348, an “ … read morearmed” oncolytic virus for the treatment of solid tumors, has been approved and, per the licensing agreement between the parties, Bristol-Myers Squibb will make a US $15 million milestone payment to PsiOxus. Under the terms of the December 2016 agreement, Bristol-Myers Squibb granted PsiOxus an upfront payment of $50 million. In aggregate, PsiOxus is eligible to receive development, regulatory and sales-based milestones of $936 million, as well as royalties on net sales. Following the completion of pre-clinical development by PsiOxus, Bristol-Myers Squibb is solely responsible for global clinical development and commercialization activities related to NG-348. In June 2016, Bristol-Myers Squibb and PsiOxus entered into an exclusive clinical collaboration to study enadenotucirev, PsiOxus’ systemically administered “unarmed” oncolytic adenovirus therapeutic, in a multi-cohort clinical trial. December 2016 PsiOxus Therapeutics has announced an agreement granting Bristol-Myers Squibb exclusive worldwide rights to NG-348, a pre-clinical stage, “armed” oncolytic virus which may serve as a novel mechanism to address solid tumours. Bristol-Myers Squibb will grant PsiOxus a US$50 million upfront payment and will be solely responsible for global clinical development and commercialisation activities related to NG-348. PsiOxus is also eligible to receive up to US$886 million in development, regulatory and sales-based milestones, and in addition, royalties on net sales. Bristol-Myers Squibb will also be responsible for providing PsiOxus funding to support activities related to the preclinical development of NG-348. [collapse expanded text] |
Genentech, Hanmi Pharmaceutical | Aug 2016 | 910 | Licensing agreement for HM95573 | Genentech (RHHBY), a member of the Roche Group (RHO), licensed HM95573 from Seoul, South Korea- … read morebased Hanmi Pharmaceutical Co. for a deal that could hit $910 million. HM95573 is a pan-RAF inhibitor currently in Phase I clinical development. The Phase I trial is being underwritten by the South Korean Ministry of Health and Welfare for $545,843 (US). Genentech is paying an upfront fee of $80 million and up to $830 million in various milestone payments. Hanmi will also be eligible for tiered double-digit royalties on any commercial products. [collapse expanded text] |
GSK, Zymeworks | Apr 2016 | 908 | Licensing and collaboration agreement for bi-specific antibodies enabled using Azymetric platform | May 2019 Zymeworks announced that GSK has expanded its 2016 licensing and collaboration … read moreagreement with Zymeworks for the research, development, and commercialization of bispecific antibodies across multiple disease areas GSK will now have access to Zymeworks’ unique heavy-light chain pairing technology, part of its proprietary Azymetric platform. Zymeworks’ Azymetric platform enables the development of bispecific and multifunctional therapeutics while maintaining the characteristics of naturally-occurring human antibodies. GSK will have the option to develop and commercialize bispecific drugs across different disease areas and Zymeworks will be eligible to receive increased preclinical, development and commercial milestone payments. If all six programs are developed and commercialized, the new potential value of the collaboration would be up to US$1.1 billion. Zymeworks is eligible to receive increased tiered royalties on worldwide sales. April 2016 Zymeworks has entered into a new licensing agreement with GSK for the research, development, and commercialization of novel bi-specific antibodies enabled using Zymeworks’ Azymetric drug discovery platform. GSK will have the option to develop and commercialize multiple bi-specific drugs across different disease areas. Zymeworks will receive upfront and preclinical payments of up to USD$36 million and is eligible to receive up to USD$152 million in development and clinical milestone payments, along with commercial sales milestone payments of up to USD$720 million, and tiered royalties on potential sales. As previously announced in December 2015, Zymeworks and GSK entered into a collaboration and license agreement to further develop Zymeworks’ Effector Function Enhancement and Control Technology (EFECT) platform and to research, develop, and commercialize novel Fc-engineered monoclonal and bi-specific antibody therapeutics that have been optimized for specific therapeutic effects. As part of this second agreement, GSK has also gained the right to combine the Azymetric platform with novel engineered Fc domains developed under the previously announced collaboration. [collapse expanded text] |
Boehringer Ingelheim Vetmedica, Elanco | Oct 2016 | 885 | Asset purchase agreement for canine, feline and rabies vaccines and research and development site | Eli Lilly & Company (LLY)’s animal health unit Elanco U.S., Inc. struck an $885 million deal … read morewith Boehringer Ingelheim Vetmedica Inc. to acquire a portfolio of canine, feline and rabies vaccines, as well as a fully-integrated research and development site. Elanco said the deal will diversify the company’s companion animal portfolio in the United States by “complementing its offerings for dogs and cats.” The deal expands Elanco’s pipeline to include vaccines for bordetella, Lyme disease, rabies and parvovirus. This year the company launched two new animal vaccines ULTRA Hybrid FVRCP and ULTRA Duramune Lyme, which were both included in the deal. Other vaccines included in the deal are the Fel-O-Vax and Fel-O-Guard lines for cats. Included in the deal is a manufacturing facility based in Fort Dodge, Iowa. [collapse expanded text] |
Exelixis, Ipsen | Mar 2016 | 855 | Licensing, marketing and development agreement for cabozantinib | Expanded July 2024 Decision adds to existing collaboration agreement with Exelixis, … read morepermitting Ipsen to seek potential marketing authorizations for Cabometyx (cabozantinib) in advanced pancreatic and extra pancreatic neuroendocrine tumors outside of the U.S. and Japan Agreement based on CABINET Phase III trial, led by the Alliance for Clinical Trials in Oncology, which demonstrated improvements in progression-free survival for Cabometyx versus placebo 1 Ipsen has engaged with regulatory authorities in the European Union and will submit a regulatory filing on the basis of these data December 2016 Ipsen and Exelixis have amended the exclusive collaboration and licensing agreement for the commercialization and continued development of cabozantinib, a promising new therapy in development for renal cell carcinoma (RCC). Moving forward, Ipsen Biopharmaceuticals Canada will have commercialization rights for cabozantinib which is not yet approved in Canada. March 2016 Exelixis and Ipsen announced that they had inked an exclusive licensing agreement to commercialize and develop cabozantinib, Exelixis’ lead cancer drug. Ipsen will gain exclusive rights to commercialize cabozantinib for current and future indications outside the U.S., Canada and Japan. This applies to rights to Cometriq, which is approved in Europe for the treatment of adults with progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC). In addition, the two companies will collaborate on developing cabozantinib for other indications. Exelixis will hold exclusive commercial rights for the drug in the U.S. and Canada, and is continuing discussions to partner commercial rights in Japan. Ipsen is paying Exelixis $200 million upfront, and Exelixis is eligible for various milestone payments, including $60 million for approval of the drug in Europe for advanced renal cell carcinoma (RCC) and $50 million when it files and gets approval for cabozantinib in Europe for advanced hematocellular carcinoma (HCC). Additional milestones are possible, as well as up to $545 million in commercial milestone payments and tiered royalties up to 26 percent of Ipsen’s net sales of the drug. [collapse expanded text] |
Mersana Therapeutics, Millennium, Takeda Pharmaceutical | Feb 2016 | 830 | Collaboration agreement for XMT-1522 | Mersana Therapeutics and Takeda Pharmaceutical have entered a new strategic partnership granting … read moreTakeda rights to Mersana’s lead product candidate, XMT-1522, outside the United States and Canada. The deal also expands an existing collaboration between the companies to provide Takeda with additional access to Mersana’s Fleximer antibody-drug conjugate (ADC) platform and grants Mersana an option at the end of Phase 1 to co-develop and co-commercialize one of these programs in the United States. In addition, the companies will co-develop new payloads for use with ADCs. Takeda and Mersana will co-develop XMT-1522, and Mersana will lead execution of the Phase 1 trial. Mersana will retain full commercial rights in the United States and Canada while Takeda will have rights in rest of world. Beyond development and commercialization of XMT-1522, the expanded partnership also grants Takeda access to additional targets within Mersana’s Fleximer-based ADC platform, with Mersana retaining the right to select one program at the end of Phase 1 for co-development and co-commercialization in the United States. Takeda and Mersana will also work together, leveraging Takeda’s proprietary small molecule libraries, to identify and develop novel payloads that both parties will be able to use in new ADC therapies. Takeda signed agreements with Mersana through its wholly owned subsidiary, Millennium Pharmaceuticals, under which, Mersana will receive an upfront payment of $40 million and an additional payment of $20 million upon clearance of the IND for XMT-1522 by the FDA. Subject to the success of the XMT-1522 and ADC programs, Mersana is eligible to receive milestone payments of more than $750 million combined, as well as royalties. Takeda will also invest up to $20 million in equity in future rounds of Mersana financing. [collapse expanded text] |
Ionis Pharmaceuticals, Janssen Biotech | Jul 2016 | 810 | Licensing agreement for IONIS-JBI1-2.5 | December 2016 Ionis Pharmaceuticals has earned $5 million milestone payment from Janssen Biotech … read moreassociated with the validation of an undisclosed target to treat patients with a gastrointestinal (GI) autoimmune disease. Under the collaboration, Ionis and Janssen will continue to evaluate the target with the goal of advancing an antisense drug into development. Under the terms of the agreement, which covers three programs, Ionis is eligible to receive nearly $800 million in development, regulatory and sales milestone payments and license fees. In addition, Ionis will receive tiered royalties that on average are double-digits on sales from any product that is successfully commercialized. July 2016 Ionis Pharmaceuticals , which is developing RNA-targeting therapeutics, struck a licensing deal with Janssen Biotech (JNJ), Inc. for its oral gastrointestinal treatment, IONIS-JBI1-2.5. The deal, which covers three programs, is worth $810 million, with the company already having been awarded $10 million. The remaining potential $800 million will be awarded to Ionis based on development, regulatory and sales milestone payments and license fees for these programs. Additionally, Ionis is expected to receive tiered royalties that on average are double-digits on sales from any product that is successfully commercialized. Under terms of the deal, Janssen will assume all global development, regulatory and commercialization responsibilities for IONIS-JBI1-2.5 upon completion of investigational new drug enabling studies. Ionis’ GI treatment, IONIS-JBI1-2.5, is antisense drug designed to locally inhibit an undisclosed target in the gastrointestinal (GI) tract. The collaboration between the two companies is focused on the development and discovery of orally administered, locally acting RNA-targeted therapeutics for autoimmune diseases in the gastrointestinal tract. [collapse expanded text] |
Les Laboratoires Servier, Sorrento Therapeutics | Jul 2016 | 807.8 | Licensing and collaboration agreement for STI-A1110 | Sorrento Therapeutics and France-based Servier announced that the two companies had inked a license … read moreand collaboration deal to develop, manufacture and commercialize products using Sorrento’s STI-A1110. STI-A1110 is a fully human immuno-oncology anti-PD-1 monoclonal antibody (mAb). Sorrento developed it using its proprietary G-MAB library platform. In the deal, Servier receives an exclusive global license to STI-A1110 for all indications, including hematological and solid tumor cancers. It also acquired full rights to develop, register and commercialize any products and will pay for all of the developmental and business activities. Servier is paying an upfront cash payment of 25 million euros. Development milestones for the initial products and each additional product are also part of the deal. In addition, Sorrento could get up to 710 million euros based on commercial sales milestones, as well as variable royalties. [collapse expanded text] |
Chiesi Farmaceutici, The Medicines Company | May 2016 | 792 | Asset purchase agreement for Cleviprex (clevidipine), Kengreal (cangrelor) and Argatroban | The Medicines Company has entered into a definitive agreement to sell Cleviprex® (clevidipine), … read moreKengreal® (cangrelor) and the Company’s rights to Argatroban for Injection to Chiesi USA, Inc. and its parent company, Chiesi Farmaceutici S.p.A., for up to $792 million, consisting of $260 million in cash payable at closing, up to $480 million in sales-based milestone payments, the assumption by Chiesi of up to $50 million in milestone payment obligations and approximately $2 million for product inventory. [collapse expanded text] |
Exicure, Purdue Pharma | Dec 2016 | 790 | Collaboration, option and licensing agreement for diseases utilizing SNA technology | Purdue Pharmaand Exicure announced a strategic research collaboration, option and license … read moreagreement to discover and develop a treatment for psoriasis, and other diseases amenable to a gene regulation approach utilizing Exicure’s Spherical Nucleic Acid (SNA) technology. Purdue Pharma, upon exercise of the options, will obtain full worldwide development and commercial rights to AST-005, and rights to three additional collaboration targets with associated intellectual property. The lead compound, AST-005, is an investigational, topically-applied SNA that targets tumor necrosis factor (TNF), a pro-inflammatory cytokine shown to be a key mediator of psoriasis. In a recently completed Phase 1 trial, fifteen patient volunteers with chronic plaque psoriasis were treated with AST-005 for ten days. The first trial with AST-005, based on Exicure’s proprietary SNA technology, met the safety and tolerability requirements in patients with mild to moderate psoriasis. In addition to the safety data typically collected from the first Phase 1 trial, pharmacodynamic assessments were performed from the treated plaque area. Exicure received an upfront payment, will receive an equity investment and could potentially receive development, regulatory and commercial milestone compensation, which together with the upfront payment and equity investment, could total up to $790 million, if all programs are fully developed, as well as royalties on potential sales of the products. [collapse expanded text] |
Crescendo Biologics, Takeda Pharmaceutical | Oct 2016 | 790 | Collaboration agreement for utilizing Humabody platform technology against multiple targets | December 2020 Crescendo Biologics has expanded its global, multi-target discovery and … read moredevelopment collaboration with Takeda Pharmaceutical after Crescendo achieved its sixth technical milestone. Under its ongoing collaboration and license agreement, Crescendo’s proprietary transgenic platform and engineering expertise is being used to build Humabody-based therapeutics against certain targets selected by Takeda. The collaboration expansion gives Takeda access to a range of Crescendo’s half-life extension Humabodies for use with its two Humabody programmes, previously licensed in November 2018 and July 2019, and Humabody programmes Takeda licenses in the future during the term of the collaboration expansion. This is the sixth technical milestone achieved by Crescendo in its collaboration with Takeda. Crescendo has successfully delivered novel oncology-targeted Humabody lead molecules using its robust in-house discovery process. September 2019 Crescendo Biologics has achieved a fifth milestone in its collaboration with Takeda Pharmaceutical. Under the global, strategic, multi-target collaboration and license agreement with Takeda that was announced in October 2016, Crescendo’s proprietary transgenic platform and engineering expertise is used to identify and configure Humabody-based therapeutics against certain targets selected by Takeda. Crescendo has successfully delivered three novel oncology-targeted Humabody lead molecules. Takeda has taken exclusive licenses to both of the first two programmes in this highly productive collaboration. May 2019 Crescendo Biologics has achieved a fourth milestone in its collaboration with Takeda Pharmaceutical. Under the global, strategic, multi-target collaboration and license agreement with Takeda that was announced in October 2016, Crescendo’s proprietary transgenic platform and engineering expertise is used to identify and configure Humabody-based therapeutics against certain targets selected by Takeda. This is the fourth collaboration milestone achieved by Crescendo and relates to the progression of an immuno-oncology programme where the Humabody lead has demonstrated in vivo anti-tumour activity. This latest milestone follows the early licensing by Takeda of Crescendo’s first oncology-targeted Humabody in November 2018. November 2018 Crescendo Biologics announced that Takeda Pharmaceutical has exercised an option under its existing, multi-target collaboration and license agreement. Takeda has taken an exclusive licence to Humabodies directed to one of its oncology targets. This licence option exercise comes substantially earlier than planned and marks the highly successful delivery and further pre-clinical evaluation by Takeda of Humabody leads meeting its stringent criteria. August 2018 Crescendo Biologics has achieved another technical milestone in its collaboration with Takeda Pharmaceutical. This milestone, for an undisclosed amount, marks the successful delivery of another highly diverse panel of functional Humabody leads against the second of Takeda’s selected targets. The achievement of an equivalent milestone related to the first of Takeda’s selected targets was announced in April 2018. October 2016 Crescendo Biologics inked a deal with Takeda Pharmaceutical that could hit $790 million. Crescendo’s Humabody platform technology will be used to discover and optimize candidates against multiple targets chosen by Takeda. The technology platform focuses on a proprietary transgenic mouse, which allows it to develop Humabodies, which are similar to monoclonal antibodies, but are small in size, less expensive, and according to the company, offer “modular plug & play engineering options for generating novel bi- or multi-specific formats.” Under the deal, Crescendo will receive up to $36 million in an upfront payment, investment, research funding and preclinical milestones. Takeda will hold the right to develop and commercialize Humabody-based therapeutics that come out of the collaboration deal. Crescendo may also receive milestone payments up to $754 million, as well as royalties on any Humabody-based product sales made by Takeda. [collapse expanded text] |
C4 Therapeutics, Roche | Jan 2016 | 750 | Collaboration agreement for TPD therapeutics using Degronimid technology | C4 Therapeutics had inked a strategic collaboration with Roche to develop TPD therapeutics using … read moreDegronimid technology. The company will begin by developing TPD drugs that use Degronimid for a specific group of target proteins. A preclinical development phase has been defined, after which Roche has the option to participate in more pre- and clinical development and commercialization. Roche is paying an undisclosed upfront fee with additional development, regulatory and commercial milestone payments per targets. There are also potential sales fees and tiered royalties on sales of products. The potential value of the deal exceeds $750 million. [collapse expanded text] |
Janssen Biotech, Macrogenics | May 2016 | 740 | Collaboration and license agreement for Dual-Affinity Re-Targeting platform to treat hematological malignancies and solid tumors | MacroGenics, headquartered in Rockville, Maryland, signed a global oncology collaboration and … read morelicense agreement with Janssen Biotech (JNJ), a Johnson & Johnson (JNJ) company. Janssen agrees to pay $75 million upfront, with potential clinical, regulatory and commercialization milestones that could hit $665 million. If commercialized, MacroGenics could receive double-digit royalties. The collaboration deal uses MacroGenics’ Dual-Affinity Re-Targeting (DART) platform that simultaneously targets CD3 and an undisclosed tumor target for possible therapeutics to treat hematological malignancies and solid tumors. The specific product is MGD015, which is designed to redirect T cells, by way of their CD3 component, to attack specific cancer cells that overexpress an antigen that has not been disclosed. [collapse expanded text] |
Accord, Actavis (acquired by Watson), Intas Pharmaceuticals, Teva Pharmaceutical Industries | Oct 2016 | 730 | Asset purchase agreement for generics businesses | Intas Pharmaceuticals, through its wholly owned subsidiary Accord Healthcare has entered into a … read moredefinitive agreement to acquire Actavis UK Ltd. & Actavis Ireland from Teva Pharmaceutical Industries, for an enterprise value of £603 million payable in cash. The transaction is part of the European Commission’s anti-trust divestiture requirements arising from Teva’s acquisition of Allergan’s generics business. [collapse expanded text] |
Conatus Pharmaceuticals, Novartis | Dec 2016 | 722 | Collaboration, option and licensing agreement for Emricasan | Conatus Pharmaceuticals has entered into an exclusive option, collaboration and license agreement … read morefor the global development and commercialization of its first-in-class, orally active pan-caspase inhibitor emricasan with Novartis. Conatus will receive $50 million upfront, and is eligible to receive $7 million following the exercise of the license option. Conatus can borrow up to $15 million in the form of convertible promissory notes under an investment agreement with Novartis. Conatus is eligible to receive significant payments if certain development, regulatory and commercial milestones are met. Conatus is eligible to receive tiered double digit royalties on emricasan single agent sales and tiered single to double digit royalties on sales of combination products containing emricasan. Conatus has the option to co-commercialize emricasan in the United States, including combination therapies, on a cost-sharing and revenue-sharing basis in lieu of U.S. royalties and with reduced ex-U.S. royalties. Conatus retains limited rights to develop other pan-caspase inhibitors. Novartis will pay 50% of Conatus’ Phase 2b emricasan development costs after the option exercise, including the planned ENCORE-LF trial in decompensated NASH cirrhosis which, under the current development plan consistent with recent regulatory agency recommendations, will be conducted as Phase 2b rather than Phase 2b/3. Phase 2b emricasan development costs also encompass the ongoing ENCORE-PH trial in primarily compensated NASH cirrhosis, POLT-HCV-SVR trial in post-transplant HCV fibrosis and cirrhosis, and ENCORE-NF trial in NASH fibrosis. Novartis will assume full responsibility for emricasan’s Phase 3 development and all combination product development. [collapse expanded text] |
GSK, Galvani Bioelectronics, Verily | Aug 2016 | 715 | Joint venture agreement for bioelectronics medicines | GlaxoSmithKline and Google ’s Verily Life Sciences have pooled their resources to form a new … read morecompany focused on the development and commercialization of bioelectronics medicines, Galvani Bioelectronics. The new partnership was formally announced on Aug. 1, with GlaxoSmithKline (GSK) being the majority partner, holding a 55 percent interest in the jointly-owned company and Verily holding the remainder. Both GSK and Verily will provide seed funding of up to $715 million over seven years. The funding is subject to the successful completion of discovery and developmental milestones, GSK said in a statement. GSK will likely provide a slightly higher amount of funding given that it has the larger stake in the new bioelectronics company. The new company will be fully consolidated in GSK's financial statements. Bioelectronic medicine uses miniaturized and implantable devices that can modify electrical signals that pass along nerves in the body, including irregular or altered impulses that occur in many illnesses. [collapse expanded text] |
IBA Molecular Imaging, Mallinckrodt Pharmaceuticals | Aug 2016 | 690 | Asset purchase agreement for Nuclear Imaging business | Mallinckrodt plc , a leading specialty pharmaceutical company, announced that it has entered into a … read moredefinitive agreement under which it will sell its Nuclear Imaging business to IBA Molecular , for approximately $690 million before tax impacts, including up-front and contingent consideration and the assumption of long-term obligations. Mallinckrodt's Nuclear Imaging business includes a portfolio of diagnostic imaging products. The total consideration of approximately $690 million (before tax impacts) consists of approximately $574 million of up-front consideration, the assumption of approximately $39 million of long-term obligations, and approximately $77 million of contingent consideration. [collapse expanded text] |
Abbvie, argenx | Apr 2016 | 685 | Collaboration and licensing agreement for ARGX-115 | August 2018 argenx announced the exercise by AbbVie of its exclusive license option to develop … read moreand commercialize ARGX-115, an antibody targeting the novel immuno-oncology target glycoprotein A repetitions predominant (GARP). April 2016 AbbVie and argenx will collaborate to develop and commercialize ARGX-115. ARGX-115 is argenx' preclinical-stage human antibody program targeting the novel immuno-oncology target GARP, a protein believed to contribute to immunosuppressive effects of T-cells. argenx will conduct research and development through IND-enabling studies. Upon successful completion of these studies, AbbVie may exercise an exclusive option to license the ARGX-115 program and assume responsibility for further clinical development and commercialization. argenx will receive an upfront payment of $40 million from AbbVie for the exclusive option to license ARGX-115 and near-term preclinical milestones of $20 million. argenx is also eligible to receive additional development, regulatory and commercial payments up to $625 million upon achievement of pre-determined milestones as well as tiered, up to double-digit royalties on net sales upon commercialization. argenx has the right to co-promote ARGX-115-based products in the European Union and Swiss Economic Area and combine the product with its own future immuno-oncology programs. Should AbbVie not exercise its option to license ARGX-115, argenx retains the right to pursue development of ARGX-115 alone. In addition to the ARGX-115 program, and upon reaching a predetermined preclinical stage milestone, AbbVie will fund further GARP-related research by argenx for an initial period of two years. AbbVie will have the right to license additional therapeutic programs emerging from this research, for which argenx could receive associated milestone and royalty payments. [collapse expanded text] |
Amgen, Arrowhead Pharmaceuticals | Sep 2016 | 673.7 | Development and marketing agreement for RNA interference therapies for cardiovascular disease | December 2022 Arrowhead Pharmaceuticals announced a $25M milestone payment from Amgen. … read moreThis milestone was triggered by the first subject enrolled in Amgen’s Phase 3 trial of olpasiran. Arrowhead is further eligible to receive up to an additional $535 million in aggregate development, regulatory, and sales milestone payments from Amgen and Royalty Pharma. August 2018 Arrowhead Pharmaceuticals has earned a $10 million milestone payment from Amgen following the administration of the first dose of AMG 890, formerly referred to as ARO-LPA, in a clinical study. Amgen is evaluating AMG 890 in a Phase 1 clinical study designed to assess its safety in volunteers with elevated levels of lipoprotein (a) (Lp(a)). Emerging research has shown that elevated levels of Lp(a) are strongly associated with cardiovascular disease. AMG 890 is an RNAi therapeutic designed to lower Lp(a) for the treatment of cardiovascular disease. November 2016 Shares of Arrowhead Pharmaceuticals (ARWR) are up more than 18 percent to $8 per share in pre-market trading after Amgen bought a stake worth up to $675 million in the company to develop and commercialize RNA interference (RNAi) therapies for cardiovascular disease. Under terms of the two deals, Pasadena, Calif.-based Arrowhead will receive $35 million in up-front payments and will then be eligible for up to $617 million in milestone payments. The company will also get an additional $21.5 million from Amgen in the form of an Amgen equity investment. Arrowhead will also be able to receive some royalties from sales. Arrowhead is developing its RNAi ARC-LPA program. The engineered molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. That is the first target for the Amgen and Arrowhead agreement. Under the second agreement, Amgen will receive an option for a worldwide and exclusive license for a RNAi therapy for an undisclosed genetically validated cardiovascular target. Under terms of both agreements, Amgen will be wholly responsible for clinical development and commercialization. [collapse expanded text] |
Amgen, Arrowhead Pharmaceuticals | Aug 2016 | 673.5 | Licensing,development,option and marketing agreement for RNA interference therapies for cardiovascular disease | Shares of Arrowhead Pharmaceuticals (ARWR) are up more than 18 percent to $8 per share in pre- … read moremarket trading after Amgen bought a stake worth up to $675 million in the company to develop and commercialize RNA interference (RNAi) therapies for cardiovascular disease. Under terms of the two deals, Pasadena, Calif.-based Arrowhead will receive $35 million in up-front payments and will then be eligible for up to $617 million in milestone payments. The company will also get an additional $21.5 million from Amgen in the form of an Amgen equity investment. Arrowhead will also be able to receive some royalties from sales. The engineered molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. That is the first target for the Amgen and Arrowhead agreement. Under the second agreement, Amgen will receive an option for a worldwide and exclusive license for a RNAi therapy for an undisclosed genetically validated cardiovascular target. Under terms of both agreements, Amgen will be wholly responsible for clinical development and commercialization. [collapse expanded text] |
Redwood Bioscience, Roche | Jan 2016 | 619 | Collaborative R&D agreement for next-generation molecules coupling therapeutic modalities using SMARTag Technology | Catalent announced, through its wholly owned subsidiary, Redwood Bioscience, Inc., a research … read morecollaboration with Roche to develop next-generation molecules coupling different therapeutic modalities using Catalent's proprietary SMARTag™ technology. Roche will gain non-exclusive access to the SMARTag platform and will have an option to take commercial licenses to develop molecules directed to a defined number of targets. Roche will pay Catalent an up-front fee of $1 million and provide additional research funding during the initial phase of the collaboration. Catalent has the potential to receive up to $618 million in development and commercial milestones, plus royalties on net sales of products, if Roche pursues commercial licenses and all options are exercised. [collapse expanded text] |
Biomedical Advanced Research and Development Authority, Protein Sciences | Sep 2016 | 610 | Contract service agreement for countermeasures against pandemic influenza and influenza strains | Protein Sciences Corporation announced that the Biomedical Advanced Research and Development … read moreAuthority (BARDA), a division of the U.S. Department of Health and Human Services, has awarded the Company a contract that is part of the Authority's medical countermeasures against pandemic influenza and influenza strains with pandemic potential. Protein Sciences will perform the contract using its proprietary platform technology for producing vaccines that according to the Food and Drug Administration has revolutionized influenza vaccine manufacturing and stands to receive up to $610 million through 2021 if BARDA exercises all options. The Company's Flublok® (seasonal) and Panblok® (pandemic) influenza vaccines can be made with unprecedented speed, safety and precision. The new contract with BARDA taps into this technology and ensures the Country will be prepared with sufficient supplies of vaccine in a timely manner should an influenza pandemic strike. [collapse expanded text] |
Novartis, Surface Oncology | Jan 2016 | 600 | Collaboration, option and licensing agreement for four pre-clinical programs that target regulatory T cell populations, inhibitory cytokines, and immunosuppressive metabolites | Novartis is adding to its diverse and deep immuno-oncology pipeline through a strategic alliance … read moreand licensing agreement with Surface Oncology. The agreement gives Novartis access to four pre-clinical programs that target regulatory T cell populations, inhibitory cytokines, and immunosuppressive metabolites in the tumor microenvironment. These programs will be explored as monotherapies and in combination with other complementary therapies in Novartis' immuno-oncology and targeted therapy portfolios. [collapse expanded text] |
Merck and Co, Quartet Medicine | Jan 2016 | 595 | Licensing and option agreement for small molecule drugs modulating the tetrahydrobiopterin (BH4) pathway | Quartet Medicine has entered into a strategic agreement with Merck in connection with Quartet's … read morepipeline of novel small molecule drugs modulating the tetrahydrobiopterin (BH4) pathway. Under the terms of the agreement, Quartet will receive up to $20 million split equally across an upfront payment and an undisclosed future development milestone. This research and development funding will be used to advance Quartet's lead program through Phase 2a clinical proof-of-concept for the treatment of pain. In return, Merck obtains an exclusive option to purchase Quartet. If Merck exercises its option, Quartet will receive a pre-determined, undisclosed option exercise payment along with potential development, regulatory and sales milestones of up to $575 million in total. About Tetrahydrobiopterin and its Link to Chronic Pain and Inflammation The de novo tetrahydrobiopterin (BH4) synthesis pathway has been implicated in a range of chronic human pain and inflammatory conditions. Up-regulation of BH4 synthesis in response to injury or inflammation increases cellular levels of BH4, an important cofactor for several classes of enzymes, that results in neuronal hypersensitivity and chronic immune cell activation. [collapse expanded text] |
Agios Pharmaceuticals, Celgene | May 2016 | 578 | Collaboration agreement for metabolic immuno-oncology | March 2020 Celgene has formally declined to exercise its opt-in right for AG-270, a first-in- … read moreclass methionine adenosyltransferase 2a (MAT2A) inhibitor development candidate currently in a Phase 1 study in combination with taxane-based therapy as a potential treatment for methylthioadenosine phosphorylase (MTAP)-deleted non-small cell lung cancer and pancreatic cancer. In addition, the research term of the companies’ metabolic immuno-oncology collaboration, focused on altering the metabolic state of immune cells to enhance the body's immune response to cancer, will conclude at the end of the initial four-year period in May 2020. There is one undisclosed, ongoing metabolic immuno-oncology research program that Celgene may designate for continued development within sixty days following the end of the research term; if it does so, Celgene would have an opt-in right for this program through the end of Phase 1 dose escalation. May 2016 Agios Pharmaceuticals inked a new global collaboration deal with Celgene. The two companies will collaborate on metabolic immuno-oncology, an offshoot from the hot field of immuno-oncology, where the immune system is programmed to attack cancer cells. In metabolic immuno-oncology, the immune system’s metabolic rate is enhanced, which is to say, supercharged, to fight cancer. As part of the deal, Celgene will pay Agios $200 million upfront in cash, with various milestone payments possible. The collaboration deal is scheduled to last four years, and Agios can extend it for an additional two. All told, the deal has the potential to surpass $1 billion. It starts with $200 million upfront, but Celgene will have the option of picking up each program through Phase I dose escalation for a minimum of $30 million. For the metabolic immuno-oncology programs, as part of a global co-development and co-commercialization agreement, they will split costs and Agios is eligible for up to $169 million in clinical and regulatory milestone payments for each program. Celgene also has the chance to choose a metabolic immuno-oncology program where it will share costs and profits 65/35, for which Agios could receive up to $209 million in milestones. And for any inflammation or autoimmune programs that might develop from the research, Celgene has an option for global licensing, development and commercialization. Agios could receive up to $385 million in various milestones, as well as double-digit tiered royalties on any net sales. [collapse expanded text] |
Sarepta Therapeutics, Summit Therapeutics | Oct 2016 | 562 | Collaboration and licensing agreement for utrophin modulator pipeline | Sarepta Therapeutics and Summit Therapeutics have entered into an exclusive license and … read morecollaboration agreement granting Sarepta rights in Europe, as well as in Turkey and the Commonwealth of Independent States, to Summit’s utrophin modulator pipeline, including its lead clinical candidate, ezutromid, for the treatment of Duchenne muscular dystrophy. As part of the agreement, Sarepta also obtains an option to license Latin American rights to Summit’s utrophin modulator pipeline. Summit retains commercialization rights in all other countries. Summit will receive an upfront fee of $40 million. In addition, Summit will be eligible for future ezutromid related development, regulatory and sales milestone payments totalling up to $522 million, including a $22 million milestone upon the first dosing of the last patient in Summit’s PhaseOut DMD trial, and escalating royalties ranging from a low to high teens percentage of net sales in the licensed territory. Summit will also be eligible to receive development and regulatory milestones related to its next-generation utrophin modulators. Sarepta and Summit will share specified utrophin modulator-related research and development costs at a 45%/55% split, respectively, beginning in 2018. If Sarepta elects to exercise its option for Latin American rights, Summit would be entitled to additional fees, milestones and royalties. [collapse expanded text] |
Advaxis, Amgen | Aug 2016 | 540 | Collaboration agreement for cancer immunotherapies | August 2016 Amgen and Advaxis announced a global agreement for the development and … read morecommercialization of Advaxis' ADXS-NEO, a novel, preclinical investigational cancer immunotherapy treatment that is designed to activate a patient's immune system to respond against the unique mutations, or neoepitopes, contained in and identified from each individual patient's tumor. This collaboration brings together Amgen's development expertise in immuno-oncology with Advaxis' MINE (My Immunotherapy Neo-Epitopes) program, which is uniquely positioned to develop a customized approach to cancer treatment. Amgen receives exclusive worldwide rights to develop and commercialize ADXS-NEO. Amgen will make an upfront payment to Advaxis of $40 million and purchase $25 million of Advaxis common stock. Amgen will be fully responsible for funding clinical and commercial activities. Advaxis will lead the clinical development of ADXS-NEO through proof-of-concept, retain manufacturing responsibilities, and receive development, regulatory and sales milestone payments of up to $475 million and potential high single digit to mid-double digit royalty payments based on worldwide sales. [collapse expanded text] |
Bayer, X-chem | Jul 2016 | 528 | Collaboration agreement for innovative lead structures for complex drug targets | October 2017 X-Chem and Bayer have further expanded their drug discovery collaboration across … read moremultiple therapeutic areas and target classes. The latest agreement with Bayer extends their access to X-Chem’s DEX technology by including the synthesis of custom Bayer DNA-Encoded Libraries and expanding the number of potential programs. The collaboration is focused on the discovery of innovative small molecule leads for complex drug targets in areas of high unmet medical need. X-Chem will receive additional research and development funding, as well as pre-clinical, clinical and regulatory milestone payments for the additional programs, consistent with the 2016 agreement. Bayer retains an exclusive option to license compounds generated in the course of the collaboration. X-Chem will also receive sales milestones and royalties for each successfully commercialized drug derived from a licensed program. July 2016 X-Chem and Bayer have entered into an expanded global drug discovery collaboration across multiple therapeutic areas and target classes. The new agreement extends Bayer’s access to X-Chem’s DEX™ technology which is based on DNA-encoded libraries of small molecules with more than 120 billion molecules. The aim of the collaboration is to discover innovative lead structures for complex drug targets in areas of high unmet medical need. Under the terms of this new agreement, X-Chem will receive an up-front payment, research and development funding, as well as potential pre-clinical, clinical and regulatory milestone payments, up to a total of $528 million. Bayer has an exclusive option to license any programs generated in the course of the collaboration. X-Chem will also receive royalties and sales milestones for each successfully commercialized drug that results from a licensed collaboration program. [collapse expanded text] |
BioInvent, Pfizer | Dec 2016 | 510 | Collaboration and licensing agreement to develop antibodies targeting tumour-associated myeloid cells | December 2020 BioInvent International announced that Pfizer has selected antibodies directed at … read morea previously-selected target under the companies' cancer immunotherapy research collaboration and license agreement. July 2020 BioInvent has further extended the research term under its cancer immunotherapy research collaboration and license agreement with Pfizer until the end of 2020. BioInvent may be eligible for further milestone payments from development of antibodies directed against these targets as well as from the selection of additional targets and the development of antibodies directed against those targets. December 2019 BioInvent announced that Pfizer has selected the second target under the companies' cancer immunotherapy research collaboration and license agreement. BioInvent has extended the research term under its collaboration and license agreement with Pfizer by six months. July 2019 BioInvent announces that Pfizer has selected the first target under the companies' cancer immunotherapy research collaboration and license agreement, into which the companies entered in December 2016 to develop antibodies targeting tumor-associated myeloid cells. The selection of a target triggers a payment from Pfizer to BioInvent of $300,000. Under the terms of the 2016 agreement, potential selection and development of antibodies directed against this target, as well as potential selection of further targets and development of antibodies directed at them, would allow BioInvent to be eligible for further milestone payments. December 2016 BioInvent has entered into a cancer immunotherapy research collaboration and license agreement with Pfizer to develop antibodies targeting tumour-associated myeloid cells. Pfizer will pay BioInvent approximately $10 million in early payments, including an upfront payment, early research funding, and a $6 million equity investment in new shares of BioInvent at a subscription price of SEK 2.56 per share, which corresponds to an approximately 30% premium to the average volume weighted price for the share during the 10 trading days prior to 21 December 2016. Assuming five antibodies are developed through to commercialization, BioInvent would be eligible for potential future payments related to certain development milestones, which could amount to more than $0.5 billion through the term of the deal, as well as up to double digit royalties related to any potential products that may result from the collaboration. Pfizer will have the right to develop and commercialize any antibodies generated to an undisclosed number of tumour-associated myeloid cell targets. BioInvent will leverage its cancer biology expertise, combined with its unbiased translational drug discovery approach (“F.I.R.S.T”), to identify novel oncology targets and therapeutic antibodies that inhibit cancer growth either by reversing the immunosuppressive activity of tumour-associated myeloid cells or by reducing the number of tumour-associated myeloid cells in the tumour. [collapse expanded text] |
Janssen Biotech, Tesaro | Apr 2016 | 500 | Collaboration and license agreement for niraparib | TESARO and Janssen Biotech Inc., one of the Janssen Pharmaceutical Companies of Johnson & … read moreJohnson, announced a global collaboration and license agreement focused on the development and commercialization of niraparib specifically for the treatment of prostate cancer. Niraparib is an oral, once daily, potent, and highly selective PARP inhibitor that is currently being evaluated in Phase 3 clinical trials for ovarian and breast cancer. Under the terms of the agreement, Janssen will develop and commercialize niraparib for patients with prostate cancer worldwide, except in Japan. TESARO will receive an upfront payment of $35 million, and is eligible to receive additional milestone payments of up to $415 million, contingent upon Janssen reaching certain pre-determined development, regulatory and commercial milestones, in addition to tiered, double-digit royalty payments. Janssen will be responsible for funding all development and commercialization activities related to niraparib in prostate cancer. Separately, Johnson & Johnson Innovation — JJDC, Inc. is making a $50 million equity investment in TESARO at a price of $44.24 per share, which is based upon the 5-day volume weighted average share price through the day prior to execution of the agreement. [collapse expanded text] |
Abbvie, CytomX Therapeutics | Apr 2016 | 500 | Co development agreement for probody drug conjugates against CD71 (updated) | June 2017 CytomX Therapeutics, Inc., a biopharmaceutical company developing investigational … read moreProbody™ therapeutics for the treatment of cancer, announced that the company has advanced CX-2029, a Probody drug conjugate (PDC) targeting CD71 and being developed in collaboration with AbbVie, into GLP toxicology studies, a key step on the path to filing an Investigational New Drug (IND) application in 2018. Upon commencement of the GLP toxicology study, CytomX will receive a $15 million milestone payment from AbbVie as part of the 2016 strategic oncology collaboration between the companies. About CD71 and the CytomX/AbbVie 2016 Strategic Oncology Collaboration AbbVie also receives exclusive worldwide rights to develop and commercialize Probody drug conjugates against up to two additional, undisclosed targets. Should AbbVie ultimately pursue these targets, CytomX is eligible to receive additional milestone and royalty payments per target on any resulting products. April 2016 AbbVie entered into another collaborative drug development agreement bolstering its oncology pipeline. The latest deal, worth up to $500 million, was struck Thursday with CytomX Therapeutics, Inc. to co-develop Probody Drug Conjugates against CD71, also known as transferrin receptor 1 (TfR1). CytomX’s Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. Probody therapeutics bind selectively to tumors and avoid binding to healthy tissue, to minimize toxicity and potentially create safer, more effective therapies. CytomX has generated preclinical data that demonstrates that Probody drug conjugates can safely and effectively target tumor antigens, such as CD71, that are not addressable by conventional antibody-drug conjugates. Under terms of the co-development agreement, CytomX will lead preclinical and early-clinical development, with AbbVie taking over for mid- to late-stage development and possible commercialization. CytomX will receive an upfront payment of $30 million and is eligible to receive up to $470 million in development, regulatory and commercial milestones, pending the achievement of pre-determined outcomes. As part of the deal, AbbVie also has exclusive rights to develop and commercialize Probody drug conjugates against up to two additional, undisclosed targets. Should AbbVie ultimately pursue these targets, CytomX is eligible to receive additional milestone and royalty payments per target on any resulting products. [collapse expanded text] |
Searching for more deal information? Current Partnering offers the following options:
|